FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Kim, KW
Lee, JM
Jeon, YS
Kang, SE
Baek, JH
Han, JK
Choi, BI
Bang, YJ
Kiefer, B
Block, KT
Ji, HJ
Bauer, S
Kim, C
AF Kim, Kyung Won
Lee, Jeong Min
Jeon, Yong Sik
Kang, Sung Eun
Baek, Jee Hyun
Han, Joon Koo
Choi, Byung Ihn
Bang, Yung-Jue
Kiefer, Berthold
Block, Kai Tobias
Ji, Hyunjun
Bauer, Simon
Kim, Chin
TI Free-breathing dynamic contrast-enhanced MRI of the abdomen and chest
using a radial gradient echo sequence with K-space weighted image
contrast (KWIC)
SO EUROPEAN RADIOLOGY
LA English
DT Article
DE Dynamic contrast-enhanced MRI; Radial MRI; Free-breathing; K-space;
Perfusion
ID TUBULIN POLYMERIZATION INHIBITOR; PROJECTION RECONSTRUCTION; DCE-MRI;
LIVER; ANGIOGRAPHY; RESOLUTION; TUMORS
AB To evaluate the feasibility of free-breathing, dynamic contrast-enhanced (DCE) MRI of the abdomen and thorax using the radial-gradient-echo sequence with k-space weighted image contrast (KWIC) reconstruction.
Institutional review board approval was obtained. Fourteen patients underwent free-breathing radial DCE-MRI. Radial MRI yielded full-frame images by gridding all k-space data and time-resolved subframe images by using KWIC reconstruction technique. Using subframe KWIC images, voxel-wise perfusion maps were created. For comparison, the breath-hold conventional Cartesian 3D-gradient-echo sequence (VIBE) was also performed during the equilibrium phase. The image qualities of radial and conventional VIBE images were compared quantitatively and qualitatively.
Radial DCE-MRI provided high spatial resolution (1.4 x 1.4 mm) and temporal resolution (4.1 s for subframe images) allowing voxel-wise perfusion mapping with negligible motion or streaking artefacts. There were no significant differences in SNR between full-frame radial images and conventional VIBE images (79.08 vs 74.80, P > 0.05). Overall image quality score of full-frame radial images was slightly lower than that of conventional VIBE images (3.88 +/- 0.59 vs. 4.31 +/- 0.97, P < 0.05), but provided clinically useful images.
The free-breathing radial DCE-MRI can provide high spatial and temporal resolution while maintaining reasonably high image quality and thus is a feasible technique for DCE-MRI in the abdomen and thorax.
aEuro cent Dynamic contrast-enhanced magnetic resonance imaging (DCE) MRI is important in oncological imaging
aEuro cent Radial MRI with k-space weighted image contrast (KWIC) reconstruction offers potential improvements
aEuro cent Radial DCE-MRI provides good image quality, reduced artefacts and high spatial/temporal resolution.
C1 [Kim, Kyung Won; Lee, Jeong Min; Jeon, Yong Sik; Kang, Sung Eun; Baek, Jee Hyun; Han, Joon Koo; Choi, Byung Ihn] Seoul Natl Univ Hosp, Dept Radiol, Seoul 110744, South Korea.
[Bang, Yung-Jue] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
[Kim, Kyung Won] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kiefer, Berthold; Block, Kai Tobias; Ji, Hyunjun; Bauer, Simon] Siemens Healthcare, Erlangen, Germany.
[Kim, Chin] Chong Kun Dang Pharmaceut, Seoul, South Korea.
[Lee, Jeong Min] Seoul Natl Univ, Coll Med, Dept Radiol, Seoul 110744, South Korea.
[Lee, Jeong Min] Seoul Natl Univ, Coll Med, Inst Radiat Med, Seoul 110744, South Korea.
RP Lee, JM (reprint author), Seoul Natl Univ, Coll Med, Dept Radiol, 28 Yeongon Dong, Seoul 110744, South Korea.
EM jmsh@snu.ac.kr
RI Bang, Yung Jue/J-2759-2012
FU National Research Foundation of Korea (NRF); Korean government
[2011-0026127]; Korea Health and Medical Technology R&D Project,
Ministry for Health, Welfare Family Affairs [A100895, A100265]
FX This work was partly supported by a National Research Foundation of
Korea (NRF) grant funded by the Korean government (2011-0026127) and
partly supported by grants of the Korea Health and Medical Technology
R&D Project, Ministry for Health, Welfare & Family Affairs (A100895,
A100265). We thank Bonnie Hami, M. A., for her editorial assistance. We
also thank Peter Gall, PhD., for technical advice about Tissue4D
software. Four coauthors (Berthold Kiefer, Kai Tobias Block, Hyunjun Ji,
and Simon Bauer) are employees of Siemens Healthcare, and one coauthor
(Chin Kim) is an employee of Chong Kun Dang Pharmaceuticals. Siemens
Medical Systems provided the radial VIBE sequence as well as technical
advice. We thank Chong Kun Dang Pharmaceuticals for allowing us to use
MRI data of patients enrolled in their ongoing clinical trial
(NCT01028859).
NR 28
TC 23
Z9 23
U1 3
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0938-7994
J9 EUR RADIOL
JI Eur. Radiol.
PD MAY
PY 2013
VL 23
IS 5
BP 1352
EP 1360
DI 10.1007/s00330-012-2699-4
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 123YC
UT WOS:000317427500025
PM 23187728
ER
PT J
AU Luo, H
Zhang, LH
Liu, XD
Leung, FW
Liu, ZG
Wang, XP
Xue, L
Wu, KC
Fan, DM
Pan, YL
Guo, XG
AF Luo, Hui
Zhang, Linhui
Liu, Xiaodong
Leung, Felix W.
Liu, Zhiguo
Wang, Xiangping
Xue, Ling
Wu, Kaichun
Fan, Daiming
Pan, Yanglin
Guo, Xuegang
TI Water exchange enhanced cecal intubation in potentially difficult
colonoscopy. Unsedated patients with prior abdominal or pelvic surgery:
a prospective, randomized, controlled trial
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID COLORECTAL-CANCER; INCOMPLETE COLONOSCOPY; SEDATION; IMMERSION;
METAANALYSIS; PREVENTION; VETERANS; STANDARD
AB Background: Colonoscopy is widely used for management of colorectal diseases. A history of abdominal or pelvic surgery is a well-recognized factor associated with difficult colonoscopy. Although water exchange colonoscopy (WEC) was effective in small groups of male U.S. veterans with such a history, its application in other cultural settings is uncertain.
Objective: To investigate the application of WEC in such patients.
Design: Prospective, randomized, controlled, patient-blinded study.
Setting: Tertiary-care referral center in China.
Patients: Outpatients with prior abdominal or pelvic surgery undergoing unsedated diagnostic, screening, or surveillance colonoscopy.
Intervention: Patients were randomized to examination by either WEC or conventional air colonoscopy (AC).
Main Outcome Measurements: Cecal intubation rate.
Results: A total of 110 patients were randomized to the WEC (n = 55) or AC (n = 55) group. WEC significantly increased the cecal intubation rate (92.7% vs 76.4%; P = .033). The maximum pain scores (+/- standard deviation) were 2.1 +/- 1.8 (WEC) and 4.6 +/- 1.7 (AC), respectively (P < .001). Multivariate analysis showed that the colonoscopy method was the only independent predictor of failed colonoscopy (odds ratio 11.44, 95% confidence interval, 1.35-97.09). A higher proportion of patients examined by WEC would be willing to have a repeat unsedated colonoscopy (90.9% vs 72.7%, P = .013).
Limitations: Single center; unblinded but experienced endoscopists.
Conclusion: This randomized, controlled trial confirms that the water exchange method significantly enhanced cecal intubation in potentially difficult colonoscopy in unsedated patients with prior abdominal or pelvic surgery. The lower pain scores and higher proportion accepting repeat of the unsedated option suggest that WEC is promising. It may enhances compliance with colonoscopy in specific populations. (Clinical trial registration number: NCT01485133.) (Gastrointest Endosc 2013; 77:767-73.)
C1 [Luo, Hui; Zhang, Linhui; Liu, Xiaodong; Liu, Zhiguo; Wang, Xiangping; Wu, Kaichun; Fan, Daiming; Pan, Yanglin; Guo, Xuegang] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Peoples R China.
[Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA.
[Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Xue, Ling] Jinan Mil Gen Hosp, Dept Cardiol, Jinan, Peoples R China.
RP Guo, XG (reprint author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, 169 Changle West Rd, Xian 710032, Peoples R China.
OI liu, zhiguo/0000-0002-8485-7356
FU National Natural Science Foundation of China [81172288]; Science
Foundation of the Ministry of Education; Technology Innovation
Foundation of Xijing Hospital
FX This work was supported in part by the National Natural Science
Foundation of China (81172288). Y. Pan received support from the Science
Foundation of the Ministry of Education. X. Guo received support from
the Technology Innovation Foundation of Xijing Hospital. No other
financial relationships relevant to this publication were disclosed.
NR 28
TC 15
Z9 16
U1 0
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD MAY
PY 2013
VL 77
IS 5
BP 767
EP 773
DI 10.1016/j.gie.2012.12.007
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 122XY
UT WOS:000317353100015
PM 23394837
ER
PT J
AU Daglilar, ES
Yoon, WJ
Mino-Kenudson, M
Brugge, WR
AF Daglilar, Ebubekir S.
Yoon, Won Jae
Mino-Kenudson, Mari
Brugge, William R.
TI Controlled swine bile duct ablation with a bipolar radiofrequency
catheter
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA; SURGICAL RESECTION; ESOPHAGUS; PORCINE; LIVER;
SIZE; VIVO
AB Background: Radiofrequency (RF) power is capable of ablation of neoplastic tissue arising from Barrett's esophagus. Endoscopic catheter bipolar RF ablation is a new technique for ablation of neoplastic tissue in the bile duct.
Objective: To determine the effect of RF power on bile duct and solid organ histology.
Design: Nonsurvival animal study.
Setting: Academic center.
Patients: This study involved 4 Yorkshire farm swine.
Intervention: After we made a midline laparotomy incision, a bipolar RF catheter was placed with 3 power (5, 7, 10 W) and voltage settings (66, 132, 190 V) in the bile duct and solid organs (liver, spleen, kidney, and pancreas). Gross and histologic examinations were performed.
Main Outcome Measurements: Depth of ablation in the bile duct wall, characteristics of the ablation in the solid organs.
Results: An endoscopic bipolar RF catheter produced incomplete (bile duct), patchy ablation (pancreas) with 5 watts, intramural (bile duct) or confluent ablation with 7 watts, and transmural (bile duct) ablation at 10 W. The depth of ablation in the bile duct was 0.9 +/- 0.3, 1.5 +/- 0.2, 2.3 +/- 0.6 mm at 5, 7, and 10 W, respectively (analysis of variance; P = .02). Histologic ablation was not achieved in the liver, although gross changes were seen.
Limitations: Animal study, normal bile duct.
Conclusion: RF energy applied to the bile duct or solid organs resulted in controlled ablation with a linear relationship between the depth of ablation in the bile duct and RF power.
C1 [Daglilar, Ebubekir S.; Yoon, Won Jae; Brugge, William R.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Brugge, WR (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St, Boston, MA 02114 USA.
FU RedPath, Inc.
FX The radiofrequency ablation catheters were provided by Emcision Ltd. W.
Brugge is a consultant for Xlumena and received grant support from
RedPath, Inc. No other financial relationships relevant to this
publication were disclosed.
NR 11
TC 6
Z9 9
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD MAY
PY 2013
VL 77
IS 5
BP 815
EP 819
DI 10.1016/j.gie.2013.01.005
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 122XY
UT WOS:000317353100022
PM 23582532
ER
PT J
AU Celik, C
Bastu, E
Abali, R
Alpsoy, S
Guzel, EC
Aydemir, B
Yeh, J
AF Celik, Cem
Bastu, Ercan
Abali, Remzi
Alpsoy, Seref
Guzel, Eda Celik
Aydemir, Birsen
Yeh, John
TI The relationship between copper, homocysteine and early vascular disease
in lean women with polycystic ovary syndrome
SO GYNECOLOGICAL ENDOCRINOLOGY
LA English
DT Article
DE Brachial artery flow mediated dilation; carotid intima-media thickness;
copper; homocysteine; polycystic ovary syndrome
ID CARDIOVASCULAR-DISEASE; ATHEROSCLEROSIS; ENDOTHELIUM; DEFICIENCY
AB This study investigates copper (Cu) levels and vascular dysfunction in lean women with polycystic ovary syndrome (PCOS). 44 subjects with PCOS, diagnosed according to Rotterdam criteria, and 42 healthy subjects matched for body mass index and age. Comparison of serum Cu, homocysteine, carotid intima-media thickness (CIMT), brachial artery flow mediated dilation (FMD) was carried out between PCOS patients and the control group. Clinical study was done in Namik Kemal University School of Medicine. The CIMT and concentration of Cu in PCOS patients was significantly higher than the healthy controls. FMD levels in PCOS patients were significantly lower than those in controls. In PCOS patients, CIMT was correlated with estrogen and Cu levels. However, FMD was correlated with age and Cu levels. Among these contributing factors, Cu levels were correlated with a change in CIMT and FMD. CIMT and FMD in PCOS patients were related to Cu levels as well as several cardiovascular risk factors. Thus, increased Cu levels may be responsible for the increased risk of early vascular disease in women with PCOS.
C1 [Celik, Cem; Abali, Remzi] Namik Kemal Univ, Fac Med, Dept Gynecol & Obstet, Tekirdag, Turkey.
[Bastu, Ercan] Istanbul Univ, Fac Med, Dept Gynecol & Obstet, Istanbul, Turkey.
[Alpsoy, Seref] Sakarya Univ, Fac Med, Dept Cardiol, Sakarya, Turkey.
[Guzel, Eda Celik] Sakarya Univ, Fac Med, Dept Biophys, Sakarya, Turkey.
[Aydemir, Birsen] Istanbul Univ, Cerrahpasa Fac Med, Dept Biophys, Istanbul, Turkey.
[Yeh, John] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA USA.
RP Celik, C (reprint author), Namik Kemal Univ, Fac Med, Dept Gynecol & Obstet, 100 Yil Mah Barbaros Cad,132, Tekirdag, Turkey.
EM cemcel@yahoo.com
NR 27
TC 6
Z9 6
U1 1
U2 12
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0951-3590
J9 GYNECOL ENDOCRINOL
JI Gynecol. Endocrinol.
PD MAY
PY 2013
VL 29
IS 5
BP 488
EP 491
DI 10.3109/09513590.2013.774361
PG 4
WC Endocrinology & Metabolism; Obstetrics & Gynecology
SC Endocrinology & Metabolism; Obstetrics & Gynecology
GA 117MA
UT WOS:000316956300020
PM 23480818
ER
PT J
AU Chien, WD
Lin, HW
Deschler, DG
AF Chien, Wade
Lin, Harrison W.
Deschler, Daniel G.
TI Serial suture ligation glossectomy for squamous cell carcinoma in the
setting of a massive lymphovascular malformation
SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND
NECK
LA English
DT Article
DE lymphovascular malformation; squamous cell carcinoma; oral cavity;
suture ligation; cancer
ID VASCULAR MALFORMATIONS; LYMPHANGIOMAS; HEMANGIOMAS; CHILDREN; CANCER;
BASE; HEAD; NECK
AB Background We describe a novel surgical technique for resection of squamous cell carcinoma in the setting of a massive tongue lymphovascular malformation (LVM). Methods and Results A 75-year-old man with a history of long-standing massive LVM of the tongue presented with a 4-cm squamous cell carcinoma of the involved oral tongue. Given the aberrant vascular anatomy of this lesion, traditional surgical treatment could not be undertaken. Therefore, serial suture ligation was performed over a 2-week period, allowing complete excision of the squamous cell carcinoma and a large portion of the tongue LVM with minimal morbidity. Return to preoperative functional status was likewise achieved. Conclusion Serial suture ligation glossectomy is a simple and effective technique for treating the uncommon case of squamous cell carcinoma of the tongue in the setting of a massive LVM. (c) 2012 Wiley Periodicals, Inc. Head Neck, 2013
C1 [Lin, Harrison W.] Harvard Univ, Sch Med, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
RP Lin, HW (reprint author), Harvard Univ, Sch Med, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
EM harrison_lin@meei.harvard.edu
NR 12
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1043-3074
J9 HEAD NECK-J SCI SPEC
JI Head Neck-J. Sci. Spec. Head Neck
PD MAY
PY 2013
VL 35
IS 5
BP E157
EP E160
DI 10.1002/hed.22010
PG 4
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 122FQ
UT WOS:000317304000005
PM 22307803
ER
PT J
AU Albers, CE
Haefeli, PC
Zimmermann, H
de Moya, M
Exadaktylos, AK
AF Albers, C. E.
Haefeli, P. C.
Zimmermann, H.
de Moya, M.
Exadaktylos, A. K.
TI Can handheld micropower impulse radar technology be used to detect
pneumothorax? Initial experience in a European trauma centre
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Pneumothorax; Detection; Micropower impulse radar; Sensitivity;
Specificity; Trauma centre; Preclinical; Quality control; Device
performance; Thorax drain; Chest tube; MIR
ID EXTENDED FOCUSED ASSESSMENT; EMERGENCY-DEPARTMENT; ULTRASOUND DETECTION;
PHYSICAL-EXAMINATION; THORACIC SONOGRAPHY; BLUNT TRAUMA; CHEST TRAUMA;
X-RAY; DIAGNOSIS; ULTRASONOGRAPHY
AB Background: Pneumothoraces are a common injury pattern in emergency medicine. Rapid and safe identification can reduce morbidity and mortality. A new handheld, battery powered device, the Pneumoscan (CE 561036, PneumoSonics Inc., Cleveland, OH, USA), using micropower impulse radar (MIR) technology, has recently been introduced in Europe for the rapid and reliable detection of PTX. However, this technology has not yet been tested in trauma patients. This is the first quality control evaluation to report on emergency room performance of a new device used in the trauma setting.
Material and methods: This study was performed at a Level I trauma centre in Switzerland. All patients with thoracic trauma and undergoing chest X-ray and CT-scan were eligible for the study. Readings were performed before the chest X-ray and CT scan. The patients had eight lung fields tested (four on each side). All readings with the Pneumoscan were performed by two junior residents in our department who had previously received an instructional tutorial of 15 min. The qualitative MIR results were blinded, and stored on the device. We then compared the results of the MIR to those of the clinical examination, chest X-ray and CT-scan.
Results: 50 patients were included, with a mean age of 46 (SD 17) years. Seven patients presented with PTX diagnosed by CT; six of these were detected by Pneumoscan, leading to an overall sensitivity of 85.7 (95% confidence interval 42.1-99.6)%. Only two of seven PTX were found during clinical examination and on chest X-ray (sensitivity 28.6 (95% CI 3.7-71.0)%). Of the remaining 43 of 50 patients without PTX, one false-positive PTX was found by the Pneumoscan, resulting in a specificity of 97.7 (95% CI 87.7-99.9)%.
Discussion: The Pneumoscan is an easy to use handheld technology with reliable results. In this series, the sensitivity to detect a PTX by the Pneumoscan was higher than by clinical examination and chest X-ray. Further studies with higher case numbers and a prospective study design are needed to confirm our findings. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Albers, C. E.; Haefeli, P. C.; Zimmermann, H.; Exadaktylos, A. K.] Univ Bern, Inselspital, Univ Hosp Bern, Dept Emergency Med, CH-3010 Bern, Switzerland.
[Albers, C. E.; Haefeli, P. C.; Zimmermann, H.; Exadaktylos, A. K.] Univ Bern, CH-3010 Bern, Switzerland.
[de Moya, M.] Massachusetts Gen Hosp, Div Trauma, Boston, MA 02114 USA.
RP Exadaktylos, AK (reprint author), Univ Hosp Bern, Dept Emergency Med, Freiburgstr, CH-3010 Bern, Switzerland.
EM christoph.albers@insel.ch; pascal.haefeli@insel.ch;
heinz.zimmermann@insel.ch; mdemoya@partners.org;
exadaktylos@exadaktylos.ch
FU PneumoSonics Inc. (Cleveland, Ohio)
FX Our unit has been equipped by the company with one hand held device.
Some financial support was received by PneumoSonics Inc. (Cleveland,
Ohio) towards a department based general trauma research grant. The
company was not granted any intellectual properties of the data nor did
the company have any rights to influence data selection, evaluation, or
discussion. The company was not involved in drafting the paper.
NR 25
TC 1
Z9 1
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
J9 INJURY
JI Injury-Int. J. Care Inj.
PD MAY
PY 2013
VL 44
IS 5
BP 650
EP 654
DI 10.1016/j.injury.2012.02.001
PG 5
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 122VE
UT WOS:000317345400015
PM 22385903
ER
PT J
AU Thase, ME
Montgomery, S
Papakostas, GI
Bauer, M
Trivedi, MH
Svedsater, H
Locklear, JC
Gustafsson, U
Datto, C
Eriksson, H
AF Thase, Michael E.
Montgomery, Stuart
Papakostas, George I.
Bauer, Michael
Trivedi, Madhukar H.
Svedsaeter, Henrik
Locklear, Julie C.
Gustafsson, Urban
Datto, Catherine
Eriksson, Hans
TI Quetiapine XR monotherapy in major depressive disorder: a pooled
analysis to assess the influence of baseline severity on efficacy
SO INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
LA English
DT Article
DE atypical antipsychotic; extended-release quetiapine fumarate; major
depressive disorder; monotherapy; severe depression; severity
ID DOUBLE-BLIND; FUMARATE MONOTHERAPY; MILD DEPRESSION; ESCITALOPRAM;
ANTIDEPRESSANTS; METAANALYSIS; TOLERABILITY; VENLAFAXINE; CITALOPRAM;
EPISODE
AB The efficacy of quetiapine XR was investigated in patients with major depressive disorder and differing levels of baseline severity. Pooled data from four placebo-controlled monotherapy studies of quetiapine XR (50-300 mg/day) were analyzed. Post-hoc analyses were carried out to assess change from baseline in the Montgomery Asberg Depression Rating Scale (MADRS) total score at endpoint (week 6 or 8) to week 1, and response (>= 50% reduction in MADRS total score) and remission (MADRS total scorer <= 10) rates at endpoint for all patients and six baseline severity cohorts (MADRS total score >= 24, >= 26, >= 28, >= 30, >= 32, and >= 34). In total, 1752 patients (all patients) were evaluated (MADRS score at baseline: >= 24, n= 1601; >= 26, n= 1467; >= 28, n= 1269; >= 30, n= 1038; >= 32, n= 745; and >= 34, n= 500). At endpoint, quetiapine XR reduced MADRS total score in all patients (P < 0.001) and each severity cohort (>= 24, >= 26, >= 28, >= 30, and >= 32, P < 0.001; >= 34, P < 0.01) versus placebo. Quetiapine XR also improved MADRS total score at week 1, response rates for each severity cohort, and remission rates in five out of six severity cohorts, versus placebo. Quetiapine XR monotherapy showed antidepressant effects in patients with major depressive disorder across different levels of baseline severity. Int Clin Psychopharmacol 28: 113-120 (C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
C1 [Thase, Michael E.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Papakostas, George I.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Trivedi, Madhukar H.] UT Southwestern Med Ctr Dallas, Dept Psychiat, Dallas, TX USA.
[Svedsaeter, Henrik; Locklear, Julie C.; Gustafsson, Urban; Eriksson, Hans] AstraZeneca, Wilmington, DE USA.
[Datto, Catherine] AstraZeneca, Wilmington, DE USA.
[Montgomery, Stuart] Univ London, Imperial Coll, London, England.
[Bauer, Michael] Univ Hosp Carl Gustav Carus, Dept Psychiat & Psychotherapy, Dresden, Germany.
RP Thase, ME (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3535 Market St, Philadelphia, PA 19104 USA.
EM thase@mail.med.upenn.edu
RI Papakostas, George/I-6905-2013
OI Papakostas, George/0000-0002-2465-5103
FU AstraZeneca
FX The authors thank Simon Vass, PhD, from Complete Medical Communications,
who provided medical writing support, funded by AstraZeneca.
NR 33
TC 2
Z9 2
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0268-1315
J9 INT CLIN PSYCHOPHARM
JI Int. Clin. Psychopharmacol.
PD MAY
PY 2013
VL 28
IS 3
BP 113
EP 120
DI 10.1097/YIC.0b013e32835fb971
PG 8
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA 115ZI
UT WOS:000316850500001
PM 23485955
ER
PT J
AU de Miguel-Yanes, JM
Porneala, B
Pencina, MJ
Fox, CS
Florez, JC
Siscovick, DS
Dupuis, J
Meigs, JB
AF de Miguel-Yanes, Jose M.
Porneala, Bianca
Pencina, Michael J.
Fox, Caroline S.
Florez, Jose C.
Siscovick, David S.
Dupuis, Josee
Meigs, James B.
TI Lack of interaction of beta-cell-function-associated variants with
hypertension on change in fasting glucose and diabetes risk: the
Framingham Offspring Study
SO JOURNAL OF HYPERTENSION
LA English
DT Article
DE fasting glucose; Framingham; genes; genetic risk scores; hypertension;
hypertension treatment; interaction test; single nucleotide
polymorphisms; type 2 diabetes mellitus
ID GENOME-WIDE ASSOCIATION; BLOOD-PRESSURE; CARDIOVASCULAR EVENTS;
SUSCEPTIBILITY LOCI; THIAZIDE DIURETICS; GENETIC-VARIATION;
HEART-DISEASE; FOLLOW-UP; MELLITUS; METAANALYSIS
AB Objective: To test whether pancreatic beta-cell genetic frailty and hypertension (HTN) interact in their associations with change over time in fasting glucose (Delta FG) or type 2 diabetes mellitus (T2D) risk.
Methods and results: We pooled data from 3471 Framingham Offspring Study participants into six similar to 4-year periods (15 852 person-examinations; mean age 52; 54% women). We defined two genetic exposures reflecting beta-cell genetic risk burden: single nucleotide polymorphism (SNP) score counts of fasting glucose-associated and T2D-associated risk alleles at 16 and 33 putative beta-cell loci, respectively; and three HTN exposures: HTN versus no-HTN; treated versus untreated HTN; and five mutually exclusive antihypertensive categories (beta-blockers, thiazides, renin-angiotensin system agents, combinations, others) versus untreated HTN. We tested similar to 4-year mean Delta FG or odds of T2D by per-risk allele score change and HTN category, seeking genetic score-by-HTN interaction. Genetic scores increased similar to 4-year Delta FG (0.6 mg/dl per-risk allele; P = 8.9 x 10(-16)) and T2D-risk (similar to 17% per-risk allele; P = 2.1 x 10(-7)). As compared to no-HTN, HTN conferred higher Delta FG (2.6 versus 1.7 mg/dl; P < 0.0001) and T2D-risk [odds ratio (OR) - 2.9, 95% confidence interval (CI) 2.8-3.0; P < 0.0001]. As compared to untreated HTN, treated HTN conferred higher Delta FG (3.4 versus 3.0 mg/dl; P < 0.0001) and T2D-risk (OR = 1.4, 95% CI 1.3-1.5; P = 0.02). Beta-blockers (OR = 1.6, 95% CI 1.1-2.4), combinations (OR = 1.6, 95% CI 1.1-2.5), and others (OR = 2.0, 95% CI 1.4-2.9) increased T2D-risk (all P < 0.02). In joint models including interaction terms, all genetic score-by-HTN interaction terms were P value greater than 0.05. In joint models without interaction, fasting glucose-SNP or T2D-SNP genetic scores (both P < 0.001) and HTN (P < 0.0001) independently increased Delta FG or T2D-risk.
Conclusion: HTN, HTN treatment, and common fasting glucose-SNP genetic score/T2D-SNP genetic score independently predicted Delta FG and T2D incidence, but did not modify each other's association with Delta FG or T2D risk.
C1 [de Miguel-Yanes, Jose M.] Univ Complutense Madrid, Hosp Gregorio Maranon, Madrid, Spain.
[de Miguel-Yanes, Jose M.] Hosp Sureste, Madrid, Spain.
[Porneala, Bianca; Meigs, James B.] Boston Univ, Sch Publ Hlth, Massachusetts Gen Hosp, Div Gen Med, Boston, MA USA.
[Pencina, Michael J.; Dupuis, Josee] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Fox, Caroline S.; Dupuis, Josee] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Fox, Caroline S.; Florez, Jose C.; Meigs, James B.] Harvard Univ, Sch Med, Boston, MA USA.
[Florez, Jose C.] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.
[Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Florez, Jose C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Siscovick, David S.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
RP de Miguel-Yanes, JM (reprint author), Massachusetts Gen Hosp, Div Gen Internal Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM jmeigs@partners.org
OI Dupuis, Josee/0000-0003-2871-3603
FU National Institute for Diabetes and Digestive and Kidney Diseases
(NIDDK) [R01 DK078616, K24 DK080140]; Framingham Heart Study of the
National Heart Lung and Blood Institute of the National Institutes of
Health; Boston University School of Medicine; National Heart, Lung and
Blood Institute's Framingham Heart Study [N01-HC-25195]; Affimetrix,
Inc. [N02-HL-6-4278]; Robert Dawson Evans Endowment of the Department of
Medicine at Boston University School of Medicine; Boston Medical Center
FX This study was supported by National Institute for Diabetes and
Digestive and Kidney Diseases (NIDDK) R01 DK078616 and K24 DK080140 and
the Framingham Heart Study of the National Heart Lung and Blood
Institute of the National Institutes of Health and Boston University
School of Medicine. The analyses reflect intellectual input and resource
development from the Framingham Heart Study investigators participating
in the SHARe Project, itself supported by the National Heart, Lung and
Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and
its contract from Affimetrix, Inc. for genotyping services (Contract No.
N02-HL-6-4278). A portion of this research utilized the Linux Cluster
for Genetic Analyses (LinGA - II) funded by the Robert Dawson Evans
Endowment of the Department of Medicine at Boston University School of
Medicine and Boston Medical Center.
NR 48
TC 0
Z9 0
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0263-6352
J9 J HYPERTENS
JI J. Hypertens.
PD MAY
PY 2013
VL 31
IS 5
BP 1001
EP 1009
DI 10.1097/HJH.0b013e32835f5a83
PG 9
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 119RL
UT WOS:000317115000023
PM 23425704
ER
PT J
AU Hartwell, KJ
Maria, MMMS
Twal, WO
Shaftman, S
DeSantis, SM
McRae-Clark, AL
Brady, KT
AF Hartwell, Karen J.
Maria, Megan M. Moran-Santa
Twal, Waleed O.
Shaftman, Stephanie
DeSantis, Stacia M.
McRae-Clark, Aimee L.
Brady, Kathleen T.
TI Association of elevated cytokines with childhood adversity in a sample
of healthy adults
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Life stress; Biological stress; Innate immunity; Cytokines; C-reactive
protein
ID POSTTRAUMATIC-STRESS-DISORDER; C-REACTIVE PROTEIN; PITUITARY-ADRENAL
AXIS; NECROSIS-FACTOR-ALPHA; EARLY-LIFE ADVERSITY; PSYCHOLOGICAL STRESS;
TNF-ALPHA; PLASMA INTERLEUKIN-6; MAJOR DEPRESSION; MENTAL STRESS
AB Objective: Childhood trauma has been associated adult stress-related disorders. However, little is known about physiologic alterations in adults with a history of early life trauma that do not have current psychiatric or medical diagnoses. In this study, the relationships between childhood adversity and cytokine and C-reactive protein (CRP) levels in healthy adults were examined.
Method: Participants included men (n = 18) and women (n = 20) who did not meet DSM-IV criteria for Axis I psychiatric disorders or any major medical illness. Cytokine and CRP levels were obtained from baseline blood samples. Subjects completed the Early Trauma Inventory Self Report (ETI-SR). The primary outcomes included serum interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL1-beta), and CRP levels. In addition, the mean numbers of traumatic experiences (sexual, physical, emotional, general, and the summed total) were measured.
Results: Significant positive associations were found between the total ETI score and IL-6 (p = 0.05), IL1-beta (p < 0.05), and TNF-alpha (p = 0.01). Significant positive correlations were found between the number of general traumas and IL1-beta (p < 0.05), TNF-alpha (p < 0.05), and IL-6 (p < 0.01). Neither the total number of traumas nor any of the trauma subscales were significantly associated with CRP levels.
Conclusions: The positive association between childhood trauma and basal cytokine levels supports the extant literature demonstrating the long-term impact of childhood trauma and stress on homeostatic systems. Importantly, this association was found in healthy adults, suggesting that these alterations may precede the development of significant stress-related psychiatric disorder or disease. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Hartwell, Karen J.; Maria, Megan M. Moran-Santa; McRae-Clark, Aimee L.; Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat & Behav Neurosci, Clin Neurosci Div, Charleston, SC 29425 USA.
[Hartwell, Karen J.; Brady, Kathleen T.] Ralph H Johnson VAMC, Charleston, SC 29401 USA.
[Twal, Waleed O.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA.
[Shaftman, Stephanie; DeSantis, Stacia M.] Med Univ S Carolina, Dept Biostat & Epidemiol, Charleston, SC 29425 USA.
RP Maria, MMMS (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Neurosci, Clin Neurosci Div, 125 Doughty St, Charleston, SC 29425 USA.
EM moranm@musc.edu
RI McRae-Clark, Aimee/I-3341-2013
OI McRae-Clark, Aimee/0000-0002-9774-318X
FU NIDA [P50 DA016511-07]; NIH-NCRR [M01 RR01070-30]; Abbott;
GlaxoSmithKline; Forest; Wyeth-Ayerst; Bristol-Myers Squibb; Eli Lilly;
Shire
FX Funding for this study was provided by NIDA P50 DA016511-07 and NIH-NCRR
M01 RR01070-30. The NIDA and the NIH had no further role in study
design; in the collection, analysis and interpretation of data; in the
writing of the report; and in the decision to submit the paper for
publication.; Authors Hartwell, Moran-Santa Maria, Shaftman, Twal, and
DeSantis have no relevant financial relationships with a commercial
interest to disclose. Kathleen Brady has no current conflicts of
interest. Past relationships include the following: Past Consultant:
Pfizer, Eli Lilly, Abbott, GlaxoSmithKline, Forest, Ovation, Marinus,
Novartis; Past Speakers' Bureau: Pfizer, Eli Lilly, Abbott,
GlaxoSmithKline, Forest; Past Research Support: Abbott, GlaxoSmithKline,
Forest, Wyeth-Ayerst; Past Scientific Advisory Board: Embera
NeuroTherapeutics; Past Independent Contractor: Medscape; Past
Investigator: Titan Pharmaceuticals. Aimee McRae-Clark has no current
conflicts of interest. Past relationships include: Past Research
Support: Bristol-Myers Squibb, Eli Lilly, Wyeth-Ayerst, Shire, and
GlaxoSmithKline.
NR 75
TC 17
Z9 18
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD MAY
PY 2013
VL 47
IS 5
BP 604
EP 610
DI 10.1016/j.jpsychires.2013.01.008
PG 7
WC Psychiatry
SC Psychiatry
GA 124EU
UT WOS:000317447400007
PM 23415658
ER
PT J
AU Ho, LL
Sinha, A
Verzi, M
Bernt, KM
Armstrong, SA
Shivdasani, RA
AF Ho, Li-Lun
Sinha, Amit
Verzi, Michael
Bernt, Kathrin M.
Armstrong, Scott A.
Shivdasani, Ramesh A.
TI DOT1L-Mediated H3K79 Methylation in Chromatin Is Dispensable for Wnt
Pathway-Specific and Other Intestinal Epithelial Functions
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID MIXED-LINEAGE LEUKEMIA; STEM-CELLS; HISTONE H3; TRANSCRIPTIONAL
ELONGATION; LYSINE METHYLATION; MAMMALIAN-CELLS; IN-VIVO; DOT1L; GENE;
EXPRESSION
AB Methylation of H3K79 is associated with chromatin at expressed genes, though it is unclear if this histone modification is required for transcription of all genes. Recent studies suggest that Wnt-responsive genes depend particularly on H3K79 methylation, which is catalyzed by the methyltransferase DOT1L. Human leukemias carrying MLL gene rearrangements show DOT1L-mediated H3K79 methylation and aberrant expression of leukemogenic genes. DOT1L inhibitors reverse these effects, but their clinical use is potentially limited by toxicity in Wnt-dependent tissues such as intestinal epithelium. Genome-wide positioning of the H3K79me2 mark in Lgr5(+) mouse intestinal stem cells and mature intestinal villus epithelium correlated with expression levels of all transcripts and not with Wnt-responsive genes per se. Selective Dot1l disruption in Lgr5(+) stem cells or in whole intestinal epithelium eliminated H3K79me2 from the respective compartments, allowing genetic evaluation of DOT1L requirements. The absence of methylated H3K79 did not impair health, intestinal homeostasis, or expression of Wnt target genes in crypt epithelium for up to 4 months, despite increased crypt cell apoptosis. Global transcript profiles in Dot1l-null cells were barely altered. Thus, H3K79 methylation is not essential for transcription of Wnt-responsive or other intestinal genes, and intestinal toxicity is not imperative when DOT1L is rendered inactive in vivo.
C1 [Ho, Li-Lun; Verzi, Michael; Shivdasani, Ramesh A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Ho, Li-Lun; Verzi, Michael; Shivdasani, Ramesh A.] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA.
[Ho, Li-Lun; Verzi, Michael; Shivdasani, Ramesh A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Ho, Li-Lun; Verzi, Michael; Shivdasani, Ramesh A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Sinha, Amit; Bernt, Kathrin M.; Armstrong, Scott A.] Boston Childrens Hosp, Dept Pediat, Boston, MA USA.
[Sinha, Amit; Bernt, Kathrin M.; Armstrong, Scott A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA USA.
RP Shivdasani, RA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM ramesh_shivdasani@dfci.harvard.edu
RI Bernt, Kathrin/L-1826-2016
OI Bernt, Kathrin/0000-0002-5400-0482
FU National Institutes of Health [R01DK082889, R01CA140575, K01DK088868,
RC2CA148222, P50CA127003]
FX This work was supported by National Institutes of Health grants
R01DK082889 (R.A.S.), R01CA140575 (S.A.A.), K01DK088868 (M.V.),
RC2CA148222 (R.A.S. and S.A.A.), and P50CA127003.
NR 58
TC 12
Z9 14
U1 0
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD MAY
PY 2013
VL 33
IS 9
BP 1735
EP 1745
DI 10.1128/MCB.01463-12
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 121VS
UT WOS:000317273300005
PM 23428873
ER
PT J
AU Li, J
Li, X
Liu, E
Copeland, P
Freudenreich, O
Goff, DC
Henderson, DC
Song, XQ
Fan, XD
AF Li, Jie
Li, Xue
Liu, Emily
Copeland, Paul
Freudenreich, Oliver
Goff, Donald C.
Henderson, David C.
Song, Xueqin
Fan, Xiaoduo
TI No effect of adjunctive, repeated dose intranasal insulin treatment on
body metabolism in patients with schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Intranasal insulin; Schizophrenia; Body composition; Lipids
ID RESTING ENERGY-EXPENDITURE; PIK3C3 PROMOTER VARIANT; FOOD-INTAKE;
DIFFERENTIAL SENSITIVITY; INTRAVENTRICULAR INSULIN; GLUCOSE-TOLERANCE;
WEIGHT-GAIN; BRAIN; OBESITY; MEN
AB Objective: This study examined the effect of adjunctive intranasal insulin therapy on body metabolism in patients with schizophrenia.
Method: Each subject had a DSM-IV diagnosis of schizophrenia or schizoaffective disorder and had been on stable dose of antipsychotic agent for at least one month. In an 8-week randomized, double-blind, placebo-controlled study, subjects received either intranasal insulin (40 IU 4 times per day) or placebo. The whole body dual-energy X-ray absorptiometry (DXA) was used to assess body composition. Lipid particles were assessed using nuclear magnetic resonance (NMR) spectroscopy. All assessments were conducted at baseline, and repeated at week 8.
Results: A total number of 39 subjects completed the study (18 in the insulin group, 21 in the placebo group). There were no significant differences between the two groups in week 8 changes for body weight, body mass index, waist circumference, as well as various measures of lipid particles (p's>0.100). The DXA assessment showed no significant differences between the two groups in week 8 changes for fat mass, lean mass or total mass (p's>0.100).
Conclusion: In the present study, adjunctive therapy of intranasal insulin did not seem to improve body metabolism in patients with schizophrenia. The implications for future studies were discussed. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Li, Jie; Song, Xueqin; Fan, Xiaoduo] Univ Massachusetts, Sch Med, Psychot Disorders Program, UMass Mem Med Ctr, Worcester, MA 01605 USA.
[Li, Jie] Tianjin Med Univ, Dept Psychiat, Tianjin, Peoples R China.
[Li, Xue; Song, Xueqin] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China.
[Liu, Emily] Partners Community Healthcare Inc, Haverhill, MA USA.
[Copeland, Paul] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
[Freudenreich, Oliver; Henderson, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Schizophrenia Program, Boston, MA USA.
[Goff, Donald C.] NYU, Sch Med, Dept Psychiat, New York, NY USA.
RP Song, XQ (reprint author), Univ Massachusetts, Sch Med, UMass Mem Med Ctr, Worcester, MA 01605 USA.
EM xueqin.song@umassmed.edu; xiaoduo.fan@umassmed.edu
FU National Institutes of Health [5K23MH082098]; NARSAD; National
Institutes of Health, National Center for Research Resources General
Clinical Research Centers Program (MGH Clinical Research Center)
[M01-RR-01066, UL1 RR025758-01]; Eli Lilly and Company; Eli Lilly;
AstraZeneca; Bristol-Myer-Squibb; Janssen; Pfizer; Cephalon;
Bristol-Myers Squibb; Indevus Pharmaceuticals; H. Lundbeck;
Schering-Plough; Takeda; Biovail; Sovay; Hoffman-La Roche; Cypress;
Dainippon Sumitomo; Abbott Laboratories; Genentech; Novartis; PamLab;
GlaxoSmithKline; Endo Pharmaceuticals; Solvay; Covance; Alkermis
FX This study was supported by grant 5K23MH082098 from the National
Institutes of Health (Dr. Fan), the NARSAD Young Investigator Award (Dr.
Fan), grant M01-RR-01066 and grant UL1 RR025758-01 from the National
Institutes of Health, National Center for Research Resources General
Clinical Research Centers Program (MGH Clinical Research Center), and an
investigator initiated trial grant from the Eli Lilly and Company (Dr.
Fan).; Dr. Fan has received research support or honoraria from Eli
Lilly, AstraZeneca, Bristol-Myer-Squibb, Janssen, and Pfizer. Dr.
Freudenreich has received research support or honoraria from
AstraZeneca, Bristol-Myer-Squibb, Janssen, Eli Lilly, Cephalon and
Pfizer. Dr. Goff has received research support or honoraria from
Bristol-Myers Squibb, Indevus Pharmaceuticals, H. Lundbeck,
Schering-Plough, Eli Lilly, Takeda, Biovail, Sovay, Hoffman-La Roche,
Cypress, Dainippon Sumitomo, Abbott Laboratories, Genentech, Pfizer,
Janssen, Novartis, PamLab, and GlaxoSmithKline and Endo Pharmaceuticals.
He served on a DSMB for Otsuka. Dr. Henderson has received research
support or honoraria from Takeda, Janssen, Solvay, Novartis, Covance,
Alkermis, and Pfizer. Dr. Copeland serves as a consultant for Sanofi.
Drs. J Li, X Li, Liu, Song report no competing interests.
NR 41
TC 3
Z9 3
U1 1
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
EI 1573-2509
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD MAY
PY 2013
VL 146
IS 1-3
BP 40
EP 45
DI 10.1016/j.schres.2013.01.034
PG 6
WC Psychiatry
SC Psychiatry
GA 122RU
UT WOS:000317336500007
PM 23434504
ER
PT J
AU Woodberry, KA
McFarlane, WR
Giuliano, AJ
Verdi, MB
Cook, WL
Faraone, SV
Seidman, LJ
AF Woodberry, Kristen A.
McFarlane, William R.
Giuliano, Anthony J.
Verdi, Mary B.
Cook, William L.
Faraone, Stephen V.
Seidman, Larry J.
TI Change in neuropsychological functioning over one year in youth at
clinical high risk for psychosis
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Prodrome; Cognition; Longitudinal; Schizophrenia; Decline; PIER
ID ASSERTIVE COMMUNITY TREATMENT; SMELL IDENTIFICATION TEST; 1ST EPISODE;
FOLLOW-UP; 1ST-EPISODE SCHIZOPHRENIA; TEST-PERFORMANCE; INDIVIDUALS;
GENETICS; PRODROME; PEOPLE
AB Schizophrenia and related psychotic disorders are associated with significant neuropsychological (NP) impairments. Yet the onset and developmental evolution of these impairments remains incompletely characterized. This study examined NP functioning over one year in a sample of youth at clinical high risk (CHR) for psychosis participating in a treatment study. We assessed functioning across six cognitive domains at two time points in a sample of 53 CHR and 32 healthy comparison (HC) subjects. Linear regression of HC one-year scores was used to predict one-year performance for CHR from baseline scores and relevant demographic variables. We used raw scores and MANOVAs of the standardized residuals to test for progressive impairment over time. NP functioning of CHR at one year fell significantly below predicted levels. Effects were largest and most consistent for a failure of normative improvement on tests of executive function. CHR who reached the highest positive symptom rating (6, severe and psychotic) on the Structured Interview of Prodromal Syndromes after the baseline assessment (n=10/53) demonstrated a particularly large (d=-1.89), although non-significant, discrepancy between observed and predicted one-year verbal memory test performance. Findings suggest that, although much of the cognitive impairment associated with psychosis is present prior to the full expression of the psychotic syndrome, some progressive NP impairments may accompany risk for psychosis and be greatest for those who develop psychotic level symptoms. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Woodberry, Kristen A.; Giuliano, Anthony J.; Seidman, Larry J.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA USA.
[Woodberry, Kristen A.; Giuliano, Anthony J.; Seidman, Larry J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[McFarlane, William R.; Verdi, Mary B.; Cook, William L.] Maine Med Ctr, Dept Psychiat, Portland, ME 04102 USA.
[Faraone, Stephen V.] SUNY Syracuse, Med Genet Res Ctr, Syracuse, NY USA.
[Faraone, Stephen V.] SUNY Syracuse, Upstate Med Univ, Dept Psychiat, Syracuse, NY USA.
[Seidman, Larry J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA.
RP Woodberry, KA (reprint author), Commonwealth Res Ctr, 75 Fenwood Rd, Boston, MA 02115 USA.
EM kwoodber@bidmc.harvard.edu
OI Faraone, Stephen/0000-0002-9217-3982
FU Sackler Scholar Programme in Psychobiology; Harvard Graduate Society
Dissertation Completion Fellowship; Commonwealth Research Center of the
Massachusetts Department of Mental Health [SCDMH82101008006]; NIMH [NIMH
P50 MH080272-02, NIMH 1 U01 MH081928-01A1, RO1MH065367]; Sidney R. Baer
Jr. Foundation; Robert Wood Johnson Foundation
FX Kristen Woodberry was supported by the Sackler Scholar Programme in
Psychobiology and a Harvard Graduate Society Dissertation Completion
Fellowship. Kristen Woodberry, Anthony Giuliano, and Larry Seidman were
also supported by the Commonwealth Research Center of the Massachusetts
Department of Mental Health (SCDMH82101008006), NIMH funding to Larry
Seidman, PI: (clinical core of NIMH P50 MH080272-02 [McCarley overall
PI], NIMH 1 U01 MH081928-01A1), and the Sidney R. Baer Jr. Foundation.
Mary Verdi, William Cook, and William McFarlane were supported by
funding to the PIER program, William McFarlane, PI: (NIMH RO1MH065367)
and the Robert Wood Johnson Foundation.
NR 62
TC 10
Z9 11
U1 10
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD MAY
PY 2013
VL 146
IS 1-3
BP 87
EP 94
DI 10.1016/j.schres.2013.01.017
PG 8
WC Psychiatry
SC Psychiatry
GA 122RU
UT WOS:000317336500014
PM 23434505
ER
PT J
AU Oribe, N
Hirano, Y
Kanba, S
del Re, EC
Seidman, LJ
Mesholam-Gately, R
Spencer, KM
McCarley, RW
Niznikiewicz, MA
AF Oribe, Naoya
Hirano, Yoji
Kanba, Shigenobu
del Re, Elisabetta C.
Seidman, Larry J.
Mesholam-Gately, Raquelle
Spencer, Kevin M.
McCarley, Robert W.
Niznikiewicz, Margaret A.
TI Early and late stages of visual processing in individuals in prodromal
state and first episode schizophrenia: An ERP study
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE EEG; Prodromal state; P300; N1; P1; Schizophrenia
ID ULTRA-HIGH RISK; NEURAL ANOMALIES; P300 AMPLITUDE; PSYCHOSIS; SYMPTOMS;
DEFICITS; SCALE
AB Background: P300 deficits in schizophrenia patients are well established, especially in the auditory modality. Several studies have also reported P300 abnormalities in schizophrenia in visual tasks, but these findings are inconsistent. Furthermore, reports on P300 in visual modality in prodromal subjects are very limited. While P300 indexes relatively late and complex cognitive functions such as context updating in working memory, sensory-evoked components such as the P1/N1 primarily index early stages of perceptual processing. Several previous studies suggest that P300 reduction in schizophrenia patients may be dissociable from these earlier components. Therefore, in this study, we measured the P300 component as well as the P1/N1 in a visual odd-ball paradigm in prodromal subjects and first episode schizophrenia patients, and compared them with those of healthy controls.
Method: Visual P300 and P1/N1 were obtained from prodromal (PRO, n=23), first episode schizophrenia patients (SZ, n=17), and healthy control subjects (HC, n=31), who silently counted infrequent target stimuli ("X") amid standard stimuli ("Y") presented on the screen while 64-channel EEG was recorded.
Results: Both PRO and SZ subjects showed reduced P300 amplitudes and delayed P300 peak latencies in comparison to control subjects. On the other hand, N1 amplitude was significantly reduced only in SZ but not in PRO. Increased severity of positive symptoms was significantly associated with smaller P300 amplitude in PRO.
Conclusions: These results suggest that visual P300 is affected already at the prodromal stage and could be a marker of the prodromal phase of schizophrenia. Published by Elsevier B. V.
C1 [Oribe, Naoya; Hirano, Yoji; del Re, Elisabetta C.; Spencer, Kevin M.; McCarley, Robert W.; Niznikiewicz, Margaret A.] Harvard Univ, Clin Neurosci Div, VA Boston Healthcare Syst, Brockton Div,Dept Psychiat,Lab Neurosci,Med Sch, Brockton, MA 02301 USA.
[Oribe, Naoya; Hirano, Yoji; Kanba, Shigenobu] Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Fukuoka 812, Japan.
[Seidman, Larry J.; Mesholam-Gately, Raquelle] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Seidman, Larry J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Niznikiewicz, MA (reprint author), Boston VA Healthcare Syst, Brockton Div, Lab Neurosci, Dept Psychiat,Clin Neurosci Div, 940 Belmont St, Brockton, MA 02301 USA.
EM Margaret_Niznikiewicz@hms.harvard.edu
RI McCarley, Robert/N-5562-2014;
OI McCarley, Robert/0000-0001-5705-7495; Spencer, Kevin/0000-0002-5500-7627
FU (Boston CIDAR) from National Institutes of Health [P50 MH080272, R01
MH40799]; Strategic Young Researcher Overseas Visits Program for
Accelerating Brain Circulation [S2208]; Japan Society for the Promotion
of Science [22791129]; Fund for Pharmacopsychiatry Research from SENSHIN
Medical Research Foundation
FX This work was supported in part by P50 MH080272 (Boston CIDAR, RWM PI)
and R01 MH40799 (RWM) from National Institutes of Health; Strategic
Young Researcher Overseas Visits Program for Accelerating Brain
Circulation S2208 (SK) and Grant-in-Aid for Young Scientists B 22791129
(YH) from Japan Society for the Promotion of Science; Fund for
Pharmacopsychiatry Research (YH) from SENSHIN Medical Research
Foundation.
NR 29
TC 9
Z9 10
U1 1
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD MAY
PY 2013
VL 146
IS 1-3
BP 95
EP 102
DI 10.1016/j.schres.2013.01.015
PG 8
WC Psychiatry
SC Psychiatry
GA 122RU
UT WOS:000317336500015
PM 23433503
ER
PT J
AU Romo-Nava, F
Hoogenboom, WS
Pelavin, PE
Alvarado, JL
Bobrow, H
MacMaster, FP
Keshavan, M
McCarley, RW
Shenton, ME
AF Romo-Nava, F.
Hoogenboom, W. S.
Pelavin, P. E.
Alvarado, J. L.
Bobrow, H.
MacMaster, F. P.
Keshavan, M.
McCarley, R. W.
Shenton, M. E.
TI Pituitary volume in schizophrenia spectrum disorders
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; First-episode; Schizotypal; Pituitary volume; MRI
ID SCHIZOTYPAL PERSONALITY-DISORDER; FIRST EPISODE SCHIZOPHRENIA; ADRENAL
AXIS FUNCTION; GRAY-MATTER VOLUME; LEFT TEMPORAL-LOBE; 1ST-EPISODE
SCHIZOPHRENIA; GYRUS VOLUME; MRI ABNORMALITIES; NEGATIVE SYMPTOMS;
PLANUM TEMPORALE
AB Introduction: There is converging evidence supporting hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in schizophrenia spectrum disorders (SSD), such as schizotypal personality disorder (SPD), first-episode schizophrenia (FESZ) and chronic schizophrenia (CHSZ). Such an aberrant HPA activity might have volumetric consequences on the pituitary gland. However, previous magnetic resonance imaging (MRI) studies assessing pituitary volume (PV) in SSD are conflicting. The main objective of this study was to examine further PV in SSD.
Methods: PV were manually traced on structural MRIs in 137 subjects, including subjects with SPD (n = 40), FESZ (n = 15), CHSZ (n = 15), and HC (n = 67). We used an ANCOVA to test PV between groups and gender while controlling for inter-subject variability in age, years of education, socioeconomic status, and whole brain volume.
Results: Overall, women had larger PV than men, and within the male sample all SSD subjects had smaller PV than HC, statistically significant only for the SPD group. In addition, dose of medication, illness duration and age of onset were not associated with PV.
Conclusion: Chronic untreated HPA hyperactivity might account for smaller PV in SPD subjects, whereas the absence of PV changes in FESZ and CHSZ patients might be related to the normalizing effects of antipsychotics on PV. SPD studies offer a way to examine HPA related alterations in SSD without the potential confounds of medication effects. Published by Elsevier B.V.
C1 [Romo-Nava, F.; Hoogenboom, W. S.; Pelavin, P. E.; Alvarado, J. L.; Bobrow, H.; McCarley, R. W.; Shenton, M. E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Psychiat Neuroimaging Lab, Boston, MA 02115 USA.
[Romo-Nava, F.] Univ Nacl Autonoma Mexico, Fac Med, Dept Psiquiatria & Salud Mental, Mexico City 04510, DF, Mexico.
[MacMaster, F. P.] Univ Calgary, Calgary, AB, Canada.
[Keshavan, M.] Harvard Univ, Sch Med, Dept Psychiat, Beth Israel Deaconess Hosp MMCH, Boston, MA 02115 USA.
[McCarley, R. W.; Shenton, M. E.] Harvard Univ, Sch Med, VA Boston HealthCare Syst,Brockton Div, Clin Neurosci Div,Lab Neurosci,Dept Psychiat, Boston, MA 02115 USA.
[Romo-Nava, F.] Inst Nacl Psiquiatria Dr Ramon de la Fuente, Clin Trastornos Afect, Mexico City, DF, Mexico.
RP Shenton, ME (reprint author), Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA.
EM shenton@bwh.harvard.edu
RI McCarley, Robert/N-5562-2014
OI McCarley, Robert/0000-0001-5705-7495
FU US Department of Veterans Affairs; VA Schizophrenia Center; US National
Institutes of Health [R01 MH050740, K05 MH070047, P50 MH080272-CIDAR,
R01 MH040799, R01 MH052807, R01 MH064023]
FX This work was supported, in part, by grants from the US Department of
Veterans Affairs (Merit Review Awards to MES and RWM, and the VA
Schizophrenia Center Grant to RWM and MES), the US National Institutes
of Health (R01 MH050740 and K05 MH070047 to MES; P50 MH080272-CIDAR
award to MES and RWM; R01 MH040799 and R01 MH052807 to RWM; and R01
MH064023 to MK), and the Cuthbertson and Fischer Chair in Paediatric
Mental Health (to FPM).
NR 53
TC 6
Z9 6
U1 2
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD MAY
PY 2013
VL 146
IS 1-3
BP 301
EP 307
DI 10.1016/j.schres.2013.02.024
PG 7
WC Psychiatry
SC Psychiatry
GA 122RU
UT WOS:000317336500045
PM 23522905
ER
PT J
AU Rissling, AJ
Park, SH
Young, JW
Rissling, MB
Sugar, CA
Sprock, J
Mathias, DJ
Pela, M
Sharp, RF
Braff, DL
Light, GA
AF Rissling, Anthony J.
Park, Sung-Hyouk
Young, Jared W.
Rissling, Michelle B.
Sugar, Catherine A.
Sprock, Joyce
Mathias, Daniel J.
Pela, Marlena
Sharp, Richard F.
Braff, David L.
Light, Gregory A.
TI Demand and modality of directed attention modulate "pre-attentive"
sensory processes in schizophrenia patients and nonpsychiatric controls
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Attention; Event related potential; Modulation; Mismatch negativity;
P300
ID EVENT-RELATED POTENTIALS; MISMATCH NEGATIVITY GENERATION;
SELECTIVE-ATTENTION; TREATING SCHIZOPHRENIA; 1ST-EPISODE PSYCHOSIS;
CLINICAL-TRIALS; TASK DEMANDS; HIGH-RISK; DEFICITS; BRAIN
AB Background: Mismatch negativity(MNN) and P3a are event related potential (ERP) measures of early sensory information processing. These components are usually conceptualized as being "pre-attentive" and therefore immune to changes with variations in attentional functioning. This study aimed to determine whether manipulations of attention influence the amplitudes and latencies of MMN and P3a and, if so, the extent to which these early sensory processes govern concurrent behavioral vigilance performance in schizophrenia patients and normal subjects.
Methods: Schizophrenia patients (SZ; n = 20) and Nonpsychiatric Control Subjects (NCS; n = 20) underwent auditory ERP testing to assess MMN and P3a across 4 EEG recording sessions in which attentional demand (low vs. high) and sensory modality of directed attention (visual vs. auditory) were experimentally varied.
Results: Across conditions, SZ patients exhibited deficits in MMN and P3a amplitudes. Significant amplitude and latency modulation were observed in both SZ and NCS but there were no group-by-condition interactions. The amount of MMN amplitude attenuation from low-to high-demand tasks was significantly associated with increased vigilance performance in both SZ and NCS groups (r = -0.67 and r = -0.60). Several other robust associations were also observed among neurophysiologic, clinical and cognitive variables.
Conclusions: Attentional demand and modality of directed attention significantly influence the amplitude and latencies of "pre-attentive" ERP components in both SZ and NCS. Deficits in MMN and P3a were not "normalized" when attention was directed to the auditory stimuli in schizophrenia patients. The adaptive modulation of early sensory information processing appears to govern concurrent attentional task performance. The temporal window reflecting automatic sensory discrimination as indexed as MMN and P3a may serve as a gateway to some higher order cognitive operations necessary for psychosocial functioning. Published by Elsevier B.V.
C1 [Rissling, Anthony J.; Park, Sung-Hyouk; Young, Jared W.; Rissling, Michelle B.; Sprock, Joyce; Mathias, Daniel J.; Pela, Marlena; Sharp, Richard F.; Braff, David L.; Light, Gregory A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Park, Sung-Hyouk] Chookryoung Evangel Hosp, Dept Psychiat, Namyangju, Gyeonggi, South Korea.
[Young, Jared W.; Sprock, Joyce; Mathias, Daniel J.; Pela, Marlena; Braff, David L.; Light, Gregory A.] VA San Diego Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 22, San Diego, CA USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA USA.
[Sugar, Catherine A.] Greater Los Angeles VA Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 22, Los Angeles, CA USA.
RP Light, GA (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM glight@ucsd.edu
FU National Institute of Mental Health [MH079777, MH042228, MH065571];
Department of Veteran Affairs (VISN 22 Mental Illness Research,
Education, and Clinical Center); NARSAD
FX This work was supported by the National Institute of Mental Health
(MH079777, MH042228 and MH065571), the Department of Veteran Affairs
(VISN 22 Mental Illness Research, Education, and Clinical Center) and
NARSAD. The funding agencies had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 99
TC 22
Z9 22
U1 2
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
EI 1573-2509
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD MAY
PY 2013
VL 146
IS 1-3
BP 326
EP 335
DI 10.1016/j.schres.2013.01.035
PG 10
WC Psychiatry
SC Psychiatry
GA 122RU
UT WOS:000317336500049
PM 23490760
ER
PT J
AU Shores, M
AF Shores, Molly
TI TESTOSTERONE AT THE HEART OF DISEASE - THE ASSOCIATION BETWEEN
TESTOSTERONE AND CARDIOVASCULAR EVENTS
SO ANDROLOGY
LA English
DT Meeting Abstract
C1 [Shores, Molly] Univ Washington, Seattle, WA 98195 USA.
[Shores, Molly] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 1
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-2919
J9 ANDROLOGY-US
JI Andrology
PD MAY
PY 2013
VL 1
SU 2
SI SI
BP 33
EP 33
PG 1
WC Andrology
SC Endocrinology & Metabolism
GA 116WD
UT WOS:000316912900013
ER
PT J
AU Jarrett, RB
Minhajuddin, A
Kangas, JL
Friedman, ES
Callan, JA
Thase, ME
AF Jarrett, Robin B.
Minhajuddin, Abu
Kangas, Julie L.
Friedman, Edward S.
Callan, Judith A.
Thase, Michael E.
TI Acute phase cognitive therapy for recurrent major depressive disorder:
Who drops out and how much do patient skills influence response?
SO BEHAVIOUR RESEARCH AND THERAPY
LA English
DT Article
DE Depression; Cognitive therapy; Predictors; Patient skills; Response
patterns; Attrition
ID COLLABORATIVE RESEARCH-PROGRAM; BEHAVIORAL THERAPY; PRIVATE-PRACTICE;
MOOD DISORDERS; NIMH-TREATMENT; PREDICTORS; INVENTORY; VARIABLES;
ALLIANCE; PHARMACOTHERAPY
AB Objective: The aims were to predict cognitive therapy (CT) noncompletion and to determine, relative to other putative predictors, the extent to which the patient skills in CT for recurrent major depressive disorder predicted response in a large, two-site trial.
Method: Among 523 outpatients aged 18-70, exposed to 12-14 weeks of CT, 21.6% dropped out. Of the 410 completers, 26.1% did not respond. To predict these outcomes, we conducted logistic regression analyses of demographics, pre-treatment illness characteristics and psychosocial measures, and mid-treatment therapeutic alliance.
Results: The 17-item Hamilton Rating Scale for Depression (HRSD17) scores at entry predicted dropout and nonresponse. Patients working for pay, of non-Hispanic white race, who were older, or had more education were significantly more likely to complete. Controlling for HRSD17, significant predictors of nonresponse included: lower scores on the Skills of Cognitive Therapy-Observer Version (SoCT-O), not working for pay, history of only two depressive episodes, greater pre-treatment social impairment. Mid-phase symptom reduction was a strong predictor of final outcome.
Conclusions: These prognostic indicators forecast which patients tend to be optimal candidates for standard CT, as well as which patients may benefit from changes in therapy, its focus, or from alternate modalities of treatment. Pending replication, the findings underscore the importance of promoting patients' understanding and use of CT skills, as well as reducing depressive symptoms early. Future research may determine the extent to which these findings generalize to other therapies, providers who vary in competency, and patients with other depressive subtypes or disorders. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Jarrett, Robin B.; Kangas, Julie L.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
[Minhajuddin, Abu] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA.
[Friedman, Edward S.; Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Callan, Judith A.] Univ Pittsburgh, Sch Nursing, Dept Hlth & Community Syst, Pittsburgh, PA 15260 USA.
[Thase, Michael E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Jarrett, RB (reprint author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM Robin.Jarrett@UTSouthwestern.edu
FU NCATS NIH HHS [KL2 TR000146, UL1 TR000005]; NIMH NIH HHS [R01 MH069619,
K24 MH001571, R01 MH058356, R01 MH058397, R01 MH069618]; NINR NIH HHS
[T32 NR008857]
NR 50
TC 17
Z9 17
U1 1
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0005-7967
J9 BEHAV RES THER
JI Behav. Res. Ther.
PD MAY
PY 2013
VL 51
IS 4-5
BP 221
EP 230
DI 10.1016/j.brat.2013.01.006
PG 10
WC Psychology, Clinical
SC Psychology
GA 115RW
UT WOS:000316830600006
PM 23485420
ER
PT J
AU Neuhaus, V
Swellengrebel, CHJ
Bossen, JKJ
Ring, D
AF Neuhaus, Valentin
Swellengrebel, Christiaan H. J.
Bossen, Jeroen K. J.
Ring, David
TI What are the Factors Influencing Outcome Among Patients Admitted to a
Hospital With a Proximal Humeral Fracture?
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID BODY-MASS INDEX; HIP FRACTURE; NONCARDIAC SURGERY; KNEE ARTHROPLASTY;
CARDIAC EVENTS; RISK-FACTORS; MORTALITY; PREDICTORS; CARE;
HEMIARTHROPLASTY
AB Fracture of the proximal humerus is common in older patients during the decline of their physical health.
Our purpose was to evaluate the association between specific risk factors in patients with fractures of the proximal humerus and any inpatient adverse events, mortality, and discharge to a short-term or long-term care facility.
The National Hospital Discharge Survey (NHDS) provided estimates of all adult patients who were admitted to hospitals after fractures of the proximal humerus in the United States between 1990 and 2007. The influences of sex, age, days of care, diagnosis and procedures (based on ICD-9 codes) on inpatient adverse events and death, and discharge to a short-term or long-term care facility, were studied in bivariate and multivariable analyses.
Among an estimated 867,282 patients admitted for proximal humerus fractures, 20% experienced adverse events, and 2.3% died in the hospital. Older age, concomitant femur and femoral neck fractures or head trauma, operative fracture care, congestive heart failure, and chronic alcoholism were associated with inpatient adverse events. Intubation, acute myocardial infarctions, malignancies, and skull fractures were associated with inpatient deaths. Older age, lower limb fractures, specific comorbidities (obesity, congestive heart failure, dementia), and inpatient adverse events (pneumonia, anemia treated with transfusion) were associated with discharges to short-term or long-term care facilities.
Knowledge of risk factors for inpatient adverse events, mortality, and discharge to facilities can help make treatment decisions, improve overall care, discharge planning, and resource utilization for patients with proximal humeral fractures.
Level II, prognostic study. See Guidelines for Authors for a complete description of levels of evidence.
C1 [Neuhaus, Valentin; Swellengrebel, Christiaan H. J.; Bossen, Jeroen K. J.; Ring, David] Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA.
RP Ring, D (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand & Upper Extrem Serv, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
OI Neuhaus, Valentin/0000-0003-4012-5628
NR 35
TC 13
Z9 14
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
EI 1528-1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD MAY
PY 2013
VL 471
IS 5
BP 1698
EP 1706
DI 10.1007/s11999-013-2876-z
PG 9
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 117NB
UT WOS:000316959100043
PM 23456187
ER
PT J
AU Neuhaus, V
King, J
Hageman, MG
Ring, DC
AF Neuhaus, Valentin
King, John
Hageman, Michiel G.
Ring, David C.
TI Charlson Comorbidity Indices and In-hospital Deaths in Patients with Hip
Fractures
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID EXCESS MORTALITY; TRAUMATIC INJURY; ELDERLY-PATIENTS; RISK;
COMPLICATIONS; VALIDATION; PREDICTORS; COHORT; STABILIZATION;
INFORMATION
AB The Charlson Comorbidity Index (CCI) and its modifications are comorbidity-based measures that predict mortality. It was developed for patients without trauma and inconsistently predicted mortality and adverse events in several previous studies of patients with trauma.
We therefore (1) determined whether the three different CCIs were predictors for in-hospital deaths in patients with hip fractures, (2) verified if the CCI mortality prediction had changed with time, (3) evaluated other predictors of in-hospital death in patients with hip fractures, and (4) determined if the CCI has predicted in-hospital adverse events.
We retrospectively reviewed a nationwide probability sample survey, the National Hospital Discharge Survey. More than 6 million adult patients with hip fractures and their associated comorbidities were scored by the original 1987 CCI, the 1994 age-adjusted CCI, and the 2011 updated, reweighted CCI. The three mortality indices' predictive values and predictors of in-hospital adverse events were compared.
For patients with hip fractures, all three CCI variations predicted in-hospital mortality. The receiver operating curves (ROC) of the models were less than 0.68, but they improved when we used statistical models that included age, sex, concomitant injuries, and other comorbidities not contained in the CCI models (ROC > 0.74). The age-adjusted CCI accuracy was slightly better than the other two CCIs. Adverse events during hospital stays were associated with a higher CCI, pertrochanteric fracture (versus transcervical), abdominal, chest, or head trauma, atrial fibrillation, multiple fractures, female sex, and longer hospital stays; however, the accuracy of this model was poor (ROC = 0.65).
While all three CCI variations predicted in-hospital mortality in patients with hip fractures, other factors may be of value in patients with trauma.
C1 [Neuhaus, Valentin; King, John; Hageman, Michiel G.; Ring, David C.] Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Yawkey Ctr, Boston, MA 02114 USA.
RP Ring, DC (reprint author), Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
OI Neuhaus, Valentin/0000-0003-4012-5628
NR 33
TC 33
Z9 35
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD MAY
PY 2013
VL 471
IS 5
BP 1712
EP 1719
DI 10.1007/s11999-012-2705-9
PG 8
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 117NB
UT WOS:000316959100045
PM 23179125
ER
PT J
AU Kazer, MW
Psutka, SP
Latini, DM
Bailey, DE
AF Kazer, Meredith W.
Psutka, Sarah P.
Latini, David M.
Bailey, Donald E., Jr.
TI Psychosocial aspects of active surveillance
SO CURRENT OPINION IN UROLOGY
LA English
DT Review
DE anxiety; psychosocial disease burden; self-management; support;
uncertainty
ID RISK PROSTATE-CANCER; QUALITY-OF-LIFE; RADICAL PROSTATECTOMY; MEN;
UNCERTAINTY; MANAGEMENT; CARCINOMA; INTERVENTION; ACCEPTANCE; SELECTION
AB Purpose of review
To summarize the literature on psychosocial responses to active surveillance as well as educational and support strategies to promote adherence.
Recent findings
There are two prevalent responses among men undergoing active surveillance; anxiety and uncertainty. The education of a patient about low-risk prostate cancer as well as the inquiry by the physician into patient's priorities and goals with respect to their prostate cancer diagnosis provide opportunities to facilitate a collaborative relationship between the physician and the patient. Supplemental support services for men undergoing active surveillance, including support groups and Internet-based interventions continue to be researched in relation to their role in promoting adherence to active surveillance.
Summary
Active surveillance continues to remain a highly valued management approach for men with early stage prostate cancer. However, it is suggested that the psychosocial burden of living with prostate cancer plays a substantial role in adherence to active surveillance and outcomes of men with the disease. Effective clinician education and counseling, as well as the referral for supplemental support services must be implemented and documented in future research studies and clinical practice.
C1 [Kazer, Meredith W.] Fairfield Univ, Sch Nursing, Fairfield, CT 06824 USA.
[Psutka, Sarah P.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
[Latini, David M.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.
[Bailey, Donald E., Jr.] Duke Univ, Sch Nursing, Duke Ctr Aging, Durham, NC USA.
RP Kazer, MW (reprint author), Fairfield Univ, Sch Nursing, 1073 North Benson Rd Fairfield, Fairfield, CT 06824 USA.
EM mkazer@fairfield.edu
OI Latini, David/0000-0002-6161-4861
NR 35
TC 16
Z9 16
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0963-0643
J9 CURR OPIN UROL
JI Curr. Opin. Urol.
PD MAY
PY 2013
VL 23
IS 3
BP 273
EP 277
DI 10.1097/MOU.0b013e32835eff24
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 118SP
UT WOS:000317046400014
PM 23422588
ER
PT J
AU Macrae, F
Ahnen, DJ
AF Macrae, Finlay
Ahnen, Dennis J.
TI Acceleration in colorectal carcinogenesis: the hare, the tortoise or
myth?
SO GUT
LA English
DT Editorial Material
ID MUTYH-ASSOCIATED POLYPOSIS; SURVEILLANCE COLONOSCOPY; COLON-CANCER;
ADENOMAS
C1 [Macrae, Finlay] Royal Melbourne Hosp, Dept Colorectal Med & Genet, Melbourne, Vic 3050, Australia.
[Ahnen, Dennis J.] Univ Colorado, Sch Med, Denver VA Med Ctr, Denver, CO USA.
RP Macrae, F (reprint author), Royal Melbourne Hosp, Dept Colorectal Med & Genet, POB 2010, Melbourne, Vic 3050, Australia.
EM Finlay.macrae@mh.org.au
NR 20
TC 1
Z9 1
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
J9 GUT
JI Gut
PD MAY
PY 2013
VL 62
IS 5
BP 657
EP 659
DI 10.1136/gutjnl-2012-302880
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 117YV
UT WOS:000316990200001
PM 22961679
ER
PT J
AU Thomas, MP
Lieberman, J
AF Thomas, Marshall P.
Lieberman, Judy
TI Live or let die: posttranscriptional gene regulation in cell stress and
cell death
SO IMMUNOLOGICAL REVIEWS
LA English
DT Review
DE stress; apoptosis; pre-mRNA splicing; translation; miRNA
ID ENDOPLASMIC-RETICULUM STRESS; MESSENGER-RNA DECAY;
THIOREDOXIN-INTERACTING PROTEIN; INITIATION-FACTOR MODIFICATIONS;
DNA-DAMAGE RESPONSE; TRANSLATION INITIATION; ER STRESS; MAMMALIAN-CELLS;
HEAT-SHOCK; INDUCED APOPTOSIS
AB Studies of the regulation of gene expression historically focused on transcription. However, during stress and apoptosis, profound gene expression changes occur more rapidly and globally than is possible by regulating transcription. Posttranscriptional changes in mRNA processing and translation in response to diverse stresses shut down most protein translation to conserve energy and lead to rapid remodeling of the proteome to promote repair. Pre-mRNA splicing and mRNA stability are fundamentally altered under some stress conditions. Stress pathways coordinate a cytoprotective repair response, while simultaneously initiating signaling that can ultimately trigger cell death. How the cell mediates the decision between repair and apoptosis is largely not understood. In some stresses, microRNAs may tip the balance. Here, we review what is known about posttranscriptional gene regulation during stress, focusing on what is still unknown and how new technologies might be used to understand what changes are most physiologically important in different forms of stress and death.
C1 [Thomas, Marshall P.; Lieberman, Judy] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
[Thomas, Marshall P.; Lieberman, Judy] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Lieberman, J (reprint author), 200 Longwood Ave,WAB 255, Boston, MA 02115 USA.
EM judy.lieberman@childrens.harvard.edu
RI Lieberman, Judy/A-2717-2015
NR 128
TC 16
Z9 17
U1 1
U2 36
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-2896
J9 IMMUNOL REV
JI Immunol. Rev.
PD MAY
PY 2013
VL 253
SI SI
BP 237
EP 252
DI 10.1111/imr.12052
PG 16
WC Immunology
SC Immunology
GA 119DX
UT WOS:000317078800017
PM 23550650
ER
PT J
AU Montgomery, AE
Hill, LL
Kane, V
Culhane, DP
AF Montgomery, Ann Elizabeth
Hill, Lindsay L.
Kane, Vincent
Culhane, Dennis P.
TI HOUSING CHRONICALLY HOMELESS VETERANS: EVALUATING THE EFFICACY OF A
HOUSING FIRST APPROACH TO HUD-VASH
SO JOURNAL OF COMMUNITY PSYCHOLOGY
LA English
DT Article
ID PSYCHIATRIC DISABILITIES; MENTAL-ILLNESS; INDIVIDUALS; COMMUNITY;
SUPPORTS
AB Rapidly placing homeless Veterans with severe mental illness into permanent housing is one important goal of the U.S. Department of Housing and Urban Development-Veterans Affairs Supportive Housing (HUD-VASH) program; however, no research has tested whether an explicit organizational alignment of this goal with revised practices could improve outcomes. A demonstration project initiated in 2010 to reform housing placement practices in a metropolitan area enabled researchers to compare an explicit Housing First programoffering immediate permanent housing without requiring treatment compliance, abstinence, or housing readinesswith a treatment-first program for 177 homeless Veterans. The Housing First initiative successfully reduced time to housing placement, from 223 to 35 days, housing retention rates were significantly higher among Housing First tenants, and emergency room use declined significantly among the Housing First cohort. The results suggest that a national Housing First model for the VA would be associated with improved outcomes for Veterans experiencing homelessness.
C1 [Montgomery, Ann Elizabeth; Hill, Lindsay L.; Kane, Vincent; Culhane, Dennis P.] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Washington, DC USA.
RP Montgomery, AE (reprint author), Natl Ctr Homelessness Vet, 4100 Chester Ave,Suite 201, Philadelphia, PA 19104 USA.
EM montga@upenn.edu
NR 14
TC 8
Z9 8
U1 0
U2 33
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0090-4392
J9 J COMMUNITY PSYCHOL
JI J. Community Psychol.
PD MAY
PY 2013
VL 41
IS 4
BP 505
EP 514
DI 10.1002/jcop.21554
PG 10
WC Public, Environmental & Occupational Health; Psychology,
Multidisciplinary; Social Work
SC Public, Environmental & Occupational Health; Psychology; Social Work
GA 113TW
UT WOS:000316692600009
ER
PT J
AU Vassoler, FM
McCarthy, DM
White, SL
Darnell, SB
Sangrey, GR
Schmidt, HD
Bhide, PG
Pierce, RC
Sadri-Vakili, G
AF Vassoler, F. M.
McCarthy, D. M.
White, S. L.
Darnell, S. B.
Sangrey, G. R.
Schmidt, H. D.
Bhide, P. G.
Pierce, R. C.
Sadri-Vakili, G.
TI Alterations in the epigenome and BDNF expression in response to
self-administration or in utero exposure to cocaine are heritable
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
CT 24th Biennial Meeting of the International-Society-for-Neurochemistry
and the American-Society-for-Neurochemistry
CY APR 20-24, 2013
CL Cancun, MEXICO
SP Int Soc Neurochemistry, Amer Soc Neurochemistry
C1 [Darnell, S. B.; Sangrey, G. R.; Sadri-Vakili, G.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Vassoler, F. M.; White, S. L.; Schmidt, H. D.; Pierce, R. C.] Univ Penn, Philadelphia, PA 19104 USA.
[McCarthy, D. M.; Bhide, P. G.] Florida State Univ, Tallahassee, FL 32306 USA.
NR 0
TC 0
Z9 0
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2013
VL 125
SU 1
SI SI
BP 19
EP 20
PG 2
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 117OB
UT WOS:000316961700034
ER
PT J
AU Sakadzic, S
Mandeville, ET
Devor, A
Yaseen, MA
Musacchiia, JJ
Gagnon, L
Ayata, C
Lo, EH
Dale, AM
Vinogradov, SA
Boas, DA
AF Sakadzic, S.
Mandeville, E. T.
Devor, A.
Yaseen, M. A.
Musacchiia, J. J.
Gagnon, L.
Ayata, C.
Lo, E. H.
Dale, A. M.
Vinogradov, S. A.
Boas, D. A.
TI High resolution in vivo recordings of brain oxygen metabolism
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
CT 24th Biennial Meeting of the International-Society-for-Neurochemistry
and the American-Society-for-Neurochemistry
CY APR 20-24, 2013
CL Cancun, MEXICO
SP Int Soc Neurochemistry, Amer Soc Neurochemistry
C1 [Sakadzic, S.; Mandeville, E. T.; Devor, A.; Yaseen, M. A.; Musacchiia, J. J.; Gagnon, L.; Ayata, C.; Lo, E. H.; Boas, D. A.] Massachusetts Gen Hosp, Charlestown, MA USA.
[Devor, A.; Dale, A. M.] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Vinogradov, S. A.] Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2013
VL 125
SU 1
SI SI
BP 47
EP 47
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 117OB
UT WOS:000316961700087
ER
PT J
AU Kaplan, JM
AF Kaplan, J. M.
TI Tuning the kinetics of synaptic responses: mechanisms regulating release
kinetics in C. elegans
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
CT 24th Biennial Meeting of the International-Society-for-Neurochemistry
and the American-Society-for-Neurochemistry
CY APR 20-24, 2013
CL Cancun, MEXICO
SP Int Soc Neurochemistry, Amer Soc Neurochemistry
C1 [Kaplan, J. M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2013
VL 125
SU 1
SI SI
BP 55
EP 55
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 117OB
UT WOS:000316961700104
ER
PT J
AU Huillard, E
Alberta, J
Phillips, JJ
Griveau, A
Kho, A
Kane, M
Wong, M
Chang, S
Harrington, EP
Israel, M
Stiles, CD
Rowitch, DR
AF Huillard, E.
Alberta, J.
Phillips, J. J.
Griveau, A.
Kho, A.
Kane, M.
Wong, M.
Chang, S.
Harrington, E. P.
Israel, M.
Stiles, C. D.
Rowitch, D. R.
TI ID4 function Antagonizes Olig1 and Olig2 to suppress aggressive
gliomagenesis
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
CT 24th Biennial Meeting of the International-Society-for-Neurochemistry
and the American-Society-for-Neurochemistry
CY APR 20-24, 2013
CL Cancun, MEXICO
SP Int Soc Neurochemistry, Amer Soc Neurochemistry
C1 [Huillard, E.; Griveau, A.; Wong, M.; Chang, S.; Harrington, E. P.; Rowitch, D. R.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA.
[Huillard, E.; Griveau, A.; Wong, M.; Chang, S.; Harrington, E. P.; Rowitch, D. R.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA.
[Huillard, E.; Phillips, J. J.; Griveau, A.; Wong, M.; Chang, S.; Harrington, E. P.; Rowitch, D. R.] Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA USA.
[Alberta, J.; Kane, M.; Stiles, C. D.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Kho, A.] Childrens Hosp Informat Program, Boston, MA USA.
[Israel, M.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Genet, Hanover, NH 03756 USA.
[Israel, M.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pediat, Hanover, NH 03756 USA.
[Huillard, E.] CNRS, CR ICM, UMR7225, Paris, France.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2013
VL 125
SU 1
SI SI
BP 101
EP 101
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 117OB
UT WOS:000316961700200
ER
PT J
AU Mayes, DA
Rizvi, TA
MIller, SJ
Ciraolo, GM
Stemmer-Rachamimov, AO
Ratner, N
AF Mayes, D. A.
Rizvi, T. A.
MIller, S. J.
Ciraolo, G. M.
Stemmer-Rachamimov, A. O.
Ratner, N.
TI Antioxidant rescue of Nf1/Ras-induced defects in myelin and vasculature
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
CT 24th Biennial Meeting of the International-Society-for-Neurochemistry
and the American-Society-for-Neurochemistry
CY APR 20-24, 2013
CL Cancun, MEXICO
SP Int Soc Neurochemistry, Amer Soc Neurochemistry
C1 [Mayes, D. A.; Rizvi, T. A.; MIller, S. J.; Ciraolo, G. M.; Ratner, N.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.
[Stemmer-Rachamimov, A. O.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Stemmer-Rachamimov, A. O.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2013
VL 125
SU 1
SI SI
BP 205
EP 205
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 117OB
UT WOS:000316961700464
ER
PT J
AU Paintlia, AS
Paintlia, MK
Singh, AK
Singh, I
AF Paintlia, A. S.
Paintlia, M. K.
Singh, A. K.
Singh, I.
TI Rho family GTPase inhibition protects immature oligodendrocytes against
cytokine toxicity via PPAR-alfa dependent mechanism
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
CT 24th Biennial Meeting of the International-Society-for-Neurochemistry
and the American-Society-for-Neurochemistry
CY APR 20-24, 2013
CL Cancun, MEXICO
SP Int Soc Neurochemistry, Amer Soc Neurochemistry
C1 [Paintlia, A. S.; Paintlia, M. K.; Singh, I.] Med Univ S Carolina, Charleston, SC USA.
[Singh, A. K.] Ralph H Johnson VA Med Ctr, Dept Pathol & Lab Med, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2013
VL 125
SU 1
SI SI
BP 206
EP 206
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 117OB
UT WOS:000316961700468
ER
PT J
AU Yu, J
Zhu, H
Gattoni-Celli, S
Kindy, MS
AF Yu, J.
Zhu, H.
Gattoni-Celli, S.
Kindy, M. S.
TI Pim-1 kinase inhibits pathological injury by promoting neuroprotective
signaling
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
CT 24th Biennial Meeting of the International-Society-for-Neurochemistry
and the American-Society-for-Neurochemistry
CY APR 20-24, 2013
CL Cancun, MEXICO
SP Int Soc Neurochemistry, Amer Soc Neurochemistry
C1 [Yu, J.; Zhu, H.; Gattoni-Celli, S.; Kindy, M. S.] Med Univ S Carolina, Charleston, SC USA.
[Gattoni-Celli, S.; Kindy, M. S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2013
VL 125
SU 1
SI SI
BP 214
EP 214
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 117OB
UT WOS:000316961700487
ER
PT J
AU Khan, M
Dhammu, TS
Shunmugavel, A
Paintlia, M
Singh, AK
Singh, I
AF Khan, M.
Dhammu, T. S.
Shunmugavel, A.
Paintlia, M.
Singh, A. K.
Singh, I.
TI S-Nitrosoglutathione stimulates mediators of neurorepair following
cerebral ischemia reperfusion injury in rats
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Meeting Abstract
CT 24th Biennial Meeting of the International-Society-for-Neurochemistry
and the American-Society-for-Neurochemistry
CY APR 20-24, 2013
CL Cancun, MEXICO
SP Int Soc Neurochemistry, Amer Soc Neurochemistry
C1 [Khan, M.; Dhammu, T. S.; Shunmugavel, A.; Paintlia, M.; Singh, I.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Singh, A. K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2013
VL 125
SU 1
SI SI
BP 216
EP 216
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 117OB
UT WOS:000316961700493
ER
PT J
AU Joshi, SK
Liu, XH
Samagh, SP
Lovett, DH
Bodine, SC
Kim, HT
Feeley, BT
AF Joshi, Sunil K.
Liu, Xuhui
Samagh, Sanjum P.
Lovett, David H.
Bodine, Sue C.
Kim, Hubert T.
Feeley, Brian T.
TI mTOR regulates fatty infiltration through SREBP-1 and PPAR gamma after a
combined massive rotator cuff tear and suprascapular nerve injury in
rats
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE rotator cuff tear; fatty infiltration; Akt; mTOR signaling; SREBP-1;
PPAR gamma
ID ADIPOSE-TISSUE; MUSCLE ATROPHY; ANIMAL-MODEL; STEM-CELL; EXPRESSION;
REPAIR; SUPRASPINATUS; ADIPOCYTE; RAPAMYCIN; GROWTH
AB Rotator cuff tears (RCTs) are among the most common injuries seen in orthopedic patients. Chronic tears can result in the development of muscular atrophy and fatty infiltration. Despite the prevalence of RCTs, little is known about the underlying molecular pathways that produce these changes. Recently, we have shown that mammalian target of rapamycin (mTOR) signaling plays an important role in muscle atrophy that results from massive RCTs in a rat model. The purpose of this study was therefore to extend our understanding of mTOR signaling and evaluate its role in fatty infiltration after a combined tendon transection and suprascapular nerve denervation surgery. Akt/mTOR signaling was significantly increased and resulted in the up-regulation of two transcription factors: SREBP-1 and PPAR gamma. We also saw an increase in expression of adipogenic markers: C/EBP-alpha and FASN. Upon treatment with rapamycin, an inhibitor of mTOR, we observed a decrease in mTOR signaling, activity of transcription factors, and reduction in fatty infiltration. Therefore, our study suggests that mTOR signaling mediates rotator cuff fatty infiltration via SREBP-1 and PPAR gamma. Clinically, our finding may alter current treatment methods to address rotator cuff fatty infiltration. (c) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 31: 724730, 2013
C1 [Joshi, Sunil K.; Liu, Xuhui; Lovett, David H.; Kim, Hubert T.; Feeley, Brian T.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Vet Affairs, San Francisco, CA 94153 USA.
[Liu, Xuhui; Samagh, Sanjum P.; Kim, Hubert T.; Feeley, Brian T.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94153 USA.
[Lovett, David H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94153 USA.
[Bodine, Sue C.] Univ Calif Davis, Dept Physiol & Membrane Biol, Davis, CA 95616 USA.
RP Feeley, BT (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Vet Affairs, 1500 Owens Ave, San Francisco, CA 94153 USA.
EM feeleyb@orthosurg.ucsf.edu
FU Orthopaedic Research & Education Foundation (OREF)
FX Grant sponsor: Orthopaedic Research & Education Foundation (OREF).
NR 40
TC 19
Z9 19
U1 2
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-0266
J9 J ORTHOP RES
JI J. Orthop. Res.
PD MAY
PY 2013
VL 31
IS 5
BP 724
EP 730
DI 10.1002/jor.22254
PG 7
WC Orthopedics
SC Orthopedics
GA 117RK
UT WOS:000316970600010
PM 23239524
ER
PT J
AU Fiellin, DA
McGinnis, KA
Maisto, SA
Justice, AC
Bryant, K
AF Fiellin, David A.
McGinnis, Kathleen A.
Maisto, Stephen A.
Justice, Amy C.
Bryant, Kendall
TI Measuring Alcohol Consumption Using Timeline Followback in
Non-Treatment-Seeking Medical Clinic Patients With and Without HIV
Infection: 7-, 14-, or 30-day Recall
SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS
LA English
DT Article
ID QUICK DRINKING SCREEN; VETERANS; INTOXICATION; INDIVIDUALS; ADHERENCE;
INTERVIEW; DRINKERS; CARE
AB Objective: The measurement of alcohol consumption is an essential component of research in patients at risk for or infected with HIV. Daily estimation measures such as the Timeline Followback (TLFB) have been validated, yet the optimal time window and its performance in non-treatment-seeking medical clinic subjects and among those with HIV are not known. Method: In 1,519 HIV-infected and 1,612 uninfected men receiving medical care in general medical or infectious disease clinics, we compared the association between 7-, 14-, and 30-day TLFB reports, obtained via telephone, of alcohol consumption using Spearman's correlation coefficients. To evaluate agreement between 7-, 14-, and 30-day reports of heavy episodic drinking, we evaluated percent agreement, sensitivity, and kappa statistics, considering 30-day report as the gold standard. Results: The estimated prevalence of heavy episodic drinking was progressively higher for longer TLFB intervals (7 days: 6.3%; 14 days: 8.0%; 30 days: 9.5%). Correlation coefficients with 30-day TLFB were higher for 14 days (.94) than for 7 days (.86) overall (p < .001) and among HIV-infected (.94 vs. .86, p < .001) and uninfected (.95 vs. .87, p < 001). Correlations were similar by HIV status. When considered overall and by HIV status, the sensitivity, percent agreement, and kappa statistics are better for heavy episodic drinking based on 14 days compared with 7 days. Conclusions: A TLFB for alcohol consumption of 14 days is preferable to 7 days for non-treatment-seeking patients in medical clinics with and without HIV infection when compared with 30 days. (J Stud. Alcohol Drugs, 74, 500-504, 2013)
C1 [Fiellin, David A.; Justice, Amy C.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA.
[Fiellin, David A.; Justice, Amy C.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT 06520 USA.
[McGinnis, Kathleen A.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Maisto, Stephen A.] Syracuse Univ, Dept Psychol, Syracuse, NY USA.
[Justice, Amy C.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA.
[Bryant, Kendall] NIAAA, Bethesda, MD 90034 USA.
RP Fiellin, DA (reprint author), Yale Univ, Sch Med, 367 Cedar St,POB 208093, New Haven, CT 06520 USA.
EM david.fiellin@yale.edu
OI Fiellin, David/0000-0002-4006-010X
FU National Institute on Alcohol Abuse and Alcoholism [U10AA013566,
U01AA020795, U01AA020790, U24AA020794]
FX This research was supported by National Institute on Alcohol Abuse and
Alcoholism Grants U10AA013566, U01AA020795, U01AA020790, and
U24AA020794. The views are not those of the Department of Veterans
Affairs or of the United States Government.
NR 25
TC 4
Z9 4
U1 4
U2 11
PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV
PI PISCATAWAY
PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA
SN 1937-1888
J9 J STUD ALCOHOL DRUGS
JI J. Stud. Alcohol Drugs
PD MAY
PY 2013
VL 74
IS 3
BP 500
EP 504
PG 5
WC Substance Abuse; Psychology
SC Substance Abuse; Psychology
GA 113CR
UT WOS:000316644300018
PM 23490581
ER
PT J
AU Saidi, RF
Elias, N
Hertl, M
Kawai, T
Cosimi, AB
Ko, DSC
AF Saidi, Reza F.
Elias, Nahel
Hertl, Martin
Kawai, Tatsuo
Cosimi, A. Benedict
Ko, Dicken S. C.
TI Urinary reconstruction after kidney transplantation: Pyeloureterostomy
or ureteroneocystostomy
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Kidney transplantation; Urinary reconstruction; Complications
ID RENAL-TRANSPLANTATION; UROLOGICAL COMPLICATIONS; EXTRAVESICAL
URETERONEOCYSTOSTOMY; EXTERNAL URETERONEOCYSTOSTOMY; URETEROVESICAL
ANASTOMOSIS; URETERAL COMPLICATIONS; EXPERIENCE; RECIPIENTS;
URETEROURETEROSTOMY; URETEROSTOMY
AB Purpose: Ureteroneocystostomy (UCN) is the most widely used urinary reconstruction technique during kidney transplantation. Disadvantages of this technique include a high incidence of hematuria and reflux, plus the potential for obstruction resulting from distal ureteral fibrosis. Pyeloureterostomy (PU) avoids these complications but increases the technical complexity.
Methods: Between January 1990 and December 2005, 1066 adults patients underwent kidney transplantations; 768 patients (72.1%) had urinary reconstruction by PU and 298 (27.9%) underwent UNC.
Results: Patients in the PU group underwent simultaneous ipsilateral native nephrectomy. The operative time was longer in the PU group compared with the UNC group: 210 +/- 36 min versus 182 +/- 24 min (P < 0.001). Overall surgical complications in the PU group were comparable to those in the UNC group (9.5% versus 12.3%). The urinary complication rate was also comparable in both groups: 3.2% (25 of 768) in the PU group and 5% (15 of 298) in the UNC group. However, urinary obstruction comprised 60% of urinary complications in the UNC group, compared with 32% in the PU group (P < 0.01). We treated most urinary complications non-operatively. However, 24% of patients (six of 25) in the PU group needed operative intervention or revision for ureteral reconstruction, compared with 46.6% (seven of 15) in the UNC group (P < 0.01).
Conclusions: Pyeloureterostomy is a safe and effective method for urinary tract reconstruction in renal transplantation. Pyeloureterostomy should be part of every transplant surgeon's armamentarium. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Saidi, Reza F.] Univ Massachusetts, Sch Med, Dept Surg, Div Organ Transplantat, Worcester, MA 01655 USA.
[Elias, Nahel; Hertl, Martin; Kawai, Tatsuo; Cosimi, A. Benedict; Ko, Dicken S. C.] Harvard Univ, Sch Med, Dept Surg, Transplantat Unit,Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Saidi, RF (reprint author), Univ Massachusetts, Sch Med, Dept Surg, Div Organ Transplantat, 55 Lake Ave North,S6-426, Worcester, MA 01655 USA.
EM reza.saidi@umassmemorial.org
NR 32
TC 2
Z9 3
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD MAY 1
PY 2013
VL 181
IS 1
BP 156
EP 159
DI 10.1016/j.jss.2012.05.043
PG 4
WC Surgery
SC Surgery
GA 115BX
UT WOS:000316788400032
PM 22683078
ER
PT J
AU Subramanian, A
Clapp, ML
Hicks, SC
Awad, SS
Liang, MK
AF Subramanian, Anuradha
Clapp, Marissa L.
Hicks, Stephanie C.
Awad, Samir S.
Liang, Mike K.
TI Laparoscopic ventral hernia repair: Primary versus secondary hernias
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Hernia; Incisional hernia; Ventral hernia; Umbilical hernia; Epigatric
hernia; Spigelian hernia; Laparoscopy; Laparoscopic; Recurrence
ID INCISIONAL HERNIA; RECURRENCE; EXPERIENCE
AB Background: Most studies regarding laparoscopic ventral hernia repair (LVHR) have merged primary hernias (PHs) and secondary (incisional) hernias (SHs) into one group of ventral hernias. This grouping could produce falsely favorable results for LVHR. Our objective was to review and compare the outcomes of laparoscopic repair of PHs and SHs.
Methods: A retrospective chart review of patients from 2000 to 2010 identified the cases of LVHR at two affiliated institutions. The demographics, comorbidities, type of hernia (PH versus SH), and short- and long-term complications were analyzed. The postoperative pain, cosmetic satisfaction, and Activities Assessment Scale scores were assessed by telephone survey.
Results: A total of 201 cases of LVHR were identified: 73 PHs (36%) and 128 SHs (64%). No difference was found in the mean age between the two groups. The PH group had a greater percentage of black patients (34% versus 14%; P < 0.05), and the SH group had a greater percentage of white patients (85% versus 65%; P < 0.05). More female patients had SHs (34% versus 14%; P < 0.05), and more male patients had PHs (86% versus 66%; P < 0.05). More patients in the SH group had chronic obstructive pulmonary disease (19% versus 7%; P < 0.05) and prostate disease (32% versus 9%; P < 0.05). Overall, the SHs were larger (37.9 +/- 4.9 cm(2) versus 11.5 +/- 1.9 cm(2); P < 0.01). No differences were found in early postoperative complications, including pneumonia, urinary tract infection, surgical site infection, and seromas between the two groups. However, those with SHs had a greater incidence of recurrence (16% versus 5%; P < 0.05) and mesh explantation (7% versus 0%; P < 0.05). The patients who also under went SH repairs had greater postoperative pain scores when followed up for a median of 25 mo than those who underwent PH repairs when followed up for a median of 24 mo (3.5 +/- 0.4 versus 1.8 +/- 0.4; P < 0.05). More patients in the SH group had chronic pain issues (26% versus 5%; P = 0.0003) and had lower satisfaction scores (7.5 +/- 0.3 versus 8.6 +/- 0.3; P < 0.05). Overall, the Activities Assessment Scale scores were not significantly different.
Conclusions: Our data have demonstrated that PHs and SHs are different. LVHR of SHs is associated with increased recurrence, greater postoperative pain scores, chronic pain issues, and lower patient satisfaction scores. We recommend that future studies evaluate LVHR for PHs separate from those for SHs. Published by Elsevier Inc.
C1 [Subramanian, Anuradha; Clapp, Marissa L.; Awad, Samir S.; Liang, Mike K.] Baylor Coll Med, Michael E DeBakey Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Hicks, Stephanie C.] Rice Univ, Dept Stat, Houston, TX 77251 USA.
RP Liang, MK (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, 2002 Holcomble Blvd,OCL 112, Houston, TX 77030 USA.
EM ml3@bcm.edu
RI Liang, Mike/L-8493-2015
OI Hicks, Stephanie/0000-0002-7858-0231; Liang, Mike/0000-0001-7063-7291
NR 19
TC 12
Z9 12
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD MAY 1
PY 2013
VL 181
IS 1
BP E1
EP E5
DI 10.1016/j.jss.2012.06.028
PG 5
WC Surgery
SC Surgery
GA 115BX
UT WOS:000316788400001
PM 22795342
ER
PT J
AU Watson, AMM
Prasad, KM
Klei, L
Wood, JA
Yolken, RH
Gur, RC
Bradford, LD
Calkins, ME
Richard, J
Edwards, N
Savage, RM
Allen, TB
Kwentus, J
McEvoy, JP
Santos, AB
Wiener, HW
Go, RCP
Perry, RT
Nasrallah, HA
Gur, RE
Devlin, B
Nimgaonkar, VL
AF Watson, A. M. M.
Prasad, K. M.
Klei, L.
Wood, J. A.
Yolken, R. H.
Gur, R. C.
Bradford, L. D.
Calkins, M. E.
Richard, J.
Edwards, N.
Savage, R. M.
Allen, T. B.
Kwentus, J.
McEvoy, J. P.
Santos, A. B.
Wiener, H. W.
Go, R. C. P.
Perry, R. T.
Nasrallah, H. A.
Gur, R. E.
Devlin, B.
Nimgaonkar, V. L.
TI Persistent infection with neurotropic herpes viruses and cognitive
impairment
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
DE Cognition; cytomegalovirus; HSV-1; HSV-2; schizophrenia
ID ALZHEIMERS-DISEASE BRAINS; SIMPLEX-VIRUS; CYTOMEGALOVIRUS-INFECTION;
SCHIZOPHRENIA PAARTNERS; PRINCIPAL-COMPONENTS; AFRICAN-AMERICANS;
LINKAGE ANALYSIS; EXPLORE RISKS; TYPE-1; HERITABILITY
AB Background. Herpes virus infections can cause cognitive impairment during and after acute encephalitis. Although chronic, latent/persistent infection is considered to be relatively benign, some studies have documented cognitive impairment in exposed persons that is untraceable to encephalitis. These studies were conducted among schizophrenia (SZ) patients or older community dwellers, among whom it is difficult to control for the effects of co-morbid illness and medications. To determine whether the associations can be generalized to other groups, we examined a large sample of younger control individuals, SZ patients and their non-psychotic relatives (n = 1852).
Method. Using multivariate models, cognitive performance was evaluated in relation to exposures to herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2) and cytomegalovirus (CMV), controlling for familial and diagnostic status and sociodemographic variables, including occupation and educational status. Composite cognitive measures were derived from nine cognitive domains using principal components of heritability (PCH). Exposure was indexed by antibodies to viral antigens.
Results. PCH1, the most heritable component of cognitive performance, declines with exposure to CMV or HSV-1 regardless of case/relative/control group status (p = 1.09 x 10(-5) and 0.01 respectively), with stronger association with exposure to multiple herpes viruses (beta = -0.25, p = 7.28 x 10(-10)). There were no significant interactions between exposure and group status.
Conclusions. Latent/persistent herpes virus infections can be associated with cognitive impairments regardless of other health status.
C1 [Watson, A. M. M.; Prasad, K. M.; Klei, L.; Wood, J. A.; Nimgaonkar, V. L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA USA.
[Yolken, R. H.] Johns Hopkins Univ, Sch Med, Stanley Div Dev Neurovirol, Baltimore, MD USA.
[Gur, R. C.; Calkins, M. E.; Richard, J.; Gur, R. E.] Univ Penn, Dept Psychiat, Neuropsychiat Sect, Philadelphia, PA 19104 USA.
[Gur, R. C.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Bradford, L. D.] Morehouse Sch Med, Dept Psychiat, Atlanta, GA 30310 USA.
[Edwards, N.] Univ Tennessee, Coll Med, Dept Psychiat, Memphis, TN USA.
[Savage, R. M.] Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA.
[Allen, T. B.; McEvoy, J. P.] Duke Univ, John Umstead Hosp, Med Ctr, Butner, NC USA.
[Kwentus, J.] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA.
[Santos, A. B.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Wiener, H. W.; Go, R. C. P.; Perry, R. T.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA.
[Nasrallah, H. A.] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH USA.
[Nasrallah, H. A.] Univ Cincinnati, Coll Med, Dept Behav Neurosci, Cincinnati, OH USA.
[Devlin, B.; Nimgaonkar, V. L.] Univ Pittsburgh, Sch Med, Dept Human Genet, Pittsburgh, PA USA.
[Devlin, B.; Nimgaonkar, V. L.] Western Psychiat Inst & Clin, Grad Sch Publ Hlth, Pittsburgh, PA USA.
RP Nimgaonkar, VL (reprint author), TDH, Room 441,3811 OHara St, Pittsburgh, PA 15213 USA.
EM nimga@pitt.edu
OI Prasad, Konasale/0000-0003-0245-1393
FU National Institute of Mental Health at the National Institute of Health
[RO1] [MH66006, R01 MH66278, R01 MH-066049, R01MH66181-03, R01 MH66121,
R01 MH066005, R01 MH66050, R01 MH66263, RO1 MH66004, K08 MH79364];
University of Mississippi; Eli Lilly; AstraZeneca; Pfizer; Bristol
Meyers; Johnson Johnson; Takeda
FX This work was supported by the National Institute of Mental Health at
the National Institute of Health [RO1 grant numbers: MH66006 (L.D.B.),
R01 MH66278 (B.D.), R01 MH-066049 (N.E.), R01MH66181-03 (R.C.P.G.), R01
MH66121 (R.E.G.), R01 MH066005 (J.K.), R01 MH66050 (J.P.M.), R01 MH66263
(V.L.N.), RO1 MH66004 (A.S.) and K08 MH79364 (M.E.C.).; Dr Kwentus
receives grant support through collaborations of the University of
Mississippi with Eli Lilly, AstraZeneca, Pfizer, Bristol Meyers, Johnson
& Johnson and Takeda.
NR 45
TC 10
Z9 10
U1 3
U2 17
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0033-2917
J9 PSYCHOL MED
JI Psychol. Med.
PD MAY
PY 2013
VL 43
IS 5
BP 1023
EP 1031
DI 10.1017/S003329171200195X
PG 9
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 119AC
UT WOS:000317067800012
PM 22975221
ER
PT J
AU Morra, L
Zade, D
McGlinchey, RE
Milberg, WP
AF Morra, L.
Zade, D.
McGlinchey, R. E.
Milberg, W. P.
TI Normal aging and cognition: The unacknowledged contribution of
cerebrovascular risk factors
SO AGING NEUROPSYCHOLOGY AND COGNITION
LA English
DT Article
DE Aging; Cognition; Cerebrovascular; Risk; Geriatric; Neuropsychology
ID BLOOD-PRESSURE; WHITE-MATTER; OLDER-ADULTS; CARDIOVASCULAR RISK;
VASCULAR RISK; UNITED-STATES; SELF-REPORT; DIFFERENTIAL VULNERABILITY;
DOPAMINERGIC SYSTEM; WORKING-MEMORY
AB Despite the widespread assumption that cognitive decline is an inherent part of the normal aging process, research suggests that part of the variance in age-related cognitive decline is attributable to modifiable factors common in geriatric populations such as cerebrovascular risk factors. We completed a literature search using Science Citation Index and evaluated the most cited articles from the last 10 years to determine the extent to which investigations of normal aging and cognition account for the influence of cerebrovascular risk factors. We found that the majority of the most frequently cited literature does not adequately account for the contribution of cerebrovascular risk factors and therefore, it is possible that many conclusions about normal aging and cognition are flawed or incomplete. Further investigation of the role of cerebrovascular risk factors in age-related cognitive decline is imperative to more accurately understand the effect of aging on cognition.
C1 [Morra, L.; Zade, D.; McGlinchey, R. E.; Milberg, W. P.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA USA.
[Morra, L.; Zade, D.; McGlinchey, R. E.; Milberg, W. P.] VA Boston Healthcare Syst, GRECC, Boston, MA USA.
[Zade, D.; McGlinchey, R. E.; Milberg, W. P.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Morra, L.] SUNY Binghamton, Dept Clin Psychol, Binghamton, NY USA.
RP Morra, L (reprint author), SUNY Binghamton, Dept Psychol, POB 6000,Clearview Halll, Binghamton, NY 13902 USA.
EM lmorra1@binghamton.edu
RI McGlinchey, Regina/R-1971-2016
NR 79
TC 3
Z9 3
U1 1
U2 18
PU PSYCHOLOGY PRESS
PI HOVE
PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND
SN 1382-5585
J9 AGING NEUROPSYCHOL C
JI Aging Neuropsychol. Cogn.
PD MAY 1
PY 2013
VL 20
IS 3
BP 271
EP 297
DI 10.1080/13825585.2012.693905
PG 27
WC Psychology, Developmental; Psychology, Experimental
SC Psychology
GA 109CC
UT WOS:000316341800002
ER
PT J
AU Kim, KY
Cho, HJ
Yu, SN
Kim, SH
Yu, HS
Park, YM
Mirkheshti, N
Kim, SY
Song, CS
Chatterjee, B
Ahn, SC
AF Kim, Kwang-Youn
Cho, Hyo-Jin
Yu, Sun-Nyoung
Kim, Sang-Hun
Yu, Hak-Sun
Park, Yeong-Min
Mirkheshti, Nooshin
Kim, So Young
Song, Chung Seog
Chatterjee, Bandana
Ahn, Soon-Cheol
TI Interplay of reactive oxygen species, intracellular Ca2+ and
mitochondrial homeostasis in the apoptosis of prostate cancer cells by
deoxypodophyllotoxin
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE DEOXYPODOPHYLLOTOXIN (DPT); APOPTOSIS; MITOCHONDRIAL MEMBRANE POTENTIAL
(MMP); REACTIVE OXYGEN SPECIES (ROS); Ca2+OVERLOAD
ID EARLY EVENT; HYPERPOLARIZATION; CHEMOTHERAPY; DYSFUNCTION; INDUCTION;
DAMAGE
AB The limited treatment option for recurrent prostate cancer and the eventual resistance to conventional chemotherapy drugs has fueled continued interest in finding new anti-neoplastic agents of natural product origin. We previously reported anti-proliferative activity of deoxypodophyllotoxin (DPT) on human prostate cancer cells. Using the PC-3 cell model of human prostate cancer, the present study reveals that DPT induced apoptosis via a caspase-3-dependent pathway that is activated due to dysregulated mitochondrial function. DPT-treated cells showed accumulation of the reactive oxygen species (ROS), intracellular Cai2+ surge, increased mitochondrial membrane potential (MMP, m), Bax protein translocation to mitochondria and cytochrome c release to the cytoplasm. This resulted in caspase-3 activation, which in turn induced apoptosis. The antioxidant N-acetylcysteine (NAC) reduced ROS accumulation, MMP and Cai2+ surge, on the other hand the Ca2+ chelator BAPTA inhibited the Cai2+ overload and MMP without affecting the increase of ROS, indicating that the generation of ROS occurred prior to Ca2+ flux. This suggested that both ROS and Cai2+ signaling play roles in the increased MMP via Cai2+-dependent and/or -independent mechanisms, since m elevation was reversed by NAC and BAPTA. This study provides the first evidence for the involvement of both ROS- and Cai2+-activated signals in the disruption of mitochondrial homeostasis and the precedence of ROS production over the failure of Ca2+ flux homeostasis. J. Cell. Biochem. 114: 11241134, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Kim, Kwang-Youn; Yu, Sun-Nyoung; Kim, Sang-Hun; Park, Yeong-Min; Ahn, Soon-Cheol] Pusan Natl Univ, Sch Med, Dept Microbiol & Immunol, Yangsan 626870, South Korea.
[Cho, Hyo-Jin] Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 443749, South Korea.
[Yu, Hak-Sun] Pusan Natl Univ, Sch Med, Dept Parasitol, Yangsan 626870, South Korea.
[Mirkheshti, Nooshin; Kim, So Young; Song, Chung Seog; Chatterjee, Bandana; Ahn, Soon-Cheol] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA.
[Mirkheshti, Nooshin; Kim, So Young; Song, Chung Seog; Chatterjee, Bandana; Ahn, Soon-Cheol] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, San Antonio, TX 78245 USA.
[Chatterjee, Bandana] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Ahn, Soon-Cheol] Pusan Natl Univ, Med Res Inst, Yangsan 626870, South Korea.
RP Chatterjee, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM chatterjee@uthscsa.edu; ahnsc@pusan.ac.kr
FU National Research Foundation of Korea (NRF) [2012R1A1A2022587]; US
Department of Veterans Affairs [1I01BX000280]; Basic Science Research
Program through the National Research Foundation of Korea (NRF);
Ministry of Education, Science and Technology [2012R1A1A2022587]
FX Grant sponsor: National Research Foundation of Korea (NRF); Grant
number: 2012R1A1A2022587; Grant sponsor: US Department of Veterans
Affairs 1I01BX000280.; This research was supported by Basic Science
Research Program through the National Research Foundation of Korea (NRF)
funded by the Ministry of Education, Science and Technology
(2012R1A1A2022587) and by a Merit Review grant (1I01BX000280) from the
US Department of Veterans Affairs. B. C. is a VA Senior Research Career
Scientist.
NR 21
TC 18
Z9 18
U1 1
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAY
PY 2013
VL 114
IS 5
BP 1124
EP 1134
DI 10.1002/jcb.24455
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 108YL
UT WOS:000316332200018
PM 23192945
ER
PT J
AU Brown, MC
Drottar, M
Benson, TE
Darrow, K
AF Brown, M. Christian
Drottar, Marie
Benson, Thane E.
Darrow, Keith
TI Commissural axons of the mouse cochlear nucleus
SO JOURNAL OF COMPARATIVE NEUROLOGY
LA English
DT Article
DE auditory brainstem; inhibitory synapse; glycine; electron microscopy;
binaural balance; multipolar cell
ID AUDITORY-NERVE FIBERS; CONTRALATERAL SOUND; FUNCTIONAL-PROPERTIES;
OLIVOCOCHLEAR BUNDLE; BINAURAL INTERACTION; CENTRAL PROJECTIONS;
MULTIPOLAR CELLS; STELLATE CELLS; BRAIN-STEM; GUINEA-PIG
AB The axons of commissural neurons that project from one cochlear nucleus to the other were studied after labeling with anterograde tracer. Injections were made into the dorsal subdivision of the cochlear nucleus in order to restrict labeling only to the group of commissural neurons that gave off collaterals to, or were located in, this subdivision. The number of labeled commissural axons in each injection was correlated with the number of labeled radiate multipolar neurons, suggesting radiate neurons as the predominant origin of the axons. The radiate commissural axons are thick and myelinated, and they exit the dorsal acoustic stria of the injected cochlear nucleus to cross the brainstem in the dorsal half, near the crossing position of the olivocochlear bundle. They enter the opposite cochlear nucleus via the dorsal and ventral acoustic stria and at its medial border. Reconstructions of single axons demonstrate that terminations are mostly in the core and typically within a single subdivision of the cochlear nucleus. Extents of termination range from narrow to broad along both the dorsoventral (i.e., tonotopic) and the rostrocaudal dimensions. In the electron microscope, labeled swellings form synapses that are symmetric (in that there is little postsynaptic density), a characteristic of inhibitory synapses. Our labeled axons do not appear to include excitatory commissural axons that end in edge regions of the nucleus. Radiate commissural axons could mediate the broadband inhibition observed in responses to contralateral sound, and they may balance input from the two ears with a quick time course. J. Comp. Neurol. 521:16831696, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Brown, M. Christian; Drottar, Marie; Benson, Thane E.; Darrow, Keith] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Brown, M. Christian] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA.
[Darrow, Keith] Worcester State Univ, Dept Commun Sci & Disorders, Worcester, MA 01602 USA.
RP Brown, MC (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
EM chris_brown@meei.harvard.edu
FU National Institute of Deafness and Other Communication Disorders
[DC01089]
FX Grant sponsor: National Institute of Deafness and Other Communication
Disorders; Grant number: DC01089 (to M.C.B.).
NR 58
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9967
J9 J COMP NEUROL
JI J. Comp. Neurol.
PD MAY 1
PY 2013
VL 521
IS 7
BP 1683
EP 1696
DI 10.1002/cne.23257
PG 14
WC Neurosciences; Zoology
SC Neurosciences & Neurology; Zoology
GA 110DI
UT WOS:000316421900013
PM 23124982
ER
PT J
AU Causse, M
Peran, P
Dehais, F
Caravasso, CF
Zeffiro, T
Sabatini, U
Pastor, J
AF Causse, Mickael
Peran, Patrice
Dehais, Frederic
Caravasso, Chiara Falletta
Zeffiro, Thomas
Sabatini, Umberto
Pastor, Josette
TI Affective decision making under uncertainty during a plausible aviation
task: An fMRI study
SO NEUROIMAGE
LA English
DT Article
DE Reward and punishment; Dorsolateral prefrontal cortex; Risk-taking;
Emotion; Aviation safety
ID ANTERIOR CINGULATE CORTEX; PREFRONTAL CORTEX; ORBITOFRONTAL CORTEX;
WORKLOAD ASSESSMENT; EXECUTIVE FUNCTIONS; RISK-TAKING; PERFORMANCE;
BEHAVIOR; FLIGHT; VALIDATION
AB In aeronautics, plan continuation error (PCE) represents failure to revise a flight plan despite emerging evidence suggesting that it is no longer safe. Assuming that PCE may be associated with a shift from cold to hot reasoning, we hypothesized that this transition may result from a large range of strong negative emotional influences linked with the decision to abort a landing and circle for a repeat attempt, referred to as a "go-around". We investigated this hypothesis by combining functional neuroimaging with an ecologically valid aviation task performed under contextual variation in incentive and situational uncertainty. Our goal was to identify regional brain activity related to the sorts of conservative or liberal decision-making strategies engaged when participants were both exposed to a financial payoff matrix constructed to bias responses in favor of landing acceptance, while they were simultaneously experiencing maximum levels of uncertainty related to high levels of stimulus ambiguity. Combined with the observed behavioral outcomes, our neuroimaging results revealed a shift from cold to hot decision making in response to high uncertainty when participants were exposed to the financial incentive. Most notably, while we observed activity increases in response to uncertainty in many frontal regions such as dorsolateral prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC), less overall activity was observed when the reward was combined with uncertainty. Moreover, participants with poor decision making, quantified as a lower discriminability index d', exhibited riskier behavior coupled with lower activity in the right DLPFC. These outcomes suggest a disruptive effect of biased financial incentive and high uncertainty on the rational decision-making neural network, and consequently, on decision relevance. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Causse, Mickael; Dehais, Frederic] Univ Toulouse, Inst Super Aeronaut & Espace, Dept Math, F-31055 Toulouse 4, France.
[Causse, Mickael; Peran, Patrice; Pastor, Josette] Fac Med Toulouse, INSERM, Imagerie Cerebrale & Handicaps Neurol UMR 825, F-31059 Toulouse, France.
[Causse, Mickael; Peran, Patrice; Pastor, Josette] Univ Toulouse, UPS, CHU Purpan, Imagerie Cerebrale & Handicaps Neurol UMR 825, F-31059 Toulouse 9, France.
[Peran, Patrice; Caravasso, Chiara Falletta; Sabatini, Umberto] IRCCS Santa Lucia Fdn, Dept Radiol, I-00149 Rome, Italy.
[Zeffiro, Thomas] Massachusetts Gen Hosp, Neural Syst Grp, Boston, MA 02114 USA.
RP Causse, M (reprint author), Univ Toulouse, Inst Super Aeronaut & Espace, Dept Math, 10 Ave E Belin, F-31055 Toulouse 4, France.
EM mickael.causse@isae.fr
RI Peran, Patrice/N-7561-2015;
OI Peran, Patrice/0000-0001-7200-0139; Dehais, frederic/0000-0003-0854-7919
NR 57
TC 9
Z9 9
U1 3
U2 41
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD MAY 1
PY 2013
VL 71
BP 19
EP 29
DI 10.1016/j.neuroimage.2012.12.060
PG 11
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 106OM
UT WOS:000316154400003
PM 23313780
ER
PT J
AU Katon, WJ
Young, BA
Russo, J
Lin, EHB
Ciechanowski, P
Ludman, EJ
Von Korff, MR
AF Katon, Wayne J.
Young, Bessie A.
Russo, Joan
Lin, Elizabeth H. B.
Ciechanowski, Paul
Ludman, Evette J.
Von Korff, Michael R.
TI Association of Depression With Increased Risk of Severe Hypoglycemic
Episodes in Patients With Diabetes
SO ANNALS OF FAMILY MEDICINE
LA English
DT Article
DE depression; diabetes; hypoglycemia; mental health
ID PROSPECTIVE COHORT; SELF-CARE; TYPE-2; COMPLICATIONS; INSULIN;
SULFONYLUREAS; MORTALITY; DEMENTIA; MELLITUS; ADULTS
AB PURPOSE Although psychosocial and clinical factors have been found to be associated with hypoglycemic episodes in patients with diabetes, few studies have examined the association of depression with severe hypoglycemic episodes. This study examined the prospective association of depression with risk of hypoglycemic episodes requiring either an emergency department visit or hospitalization.
METHODS In a longitudinal cohort study, a sample of 4,117 patients with diabetes enrolled between 2000 and 2002 were observed from 2005 to 2007. Meeting major depression criteria on the Patient Health Questionnaire-9 was the exposure of interest, and the outcome of interest was an International Classification of Disease, Ninth Revision code for a hypoglycemic episode requiring an emergency department visit or hospitalization. Proportional hazard models were used to analyze the association of baseline depression and risk of one or more severe hypoglycemic episodes. Poisson regression was used to determine whether depression status was associated with the number of hypoglycemic episodes.
RESULTS After adjusting for sociodemographic, clinical measures of diabetes severity, non-diabetes-related medical comorbidity, prior hypoglycemic episodes, and health risk behaviors, depressed compared with nondepressed patients who had diabetes had a significantly higher risk of a severe hypoglycemic episode (hazard ratio = 1.42, 95% CI, 1.03-1.96) and a greater number of hypoglycemic episodes (odds ratio = 1.34, 95% CI, 1.03-1.74).
CONCLUSION Depression was significantly associated with time to first severe hypoglycemic episode and number of hypoglycemic episodes. Research assessing whether recognition and effective treatment of depression among persons with diabetes prevents severe hypoglycemic episodes is needed.
C1 [Katon, Wayne J.; Russo, Joan; Ciechanowski, Paul] Univ Washington, Sch Med, Dept Psychiat, Seattle, WA USA.
[Young, Bessie A.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Kidney Res Inst, Seattle, WA USA.
[Lin, Elizabeth H. B.; Ludman, Evette J.; Von Korff, Michael R.] Grp Hlth Res Inst, Seattle, WA USA.
RP Katon, WJ (reprint author), 1959 NE Pacific St, Seattle, WA 98195 USA.
EM wkaton@u.washington.edu
FU Services Division of the National Institute of Mental Health [MH069741,
MH073686]
FX Supported by grants MH069741 (Katon) and MH073686 (Von Korff) from the
Services Division of the National Institute of Mental Health.
NR 28
TC 28
Z9 29
U1 0
U2 11
PU ANNALS FAMILY MEDICINE
PI LEAWOOD
PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA
SN 1544-1709
EI 1544-1717
J9 ANN FAM MED
JI Ann. Fam. Med.
PD MAY-JUN
PY 2013
VL 11
IS 3
BP 245
EP 250
DI 10.1370/afm.1501
PG 6
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA AI3WS
UT WOS:000336796600010
PM 23690324
ER
PT J
AU McAllister, JW
Cooley, WC
Van Cleave, J
Boudreau, AA
Kuhlthau, K
AF McAllister, Jeanne W.
Cooley, W. Carl
Van Cleave, Jeanne
Boudreau, Alexy Arauz
Kuhlthau, Karen
TI Medical Home Transformation in Pediatric Primary Care-What Drives
Change?
SO ANNALS OF FAMILY MEDICINE
LA English
DT Article
DE change, organizational; children with special health care needs;
disabled children; medical home; practice-based research; primary care;
transformation
ID FAMILY-CENTERED CARE; HEALTH-CARE; COORDINATION; CHILDREN; NEEDS;
QUALITY; INDEX
AB PURPOSE The aim of this study was to characterize essential factors to the medical home transformation of high-performing pediatric primary care practices 6 to 7 years after their participation in a national medical home learning collaborative.
METHODS We evaluated the 12 primary care practice teams having the highest Medical Home Index (MHI) scores after participation in a national medical home learning collaborative with current MHI scores, a clinician staff questionnaire (assessing adaptive reserve), and semistructured interviews. We reviewed factors that emerged from interviews and analyzed domains and subdomains for their agreement with MHI and adaptive reserve domains and subthemes using a process of triangulation.
RESULTS At 6 to 7 years after learning collaborative participation, 4 essential medical home attributes emerged as drivers of transformation: (1) a culture of quality improvement, (2) family-centered care with parents as improvement partners, (3) team-based care, and (4) care coordination. These high-performing practices developed comprehensive, family-centered, planned care processes including flexible access options, population approaches, and shared care plans. Eleven practices evolved to employ care coordinators. Family satisfaction appeared to stem from better access, care, and safety, and having a strong relationship with their health care team. Physician and staff satisfaction was high even while leadership activities strained personal time.
CONCLUSIONS Participation in a medical home learning collaborative stimulated, but did not complete, medical home changes in 12 pediatric practices. Medical home transformation required continuous development, ongoing quality improvement, family partnership skills, an attitude of teamwork, and strong care coordination functions.
C1 [McAllister, Jeanne W.; Cooley, W. Carl] Crotched Mt Fdn, Ctr Med Home Improvement, Concord, NH 03301 USA.
[Van Cleave, Jeanne; Boudreau, Alexy Arauz; Kuhlthau, Karen] Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Res & Policy, Boston, MA 02114 USA.
RP McAllister, JW (reprint author), Crotched Mt Fdn, Ctr Med Home Improvement, 8 Low Ave,Ste 1, Concord, NH 03301 USA.
EM mcallisterjeanne3@gmail.com
FU Agency for Healthcare Research and Quality (AHRQ) [R18HS019157-01]; US
Maternal and Child Health Bureau (USMCHB), Division for Children with
Special Health Care Needs (CSHCN); state Title V Program; NIMH
[K23MH083885, R25MH080916]
FX This work was supported by Agency for Healthcare Research and Quality
(AHRQ) grant R18HS019157-01 and in part by the US Maternal and Child
Health Bureau (USMCHB), Division for Children with Special Health Care
Needs (CSHCN). The medical home learning collaborative described herein
was funded under a cooperative agreement with the USMCHB CSHCN.
Participation of each practice team was supported by their state Title V
Program dedicated to the care of CSHCN. Additional funding support
included NIMH grant K23MH083885 and NIMH grant R25MH080916.
NR 32
TC 14
Z9 14
U1 1
U2 12
PU ANNALS FAMILY MEDICINE
PI LEAWOOD
PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA
SN 1544-1709
EI 1544-1717
J9 ANN FAM MED
JI Ann. Fam. Med.
PD MAY-JUN
PY 2013
VL 11
SU 1
BP S90
EP S98
DI 10.1370/afm.1528
PG 9
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA AI3XE
UT WOS:000336798200013
PM 23690392
ER
PT J
AU Schalock, PC
AF Schalock, Peter C.
TI Pragmatism and the Evaluation of Metal Hypersensitivity Reactions
SO DERMATITIS
LA English
DT Article
ID IMPLANTS
AB Evaluating patients with potential metal hypersensitivity reactions is challenging. Clear evidence-based guidelines based on randomized studies are lacking. A pragmatic approach to evaluation of these patients is useful due to this lack of evidence. Patch testing remains the gold standard for evaluating type IV reactions on the skin and is also likely the best test for metal reactions to implanted devices until more hard data is available.
C1 [Schalock, Peter C.] Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Schalock, PC (reprint author), Massachusetts Gen Hosp, Dept Dermatol, BAR622 55 Fruit St, Boston, MA 02114 USA.
EM schalock.prof@gmail.com
OI Schalock, Peter/0000-0001-8953-4639
NR 5
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1710-3568
EI 2162-5220
J9 DERMATITIS
JI Dermatitis
PD MAY-JUN
PY 2013
VL 24
IS 3
BP 104
EP 105
DI 10.1097/DER.0b013e3182979762
PG 2
WC Dermatology
SC Dermatology
GA AG5LD
UT WOS:000335459600002
PM 23665837
ER
PT J
AU Ambrosy, A
Chioncel, O
Vinereanu, D
Bubenek, S
Deleanu, D
Filipescu, D
Vaduganathan, M
Greene, S
Macarie, C
Gheorghiade, M
AF Ambrosy, A.
Chioncel, O.
Vinereanu, D.
Bubenek, S.
Deleanu, D.
Filipescu, D.
Vaduganathan, M.
Greene, S.
Macarie, C.
Gheorghiade, M.
TI The association between Triglycerides at admission and mortality in
patients hospitalized for heart failure: an analysis of the RO-AHFS
Registry
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Meeting Abstract
C1 [Ambrosy, A.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
[Chioncel, O.; Bubenek, S.; Deleanu, D.; Filipescu, D.; Macarie, C.] Inst Cardiovasc Dis Prof Dr CC Iliescu, Bucharest, Romania.
[Vinereanu, D.] Emergency Hosp Bucharest, Bucharest, Romania.
[Vaduganathan, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Greene, S.; Gheorghiade, M.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD MAY
PY 2013
VL 12
SU 1
BP S298
EP S298
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AC4KE
UT WOS:000332489101410
ER
PT J
AU Chioncel, O
Ambrosy, AP
Vinereanu, D
Bubenek, S
Deleanu, D
Petris, A
Vaduganathan, M
Greene, S
Macarie, C
Gheorghiade, M
AF Chioncel, O.
Ambrosy, A. P.
Vinereanu, D.
Bubenek, S.
Deleanu, D.
Petris, A.
Vaduganathan, M.
Greene, S.
Macarie, C.
Gheorghiade, M.
TI The association between total cholesterol at admission and mortality in
patients hospitalized for heart failure: an analysis of the RO-AHFS
registry
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Meeting Abstract
C1 [Chioncel, O.; Bubenek, S.; Deleanu, D.; Macarie, C.] Inst Cardiovasc Dis Prof Dr CC Iliescu, Bucharest, Romania.
[Ambrosy, A. P.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
[Vinereanu, D.] Univ Bucharest, Bucharest, Romania.
[Petris, A.] St Spiridon Univ Hosp, Iasi, Romania.
[Vaduganathan, M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Greene, S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Gheorghiade, M.] NW Mem Hosp, Cardiovasc Inst, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD MAY
PY 2013
VL 12
SU 1
BP S297
EP S298
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AC4KE
UT WOS:000332489101409
ER
PT J
AU De Berardinis, B
Zancla, B
Magrini, L
Gaggin, HK
Salerno, G
Cardelli, P
Januzzi, JJ
Di Somma, S
AF De Berardinis, B.
Zancla, B.
Magrini, L.
Gaggin, H. K.
Salerno, G.
Cardelli, P.
Januzzi, J. J.
Di Somma, S.
TI In-hospital and 30 days predictive value of Worsening Renal Function
(WRF) and Galectin 3 (Gal 3) in patients with acute heart failure in
emergency department
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Meeting Abstract
C1 [De Berardinis, B.; Zancla, B.; Magrini, L.; Salerno, G.; Cardelli, P.; Di Somma, S.] Univ Roma La Sapienza, St Andrea Hosp, Fac Med 2, I-00185 Rome, Italy.
[Gaggin, H. K.; Januzzi, J. J.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD MAY
PY 2013
VL 12
SU 1
BP S201
EP S201
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AC4KE
UT WOS:000332489101006
ER
PT J
AU Mark, A
Luis, G
Robert, L
Igor, P
AF Mark, Arokiaraj
Luis, Guerrero
Robert, Levine
Igor, Palacios
TI A cardiac resynchronization therapy method to augment ventricular
contraction using polymer based actuators and mitral regurgitation
control devices over pacing wire- Investigational Results
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Meeting Abstract
C1 [Mark, Arokiaraj] Pondicherry Inst Med Sci, Pondicherry, India.
[Luis, Guerrero; Robert, Levine; Igor, Palacios] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD MAY
PY 2013
VL 12
SU 1
BP S73
EP S73
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AC4KE
UT WOS:000332489100275
ER
PT J
AU Matura, LA
Mcdonough, A
Carroll, DL
AF Matura, L. A.
Mcdonough, A.
Carroll, D. L.
TI Are predictors of health-related quality of life in pulmonary arterial
hypertension different for women and men?
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Meeting Abstract
C1 [Matura, L. A.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
[Mcdonough, A.] Univ Massachusetts, Lowell, MA USA.
[Carroll, D. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD MAY
PY 2013
VL 12
SU 1
BP S85
EP S85
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AC4KE
UT WOS:000332489100325
ER
PT J
AU Shah, A
Kraigher-Krainer, E
Pieske, B
Zile, M
Voors, A
Bransford, T
Lefkowitz, M
Packer, M
Mcmurray, J
Solomon, S
AF Shah, A.
Kraigher-Krainer, E.
Pieske, B.
Zile, M.
Voors, A.
Bransford, T.
Lefkowitz, M.
Packer, M.
Mcmurray, J.
Solomon, S.
TI Relationship of NT-proBNP to systolic and diastolic function in HFpEF:
Findings from the PARAMOUNT trial
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Meeting Abstract
C1 [Shah, A.; Solomon, S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Kraigher-Krainer, E.; Pieske, B.] Med Univ Graz, Graz, Austria.
[Zile, M.] Med Univ S Carolina, Charleston, SC USA.
[Zile, M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Voors, A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.
[Bransford, T.; Lefkowitz, M.] Novartis Pharmaceut, E Hanover, NJ USA.
[Packer, M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Mcmurray, J.] Univ Glasgow, Div Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD MAY
PY 2013
VL 12
SU 1
BP S275
EP S276
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AC4KE
UT WOS:000332489101312
ER
PT J
AU Suter, T
Gianni, L
Krop, I
Xu, N
Smitt, M
Dang, C
AF Suter, T.
Gianni, L.
Krop, I.
Xu, N.
Smitt, M.
Dang, C.
TI Cardiac safety of trastuzumab emtansine (T-DM1), a novel cancer drug
linking trastuzumab to a chemotherapeutic agent for early-stage
HER2-positive breast cancer
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Meeting Abstract
C1 [Suter, T.] Univ Hosp Bern, Swiss Cardiovasc Ctr, CH-3010 Bern, Switzerland.
[Gianni, L.] San Raffaele Hosp IRCCS, Milan, Italy.
[Krop, I.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Xu, N.; Smitt, M.] Genentech Inc, San Francisco, CA 94080 USA.
[Dang, C.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD MAY
PY 2013
VL 12
SU 1
BP S101
EP S101
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AC4KE
UT WOS:000332489100390
ER
PT J
AU Swinnen, M
Hermans, H
Vandenwijngaert, S
Pokreisz, P
Caluwe, E
Gillijns, H
Van de Werf, F
Bloch, KD
Janssens, S
AF Swinnen, M.
Hermans, H.
Vandenwijngaert, S.
Pokreisz, P.
Caluwe, E.
Gillijns, H.
Van de Werf, F.
Bloch, K. D.
Janssens, S.
TI MicroRNA signatures in left ventricular hypertrophy
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Meeting Abstract
C1 [Swinnen, M.; Hermans, H.; Vandenwijngaert, S.; Pokreisz, P.; Caluwe, E.; Gillijns, H.; Van de Werf, F.; Janssens, S.] Katholieke Univ Leuven, Dept Cardiovasc Sci, Leuven, Belgium.
[Bloch, K. D.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Bloch, K. D.] Harvard Univ, Sch Med, Dep Anesthesia Crit Care & Paine Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD MAY
PY 2013
VL 12
SU 1
BP S59
EP S59
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AC4KE
UT WOS:000332489100220
ER
PT J
AU Camargo, CA
Guana, A
Wang, S
Simons, FER
AF Camargo, Carlos A., Jr.
Guana, Adriana
Wang, Sheldon
Simons, F. Estelle R.
TI Auvi-Q Versus EpiPen: Preferences of Adults, Caregivers, and Children
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Article
DE Epinephrine autoinjector; Adrenaline autoinjector; Auvi-Q; EpiPen; User
preference; Anaphylaxis; Caregivers; Children; Adults; Allergy
AB BACKGROUND: Auvi-Q is a novel epinephrine autoinjector (EAI) that provides audio and visual cues for patients at risk for life-threatening allergic reactions.
OBJECTIVE: We tested the preference for Auvi-Q or EpiPen with regard to method of instruction, preference to carry, device size, and device shape.
METHODS: This large, multicenter, simulated-use study evaluated whether adults (aged 18-65 years), caregivers (parents/guardians aged 18-65 years of children aged 5-17 years), and children (aged 11-17 years), with and without experience in using an EAI, had a preference for the current design of Auvi-Q or the current design of EpiPen. Participants were given a scenario that involved anaphylaxis and were instructed to simulate use of an EAI. They received and tested each device individually according to the randomization assignment. After testing both devices, they completed a survey to indicate their preference for Auvi-Q versus EpiPen.
RESULTS: Among all 693 participants combined, Auvi-Q was preferred over EpiPen on all study end points (P < .001). For experienced and inexperienced participants in all 3 groups (adults, caregivers, and children), Auvi-Q was preferred over EpiPen for method of instruction, preference to carry, and device size (all P < .001). The preference for Auvi-Q device shape was not significant among experienced children (P = .10); however, it was significant for inexperienced children (P = .04) and highly significant for experienced and inexperienced adults and caregivers (P < .001).
CONCLUSION: In this large multicenter, simulated-use study, Auvi-Q was preferred over EpiPen by experienced and inexperienced adults, caregivers, and children. (C) 2013 American Academy of Allergy, Asthma & Immunology
C1 [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol,Dept Med, Boston, MA USA.
[Guana, Adriana; Wang, Sheldon] Sanofi US, US Med Affairs, Gen Therapeut, Bridgewater, MA USA.
[Simons, F. Estelle R.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada.
[Simons, F. Estelle R.] Univ Manitoba, Dept Immunol, Winnipeg, MB, Canada.
RP Camargo, CA (reprint author), Massachusetts Gen Hosp, 326 Cambridge St,Ste 410, Boston, MA 02114 USA.
EM ccamargo@partners.org
FU Sanofi US
FX We thank Jeff Butler (Sanofi US) and the Lieberman Research Group for
assistance in conducting the study. We also thank Pieter van Bokhoven,
PhD, of Excerpta Medica, funded by Sanofi US, for writing/editorial
support.
NR 17
TC 10
Z9 10
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD MAY-JUN
PY 2013
VL 1
IS 3
BP 266
EP +
DI 10.1016/j.jaip.2013.02.004
PG 10
WC Allergy; Immunology
SC Allergy; Immunology
GA V38WV
UT WOS:000209374400008
PM 24565484
ER
PT J
AU Kohli, P
Giugliano, RP
AF Kohli, Payal
Giugliano, Robert P.
TI Low-Density Lipoprotein Lowering in 2013 by Nonstatin Agents: The
Discovery and Development of Promising Novel Targeted Therapies
SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Review
DE dyslipidemia; hypercholesterolemia
ID ESTER TRANSFER PROTEIN; SUBTILISIN/KEXIN TYPE 9; TRIGLYCERIDE TRANSFER
PROTEIN; SINGLE-DOSE PHARMACOKINETICS; STATIN-INTOLERANT PATIENTS;
PLACEBO-CONTROLLED TRIAL; CORONARY-HEART-DISEASE; B SYNTHESIS INHIBITOR;
LAPLACE-TIMI 57; MONOCLONAL-ANTIBODY
AB Dyslipidemia is a major risk factor for the development of coronary artery disease, a leading cause of morbidity and mortality worldwide. Lowering low-density lipoprotein (LDL) has significantly reduced the risk of death and other major cardiovascular events, and statins remain the therapy of choice. However, as some patients are limited by the side effects of statins, cannot achieve their target LDL on statin therapy, or have other abnormalities in their lipid profile, alternative agents are being developed. In this review, we highlight the major classes of novel nonstatin LDL-lowering agents that are currently in various stages of development. Although many hold great promise, the results of large Phase III trials will be needed to definitely establish the efficacy, safety, and clinical utility of these agents in the general population.
C1 [Kohli, Payal; Giugliano, Robert P.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.
[Kohli, Payal; Giugliano, Robert P.] Harvard Univ, Sch Med, Boston, MA USA.
[Kohli, Payal] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA.
RP Giugliano, RP (reprint author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, TIMI Study Grp, 350 Longwood Ave,1st Floor Off, Boston, MA 02115 USA.
EM rgiugliano@partners.org
FU Amgen
FX The author(s) declared a potential conflict of interest as follows: Both
authors participated in the LAPLACE-TIMI 57 trial sponsored by Amgen. Dr
Kohli has served on the advisory board for Daiichi-Sankyo. Dr Giugliano
has received honoraria for consulting from Amgen, Regeneron, and Sanofi.
NR 66
TC 1
Z9 1
U1 0
U2 12
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1074-2484
EI 1940-4034
J9 J CARDIOVASC PHARM T
JI J. Cardiovasc. Pharmacol. Ther.
PD MAY
PY 2013
VL 18
IS 3
BP 199
EP 210
DI 10.1177/1074248413480270
PG 12
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA 123YG
UT WOS:000317428000002
PM 23580658
ER
PT J
AU Dutta, J
El Fakhri, G
Huang, C
Petibon, Y
Reese, T
Li, QZ
AF Dutta, Joyita
El Fakhri, Georges
Huang, Chuan
Petibon, Yoann
Reese, Timothy
Li, Quanzheng
TI Respiratory motion compensated pulmonary imaging using simultaneous
PET-MR
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Meeting Abstract
C1 [Dutta, Joyita; El Fakhri, Georges; Huang, Chuan; Petibon, Yoann; Reese, Timothy; Li, Quanzheng] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Radiol,Ctr Adv Med Imaging Sci,NMMI, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
EI 1535-5667
J9 J NUCL MED
JI J. Nucl. Med.
PD MAY
PY 2013
VL 54
SU 2
MA 45
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA V40KY
UT WOS:000209478700039
ER
PT J
AU Esfahani, S
Heidari, P
Sheth, R
Mahmood, U
AF Esfahani, Shadi
Heidari, Pedram
Sheth, Rahul
Mahmood, Umar
TI Non-invasive imaging of C-MET receptor for delineation of liver
metastasis of colorectal cancer
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Meeting Abstract
C1 [Esfahani, Shadi; Heidari, Pedram; Sheth, Rahul; Mahmood, Umar] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
EI 1535-5667
J9 J NUCL MED
JI J. Nucl. Med.
PD MAY
PY 2013
VL 54
SU 2
MA 2
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA V40KY
UT WOS:000209478700003
ER
PT J
AU Huang, C
Ackerman, J
Petibon, Y
Brady, T
El Fakhri, G
Ouyang, JS
AF Huang, Chuan
Ackerman, Jerome
Petibon, Yoann
Brady, Thomas
El Fakhri, Georges
Ouyang, Jinsong
TI Real-time 3D motion tracking using MR micro-coils for PET imaging
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Meeting Abstract
C1 [Huang, Chuan; Petibon, Yoann; Brady, Thomas; El Fakhri, Georges; Ouyang, Jinsong] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Adv Med Imaging Sci,NMMI,Radiol, Boston, MA USA.
[Ackerman, Jerome] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr Biomed Imaging, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
EI 1535-5667
J9 J NUCL MED
JI J. Nucl. Med.
PD MAY
PY 2013
VL 54
SU 2
MA 44
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA V40KY
UT WOS:000209478700038
ER
PT J
AU Li, H
El Fakhri, G
Li, QZ
AF Li, Hao
El Fakhri, Georges
Li, Quanzheng
TI Direct MAP estimation of attenuation sinogram using TOF PET emission
data
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Meeting Abstract
C1 [Li, Hao; El Fakhri, Georges; Li, Quanzheng] Massachusetts Gen Hosp, NMMI, Ctr Adv Med Imaging Sci, Radiol, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
EI 1535-5667
J9 J NUCL MED
JI J. Nucl. Med.
PD MAY
PY 2013
VL 54
SU 2
MA 47
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA V40KY
UT WOS:000209478700041
ER
PT J
AU Pamarthy, S
Bohnen, N
Assaly, WB
Gross, M
Fig, L
AF Pamarthy, Sarika
Bohnen, Nicolaas
Assaly, Wessam Bou
Gross, Milton
Fig, Lorraine
TI MRI for correlative imaging of the nigrostriatal dopaminergic system: A
guide for nuclear medicine physicians
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Meeting Abstract
C1 [Pamarthy, Sarika; Bohnen, Nicolaas] Univ Michigan, Radiol Nucl Med, Ann Arbor, MI 48109 USA.
[Assaly, Wessam Bou; Gross, Milton; Fig, Lorraine] US Dept Vet Affairs, Nucl Med, Ann Arbor, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
EI 1535-5667
J9 J NUCL MED
JI J. Nucl. Med.
PD MAY
PY 2013
VL 54
SU 2
MA 1282
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA V40KY
UT WOS:000209478700103
ER
PT J
AU Angin, M
King, M
Addo, MM
AF Angin, Mathieu
King, Melanie
Addo, Marylyn Martina
TI New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Infection; Issue 75; Infectious Diseases; Medicine; Immunology;
Virology; Cellular Biology; Molecular Biology; Lymphocytes;
T-Lymphocytes; Regulatory; HIV; Culture Techniques; flow cytometry; cell
culture; Treg expansion; regulatory T cells; CD4+T cells; Tregs; HIV-1;
virus; HIV-1 infection; AIDS; clinical techniques
AB CD4+ Regulatory T cells (Tregs) are potent immune modulators and serve an important function in human immune homeostasis. Depletion of Tregs has led to measurable increases in antigen-specific T cell responses in vaccine settings for cancer and infectious pathogens. However, their role in HIV-1 immuno-pathogenesis remains controversial, as they could either serve to suppress deleterious HIV-1-associated immune activation and thus slow HIV-1 disease progression or alternatively suppress HIV-1-specific immunity and thereby promote virus spread. Understanding and modulating Treg function in the context of HIV-1 could lead to potential new strategies for immunotherapy or HIV vaccines. However, important open questions remain on their role in the context of HIV-1 infection, which needs to be carefully studied.
Representing roughly 5% of human CD4+ T cells in the peripheral blood, studying the Treg population has proven to be difficult, especially in HIV-1 infected individuals where HIV-1-associated CD4 T cell and with that Treg depletion occurs. The characterization of regulatory T cells in individuals with advanced HIV-1 disease or tissue samples, for which only very small biological samples can be obtained, is therefore extremely challenging. We propose a technical solution to overcome these limitations using isolation and expansion of Tregs from HIV-1-positive individuals.
Here we describe an easy and robust method to successfully expand Tregs isolated from HIV-1-infected individuals in vitro. Flow-sorted CD3+ CD4+ CD25+ CD127(low) Tregs were stimulated with anti-CD3/anti-CD28 coated beads and cultured in the presence of IL-2. The expanded Tregs expressed high levels of FOXP3, CTLA4 and HELIOS compared to conventional T cells and were shown to be highly suppressive. Easier access to large numbers of Tregs will allow researchers to address important questions concerning their role in HIV-1 immunopathogenesis. We believe answering these questions may provide useful insight for the development of an effective HIV-1 vaccine.
C1 [Angin, Mathieu; King, Melanie; Addo, Marylyn Martina] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.
[Addo, Marylyn Martina] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Addo, MM (reprint author), Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.
EM maddo@partners.org
OI Angin, Mathieu/0000-0002-6867-4680
FU Elisabeth Glaser Pediatric AIDS Foundation (Pediatric HIV Vaccine
Program) [MV-00-9-900-1429-0-00]; MGH/ECOR (Physician Scientist
Development Award); NIH NIAID [KO8219 AI074405, AI074405-03S1]; Harvard
University Center for AIDS Research (CFAR); NIH [P30 AI060354]; NIAID;
NCI; NICHD; NHLBI; NIDA; NIMH; NIA; FIC; OARBill & Melinda Gates
Foundation; Terry and Susan Ragon Foundation
FX This work was supported in part by research funding from the Elisabeth
Glaser Pediatric AIDS Foundation (Pediatric HIV Vaccine Program Award
MV-00-9-900-1429-0-00 to MMA), MGH/ECOR (Physician Scientist Development
Award to MMA), NIH NIAID (KO8219 AI074405 and AI074405-03S1 to MMA), and
the Harvard University Center for AIDS Research (CFAR), an NIH funded
program (P30 AI060354) which is supported by the following NIH
Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD,
NHLBI, NIDA, NIMH, NIA, FIC, and OAR. These studies were furthermore
supported by the Bill & Melinda Gates Foundation and the Terry and Susan
Ragon Foundation.
NR 30
TC 1
Z9 2
U1 2
U2 5
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD MAY
PY 2013
IS 75
AR UNSP e50244
DI 10.3791/50244
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36RE
UT WOS:000209227700026
PM 23748671
ER
PT J
AU Rigotti, NA
AF Rigotti, Nancy A.
TI Smoking cessation in patients with respiratory disease: existing
treatments and future directions
SO LANCET RESPIRATORY MEDICINE
LA English
DT Review
ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL;
SUSTAINED-RELEASE BUPROPION; NICOTINE REPLACEMENT THERAPY; AMERICAN
THORACIC SOCIETY; RECEPTOR PARTIAL AGONIST; AIR-FLOW LIMITATION;
CLINICAL-TRIAL; UNITED-STATES; GENERAL-PRACTICE
AB Tobacco use is a leading cause of preventable death worldwide. Respiratory diseases, including chronic obstructive pulmonary disease (COPD) and lung cancer, account for a large proportion of tobacco-related deaths. Smoking cessation benefits almost all smokers, irrespective of the age at which they quit, making smoking cessation a core component of prevention and treatment of respiratory diseases. Evidence shows that psychosocial counselling and pharmacotherapy are effective smoking cessation methods and are most effective when used together. The first-line drugs licensed to aid smoking cessation (nicotine replacement therapy, bupropion, and varenicline) are effective in patients with COPD. Efforts are underway to improve the efficacy of existing treatments and increase the proportion of smokers who try to quit, and who use treatment when doing so. However, existing smoking cessation counselling and drugs are among the most cost-effective clinical preventive services available. Incorporation of such treatment into routine clinical practice is essential for provision of high-quality care to all patients, especially those with respiratory disease.
C1 [Rigotti, Nancy A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Rigotti, Nancy A.] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA.
RP Rigotti, NA (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM nrigotti@partners.org
NR 86
TC 17
Z9 18
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD MAY
PY 2013
VL 1
IS 3
BP 241
EP 250
DI 10.1016/S2213-2600(13)70063-8
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AQ3JL
UT WOS:000342688600021
PM 24429130
ER
PT J
AU Zeidan, A
Zhuoxin, S
Prebet, T
Greenberg, P
Juckett, M
Smith, M
Paietta, E
Gabrilove, J
Erba, H
Gore, S
Tallman, M
AF Zeidan, A.
Zhuoxin, S.
Prebet, T.
Greenberg, P.
Juckett, M.
Smith, M.
Paietta, E.
Gabrilove, J.
Erba, H.
Gore, S.
Tallman, M.
TI Application of the French Prognostic Score to assess overall survival in
a US-based cohort of patients treated with azacitidine
SO LEUKEMIA RESEARCH
LA English
DT Meeting Abstract
C1 [Zeidan, A.; Gore, S.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD USA.
[Zhuoxin, S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Prebet, T.] Dept Hematol, Paris, France.
[Prebet, T.] Aix Marseille Univ, Marseille, France.
[Greenberg, P.] Stanford Univ, Ctr Canc, Div Hematol, Stanford, CA 94305 USA.
[Juckett, M.] Univ Wisconsin, Oncol, Madison, WI USA.
[Smith, M.] Cleveland Clin, Oncol, Cleveland, OH 44106 USA.
[Paietta, E.] Montefiore Med Ctr, North Div, Bronx, NY 10467 USA.
[Gabrilove, J.] Mt Sinai Sch Med, Oncol, New York, NY USA.
[Erba, H.] Univ Alabama Birmingham, Oncol, Birmingham, AL USA.
[Tallman, M.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145-2126
EI 1873-5835
J9 LEUKEMIA RES
JI Leuk. Res.
PD MAY
PY 2013
VL 37
SU 1
MA P-124
BP S79
EP S80
PG 2
WC Oncology; Hematology
SC Oncology; Hematology
GA V40RR
UT WOS:000209496200171
ER
PT J
AU Corcoran, RB
Cheng, KA
Hata, AN
Faber, AC
Ebi, H
Coffee, EM
Greninger, P
Brown, RD
Godfrey, JT
Cohoon, TJ
Song, Y
Lifshits, E
Shioda, T
Dias-Santagata, D
Singh, A
Settleman, J
Benes, CH
Mino-Kenudson, M
Wong, KK
Engelman, JA
AF Corcoran, Ryan B.
Cheng, Katherine A.
Hata, Aaron N.
Faber, Anthony C.
Ebi, Hiromichi
Coffee, Erin M.
Greninger, Patricia
Brown, Ronald D.
Godfrey, Jason T.
Cohoon, Travis J.
Song, Youngchul
Lifshits, Eugene
Shioda, Toshi
Dias-Santagata, Dora
Singh, Anurag
Settleman, Jeffrey
Benes, Cyril H.
Mino-Kenudson, Mari
Wong, Kwok-Kin
Engelman, Jeffrey A.
TI Synthetic lethal interaction of combined BCL-XL and MEK inhibition
promotes tumor regressions in KRAS-mutant cancer models
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Meeting Abstract
C1 [Corcoran, Ryan B.; Hata, Aaron N.; Faber, Anthony C.; Ebi, Hiromichi; Coffee, Erin M.; Greninger, Patricia; Brown, Ronald D.; Godfrey, Jason T.; Song, Youngchul; Lifshits, Eugene; Shioda, Toshi; Dias-Santagata, Dora; Benes, Cyril H.; Mino-Kenudson, Mari; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Cheng, Katherine A.; Cohoon, Travis J.; Wong, Kwok-Kin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Singh, Anurag] Boston Univ, Boston, MA 02215 USA.
[Settleman, Jeffrey] Genentech Inc, San Francisco, CA 94080 USA.
OI wong, kwok kin/0000-0001-6323-235X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD MAY
PY 2013
VL 12
IS 5
SU S
MA PR09
DI 10.1158/1535-7163.PMS-PR09
PG 1
WC Oncology
SC Oncology
GA V40RW
UT WOS:000209496700078
ER
PT J
AU Johannessen, CM
Johnson, LA
Piccioni, F
Townes, A
Frederick, DT
Flaherty, KT
Wargo, JA
Root, DE
Garraway, LA
AF Johannessen, Cory M.
Johnson, Laura A.
Piccioni, Federica
Townes, Aisha
Frederick, Dennie T.
Flaherty, Keith T.
Wargo, Jennifer A.
Root, David E.
Garraway, Levi A.
TI A cyclic AMP-regulated melanocyte lineage program confers resistance to
MAP kinase pathway inhibition
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Meeting Abstract
C1 [Johannessen, Cory M.; Johnson, Laura A.; Piccioni, Federica; Townes, Aisha; Root, David E.; Garraway, Levi A.] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Frederick, Dennie T.; Flaherty, Keith T.; Wargo, Jennifer A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD MAY
PY 2013
VL 12
IS 5
SU S
MA PR10
DI 10.1158/1535-7163.PMS-PR10
PG 1
WC Oncology
SC Oncology
GA V40RW
UT WOS:000209496700079
ER
PT J
AU Kawasumi, M
Bradner, JE
Tolliday, N
Thibodeau, R
Sloan, H
Brummond, KM
Nghiem, P
AF Kawasumi, Masaoki
Bradner, James E.
Tolliday, Nicola
Thibodeau, Renee
Sloan, Heather
Brummond, Kay M.
Nghiem, Paul
TI A chemical genetic screen identifies novel ATM/ATR pathway inhibitors
that sensitize p53-deficient cells to DNA-damaging agents without
affecting ATR kinase catalytic activity
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Meeting Abstract
C1 [Kawasumi, Masaoki; Thibodeau, Renee; Sloan, Heather; Nghiem, Paul] Univ Washington, Seattle, WA 98195 USA.
[Bradner, James E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tolliday, Nicola] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Brummond, Kay M.] Univ Pittsburgh, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD MAY
PY 2013
VL 12
IS 5
SU S
MA B04
DI 10.1158/1535-7163.PMS-B04
PG 1
WC Oncology
SC Oncology
GA V40RW
UT WOS:000209496700030
ER
PT J
AU Hsieh, DT
Thiele, EA
AF Hsieh, David T.
Thiele, Elizabeth A.
TI Efficacy and safety of rufinamide in pediatric epilepsy
SO THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
LA English
DT Review
DE anticonvulsants; epilepsy; Lennox-Gastaut syndrome; rufinamide
ID LENNOX-GASTAUT-SYNDROME; ADD-ON RUFINAMIDE; DOUBLE-BLIND; REFRACTORY
EPILEPSY; LONG-TERM; CHILDREN; SEIZURES; TOLERABILITY; TRIAL; POPULATION
AB Rufinamide is a novel anticonvulsant medication approved by the US Food and Drug Administration (FDA) in 2008 for the treatment of seizures associated with Lennox-Gastaut syndrome in patients 4 years of age and older, based upon clinical trials demonstrating clinical efficacy and tolerability. Rufinamide is especially effective for tonic-atonic seizures in Lennox-Gastaut syndrome, but is subsequently proving to be safe and effective in clinical practice for a broad patient population with refractory epilepsy. Although further research and clinical experience is needed, rufinamide holds the promise to positively impact the care of children with epilepsy. In this review, we review the use of rufinamide in pediatric epilepsy, with a focus on efficacy and safety.
C1 [Thiele, Elizabeth A.] Massachusetts Gen Hosp, Pediat Epilepsy Program, Dept Neurol, Boston, MA 02114 USA.
[Hsieh, David T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Thiele, EA (reprint author), Massachusetts Gen Hosp, Pediat Epilepsy Program, Dept Neurol, 175 Cambridge St,Suite 340, Boston, MA 02114 USA.
EM ethiele@partners.org
NR 42
TC 8
Z9 8
U1 2
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1756-2856
EI 1756-2864
J9 THER ADV NEUROL DISO
JI Ther. Adv. Neurol. Disord.
PD MAY
PY 2013
VL 6
IS 3
BP 189
EP 198
DI 10.1177/1756285613481083
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA AH0QI
UT WOS:000335824800004
PM 23634191
ER
PT J
AU Pinsky, PF
Zhu, C
Skates, SJ
Black, A
Partridge, E
Buys, SS
Berg, CD
AF Pinsky, Paul F.
Zhu, Claire
Skates, Steve J.
Black, Amanda
Partridge, Edward
Buys, Saundra S.
Berg, Christine D.
TI Potential effect of the risk of ovarian cancer algorithm (ROCA) on the
mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO)
trial
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE ovarian cancer; Prostate; Lung; Colorectal and Ovarian (PLCO) cancer
trial; risk of ovarian cancer algorithm (ROCA); screening; mortality
AB Recently, the Prostate, Lung, Colorectal and Ovarian (PLCO) Trial reported no mortality benefit for annual screening with CA-125 and transvaginal ultrasound (TVU). Currently ongoing is the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), which utilizes the risk of ovarian cancer algorithm (ROCA), a statistical tool that considers current and past CA125 values to determine ovarian cancer risk. In contrast, PLCO used a single cutoff for CA125, based on current levels alone. We investigated whether having had used ROCA in PLCO could have, under optimal assumptions, resulted in a significant mortality benefit by applying ROCA to PLCO CA125 screening values. A best-case scenario assumed that all cancers showing a positive screen result earlier with ROCA than under the PLCO protocol would have avoided mortality; under a stage-shift scenario, such women were assigned survival equivalent to Stage I/II screen-detected cases. Updated PLCO data show 132 intervention arm ovarian cancer deaths versus 119 in usual care (relative risk, RR = 1.11). Forty-three ovarian cancer cases, 25 fatal, would have been detected earlier with ROCA, with a median (minimum) advance time for fatal cases of 344 (147) days. Best-case and stage-shift scenarios gave 25 and 19 deaths prevented with ROCA, for RRs of 0.90 (95% CI: 0.691.17) and 0.95 (95% CI: 0.741.23), respectively. Having utilized ROCA in PLCO would not have led to a significant mortality benefit of screening. However, ROCA could still show a significant effect in other screening trials, including UKCTOCS.
C1 [Pinsky, Paul F.; Zhu, Claire; Berg, Christine D.] NCI, Canc Prevent Div, NIH, Bethesda, MD 20892 USA.
[Skates, Steve J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Black, Amanda] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Partridge, Edward] Univ Alabama Birmingham, Birmingham, AL USA.
[Buys, Saundra S.] Univ Utah, Salt Lake City, UT USA.
RP Pinsky, PF (reprint author), 6130 Execut Blvd,EPN 3064, Bethesda, MD 20892 USA.
EM pp4f@nih.gov
RI Berg , Christine/K-1047-2014
NR 9
TC 16
Z9 16
U1 0
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD MAY 1
PY 2013
VL 132
IS 9
BP 2127
EP 2133
DI 10.1002/ijc.27909
PG 7
WC Oncology
SC Oncology
GA 092KV
UT WOS:000315121100016
PM 23065684
ER
PT J
AU Pavlova, NN
Pallasch, C
Elia, AEH
Braun, CJ
Westbrook, TF
Hemann, M
Elledge, SJ
AF Pavlova, Natalya N.
Pallasch, Christian
Elia, Andrew E. H.
Braun, Christian J.
Westbrook, Thomas F.
Hemann, Michael
Elledge, Stephen J.
TI A role for PVRL4-driven cell-cell interactions in tumorigenesis
SO ELIFE
LA English
DT Article
ID CIRCULATING TUMOR-CELLS; BREAST-CANCER; LUNG-CANCER; EXPRESSION;
NECTIN-4; METASTASIS; CARCINOMA; MIGRATION; INTEGRIN-BETA-4;
IDENTIFICATION
AB During all stages of tumor progression, cancer cells are subjected to inappropriate extracellular matrix environments and must undergo adaptive changes in order to evade growth constraints associated with the loss of matrix attachment. A gain of function screen for genes that enable proliferation independently of matrix anchorage identified a cell adhesion molecule PVRL4 (poliovirus-receptor-like 4), also known as Nectin-4. PVRL4 promotes anchorage-independence by driving cell-to-cell attachment and matrix-independent integrin beta 4/SHP-2/c-Src activation. Solid tumors frequently have copy number gains of the PVRL4 locus and some have focal amplifications. We demonstrate that the transformation of breast cancer cells is dependent on PVRL4. Furthermore, growth of orthotopically implanted tumors in vivo is inhibited by blocking PVRL4-driven cell-to-cell attachment with monoclonal antibodies, demonstrating a novel strategy for targeted therapy of cancer.
C1 [Pavlova, Natalya N.; Elia, Andrew E. H.; Elledge, Stephen J.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.
[Pavlova, Natalya N.; Elia, Andrew E. H.; Elledge, Stephen J.] Brigham & Womens Hosp, Howard Hughes Med Inst, Div Genet, Boston, MA 02115 USA.
[Pallasch, Christian; Braun, Christian J.; Hemann, Michael] MIT, Koch Inst Integrat Canc Res, Dept Biol, Boston, MA USA.
[Elia, Andrew E. H.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Westbrook, Thomas F.] Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Pediat,Dept Mol & Human Genet, Verna & Marrs McLean Dept Biochem & Mol Biol, Boston, MA USA.
RP Elledge, SJ (reprint author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.
EM selledge@genetics.med.harvard.edu
RI Braun, Christoph/J-4160-2014;
OI Braun, Christoph/0000-0002-7836-4010; Pallasch, Christian
P./0000-0001-5675-6905
FU Department of Defense BCRP; Howard Hughes Medical Institute
FX Department of Defense BCRP Stephen Elledge; Howard Hughes Medical
Institute Stephen Elledge
NR 44
TC 22
Z9 22
U1 0
U2 1
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD APR 30
PY 2013
VL 2
AR e00358
DI 10.7554/eLife.00358
PG 24
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 274OB
UT WOS:000328614700001
PM 23682311
ER
PT J
AU McAndrew, LM
D'Andrea, E
Lu, SE
Abbi, B
Yan, GW
Engel, C
Quigley, KS
AF McAndrew, Lisa M.
D'Andrea, Elizabeth
Lu, Shou-En
Abbi, Bhavna
Yan, Grace W.
Engel, Charles
Quigley, Karen S.
TI What pre-deployment and early post-deployment factors predict health
function after combat deployment?: a prospective longitudinal study of
Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) soldiers
SO HEALTH AND QUALITY OF LIFE OUTCOMES
LA English
DT Article
DE Health function; Quality of life; Veterans; Military; Prospective;
SF-36; Iraq; Afghanistan; Combat
ID POSTTRAUMATIC-STRESS-DISORDER; OF-VETERANS-AFFAIRS; MENTAL-HEALTH;
PHYSICAL HEALTH; SOCIAL SUPPORT; WAR VETERANS; VIETNAM VETERANS; SOMATIC
SYMPTOMS; CARE UTILIZATION; AFGHANISTAN
AB Background: Physical and mental function are strong indicators of disability and mortality. OEF/OIF Veterans returning from deployment have been found to have poorer function than soldiers who have not deployed; however the reasons for this are unknown.
Methods: A prospective cohort of 790 soldiers was assessed both pre- and immediately after deployment to determine predictors of physical and mental function after war.
Results: On average, OEF/OIF Veterans showed significant declines in both physical (t=6.65, p<.0001) and mental function (t=7.11, p<.0001). After controlling for pre-deployment function, poorer physical function after deployment was associated with older age, more physical symptoms, blunted systolic blood pressure reactivity and being injured. After controlling for pre-deployment function, poorer mental function after deployment was associated with younger age, lower social desirability, lower social support, greater physical symptoms and greater PTSD symptoms.
Conclusions: Combat deployment was associated with an immediate decline in both mental and physical function. The relationship of combat deployment to function is complex and influenced by demographic, psychosocial, physiological and experiential factors. Social support and physical symptoms emerged as potentially modifiable factors.
C1 [McAndrew, Lisa M.; Abbi, Bhavna; Yan, Grace W.] Dept Vet Affairs, NJ War Related Illness & Injury Study Ctr, E Orange, NJ 07018 USA.
[McAndrew, Lisa M.; Lu, Shou-En] Univ Med & Dent New Jersey, Sch Publ Hlth, Piscataway, NJ 08854 USA.
[D'Andrea, Elizabeth] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Engel, Charles] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Psychiat, Bethesda, MD 20814 USA.
[Quigley, Karen S.] Bedford Mem Hosp, Dept Vet Affairs, Bedford, MA USA.
[Quigley, Karen S.] Northeastern Univ, Interdisciplinary Affect Sci Lab, Boston, MA USA.
RP McAndrew, LM (reprint author), Dept Vet Affairs, NJ War Related Illness & Injury Study Ctr, 385 Tremont Ave Mailstop 129, E Orange, NJ 07018 USA.
EM Lisa.mcandrew@va.gov
FU Department of Veterans Affairs, Health Services Research & Development
Service [IIR 0202-296]; NJ War Related Illness and Injury Study Center;
NJ REAP [REA 03-021]; Deployment Health Clinical Center, Walter Reed
Army Medical Center
FX This study was supported by grants from the Department of Veterans
Affairs, Health Services Research & Development Service (IIR 0202-296 to
K. Quigley); the NJ War Related Illness and Injury Study Center, the NJ
REAP (REA 03-021); and the Deployment Health Clinical Center, Walter
Reed Army Medical Center.
NR 52
TC 10
Z9 10
U1 3
U2 21
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-7525
J9 HEALTH QUAL LIFE OUT
JI Health Qual. Life Outcomes
PD APR 30
PY 2013
VL 11
AR 73
DI 10.1186/1477-7525-11-73
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 178NR
UT WOS:000321455200001
PM 23631419
ER
PT J
AU Menden, MP
Iorio, F
Garnett, M
McDermott, U
Benes, CH
Ballester, PJ
Saez-Rodriguez, J
AF Menden, Michael P.
Iorio, Francesco
Garnett, Mathew
McDermott, Ultan
Benes, Cyril H.
Ballester, Pedro J.
Saez-Rodriguez, Julio
TI Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on
Genomic and Chemical Properties
SO PLOS ONE
LA English
DT Article
ID GENE-EXPRESSION SIGNATURES; INTEGRATIVE ANALYSIS; DISCOVERY DATABASES;
ANTICANCER ACTIVITY; SMALL MOLECULES; LINE SET; INHIBITION; PATTERNS;
COMPARE; QSAR
AB Predicting the response of a specific cancer to a therapy is a major goal in modern oncology that should ultimately lead to a personalised treatment. High-throughput screenings of potentially active compounds against a panel of genomically heterogeneous cancer cell lines have unveiled multiple relationships between genomic alterations and drug responses. Various computational approaches have been proposed to predict sensitivity based on genomic features, while others have used the chemical properties of the drugs to ascertain their effect. In an effort to integrate these complementary approaches, we developed machine learning models to predict the response of cancer cell lines to drug treatment, quantified through IC50 values, based on both the genomic features of the cell lines and the chemical properties of the considered drugs. Models predicted IC50 values in a 8-fold cross-validation and an independent blind test with coefficient of determination R-2 of 0.72 and 0.64 respectively. Furthermore, models were able to predict with comparable accuracy (R-2 of 0.61) IC50s of cell lines from a tissue not used in the training stage. Our in silico models can be used to optimise the experimental design of drug-cell screenings by estimating a large proportion of missing IC50 values rather than experimentally measuring them. The implications of our results go beyond virtual drug screening design: potentially thousands of drugs could be probed in silico to systematically test their potential efficacy as anti-tumour agents based on their structure, thus providing a computational framework to identify new drug repositioning opportunities as well as ultimately be useful for personalized medicine by linking the genomic traits of patients to drug sensitivity.
C1 [Menden, Michael P.; Iorio, Francesco; Ballester, Pedro J.; Saez-Rodriguez, Julio] Wellcome Trust Genome Campus Cambridge, European Bioinformat Inst, Cambridge, England.
[Iorio, Francesco; Garnett, Mathew; McDermott, Ultan] Wellcome Trust Genome Campus Cambridge, Wellcome Trust Sanger Inst, Canc Genome Project, Cambridge, England.
[Benes, Cyril H.] Massachusetts Gen Hosp, Ctr Canc, Ctr Mol Therapeut, Charlestown, MA USA.
[Benes, Cyril H.] Harvard Univ, Sch Med, Charlestown, MA USA.
RP Ballester, PJ (reprint author), Wellcome Trust Genome Campus Cambridge, European Bioinformat Inst, Cambridge, England.
EM pedro.ballester@ebi.ac.uk; saezrodriguez@ebi.ac.uk
RI Ballester, Pedro/A-1148-2008;
OI Ballester, Pedro/0000-0002-4078-743X; Iorio,
Francesco/0000-0001-7063-8913; McDermott, Ultan/0000-0001-9032-4700;
Saez-Rodriguez, Julio/0000-0002-8552-8976
FU European Molecular Biology Laboratory PhD programme; Sanger/European
Bioinformatics Institute ESPOD programme; Medical Research Council
Methodology Research Fellowship; Wellcome Trust grant; Cancer Research
UK
FX This work was funded by the European Molecular Biology Laboratory PhD
programme to MPM, the Sanger/European Bioinformatics Institute ESPOD
programme to FI, a Medical Research Council Methodology Research
Fellowship to PJB, a Wellcome Trust grant to MG and CHB, and Cancer
Research UK to UM. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 41
TC 40
Z9 40
U1 3
U2 30
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 30
PY 2013
VL 8
IS 4
AR e61318
DI 10.1371/journal.pone.0061318
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146GG
UT WOS:000319077300006
PM 23646105
ER
PT J
AU Cesana, M
Daley, GQ
AF Cesana, Marcella
Daley, George Q.
TI Deciphering the rules of ceRNA networks
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Editorial Material
ID MICRORNA SPONGES; RNAS
C1 [Cesana, Marcella; Daley, George Q.] Boston Childrens Hosp, Div Pediat Hematol Oncol, Stem Cell Transplantat Program, Boston, MA 02115 USA.
[Cesana, Marcella; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cesana, Marcella; Daley, George Q.] Harvard Stem Cell Inst, Boston, MA 02115 USA.
[Cesana, Marcella; Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Cesana, Marcella; Daley, George Q.] Manton Ctr Orphan Dis Res, Boston, MA 02115 USA.
[Cesana, Marcella; Daley, George Q.] Howard Hughes Med Inst, Boston, MA 02115 USA.
RP Daley, GQ (reprint author), Boston Childrens Hosp, Div Pediat Hematol Oncol, Stem Cell Transplantat Program, Boston, MA 02115 USA.
EM george.daley@childrens.harvard.edu
FU Howard Hughes Medical Institute; NHGRI NIH HHS [P50 HG005550]; NHLBI NIH
HHS [U01 HL100001, UO1-HL100001]; NIAID NIH HHS [R01 AI100887]; NIDDK
NIH HHS [R24 DK092760, R24-DK092760, RC4 DK090913, RC4DK 090913]; NIGMS
NIH HHS [P01 GM099117]
NR 13
TC 17
Z9 17
U1 1
U2 27
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 30
PY 2013
VL 110
IS 18
BP 7112
EP 7113
DI 10.1073/pnas.1305322110
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 140UV
UT WOS:000318682300014
PM 23620514
ER
PT J
AU Ueno, K
Hirata, H
Shahryari, V
Deng, G
Tanaka, Y
Tabatabai, ZL
Hinoda, Y
Dahiya, R
AF Ueno, K.
Hirata, H.
Shahryari, V.
Deng, G.
Tanaka, Y.
Tabatabai, Z. L.
Hinoda, Y.
Dahiya, R.
TI microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE prostate cancer; miRNA-183; Dkk-3; SMAD4
ID GROWTH-FACTOR-BETA; DPC4 SMAD4; EXPRESSION; CELLS; GENE; PROGRESSION;
CARCINOMA; RISK; APOPTOSIS; DEATH
AB Background: The purpose of this study was to identify prostate cancer (PC) oncogenic microRNAs (miRs) based on miR microarray and to investigate whether these oncogenic miRs may be useful as PC biomarkers.
Methods: Initially, we carried out miR microarray and real-time PCR using RWPE-1, PC-3, DU-145 and LNCaP cells. To investigate the function of miR-183, we used a miR-183 knockdown inhibitor in cell growth and wound-healing assays. We used several algorithms and confirmed that they are directly regulated by miR-183.
Results: We identified three potential oncogenic miRs (miR-146a, miR-183 and miR-767-5P). The expression of miR-183 in PC cells (PC-3, DU-145 and LNCaP) was upregulated compared with RWPE-1 cells. MiR-183 expression was also significantly higher in PC tissues compared with that in matched normal prostate tissues. Additionally, miR-183 expression was correlated with higher prostate-specific antigen, higher pT and shorter overall survival. MiR-183 knockdown decreased cell growth and motility in PC cells and significantly decreased prostate tumour growth in in vivo nude mice experiments. We identified Dkk-3 and SMAD4 as potential target genes of miR-183.
Conclusion: Our data suggest that oncogenic miR-183 may be useful as a new PC biomarker and that inhibition of miR-183 expression may be therapeutically beneficial as a PC treatment.
C1 [Ueno, K.; Hirata, H.; Shahryari, V.; Deng, G.; Tanaka, Y.; Dahiya, R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Urol, San Francisco, CA 94121 USA.
[Tabatabai, Z. L.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Pathol, San Francisco, CA 94121 USA.
[Hinoda, Y.] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Ube, Yamaguchi 755, Japan.
RP Dahiya, R (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU National Center for Research Resources of the National Institutes of
Health [R01CA138642, R01CA130860, R01CA160079]; VA Merit Review grants;
VA Program Project
FX We thank Dr Roger Erickson for his support and assistance with the
preparation of the manuscript. This study was supported by National
Center for Research Resources of the National Institutes of Health
through Grant Number R01CA138642, R01CA130860, R01CA160079, VA Merit
Review grants and VA Program Project.
NR 31
TC 45
Z9 49
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD APR 30
PY 2013
VL 108
IS 8
BP 1659
EP 1667
DI 10.1038/bjc.2013.125
PG 9
WC Oncology
SC Oncology
GA 137AJ
UT WOS:000318406400014
PM 23538390
ER
PT J
AU Nallamothu, BK
Spertus, JA
Lansky, AJ
Cohen, DJ
Jones, PG
Kureshi, F
Dehmer, GJ
Drozda, JP
Walsh, MN
Brush, JE
Koenig, GC
Waites, TF
Gantt, S
Kichura, G
Chazal, RA
O'Brien, PK
Valentine, CM
Rumsfeld, JS
Reiber, JHC
Elmore, JG
Krumholz, RA
Weaver, WD
Krumholz, HM
AF Nallamothu, Brahmajee K.
Spertus, John A.
Lansky, Alexandra J.
Cohen, David J.
Jones, Philip G.
Kureshi, Faraz
Dehmer, Gregory J.
Drozda, Joseph P., Jr.
Walsh, Mary Norine
Brush, John E., Jr.
Koenig, Gerald C.
Waites, Thad F.
Gantt, Scott
Kichura, George
Chazal, Richard A.
O'Brien, Peter K.
Valentine, C. Michael
Rumsfeld, John S.
Reiber, Johan H. C.
Elmore, Joann G.
Krumholz, Richard A.
Weaver, W. Douglas
Krumholz, Harlan M.
TI Comparison of Clinical Interpretation With Visual Assessment and
Quantitative Coronary Angiography in Patients Undergoing Percutaneous
Coronary Intervention in Contemporary Practice The Assessing Angiography
(A2) Project
SO CIRCULATION
LA English
DT Article
DE coronary angiography; health policy; outcome assessment (health care);
percutaneous coronary intervention; quality improvement
ID COMPUTER-AIDED DETECTION; ASSOCIATION TASK-FORCE; CARDIOVASCULAR
ANGIOGRAPHY; CARDIAC-CATHETERIZATION; SCREENING MAMMOGRAPHY; PRACTICE
GUIDELINES; LESION SEVERITY; STENOSIS; ARTERIOGRAMS; VARIABILITY
AB Background-Studies conducted decades ago described substantial disagreement and errors in physicians' angiographic interpretation of coronary stenosis severity. Despite the potential implications of such findings, no large-scale efforts to measure or improve clinical interpretation were subsequently undertaken.
Methods and Results-We compared clinical interpretation of stenosis severity in coronary lesions with an independent assessment using quantitative coronary angiography (QCA) in 175 randomly selected patients undergoing elective percutaneous coronary intervention at 7 US hospitals in 2011. To assess agreement, we calculated mean difference in percent diameter stenosis between clinical interpretation and QCA and a Cohen weighted kappa statistic. Of 216 treated lesions, median percent diameter stenosis was 80.0% (quartiles 1 and 3, 80.0% and 90.0%), with 213 (98.6%) assessed as >= 70%. Mean difference in percent diameter stenosis between clinical interpretation and QCA was 8.2 +/- 8.4%, reflecting an average higher percent diameter stenosis by clinical interpretation (P<0.001). A weighted kappa of 0.27 (95% confidence interval, 0.18-0.36) was found between the 2 measurements. Of 213 lesions considered >= 70% by clinical interpretation, 56 (26.3%) were <70% by QCA, although none were <50%. Differences between the 2 measurements were largest for intermediate lesions by QCA (50% to <70%), with variation existing across sites.
Conclusions-Physicians tended to assess coronary lesions treated with percutaneous coronary intervention as more severe than measurements by QCA. Almost all treated lesions were >= 70% by clinical interpretation, whereas approximately one quarter were <70% by QCA. These findings suggest opportunities to improve clinical interpretation of coronary angiography. (Circulation. 2013;127:1793-1800.)
C1 [Nallamothu, Brahmajee K.] Ann Arbor VA Ctr Clin Management & Res, Ann Arbor, CT USA.
[Nallamothu, Brahmajee K.] Univ Michigan Hlth Syst, Ann Arbor, CT USA.
[Spertus, John A.; Cohen, David J.; Jones, Philip G.; Kureshi, Faraz] St Lukes Mid Amer Heart Inst, Kansas City, CT USA.
[Spertus, John A.; Cohen, David J.; Jones, Philip G.; Kureshi, Faraz] Univ Missouri Kansas City, Kansas City, CT USA.
[Lansky, Alexandra J.] Yale Univ, Sch Med, New Haven, CT USA.
[Dehmer, Gregory J.] Texas A&M Univ, Coll Med, Hlth Sci Ctr, Temple, TX 76508 USA.
[Dehmer, Gregory J.] Scott & White Healthcare, Temple, TX USA.
[Drozda, Joseph P., Jr.; Kichura, George] Mercy Hlth, St Louis, MO USA.
[Walsh, Mary Norine] St Vincent Heart Ctr Indiana, Indianapolis, VA USA.
[Brush, John E., Jr.] Sentara Cardiovasc Res Inst, Norfolk, VA USA.
[Brush, John E., Jr.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA.
[Koenig, Gerald C.; Weaver, W. Douglas] Henry Ford Hlth Syst, Detroit, MI USA.
[Waites, Thad F.; Weaver, W. Douglas] Wayne State Univ, Detroit, MI USA.
[Waites, Thad F.] Forrest Gen, Hattiesburg, MS USA.
[Chazal, Richard A.] Lee Mem Hlth Syst, Ft Myers, FL USA.
[O'Brien, Peter K.; Valentine, C. Michael] Centra Lynchburg Gen Hosp, Lynchburg, VA USA.
[Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA.
[Reiber, Johan H. C.] Leiden Univ, Dept Radiol, Med Ctr, Leiden, Netherlands.
[Elmore, Joann G.] Univ Washington, Dept Med, Seattle, FL USA.
[Krumholz, Richard A.] ImageCor, Bradenton, FL USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA.
[Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Ctr Outcomes Res & Evaluat, New Haven, CT USA.
[Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Adm, New Haven, CT USA.
RP Nallamothu, BK (reprint author), Univ Michigan, Ctr Cardiovasc, SPC 5869,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM bnallamo@umich.edu
FU Aetna, Inc.; National Institutes of Health [T32HL110837]; Yale
University, from Medtronic; National Heart, Lung, and Blood Institute
[U01 HL105270-03]
FX Dr Spertus reports grant funding from Aetna, Inc. Dr Cohen reports
consulting income from United Healthcare. Dr Kureshi received support
from National Institutes of Health grant T32HL110837. Dr Walsh reports
consulting income from United Healthcare and Eli Lilly. Dr Chazal
reports being a member of the Scientific Advisory Board of United
Healthcare. Dr Rumsfeld reports being the chief science officer for the
NCDR. Dr Reiber reports being the president and chief executive officer
of Medis, which provides software for the quantification of
cardiovascular images. Dr Richard Krumholz reports being the General
Manager of ImageCor, a company focused on improving clinical
interpretation of medical imaging. Dr Harlan Krumholz reports equity
interest in ImageCor and being chair of the Scientific Advisory Board of
United Healthcare and a recipient of a research grant, through Yale
University, from Medtronic. Dr Harlan Krumholz also is supported by
grant U01 HL105270-03 (Center for Cardiovascular Outcomes Research at
Yale University) from the National Heart, Lung, and Blood Institute. The
other authors report no conflicts.
NR 32
TC 34
Z9 35
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD APR 30
PY 2013
VL 127
IS 17
BP 1793
EP +
DI 10.1161/CIRCULATIONAHA.113.001952
PG 13
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 134MT
UT WOS:000318215000013
PM 23470859
ER
PT J
AU Beaudoin, J
Handschumacher, MD
Zeng, X
Hung, JD
Morris, EL
Levine, RA
Schwammenthal, E
AF Beaudoin, Jonathan
Handschumacher, Mark D.
Zeng, Xin
Hung, Judy
Morris, Eleanor L.
Levine, Robert A.
Schwammenthal, Ehud
TI Mitral Valve Enlargement in Chronic Aortic Regurgitation as a
Compensatory Mechanism to Prevent Functional Mitral Regurgitation in the
Dilated Left Ventricle
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE aortic regurgitation; functional mitral regurgitation; valvular disease
ID ACUTE MYOCARDIAL-INFARCTION; NATURAL-HISTORY; HEART-FAILURE;
EXTRACELLULAR-MATRIX; DOPPLER-ECHOCARDIOGRAPHY; ASYMPTOMATIC PATIENTS;
LEAFLET ADAPTATION; CARDIOMYOPATHY; OVERLOAD; DISEASE
AB Objectives The aim of this study was to test the hypothesis that mitral valve (MV) enlargement occurring in chronic aortic regurgitation (AR) prevents functional mitral regurgitation (FMR).
Background Chronic AR causes left ventricular (LV) dilation, creating the potential for FMR. However, FMR is typically absent during compensated AR despite substantial LV enlargement. Increased mitral leaflet area has been identified in AR, but it is unknown whether increased MV size can represent a compensatory mechanism capable of preventing FMR.
Methods Database review of 816 patients with at least moderate AR evaluated the prevalence of FMR. A total of 90 patients were enrolled prospectively for 3-dimensional echocardiography (30 AR, 30 FMR, and 30 controls) to assess MV geometry including total leaflet area.
Results FMR was present in 5.6% of AR patients by database review. Prospectively, only 1 AR patient had more than mild FMR despite increased LV end-diastolic volume (82 +/- 22, 86 +/- 23, and 51 +/- 12 cm(3)/m(2), respectively, for AR, FMR vs. control patients; p < 0.01) and similar sphericity index, annular area, and tethering distances compared with FMR. Total MV area was largest in AR (31.3% greater than normal), increasing significantly more than in FMR. The ratio of valve size to closure area was maintained in AR, whereas decreases in this ratio and LV ejection fraction independently predicted FMR.
Conclusions FMR prevalence is low in chronic AR. MV leaflet area is significantly increased compared with control and FMR patients, preserving a normal relationship to the area needed for closure in the dilated LV. Understanding the mechanisms underlying this adaptation could lead to new therapeutic interventions to prevent FMR. (J Am Coll Cardiol 2013;61:1809-16) (C) 2013 by the American College of Cardiology Foundation
C1 [Beaudoin, Jonathan; Handschumacher, Mark D.; Zeng, Xin; Hung, Judy; Morris, Eleanor L.; Levine, Robert A.] Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
[Beaudoin, Jonathan; Handschumacher, Mark D.; Zeng, Xin; Hung, Judy; Morris, Eleanor L.; Levine, Robert A.] Harvard Univ, Sch Med, Boston, MA USA.
[Schwammenthal, Ehud] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel.
RP Schwammenthal, E (reprint author), Chaim Sheba Med Ctr, Ctr Heart, IL-52621 Tel Hashomer, Israel.
EM ehudsc@gmail.com
FU AHA [10POST4580055]; Leducq Foundation, Paris, France [07CVD04]; NIH
[K24 HL67434, R01 HL109506]
FX Dr. Beaudoin is funded by an AHA-Founders Affiliate post-doctoral
fellowship grant 10POST4580055. Supported in part by grant 07CVD04 of
the Leducq Foundation, Paris, France, for the Leducq Transatlantic
MITRAL Network, and by NIH K24 HL67434 and R01 HL109506. Dr.
Schwammenthal is a consultant to Medtronic Ventor Technologies Ltd. All
other authors have reported that they have no relationships relevant to
the contents of this paper to disclose.
NR 45
TC 24
Z9 25
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 30
PY 2013
VL 61
IS 17
BP 1809
EP 1816
DI 10.1016/j.jacc.2013.01.064
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 129LT
UT WOS:000317842200009
PM 23500248
ER
PT J
AU Hage, FG
AlJaroudi, W
Aggarwal, H
Bhatia, V
Miller, J
Doppalapudi, H
Wazni, O
Iskandrian, AE
AF Hage, Fadi G.
AlJaroudi, Wael
Aggarwal, Himanshu
Bhatia, Vikas
Miller, John
Doppalapudi, Harish
Wazni, Oussama
Iskandrian, Ami E.
TI Outcomes of patients with chronic kidney disease and implantable cardiac
defibrillator: Primary versus secondary prevention
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Chronic kidney disease; Implantable cardiac defibrillator; Mortality;
Primary prevention; Secondary prevention; Sudden cardiac death
ID GLOMERULAR-FILTRATION-RATE; CORONARY-ARTERY-DISEASE; SERUM CREATININE
VALUES; CARDIOVERTER-DEFIBRILLATOR; RENAL-FUNCTION; INDEPENDENT
PREDICTOR; SUDDEN-DEATH; MORTALITY; THERAPY; IMPACT
AB Background: Chronic kidney disease (CKD) is associated with worse survival in patients with implantable cardiac defibrillators (ICDs). This study examined the association of outcomes with CKD in patients receiving an ICD for primary versus secondary prevention.
Methods: The study included 696 patients who underwent ICD placement for clinical reasons (59% primary, 41% secondary prevention) at the University of Alabama at Birmingham between January 2002 and September 2007. CKD was defined as an estimated glomerular filtration rate <60 ml/min/1.73 m(2) but not on dialysis. Outcomes of interest included overall mortality and first appropriate ICD therapy (shocks or anti-tachycardia pacing).
Results: After a follow-up of 50 +/- 24 months, 213 patients died (31%) and 111 (16%) received appropriate ICD therapy. Patients with CKD had higher mortality than patients with no CKD in the primary (43% vs. 15%, p<0.001) and secondary prevention (37% vs. 23%, p=0.003) groups. Patients with CKD were at higher risk of receiving an appropriate ICD therapy than patients without CKD in the primary (p<0.001) but not secondary prevention (p=0.9) cohort. After adjusting for age, gender and multiple risk factors, CKD was independently associated with all-cause mortality and ICD therapy in the primary prevention group (HR 2.08 [1.34-3.23] and 3.53 [1.75-7.10], p=0.001 and <0.0001, respectively) but not in the secondary prevention group (HR 1.27 [0.81-2.00], and 0.63 [0.35-1.13], p=0.3 and 0.2, respectively).
Conclusions: CKD is independently associated with increased mortality and appropriate ICD therapy in patients undergoing ICD implantation for primary but not secondary prevention. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Hage, Fadi G.; Doppalapudi, Harish; Iskandrian, Ami E.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA.
[AlJaroudi, Wael; Wazni, Oussama] Cleveland Clin, Div Cardiovasc Med, Sect Imaging, Cleveland, OH USA.
[Aggarwal, Himanshu; Bhatia, Vikas; Miller, John] Univ Alabama Birmingham, Dept Med, Div Internal Med, Birmingham, AL 35294 USA.
RP Hage, FG (reprint author), Zeigler Res Bldg 1024,1530 3rd AVE S, Birmingham, AL 35294 USA.
EM fadihage@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
NR 19
TC 8
Z9 8
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD APR 30
PY 2013
VL 165
IS 1
BP 113
EP 116
DI 10.1016/j.ijcard.2011.07.087
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 122VU
UT WOS:000317347100026
PM 21862150
ER
PT J
AU Martinelli, R
Kamei, M
Sage, PT
Massol, R
Varghese, L
Sciuto, T
Toporsian, M
Dvorak, AM
Kirchhausen, T
Springer, TA
Carman, CV
AF Martinelli, Roberta
Kamei, Masataka
Sage, Peter T.
Massol, Ramiro
Varghese, Laya
Sciuto, Tracey
Toporsian, Mourad
Dvorak, Ann M.
Kirchhausen, Tomas
Springer, Timothy A.
Carman, Christopher V.
TI Release of cellular tension signals self-restorative ventral
lamellipodia to heal barrier micro-wounds
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID INVADOSOME-LIKE PROTRUSIONS; MEMBRANE TENSION; NAD(P)H OXIDASE;
BLOOD-CELLS; NEUTROPHIL EXTRAVASATION; TRANSCELLULAR DIAPEDESIS;
LEUKOCYTE DIAPEDESIS; ENDOTHELIAL-CELLS; FOCAL ADHESIONS; STRESS FIBERS
AB Basic mechanisms by which cellular barriers sense and respond to integrity disruptions remain poorly understood. Despite its tenuous structure and constitutive exposure to disruptive strains, the vascular endothelium exhibits robust barrier function. We show that in response to micrometer-scale disruptions induced by transmigrating leukocytes, endothelial cells generate unique ventral lamellipodia that propagate via integrins toward and across these "micro-wounds" to close them. This novel actin remodeling activity progressively healed multiple micro-wounds in succession and changed direction during this process. Mechanical probe-induced micro-wounding of both endothelia and epithelia suggests that ventral lamellipodia formed as a response to force imbalance and specifically loss of isometric tension. Ventral lamellipodia were enriched in the Rac1 effectors cortactin, IQGAP, and p47Phox and exhibited localized production of hydrogen peroxide. Together with Apr2/3, these were functionally required for effective micro-wound healing. We propose that barrier disruptions are detected as local release of isometric tension/force unloading, which is directly coupled to reactive oxygen species-dependent self-restorative actin remodeling dynamics.
C1 [Martinelli, Roberta; Kamei, Masataka; Sage, Peter T.; Varghese, Laya; Toporsian, Mourad; Carman, Christopher V.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Ctr Vasc Biol Res, Boston, MA 02215 USA.
[Sciuto, Tracey; Dvorak, Ann M.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol,Ctr Vasc Biol Res, Boston, MA 02215 USA.
[Massol, Ramiro; Kirchhausen, Tomas; Springer, Timothy A.] Harvard Univ, Sch Med, Childrens Hosp, Dept Pediat, Boston, MA 02115 USA.
[Kirchhausen, Tomas; Springer, Timothy A.] Harvard Univ, Sch Med, Childrens Hosp, Immune Dis Inst, Boston, MA 02115 USA.
[Kirchhausen, Tomas] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
[Springer, Timothy A.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
RP Carman, CV (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Ctr Vasc Biol Res, Boston, MA 02215 USA.
EM ccarman@bidmc.harvard.edu
RI Carman, Christopher/L-8108-2016
OI Carman, Christopher/0000-0001-7358-2548
FU National Institutes of Health [R01 GM075252, R01 CA31798, R01 HL104006]
FX This work was supported by National Institutes of Health grants R01
GM075252 (T. Kirchhausen), R01 CA31798 (T.A. Springer), and R01 HL104006
(C.V. Carman).
NR 78
TC 36
Z9 36
U1 0
U2 9
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0021-9525
J9 J CELL BIOL
JI J. Cell Biol.
PD APR 29
PY 2013
VL 201
IS 3
BP 449
EP 465
DI 10.1083/jcb.201209077
PG 17
WC Cell Biology
SC Cell Biology
GA 134MU
UT WOS:000318215100010
PM 23629967
ER
PT J
AU Salmon, DA
Proschan, M
Forshee, R
Gargiullo, P
Bleser, W
Burwen, DR
Cunningham, F
Garman, P
Greene, SK
Lee, GM
Vellozzi, C
Yih, WK
Gellin, B
Lurie, N
AF Salmon, Daniel A.
Proschan, Michael
Forshee, Richard
Gargiullo, Paul
Bleser, William
Burwen, Dale R.
Cunningham, Francesca
Garman, Patrick
Greene, Sharon K.
Lee, Grace M.
Vellozzi, Claudia
Yih, W. Katherine
Gellin, Bruce
Lurie, Nicole
CA H1N1 GBS Meta-Anal Working Grp
TI Association between Guillain-Barre syndrome and influenza A (H1N1) 2009
monovalent inactivated vaccines in the USA: a meta-analysis
SO LANCET
LA English
DT Article
ID SAFETY DATALINK PROJECT; PRACTICE RESEARCH DATABASE; UNITED-STATES;
IMMUNIZATION-SAFETY; VACCINATION; SURVEILLANCE; RECEIPT; PROGRAM;
KINGDOM; COHORT
AB Background The influenza A (H1N1) 2009 monovalent vaccination programme was the largest mass vaccination initiative in recent US history. Commensurate with the size and scope of the vaccination programme, a project to monitor vaccine adverse events was undertaken, the most comprehensive safety surveillance agenda in the USA to date. The adverse event monitoring project identified an increased risk of Guillain-Barre syndrome after vaccination; however, some individual variability in results was noted. Guillain-Barre syndrome is a rare but serious health disorder in which a person's own immune system damages their nerve cells, causing muscle weakness, sometimes paralysis, and infrequently death. We did a meta-analysis of data from the adverse event monitoring project to ascertain whether influenza A (H1N1) 2009 monovalent inactivated vaccines used in the USA increased the risk of Guillain-Barre syndrome.
Methods Data were obtained from six adverse event monitoring systems. About 23 million vaccinated people were included in the analysis. The primary analysis entailed calculation of incidence rate ratios and attributable risks of excess cases of Guillain-Barre syndrome per million vaccinations. We used a self-controlled risk-interval design.
Findings Influenza A (H1N1) 2009 monovalent inactivated vaccines were associated with a small increased risk of Guillain-Barre syndrome (incidence rate ratio 2.35, 95% CI 1.42-4.01, p=0.0003). This finding translated to about 1.6 excess cases of Guillain-Barre syndrome per million people vaccinated.
Interpretation The modest risk of Guillain-Barre syndrome attributed to vaccination is consistent with previous estimates of the disorder after seasonal influenza vaccination. A risk of this small magnitude would be difficult to capture during routine seasonal influenza vaccine programmes, which have extensive, but comparatively less, safety monitoring. In view of the morbidity and mortality caused by 2009 H1N1 influenza and the effectiveness of the vaccine, clinicians, policy makers, and those eligible for vaccination should be assured that the benefits of inactivated pandemic vaccines greatly outweigh the risks.
C1 [Salmon, Daniel A.; Bleser, William; Gellin, Bruce] Dept Hlth & Human Serv, Natl Vaccine Program Off, Off Assistant Secretary Hlth, Washington, DC USA.
[Lurie, Nicole] Dept Hlth & Human Serv, Washington, DC USA.
[Salmon, Daniel A.] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, Baltimore, MD 21205 USA.
[Proschan, Michael] NIH, Bethesda, MD 20892 USA.
[Forshee, Richard; Burwen, Dale R.] US FDA, Rockville, MD 20857 USA.
[Gargiullo, Paul; Vellozzi, Claudia] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Cunningham, Francesca] US Dept Vet Affairs, Hines, IL USA.
[Garman, Patrick] US Dept Def, Washington, DC 20305 USA.
[Greene, Sharon K.; Lee, Grace M.; Yih, W. Katherine] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA.
[Greene, Sharon K.; Lee, Grace M.; Yih, W. Katherine] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
RP Salmon, DA (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, Baltimore, MD 21205 USA.
EM dsalmon@jhsph.edu
OI Jacobsen, Steven/0000-0002-8174-8533; Bleser,
William/0000-0002-4640-8680
FU US Federal Government
FX US Federal Government.
NR 40
TC 55
Z9 55
U1 0
U2 74
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 27
PY 2013
VL 381
IS 9876
BP 1461
EP 1468
DI 10.1016/S0140-6736(12)62189-8
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 139TK
UT WOS:000318607300035
PM 23498095
ER
PT J
AU Tsai, TY
Li, JS
Wang, SB
Lin, H
Malchau, H
Li, GA
Rubash, H
Kwon, YM
AF Tsai, Tsung-Yuan
Li, Jing-Sheng
Wang, Shaobai
Lin, Hao
Malchau, Henrik
Li, Guoan
Rubash, Harry
Kwon, Young-Min
TI A novel dual fluoroscopic imaging method for determination of THA
kinematics: In-vitro and in-vivo study
SO JOURNAL OF BIOMECHANICS
LA English
DT Article
DE Total hip arthroplasty; Kinematics; Fluoroscope; Validation;
Non-invasive
ID TOTAL HIP-ARTHROPLASTY; SINGLE-PLANE FLUOROSCOPY; METAL-ON-METAL;
MATCHING METHOD; JOINT; SYSTEM; REGISTRATION; SEPARATION; WALKING;
IMAGES
AB Accurate measurement of six-degrees-of-freedom in-vivo kinematics of the total hip arthroplasty (THA) is essential in gaining insights into in-vivo THA performance. The objective of this study was to validate a novel dual fluoroscopy imaging system (DFIS) for determination of the THA kinematics using both in-vitro and in-vivo approaches. The in-vitro validation utilized cadaveric hip specimens to compare the THA motion using the DFIS technique with those measured by a radiostereometric analysis (RSA). The differences between the DFIS technique and the RSA were within 033 +/- 0.81 mm (mean +/- SD) in translation and 0.45 +/- 0.65 degrees in rotation during dynamic motion of the hips. In the in-vivo validation, the THA kinematics of two patients during a treadmill gait was assessed for the feasibility/repeatability of the DFIS technique in measurement of THA kinematics. The poses of the THAs during the treadmill gait was measured using the DFIS technique with the maximum standard deviation of 0.35 mm in translation and of 0.55 degrees in rotation. This study demonstrated that the DFIS technique has comparable accuracy of the RSA and is highly repeatable for measurement of dynamic THA motion, suggesting that the DFIS is a promising tool in evaluating the in-vivo THA biomechanics during functional activities. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Tsai, Tsung-Yuan; Li, Jing-Sheng; Wang, Shaobai; Lin, Hao; Malchau, Henrik; Li, Guoan; Rubash, Harry; Kwon, Young-Min] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab,Dept Orthopaed Surg, Boston, MA 02114 USA.
[Lin, Hao] Fujian Prov Hosp, Trauma Dept, Fuzhou 350001, Fujian, Peoples R China.
RP Li, GA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab,Dept Orthopaed Surg, 55 Fruit St, Boston, MA 02114 USA.
EM gli1@partners.org
OI Malchau, Henrik/0000-0002-4291-2441; Tsai,
Tsung-Yuan/0000-0003-1522-2987
FU Department of Orthopaedic Surgery/MGH
FX Department of Orthopaedic Surgery/MGH, Mako Medical Ethical approval:
Research protocol has been reviewed and approved by Massachusetts
General Hospital IRB.
NR 36
TC 11
Z9 12
U1 0
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0021-9290
J9 J BIOMECH
JI J. Biomech.
PD APR 26
PY 2013
VL 46
IS 7
BP 1300
EP 1304
DI 10.1016/j.jbiomech.2013.02.010
PG 5
WC Biophysics; Engineering, Biomedical
SC Biophysics; Engineering
GA 139LI
UT WOS:000318583800012
PM 23497800
ER
PT J
AU Wang, JM
Ma, CJ
Li, GY
Wu, XY
Thayer, P
Greer, P
Smith, AM
High, KP
Moorman, JP
Yao, ZQ
AF Wang, Jia M.
Ma, Cheng J.
Li, Guang Y.
Wu, Xiao Y.
Thayer, Penny
Greer, Pamela
Smith, Ashley M.
High, Kevin P.
Moorman, Jonathan P.
Yao, Zhi Q.
TI Tim-3 alters the balance of IL-12/IL-23 and drives T(H)17 cells: Role in
hepatitis B vaccine failure during hepatitis C infection
SO VACCINE
LA English
DT Article
DE Tim-3; IL-12; IL-23; IL-17; Hepatitis B vaccine; Hepatitis C infection
ID VIRUS CORE PROTEIN; T-CELL; ELEVATED FREQUENCIES; IMMUNE-RESPONSE;
LIVER-DISEASE; EXPRESSION; IL-23; CYTOKINE; PD-1; INDIVIDUALS
AB Hepatitis B virus (HBV) vaccination is recommended for individuals with hepatitis C virus (HCV) infection given their shared risk factors and increased liver-related morbidity and mortality upon super-infection. Vaccine responses in this setting are often blunted, with poor response rates to HBV vaccinations in chronically HCV-infected individuals compared to healthy subjects. In this study, we investigated the role of T cell immunoglobulin mucin domain-3 (Tim-3)-mediated immune regulation in HBV vaccine responses during HCV infection. We found that Tim-3, a marker for T cell exhaustion, was over-expressed on monocytes, leading to a differential regulation of IL-12/IL-23 production which in turn T(H)17 cell accumulation, in HCV-infected HBV vaccine non-responders compared to HCV-infected HBV vaccine responders or healthy subjects (HS). Importantly, ex vivo blockade of Tim-3 signaling corrected the imbalance of IL-12/IL-23 as well as the IL-17 bias observed in HBV vaccine non-responders during HCV infection. These results suggest that Tim-3-mediated dysregulation of innate to adaptive immune responses is involved in HBV vaccine failure in individuals with chronic HCV infection, raising the possibility that blocking this negative signaling pathway might improve the success rate of HBV immunization in the setting of chronic viral infection. Published by Elsevier Ltd.
C1 [Thayer, Penny; Greer, Pamela; Smith, Ashley M.; Moorman, Jonathan P.; Yao, Zhi Q.] US Dept Vet Affairs, James H Quillen VA Med Ctr, Hepatitis HCV HIV Program, Johnson City, TN USA.
[Wang, Jia M.; Ma, Cheng J.; Li, Guang Y.; Wu, Xiao Y.; Moorman, Jonathan P.; Yao, Zhi Q.] E Tennessee State Univ, James H Quillen Coll Med, Dept Internal Med, Div Infect Dis, Johnson City, TN 37614 USA.
[Wang, Jia M.] Soochow Univ, Sch Med, Dept Biochem & Mol Biol, Suzhou, Peoples R China.
[High, Kevin P.] Wake Forest Univ, Baptist Med Ctr, Infect Dis Sect, Dept Internal Med, Winston Salem, NC 27109 USA.
RP Moorman, JP (reprint author), E Tennessee State Univ, Coll Med, Dept Internal Med, Div Infect Dis, Johnson City, TN 37614 USA.
EM Moorman@etsu.edu
RI sebastianovitsch, stepan/G-8507-2013
FU NIH NIDDK [R01DK093526]; Wake Forrest University; East Tennessee State
University
FX This work was supported by an NIH NIDDK grant to ZQY/JPM (R01DK093526)
and by a Wake Forrest University and East Tennessee State University
Collaborative Research Pilot Award. This publication is the result of
work supported with resources and the use of facilities at the James H.
Quillen Veterans Affairs Medical Center. The contents in this
publication do not represent the views of the Department of Veterans
Affairs or the United States Government.
NR 58
TC 10
Z9 13
U1 0
U2 19
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD APR 26
PY 2013
VL 31
IS 18
BP 2238
EP 2245
DI 10.1016/j.vaccine.2013.03.003
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 135ZP
UT WOS:000318329500004
PM 23499521
ER
PT J
AU Agus, DB
Alexander, JF
Arap, W
Ashili, S
Aslan, JE
Austin, RH
Backman, V
Bethel, KJ
Bonneau, R
Chen, WC
Chen-Tanyolac, C
Choi, NC
Curley, SA
Dallas, M
Damania, D
Davies, PCW
Decuzzi, P
Dickinson, L
Estevez-Salmeron, L
Estrella, V
Ferrari, M
Fischbach, C
Foo, J
Fraley, SI
Frantz, C
Fuhrmann, A
Gascard, P
Gatenby, RA
Geng, Y
Gerecht, S
Gillies, RJ
Godin, B
Grady, WM
Greenfield, A
Hemphill, C
Hempstead, BL
Hielscher, A
Hillis, WD
Holland, EC
Ibrahim-Hashim, A
Jacks, T
Johnson, RH
Joo, A
Katz, JE
Kelbauskas, L
Kesselman, C
King, MR
Konstantopoulos, K
Kraning-Rush, CM
Kuhn, P
Kung, K
Kwee, B
Lakins, JN
Lambert, G
Liao, D
Licht, JD
Liphardt, JT
Liu, LY
Lloyd, MC
Lyubimova, A
Mallick, P
Marko, J
McCarty, OJT
Meldrum, DR
Michor, F
Mumenthaler, SM
Nandakumar, V
O'Halloran, TV
Oh, S
Pasqualini, R
Paszek, MJ
Philips, KG
Poultney, CS
Rana, K
Reinhart-King, CA
Ros, R
Semenza, GL
Senechal, P
Shuler, ML
Srinivasan, S
Staunton, JR
Stypula, Y
Subramanian, H
Tlsty, TD
Tormoen, GW
Tseng, Y
van Oudenaarden, A
Verbridge, SS
Wan, JC
Weaver, VM
Widom, J
Will, C
Wirtz, D
Wojtkowiak, J
Wu, PH
AF Agus, David B.
Alexander, Jenolyn F.
Arap, Wadih
Ashili, Shashanka
Aslan, Joseph E.
Austin, Robert H.
Backman, Vadim
Bethel, Kelly J.
Bonneau, Richard
Chen, Wei-Chiang
Chen-Tanyolac, Chira
Choi, Nathan C.
Curley, Steven A.
Dallas, Matthew
Damania, Dhwanil
Davies, Paul C. W.
Decuzzi, Paolo
Dickinson, Laura
Estevez-Salmeron, Luis
Estrella, Veronica
Ferrari, Mauro
Fischbach, Claudia
Foo, Jasmine
Fraley, Stephanie I.
Frantz, Christian
Fuhrmann, Alexander
Gascard, Philippe
Gatenby, Robert A.
Geng, Yue
Gerecht, Sharon
Gillies, Robert J.
Godin, Biana
Grady, William M.
Greenfield, Alex
Hemphill, Courtney
Hempstead, Barbara L.
Hielscher, Abigail
Hillis, W. Daniel
Holland, Eric C.
Ibrahim-Hashim, Arig
Jacks, Tyler
Johnson, Roger H.
Joo, Ahyoung
Katz, Jonathan E.
Kelbauskas, Laimonas
Kesselman, Carl
King, Michael R.
Konstantopoulos, Konstantinos
Kraning-Rush, Casey M.
Kuhn, Peter
Kung, Kevin
Kwee, Brian
Lakins, Johnathon N.
Lambert, Guillaume
Liao, David
Licht, Jonathan D.
Liphardt, Jan T.
Liu, Liyu
Lloyd, Mark C.
Lyubimova, Anna
Mallick, Parag
Marko, John
McCarty, Owen J. T.
Meldrum, Deirdre R.
Michor, Franziska
Mumenthaler, Shannon M.
Nandakumar, Vivek
O'Halloran, Thomas V.
Oh, Steve
Pasqualini, Renata
Paszek, Matthew J.
Philips, Kevin G.
Poultney, Christopher S.
Rana, Kuldeepsinh
Reinhart-King, Cynthia A.
Ros, Robert
Semenza, Gregg L.
Senechal, Patti
Shuler, Michael L.
Srinivasan, Srimeenakshi
Staunton, Jack R.
Stypula, Yolanda
Subramanian, Hariharan
Tlsty, Thea D.
Tormoen, Garth W.
Tseng, Yiider
van Oudenaarden, Alexander
Verbridge, Scott S.
Wan, Jenny C.
Weaver, Valerie M.
Widom, Jonathan
Will, Christine
Wirtz, Denis
Wojtkowiak, Jonathan
Wu, Pei-Hsun
CA Phys Sci Oncology Ctr Network
TI A physical sciences network characterization of non-tumorigenic and
metastatic cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HYPOXIA-INDUCED METASTASIS; BREAST-CANCER; LYSYL OXIDASE; ADHESION;
PROGRESSION; MIGRATION; PROTEIN; MORPHOLOGY; MECHANISM; SURVIVAL
AB To investigate the transition from non-cancerous to metastatic from a physical sciences perspective, the Physical Sciences-Oncology Centers (PS-OC) Network performed molecular and biophysical comparative studies of the non-tumorigenic MCF-10A and metastatic MDA-MB-231 breast epithelial cell lines, commonly used as models of cancer metastasis. Experiments were performed in 20 laboratories from 12 PS-OCs. Each laboratory was supplied with identical aliquots and common reagents and culture protocols. Analyses of these measurements revealed dramatic differences in their mechanics, migration, adhesion, oxygen response, and proteomic profiles. Model-based multi-omics approaches identified key differences between these cells' regulatory networks involved in morphology and survival. These results provide a multifaceted description of cellular parameters of two widely used cell lines and demonstrate the value of the PS-OC Network approach for integration of diverse experimental observations to elucidate the phenotypes associated with cancer metastasis.
C1 [Agus, David B.; Choi, Nathan C.; Hillis, W. Daniel; Joo, Ahyoung; Katz, Jonathan E.; Mallick, Parag; Mumenthaler, Shannon M.; Wan, Jenny C.] Univ So Calif, Keck Sch Med, Ctr Appl Mol Med, Los Angeles, CA 90033 USA.
[Alexander, Jenolyn F.; Decuzzi, Paolo; Ferrari, Mauro; Godin, Biana; Srinivasan, Srimeenakshi] Methodist Hosp, Dept Nanomed, Res Inst, Houston, TX 77030 USA.
[Arap, Wadih; Pasqualini, Renata] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr, Houston, TX 77030 USA.
[Ashili, Shashanka; Hemphill, Courtney; Johnson, Roger H.; Kelbauskas, Laimonas; Meldrum, Deirdre R.; Nandakumar, Vivek; Senechal, Patti] Arizona State Univ, Ctr Biosignatures Discovery Automat, Biodesign Inst, Tempe, AZ 85287 USA.
[Aslan, Joseph E.; McCarty, Owen J. T.; Philips, Kevin G.; Tormoen, Garth W.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Sch Med, Portland, OR 97239 USA.
[Aslan, Joseph E.; McCarty, Owen J. T.] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Sch Med, Portland, OR 97239 USA.
[Austin, Robert H.; Lambert, Guillaume; Liu, Liyu] Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.
[Backman, Vadim; Damania, Dhwanil; Stypula, Yolanda; Subramanian, Hariharan] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
[Bethel, Kelly J.] Scripps Clin, Dept Pathol, La Jolla, CA 92037 USA.
[Bonneau, Richard; Greenfield, Alex; Poultney, Christopher S.] NYU, Dept Biol, Dept Comp Sci, New York, NY 10003 USA.
[Chen, Wei-Chiang; Dallas, Matthew; Dickinson, Laura; Fraley, Stephanie I.; Gerecht, Sharon; Hielscher, Abigail; Konstantopoulos, Konstantinos; Tseng, Yiider; Wirtz, Denis; Wu, Pei-Hsun] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.
[Chen-Tanyolac, Chira; Estevez-Salmeron, Luis; Gascard, Philippe; Liao, David; Oh, Steve; Tlsty, Thea D.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.
[Chen-Tanyolac, Chira; Estevez-Salmeron, Luis; Gascard, Philippe; Liao, David; Oh, Steve; Tlsty, Thea D.] Univ Calif San Francisco, UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Curley, Steven A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
[Davies, Paul C. W.] Arizona State Univ, Beyond Ctr Fundamental Concepts Sci, Tempe, AZ 85287 USA.
[Estrella, Veronica; Gatenby, Robert A.; Gillies, Robert J.; Ibrahim-Hashim, Arig; Lloyd, Mark C.; Wojtkowiak, Jonathan] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiol, Tampa, FL 33612 USA.
[Estrella, Veronica; Gatenby, Robert A.; Gillies, Robert J.; Ibrahim-Hashim, Arig; Lloyd, Mark C.; Wojtkowiak, Jonathan] H Lee Moffitt Canc Ctr & Res Inst, Dept Integrated Math Oncol, Tampa, FL 33612 USA.
[Fischbach, Claudia; Geng, Yue; King, Michael R.; Kraning-Rush, Casey M.; Kwee, Brian; Rana, Kuldeepsinh; Reinhart-King, Cynthia A.; Shuler, Michael L.; Verbridge, Scott S.] Cornell Univ, Dept Biomed Engn, Ithaca, NY 14853 USA.
[Foo, Jasmine] Univ Minnesota Twin Cities, Sch Math, Minneapolis, MN 55455 USA.
[Frantz, Christian; Lakins, Johnathon N.; Paszek, Matthew J.; Weaver, Valerie M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA.
[Frantz, Christian; Lakins, Johnathon N.; Paszek, Matthew J.; Weaver, Valerie M.] Univ Calif San Francisco, Ctr Bioengn & Tissue Regenerat, San Francisco, CA 94143 USA.
[Fuhrmann, Alexander; Ros, Robert; Staunton, Jack R.] Arizona State Univ, Dept Phys, Tempe, AZ 85287 USA.
[Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.
[Grady, William M.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Hempstead, Barbara L.] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA.
[Hillis, W. Daniel] Appl Minds Inc, Glendale, CA 91201 USA.
[Holland, Eric C.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Dept Neurosurg, New York, NY 10065 USA.
[Jacks, Tyler; van Oudenaarden, Alexander] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Jacks, Tyler] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Jacks, Tyler] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.
[Kesselman, Carl] Univ So Calif, Inst Informat Sci, Marina Del Rey, CA 90292 USA.
[Kuhn, Peter] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.
[Kung, Kevin; Lyubimova, Anna; van Oudenaarden, Alexander] MIT, Dept Phys, Cambridge, MA 02139 USA.
[Licht, Jonathan D.; Will, Christine] Northwestern Univ, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA.
[Liphardt, Jan T.] Univ Calif Berkeley, Dept Phys, Biophys Grad Grp, Berkeley, CA 94720 USA.
[Liphardt, Jan T.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA.
[Lloyd, Mark C.] H Lee Moffitt Canc Ctr & Res Inst, Dept Analyt Microscopy, Tampa, FL 33612 USA.
[Mallick, Parag] Stanford Univ, Dept Radiol, Sch Med, Stanford, CA 94305 USA.
[Marko, John; Widom, Jonathan] Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.
[Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dept Biostat & Computat Biol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[O'Halloran, Thomas V.] Northwestern Univ, Dept Chem, Chem Life Proc Inst, Evanston, IL 60208 USA.
[Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn, Baltimore, MD 21205 USA.
[Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA.
[Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA.
[Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
[Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol, Baltimore, MD 21205 USA.
[Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.
[Shuler, Michael L.] Cornell Univ, Sch Chem & Biomol Engn, Ithaca, NY 14853 USA.
[Weaver, Valerie M.] Univ Calif San Francisco, Dept Anat, Dept Bioengn & Therapeut Sci, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA.
[Weaver, Valerie M.] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA.
RP Wirtz, D (reprint author), Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.
EM wirtz@jhu.edu
RI Decuzzi, Paolo/F-1899-2016; Backman, Vadim/B-6689-2009; Fischbach,
Claudia/C-8550-2009; Rana, Kuldeepsinh/G-3262-2010; Konstantopoulos,
Konstantinos/A-7045-2011; Staunton, Jack/G-3786-2010; Ros,
Robert/G-2154-2012; Reinhart-King, Cynthia/A-9264-2016
OI Gillies, Robert/0000-0002-8888-7747; Aslan, Joseph/0000-0002-8873-0387;
Decuzzi, Paolo/0000-0001-6050-4188; Ashili,
Shashanka/0000-0001-6335-0954; Kesselman, Carl/0000-0003-0917-1562; ,
/0000-0001-7080-9196; Rana, Kuldeepsinh/0000-0001-8808-8518; Staunton,
Jack/0000-0001-9773-8025; Reinhart-King, Cynthia/0000-0001-6959-3914
FU United States National Cancer Institute [U54CA143862, U54CA143876,
U54CA143798, U54CA143970, U54CA143868, U54CA143874, U54CA143837,
U54CA143869, U54CA143803, U54CA143906, U54CA143836, U54CA143907]
FX We thank Jack R. Staunton and Denis Wirtz for taking leadership in
preparing this manuscript, and we thank Thea D. Tlsty and Barbara L.
Hempstead for their input on the choice of cell lines for this project.
Thiswork was supported by the following grants from the United States
National Cancer Institute: U54CA143862 to P. C. W. D., U54CA143876 to M.
L. S., U54CA143798 to F. M., U54CA143970 to R. A. G., U54CA143868 to D.
W., U54CA143874 to A. V. O., U54CA143837 to M. F., U54CA143869 to T. V.
O., U54CA143803 to R. H. A., U54CA143906 to P. K., U54CA143836 to J. T.
L., and U54CA143907 to W. D. H. The content is solely the responsibility
of the authors and does not necessarily represent the official views of
the National Cancer Institute or the National Institutes of Health.
NR 41
TC 46
Z9 46
U1 8
U2 112
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 26
PY 2013
VL 3
AR 1449
DI 10.1038/srep01449
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 132IO
UT WOS:000318061300001
ER
PT J
AU Field, JJ
Lin, G
Okam, MM
Majerus, E
Keefer, J
Onyekwere, O
Ross, A
Campigotto, F
Neuberg, D
Linden, J
Nathan, DG
AF Field, Joshua J.
Lin, Gene
Okam, Maureen M.
Majerus, Elaine
Keefer, Jeffrey
Onyekwere, Onyinye
Ross, Ainsley
Campigotto, Federico
Neuberg, Donna
Linden, Joel
Nathan, David G.
TI Sickle cell vaso-occlusion causes activation of iNKT cells that is
decreased by the adenosine A(2A) receptor agonist regadenoson
SO BLOOD
LA English
DT Article
ID KILLER T-CELLS; NF-KAPPA-B; PULMONARY INFLAMMATION; VASCULAR
ENDOTHELIUM; NKT CELLS; DISEASE; MONOCYTES; ADHESION; PRIAPISM; CRISIS
AB Adenosine A(2A) receptor (A(2A)R) agonists reduce invariant natural killer T (iNKT) cell activation and decrease inflammation in sickle cell disease (SCD) mice. We conducted a phase 1 trial of the A(2A)R agonist regadenoson in adults with SCD. The target dose was 1.44 mu g/kg/h. iNKT cell activation was evaluated using antibodies targeting the p65 subunit of nuclear factor-kappa B (phospho-NF-kappa B p65), interferon-gamma (IFN-gamma), and A(2A)R. Regadenoson was administered to 27 adults with SCD. We examined 21 patients at steady state and 6 during painful vaso-occlusive crises (pVOC). iNKT cell activation was also measured in 14 African-American controls. During pVOC, the fraction of iNKT cells demonstrating increased phospho-NF-kappa B p65 and A(2A)R expression was significantly higher compared with controls (P < .01) and steady-state patients (P < .05). IFN-gamma expression was also significantly higher compared with controls (P = .02). After a 24-hour infusion of regadenoson during pVOC, phospho-NF-kappa B p65 activation in iNKT cells decreased compared to baseline by a median of 48% (P = .03) to levels similar to controls and steady-state SCD. No toxicities were identified. Infusional regadenoson administered to adults with SCD at 1.44 mu g/kg/h during pVOC decreases activation of iNKT cells without toxicity. This trial was registered at www.clinicaltrials.gov as #NCT01085201.
C1 [Field, Joshua J.] Blood Ctr SE Wisconsin Inc, Milwaukee, WI 53226 USA.
[Field, Joshua J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Lin, Gene; Linden, Joel] La Jolla Inst Allergy & Immunol, San Diego, CA USA.
[Okam, Maureen M.; Ross, Ainsley] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Okam, Maureen M.; Nathan, David G.] Harvard Univ, Sch Med, Boston, MA USA.
[Majerus, Elaine] Washington Univ, Sch Med, St Louis, MO USA.
[Keefer, Jeffrey] Johns Hopkins Sch Med, Baltimore, MD USA.
[Onyekwere, Onyinye] Howard Univ, Coll Med, Washington, DC USA.
[Campigotto, Federico; Neuberg, Donna; Nathan, David G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Nathan, David G.] Boston Childrens Hosp, Boston, MA USA.
RP Field, JJ (reprint author), Blood Ctr SE Wisconsin Inc, 8733 Watertown Plank Rd, Milwaukee, WI 53226 USA.
EM joshua.field@bcw.edu
FU National Heart, Lung, and Blood Institute [RC2HL101367, R34HL108757];
Astellas Pharma; Clinical and Translational Science Awards
FX This study was supported by National Heart, Lung, and Blood Institute
grants RC2HL101367 and R34HL108757 and a grant from Astellas Pharma
(D.G.N.). The authors also acknowledge the support provided by Clinical
and Translational Science Awards at all participating institutions.
NR 26
TC 35
Z9 35
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 25
PY 2013
VL 121
IS 17
BP 3329
EP 3334
DI 10.1182/blood-2012-11-465963
PG 6
WC Hematology
SC Hematology
GA 183QG
UT WOS:000321831600008
PM 23377438
ER
PT J
AU Ouyang, J
Plutschow, A
von Strandmann, EP
Reiners, KS
Ponader, S
Rabinovich, GA
Neuberg, D
Engert, A
Shipp, MA
AF Ouyang, Jing
Pluetschow, Annette
von Strandmann, Elke Pogge
Reiners, Katrin S.
Ponader, Sabine
Rabinovich, Gabriel A.
Neuberg, Donna
Engert, Andreas
Shipp, Margaret A.
TI Galectin-1 serum levels reflect tumor burden and adverse clinical
features in classical Hodgkin lymphoma
SO BLOOD
LA English
DT Article
ID GLYCAN INTERACTIONS; IMMUNE PRIVILEGE; PROGNOSTIC SCORE; DISEASE;
EXPRESSION
AB Galectin-1 (Gal1) is a member of a highly conserved family of carbohydrate-binding proteins. It modulates innate and adaptive immune responses and fosters tumor-immune escape. Hodgkin lymphoma (HL) Reed-Sternberg cells overexpress and secrete Gal1, which selectively kills T helper (Th)1 and Th17 cells and cytotoxic T cells and promotes the immunosuppressive Th2/regulatory T-cell-predominant HL microenvironment. We developed a sandwich enzyme-linked immunosorbent assay and assessed serum Gal1 levels in 293 newly diagnosed, previously untreated patients with classical HL (cHL) enrolled in 3 risk-adapted clinical trials. Serum Gal1 levels were significantly higher in patients with cHL than in normal controls (P < .0001). Gal1 serum levels also increased with Ann Arbor stage (P = .012), areas of nodal involvement (P < .0001), and the International Prognostic Score (2-7, P = .019). We conclude that Gal1 serum levels are significantly associated with tumor burden and related clinical features in newly diagnosed cHL patients.
C1 [Ouyang, Jing; Shipp, Margaret A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Pluetschow, Annette; Ponader, Sabine; Engert, Andreas] Univ Hosp Cologne, German Hodgkin Study Grp, Cologne, Germany.
[von Strandmann, Elke Pogge; Reiners, Katrin S.] Univ Hosp Cologne, Lab Immunotherapy, Cologne, Germany.
[Rabinovich, Gabriel A.] Consejo Nacl Invest Cient & Tecn, Lab Inmunopatol, Inst Biol & Med Expt, Buenos Aires, DF, Argentina.
[Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02215 USA.
RP Shipp, MA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM margaret_shipp@dfci.harvard.edu
FU Leukemia and Lymphoma Society (SCOR) [7009-12]; DFG [SFB832, TP19]
FX This work was supported by the Leukemia and Lymphoma Society (SCOR
#7009-12) (M. A. S.) and (DFG #SFB832, TP19) (E.P.v.S.).
NR 17
TC 20
Z9 20
U1 0
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 25
PY 2013
VL 121
IS 17
BP 3431
EP 3433
DI 10.1182/blood-2012-12-474569
PG 3
WC Hematology
SC Hematology
GA 183QG
UT WOS:000321831600019
PM 23444403
ER
PT J
AU Bai, XY
Feldman, NE
Chmura, K
Ovrutsky, AR
Su, WL
Griffin, L
Pyeon, D
McGibney, MT
Strand, MJ
Numata, M
Murakami, S
Gaido, L
Honda, JR
Kinney, WH
Oberley-Deegan, RE
Voelker, DR
Ordway, DJ
Chan, ED
AF Bai, Xiyuan
Feldman, Nicole E.
Chmura, Kathryn
Ovrutsky, Alida R.
Su, Wen-Lin
Griffin, Laura
Pyeon, Dohun
McGibney, Mischa T.
Strand, Matthew J.
Numata, Mari
Murakami, Seiji
Gaido, Loretta
Honda, Jennifer R.
Kinney, William H.
Oberley-Deegan, Rebecca E.
Voelker, Dennis R.
Ordway, Diane J.
Chan, Edward D.
TI Inhibition of Nuclear Factor-Kappa B Activation Decreases Survival of
Mycobacterium tuberculosis in Human Macrophages
SO PLOS ONE
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; DRUG-RESISTANT TUBERCULOSIS; TOLL-LIKE RECEPTORS;
NITRIC-OXIDE; TRANSCRIPTION FACTOR; HOST-DEFENSE; TNF-ALPHA; ALVEOLAR
MACROPHAGES; MURINE MACROPHAGES; INTERLEUKIN-8 GENE
AB Nuclear factor-kappa B (NF kappa B) is a ubiquitous transcription factor that mediates pro-inflammatory responses required for host control of many microbial pathogens; on the other hand, NF kappa B has been implicated in the pathogenesis of other inflammatory and infectious diseases. Mice with genetic disruption of the p50 subunit of NF kappa B are more likely to succumb to Mycobacterium tuberculosis (MTB). However, the role of NF kappa B in host defense in humans is not fully understood. We sought to examine the role of NFkB activation in the immune response of human macrophages to MTB. Targeted pharmacologic inhibition of NF kappa B activation using BAY 11-7082 (BAY, an inhibitor of I kappa B alpha kinase) or an adenovirus construct with a dominant-negative IkBa significantly decreased the number of viable intracellular mycobacteria recovered from THP-1 macrophages four and eight days after infection. The results with BAY were confirmed in primary human monocyte-derived macrophages and alveolar macrophages. NF kappa B inhibition was associated with increased macrophage apoptosis and autophagy, which are well-established killing mechanisms of intracellular MTB. Inhibition of the executioner protease caspase-3 or of the autophagic pathway significantly abrogated the effects of BAY. We conclude that NF kappa B inhibition decreases viability of intracellular MTB in human macrophages via induction of apoptosis and autophagy.
C1 [Bai, Xiyuan; Chan, Edward D.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA.
[Bai, Xiyuan; Feldman, Nicole E.; Chmura, Kathryn; Ovrutsky, Alida R.; McGibney, Mischa T.; Strand, Matthew J.; Numata, Mari; Murakami, Seiji; Honda, Jennifer R.; Kinney, William H.; Oberley-Deegan, Rebecca E.; Voelker, Dennis R.; Chan, Edward D.] Natl Jewish Hlth, Dept Med & Acad Affairs, Denver, CO USA.
[Bai, Xiyuan; Chmura, Kathryn; Ovrutsky, Alida R.; Honda, Jennifer R.; Kinney, William H.; Chan, Edward D.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA.
[Gaido, Loretta] Denver Hlth Med Ctr, Denver, CO USA.
[Griffin, Laura; Pyeon, Dohun] Univ Colorado, Sch Med, Dept Microbiol, Aurora, CO USA.
[Su, Wen-Lin] Natl Def Med Ctr, Dept Med, Tri Serv Gen Hosp, Taipei, Taiwan.
[Ordway, Diane J.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
RP Bai, XY (reprint author), Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA.
EM baix@njhealth.org; chane@njhealth.org
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development [1 I01 BX001028-01A2]; National Institutes
of Health (NIH) [PHL073907]; General Clinical Research Center Program
Grant [M01-RR00051]
FX This work was supported by the Department of Veterans Affairs, Veterans
Health Administration, Office of Research and Development 1 I01
BX001028-01A2 (to EDC), National Institutes of Health (NIH) PHL073907
(to DRV), and General Clinical Research Center Program Grant No.
M01-RR00051. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 75
TC 13
Z9 14
U1 1
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 25
PY 2013
VL 8
IS 4
AR e61925
DI 10.1371/journal.pone.0061925
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 136DM
UT WOS:000318341400027
PM 23634218
ER
PT J
AU Howe, K
Clark, MD
Torroja, CF
Torrance, J
Berthelot, C
Muffato, M
Collins, JE
Humphray, S
McLaren, K
Matthews, L
McLaren, S
Sealy, I
Caccamo, M
Churcher, C
Scott, C
Barrett, JC
Koch, R
Rauch, GJ
White, S
Chow, W
Kilian, B
Quintais, LT
Guerra-Assuncao, JA
Zhou, Y
Gu, Y
Yen, J
Vogel, JH
Eyre, T
Redmond, S
Banerjee, R
Chi, JX
Fu, BY
Langley, E
Maguire, SF
Laird, GK
Lloyd, D
Kenyon, E
Donaldson, S
Sehra, H
Almeida-King, J
Loveland, J
Trevanion, S
Jones, M
Quail, M
Willey, D
Hunt, A
Burton, J
Sims, S
McLay, K
Plumb, B
Davis, J
Clee, C
Oliver, K
Clark, R
Riddle, C
Eliott, D
Threadgold, G
Harden, G
Ware, D
Mortimer, B
Kerry, G
Heath, P
Phillimore, B
Tracey, A
Corby, N
Dunn, M
Johnson, C
Wood, J
Clark, S
Pelan, S
Griffiths, G
Smith, M
Glithero, R
Howden, P
Barker, N
Stevens, C
Harley, J
Holt, K
Panagiotidis, G
Lovell, J
Beasley, H
Henderson, C
Gordon, D
Auger, K
Wright, D
Collins, J
Raisen, C
Dyer, L
Leung, K
Robertson, L
Ambridge, K
Leongamornlert, D
McGuire, S
Gilderthorp, R
Griffiths, C
Manthravadi, D
Nichol, S
Barker, G
Whitehead, S
Kay, M
Brown, J
Murnane, C
Gray, E
Humphries, M
Sycamore, N
Barker, D
Saunders, D
Wallis, J
Babbage, A
Hammond, S
Mashreghi-Mohammadi, M
Barr, L
Martin, S
Wray, P
Ellington, A
Matthews, N
Ellwood, M
Woodmansey, R
Clark, G
Cooper, J
Tromans, A
Grafham, D
Skuce, C
Pandian, R
Andrews, R
Harrison, E
Kimberley, A
Garnett, J
Fosker, N
Hall, R
Garner, P
Kelly, D
Bird, C
Palmer, S
Gehring, I
Berger, A
Dooley, CM
Ersan-Urun, Z
Eser, C
Geiger, H
Geisler, M
Karotki, L
Kirn, A
Konantz, J
Konantz, M
Oberlander, M
Rudolph-Geiger, S
Teucke, M
Osoegawa, K
Zhu, BL
Rapp, A
Widaa, S
Langford, C
Yang, FT
Carter, NP
Harrow, J
Ning, ZM
Herrero, J
Searle, SMJ
Enright, A
Geisler, R
Plasterk, RHA
Lee, C
Westerfield, M
de Jong, PJ
Zon, LI
Postlethwait, JH
Nusslein-Volhard, C
Hubbard, TJP
Crollius, HR
Rogers, J
Stemple, DL
AF Howe, Kerstin
Clark, Matthew D.
Torroja, Carlos F.
Torrance, James
Berthelot, Camille
Muffato, Matthieu
Collins, John E.
Humphray, Sean
McLaren, Karen
Matthews, Lucy
McLaren, Stuart
Sealy, Ian
Caccamo, Mario
Churcher, Carol
Scott, Carol
Barrett, Jeffrey C.
Koch, Romke
Rauch, Gerd-Joerg
White, Simon
Chow, William
Kilian, Britt
Quintais, Leonor T.
Guerra-Assuncao, Jose A.
Zhou, Yi
Gu, Yong
Yen, Jennifer
Vogel, Jan-Hinnerk
Eyre, Tina
Redmond, Seth
Banerjee, Ruby
Chi, Jianxiang
Fu, Beiyuan
Langley, Elizabeth
Maguire, Sean F.
Laird, Gavin K.
Lloyd, David
Kenyon, Emma
Donaldson, Sarah
Sehra, Harminder
Almeida-King, Jeff
Loveland, Jane
Trevanion, Stephen
Jones, Matt
Quail, Mike
Willey, Dave
Hunt, Adrienne
Burton, John
Sims, Sarah
McLay, Kirsten
Plumb, Bob
Davis, Joy
Clee, Chris
Oliver, Karen
Clark, Richard
Riddle, Clare
Eliott, David
Threadgold, Glen
Harden, Glenn
Ware, Darren
Mortimer, Beverly
Kerry, Giselle
Heath, Paul
Phillimore, Benjamin
Tracey, Alan
Corby, Nicole
Dunn, Matthew
Johnson, Christopher
Wood, Jonathan
Clark, Susan
Pelan, Sarah
Griffiths, Guy
Smith, Michelle
Glithero, Rebecca
Howden, Philip
Barker, Nicholas
Stevens, Christopher
Harley, Joanna
Holt, Karen
Panagiotidis, Georgios
Lovell, Jamieson
Beasley, Helen
Henderson, Carl
Gordon, Daria
Auger, Katherine
Wright, Deborah
Collins, Joanna
Raisen, Claire
Dyer, Lauren
Leung, Kenric
Robertson, Lauren
Ambridge, Kirsty
Leongamornlert, Daniel
McGuire, Sarah
Gilderthorp, Ruth
Griffiths, Coline
Manthravadi, Deepa
Nichol, Sarah
Barker, Gary
Whitehead, Siobhan
Kay, Michael
Brown, Jacqueline
Murnane, Clare
Gray, Emma
Humphries, Matthew
Sycamore, Neil
Barker, Darren
Saunders, David
Wallis, Justene
Babbage, Anne
Hammond, Sian
Mashreghi-Mohammadi, Maryam
Barr, Lucy
Martin, Sancha
Wray, Paul
Ellington, Andrew
Matthews, Nicholas
Ellwood, Matthew
Woodmansey, Rebecca
Clark, Graham
Cooper, James
Tromans, Anthony
Grafham, Darren
Skuce, Carl
Pandian, Richard
Andrews, Robert
Harrison, Elliot
Kimberley, Andrew
Garnett, Jane
Fosker, Nigel
Hall, Rebekah
Garner, Patrick
Kelly, Daniel
Bird, Christine
Palmer, Sophie
Gehring, Ines
Berger, Andrea
Dooley, Christopher M.
Ersan-Ueruen, Zuebeyde
Eser, Cigdem
Geiger, Horst
Geisler, Maria
Karotki, Lena
Kirn, Anette
Konantz, Judith
Konantz, Martina
Oberlaender, Martina
Rudolph-Geiger, Silke
Teucke, Mathias
Osoegawa, Kazutoyo
Zhu, Baoli
Rapp, Amanda
Widaa, Sara
Langford, Cordelia
Yang, Fengtang
Carter, Nigel P.
Harrow, Jennifer
Ning, Zemin
Herrero, Javier
Searle, Steve M. J.
Enright, Anton
Geisler, Robert
Plasterk, Ronald H. A.
Lee, Charles
Westerfield, Monte
de Jong, Pieter J.
Zon, Leonard I.
Postlethwait, John H.
Nuesslein-Volhard, Christiane
Hubbard, Tim J. P.
Crollius, Hugues Roest
Rogers, Jane
Stemple, Derek L.
TI The zebrafish reference genome sequence and its relationship to the
human genome
SO NATURE
LA English
DT Article
ID DANIO-RERIO; DUPLICATION; EVOLUTION; FISH; GENE; MUTATIONS; VERTEBRATES;
REVEALS; MAP
AB Zebrafish have become a popular organism for the study of vertebrate gene function(1,2). The virtually transparent embryos of this species, and the ability to accelerate genetic studies by gene knockdown or overexpression, have led to the widespread use of zebrafish in the detailed investigation of vertebrate gene function and increasingly, the study of human genetic disease(3-5). However, for effective modelling of human genetic disease it is important to understand the extent to which zebrafish genes and gene structures are related to orthologous human genes. To examine this, we generated a high-quality sequence assembly of the zebrafish genome, made up of an overlapping set of completely sequenced large-insert clones that were ordered and oriented using a high-resolution high-density meiotic map. Detailed automatic and manual annotation provides evidence of more than 26,000 protein-coding genes(6), the largest gene set of any vertebrate so far sequenced. Comparison to the human reference genome shows that approximately 70% of human genes have at least one obvious zebrafish orthologue. In addition, the high quality of this genome assembly provides a clearer understanding of key genomic features such as a unique repeat content, a scarcity of pseudogenes, an enrichment of zebrafish-specific genes on chromosome 4 and chromosomal regions that influence sex determination.
C1 [Howe, Kerstin; Clark, Matthew D.; Torroja, Carlos F.; Torrance, James; Collins, John E.; Humphray, Sean; McLaren, Karen; Matthews, Lucy; McLaren, Stuart; Sealy, Ian; Churcher, Carol; Scott, Carol; Barrett, Jeffrey C.; White, Simon; Chow, William; Kilian, Britt; Gu, Yong; Yen, Jennifer; Vogel, Jan-Hinnerk; Eyre, Tina; Redmond, Seth; Banerjee, Ruby; Chi, Jianxiang; Fu, Beiyuan; Langley, Elizabeth; Maguire, Sean F.; Laird, Gavin K.; Lloyd, David; Kenyon, Emma; Donaldson, Sarah; Sehra, Harminder; Almeida-King, Jeff; Loveland, Jane; Trevanion, Stephen; Jones, Matt; Quail, Mike; Willey, Dave; Hunt, Adrienne; Burton, John; Sims, Sarah; McLay, Kirsten; Plumb, Bob; Davis, Joy; Clee, Chris; Oliver, Karen; Clark, Richard; Riddle, Clare; Eliott, David; Threadgold, Glen; Harden, Glenn; Ware, Darren; Mortimer, Beverly; Kerry, Giselle; Heath, Paul; Phillimore, Benjamin; Tracey, Alan; Corby, Nicole; Dunn, Matthew; Johnson, Christopher; Wood, Jonathan; Clark, Susan; Pelan, Sarah; Griffiths, Guy; Smith, Michelle; Glithero, Rebecca; Howden, Philip; Barker, Nicholas; Stevens, Christopher; Harley, Joanna; Holt, Karen; Panagiotidis, Georgios; Lovell, Jamieson; Beasley, Helen; Henderson, Carl; Gordon, Daria; Auger, Katherine; Wright, Deborah; Collins, Joanna; Raisen, Claire; Dyer, Lauren; Leung, Kenric; Robertson, Lauren; Ambridge, Kirsty; Leongamornlert, Daniel; McGuire, Sarah; Gilderthorp, Ruth; Griffiths, Coline; Manthravadi, Deepa; Nichol, Sarah; Barker, Gary; Whitehead, Siobhan; Kay, Michael; Brown, Jacqueline; Murnane, Clare; Gray, Emma; Humphries, Matthew; Sycamore, Neil; Barker, Darren; Saunders, David; Wallis, Justene; Babbage, Anne; Hammond, Sian; Mashreghi-Mohammadi, Maryam; Barr, Lucy; Martin, Sancha; Wray, Paul; Ellington, Andrew; Matthews, Nicholas; Ellwood, Matthew; Woodmansey, Rebecca; Clark, Graham; Cooper, James; Tromans, Anthony; Grafham, Darren; Skuce, Carl; Pandian, Richard; Andrews, Robert; Harrison, Elliot; Kimberley, Andrew; Garnett, Jane; Fosker, Nigel; Hall, Rebekah; Garner, Patrick; Kelly, Daniel; Bird, Christine; Palmer, Sophie; Berger, Andrea; Dooley, Christopher M.; Widaa, Sara; Langford, Cordelia; Yang, Fengtang; Carter, Nigel P.; Harrow, Jennifer; Ning, Zemin; Searle, Steve M. J.; Hubbard, Tim J. P.; Rogers, Jane; Stemple, Derek L.] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
[Clark, Matthew D.; Caccamo, Mario; Rogers, Jane] Genome Anal Ctr, Norwich NR4 7UH, Norfolk, England.
[Torroja, Carlos F.] Ctr Nacl Invest Cardiovasc, Bioinformat Unit, Madrid 28029, Spain.
[Berthelot, Camille; Crollius, Hugues Roest] ENS, Inst Biol, IBENS, F-75005 Paris, France.
[Berthelot, Camille; Crollius, Hugues Roest] INSERM, U1024, F-75005 Paris, France.
[Berthelot, Camille; Crollius, Hugues Roest] CNRS, UMR 8197, F-75005 Paris, France.
[Muffato, Matthieu; Quintais, Leonor T.; Guerra-Assuncao, Jose A.; Herrero, Javier; Enright, Anton] EMBL European Bioinformat Inst, Cambridge CB10 1SD, England.
[Humphray, Sean] Illumina Cambridge, Saffron Walden CB10 1XL, Essex, England.
[Koch, Romke; Plasterk, Ronald H. A.] Hubrecht Lab, NL-3584 CT Utrecht, Netherlands.
[Rauch, Gerd-Joerg; Gehring, Ines; Berger, Andrea; Dooley, Christopher M.; Ersan-Ueruen, Zuebeyde; Eser, Cigdem; Geiger, Horst; Geisler, Maria; Karotki, Lena; Kirn, Anette; Konantz, Judith; Konantz, Martina; Oberlaender, Martina; Rudolph-Geiger, Silke; Teucke, Mathias; Geisler, Robert; Nuesslein-Volhard, Christiane] Max Planck Inst Dev Biol, D-72076 Tubingen, Germany.
[Zhou, Yi; Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA.
[Zhou, Yi; Zon, Leonard I.] Childrens Hosp, Div Hematol & Oncol, Boston, MA 02115 USA.
[Zhou, Yi; Zon, Leonard I.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Osoegawa, Kazutoyo; Zhu, Baoli; de Jong, Pieter J.] Childrens Hosp Oakland, Oakland, CA 94609 USA.
[Rapp, Amanda; Westerfield, Monte; Postlethwait, John H.] Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA.
[Geisler, Robert] KIT, ITG, D-76344 Eggenstein Leopoldshafen, Germany.
[Lee, Charles] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Lee, Charles] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Stemple, DL (reprint author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.
EM ds4@sanger.ac.uk
RI sebastianovitsch, stepan/G-8507-2013; Torroja, Carlos/N-6022-2014; Ning,
Zemin/D-2411-2013; Hubbard, Tim/C-2567-2008; Vogel,
Jan-Hinnerk/C-4582-2013;
OI Stemple, Derek/0000-0002-8296-9928; Muffato,
Matthieu/0000-0002-7860-3560; Chow, William/0000-0002-9056-201X; ROEST
CROLLIUS, Hugues/0000-0002-8209-173X; Ning, Zemin/0000-0003-4359-776X;
Guerra-Assuncao, Jose Afonso/0000-0001-6593-403X; Almeida-King,
Jeff/0000-0002-3716-4880; Herrero, Javier/0000-0001-7313-717X; Barrett,
Jeffrey/0000-0002-1152-370X; Enright, Anton/0000-0002-6090-3100;
Leongamornlert, Daniel/0000-0002-3486-3168; Martin,
Sancha/0000-0001-6213-5259; Hunt, Adrienne/0000-0002-1227-0310; Cooper,
James/0000-0002-4932-1740; Torroja, Carlos/0000-0001-8914-3400; Hubbard,
Tim/0000-0002-1767-9318; Kilian, Britt/0000-0003-1493-2768; Kerry,
Giselle/0000-0002-2380-6707; Howe, Kerstin/0000-0003-2237-513X;
Berthelot, Camille/0000-0001-5054-2690; Trevanion,
Stephen/0000-0002-4862-3333
FU National Institutes of Health (NIH) [R01 GM085318, P01 HD22486, R01
OD011116, R01 RR020833, 1 R01 DK55377-01A1]; European Commission
[LSHG-CT-2003-503496, HEALTH-F4-2010-242048]; German Human Genome
Project (DHGP) [01 KW 9627, 01 KW 9919]; Wellcome Trust [098051]
FX We wish to thank R. Durbin, E. Birney, A. Scally, C. P. Ponting, E.
Busch-Nentwich and R. Kettleborough for helpful discussions, as well as
F. L. Marlow and P. Aanstad for critical reading and helpful comments on
manuscripts. We thank the zebrafish information network (ZFIN) for
funding part of the manual annotation of the zebrafish genome and the
ZFIN staff for support with gene nomenclature and other genome issues.
We also thank the Genome Reference Consortium for the maintenance and
improvement of the zebrafish genome assembly. We are indebted to the
Ensembl team for providing a browser and database that greatly
facilitated the use and the analyses of the zebrafish genome. We thank
A. Pirani at Affymetrix for genotyping advice support, and the Zebrafish
International Resource Center (ZIRC) for distributing the SAT strain.
J.H.P. was supported by the National Institutes of Health (NIH) grant
R01 GM085318 (to J.H.P.), NIH grant P01 HD22486 (to J.H.P.) and R01
OD011116 (later changed to R01 RR020833) (to J.H.P.). We would like to
acknowledge the support of the European Commission's Sixth Framework
Programme (contract no. LSHG-CT-2003-503496, ZF-MODELS) and Seventh
Framework Programme (grant no. HEALTH-F4-2010-242048, ZF-HEALTH). R. G.
was supported by the German Human Genome Project (DHGP Grant 01 KW 9627
and 01 KW 9919). C. N.-V., G.-J.R. and R. G. were supported by the NIH
(NIH grant 1 R01 DK55377-01A1). The Zebrafish Genome Project at the
Wellcome Trust Sanger Institute was funded by Wellcome Trust grant
number 098051.
NR 30
TC 588
Z9 1607
U1 59
U2 351
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD APR 25
PY 2013
VL 496
IS 7446
BP 498
EP 503
DI 10.1038/nature12111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 131HU
UT WOS:000317984400040
PM 23594743
ER
PT J
AU Montgomery, TA
Ruvkun, G
AF Montgomery, Taiowa A.
Ruvkun, Gary
TI MicroRNAs Visit the ER
SO CELL
LA English
DT Editorial Material
ID MIRNA; PROTEIN; FAMILY; DECAY
AB Little is known about where microRNAs (miRNAs) regulate their targets within the cell. In this issue, Li et al. identify a new player in the plant miRNA pathway that implicates the endoplasmic reticulum in miRNA-mediated gene silencing.
C1 [Montgomery, Taiowa A.; Ruvkun, Gary] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol,Dept Genet, Boston, MA 02114 USA.
RP Ruvkun, G (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol,Dept Genet, Boston, MA 02114 USA.
EM ruvkun@molbio.mgh.harvard.edu
OI Montgomery, Taiowa/0000-0001-7857-3253
NR 10
TC 1
Z9 1
U1 0
U2 38
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD APR 25
PY 2013
VL 153
IS 3
BP 511
EP 512
DI 10.1016/j.cell.2013.04.014
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 132JK
UT WOS:000318063500004
PM 23622236
ER
PT J
AU Baca, SC
Prandi, D
Lawrence, MS
Mosquera, JM
Romanel, A
Drier, Y
Park, K
Kitabayashi, N
MacDonald, TY
Ghandi, M
Van Allen, E
Kryukov, GV
Sboner, A
Theurillat, JP
Soong, TD
Nickerson, E
Auclair, D
Tewari, A
Beltran, H
Onofrio, RC
Boysen, G
Guiducci, C
Barbieri, CE
Cibulskis, K
Sivachenko, A
Carter, SL
Saksena, G
Voet, D
Ramos, AH
Winckler, W
Cipicchio, M
Ardlie, K
Kantoff, PW
Berger, MF
Gabriel, SB
Golub, TR
Meyerson, M
Lander, ES
Elemento, O
Getz, G
Demichelis, F
Rubin, MA
Garraway, LA
AF Baca, Sylvan C.
Prandi, Davide
Lawrence, Michael S.
Mosquera, Juan Miguel
Romanel, Alessandro
Drier, Yotam
Park, Kyung
Kitabayashi, Naoki
MacDonald, Theresa Y.
Ghandi, Mahmoud
Van Allen, Eliezer
Kryukov, Gregory V.
Sboner, Andrea
Theurillat, Jean-Philippe
Soong, T. David
Nickerson, Elizabeth
Auclair, Daniel
Tewari, Ashutosh
Beltran, Himisha
Onofrio, Robert C.
Boysen, Gunther
Guiducci, Candace
Barbieri, Christopher E.
Cibulskis, Kristian
Sivachenko, Andrey
Carter, Scott L.
Saksena, Gordon
Voet, Douglas
Ramos, Alex H.
Winckler, Wendy
Cipicchio, Michelle
Ardlie, Kristin
Kantoff, Philip W.
Berger, Michael F.
Gabriel, Stacey B.
Golub, Todd R.
Meyerson, Matthew
Lander, Eric S.
Elemento, Olivier
Getz, Gad
Demichelis, Francesca
Rubin, Mark A.
Garraway, Levi A.
TI Punctuated Evolution of Prostate Cancer Genomes
SO CELL
LA English
DT Article
ID TMPRSS2-ERG FUSION; REARRANGEMENTS; MUTATIONS; CHD1; SAMPLES; EVENT
AB The analysis of exonic DNA from prostate cancers has identified recurrently mutated genes, but the spectrum of genome-wide alterations has not been profiled extensively in this disease. We sequenced the genomes of 57 prostate tumors and matched normal tissues to characterize somatic alterations and to study how they accumulate during oncogenesis and progression. By modeling the genesis of genomic rearrangements, we identified abundant DNA translocations and deletions that arise in a highly interdependent manner. This phenomenon, which we term "chromoplexy," frequently accounts for the dysregulation of prostate cancer genes and appears to disrupt multiple cancer genes coordinately. Our modeling suggests that chromoplexy may induce considerable genomic derangement over relatively few events in prostate cancer and other neoplasms, supporting a model of punctuated cancer evolution. By characterizing the clonal hierarchy of genomic lesions in prostate tumors, we charted a path of oncogenic events along which chromoplexy may drive prostate carcinogenesis.
C1 [Baca, Sylvan C.; Kryukov, Gregory V.; Ramos, Alex H.; Kantoff, Philip W.; Meyerson, Matthew; Lander, Eric S.; Garraway, Levi A.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Baca, Sylvan C.; Lawrence, Michael S.; Drier, Yotam; Ghandi, Mahmoud; Van Allen, Eliezer; Kryukov, Gregory V.; Theurillat, Jean-Philippe; Nickerson, Elizabeth; Auclair, Daniel; Onofrio, Robert C.; Guiducci, Candace; Cibulskis, Kristian; Sivachenko, Andrey; Carter, Scott L.; Saksena, Gordon; Voet, Douglas; Ramos, Alex H.; Winckler, Wendy; Cipicchio, Michelle; Ardlie, Kristin; Gabriel, Stacey B.; Golub, Todd R.; Meyerson, Matthew; Lander, Eric S.; Getz, Gad; Garraway, Levi A.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Baca, Sylvan C.; Van Allen, Eliezer; Kantoff, Philip W.; Meyerson, Matthew; Garraway, Levi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Golub, Todd R.; Meyerson, Matthew; Garraway, Levi A.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02215 USA.
[Golub, Todd R.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
[Prandi, Davide; Romanel, Alessandro; Demichelis, Francesca] Univ Trento, Ctr Integrat Biol, I-38123 Povo, Trento, Italy.
[Drier, Yotam] Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel.
[Mosquera, Juan Miguel; Park, Kyung; Kitabayashi, Naoki; MacDonald, Theresa Y.; Sboner, Andrea; Boysen, Gunther; Barbieri, Christopher E.; Rubin, Mark A.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA.
[Sboner, Andrea; Soong, T. David; Elemento, Olivier; Demichelis, Francesca] Weill Cornell Med Coll, Dept Physiol & Biophys, Inst Computat Biomed, New York, NY 10065 USA.
[Tewari, Ashutosh] Weill Cornell Med Coll, Lefrak Ctr Robot Surg, New York, NY 10065 USA.
[Tewari, Ashutosh] Weill Cornell Med Coll, Ctr Prostate Canc Res & Clin Care, New York, NY 10065 USA.
[Tewari, Ashutosh; Barbieri, Christopher E.; Rubin, Mark A.] Weill Cornell Med Coll, Brady Fdn Dept Urol, New York, NY 10065 USA.
[Beltran, Himisha] Weill Cornell Med Coll, Div Hematol & Med Oncol, Dept Med, New York, NY 10065 USA.
[Kryukov, Gregory V.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
[Berger, Michael F.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA.
[Golub, Todd R.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
[Lander, Eric S.] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Lander, Eric S.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
RP Demichelis, F (reprint author), Univ Trento, Ctr Integrat Biol, I-38123 Povo, Trento, Italy.
EM demichelis@science.unitn.it; levi_garraway@dfci.harvard.edu
RI Kryukov, Gregory/A-9592-2008; Sboner, Andrea/C-6487-2008; Drier,
Yotam/K-5208-2012;
OI Romanel, Alessandro/0000-0003-4855-8620; Sboner,
Andrea/0000-0001-6915-3070; Drier, Yotam/0000-0003-1725-2995; Van Allen,
Eliezer/0000-0002-0201-4444; Barbieri, Christopher/0000-0002-0381-1947;
Prandi, Davide/0000-0001-9885-6074; Boysen, Gunther/0000-0002-7610-6085;
Rubin, Mark/0000-0002-8321-9950; Demichelis,
Francesca/0000-0002-8266-8631; Ghandi, Mahmoud/0000-0003-1897-2265
FU US National Human Genome Research Institute (NHGRI) Large Scale
Sequencing Program [U54 HG003067]; Kohlberg Foundation; Starr Cancer
Consortium; Prostate Cancer Foundation; US Department of Defense Synergy
Awards [PC101020]; Dana-Farber/Harvard Cancer Center Prostate Cancer
SPORE (US National Institutes of Health [NIH]) [P50 CA090381]; US
National Cancer Institute, Early Detection Research Network
[U01CA111275]; NCI EDRN; US National Cancer Institute [R01 CA125612];
Fondazione Trentina per la Ricerca sui Tumori; Swiss Science Foundation
[PASMP3_134379/1]; National Institute of General Medical Sciences
[T32GM007753]; US NIH Director's New Innovator Award [DP2OD002750];
Novartis; [PC094516]
FX We thank the members of the Broad Institute Genome Sequencing Platform
for their part in this work. This study was supported by the US National
Human Genome Research Institute (NHGRI) Large Scale Sequencing Program
(U54 HG003067 to the Broad Institute, E.S.L.), the Kohlberg Foundation
(L.A.G.), the Starr Cancer Consortium (M.A.R., F.D., A.T., G.G., and
L.A.G.), the Prostate Cancer Foundation (M.A.R.), US Department of
Defense Synergy Awards (PC101020 to F.D., L.A.G., and M.A.R.) and a New
Investigator Award (PC094516 to F.D.), the Dana-Farber/Harvard Cancer
Center Prostate Cancer SPORE (US National Institutes of Health [NIH] P50
CA090381), the US National Cancer Institute, Early Detection Research
Network (U01CA111275 and NCI EDRN to F.D. and M.A.R.), the US National
Cancer Institute (R01 CA125612 to F.D. and M.A.R.), the Fondazione
Trentina per la Ricerca sui Tumori (F.D.), the Swiss Science Foundation
(PASMP3_134379/1 to J.-P.T.), the National Institute of General Medical
Sciences (T32GM007753 to S.C.B.), and a US NIH Director's New Innovator
Award (DP2OD002750 to L.A.G.). L.A.G. is an equity holder and consultant
in Foundation Medicine, a consultant to Novartis and Millenium/Takeda,
and a recipient of a grant from Novartis.
NR 38
TC 315
Z9 321
U1 5
U2 44
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD APR 25
PY 2013
VL 153
IS 3
BP 666
EP 677
DI 10.1016/j.cell.2013.03.021
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 132JK
UT WOS:000318063500018
PM 23622249
ER
PT J
AU Shen, L
Wu, H
Diep, D
Yamaguchi, S
D'Alessio, AC
Fung, HL
Zhang, K
Zhang, Y
AF Shen, Li
Wu, Hao
Diep, Dinh
Yamaguchi, Shinpei
D'Alessio, Ana C.
Fung, Ho-Lim
Zhang, Kun
Zhang, Yi
TI Genome-wide Analysis Reveals TET- and TDG-Dependent 5-Methylcytosine
Oxidation Dynamics
SO CELL
LA English
DT Article
ID EMBRYONIC STEM-CELLS; THYMINE DNA GLYCOSYLASE; GENE-EXPRESSION;
POSTNATAL-DEVELOPMENT; METHYLATION PATTERNS; BASE-RESOLUTION; MAMMALIAN
DNA; 5-HYDROXYMETHYLCYTOSINE; DEMETHYLATION; CHROMATIN
AB TET dioxygenases successively oxidize 5-methylcytosine (5mC) in mammalian genomes to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC). 5fC/5caC can be excised and repaired to regenerate unmodified cytosines by thymine-DNA glycosylase (TDG) and base excision repair (BER) pathway, but it is unclear to what extent and at which part of the genome this active demethylation process takes place. Here, we have generated genome-wide distribution maps of 5hmC/5fC/5caC using modification-specific antibodies in wild-type and Tdg-deficient mouse embryonic stem cells (ESCs). In wild-type mouse ESCs, 5fC/5caC accumulates to detectable levels at major satellite repeats but not at nonrepetitive loci. In contrast, Tdg depletion in mouse ESCs causes marked accumulation of 5fC and 5caC at a large number of proximal and distal gene regulatory elements. Thus, these results reveal the genome-wide view of iterative 5mC oxidation dynamics and indicate that TET/TDG-dependent active DNA demethylation process occurs extensively in the mammalian genome.
C1 [Shen, Li; Wu, Hao; Yamaguchi, Shinpei; D'Alessio, Ana C.; Zhang, Yi] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Shen, Li; Wu, Hao; Yamaguchi, Shinpei; D'Alessio, Ana C.; Zhang, Yi] Harvard Univ, Sch Med, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Shen, Li; Wu, Hao; Yamaguchi, Shinpei; D'Alessio, Ana C.; Zhang, Yi] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Zhang, Yi] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA 02115 USA.
[Wu, Hao] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Diep, Dinh; Fung, Ho-Lim; Zhang, Kun] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
RP Wu, H (reprint author), Harvard Univ, Sch Med, Howard Hughes Med Inst, WAB-149G,200 Longwood Ave, Boston, MA 02115 USA.
EM haowu7@gmail.com; yzhang@genetics.med.harvard.edu
RI Wu, Hao/G-4145-2013;
OI Wu, Hao/0000-0002-1256-6891; Yamaguchi, Shinpei/0000-0002-9377-4835
FU NIH [U01DK089565, R01GM097253]; Jane Coffin Childs Funds for Medical
Research
FX We thank Drs. Jin He and Falong Lu for their helpful discussions. This
project is supported by NIH grant U01DK089565 (to Y.Z.) and R01GM097253
(to K.Z.). H.W. is supported by a postdoctoral fellowship (Merck Fellow)
from Jane Coffin Childs Funds for Medical Research. D.D. is a CIRM
predoctoral fellow. Y.Z. is an investigator of the Howard Hughes Medical
Institute.
NR 73
TC 199
Z9 200
U1 10
U2 80
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD APR 25
PY 2013
VL 153
IS 3
BP 692
EP 706
DI 10.1016/j.cell.2013.04.002
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 132JK
UT WOS:000318063500020
PM 23602152
ER
PT J
AU Zhang, B
Gaiteri, C
Bodea, LG
Wang, Z
McElwee, J
Podtelezhnikov, AA
Zhang, CS
Xie, T
Tran, L
Dobrin, R
Fluder, E
Clurman, B
Melquist, S
Narayanan, M
Suver, C
Shah, H
Mahajan, M
Gillis, T
Mysore, J
MacDonald, ME
Lamb, JR
Bennett, DA
Molony, C
Stone, DJ
Gudnason, V
Myers, AJ
Schadt, EE
Neumann, H
Zhu, J
Emilsson, V
AF Zhang, Bin
Gaiteri, Chris
Bodea, Liviu-Gabriel
Wang, Zhi
McElwee, Joshua
Podtelezhnikov, Alexei A.
Zhang, Chunsheng
Xie, Tao
Tran, Linh
Dobrin, Radu
Fluder, Eugene
Clurman, Bruce
Melquist, Stacey
Narayanan, Manikandan
Suver, Christine
Shah, Hardik
Mahajan, Milind
Gillis, Tammy
Mysore, Jayalakshmi
MacDonald, Marcy E.
Lamb, John R.
Bennett, David A.
Molony, Cliona
Stone, David J.
Gudnason, Vilmundur
Myers, Amanda J.
Schadt, Eric E.
Neumann, Harald
Zhu, Jun
Emilsson, Valur
TI Integrated Systems Approach Identifies Genetic Nodes and Networks in
Late-Onset Alzheimer's Disease
SO CELL
LA English
DT Article
ID MOLECULAR NETWORKS; HUMAN BRAIN; EXPRESSION; DYSFUNCTION; MICROGLIA;
RISK
AB The genetics of complex disease produce alterations in the molecular interactions of cellular pathways whose collective effect may become clear through the organized structure of molecular networks. To characterize molecular systems associated with late-onset Alzheimer's disease (LOAD), we constructed gene-regulatory networks in 1,647 postmortem brain tissues from LOAD patients and nondemented subjects, and we demonstrate that LOAD reconfigures specific portions of the molecular interaction structure. Through an integrative network-based approach, we rank-ordered these network structures for relevance to LOAD pathology, highlighting an immune- and microglia-specific module that is dominated by genes involved in pathogen phagocytosis, contains TYROBP as a key regulator, and is upregulated in LOAD. Mouse microglia cells overexpressing intact or truncated TYROBP revealed expression changes that significantly overlapped the human brain TYROBP network. Thus the causal network structure is a useful predictor of response to gene perturbations and presents a framework to test models of disease mechanisms underlying LOAD.
C1 [Zhang, Bin; Shah, Hardik; Mahajan, Milind; Schadt, Eric E.; Zhu, Jun] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.
[Zhang, Bin; Shah, Hardik; Mahajan, Milind; Schadt, Eric E.; Zhu, Jun] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA.
[Zhang, Bin; Mahajan, Milind; Schadt, Eric E.; Zhu, Jun] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA.
[Zhang, Bin; Gaiteri, Chris; Wang, Zhi; Tran, Linh; Suver, Christine] Sage Bionetworks, Seattle, WA 98109 USA.
[Bodea, Liviu-Gabriel; Neumann, Harald] Univ Bonn, Neural Regenerat Grp, Inst Reconstruct Neurobiol, D-53127 Bonn, Germany.
[McElwee, Joshua; Zhang, Chunsheng; Xie, Tao; Dobrin, Radu; Fluder, Eugene; Melquist, Stacey; Narayanan, Manikandan; Molony, Cliona] Merck & Co Inc, Merck Res Labs, Boston, MA 02115 USA.
[Podtelezhnikov, Alexei A.; Stone, David J.] Merck & Co Inc, Merck Res Labs, West Point, PA 19486 USA.
[Clurman, Bruce] Fred Hutch Canc Res Ctr, Seattle, WA 98109 USA.
[Gillis, Tammy; Mysore, Jayalakshmi; MacDonald, Marcy E.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Lamb, John R.] GNF Novartis, San Diego, CA 92121 USA.
[Bennett, David A.] Rush Univ, Med Ctr, Rush Alzheimer Dis Ctr, Chicago, IL 60612 USA.
[Gudnason, Vilmundur; Emilsson, Valur] Iceland Heart Assoc, IS-201 Kopavogur, Iceland.
[Gudnason, Vilmundur; Emilsson, Valur] Univ Iceland, IS-201 Kopavogur, Iceland.
[Myers, Amanda J.] Univ Miami, Miller Sch Med, Div Neurosci, Dept Psychiat & Behav Sci, Miami, FL 33136 USA.
RP Zhang, B (reprint author), Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, 1425 Madison Ave, New York, NY 10029 USA.
EM bin.zhang@mssm.edu; valur@hjarta.is
RI Myers, Amanda/B-1796-2010; Bodea, Liviu/F-9480-2012; Gudnason,
Vilmundur/K-6885-2015; Neumann, Harald/A-9718-2010;
OI Myers, Amanda/0000-0002-3100-9396; Bodea, Liviu/0000-0002-9604-9524;
Gudnason, Vilmundur/0000-0001-5696-0084; Neumann,
Harald/0000-0002-5071-5202; Suver, Christine/0000-0002-2986-385X;
Dobrin, Radu/0000-0002-3336-0091
FU Hertie-Foundation; Deutsche Forschungsgemeinschaft [FOR1336, SFB704,
KFO177]; DFG; National Institutes of Health [R01 AG034504, R01 AG030146,
P30 AG10161, R01 AG17917, R01 AG15819, K08 AG034290, R01 AG11101,
NS032765]; Illinois Department of Public Health; University of Miami;
Miller School of Medicine
FX H.N. and L.-G.B. were supported by the Hertie-Foundation and the
Deutsche Forschungsgemeinschaft (FOR1336, SFB704, KFO177). H.N. is a
member of the DFG-funded excellence cluster ImmunoSensation. We thank
Jessica Schumacher and Rita Hass for technical assistance. We are
grateful to the HBTRC for the generous gift of human postmortem brain
samples. The authors are also grateful to the participants in the
Religious Orders Study and the Memory and Aging Project. This work is
supported by the National Institutes of Health (R01 AG034504, R01
AG030146, P30 AG10161, R01 AG17917, R01 AG15819, K08 AG034290, P30
AG10161, R01 AG11101, and NS032765), the Illinois Department of Public
Health, and start-up funding from the University of Miami, Miller School
of Medicine. J.M., A.A.P., C.Z., T.X., R.D., E.F., S.M., M.N., C.M., and
D.J.S. are employees and shareholders of Merck & Co., Inc. J.R.L. is an
employee and shareholder of Novartis.
NR 41
TC 300
Z9 303
U1 13
U2 101
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD APR 25
PY 2013
VL 153
IS 3
BP 707
EP 720
DI 10.1016/j.cell.2013.03.030
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 132JK
UT WOS:000318063500021
PM 23622250
ER
PT J
AU Lee, PCW
Dodart, JC
Aron, L
Finley, LW
Bronson, RT
Haigis, MC
Yankner, BA
Harper, JW
AF Lee, Peter C. W.
Dodart, Jean-Cosme
Aron, Liviu
Finley, Lydia W.
Bronson, Roderick T.
Haigis, Marcia C.
Yankner, Bruce A.
Harper, J. Wade
TI Altered Social Behavior and Neuronal Development in Mice Lacking the
Uba6-Use1 Ubiquitin Transfer System
SO MOLECULAR CELL
LA English
DT Article
ID DENDRITIC SPINE MORPHOLOGY; END RULE PATHWAY; HIPPOCAMPAL-NEURONS;
PROTEIN LIGASE; DEGRADATION; ENZYME; PLASTICITY; COMPLEX; SYNAPSE; E2
AB The Uba6 (E1)-Use1 (E2) ubiquitin transfer cascade is a poorly understood alternative arm of the ubiquitin proteasome system (UPS) and is required for mouse embryonic development, independent of the canonical Uba1-E2-E3 pathway. Loss of neuronal Uba6 during embryonic development results in altered patterning of neurons in the hippocampus and the annygdala, decreased dendritic spine density, and numerous behavioral disorders. The levels of the E3 ubiquitin ligase Ube3a (E6-AP) and Shank3, both linked with dendritic spine function, are elevated in the amygdala of Uba6-deficient mice, while levels of the Ube3a substrate Arc are reduced. Uba6 and Use1 promote proteasomal turnover of Ube3a in mouse embryo fibroblasts (MEFs) and catalyze Ube3a ubiquitylation in vitro. These activities occur in parallel with an independent pathway involving Uba1-UbcH7, but in a spatially distinct manner in MEFs. These data reveal an unanticipated role for Uba6 in neuronal development, spine architecture, mouse behavior, and turnover of Ube3a.
C1 [Lee, Peter C. W.; Finley, Lydia W.; Haigis, Marcia C.; Harper, J. Wade] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
[Dodart, Jean-Cosme] Harvard Univ, Sch Med, Harvard Neurodiscovery Ctr, Boston, MA 02115 USA.
[Aron, Liviu; Yankner, Bruce A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Bronson, Roderick T.] Harvard Univ, Sch Med, Dana Farber Harvard Canc Ctr, Rodent Pathol Core, Boston, MA 02115 USA.
[Dodart, Jean-Cosme] Univ Ulsan, Coll Med, Dept Biomed Sci, Seoul, South Korea.
RP Lee, PCW (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
EM peter_lee@hms.harvard.edu; wade_harper@hms.harvard.edu
FU Millennium Pharmaceuticals, Inc.; NIH [AG011085]
FX We thank L.-H. Tsai and J. Graeff for advice; P. Howley for reagents; D.
Finley for purified proteasomes; the Nikon Imaging Center at Harvard
Medical School for microscopy support; and J. Bolen, J. Brownell, L.
Dick, and B. Amidon for numerous discussions. This work was supported by
grants to J.W.H. from Millennium Pharmaceuticals, Inc. and the NIH
(AG011085). J.W.H. is a consultant for Millenium Pharmaceutics.
NR 39
TC 12
Z9 12
U1 0
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
J9 MOL CELL
JI Mol. Cell
PD APR 25
PY 2013
VL 50
IS 2
BP 172
EP 184
DI 10.1016/j.molcel.2013.02.014
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 134KH
UT WOS:000318208600004
PM 23499007
ER
PT J
AU Snyder, EL
Watanabe, H
Magendantz, M
Hoersch, S
Chen, TA
Wang, DG
Crowley, D
Whittaker, CA
Meyerson, M
Kimura, S
Jacks, T
AF Snyder, Eric L.
Watanabe, Hideo
Magendantz, Margaret
Hoersch, Sebastian
Chen, Tiffany A.
Wang, Diana G.
Crowley, Denise
Whittaker, Charles A.
Meyerson, Matthew
Kimura, Shioko
Jacks, Tyler
TI Nkx2-1 Represses a Latent Gastric Differentiation Program in Lung
Adenocarcinoma
SO MOLECULAR CELL
LA English
DT Article
ID NUCLEAR FACTOR 4-ALPHA; THYROID TRANSCRIPTION FACTOR-1; K-RAS;
BRONCHIOLOALVEOLAR CARCINOMA; PULMONARY ADENOCARCINOMA; EPIGENETIC
SIGNATURES; EPITHELIAL-CELLS; GENE-EXPRESSION; IN-VIVO; CANCER
AB Tissue-specific differentiation programs become dysregulated during cancer evolution. The transcription factor Nkx2-1 is a master regulator of pulmonary differentiation that is downregulated in poorly differentiated lung adenocarcinoma. Here we use conditional murine genetics to determine how the identity of lung epithelial cells changes upon loss of their master cell-fate regulator. Nkx2-1 deletion in normal and neoplastic lungs causes not only loss of pulmonary identity but also conversion to a gastric lineage. Nkx2-1 is likely to maintain pulmonary identity by recruiting transcription factors Foxa1 and Foxa2 to lung-specific loci, thus preventing them from binding gastrointestinal targets. Nkx2-1-negative murine lung tumors mimic mucinous human lung adenocarcinomas, which express gastric markers. Loss of the gastrointestinal transcription factor Hnf4 alpha leads to derepression of the embryonal proto-oncogene Hmga2 in Nkx2-1-negative tumors. These observations suggest that loss of both active and latent differentiation programs is required for tumors to reach a primitive, poorly differentiated state.
C1 [Snyder, Eric L.; Magendantz, Margaret; Hoersch, Sebastian; Chen, Tiffany A.; Wang, Diana G.; Crowley, Denise; Whittaker, Charles A.; Jacks, Tyler] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02142 USA.
[Crowley, Denise; Jacks, Tyler] MIT, Howard Hughes Med Inst, Cambridge, MA 02142 USA.
[Snyder, Eric L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Watanabe, Hideo; Meyerson, Matthew] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Watanabe, Hideo; Meyerson, Matthew] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02215 USA.
[Watanabe, Hideo; Meyerson, Matthew] Broad Inst Harvard, Canc Program, Cambridge, MA 02142 USA.
[Watanabe, Hideo; Meyerson, Matthew] MIT, Cambridge, MA 02142 USA.
[Meyerson, Matthew] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Kimura, Shioko] NCI, Lab Metab, NIH, Bethesda, MD 20892 USA.
RP Jacks, T (reprint author), MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02142 USA.
EM tjacks@mit.edu
FU Burroughs Wellcome Fund; National Institutes of Health [U01-CA84306,
K08-CA154784-01]; Howard Hughes Medical Institute; Ludwig Center for
Molecular Oncology at MIT; National Cancer Institute [P30-CA14051]
FX We thank N. Dimitrova, D. Feldser, and M. Mendoza for critical reading
of the manuscript; the Swanson Biotechnology Center for histology,
Illumina sequencing, and bioinformatic support; the BioMicro Center for
library preparation and Illumina sequencing; L. Sholl and L. Chirieac
for assistance with human lung adenocarcinoma collection; and M. Winslow
and the entire Jacks Lab for helpful discussions. E.L.S. holds a Career
Award for Medical Scientists from the Burroughs Wellcome Fund. This work
was supported by National Institutes of Health grants U01-CA84306 (to
T.J.) and K08-CA154784-01 (to E.L.S.), the Howard Hughes Medical
Institute, the Ludwig Center for Molecular Oncology at MIT, and in part
by the Cancer Center Support (core) grant P30-CA14051 from the National
Cancer Institute. T.J. is the David H. Koch Professor of Biology and a
Daniel K. Ludwig Scholar.
NR 65
TC 48
Z9 48
U1 1
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
J9 MOL CELL
JI Mol. Cell
PD APR 25
PY 2013
VL 50
IS 2
BP 185
EP 199
DI 10.1016/j.molcel.2013.02.018
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 134KH
UT WOS:000318208600005
PM 23523371
ER
PT J
AU Jin, C
Rajabi, H
Rodrigo, CM
Porco, JA
Kufe, D
AF Jin, C.
Rajabi, H.
Rodrigo, C. M.
Porco, J. A., Jr.
Kufe, D.
TI Targeting the eIF4A RNA helicase blocks translation of the MUC1-C
oncoprotein
SO ONCOGENE
LA English
DT Article
DE MUC1-C; translation; AKT; mTOR; PDCD4; silvestrol
ID GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR PROTEIN; MESSENGER-RNA;
MOLECULAR-MECHANISMS; CARCINOMA ANTIGEN; REGULATORY LOOP; MAMMARY-GLAND;
BETA-CATENIN; CANCER CELLS; ACTIVATION
AB The oncogenic MUC1 C-terminal subunit (MUC1-C) subunit is aberrantly overexpressed in most human breast cancers by mechanisms that are not well understood. The present studies demonstrate that stimulation of non-malignant MCF-10A cells with epidermal growth factor (EGF) or heregulin (HRG) results in marked upregulation of MUC1-C translation. Growth factor-induced MUC1-C translation was found to be mediated by PI3K -> AKT, and not by MEK -> ERK1/2, signaling. We also show that activation of the mammalian target of rapamycin complex 1 (mTORC1)-> ribosomal protein S6 kinase 1 (S6K1) pathway decreases tumor suppressor programmed cell death protein 4 (PDCD4), an inhibitor of the eIF4A RNA helicase, and contributes to the induction of MUC1-C translation. In concert with these results, treatment of growth factor-stimulated MCF-10A cells with the eIF4A RNA helicase inhibitors, silvestrol and CR-1-31-B, blocked increases in MUC1-C abundance. The functional significance of the increase in MUC1-C translation is supported by the demonstration that MUC1-C, in turn, forms complexes with EGF receptor (EGFR) and promotes EGFR-mediated activation of the PI3K -> AKT pathway and the induction of growth. Compared with MCF-10A cells, constitutive overexpression of MUC1-C in breast cancer cells was unaffected by EGF stimulation, but was blocked by inhibiting PI3K -> AKT signaling. The overexpression of MUC1-C in breast cancer cells was also inhibited by blocking eIF4A RNA helicase activity with silvestrol and CR-1-31-B. These findings indicate that EGF-induced MUC1-C expression is mediated by the PI3K -> AKT pathway and the eIF4A RNA helicase, and that this response promotes EGFR signaling in an autoinductive loop. The findings also indicate that targeting the eIF4A RNA helicase is a novel approach for blocking MUC1-C overexpression in breast cancer cells. Oncogene (2013) 32, 2179-2188; doi:10.1038/onc.2012.236; published online 11 June 2012
C1 [Jin, C.; Rajabi, H.; Kufe, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rodrigo, C. M.; Porco, J. A., Jr.] Boston Univ, Dept Chem, Ctr Chem Methodol & Lib Dev, Boston, MA 02215 USA.
RP Kufe, D (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Dana 830, Boston, MA 02115 USA.
EM donald_kufe@dfci.harvard.edu
FU National Cancer Institute [CA97098, CA42802, CA100707]; National
Institutes of Health Grant [GM-073855]; American Cancer Society
[PF-11-077-01-CDD]
FX This work was supported by the National Cancer Institute Grants CA97098,
CA42802 and CA100707; the National Institutes of Health Grant GM-073855
(JAP), and a postdoctoral fellowship from the American Cancer Society
PF-11-077-01-CDD (CMR).
NR 44
TC 11
Z9 13
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD APR 25
PY 2013
VL 32
IS 17
BP 2179
EP 2188
DI 10.1038/onc.2012.236
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 132JD
UT WOS:000318062800007
PM 22689062
ER
PT J
AU Kelly, MJ
Sagar, P
Klepeis, VE
AF Kelly, Michael J.
Sagar, Pallavi
Klepeis, Veronica E.
TI Case 13-2013: A 6-Year-Old Girl with Bone and Joint Pain and Abdominal
Distention
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; CLINICAL-FEATURES; CHILDHOOD; LYMPHOMA;
CHILDREN; NEUROBLASTOMA; DISEASE; TUMOR
C1 [Kelly, Michael J.] Tufts Univ, Sch Med, Div Pediat Hematol Oncol, Dept Pediat,Floating Hosp Children,Tufts Med Ctr, Boston, MA 02111 USA.
[Kelly, Michael J.] Tufts Univ, Sch Med, Dept Pediat, Boston, MA 02111 USA.
[Sagar, Pallavi] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Klepeis, Veronica E.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Sagar, Pallavi] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Klepeis, Veronica E.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Kelly, MJ (reprint author), Tufts Univ, Sch Med, Div Pediat Hematol Oncol, Dept Pediat,Floating Hosp Children,Tufts Med Ctr, Boston, MA 02111 USA.
NR 19
TC 0
Z9 0
U1 0
U2 7
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 25
PY 2013
VL 368
IS 17
BP 1636
EP 1645
DI 10.1056/NEJMcpc1208151
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 130YK
UT WOS:000317956300013
PM 23614590
ER
PT J
AU Kasmar, AG
Turner, MT
AF Kasmar, Anne G.
Turner, Marie T.
TI Case 3-2013: A Woman with Abdominal Pain and Distention after Peritoneal
Dialysis Reply
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID TUBERCULOSIS; ETHAMBUTOL
C1 [Kasmar, Anne G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Turner, Marie T.] Lemuel Shattuck Hosp, Boston, MA USA.
RP Kasmar, AG (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
FU NIAID NIH HHS [K08 AI089858]
NR 3
TC 0
Z9 0
U1 0
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 25
PY 2013
VL 368
IS 17
BP 1656
EP 1657
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 130YK
UT WOS:000317956300025
PM 23614601
ER
PT J
AU Shimamoto, SA
Ryapolova-Webb, ES
Ostrem, JL
Galifianakis, NB
Miller, KJ
Starr, PA
AF Shimamoto, Shoichi A.
Ryapolova-Webb, Elena S.
Ostrem, Jill L.
Galifianakis, Nicholas B.
Miller, Kai J.
Starr, Philip A.
TI Subthalamic Nucleus Neurons Are Synchronized to Primary Motor Cortex
Local Field Potentials in Parkinson's Disease
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID DEEP BRAIN-STIMULATION; BASAL GANGLIA; OSCILLATORY ACTIVITY;
SENSORIMOTOR CORTEX; BETA-OSCILLATIONS; GLOBUS-PALLIDUS;
CEREBRAL-CORTEX; SPECTRAL-ANALYSIS; DOPAMINE; SPIKE
AB In Parkinson's disease (PD), striatal dopamine denervation results in a cascade of abnormalities in the single-unit activity of downstream basal ganglia nuclei that include increased firing rate, altered firing patterns, and increased oscillatory activity. However, the effects of these abnormalities on cortical function are poorly understood. Here, in humans undergoing deep brain stimulator implantation surgery, we use the novel technique of subdural electrocorticography in combination with subthalamic nucleus (STN) single-unit recording to study basal ganglia-cortex interactions at the millisecond time scale. We show that in patients with PD, STN spiking is synchronized with primary motor cortex (M1) local field potentials in two distinct patterns: first, STN spikes are phase-synchronized with M1 rhythms in the theta, alpha, or beta (4-30 Hz) bands. Second, STN spikes are synchronized with M1 gamma activity over a broad spectral range (50-200Hz). The amplitude of STN spike-synchronized gamma activity in M1 is itself rhythmically modulated by the phase of a lower-frequency rhythm (phase-amplitude coupling), such that "waves" of phase-synchronized gamma activity precede the occurrence of STN spikes. We show the disease specificity of these phenomena in PD, by comparison with STN-M1 paired recordings performed in a group of patients with a different disorder, primary craniocervical dystonia. Our findings support a model of the basal ganglia-thalamocortical loop in PD in which gamma activity in primary motor cortex, modulated by the phase of low-frequency rhythms, drives STN unit discharge.
C1 [Shimamoto, Shoichi A.; Ryapolova-Webb, Elena S.; Starr, Philip A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
[Ostrem, Jill L.; Galifianakis, Nicholas B.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Galifianakis, Nicholas B.; Starr, Philip A.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Care Ctr, San Francisco, CA 94143 USA.
[Miller, Kai J.] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA.
RP Starr, PA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 779 Moffitt,505 Parnassus Ave, San Francisco, CA 94143 USA.
EM starrp@neurosurg.ucsf.edu
FU National Institutes of Health [R01NS069779]; Dystonia Medical Research
Foundation
FX This work was supported by the National Institutes of Health (Grant
R01NS069779 to P. A. S.), and the Dystonia Medical Research Foundation.
We thank Leslie Markun and Marta San Luciano for assistance with
clinical data and statistical analyses, and Coralie de Hemptinne for
critical review of the paper.
NR 63
TC 45
Z9 46
U1 4
U2 22
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD APR 24
PY 2013
VL 33
IS 17
BP 7220
EP 7233
DI 10.1523/JNEUROSCI.4676-12.2013
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 137EW
UT WOS:000318419300011
PM 23616531
ER
PT J
AU Bleier, BS
Kohman, RE
Feldman, RE
Ramanlal, S
Han, X
AF Bleier, Benjamin S.
Kohman, Richie E.
Feldman, Rachel E.
Ramanlal, Shreshtha
Han, Xue
TI Permeabilization of the Blood-Brain Barrier via Mucosal Engrafting:
Implications for Drug Delivery to the Brain
SO PLOS ONE
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; NEUROTROPHIC FACTOR; PARKINSONS-DISEASE;
DOUBLE-BLIND; MODEL; FLUORESCEIN; GDNF
AB Utilization of neuropharmaceuticals for central nervous system(CNS) disease is highly limited due to the blood-brain barrier(BBB) which restricts molecules larger than 500Da from reaching the CNS. The development of a reliable method to bypass the BBB would represent an enormous advance in neuropharmacology enabling the use of many potential disease modifying therapies. Previous attempts such as transcranial catheter implantation have proven to be temporary and associated with multiple complications. Here we describe a novel method of creating a semipermeable window in the BBB using purely autologous tissues to allow for high molecular weight(HMW) drug delivery to the CNS. This approach is inspired by recent advances in human endoscopic transnasal skull base surgical techniques and involves engrafting semipermeable nasal mucosa within a surgical defect in the BBB. The mucosal graft thereby creates a permanent transmucosal conduit for drugs to access the CNS. The main objective of this study was to develop a murine model of this technique and use it to evaluate transmucosal permeability for the purpose of direct drug delivery to the brain. Using this model we demonstrate that mucosal grafts allow for the transport of molecules up to 500 kDa directly to the brain in both a time and molecular weight dependent fashion. Markers up to 40 kDa were found within the striatum suggesting a potential role for this technique in the treatment of Parkinson's disease. This proof of principle study demonstrates that mucosal engrafting represents the first permanent and stable method of bypassing the BBB thereby providing a pathway for HMW therapeutics directly into the CNS.
C1 [Bleier, Benjamin S.; Feldman, Rachel E.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Kohman, Richie E.; Ramanlal, Shreshtha; Han, Xue] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
RP Bleier, BS (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
EM benjamin_bleier@meei.harvard.edu
FU Michael J. Fox Foundation for Parkinson's Research 2011 Rapid Response
Innovations Awards Program
FX This study was funded by the Michael J. Fox Foundation for Parkinson's
Research 2011 Rapid Response Innovations Awards Program. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 22
TC 10
Z9 10
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 24
PY 2013
VL 8
IS 4
AR e61694
DI 10.1371/journal.pone.0061694
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 136DE
UT WOS:000318340400041
PM 23637885
ER
PT J
AU Sukhotinsky, I
Chan, AM
Ahmed, OJ
Rao, VR
Gradinaru, V
Ramakrishnan, C
Deisseroth, K
Majewska, AK
Cash, SS
AF Sukhotinsky, Inna
Chan, Alexander M.
Ahmed, Omar J.
Rao, Vikram R.
Gradinaru, Viviana
Ramakrishnan, Charu
Deisseroth, Karl
Majewska, Ania K.
Cash, Sydney S.
TI Optogenetic Delay of Status Epilepticus Onset in an In Vivo Rodent
Epilepsy Model
SO PLOS ONE
LA English
DT Article
ID TEMPORAL-LOBE EPILEPSY; ANTIEPILEPTIC DRUGS; NEURAL CIRCUITRY; OPTICAL
CONTROL; TREATED RATS; PILOCARPINE; SEIZURES; LITHIUM; PATHOGENESIS;
INJURY
AB Epilepsy is a devastating disease, currently treated with medications, surgery or electrical stimulation. None of these approaches is totally effective and our ability to control seizures remains limited and complicated by frequent side effects. The emerging revolutionary technique of optogenetics enables manipulation of the activity of specific neuronal populations in vivo with exquisite spatiotemporal resolution using light. We used optogenetic approaches to test the role of hippocampal excitatory neurons in the lithium-pilocarpine model of acute elicited seizures in awake behaving rats. Hippocampal pyramidal neurons were transduced in vivo with a virus carrying an enhanced halorhodopsin (eNpHR), a yellow light activated chloride pump, and acute seizure progression was then monitored behaviorally and electrophysiologically in the presence and absence of illumination delivered via an optical fiber. Inhibition of those neurons with illumination prior to seizure onset significantly delayed electrographic and behavioral initiation of status epilepticus, and altered the dynamics of ictal activity development. These results reveal an essential role of hippocampal excitatory neurons in this model of ictogenesis and illustrate the power of optogenetic approaches for elucidation of seizure mechanisms. This early success in controlling seizures also suggests future therapeutic avenues.
C1 [Sukhotinsky, Inna; Chan, Alexander M.; Ahmed, Omar J.; Rao, Vikram R.; Cash, Sydney S.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Sukhotinsky, Inna; Chan, Alexander M.; Ahmed, Omar J.; Rao, Vikram R.; Cash, Sydney S.] Harvard Univ, Sch Med, Boston, MA USA.
[Chan, Alexander M.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Gradinaru, Viviana; Ramakrishnan, Charu; Deisseroth, Karl] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.
[Majewska, Ania K.] Univ Rochester, Ctr Visual Sci, Dept Neurobiol & Anat, Rochester, NY 14627 USA.
RP Cash, SS (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
EM scash@partners.org
OI Ramakrishnan, Charu/0000-0002-3474-6332
FU DOD [W81xWH-09-1-0480]
FX DOD grant # W81xWH-09-1-0480. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 43
TC 23
Z9 24
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 24
PY 2013
VL 8
IS 4
AR e62013
DI 10.1371/journal.pone.0062013
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 136DE
UT WOS:000318340400068
PM 23637949
ER
PT J
AU Zhang, XL
Kuo, C
Moore, A
Ran, CZ
AF Zhang, Xueli
Kuo, Chaincy
Moore, Anna
Ran, Chongzhao
TI In Vivo Optical Imaging of Interscapular Brown Adipose Tissue with
F-18-FDG via Cerenkov Luminescence Imaging
SO PLOS ONE
LA English
DT Article
ID POSITRON-EMITTING RADIOTRACERS; ENERGY-EXPENDITURE; ADULT HUMANS; FAT;
OBESITY; MICE; THERMOGENESIS; RADIONUCLIDES; ADIPOGENESIS; TOMOGRAPHY
AB Objective: Brown adipose tissue (BAT), a specialized tissue for thermogenesis, plays important roles for metabolism and energy expenditure. Recent studies validated BAT's presence in human adults, making it an important re-emerging target for various pathologies. During this validation, PET images with F-18-FDG showed significant uptake of F-18-FDG by BAT under certain conditions. Here, we demonstrated that Cerenkov luminescence imaging (CLI) using F-18-FDG could be utilized for in vivo optical imaging of BAT in mice.
Methods: Mice were injected with F-18-FDG and imaged 60 minutes later with open filter and 2 minute acquisition. In vivo activation of BAT was performed by norepinephrine and cold treatment under isoflurane or ketamine anesthesia. Spectral unmixing and 3D imaging reconstruction were conducted with multiple-filter CLI images.
Results: 1) It was feasible to use CLI with F-18-FDG to image interscapular BAT in mice, with the majority of the signal (>85%) at the interscapular site originating from BAT; 2) The method was reliable because excellent correlations between in vivo CLI, ex vivo CLI, and ex vivo radioactivity were observed; 3) CLI could be used for monitoring BAT activation under different conditions; 4) CLI signals from the group under short-term isoflurane anesthesia were significantly higher than that from the group under long-term anesthesia; 5) The CLI spectrum of F-18-FDG with a peak at 640 nm in BAT after spectral unmixing reflected the actual context of BAT; 6) Finally 3D reconstruction images showed excellent correlation between the source of the light signal and the location and physical shape of BAT.
Conclusion: CLI with F-18-FDG is a feasible and reliable method for imaging BAT in mice. Compared to PET imaging, CLI is significantly cheaper, faster for 2D planar imaging and easier to use. We believe that this method could be used as an important tool for researchers investigating BAT.
C1 [Zhang, Xueli; Moore, Anna; Ran, Chongzhao] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Dept Radiol,Mol Imaging La, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA USA.
[Zhang, Xueli] China Pharmaceut Univ, Sch Pharm, Ctr Drug Discovery, Nanjing, Jiangsu, Peoples R China.
[Kuo, Chaincy] Caliper, Alameda, CA USA.
RP Moore, A (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp,Dept Radiol,Mol Imaging La, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA USA.
EM amoore@helix.mgh.harvard.edu; cran@nmr.mgh.harvard.edu
RI Kuo, Chaincy/G-2403-2015; Kuo, Chaincy/H-9475-2016
OI Kuo, Chaincy/0000-0001-7958-8764
FU NCRR NIH HHS [S10 RR025504]
NR 55
TC 15
Z9 16
U1 1
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 24
PY 2013
VL 8
IS 4
AR e62007
DI 10.1371/journal.pone.0062007
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 136DE
UT WOS:000318340400066
PM 23637947
ER
PT J
AU Pomerantz, M
Freedman, ML
AF Pomerantz, Mark
Freedman, Matthew L.
TI Clinical Uncertainty of Prostate Cancer Genetic Risk Panels
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Editorial Material
ID GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; MEN
C1 [Pomerantz, Mark] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Freedman, Matthew L.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Freedman, Matthew L.] Dana Farber Canc Inst, Med Oncol Serv, Boston, MA 02115 USA.
RP Pomerantz, M (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
EM freedman@broadinstitute.org
NR 10
TC 1
Z9 1
U1 0
U2 2
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD APR 24
PY 2013
VL 5
IS 182
AR 182ed6
DI 10.1126/scitranslmed.3004696
PG 3
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 131TF
UT WOS:000318018300001
PM 23616119
ER
PT J
AU Gu, LY
Dai, Y
Xu, J
Mallipattu, S
Kaufman, L
Klotman, PE
He, JC
Chuang, PY
AF Gu, Leyi
Dai, Yan
Xu, Jin
Mallipattu, Sandeep
Kaufman, Lewis
Klotman, Paul E.
He, John C.
Chuang, Peter Y.
TI Deletion of podocyte STAT3 mitigates the entire spectrum of
HIV-1-associated nephropathy
SO AIDS
LA English
DT Article
DE dedifferentiation; glomerular disease; HIV-1-associated nephropathy;
kidney; podocyte; STAT3
ID HIV-ASSOCIATED NEPHROPATHY; ANTIRETROVIRAL THERAPY;
DIABETIC-NEPHROPATHY; SIGNAL TRANSDUCER; KIDNEY; MICE; EXPRESSION;
GLOMERULI; INFECTION; ACTIVATOR
AB Objective: HIV-1 gene expression in kidney epithelial cells is thought to be responsible for the pathogenesis of HIV-1-associated nephropathy (HIVAN). Signal transducer and activator of transcription (STAT) 3 signaling is activated in podocytes of patients with HIVAN and drives the dedifferentiation and proliferation of podocytes in culture. We confirm here that deletion of podocyte STAT3 is sufficient to mitigate the glomerular as well as tubulointerstitial findings of HIVAN.
Methods: To demonstrate the functional role of podocyte STAT3 in the pathogenesis of HIVAN we compared the development of HIVAN in Tg26 HIV-transgenic mice with and without deletion of STAT3 in the podocyte.
Results: Tg26 mice with podocyte-specific STAT3 deletion developed significantly less weight loss, albuminuria, and renal function impairment compared to Tg26 mice without STAT3 deletion. Tg26 mice with podocyte STAT3 deletion also had significantly less glomerular collapse, sclerosis, epithelial cell hyperplasia, podocyte dedifferentiation, and proinflammatory STAT3 target gene expression; and tubulointerstitial changes of HIVAN, including tubular atrophy, degeneration, apoptosis, and lymphocyte infiltration, were also significantly reduced compared to Tg26 mice without STAT3 deletion.
Conclusion: Development of glomerular as well as tubulointerstitial injuries in the Tg26 HIVAN model is dependent on podocyte STAT3 expression. Inhibition of STAT3 could be a potential adjunctive therapy for the treatment of HIVAN. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins AIDS 2013, 27:1091-1098
C1 [Gu, Leyi; Dai, Yan; Xu, Jin; Mallipattu, Sandeep; Kaufman, Lewis; He, John C.; Chuang, Peter Y.] Mt Sinai Sch Med, Div Nephrol, New York, NY 10029 USA.
[Gu, Leyi] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Renal, Shanghai 200030, Peoples R China.
[Gu, Leyi] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Mol Cell Lab Kidney Dis, Shanghai 200030, Peoples R China.
[Dai, Yan] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Div Nephrol, Shanghai 200030, Peoples R China.
[Klotman, Paul E.] Baylor Coll Med, Houston, TX 77030 USA.
[He, John C.] James J Peter Vet Affairs Med Ctr, Renal Sect, Bronx, NY USA.
RP Chuang, PY (reprint author), Mt Sinai Sch Med, Dept Med, Div Nephrol, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA.
EM peter.chuang@mssm.edu
RI Mallipattu , Sandeep/M-7009-2014
FU NIH [1R01DK078897, 1R01DK088541-01A1, 5K08DK082760, R01DK078897,
K08DK082760, R01DK088541-01A1, RC4DK090860, P01DK056492]; Veterans
Affairs Merit Review Award [1I01BX000345]
FX J.C.H. is supported by NIH 1R01DK078897 and 1R01DK088541-01A1 and a
Veterans Affairs Merit Review Award 1I01BX000345; P.Y.C. is supported by
NIH 5K08DK082760.; Source of Support: NIH R01DK078897, K08DK082760,
R01DK088541-01A1, RC4DK090860, P01DK056492 and Veterans Affairs Merit
Review Award 1I01BX000345.
NR 31
TC 16
Z9 16
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD APR 24
PY 2013
VL 27
IS 7
BP 1091
EP 1098
DI 10.1097/QAD.0b013e32835f1ea1
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 124QE
UT WOS:000317479500005
PM 23343908
ER
PT J
AU London, MJ
Hur, K
Schwartz, GG
Henderson, WG
AF London, Martin J.
Hur, Kwan
Schwartz, Gregory G.
Henderson, William G.
TI Association of Perioperative beta-Blockade With Mortality and
Cardiovascular Morbidity Following Major Noncardiac Surgery
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID OF-VETERANS-AFFAIRS; QUALITY IMPROVEMENT PROGRAM; VASCULAR-SURGERY;
AMERICAN-COLLEGE; PRACTICE GUIDELINES; HEART-ASSOCIATION; SURGICAL CARE;
OUTCOMES; RISK; THERAPY
AB Importance The effectiveness of perioperative beta-blockade in patients undergoing noncardiac surgery remains controversial.
Objective To determine the associations of early perioperative exposure to beta-blockers with 30-day postoperative outcome in patients undergoing noncardiac surgery.
Design, Setting, and Patients A retrospective cohort analysis evaluating exposure to beta-blockers on the day of or following major noncardiac surgery among a population-based sample of 136 745 patients who were 1: 1 matched on propensity scores (37 805 matched pairs) treated at 104 VA medical centers from January 2005 through August 2010.
Main Outcomes and Measures All cause 30-day mortality and cardiac morbidity (cardiac arrest or Q-wave myocardial infarction).
Results Overall 55 138 patients (40.3%) were exposed to beta-blockers. Exposure was higher in the 66.7% of 13 863 patients undergoing vascular surgery (95% CI, 65.9%-67.5%) than in the 37.4% of 122 882 patients undergoing nonvascular surgery (95% CI, 37.1%-37.6%; P<.001). Exposure increased as Revised Cardiac Risk Index factors increased, with 25.3% (95% CI, 24.9%-25.6%) of those with no risk vs 71.3% (95% CI, 69.5%-73.2%) of those with 4 risk factors or more exposed to beta-blockers (P<.001). Death occurred among 1.1% (95% CI, 1.1%-1.2%) and cardiac morbidity occurred among 0.9% (95% CI, 0.8%-0.9%) of patients. In the propensity matched cohort, exposure was associated with lower mortality (relative risk [RR], 0.73; 95% CI, 0.65-0.83; P<.001; number need to treat [NNT], 241; 95% CI, 173-397). When stratified by cumulative numbers of Revised Cardiac Risk Index factors, beta-blocker exposure was associated with significantly lower mortality among patients with 2 factors (RR, 0.63 [95% CI, 0.50-0.80]; P<.001; NNT, 105 [95% CI, 69-212]), 3 factors (RR, 0.54 [95% CI, 0.39-0.73]; P<.001; NNT, 41 [95% CI, 28-80]), or 4 factors or more (RR, 0.40 [95% CI, 0.25-0.73]; P<.001; NNT, 18 [95% CI, 12-34]). This association was limited to patients undergoing nonvascular surgery. beta-Blocker exposure was also associated with a lower rate of nonfatal Q-wave infarction or cardiac arrest (RR, 0.67 [95% CI, 0.57-0.79]; P<.001; NNT, 339 [95% CI, 240-582]), again limited to patients undergoing nonvascular surgery.
Conclusions and Relevance Among propensity-matched patients undergoing noncardiac, nonvascular surgery, perioperative beta-blocker exposure was associated with lower rates of 30-day all-cause mortality in patients with 2 or more Revised Cardiac Risk Index factors. Our findings support use of a cumulative number of Revised Cardiac Risk Index predictors in decision making regarding institution and continuation of perioperative beta-blockade. A multicenter randomized trial involving patients at a low to intermediate risk by these factors would be of interest to validate these observational findings. JAMA. 0;0(16):1704-1713 www.jama.com
C1 [London, Martin J.] US Dept Vet Affairs Med Ctr, Dept Anesthesia & Perioperat Care, San Francisco, CA USA.
[London, Martin J.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Hur, Kwan] US Dept Vet Affairs Med Ctr, Ctr Medicat Safety, Pharm Benefits Management Serv, Hines, IL USA.
[Schwartz, Gregory G.] US Dept Vet Affairs Med Ctr, Cardiol Sect, Denver, CO USA.
[Schwartz, Gregory G.] Univ Colorado, Denver, CO 80202 USA.
[Henderson, William G.] Colorado Sch Publ Hlth, Hlth Outcomes Program, Aurora, CO USA.
[Henderson, William G.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA.
RP London, MJ (reprint author), San Francisco VA Med Ctr, Dept Anesthesia & Perioperat Care, 4150 Clement St, San Francisco, CA 94121 USA.
EM londonm@anesthesia.ucsf.edu
FU Anesthesia Patient Safety Foundation
FX This study was supported by a grant from the Anesthesia Patient Safety
Foundation.
NR 37
TC 87
Z9 88
U1 3
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 24
PY 2013
VL 309
IS 16
BP 1704
EP 1713
DI 10.1001/jama.2013.4135
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 130IG
UT WOS:000317906700027
PM 23613075
ER
PT J
AU Neely, LA
Audeh, M
Phung, NA
Min, M
Suchocki, A
Plourde, D
Blanco, M
Demas, V
Skewis, LR
Anagnostou, T
Coleman, JJ
Wellman, P
Mylonakis, E
Lowery, TJ
AF Neely, Lori A.
Audeh, Mark
Nu Ai Phung
Min, Michael
Suchocki, Adam
Plourde, Daniella
Blanco, Matthew
Demas, Vasiliki
Skewis, Lynell R.
Anagnostou, Theodora
Coleman, Jeffrey J.
Wellman, Parris
Mylonakis, Eleftherios
Lowery, Thomas J.
TI T2 Magnetic Resonance Enables Nanoparticle-Mediated Rapid Detection of
Candidemia in Whole Blood
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; INVASIVE CANDIDIASIS; PCR AMPLIFICATION;
FUNGAL-INFECTIONS; CULTURE-SYSTEM; IDENTIFICATION; PATHOGENS; DIAGNOSIS;
GUIDELINES; INITIATION
AB Candida spp. cause both local and disseminated infections in immunocompromised patients. Bloodstream infections of Candida spp., known as "candidemia," are associated with a high mortality rate (40%), which is mainly attributed to the long diagnostic time required by blood culture. We introduce a diagnostic platform based on T2 magnetic resonance (T2MR), which is capable of sensitive and rapid detection of fungal targets in whole blood. In our approach, blood-compatible polymerase chain reaction is followed by hybridization of the amplified pathogen DNA to capture probe-decorated nanoparticles. Hybridization yields nanoparticle microclusters that cause large changes in the sample's T2MR signal. With this T2MR-based method, Candida spp. can be detected directly in whole blood, thus eliminating the need for analyte purification. Using a small, portable T2MR detection device, we were able to rapidly, accurately, and reproducibly detect five Candida species within human whole blood with a limit of detection of 1 colony-forming unit/ml and a time to result of < 3 hours. Spiked blood samples showed 98% positive agreement and 100% negative agreement between T2MR and blood culture. Additionally, performance of the assay was evaluated on 21 blinded clinical specimens collected serially. This study shows that the nanoparticle-and T2MR-based detection method is rapid and amenable to automation and offers clinicians the opportunity to detect and identify multiple human pathogens within hours of sample collection.
C1 [Neely, Lori A.; Audeh, Mark; Nu Ai Phung; Min, Michael; Suchocki, Adam; Plourde, Daniella; Blanco, Matthew; Demas, Vasiliki; Skewis, Lynell R.; Wellman, Parris; Lowery, Thomas J.] T2 Biosyst, Lexington, MA 02421 USA.
[Anagnostou, Theodora; Coleman, Jeffrey J.; Mylonakis, Eleftherios] Brown Univ, Div Infect Dis, Providence, RI 02906 USA.
[Coleman, Jeffrey J.; Mylonakis, Eleftherios] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Coleman, Jeffrey J.; Mylonakis, Eleftherios] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Lowery, TJ (reprint author), T2 Biosyst, Lexington, MA 02421 USA.
EM tlowery@t2biosystems.com
RI Coleman, Jeffrey/E-2981-2015
FU T2 Biosystems Inc.
FX This work was funded by T2 Biosystems Inc.
NR 39
TC 44
Z9 44
U1 0
U2 5
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD APR 24
PY 2013
VL 5
IS 182
AR 182ra54
PG 8
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 131TF
UT WOS:000318018300006
PM 23616121
ER
PT J
AU Sadreyev, RI
Yildirim, E
Pinter, SF
Lee, JT
AF Sadreyev, Ruslan I.
Yildirim, Eda
Pinter, Stefan F.
Lee, Jeannie T.
TI Bimodal quantitative relationships between histone modifications for
X-linked and autosomal loci
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE embryonic stem cells; allele-specific ChIP-seq
ID EMBRYONIC STEM-CELLS; GENE-EXPRESSION; CHROMOSOME INACTIVATION;
LYSINE-27 METHYLATION; DOSAGE COMPENSATION; CHROMATIN-STRUCTURE;
RNA-SEQ; GENOME; TRANSCRIPTION; STATES
AB Gene expression is controlled by coordinated action of many epigenetic mechanisms including covalent histone modifications. Although numerous recurrent patterns of colocalized histone modifications have been associated with specific gene expression states, interrelationships between individual modifications are largely unknown. Here, we analyze quantitative relationships between colocalized histone marks during embryonic stem cell (ESC) differentiation and find that, for autosomal genes, these densities follow bimodal patterns. Analysis of repressive H3K27me3 and activating H3K4me3 modifications reveals the expected anti-correlation between them at active promoters but an unexpected positive correlation at inactive promoters. The two trends connect in a region corresponding to bivalent genes. Interestingly, this region is characterized by maximal H3K27 methylation. Resolving gene bivalency during ESC differentiation does not conform to the expected model of two marks as counteracting and competing forces. Although activated genes acquire H3K4me3 and lose H3K27me3, repressed genes lose H3K4me3 without gaining H3K27me3. The behavior of X-linked genes also deviates from expected models. Allele-specific analysis of chromatin modifications during X-chromosome inactivation (XCI) suggests that the silencing machinery focuses on active genes and depletion of H3K4me3 and that H3K27me3 is most significant during establishment of gene silencing. Our analysis reveals nontrivial relationships between H3K4me3 and H3K27me3, reveals unique aspects of gene bivalency, and demonstrates that XCI does not conform neatly to autosomal models.
C1 [Sadreyev, Ruslan I.; Yildirim, Eda; Pinter, Stefan F.; Lee, Jeannie T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Sadreyev, Ruslan I.; Lee, Jeannie T.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02114 USA.
[Yildirim, Eda; Pinter, Stefan F.; Lee, Jeannie T.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.
[Yildirim, Eda; Pinter, Stefan F.; Lee, Jeannie T.] Howard Hughes Med Inst, Boston, MA 02114 USA.
RP Lee, JT (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM lee@molbio.mgh.harvard.edu
OI Yildirim, Eda/0000-0002-4796-3854; Pinter, Stefan/0000-0003-4750-1403
FU Massachusetts General Hospital Executive Committee on Research Medical
Discovery Fund; Deutsche Forschungsgemeinschaft; National Institutes of
Health [RO1-GM090278]
FX We thank the J.T.L. laboratory and Brad Bernstein for valuable
discussion. This work was supported by the Massachusetts General
Hospital Executive Committee on Research Medical Discovery Fund (E.Y.),
Deutsche Forschungsgemeinschaft (S.F.P.), and National Institutes of
Health Grant RO1-GM090278 (to J.T.L.). J.T.L. is an investigator of the
Howard Hughes Medical Institute.
NR 36
TC 4
Z9 4
U1 0
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 23
PY 2013
VL 110
IS 17
BP 6949
EP 6954
DI 10.1073/pnas.1216449110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 140TE
UT WOS:000318677300075
PM 23564346
ER
PT J
AU Kaliannan, K
Hamarneh, SR
Economopoulos, KP
Alam, SN
Moaven, O
Patel, P
Malo, NS
Ray, M
Abtahi, SM
Muhammad, N
Raychowdhury, A
Teshager, A
Mohamed, MMR
Moss, AK
Ahmed, R
Hakimian, S
Narisawa, S
Millan, JL
Hohmann, E
Warren, HS
Bhan, AK
Malo, MS
Hodin, RA
AF Kaliannan, Kanakaraju
Hamarneh, Sulaiman R.
Economopoulos, Konstantinos P.
Alam, Sayeda Nasrin
Moaven, Omeed
Patel, Palak
Malo, Nondita S.
Ray, Madhury
Abtahi, Seyed M.
Muhammad, Nur
Raychowdhury, Atri
Teshager, Abeba
Mohamed, Mussa M. Rafat
Moss, Angela K.
Ahmed, Rizwan
Hakimian, Shahrad
Narisawa, Sonoko
Millan, Jose Luis
Hohmann, Elizabeth
Warren, H. Shaw
Bhan, Atul K.
Malo, Madhu S.
Hodin, Richard A.
TI Intestinal alkaline phosphatase prevents metabolic syndrome in mice
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE atherosclerosis; cytokines; diabetes; dysbiosis; steatosis
ID HIGH-FAT DIET; GUT MICROBIOTA; INDUCED OBESITY; INSULIN-RESISTANCE;
INFLAMMATION; ENDOTOXEMIA; MECHANISMS; LIPOPOLYSACCHARIDE; DISEASE;
ADULTS
AB Metabolic syndrome comprises a cluster of related disorders that includes obesity, glucose intolerance, insulin resistance, dyslipidemia, and fatty liver. Recently, gut-derived chronic endotoxemia has been identified as a primary mediator for triggering the low-grade inflammation responsible for the development of metabolic syndrome. In the present study we examined the role of the small intestinal brush-border enzyme, intestinal alkaline phosphatase (IAP), in preventing a high-fat-diet-induced metabolic syndrome in mice. We found that both endogenous and orally supplemented IAP inhibits absorption of endotoxin (lipopolysaccharides) that occurs with dietary fat, and oral IAP supplementation prevents as well as reverses metabolic syndrome. Furthermore, IAP supplementation improves the lipid profile in mice fed a standard, low-fat chow diet. These results point to a potentially unique therapy against metabolic syndrome in at-risk humans.
C1 [Kaliannan, Kanakaraju; Hamarneh, Sulaiman R.; Economopoulos, Konstantinos P.; Alam, Sayeda Nasrin; Moaven, Omeed; Patel, Palak; Malo, Nondita S.; Ray, Madhury; Abtahi, Seyed M.; Muhammad, Nur; Raychowdhury, Atri; Teshager, Abeba; Mohamed, Mussa M. Rafat; Moss, Angela K.; Ahmed, Rizwan; Hakimian, Shahrad; Malo, Madhu S.; Hodin, Richard A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Narisawa, Sonoko; Millan, Jose Luis] Sanford Burnham Med Res Inst, Sanford Childrens Hlth Res Ctr, La Jolla, CA 92037 USA.
[Hohmann, Elizabeth; Warren, H. Shaw] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med & Pediat,Infect Dis Unit, Boston, MA 02114 USA.
[Bhan, Atul K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Malo, MS (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
EM mmalo@partners.org
RI kaliannan, kanakaraju/P-9094-2014;
OI Economopoulos, Konstantinos/0000-0003-4856-0405; Moaven,
Omeed/0000-0002-0560-0457; Kuhnen, Angela/0000-0003-4944-9143
FU National Institutes of Health (NIH) [R01DK050623, R01DK047186, 2P30
DK43351]; Junior Faculty Award from the MGH Department of Surgery; Grand
Challenge Exploration Grant from the Bill and Melinda Gates Foundation
FX We thank Dr. Hang Lee (Department of Biostatistics, MGH) for help with
statistical analyses. This work was supported by National Institutes of
Health (NIH) Grants R01DK050623 and R01DK047186 (to R.A.H.), a Junior
Faculty Award (to M.S.M.) from the MGH Department of Surgery, and a
Grand Challenge Exploration Grant from the Bill and Melinda Gates
Foundation (to M.S.M.). The work was also supported by NIH Grant 2P30
DK43351 to the Center for the Study of Inflammatory Bowel Disease, MGH.
NR 31
TC 46
Z9 47
U1 0
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 23
PY 2013
VL 110
IS 17
BP 7003
EP 7008
DI 10.1073/pnas.1220180110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 140TE
UT WOS:000318677300084
PM 23569246
ER
PT J
AU Fosbol, EL
Zhao, Y
Shahian, DM
Grover, FL
Edwards, FH
Peterson, ED
AF Fosbol, Emil L.
Zhao, Yue
Shahian, David M.
Grover, Frederick L.
Edwards, Fred H.
Peterson, Eric D.
TI Repeat Coronary Revascularization After Coronary Artery Bypass Surgery
in Older Adults The Society of Thoracic Surgeons' National Experience,
1991-2007
SO CIRCULATION
LA English
DT Article
DE aged; coronary artery bypass surgery; revascularization
ID SAPHENOUS-VEIN GRAFTS; 5-YEAR OUTCOMES; SURVIVAL; PATENCY; PREDICTORS;
DATABASE; REGISTRY; TRIAL
AB Background-A major advantage of coronary artery bypass graft surgery (CABG) relative to percutaneous coronary intervention is its durability, yet there is a paucity of information on rates and predictors of repeat coronary revascularization after CABG in the modern era.
Methods and Results-We included patients >= 65 years from the Society of Thoracic Surgeons' National Adult Cardiac Surgery Database who were undergoing first-time isolated CABG from 1991 to 2007 (n=723 134, median age 73 years). After linking to Medicare claims data, long-term outcomes of CABG (up to 18 years after surgery) were examined by use of cumulative incidence curves. Multivariable Cox proportional hazard analysis was used to identify factors associated with 1- and 5-year repeat revascularization trends and variability. We found that the overall 18-year survival rate was 20%. Cumulative incidences of any repeat revascularization (percutaneous coronary intervention or CABG, yet most often percutaneous coronary intervention) were 2%, 7%, 13%, and 16% at 1, 5, 10, and 18 years after surgery, respectively. The rates of repeat CABG procedures were quite low for all time points (0.1%, 0.6%, 1.3%, and 1.7%, respectively). Female sex, disease severity represented by a history of percutaneous coronary intervention, preoperative dialysis, and partial revascularization were strongly associated with a higher revascularization rate, whereas advanced age, left main disease, and smoking were associated with a lower rate. There was approximately a 2-fold variation in repeat revascularization rates across centers at 1 year (interquartile range 1.7-3.6%) and 5 years (interquartile range 6.7-12.0%).
Conclusions-Repeat revascularization is performed infrequently among older patients who undergo CABG; however, these rates vary substantially by patient subgroups and among providers. (Circulation. 2013; 127:1656-1663.)
C1 [Fosbol, Emil L.; Zhao, Yue; Peterson, Eric D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Shahian, David M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA USA.
[Shahian, David M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Qual & Safety, Boston, MA USA.
[Grover, Frederick L.] Univ Colorado, Sch Med, Div Cardiothorac Surg, Denver, CO USA.
[Grover, Frederick L.] Denver VA Med Ctr, Surg Serv, Denver, CO USA.
[Edwards, Fred H.] Univ Florida, Dept Cardiothorac Surg, Jacksonville, FL USA.
RP Fosbol, EL (reprint author), Duke Clin Res Inst, 2400 Pratt St,Room 7461,Terrace Level, Durham, NC 27705 USA.
EM emil.fosbol@duke.edu
FU American Heart Association-Pharmaceutical Roundtable; Eli Lilly Company;
Ortho-McNeil-Janssen Pharmaceuticals, Inc; Society of Thoracic Surgeons;
American Heart Association; American College of Cardiology; AstraZeneca;
Boehringer Ingelheim; Genentech; Johnson Johnson; Pfizer;
Sanofi-Aventis; WebMD
FX This work was supported by an award from the American Heart
Association-Pharmaceutical Roundtable and David and Stevie Spina.; Dr
Peterson reports the receipt of research funding from Eli Lilly &
Company, Ortho-McNeil-Janssen Pharmaceuticals, Inc, Society of Thoracic
Surgeons, American Heart Association, and the American College of
Cardiology (all significant) and consulting fees from AstraZeneca,
Boehringer Ingelheim, Genentech, Johnson & Johnson, Ortho-McNeil-Janssen
Pharmaceuticals, Inc, Pfizer, Sanofi-Aventis, and WebMD (all modest).
All of Dr Peterson's disclosures can be found online at www.dcri.org.
The remaining authors have no conflicts to disclose.
NR 16
TC 2
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD APR 23
PY 2013
VL 127
IS 16
BP 1656
EP +
DI 10.1161/CIRCULATIONAHA.113.001882
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 131XM
UT WOS:000318031800008
PM 23532630
ER
PT J
AU Regan, S
Losina, E
Chetty, S
Giddy, J
Walensky, RP
Ross, D
Holst, H
Katz, JN
Freedberg, KA
Bassett, IV
AF Regan, Susan
Losina, Elena
Chetty, Senica
Giddy, Janet
Walensky, Rochelle P.
Ross, Douglas
Holst, Helga
Katz, Jeffrey N.
Freedberg, Kenneth A.
Bassett, Ingrid V.
TI Factors Associated with Self-Reported Repeat HIV Testing after a
Negative Result in Durban, South Africa
SO PLOS ONE
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; SEXUAL-BEHAVIOR; CARE; INFECTION; DIAGNOSIS;
OUTPATIENT; BARRIERS; PROGRAM; IMPACT; COHORT
AB Background: Routine screening for HIV infection leads to early detection and treatment. We examined patient characteristics associated with repeated screening in a high prevalence country.
Methods: We analyzed data from a cohort of 5,229 adults presenting for rapid HIV testing in the outpatient departments of 2 South African hospitals from November 2006 to August 2010. Patients were eligible if they were >= 18 years, reported no previous diagnosis with HIV infection, and not pregnant. Before testing, participants completed a questionnaire including gender, age, HIV testing history, health status, and knowledge about HIV and acquaintances with HIV. Enrollment HIV test results and CD4 counts were abstracted from the medical record. We present prevalence of HIV infection and median CD4 counts by HIV testing history (first-time vs. repeat). We estimated adjusted relative risks (ARR's) for repeat testing by demographics, health status, and knowledge of HIV and others with HIV in a generalized linear model.
Results: Of 4,877 participants with HIV test results available, 26% (N = 1258) were repeat testers. Repeat testers were less likely than first-time testers to be HIV-infected (34% vs. 54%, p < 0.001). Median CD4 count was higher among repeat than first-time testers (201/uL vs. 147/uL, p < 0.001). Among those HIV negative at enrollment (N = 2,499), repeat testing was more common among those with family or friends living with HIV (ARR 1.50, 95% CI: 1.33-1.68), women (ARR: 1.24, 95% CI: 1.11-1.40), and those self-reporting very good health (ARR: 1.28, 95% CI: 1.12-1.45).
Conclusions: In this high prevalence setting, repeat testing was common among those undergoing HIV screening, and was associated with female sex, lower prevalence of HIV infection, and higher CD4 counts at diagnosis.
C1 [Regan, Susan; Losina, Elena; Walensky, Rochelle P.; Freedberg, Kenneth A.; Bassett, Ingrid V.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Losina, Elena; Katz, Jeffrey N.] Brigham & Womens Hosp, Dept Med, Div Rheumatol, Boston, MA 02115 USA.
[Losina, Elena; Katz, Jeffrey N.] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
[Losina, Elena] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Chetty, Senica; Giddy, Janet; Holst, Helga] McCord Hosp, Durban, South Africa.
[Walensky, Rochelle P.; Freedberg, Kenneth A.; Bassett, Ingrid V.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Ross, Douglas] St Marys Hosp, Durban, South Africa.
[Losina, Elena; Walensky, Rochelle P.; Freedberg, Kenneth A.] Harvard Univ, Ctr AIDS Res CFAR, Boston, MA 02115 USA.
[Katz, Jeffrey N.; Freedberg, Kenneth A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Regan, Susan; Losina, Elena; Walensky, Rochelle P.; Freedberg, Kenneth A.; Bassett, Ingrid V.] Massachusetts Gen Hosp, Dept Med, Med Practice Evaluat Ctr, Boston, MA 02114 USA.
RP Regan, S (reprint author), Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
EM sregan@partners.org
OI Walensky, Rochelle P./0000-0002-8795-379X; Regan,
Susan/0000-0003-0940-2017
FU National Institute of Allergy and Infectious Disease [K23 AI068458, K24
AI062476]; Harvard University Center for AIDS Research [P30 AI060354];
National Institute of Mental Health [R01 MH090326, R01 MH073445];
Claflin Distinguished Scholar Award; Burke Global Health Fellowship;
Harvard Catalyst [UL1 RR 025758]
FX This work was supported by the National Institute of Allergy and
Infectious Disease: K23 AI068458; K24 AI062476; the Harvard University
Center for AIDS Research P30 AI060354; the National Institute of Mental
Health: R01 MH090326; R01 MH073445; the Claflin Distinguished Scholar
Award, the Burke Global Health Fellowship, and the Harvard Catalyst (UL1
RR 025758). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 30
TC 7
Z9 7
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 23
PY 2013
VL 8
IS 4
AR e62362
DI 10.1371/journal.pone.0062362
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 131QH
UT WOS:000318008400172
PM 23626808
ER
PT J
AU Shah, RV
Abbasi, SA
Heydari, B
Rickers, C
Jacobs, DR
Wang, L
Kwong, RY
Bluemke, DA
Lima, JAC
Jerosch-Herold, M
AF Shah, Ravi V.
Abbasi, Siddique A.
Heydari, Bobak
Rickers, Carsten
Jacobs, David R., Jr.
Wang, Lu
Kwong, Raymond Y.
Bluemke, David A.
Lima, Joao A. C.
Jerosch-Herold, Michael
TI Insulin Resistance, Subclinical Left Ventricular Remodeling, and the
Obesity Paradox MESA (Multi-Ethnic Study of Atherosclerosis)
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE LV remodeling; MESA; metabolic syndrome; obesity
ID INCIDENT CARDIOVASCULAR EVENTS; HEART-FAILURE RISK; METABOLIC SYNDROME;
BARIATRIC SURGERY; SYSTOLIC FUNCTION; ABDOMINAL FAT; DISEASE;
INFLAMMATION; DYSFUNCTION; MASS
AB Objectives This study assessed whether impaired fasting glucose (IFG), insulin resistance, and waist-to-hip ratio (WHR) had effects on cardiac remodeling, independent of obesity, in the MESA (Multi-Ethnic Study of Atherosclerosis) trial.
Background Recent studies have suggested that central obesity and insulin resistance may be primary mediators of obesity-related cardiac remodeling independent of body mass index (BMI).
Methods We investigated 4,364 subjects without diabetes in the MESA trial. IFG (100 to 125 mg/dl) or insulin resistance (by homeostatic model assessment of insulin resistance [HOMA-IR]) and WHR were used for cardiometabolic phenotyping. Multivariate linear regression analysis was used to determine the effects of the cardiometabolic markers on left ventricular (LV) remodeling, assessed primarily through the LV mass-to-volume ratio obtained by cine cardiac magnetic resonance imaging.
Results Individuals with IFG were more likely to be older and hypertensive, with increased prevalence of cardiometabolic risk factors regardless of BMI. In each quartile of BMI, subjects with above-median HOMA-IR, above-median WHR, or IFG had a higher LV mass-to-volume ratio (p < 0.05 for all). HOMA-IR (p < 0.0001), WHR (p < 0.0001), and the presence of IFG (p = 0.04), but not BMI (p = 0.24), were independently associated with LV mass-to-volume ratio after adjustment for age, sex, hypertension, race, and dyslipidemia.
Conclusions Insulin resistance and WHR were associated with concentric LV remodeling independent of BMI. These results support the emerging hypothesis that the cardiometabolic phenotype, defined by insulin resistance and central obesity, may play a critical role in LV remodeling independently of BMI. (J Am Coll Cardiol 2013;61:1698-706) (C) 2013 by the American College of Cardiology Foundation
C1 [Shah, Ravi V.; Abbasi, Siddique A.; Heydari, Bobak; Kwong, Raymond Y.; Jerosch-Herold, Michael] Brigham & Womens Hosp, Noninvas Cardiovasc Imaging Lab, Boston, MA 02115 USA.
[Shah, Ravi V.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Rickers, Carsten] Univ Hosp Schleswig Holstein, Dept Pediat Cardiol, Kiel, Germany.
[Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Wang, Lu] Harvard Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Boston, MA 02115 USA.
[Bluemke, David A.; Lima, Joao A. C.] Natl Inst Biomed Imaging & Bioengn, NIH, Ctr Clin, Bethesda, MD USA.
[Jerosch-Herold, Michael] Harvard Univ, Sch Med, Dept Radiol, Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Jerosch-Herold, M (reprint author), Brigham & Womens Hosp, Dept Radiol, 75 Francis St,L1-RA050, Boston, MA 02115 USA.
EM mjerosch-herold@partners.org
OI Abbasi, Siddique/0000-0002-9601-7565; Bluemke, David/0000-0002-8323-8086
FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95160,
N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165,
N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169]; American Heart
Association [11POST000002]; Heart Failure National Institutes of Health
Clinical Research Network [U01-HL084877]; [R01-HL-65580]
FX The MESA trial was supported by contracts N01-HC-95159 through
N01-HC-95169 from the National Heart, Lung, and Blood Institute. Dr.
Shah is supported by an American Heart Association post-doctoral
fellowship award (11POST000002) and a training grant from the Heart
Failure National Institutes of Health Clinical Research Network
(U01-HL084877). Dr. Jerosch-Herold receives support through contract
R01-HL-65580. All other authors have reported that they have no
relationships relevant to the contents of this paper to disclose.
NR 36
TC 18
Z9 19
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 23
PY 2013
VL 61
IS 16
BP 1698
EP 1706
DI 10.1016/j.jacc.2013.01.053
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 125WZ
UT WOS:000317573900007
PM 23500236
ER
PT J
AU Packer, DL
Kowal, RC
Wheelan, KR
Irwin, JM
Champagne, J
Guerra, PG
Dubuc, M
Reddy, V
Nelson, L
Holcomb, RG
Lehmann, JW
Ruskin, JN
AF Packer, Douglas L.
Kowal, Robert C.
Wheelan, Kevin R.
Irwin, James M.
Champagne, Jean
Guerra, Peter G.
Dubuc, Marc
Reddy, Vivek
Nelson, Linda
Holcomb, Richard G.
Lehmann, John W.
Ruskin, Jeremy N.
CA STOP AF Cryoablation Investigators
TI Cryoballoon Ablation of Pulmonary Veins for Paroxysmal Atrial
Fibrillation First Results of the North American Arctic Front (STOP AF)
Pivotal Trial
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE atrial fibrillation; catheter ablation; cryoballoon ablation
ID ANTIARRHYTHMIC-DRUG THERAPY; CATHETER ABLATION; RADIOFREQUENCY ABLATION;
RANDOMIZED-TRIAL; ESOPHAGEAL FISTULA; FOLLOW-UP; SAFETY; EFFICACY;
MULTICENTER; SYSTEM
AB Objectives This study sought to assess the safety and effectiveness of a novel cryoballoon ablation technology designed to achieve single-delivery pulmonary vein (PV) isolation.
Background Standard radiofrequency ablation is effective in eliminating atrial fibrillation (AF) but requires multiple lesion delivery at the risk of significant complications.
Methods Patients with documented symptomatic paroxysmal AF and previously failed therapy with >= 1 membrane active antiarrhythmic drug underwent 2: 1 randomization to either cryoballoon ablation (n = 163) or drug therapy (n = 82). A 90-day blanking period allowed for optimization of antiarrhythmic drug therapy and reablation if necessary. Effectiveness of the cryoablation procedure versus drug therapy was determined at 12 months.
Results Patients had highly symptomatic AF (78% paroxysmal, 22% early persistent) and experienced failure of at least one antiarrhythmic drug. Cryoablation produced acute isolation of three or more PVs in 98.2% and all four PVs in 97.6% of patients. PVs isolation was achieved with the balloon catheter alone in 83%. At 12 months, treatment success was 69.9% (114 of 163) of cryoblation patients compared with 7.3% of antiarrhythmic drug patients (absolute difference, 62.6% [p < 0.001]). Sixty-five (79%) drug-treated patients crossed over to cryoablation during 12 months of study follow-up due to recurrent, symptomatic AF, constituting drug treatment failure. There were 7 of the resulting 228 cryoablated patients (3.1%) with a >75% reduction in PV area during 12 months of follow-up. Twenty-nine of 259 procedures (11.2%) were associated with phrenic nerve palsy as determined by radiographic screening; 25 of these had resolved by 12 months. Cryoablation patients had significantly improved symptoms at 12 months.
Conclusions The STOP AF trial demonstrated that cryoballoon ablation is a safe and effective alternative to antiarrhythmic medication for the treatment of patients with symptomatic paroxysmal AF, for whom at least one antiarrhythmic drug has failed, with risks within accepted standards for ablation therapy. (A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation [Stop AF]; NCT00523978) (J Am Coll Cardiol 2013;61:1713-23) (C) 2013 by the American College of Cardiology Foundation
C1 [Packer, Douglas L.] Mayo Clin, Rochester, MN 55905 USA.
[Kowal, Robert C.; Wheelan, Kevin R.] Baylor Heart & Vasc Hosp, Dallas, TX USA.
[Irwin, James M.] Bay Heart Grp, Tampa, FL USA.
[Champagne, Jean] Inst Univ Cardiol & Pneumol Quebec, Electrophysiol EP Quebec City, Quebec City, PQ, Canada.
[Guerra, Peter G.; Dubuc, Marc] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.
[Reddy, Vivek] Mt Sinai Sch Med, New York, NY USA.
[Nelson, Linda] Medtronic Inc, Minneapolis, MN USA.
[Holcomb, Richard G.] Stat Consulting, Minneapolis, MN USA.
[Lehmann, John W.] Lehmann Consulting, Med Monitor, Wayland, MA USA.
[Ruskin, Jeremy N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Packer, DL (reprint author), Mayo Clin, St Marys Hosp, 2-416 Alfred Bldg,1216 2nd St,SW, Rochester, MN 55905 USA.
EM packer@mayo.edu
FU St. Jude Medical; Medtronic; Medtronic/CryoCath
FX Dr. Kowal is a Medtronic advisor; and teaches at Arctic Front Programs.
Dr. Wheelan receives honoraria as a Medtronic consultant and has stock
ownership. Dr. Irwin contracts with Medtronic to train other EPs in the
use of Arctic Front. Dr. Guerra is a Sanofi-Aventis board member and
receives payment for lectures, including service on speakers bureaus at
St. Jude Medical and Medtronic. Dr. Dubuc received a research grant,
consulting fees and/or honoraria, and payment for lectures, including
service on speakers' bureau, from Medtronic/CryoCath. Dr. Reddy is a
consultant for Medtronic. Dr. Lehmann is an hourly consultant with
Medtronic for STOP AF clinical trial design and implementation and holds
patents assigned to Medtronics, although no royalties or benefits are
received. Dr. Ruskin receives research grants from Medtronic/CryoCath,
Biosense Webster, Boston Scientific, and St. Jude Medical; is an
advisory board member for Medtronic/CryoCath and CardioFocus (no
personal compensation) and a board member for Pfizer, Biosense Webster,
CardioInsight Scientific, and Sequel (no personal compensation); a
compensated consultant with Astellas/Cardiome, GE Healthcare,
Sanofi-Aventis, Medtronic, Portola, MedIQ, and Third Rock Ventures; and
receives honoraria for lectures from Med-IQ and holds stock/options with
Portola. Dr. Nelson is an employee of Medtronic, Inc. All other authors
have reported that they have no relationships relevant to the contents
of this paper to disclose.
NR 33
TC 197
Z9 205
U1 2
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 23
PY 2013
VL 61
IS 16
BP 1713
EP 1723
DI 10.1016/j.jacc.2012.11.064
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 125WZ
UT WOS:000317573900009
PM 23500312
ER
PT J
AU Freiberg, MS
Chang, CCH
Kuller, LH
Skanderson, M
Lowy, E
Kraemer, KL
Butt, AA
Goetz, MB
Leaf, D
Oursler, KA
Rimland, D
Barradas, MR
Brown, S
Gibert, C
McGinnis, K
Crothers, K
Sico, J
Crane, H
Warner, A
Gottlieb, S
Gottdiener, J
Tracy, RP
Budoff, M
Watson, C
Armah, KA
Doebler, D
Bryant, K
Justice, AC
AF Freiberg, Matthew S.
Chang, Chung-Chou H.
Kuller, Lewis H.
Skanderson, Melissa
Lowy, Elliott
Kraemer, Kevin L.
Butt, Adeel A.
Goetz, Matthew Bidwell
Leaf, David
Oursler, Kris Ann
Rimland, David
Barradas, Maria Rodriguez
Brown, Sheldon
Gibert, Cynthia
McGinnis, Kathy
Crothers, Kristina
Sico, Jason
Crane, Heidi
Warner, Alberta
Gottlieb, Stephen
Gottdiener, John
Tracy, Russell P.
Budoff, Matthew
Watson, Courtney
Armah, Kaku A.
Doebler, Donna
Bryant, Kendall
Justice, Amy C.
TI HIV Infection and the Risk of Acute Myocardial Infarction
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID CORONARY-HEART-DISEASE; REGIONAL ADIPOSE-TISSUE; ANTIRETROVIRAL THERAPY;
CARDIOVASCULAR-DISEASE; VETERANS; HEALTH; COHORT; PREVALENCE; ADULTS;
MEN
AB Importance: Whether people infected with human immunodeficiency virus (HIV) are at an increased risk of acute myocardial infarction (AMI) compared with uninfected people is not clear. Without demographically and behaviorally similar uninfected comparators and without uniformly measured clinical data on risk factors and fatal and nonfatalAMIevents, any potential association between HIV status and AMI may be confounded.
Objective: To investigate whether HIV is associated with an increased risk of AMI after adjustment for all standard Framingham risk factors among a large cohort of HIV-positive and demographically and behaviorally similar (ie, similar prevalence of smoking, alcohol, and cocaine use) uninfected veterans in care.
Design and Setting: Participants in the Veterans Aging Cohort Study Virtual Cohort from April 1, 2003, through December 31, 2009.
Participants: After eliminating those with baseline cardiovascular disease, we analyzed data on HIV status, age, sex, race/ethnicity, hypertension, diabetes mellitus, dyslipidemia, smoking, hepatitis C infection, body mass index, renal disease, anemia, substance use, CD4 cell count, HIV-1 RNA, antiretroviral therapy, and incidence of AMI.
Main Outcome Measure: Acute myocardial infarction.
Results: We analyzed data on 82 459 participants. During a median follow-up of 5.9 years, there were 871 AMI events. Across 3 decades of age, the mean (95% CI) AMI events per 1000 person-years was consistently and significantly higher for HIV-positive compared with uninfected veterans: for those aged 40 to 49 years, 2.0 (1.6-2.4) vs 1.5 (1.3-1.7); for those aged 50 to 59 years, 3.9 (3.3-4.5) vs 2.2 (1.9-2.5); and for those aged 60 to 69 years, 5.0 (3.8-6.7) vs 3.3 (2.6-4.2) (P<.05 for all). After adjusting for Framingham risk factors, comorbidities, and substance use, HIV-positive veterans had an increased risk of incident AMI compared with uninfected veterans (hazard ratio, 1.48; 95% CI, 1.27-1.72). An excess risk remained among those achieving an HIV-1 RNA level less than 500 copies/mL compared with uninfected veterans in time-updated analyses (hazard ratio, 1.39; 95% CI, 1.17-1.66).
Conclusions and Relevance: Infection with HIV is associated with a 50% increased risk of AMI beyond that explained by recognized risk factors.
C1 [Freiberg, Matthew S.; Chang, Chung-Chou H.; Kraemer, Kevin L.; Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA.
[Freiberg, Matthew S.; Chang, Chung-Chou H.; Kuller, Lewis H.; Armah, Kaku A.; Doebler, Donna] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
[Skanderson, Melissa; McGinnis, Kathy; Sico, Jason; Justice, Amy C.] West Haven Vet Adm, Med Ctr, Vet Affairs VA Connecticut Hlth Care Syst, West Haven, CT USA.
[Sico, Jason; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA.
[Lowy, Elliott] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Lowy, Elliott] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Crothers, Kristina; Crane, Heidi] Univ Washington, Harborview Med Ctr, Sch Med, Seattle, WA 98104 USA.
[Goetz, Matthew Bidwell; Leaf, David] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Goetz, Matthew Bidwell; Leaf, David; Warner, Alberta] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
[Budoff, Matthew] Harbor UCLA Med Ctr, Los Angeles, CA USA.
[Budoff, Matthew] Los Angeles Biomed Res Inst, Los Angeles, CA USA.
[Oursler, Kris Ann; Gottlieb, Stephen; Gottdiener, John] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Oursler, Kris Ann] Baltimore VA Hlth Care Syst, Baltimore, MD USA.
[Bryant, Kendall] NIAAA, Bethesda, MD 90034 USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
[Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA.
[Barradas, Maria Rodriguez] Baylor Coll Med, Houston, TX 77030 USA.
[Barradas, Maria Rodriguez] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
[Brown, Sheldon] James J Peters VA Med Ctr, Bronx, NY USA.
[Brown, Sheldon] Mt Sinai Sch Med, New York, NY USA.
[Gibert, Cynthia] George Washington Univ, Sch Med, Washington, DC USA.
[Gibert, Cynthia] VA Med Ctr, Washington, DC USA.
[Tracy, Russell P.] Univ Vermont, Coll Med, Burlington, VT 05405 USA.
[Watson, Courtney] Univ S Carolina, Arnold Sch Publ Hlth, Columbia, SC 29208 USA.
RP Freiberg, MS (reprint author), Univ Pittsburgh, Sch Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA.
EM Freibergms@upmc.edu
OI Goetz, Matthew/0000-0003-4542-992X; Crothers,
Kristina/0000-0001-9702-0371
FU Merck [P08569 MIISP 39996]; National Heart, Lung, and Blood Institute
[HL095136-04]; National Institute on Alcohol Abuse and Alcoholism at the
National Institutes of Health [AA013566-10, AA020790, AA020794]
FX Dr Butt reports that he received Investigator-Initiated Studies Program
grant P08569 MIISP 39996 from Merck and gave a scientific talk for
Gilead in 2011.; This work was supported by grant HL095136-04 from the
National Heart, Lung, and Blood Institute and grants AA013566-10,
AA020790, and AA020794 from the National Institute on Alcohol Abuse and
Alcoholism at the National Institutes of Health.
NR 40
TC 261
Z9 264
U1 5
U2 30
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR 22
PY 2013
VL 173
IS 8
BP 614
EP 622
DI 10.1001/jamainternmed.2013.3728
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159IR
UT WOS:000320039600002
PM 23459863
ER
PT J
AU Sen, S
Kranzler, HR
Didwania, AK
Schwartz, AC
Amarnath, S
Kolars, JC
Dalack, GW
Nichols, B
Guille, C
AF Sen, Srijan
Kranzler, Henry R.
Didwania, Aashish K.
Schwartz, Ann C.
Amarnath, Sudha
Kolars, Joseph C.
Dalack, Gregory W.
Nichols, Breck
Guille, Constance
TI Effects of the 2011 Duty Hour Reforms on Interns and Their Patients A
Prospective Longitudinal Cohort Study
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID RESIDENTS WORK HOURS; MEDICAL ERRORS; ACCREDITATION-COUNCIL; 1ST-YEAR
RESIDENTS; ADVERSE EVENTS; FOLLOW-UP; SLEEP; LIMITS; DEPRESSION;
EDUCATION
AB Importance: In 2003, the first phase of duty hour requirements for US residency programs recommended by the Accreditation Council for Graduate Medical Education (ACGME) was implemented. Evidence suggests that this first phase of duty hour requirements resulted in a modest improvement in resident well-being and patient safety. To build on these initial changes, the ACGME recommended a new set of duty hour requirements that took effect in July 2011.
Objective: To determine the effects of the 2011 duty hour reforms on first-year residents (interns) and their patients.
Design: As part of the Intern Health Study, we conducted a longitudinal cohort study comparing interns serving before (2009 and 2010) and interns serving after (2011) the implementation of the new duty hour requirements.
Setting: Fifty-one residency programs at 14 university and community-based GME institutions.
Participants: A total of 2323 medical interns.
Main Outcome Measures: Self-reported duty hours, hours of sleep, depressive symptoms, well-being, and medical errors at 3, 6, 9, and 12 months of the internship year.
Results: Fifty-eight percent of invited interns chose to participate in the study. Reported duty hours decreased from an average of 67.0 hours per week before the new rules to 64.3 hours per week after the new rules were instituted (P < .001). Despite the decrease in duty hours, there were no significant changes in hours slept (6.8.-> 7.0; P = .17), depressive symptoms (5.8.-> 5.7; P =. 55) or wellbeing score (48.5 -> 48.4; P = .86) reported by interns. With the new duty hour rules, the percentage of interns who reported concern about making a serious medical error increased from 19.9% to 23.3% (P = .007).
Conclusions and Relevance: Although interns report working fewer hours under the new duty hour restrictions, this decrease has not been accompanied by an increase in hours of sleep or an improvement in depressive symptoms or well-being but has been accompanied by an unanticipated increase in self-reported medical errors.
C1 [Sen, Srijan; Dalack, Gregory W.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
[Kolars, Joseph C.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Kranzler, Henry R.] Perelman Sch Med, Dept Psychiat, Philadelphia, PA USA.
[Kranzler, Henry R.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Didwania, Aashish K.] Northwestern Univ Feinberg Sch Med, Dept Internal Med, Chicago, IL USA.
[Schwartz, Ann C.] Emory Univ Sch Med, Dept Psychiat, Atlanta, GA USA.
[Amarnath, Sudha] Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA.
[Nichols, Breck] Los Angeles Cty Univ Southern Calif Med Ctr, Keck Univ Southern Calif Sch Med, Dept Pediat, Los Angeles, CA USA.
[Nichols, Breck] Los Angeles Cty Univ So Calif Med Ctr, Keck Univ Southern Calif Sch Med, Dept Med, Los Angeles, CA USA.
[Guille, Constance] Med Univ S Carolina, Dept Psychiat, Charleston, SC USA.
RP Sen, S (reprint author), Univ Michigan, Dept Psychiat, 5047 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.
EM srijan@umich.edu
RI Sen, Srijan/J-8053-2013
FU American Foundation for Suicide Prevention; National Center for Research
Resources [UL1RR024986]; National Institute of Mental Health [MH095109];
National Institute on Alcohol Abuse and Alcoholism [AA013736]; Lilly;
Lundbeck; Abbott; Pfizer
FX The project was supported by the following grants: a Young Investigator
Grant from the American Foundation for Suicide Prevention (Dr Sen),
UL1RR024986 from the National Center for Research Resources (Dr Sen),
MH095109 from the National Institute of Mental Health (Dr Sen), and
AA013736 from the National Institute on Alcohol Abuse and Alcoholism (Dr
Kranzler).; Dr Krantzler has been a consultant or advisory board member
for Alkermes, Lilly, Lundbeck, Pfizer, and Roche. He is also a member of
the American Society of Clinical Psychopharmacology, which is supported
by Lilly, Lundbeck, Abbott, and Pfizer.
NR 40
TC 40
Z9 40
U1 0
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR 22
PY 2013
VL 173
IS 8
BP 657
EP 662
DI 10.1001/jamainternmed.2013.351
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159IR
UT WOS:000320039600011
PM 23529201
ER
PT J
AU Gellad, WF
Yealy, D
Fine, M
AF Gellad, Walid F.
Yealy, Donald
Fine, Michael
TI Computers and the Diagnosis of Pneumonia
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID COMMUNITY-ACQUIRED PNEUMONIA; OUTCOMES
C1 [Gellad, Walid F.; Fine, Michael] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Gellad, Walid F.; Fine, Michael] Univ Pittsburgh, Dept Med, Div Gen Med, Pittsburgh, PA USA.
[Yealy, Donald] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA.
RP Gellad, WF (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM walid.gellad@va.gov
NR 8
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR 22
PY 2013
VL 173
IS 8
BP 701
EP 702
DI 10.1001/jamainternmed.2013.4083
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159IR
UT WOS:000320039600022
PM 23553079
ER
PT J
AU Singh, H
Spitzmueller, C
Petersen, NJ
Sawhney, MK
Sittig, DF
AF Singh, Hardeep
Spitzmueller, Christiane
Petersen, Nancy J.
Sawhney, Mona K.
Sittig, Dean F.
TI Information Overload and Missed Test Results in Electronic Health
Record-Based Settings
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Singh, Hardeep; Petersen, Nancy J.; Sawhney, Mona K.] Michael E DeBakey Vet Affairs Med Ctr 152, Houston VA Hlth Serv Res & Dev Ctr Excellence, Ctr Inquiry Improve Outpatient Safety Effect Elec, Houston, TX 77030 USA.
[Singh, Hardeep; Petersen, Nancy J.; Sawhney, Mona K.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Spitzmueller, Christiane] Univ Houston, Dept Psychol, Houston, TX USA.
[Sittig, Dean F.] Univ Texas Hlth Sci Ctr, Sch Biomed Informat, Houston, TX USA.
[Sittig, Dean F.] Univ Texas Hlth Sci Ctr, Univ Texas Mem Hermann Ctr Healthcare Qual & Safe, Houston, TX USA.
RP Singh, H (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.edu
FU NCI NIH HHS [K23 CA125585, K23CA125585]
NR 11
TC 34
Z9 34
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR 22
PY 2013
VL 173
IS 8
BP 702
EP 704
DI 10.1001/2013.jamainternmed.61
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159IR
UT WOS:000320039600023
PM 23460235
ER
PT J
AU Shuman, AG
Li, X
Halpin, CF
Rauch, SD
Telian, SA
AF Shuman, Andrew G.
Li, Xue
Halpin, Chris F.
Rauch, Steven D.
Telian, Steven A.
TI Tuning Fork Testing in Sudden Sensorineural Hearing Loss
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Shuman, Andrew G.] Mem Sloan Kettering Canc Ctr, Dept Surg, Head & Neck Serv, New York, NY 10021 USA.
[Li, Xue] Hines VA Hosp, Cooperat Studies Program Coordinating Ctr, Hines, IL USA.
[Halpin, Chris F.; Rauch, Steven D.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
[Telian, Steven A.] Univ Michigan Med Sch, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA.
RP Telian, SA (reprint author), Univ Michigan Med Sch, Dept Otolaryngol Head & Neck Surg, Taubman Ctr 1904, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM telian@umich.edu
FU NIDCD NIH HHS [U01 DC006296]
NR 7
TC 0
Z9 1
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR 22
PY 2013
VL 173
IS 8
BP 706
EP 707
DI 10.1001/jamainternmed.2013.2813
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159IR
UT WOS:000320039600025
PM 23529707
ER
PT J
AU Barteneva, NS
Fasler-Kan, E
Bernimoulin, M
Stern, JNH
Ponomarev, ED
Duckett, L
Vorobjev, IA
AF Barteneva, Natasha S.
Fasler-Kan, Elizaveta
Bernimoulin, Michael
Stern, Joel N. H.
Ponomarev, Eugeny D.
Duckett, Larry
Vorobjev, Ivan A.
TI Circulating microparticles: square the circle
SO BMC CELL BIOLOGY
LA English
DT Review
DE Circulating; Microparticles; Exosomes; Microvesicles; Disease;
Diagnostics; Therapy
ID CELL-DERIVED MICROPARTICLES; MEMBRANE PHOSPHOLIPID ASYMMETRY;
PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; RESPIRATORY-DISTRESS-SYNDROME;
HUMAN ATHEROSCLEROTIC PLAQUES; ENDOTHELIAL PROGENITOR CELLS;
SYSTEMIC-LUPUS-ERYTHEMATOSUS; DYNAMIC LIGHT-SCATTERING; TISSUE FACTOR
ACTIVITY; PLATELET-RICH PLASMA
AB Background: The present review summarizes current knowledge about microparticles (MPs) and provides a systematic overview of last 20 years of research on circulating MPs, with particular focus on their clinical relevance.
Results: MPs are a heterogeneous population of cell-derived vesicles, with sizes ranging between 50 and 1000 nm. MPs are capable of transferring peptides, proteins, lipid components, microRNA, mRNA, and DNA from one cell to another without direct cell-to-cell contact. Growing evidence suggests that MPs present in peripheral blood and body fluids contribute to the development and progression of cancer, and are of pathophysiological relevance for autoimmune, inflammatory, infectious, cardiovascular, hematological, and other diseases. MPs have large diagnostic potential as biomarkers; however, due to current technological limitations in purification of MPs and an absence of standardized methods of MP detection, challenges remain in validating the potential of MPs as a non-invasive and early diagnostic platform.
Conclusions: Improvements in the effective deciphering of MP molecular signatures will be critical not only for diagnostics, but also for the evaluation of treatment regimens and predicting disease outcomes.
C1 [Barteneva, Natasha S.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Barteneva, Natasha S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Fasler-Kan, Elizaveta] Univ Appl Sci Northwestern Switzerland FHNW, Inst Chem & Bioanalyt, Muttenz, Switzerland.
[Fasler-Kan, Elizaveta] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland.
[Bernimoulin, Michael] Univ Hosp Geneva, Div Hematol, Geneva, Switzerland.
[Stern, Joel N. H.] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.
[Ponomarev, Eugeny D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.
[Ponomarev, Eugeny D.] Chinese Univ Hong Kong, Themat Res Program Neurodegenerat, Shatin, Hong Kong, Peoples R China.
[Duckett, Larry] BD Biosci Inc, San Jose, CA USA.
[Vorobjev, Ivan A.] Moscow MV Lomonosov State Univ, Fac Biol, AN Belozersky Inst Physicochem Biol, Moscow, Russia.
[Vorobjev, Ivan A.] Moscow MV Lomonosov State Univ, Fac Biol, Dept Cell Biol, Moscow, Russia.
RP Barteneva, NS (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, D-249,200 Longwood Ave, Boston, MA 02115 USA.
EM Natasha.Barteneva@childrens.harvard.edu
OI Stern, Joel N.H./0000-0002-1259-2256
FU Harvard Pilot Grant; Immune Disease Institute; Russian Foundation for
Basic Research [11-01517a, 11-01749a]
FX We are thankful to Luke Jasenosky and Aleksandra Gorelova (Harvard
University) for editorial help with the manuscript. NSB was supported by
a Harvard Pilot Grant and the Immune Disease Institute, and IAV was
supported by Russian Foundation for Basic Research grants 11-01517a and
11-01749a.
NR 230
TC 70
Z9 73
U1 1
U2 49
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2121
J9 BMC CELL BIOL
JI BMC Cell Biol.
PD APR 22
PY 2013
VL 14
AR 23
DI 10.1186/1471-2121-14-23
PG 21
WC Cell Biology
SC Cell Biology
GA 144AJ
UT WOS:000318911100002
PM 23607880
ER
PT J
AU Deo, AJ
Goldszer, IM
Li, SY
DiBitetto, JV
Henteleff, R
Sampson, A
Lewis, DA
Penzes, P
Sweet, RA
AF Deo, Anthony J.
Goldszer, Isaac M.
Li, Siyu
DiBitetto, James V.
Henteleff, Ruth
Sampson, Allan
Lewis, David A.
Penzes, Peter
Sweet, Robert A.
TI PAK1 Protein Expression in the Auditory Cortex of Schizophrenia Subjects
SO PLOS ONE
LA English
DT Article
ID DENDRITIC SPINE DENSITY; CORTICAL PYRAMIDAL NEURONS; PREFRONTAL CORTEX;
IN-VIVO; KINASE; MORPHOGENESIS; SPINOPHILIN; MECHANISMS; DEFICITS;
GENERATION
AB Deficits in auditory processing are among the best documented endophenotypes in schizophrenia, possibly due to loss of excitatory synaptic connections. Dendritic spines, the principal post-synaptic target of excitatory projections, are reduced in schizophrenia. p21-activated kinase 1 (PAK1) regulates both the actin cytoskeleton and dendritic spine density, and is a downstream effector of both kalirin and CDC42, both of which have altered expression in schizophrenia. This study sought to determine if there is decreased auditory cortex PAK1 protein expression in schizophrenia through the use of quantitative western blots of 25 schizophrenia subjects and matched controls. There was no significant change in PAK1 level detected in the schizophrenia subjects in our cohort. PAK1 protein levels within subject pairs correlated positively with prior measures of total kalirin protein in the same pairs. PAK1 level also correlated with levels of a marker of dendritic spines, spinophilin. These latter two findings suggest that the lack of change in PAK1 level in schizophrenia is not due to limited sensitivity of our assay to detect meaningful differences in PAK1 protein expression. Future studies are needed to evaluate whether alterations in PAK1 phosphorylation states, or alterations in protein expression of other members of the PAK family, are present in schizophrenia.
C1 [Deo, Anthony J.; Goldszer, Isaac M.; DiBitetto, James V.; Henteleff, Ruth; Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Translat Neurosci Program, Pittsburgh, PA 15213 USA.
[Deo, Anthony J.] Univ Pittsburgh, Sch Med, Phys Scientist Training Program, Pittsburgh, PA USA.
[Li, Siyu; Sampson, Allan] Univ Pittsburgh, Dept Stat, Pittsburgh, PA USA.
[Lewis, David A.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA.
[Penzes, Peter] Northwestern Univ, Dept Physiol, Feinberg Sch Med, Chicago, IL 60611 USA.
[Penzes, Peter] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, Chicago, IL 60611 USA.
[Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
[Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA.
RP Sweet, RA (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Translat Neurosci Program, Pittsburgh, PA 15213 USA.
EM sweetra@upmc.edu
RI Lewis, David/G-4053-2014; Penzes, Peter/L-3987-2016
OI Lewis, David/0000-0002-3225-6778; Penzes, Peter/0000-0001-5449-1640
FU National Institutes of Mental Health [MH071533, MH084053, MH071316];
Doris Duke Charitable Foundation; Johnson & Johnson Pharmaceutical
Research and Development
FX This work was supported by grants MH071533, MH084053 and MH071316 from
the National Institutes of Mental Health. Anthony Deo was supported by a
Clinical Research Fellow grant from the Doris Duke Charitable Foundation
to the University of Pittsburgh School of Medicine. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.; Allan R. Sampson is a paid
statistical consultant on design and analysis issues to Johnson &
Johnson Pharmaceutical Research and Development. This does not alter his
adherence to all the PLOS ONE policies on sharing data and materials.
NR 44
TC 5
Z9 6
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 22
PY 2013
VL 8
IS 4
AR e59458
DI 10.1371/journal.pone.0059458
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130JR
UT WOS:000317911500002
PM 23613712
ER
PT J
AU Eswaran, J
Horvath, A
Godbole, S
Reddy, SD
Mudvari, P
Ohshiro, K
Cyanam, D
Nair, S
Fuqua, SAW
Polyak, K
Florea, LD
Kumar, R
AF Eswaran, Jeyanthy
Horvath, Anelia
Godbole, Sucheta
Reddy, Sirigiri Divijendra
Mudvari, Prakriti
Ohshiro, Kazufumi
Cyanam, Dinesh
Nair, Sujit
Fuqua, Suzanne A. W.
Polyak, Kornelia
Florea, Liliana D.
Kumar, Rakesh
TI RNA sequencing of cancer reveals novel splicing alterations
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PRE-MESSENGER-RNA; BREAST-CANCER; SEQ; EXPRESSION; GENOME; BETA; P53;
PREDISPOSITION; QUANTIFICATION; IDENTIFICATION
AB Breast cancer transcriptome acquires a myriad of regulation changes, and splicing is critical for the cell to "tailor-make'' specific functional transcripts. We systematically revealed splicing signatures of the three most common types of breast tumors using RNA sequencing: TNBC, non-TNBC and HER2-positive breast cancer. We discovered subtype specific differentially spliced genes and splice isoforms not previously recognized in human transcriptome. Further, we showed that exon skip and intron retention are predominant splice events in breast cancer. In addition, we found that differential expression of primary transcripts and promoter switching are significantly deregulated in breast cancer compared to normal breast. We validated the presence of novel hybrid isoforms of critical molecules like CDK4, LARP1, ADD3, and PHLPP2. Our study provides the first comprehensive portrait of transcriptional and splicing signatures specific to breast cancer sub-types, as well as previously unknown transcripts that prompt the need for complete annotation of tissue and disease specific transcriptome.
C1 [Eswaran, Jeyanthy; Horvath, Anelia; Godbole, Sucheta; Mudvari, Prakriti; Cyanam, Dinesh; Kumar, Rakesh] George Washington Univ, McCormick Genom & Prote Ctr, Washington, DC 20037 USA.
[Eswaran, Jeyanthy; Horvath, Anelia; Reddy, Sirigiri Divijendra; Ohshiro, Kazufumi; Nair, Sujit; Kumar, Rakesh] George Washington Univ, Dept Biochem & Mol Med, Washington, DC 20037 USA.
[Fuqua, Suzanne A. W.] Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA.
[Polyak, Kornelia] Harvard Univ, Dept Med Oncol, Brigham & Womens Hosp, Dana Farber Canc Inst,Sch Med, Boston, MA 02215 USA.
[Florea, Liliana D.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA.
RP Kumar, R (reprint author), George Washington Univ, McCormick Genom & Prote Ctr, Washington, DC 20037 USA.
EM bcmrxk@gwu.edu
RI sirigiri, divijendra reddy/E-1031-2017
OI sirigiri, divijendra reddy/0000-0003-4657-2285
FU McCormick Genomic and Proteomics Center
FX This work is supported by the McCormick Genomic and Proteomics Center.
NR 54
TC 59
Z9 61
U1 1
U2 25
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 22
PY 2013
VL 3
AR 1689
DI 10.1038/srep01689
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 129BZ
UT WOS:000317814700001
PM 23604310
ER
PT J
AU Evens, AM
Hong, FX
AF Evens, Andrew M.
Hong, Fangxin
TI How Can Outcomes Be Improved for Older Patients With Hodgkin Lymphoma?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID EPSTEIN-BARR-VIRUS; INVOLVED-FIELD RADIOTHERAPY; LONG-TERM SURVIVAL;
ELDERLY-PATIENTS; DISEASE PATIENTS; CUMULATIVE INCIDENCE; POPULATION;
CHEMOTHERAPY; BLEOMYCIN; DOXORUBICIN
C1 [Evens, Andrew M.] Univ Massachusetts Med Sch, Worcester, MA USA.
[Evens, Andrew M.] Univ Massachusetts Mem Canc Ctr, Worcester, MA USA.
[Hong, Fangxin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hong, Fangxin] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP Evens, AM (reprint author), Univ Massachusetts Med Sch, Worcester, MA USA.
NR 41
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR 20
PY 2013
VL 31
IS 12
BP 1502
EP 1505
DI 10.1200/JCO.2012.47.3058
PG 4
WC Oncology
SC Oncology
GA 129IC
UT WOS:000317831500011
PM 23509323
ER
PT J
AU Storb, R
Gyurkocza, B
Storer, BE
Sorror, ML
Blume, K
Niederwieser, D
Chauncey, TR
Pulsipher, MA
Petersen, FB
Sahebi, F
Agura, ED
Hari, P
Bruno, B
McSweeney, PA
Maris, MB
Maziarz, RT
Langston, AA
Bethge, W
Vindelov, L
Franke, GN
Laport, GG
Yeager, AM
Hubel, K
Deeg, HJ
Georges, GE
Flowers, MED
Martin, PJ
Mielcarek, M
Woolfrey, AE
Maloney, DG
Sandmaier, BM
AF Storb, Rainer
Gyurkocza, Boglarka
Storer, Barry E.
Sorror, Mohamed L.
Blume, Karl
Niederwieser, Dietger
Chauncey, Thomas R.
Pulsipher, Michael A.
Petersen, Finn B.
Sahebi, Firoozeh
Agura, Edward D.
Hari, Parameswaran
Bruno, Benedetto
McSweeney, Peter A.
Maris, Michael B.
Maziarz, Richard T.
Langston, Amelia A.
Bethge, Wolfgang
Vindelov, Lars
Franke, Georg-Nikolaus
Laport, Ginna G.
Yeager, Andrew M.
Huebel, Kai
Deeg, H. Joachim
Georges, George E.
Flowers, Mary E. D.
Martin, Paul J.
Mielcarek, Marco
Woolfrey, Ann E.
Maloney, David G.
Sandmaier, Brenda M.
TI Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After
Allogeneic Hematopoietic Cell Transplantation
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID BONE-MARROW TRANSPLANTATION; MATCHED UNRELATED DONORS; TOTAL-BODY
IRRADIATION; HEMATOLOGIC MALIGNANCIES; MYELOGENOUS LEUKEMIA; RISK;
OUTCOMES; RELAPSE; HCT; IMMUNOSUPPRESSION
AB Purpose
We designed a minimal-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies unable to tolerate high-intensity regimens because of age, serious comorbidities, or previous high-dose HCT. The regimen allows the purest assessment of graft-versus-tumor (GVT) effects apart from conditioning and graft-versus-host disease (GVHD) not augmented by regimen-related toxicities.
Patients and Methods
Patients received low-dose total-body irradiation +/- fludarabine before HCT from HLA-matched related (n = 611) or unrelated (n = 481) donors, followed by mycophenolate mofetil and a calcineurin inhibitor to aid engraftment and control GVHD. Median patient age was 56 years (range, 7 to 75 years). Forty-five percent of patients had comorbidity scores of >= 3. Median follow-up time was 5 years (range, 0.6 to 12.7 years).
Results
Depending on disease risk, comorbidities, and GVHD, lasting remissions were seen in 45% to 75% of patients, and 5-year survival ranged from 25% to 60%. At 5 years, the nonrelapse mortality (NRM) rate was 24%, and the relapse mortality rate was 34.5%. Most NRM was a result of GVHD. The most significant factors associated with GVHD-associated NRM were serious comorbidities and grafts from unrelated donors. Most relapses occurred early while the immune system was compromised. GVT effects were comparable after unrelated and related grafts. Chronic GVHD, but not acute GVHD, further increased GVT effects. The potential benefit associated with chronic GVHD was outweighed by increased NRM.
Conclusion
Allogeneic HCT relying on GVT effects is feasible and results in cures of an appreciable number of malignancies. Improved results could come from methods that control progression of malignancy early after HCT and effectively prevent GVHD. J Clin Oncol 31:1530-1538. (C) 2013 by American Society of Clinical Oncology
C1 [Storb, Rainer; Gyurkocza, Boglarka; Storer, Barry E.; Sorror, Mohamed L.; Deeg, H. Joachim; Georges, George E.; Flowers, Mary E. D.; Martin, Paul J.; Mielcarek, Marco; Woolfrey, Ann E.; Maloney, David G.; Sandmaier, Brenda M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
[Storb, Rainer; Gyurkocza, Boglarka; Storer, Barry E.; Sorror, Mohamed L.; Chauncey, Thomas R.; Deeg, H. Joachim; Georges, George E.; Flowers, Mary E. D.; Martin, Paul J.; Mielcarek, Marco; Woolfrey, Ann E.; Maloney, David G.; Sandmaier, Brenda M.] Univ Washington, Seattle, WA 98195 USA.
[Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Blume, Karl; Laport, Ginna G.] Stanford Univ, Palo Alto, CA 94304 USA.
[Sahebi, Firoozeh] City Hope Kaiser Permanente Med Grp, Duarte, CA USA.
[Pulsipher, Michael A.] Univ Utah, Salt Lake City, UT USA.
[Petersen, Finn B.] Intermt Hlth Care LDS Hosp, Salt Lake City, UT USA.
[Agura, Edward D.] Baylor Univ, Dallas, TX USA.
[Hari, Parameswaran] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[McSweeney, Peter A.; Maris, Michael B.] Colorado Blood Canc Inst Presbyterian St Lukes, Denver, CO USA.
[Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR USA.
[Langston, Amelia A.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Yeager, Andrew M.] Univ Arizona Canc Ctr, Tucson, AZ USA.
[Niederwieser, Dietger; Franke, Georg-Nikolaus] Univ Leipzig, D-04109 Leipzig, Germany.
[Bethge, Wolfgang] Univ Tubingen, Tubingen, Germany.
[Huebel, Kai] Univ Hosp Cologne, Cologne, Germany.
[Bruno, Benedetto] Univ Turin, Turin, Italy.
[Vindelov, Lars] Univ Copenhagen Rigshosp, Copenhagen, Denmark.
RP Storb, R (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,Mail Stop D1-100,POB 19024, Seattle, WA 98109 USA.
EM rstorb@fhcrc.org
OI Gyurkocza, Boglarka/0000-0002-2933-2119; Hari,
Parameswaran/0000-0002-8800-297X
FU National Institutes of Health, Bethesda, MD [P01 HL036444, P01 CA078902,
P01 CA018029, P30 CA015704, P30 CA023074, R01 HL108307, R00 HL088021];
Leukemia/Lymphoma Society [7008-08]; Laura Landro Salomon Endowment
Fund; Danish Cancer Society; Lundbeck Foundation; Ricerca Finalizzata;
Compagnia di San Paolo and Comitato Gigi Ghirotti
FX Supported by Grants No. P01 HL036444, P01 CA078902, P01 CA018029, P30
CA015704, P30 CA023074, R01 HL108307, and R00 HL088021 from the National
Institutes of Health, Bethesda, MD. Further support came from grants
from the Leukemia/Lymphoma Society (Grant No. 7008-08), the Laura Landro
Salomon Endowment Fund, the Danish Cancer Society, the Lundbeck
Foundation, the Ricerca Finalizzata 2008-2009, and the Compagnia di San
Paolo and Comitato Gigi Ghirotti.
NR 39
TC 71
Z9 73
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR 20
PY 2013
VL 31
IS 12
BP 1530
EP 1538
DI 10.1200/JCO.2012.45.0247
PG 9
WC Oncology
SC Oncology
GA 129IC
UT WOS:000317831500015
PM 23478054
ER
PT J
AU Mayer, RJ
AF Mayer, Robert J.
TI Disease-Free Survival in Colon Cancer: Still Relevant After All These
Years! Reply
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Letter
ID ADJUVANT CHEMOTHERAPY
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Mayer, RJ (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 7
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR 20
PY 2013
VL 31
IS 12
BP 1612
EP 1613
DI 10.1200/JCO.2012.47.8859
PG 3
WC Oncology
SC Oncology
GA 129IC
UT WOS:000317831500029
PM 23734371
ER
PT J
AU Smoller, JW
Craddock, N
Kendler, K
Lee, PH
Neale, BM
Nurnberger, JI
Ripke, S
Santangelo, S
Sullivan, PF
AF Smoller, Jordan W.
Craddock, Nicholas
Kendler, Kenneth
Lee, Phil Hyoun
Neale, Benjamin M.
Nurnberger, John I.
Ripke, Stephan
Santangelo, Susan
Sullivan, Patrick F.
CA Psychiatric Genomics Consortium
TI Identification of risk loci with shared effects on five major
psychiatric disorders: a genome-wide analysis
SO LANCET
LA English
DT Article
ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; AUTISM SPECTRUM DISORDERS;
BIPOLAR DISORDER; GENE-EXPRESSION; SCHIZOPHRENIA; ASSOCIATION;
METAANALYSIS; POPULATION; CACNA1C; DEPRESSION
AB Background Findings from family and twin studies suggest that genetic contributions to psychiatric disorders do not in all cases map to present diagnostic categories. We aimed to identify specific variants underlying genetic effects shared between the five disorders in the Psychiatric Genomics Consortium: autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia.
Methods We analysed genome-wide single-nucleotide polymorphism (SNP) data for the five disorders in 33 332 cases and 27 888 controls of European ancestory. To characterise allelic effects on each disorder, we applied a multinomial logistic regression procedure with model selection to identify the best-fitting model of relations between genotype and phenotype. We examined cross-disorder effects of genome-wide significant loci previously identified for bipolar disorder and schizophrenia, and used polygenic risk-score analysis to examine such effects from a broader set of common variants. We undertook pathway analyses to establish the biological associations underlying genetic overlap for the five disorders. We used enrichment analysis of expression quantitative trait loci (eQTL) data to assess whether SNPs with cross-disorder association were enriched for regulatory SNPs in post-mortem brain-tissue samples.
Findings SNPs at four loci surpassed the cutoff for genome-wide significance (p<5x10(-8)) in the primary analysis: regions on chromosomes 3p21 and 10q24, and SNPs within two L-type voltage-gated calcium channel subunits, CACNA1C and CACNB2. Model selection analysis supported effects of these loci for several disorders. Loci previously associated with bipolar disorder or schizophrenia had variable diagnostic specificity. Polygenic risk scores showed cross-disorder associations, notably between adult-onset disorders. Pathway analysis supported a role for calcium channel signalling genes for all five disorders. Finally, SNPs with evidence of cross-disorder association were enriched for brain eQTL markers.
Interpretation Our findings show that specific SNPs are associated with a range of psychiatric disorders of childhood onset or adult onset. In particular, variation in calcium-channel activity genes seems to have pleiotropic effects on psychopathology. These results provide evidence relevant to the goal of moving beyond descriptive syndromes in psychiatry, and towards a nosology informed by disease cause.
C1 [Smoller, Jordan W.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Smoller, JW (reprint author), Massachusetts Gen Hosp, Simches Res Bldg, Boston, MA 02114 USA.
EM jsmoller@hms.harvard.edu
RI Holmans, Peter/F-4518-2015; Mattheisen, Manuel/B-4949-2012; Ruderfer,
Douglas/M-5795-2016; Lohoff, Falk/M-7951-2016; BELLIVIER,
FRANK/H-5197-2012; McQuillin, Andrew/C-1623-2008; Lesch,
Klaus-Peter/J-4906-2013; Wray, Naomi/C-8639-2015; Franke,
Barbara/D-4836-2009; Sonuga-Barke, Edmund/D-9137-2011; Breen,
Gerome/A-5540-2010; Medland, Sarah/C-7630-2013; Hansen,
Thomas/O-5965-2014; Kuntsi, Jonna/G-9750-2011; van Grootheest,
Gerard/C-6942-2014; Sigurdsson, Engilbert/D-2486-2014; Kahler,
Anna/J-2874-2012; Nolen, Willem/E-9006-2014; Zhang, Peng/N-2920-2014
OI Anney, Richard/0000-0002-6083-407X; Agartz, Ingrid/0000-0002-9839-5391;
Nothen, Markus/0000-0002-8770-2464; Andreassen, Ole
A./0000-0002-4461-3568; Thapar, Anita/0000-0002-3689-737X; Etain,
Bruno/0000-0002-5377-1488; Visscher, Peter/0000-0002-2143-8760; Pickard,
Benjamin/0000-0002-2374-6329; de Geus, Eco/0000-0001-6022-2666;
Hamilton, Steven/0000-0001-8106-6260; Backlund,
Lena/0000-0001-9399-5024; Zammit, Stanley/0000-0002-2647-9211; Jamain,
Stephane/0000-0002-4321-4100; Greenwood, Tiffany/0000-0002-6080-6503;
KELLER, MATTHEW/0000-0002-6075-9882; lichtenstein,
paul/0000-0003-3037-5287; Stefansson, Hreinn/0000-0002-9331-6666;
Holmans, Peter/0000-0003-0870-9412; Mattheisen,
Manuel/0000-0002-8442-493X; Ruderfer, Douglas/0000-0002-2365-386X;
McQuillin, Andrew/0000-0003-1567-2240; Lesch,
Klaus-Peter/0000-0001-8348-153X; Wray, Naomi/0000-0001-7421-3357; Craig,
Ian/0000-0002-4063-1005; Bergen, Sarah/0000-0002-5888-0034; Tozzi,
Federica/0000-0002-3536-2920; McMahon, Francis/0000-0002-9469-305X;
MacIntyre, Donald J/0000-0001-6963-1335; Franke,
Barbara/0000-0003-4375-6572; Breen, Gerome/0000-0003-2053-1792; Medland,
Sarah/0000-0003-1382-380X; Hansen, Thomas/0000-0001-6703-7762; van
Grootheest, Gerard/0000-0003-4350-6661; Sigurdsson,
Engilbert/0000-0001-9404-7982; Zhang, Peng/0000-0003-1182-1392
FU NIMH [U01 MH085520]; National Institutes of Health (USA); National
Institute of Mental Health
FX National Institute of Mental Health.; We thank the study participants,
and the research staff at the many study sites. This work was supported
by NIMH grant U01 MH085520. Numerous grants from the National Institutes
of Health (USA), and similar numbers of government grants from other
countries, and substantial private and foundation support enabled this
work.
NR 50
TC 609
Z9 614
U1 30
U2 271
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 20
PY 2013
VL 381
IS 9875
BP 1371
EP 1379
DI 10.1016/S0140-6736(12)62129-1
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 130EF
UT WOS:000317894800034
PM 23453885
ER
PT J
AU Hart, RA
Cabalo, A
Bess, S
Akbarnia, BA
Boachie-Adjei, O
Burton, D
Cunningham, ME
Gupta, M
Hostin, R
Kebaish, K
Klineberg, E
Mundis, G
Shaffrey, C
Smith, JS
Wood, K
AF Hart, Robert A.
Cabalo, Adam
Bess, Shay
Akbarnia, Behrooz A.
Boachie-Adjei, Oheneba
Burton, Douglas
Cunningham, Matthew E.
Gupta, Munish
Hostin, Richard
Kebaish, Khaled
Klineberg, Eric
Mundis, Gregory
Shaffrey, Christopher
Smith, Justin S.
Wood, Kirkham
CA Int Spine Study Grp
TI Comparison of Patient and Surgeon Perceptions of Adverse Events After
Adult Spinal Deformity Surgery
SO SPINE
LA English
DT Article
DE adverse events; outcomes; scoliosis; spinal fusion; spine surgery
ID HEALTH SURVEY SF-36; COMPLICATIONS; SCOLIOSIS; OUTCOMES; RELIABILITY;
AGE; MORTALITY; VALIDITY; FUSIONS; QUALITY
AB Study Design. Survey based on complication scenarios.
Objective. To assess and compare perceived potential impacts of various perioperative adverse events by both surgeons and patients.
Summary of Background Data. Incidence of adverse events after adult spinal deformity surgery remains substantial. Patient-centered outcomes tools measuring the impact of these events have not been developed. An important first step is to assess the perceptions of surgeons and patients regarding the impact of these events on surgical outcome and quality of life.
Methods. Descriptions of 22 potential adverse events of surgery (heart attack, stroke, spinal cord injury, nerve root injury, cauda equina injury, blindness, dural tear, blood transfusion, deep vein thrombosis, pulmonary embolism, superficial infection, deep infection, lung failure, urinary tract infection, nonunion, adjacent segment disease, persistent deformity, implant failure, death, renal failure, gastrointestinal complications, and sexual dysfunction) were presented to 14 spinal surgeons and 16 adult patients with spinal deformity. Impact scores were assigned to each complication on the basis of perceptions of overall severity, satisfaction with surgery, and effect on quality of life. Impact scores were compared between surgeons and patients with a Wilcoxon/Kruskal-Wallis test.
Results. Mean impact scores varied from 0.9 (blood transfusion) to 10.0 (death) among surgeons and 2.3 (urinary tract infection) to 9.2 (stroke) among patients. Patients' scores were consistently higher (P < 0.05) than surgeons in all 3 categories for 6 potential adverse events: stroke, lung failure, heart attack, pulmonary embolism, dural tear, and blood transfusion. Three additional complications (renal failure, non-union, and deep vein thrombosis) were rated higher in 1 or 2 categories by patients.
Conclusion. There was substantial variation in how both surgeons and patients perceived impacts of various adverse events after spine surgery. Patients generally perceived the impact of adverse events to be greater than surgeons. Patient-centered descriptions of adverse events would provide a more complete description of surgical outcomes.
C1 [Hart, Robert A.; Cabalo, Adam] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Bess, Shay] Rocky Mt Hosp Children, Denver, CO USA.
[Akbarnia, Behrooz A.; Mundis, Gregory] San Diego Ctr Spinal Disorders, La Jolla, CA USA.
[Boachie-Adjei, Oheneba; Cunningham, Matthew E.] Hosp Special Surg, New York, NY 10021 USA.
[Burton, Douglas; Klineberg, Eric] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.
[Gupta, Munish] Univ Calif Davis, Sacramento, CA 95817 USA.
[Hostin, Richard] Baylor Scoliosis Ctr, Plano, TX USA.
[Kebaish, Khaled] Johns Hopkins Univ, Baltimore, MD USA.
[Shaffrey, Christopher; Smith, Justin S.] Univ Virginia, Charlottesville, VA USA.
[Int Spine Study Grp] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Hart, RA (reprint author), Oregon Hlth & Sci Univ, Sam Jackson Hall,Ste 2360,3181 SW Sam Jackson Pk, Portland, OR 97239 USA.
EM hartro@ohsu.edu
RI sebastianovitsch, stepan/G-8507-2013;
OI bess, shay/0000-0002-9697-8999
FU Depuy Spine; Children's Research Foundation
FX Depuy Spine and Children's Research Foundation funds were received to
support this work.
NR 33
TC 6
Z9 6
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0362-2436
J9 SPINE
JI SPINE
PD APR 20
PY 2013
VL 38
IS 9
BP 732
EP 736
DI 10.1097/BRS.0b013e31827ae242
PG 5
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 130JH
UT WOS:000317910300013
PM 24477053
ER
PT J
AU Luo, NL
Wang, XD
Zhang, W
Garvey, WT
Fu, YC
AF Luo, Nanlan
Wang, Xiangdong
Zhang, Wei
Garvey, W. T.
Fu, Yuchang
TI AdR1-TG/TALLYHO mice have improved lipid accumulation and insulin
sensitivity
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Adiponectin receptor; TALLYHO mouse model; Diabetes
ID MONOCYTE-DERIVED MACROPHAGES; PIMA INDIAN POPULATION; MOUSE MODEL;
ADIPONECTIN RECEPTORS; METABOLIC SYNDROME; DIABETES RESEARCH; OBESITY;
GLUCOSE; DISEASE; PROTEIN
AB Background: Overexpression of adiponectin receptor 1 in macrophages can physiologically modulate metabolic activities in vivo by enhancing adiponectin actions in distal metabolically active tissues. To investigate the effects of enhanced adiponectin actions in TALLYHO (TH) diabetic mouse model, we crossed the adiponectin receptor 1 macrophage-specific transgenic mice (AdR1-TG) with the TALLYHO diabetic mice (TH) to examine the changes of lipid accumulation and insulin sensitivity in these mice.
Methods: AdR1-TG/TH and the control WT/TH mice were fed either normal diet or high fat diet for 28 weeks. Whole body weights of these mice were measured and mouse sera were analyzed for the levels of cholesterol, triglyceride, and free fatty acids. Glucose tolerance testing (GTT) and insulin tolerance testing (ITT) in these mice were performed to investigate systemic insulin sensitivity in vivo. Molecular markers for insulin signaling pathway in mouse skeletal muscle tissues, IRS-1 and AKT, were examined. Mouse serum insulin levels were measured and Sirt1 gene expression in mouse pancreatic tissues was also quantified related to the insulin secretion. The Caspase 3 protein levels were analyzed by Western blot methods.
Results: Compared to the control WT/TH mice, AdR1-TG/TH mice showed significantly lower body weights under either normal diet or high fat diet and the mouse serum levels of cholesterol, triglyceride and free fatty acids were significantly decreased in the transgenic crossed mice when compared to those from the control mice. Improved GTF and ITT tests indicating increased systemic insulin sensitivity in the transgenic crossed mice demonstrated the enhanced adiponectin actions on the systemic metabolism in vivo. The increases of insulin secretion and its related gene expression were also detected in the transgenic crossed mice. In contrast, the control mice showed hypertrophy pancreases companying with high apoptosis gene expression. These results suggest that enhanced adiponectin actions by overexpressing adiponectin receptor 1 in macrophages can provide unique interactions with the metabolic tissues/cells, improving lipid accumulation and insulin sensitivity in TALLYHO diabetic mice. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Luo, Nanlan; Zhang, Wei; Garvey, W. T.; Fu, Yuchang] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Wang, Xiangdong] Shandong Univ, Inst Cell Biol, Jinan 250012, Peoples R China.
[Garvey, W. T.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
RP Fu, YC (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Shelby Bldg 1213,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM yfu@uab.edu
FU American Diabetes Association [1-07-RA-49, 1-13-IN-19]; NIH [DK-083562]
FX We are grateful to the UAB Diabetes Research and Training Center for
providing outstanding core services (NIH P30 DK-56336). This work was
supported by grants from American Diabetes Association (1-07-RA-49 and
1-13-IN-19) to Y.F., and grant from NIH (DK-083562) to T.G.
NR 29
TC 2
Z9 3
U1 2
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 19
PY 2013
VL 433
IS 4
BP 567
EP 572
DI 10.1016/j.bbrc.2013.03.030
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 135AT
UT WOS:000318259100037
PM 23523784
ER
PT J
AU Baker, A
Braggio, E
Jacobus, S
Jung, S
Larson, D
Therneau, T
Dispenzieri, A
Van Wier, SA
Ahmann, G
Levy, J
Perkins, L
Kim, S
Henderson, K
Vesole, D
Rajkumar, SV
Jelinek, DF
Carpten, J
Fonseca, R
AF Baker, Angela
Braggio, Esteban
Jacobus, Susanna
Jung, Sungwon
Larson, Dirk
Therneau, Terry
Dispenzieri, Angela
Van Wier, Scott A.
Ahmann, Gregory
Levy, Joan
Perkins, Louise
Kim, Seungchan
Henderson, Kimberly
Vesole, David
Rajkumar, S. Vincent
Jelinek, Diane F.
Carpten, John
Fonseca, Rafael
TI Uncovering the biology of multiple myeloma among African Americans: a
comprehensive genomics approach
SO BLOOD
LA English
DT Article
ID UNDETERMINED SIGNIFICANCE MGUS; COOPERATIVE-ONCOLOGY-GROUP; MONOCLONAL
GAMMOPATHY; PROGNOSTIC-SIGNIFICANCE; CHROMOSOME-13 ABNORMALITIES;
INTERGROUPE FRANCOPHONE; EXPRESSION; RISK; DELETIONS; CLASSIFICATION
AB Epidemiological data have suggested that African American (AA) persons are twice as likely to be diagnosed with multiple myeloma (MM) compared with European American (EA) persons. Here, we have analyzed a set of cytogenetic and genomic data derived from AA and EA MM patients. We have compared the frequency of IgH translocations in a series of data from 115 AA patients from 3 studies and 353 EA patients from the Eastern Cooperative Oncology Group (ECOG) studies E4A03 and E9487. We have also interrogated tumors from 45 AA and 196 EA MM patients for somatic copy number abnormalities associated with poor outcome. In addition, 35 AA and 178 EA patients were investigated for a transcriptional profile associated with high-risk disease. Overall, based on this cohort, genetic profiles were similar except for a significantly lower frequency of IgH translocations (40% vs 52%; P = .032) in AA patients. Frequency differences of somatic copy number aberrations were not significant after correction for multiple testing. There was also no significant difference in the frequency of high-risk disease based on gene expression profiling. Our study represents the first comprehensive comparisons of the frequency and distribution of molecular alterations in MM tumors between AA and EA patients. ECOG E4A03 is registered with ClinicalTrials.gov, number NCT00098475. ECOG E9487 is a companion validation set to the ECOG study E9486 and is registered with the National Institutes of Health, National Cancer Institute, Clinical Trials (PDQ), number EST-9486.
C1 [Baker, Angela; Jung, Sungwon; Kim, Seungchan; Carpten, John] Translat Genom Res Inst, Phoenix, AZ USA.
[Braggio, Esteban; Van Wier, Scott A.; Ahmann, Gregory; Fonseca, Rafael] Mayo Clin Scottsdale, Scottsdale, AZ 85259 USA.
[Jacobus, Susanna] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Larson, Dirk; Therneau, Terry; Dispenzieri, Angela; Henderson, Kimberly; Rajkumar, S. Vincent; Jelinek, Diane F.] Mayo Clin Rochester, Rochester, MN USA.
[Levy, Joan; Perkins, Louise] Multiple Myeloma Res Fdn, Norwalk, CT USA.
[Vesole, David] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
RP Fonseca, R (reprint author), Mayo Clin Scottsdale, 13400 East Shea Blvd,Collaborat Res Bldg,3-006, Scottsdale, AZ 85259 USA.
EM fonseca.rafael@mayo.edu
OI Rajkumar, S. Vincent/0000-0002-5862-1833; Fonseca,
Rafael/0000-0002-5938-3769; Dispenzieri, Angela/0000-0001-8780-9512
FU Multiple Myeloma Research Consortium [SPORE CA90297052, P01 CA62242, R01
CA83724, ECOG CA 21115T]; Predolin Foundation; Mayo Clinic Cancer
Center; Mayo Foundation; Damon Runyon Cancer Research Fund; Medtronic;
Otsuka; Celgene; Genzyme; BMS; AMGEN; Cylene; Onyx
FX This work was supported by the Multiple Myeloma Research Consortium
(grants SPORE CA90297052, P01 CA62242, R01 CA83724, and ECOG CA 21115T);
Predolin Foundation; Mayo Clinic Cancer Center; and the Mayo Foundation.
This research was also funded in part by Damon Runyon Cancer Research
Fund (to R.F.).; Relevant to this work, Dr Fonseca has received a patent
for the prognostication of MM based on genetic categorization of the
disease. He has received consulting fees from Medtronic, Otsuka,
Celgene, Genzyme, BMS, and AMGEN. He also has sponsored research from
Cylene and Onyx. The remaining authors declare no competing financial
interests.
NR 42
TC 13
Z9 13
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 18
PY 2013
VL 121
IS 16
BP 3147
EP 3152
DI 10.1182/blood-2012-07-443606
PG 6
WC Hematology
SC Hematology
GA 183PK
UT WOS:000321829200015
PM 23422747
ER
PT J
AU Rychert, J
Jones, L
McGrath, G
Bazner, S
Rosenberg, ES
AF Rychert, Jenna
Jones, Lindsay
McGrath, Graham
Bazner, Sue
Rosenberg, Eric S.
TI A monoclonal antibody against lymphocyte function-associated antigen-1
decreases HIV-1 replication by inducing the secretion of an antiviral
soluble factor
SO VIROLOGY JOURNAL
LA English
DT Article
DE HIV-1; LFA-1; Monoclonal antibody therapy
ID IMMUNODEFICIENCY-VIRUS TYPE-1; T-LYMPHOCYTES; CELLS; EPITOPES; VIRIONS;
LFA-1; INDIVIDUALS; COMPONENTS; INFECTION; RESPONSES
AB Background: Lymphocyte Function-Associated Antigen-1 (LFA-1) likely plays a role in the pathogenesis of against HIV-1 and is known to facilitate cell-to-cell transmission of the virus. A monoclonal antibody specific for LFA-1 (Cytolin (R)) was evaluated as a potential therapeutic in pilot studies performed in the mid-1990s. These uncontrolled human studies suggested that administration of this anti-LFA-1 antibody to HIV-1 infected individuals could provide a modest benefit by decreasing circulating HIV-1 RNA and increasing CD4+ T cell counts. At the time, it was proposed that when bound to cytolytic T cells, the antibody inhibited lysis of activated CD4+ T cells. Given the renewed interest in monoclonal antibody therapy for HIV-1 infected individuals, we investigated possible mechanisms of action of this antibody in vitro.
Methods: To assess whether this anti-LFA-1 antibody binds to HIV-1, a virus capture assay was performed. Binding of the antibody to cells was assessed using flow cytometry. Inhibition of HIV-1 replication was determined in culture by measuring the amount of p24 produced by ELISA. After co-culture of the antibody with peripheral blood mononuclear cells, supernatants were assayed for cytokines and chemokines using various immunoassays.
Results: Our experiments demonstrate that anti-LFA-1 antibody binds to CCR5 and CXCR4 utilizing strains of HIV-1. It also binds to CD8+ T cells and dendritic cells. When bound to virus prior to infection, there is no decrease in HIV-1 replication, suggesting it does not directly inhibit viral replication via virus binding. When bound to cells, it does not inhibit lysis of CD4+ T cells, as was originally hypothesized. Binding to cells does appear to induce the production of a soluble factor that inhibits HIV-1 replication. We determined that this soluble factor was not any of the cytokines or chemokines with known anti-HIV-1 activity. Further, the antibody does not appear to induce any common immune modulating cytokines or chemokines.
Conclusions: These results suggest that one possible mechanism of action of this anti-LFA-1 antibody is to inhibit HIV-1 replication via the production of a soluble antiviral factor that is induced upon binding to cells.
C1 [Rychert, Jenna] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Rychert, J (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
EM jrychert@partners.org
FU Cytodyn
FX This study was funded by Cytodyn. The study design, subject recruitment,
and experiments were conceived of and carried out by members of the
study team without input from the company.
NR 27
TC 1
Z9 2
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD APR 18
PY 2013
VL 10
AR 120
DI 10.1186/1743-422X-10-120
PG 10
WC Virology
SC Virology
GA 141WS
UT WOS:000318757800001
PM 23594747
ER
PT J
AU Michaud, DS
Siddiq, A
Cox, DG
Backes, DM
Calboli, FCF
Sughrue, ME
Gaziano, JM
Ma, J
Stampfer, M
Tworoger, SS
Hunter, DJ
Camargo, CA
Parsa, AT
AF Michaud, Dominique S.
Siddiq, Afshan
Cox, David G.
Backes, Danielle M.
Calboli, Federico C. F.
Sughrue, Michael E.
Gaziano, J. Michael
Ma, Jing
Stampfer, Meir
Tworoger, Shelley S.
Hunter, David J.
Camargo, Carlos A., Jr.
Parsa, Andrew T.
TI Mannose-Binding Lectin 2 Gene and Risk of Adult Glioma
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; HUMAN-PAPILLOMAVIRUS INFECTION; CANCER RISK;
FUNCTIONAL POLYMORPHISMS; UNRELATED INDIVIDUALS; BREAST-CANCER; MBL2;
WOMEN; SUSCEPTIBILITY; POPULATION
AB Background and Aims: The immune system is likely to play a key role in the etiology of gliomas. Genetic polymorphisms in the mannose-binding lectin gene, a key activator in the lectin complement pathway, have been associated with risk of several cancers.
Methods: To examine the role of the lectin complement pathway, we combined data from prospectively collected cohorts with available DNA specimens. Using a nested case-control design, we genotyped 85 single nucleotide polymorphisms (SNPs) in 9 genes in the lectin complement pathway and 3 additional SNPs in MBL2 were tested post hoc). Initial SNPs were selected using tagging SNPs for haplotypes; the second group of SNPs for MBL2 was selected based on functional SNPs related to phenotype. Associations were examined using logistic regression analysis. All statistical tests were two-sided. Nominal p-values are presented and are not corrected for multiple comparisons.
Results: A total of 143 glioma cases and 419 controls were available for this analysis. Statistically significant associations were observed for two SNPs in the mannose-binding lectin 2 (ML2) gene and risk of glioma (rs1982266 and rs1800450, test for trend p = 0.003 and p = 0.04, respectively, using the additive model). One of these SNPs, rs1800450, was associated with a 58% increase in glioma risk among those carrying one or two mutated alleles (odds ratio = 1.58, 95% confidence interval = 0.99-2.54), compared to those homozygous for the wild type allele.
Conclusions: Overall, our findings suggest that MBL may play a role in the etiology of glioma. Future studies are needed to confirm these findings which may be due to chance, and if reproduced, to determine mechanisms that link glioma pathogenesis with the MBL complement pathway.
C1 [Michaud, Dominique S.; Backes, Danielle M.] Brown Univ, Brown Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA.
[Michaud, Dominique S.; Siddiq, Afshan; Cox, David G.; Calboli, Federico C. F.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Sch Publ Hlth, London, England.
[Cox, David G.] UCBL1, CNRS UMR 5286, INSERM U1052, Lyon Canc Res Ctr, Lyon, France.
[Sughrue, Michael E.] Univ Oklahoma, Dept Neurol Surg, Norma, OK USA.
[Gaziano, J. Michael] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
[Ma, Jing; Stampfer, Meir; Tworoger, Shelley S.; Hunter, David J.; Camargo, Carlos A., Jr.] Brigham & Womens Hosp, Dept Med, Channing Div, Med Network, Boston, MA 02115 USA.
[Ma, Jing; Stampfer, Meir; Tworoger, Shelley S.; Hunter, David J.; Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Boston, MA USA.
[Stampfer, Meir; Tworoger, Shelley S.; Hunter, David J.; Camargo, Carlos A., Jr.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Stampfer, Meir; Hunter, David J.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Parsa, Andrew T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.
RP Michaud, DS (reprint author), Brown Univ, Brown Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA.
EM Dominique_Michaud@brown.edu
RI Michaud, Dominique/I-5231-2014; Cox, David/A-2023-2009;
OI Cox, David/0000-0002-2152-9259; Tworoger, Shelley/0000-0002-6986-7046
FU National Institutes of Health [R01 CA114205, P01 CA097193, P01 CA087969,
P01 CA055075-]
FX This work was supported by the National Institutes of Health (R01
CA114205; P01 CA097193; P01 CA087969; P01 CA055075-). The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 32
TC 2
Z9 2
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 18
PY 2013
VL 8
IS 4
AR e61117
DI 10.1371/journal.pone.0061117
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130IU
UT WOS:000317908700014
PM 23637788
ER
PT J
AU Shanmugasundaram, K
Block, K
Nayak, BK
Livi, CB
Venkatachalam, MA
Sudarshan, S
AF Shanmugasundaram, K.
Block, K.
Nayak, B. K.
Livi, C. B.
Venkatachalam, M. A.
Sudarshan, S.
TI PI3K regulation of the SKP-2/p27 axis through mTORC2
SO ONCOGENE
LA English
DT Article
DE p27; SKP-2; mTOR; RICTOR
ID RENAL-CELL CARCINOMA; RAPAMYCIN COMPLEX 2; PROTEIN-KINASE B; TISSUE
MICROARRAY; SUBCELLULAR-LOCALIZATION; CYTOPLASMIC LOCALIZATION; AKT
PHOSPHORYLATION; MAMMALIAN TARGET; UBIQUITIN LIGASE; SKP2
AB The cyclin-dependent kinase inhibitor p27 is a key regulator of cell-cycle progression. Its expression and localization are altered in several types of malignancies, which has prognostic significance in cancers such as renal cell carcinoma (RCC). S-phase kinase-associated protein 2 (SKP-2) is an F-box protein that is part of the SKP-1/Cul1/F-box ubiquitin ligase complex that targets nuclear p27 among many other cell-cycle proteins for proteosomal degradation. Its overexpression has been observed in several tumor types. Signaling by phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) has previously been shown to regulate the SKP-2/p27 axis. Recent evidence suggests that PI3K signaling may activate mammalian target of rapamycin complex 2 (mTORC2) activity. As PI3K signaling is known to regulate SKP-2 and p27, we sought to determine whether these effects were mediated by mTORC2. Here we provide additional genetic evidence that PI3K signaling activates mTORC2 kinase activity. We also demonstrate a novel role for mTORC2 in the modulation of nuclear p27 levels. In particular, mTORC2 signaling promotes the reduction of nuclear p27 protein levels through the increased protein expression of SKP-2. These are the first data to demonstrate a role for mTOR in the regulation of SKP-2. In concordance with these findings, mTORC2 activity promotes cell proliferation of RCC cells at the G1-S interphase of the cell cycle. Collectively, these data implicate mTORC2 signaling in the regulation of the SKP-2/p27 axis, a signaling node commonly altered in cancer. Oncogene (2013) 32, 2027-2036; doi:10.1038/onc.2012.226; published online 25 June 2012
C1 [Shanmugasundaram, K.; Sudarshan, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA.
[Block, K.; Nayak, B. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Livi, C. B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA.
[Venkatachalam, M. A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Block, K.] Audie L Murphy Mem Hosp Div, South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Sudarshan, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, 7703 Floyd Curl Dr,MC 7845, San Antonio, TX 78229 USA.
EM sudarshan@uthscsa.edu
FU Cancer Therapy and Research Center (CTRC) at the University of Texas
Health Science Center [NIH P30 CA054174-17]; NIH [K08 CA138774, R01 NCI
CA131272]; Voelcker Fund Young Investigator Award; AUA
Foundation/Astellas Rising Star Award; Veterans Administration Career
Development Award [CDA-2]
FX This work was supported in part by the Cancer Therapy and Research
Center (CTRC) at the University of Texas Health Science Center (NIH P30
CA054174-17). SS is supported by NIH K08 CA138774, Voelcker Fund Young
Investigator Award, AUA Foundation/Astellas Rising Star Award and a
special gift from Mr Charles Butt and the employees of HEB. KB is
supported by Veterans Administration Career Development Award (CDA-2)
and NIH R01 NCI CA131272. We thank Z David Sharp for critical review of
the manuscript. We thank William Friedrichs and Korri Weldon for
technical assistance.
NR 43
TC 12
Z9 14
U1 1
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD APR 18
PY 2013
VL 32
IS 16
BP 2027
EP 2036
DI 10.1038/onc.2012.226
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 130LY
UT WOS:000317919900004
PM 22733130
ER
PT J
AU Hunt, DP
Muse, VV
Pitman, MB
AF Hunt, Daniel P.
Muse, Victorine V.
Pitman, Martha B.
TI Case 12-2013: An 18-Year-Old Woman with Pulmonary Infiltrates and
Respiratory Failure Herpes simplex virus type 1 pneumonia.
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID EPSTEIN-BARR-VIRUS; INFECTIOUS-MONONUCLEOSIS; TULAREMIA; MARIJUANA
C1 [Hunt, Daniel P.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Muse, Victorine V.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Pitman, Martha B.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Hunt, Daniel P.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Muse, Victorine V.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Pitman, Martha B.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Hunt, DP (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
NR 17
TC 0
Z9 0
U1 0
U2 4
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 18
PY 2013
VL 368
IS 16
BP 1537
EP 1545
DI 10.1056/NEJMcpc1209608
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 126HC
UT WOS:000317603300013
PM 23594007
ER
PT J
AU Kirienko, NV
Kirienko, DR
Larkins-Ford, J
Wahlby, C
Ruvkun, G
Ausubel, FM
AF Kirienko, Natalia V.
Kirienko, Daniel R.
Larkins-Ford, Jonah
Wahlby, Carolina
Ruvkun, Gary
Ausubel, Frederick M.
TI Pseudomonas aeruginosa Disrupts Caenorhabditis elegans Iron Homeostasis,
Causing a Hypoxic Response and Death
SO CELL HOST & MICROBE
LA English
DT Article
ID SENSOR KINASE KINB; CYSTIC-FIBROSIS; VIRULENCE FACTORS; REGULATES
VIRULENCE; HUMAN-SERUM; INFECTION; BACTERIAL; MODEL; PATHOGENESIS;
SIDEROPHORES
AB The opportunistic pathogen Pseudomonas aeruginosa causes serious human infections, but effective treatments and the mechanisms mediating pathogenesis remain elusive. Caenorhabditis elegans shares innate immune pathways with humans, making it invaluable to investigate infection. To determine how P. aeruginosa disrupts host biology, we studied how P. aeruginosa kills C. elegans in a liquid-based pathogenesis model. We found that P. aeruginosa-mediated killing does not require quorum-sensing pathways or host colonization. A chemical genetic screen revealed that iron chelators alleviate P. aeruginosa-mediated killing. Consistent with a role for iron in P. aeruginosa pathogenesis, the bacterial siderophore pyoverdin was required for virulence and was sufficient to induce a hypoxic response and death in the absence of bacteria. Loss of the C. elegans hypoxia-inducing factor HIF-1, which regulates iron homeostasis, exacerbated P. aeruginosa pathogenesis, further linking hypoxia and killing. As pyoverdin is indispensable for virulence in mice, pyoverdin-mediated hypoxia is likely to be relevant in human pathogenesis.
C1 [Kirienko, Natalia V.; Kirienko, Daniel R.; Larkins-Ford, Jonah; Ruvkun, Gary; Ausubel, Frederick M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Kirienko, Natalia V.; Kirienko, Daniel R.; Ruvkun, Gary; Ausubel, Frederick M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Wahlby, Carolina] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Wahlby, Carolina] Uppsala Univ, Ctr Image Anal, SciLifeLab, S-75105 Uppsala, Sweden.
RP Ausubel, FM (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM ausubel@molbio.mgh.harvard.edu
FU Massachusetts Biomedical Research Corporation Tosteson Postdoctoral
Fellowship Award; National Institutes of Health [F32 AI100501, R01
AI085581, R01 GM095672, T32 DA013911, U54 AI057159]
FX We are grateful to L. Rahme, L. Dietrich, D. Newman, D. Hung, I. Schalk,
S. Lory, C. Manoil, and D. Haas for providing bacterial strains and the
Caenorhabditis Genetics Center for worm strains. We also wish to express
our gratitude to V. Mootha and V. Cracan for helpful discussions. We
thank members of the Ausubel and Ruvkun labs for critical reading of the
manuscript and experimental advice. Finally, we wish to express our
gratitude to S. Chiang and the staff of the NSRB for providing resources
and facilities for high-throughput screening. This study was supported
by the Massachusetts Biomedical Research Corporation Tosteson
Postdoctoral Fellowship Award to N.V.K. and by the following grants from
the National Institutes of Health: F32 AI100501 awarded to N.V.K., R01
AI085581 awarded to F. M. A., R01 GM095672 awarded to C. W., T32
DA013911 awarded to D. R. K., and U54 AI057159 awarded to N.S.R.B.
NR 64
TC 35
Z9 38
U1 2
U2 32
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD APR 17
PY 2013
VL 13
IS 4
BP 406
EP 416
DI 10.1016/j.chom.2013.03.003
PG 11
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA AA1IT
UT WOS:000330850500006
PM 23601103
ER
PT J
AU Hipple, B
Nabi-Burza, E
Hall, N
Regan, S
Winickoff, JP
AF Hipple, Bethany
Nabi-Burza, Emara
Hall, Nicole
Regan, Susan
Winickoff, Jonathan P.
TI Distance-based training in two community health centers to address
tobacco smoke exposure of children
SO BMC PEDIATRICS
LA English
DT Article
DE Tobacco smoke exposure; Secondhand smoke; Tobacco control; Online
education; Community health centers; Parental smoking; Tobacco cessation
ID PARENTS QUIT SMOKING; HOMES; CARE
AB Background: The CEASE (Clinical Effort Against Secondhand Smoke Exposure) intervention was developed to help pediatricians routinely and effectively address the harms of family smoking behaviors. Based on paper versions of CEASE, we partnered with the American Academy of Pediatrics' online education department and developed a completely distance-based training, including an online CME training, handouts and education materials for families, and phone and email support.
Methods: The pediatric offices of two low income health clinics with primarily Medicaid populations were selected for the study. Pre and post intervention data by survey of the parents was collected in both practices (Practice 1 n = 470; Practice 2 n = 177). The primary outcome for this study was a comparison of rates of clinician's asking and advising parents about smoking and smoke-free home and cars.
Results: Exit surveys of parents revealed statistically significant increases in rates of clinicians asking about parental smoking (22% vs. 41%), smoke-free rules (25% vs. 44%), and asking about other smoking household members (26% vs. 48%).
Conclusions: Through a completely distance based intervention, we were able to train pediatricians who see low income children to ask parents about smoking, smoke-free home and car rules, and whether other household members smoke. Implementing a system to routinely ask about family tobacco use and smoke-free home and car rules is a first step to effectively addressing tobacco in a pediatric office setting. By knowing which family members use tobacco, pediatricians can take the next steps to help families become completely tobacco-free.
C1 [Hipple, Bethany; Nabi-Burza, Emara; Hall, Nicole; Winickoff, Jonathan P.] Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Res & Policy, Boston, MA 02144 USA.
[Winickoff, Jonathan P.] Amer Acad Pediat, AAP Richmond Ctr Excellence, Elk Grove Village, IL USA.
[Hipple, Bethany; Nabi-Burza, Emara; Hall, Nicole; Regan, Susan; Winickoff, Jonathan P.] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 02144 USA.
RP Winickoff, JP (reprint author), Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Res & Policy, 50 Staniford St Suite 901, Boston, MA 02144 USA.
EM jwinickoff@partners.org
OI Regan, Susan/0000-0003-0940-2017
FU Clinical Innovator Award from the Flight Attendant Medical Research
Institute; AAP Julius B. Richmond Center; American Academy of
Pediatrics' PediaLink Online Center for Lifelong Learning; Massachusetts
Tobacco Cessation and Prevention Program
FX This study was supported by a Clinical Innovator Award from the Flight
Attendant Medical Research Institute. The study was also supported by
the AAP Julius B. Richmond Center and the American Academy of
Pediatrics' PediaLink Online Center for Lifelong Learning. The video
included in the module was supported by the Massachusetts Tobacco
Cessation and Prevention Program.
NR 19
TC 3
Z9 3
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2431
J9 BMC PEDIATR
JI BMC Pediatr.
PD APR 17
PY 2013
VL 13
AR 56
DI 10.1186/1471-2431-13-56
PG 7
WC Pediatrics
SC Pediatrics
GA 139VQ
UT WOS:000318613500001
PM 23594832
ER
PT J
AU Wachter, F
Grunert, M
Blaj, C
Weinstock, DM
Jeremias, I
Ehrhardt, H
AF Wachter, Franziska
Grunert, Michaela
Blaj, Cristina
Weinstock, David M.
Jeremias, Irmela
Ehrhardt, Harald
TI Impact of the p53 status of tumor cells on extrinsic and intrinsic
apoptosis signaling
SO CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE p53; Mutant p53; Extrinsic; Intrinsic; TRAIL; Doxorubicin; Apoptosis
ID DNA-BINDING COOPERATIVITY; MUTANT P53; GENE-EXPRESSION; VINCA ALKALOIDS;
CANCER; TRANSCRIPTION; SUPPRESSION; ACTIVATION; MUTATIONS; CASPASE-8
AB Background: The p53 protein is the best studied target in human cancer. For decades, p53 has been believed to act mainly as a tumor suppressor and by transcriptional regulation. Only recently, the complex and diverse function of p53 has attracted more attention. Using several molecular approaches, we studied the impact of different p53 variants on extrinsic and intrinsic apoptosis signaling.
Results: We reproduced the previously published results within intrinsic apoptosis induction: while wild-type p53 promoted cell death, different p53 mutations reduced apoptosis sensitivity. The prediction of the impact of the p53 status on the extrinsic cell death induction was much more complex. The presence of p53 in tumor cell lines and primary xenograft tumor cells resulted in either augmented, unchanged or reduced cell death. The substitution of wild-type p53 by mutant p53 did not affect the extrinsic apoptosis inducing capacity.
Conclusions: In summary, we have identified a non-expected impact of p53 on extrinsic cell death induction. We suggest that the impact of the p53 status of tumor cells on extrinsic apoptosis signaling should be studied in detail especially in the context of therapeutic approaches that aim to restore p53 function to facilitate cell death via the extrinsic apoptosis pathway.
C1 [Wachter, Franziska; Grunert, Michaela; Blaj, Cristina; Jeremias, Irmela; Ehrhardt, Harald] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, D-81377 Munich, Germany.
[Weinstock, David M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Jeremias, Irmela] Univ Munich, Dr von Haunersches Kinderspital, Dept Hematol Oncol, D-80337 Munich, Germany.
[Ehrhardt, Harald] Univ Munich, Perinatal Ctr, Univ Childrens Hosp, Div Neonatol, D-81377 Munich, Germany.
RP Ehrhardt, H (reprint author), German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Marchioninistr 25, D-81377 Munich, Germany.
EM Harald.Ehrhardt@helmholtz-muenchen.de
RI Jeremias, Irmela/C-6090-2015;
OI Ehrhardt, Harald/0000-0003-4587-1734
NR 39
TC 3
Z9 3
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478-811X
J9 CELL COMMUN SIGNAL
JI Cell Commun. Signal.
PD APR 17
PY 2013
VL 11
AR 27
DI 10.1186/1478-811X-11-27
PG 10
WC Cell Biology
SC Cell Biology
GA 139UM
UT WOS:000318610400001
PM 23594441
ER
PT J
AU Berry, JD
Shefner, JM
Conwit, R
Schoenfeld, D
Keroack, M
Felsenstein, D
Krivickas, L
David, WS
Vriesendorp, F
Pestronk, A
Caress, JB
Katz, J
Simpson, E
Rosenfeld, J
Pascuzzi, R
Glass, J
Rezania, K
Rothstein, JD
Greenblatt, DJ
Cudkowicz, ME
AF Berry, James D.
Shefner, Jeremy M.
Conwit, Robin
Schoenfeld, David
Keroack, Myles
Felsenstein, Donna
Krivickas, Lisa
David, William S.
Vriesendorp, Francine
Pestronk, Alan
Caress, James B.
Katz, Jonathan
Simpson, Ericka
Rosenfeld, Jeffrey
Pascuzzi, Robert
Glass, Jonathan
Rezania, Kourosh
Rothstein, Jeffrey D.
Greenblatt, David J.
Cudkowicz, Merit E.
CA Northeast ALS Consortium
TI Design and Initial Results of a Multi-Phase Randomized Trial of
Ceftriaxone in Amyotrophic Lateral Sclerosis
SO PLOS ONE
LA English
DT Article
ID INCREASES GLUTAMATE UPTAKE; CEREBROSPINAL-FLUID; UP-REGULATION;
LYME-DISEASE; MODEL; EXPRESSION; SURVIVAL; HISTORY; STROKE; EAAT2
AB Objective: Ceftriaxone increases expression of the astrocytic glutamate transporter, EAAT2, which might protect from glutamate-mediated excitotoxicity. A trial using a novel three stage nonstop design, incorporating Phases I-III, tested ceftriaxone in ALS. Stage 1 determined the cerebrospinal fluid pharmacokinetics of ceftriaxone in subjects with ALS. Stage 2 evaluated safety and tolerability for 20-weeks. Analysis of the pharmacokinetics, tolerability, and safety was used to determine the ceftriaxone dosage for Stage 3 efficacy testing.
Methods: In Stage 1, 66 subjects at ten clinical sites were enrolled and randomized equally into three study groups receiving intravenous placebo, ceftriaxone 2 grams daily or ceftriaxone 4 grams daily divided BID. Participants provided serum and cerebrospinal fluid for pharmacokinetic analysis on study day 7. Participants continued their assigned treatment in Stage 2. The Data and Safety Monitoring Board (DSMB) reviewed the data after the last participants completed 20 weeks on study drug.
Results: Stage 1 analysis revealed linear pharmacokinetics, and CSF trough levels for both dosage levels exceeding the pre-specified target trough level of 1 mu M (0.55 mu g/mL). Tolerability (Stages 1 and 2) results showed that ceftriaxone at dosages up to 4 grams/day was well tolerated at 20 weeks. Biliary adverse events were more common with ceftriaxone but not dose-dependent and improved with ursodeoxycholic (ursodiol) therapy.
Conclusions: The goals of Stages 1 and 2 of the ceftriaxone trial were successfully achieved. Based on the pre-specified decision rules, the DSMB recommended the use of ceftriaxone 4 g/d (divided BID) for Stage 3, which recently closed.
C1 [Berry, James D.; Krivickas, Lisa; David, William S.; Cudkowicz, Merit E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurol Clin Res Inst, Boston, MA 02115 USA.
[Shefner, Jeremy M.; Vriesendorp, Francine] SUNY Upstate Med Univ, Dept Neurol, Syracuse, NY 13210 USA.
[Conwit, Robin] Natl Inst Neurol Disorders & Stroke, Bethesda, MD USA.
[Schoenfeld, David] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA.
[Keroack, Myles] Marshfield Clin Fdn Med Res & Educ, Dept Gastroenterol, Eau Claire, WI USA.
[Felsenstein, Donna] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Infect Dis Unit,Dept Med, Boston, MA USA.
[Pestronk, Alan] Washington Univ, Dept Neurol, St Louis, MO USA.
[Caress, James B.] Wake Forest Univ, Dept Neurol, Winston Salem, NC 27109 USA.
[Katz, Jonathan] Calif Pacific Med Ctr, Dept Neurol, San Francisco, CA USA.
[Simpson, Ericka] Methodist Neurol Inst, Dept Neurol, Houston, TX USA.
[Rosenfeld, Jeffrey] Univ Calif San Francisco, Inst Neurosci, Dept Neurol, Fresno, CA USA.
[Pascuzzi, Robert] Indiana Univ, Dept Neurol, Indianapolis, IN 46204 USA.
[Glass, Jonathan] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA.
[Rezania, Kourosh] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA.
[Rothstein, Jeffrey D.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA.
[Greenblatt, David J.] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA.
RP Berry, JD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurol Clin Res Inst, Boston, MA 02115 USA.
EM jdberry@partners.org
OI Caress, James/0000-0002-5814-6083
FU National Institute of Neurological Disorders and Stroke (NINDS),
National Institutes of Health [U01 NS049640-05]; Institute of Clinical
and Translational Sciences [UL1 TR000448]; Muscular Dystrophy
Association; ALS Association; ALS Therapy Alliance; Cytokinetics; Biogen
Idec; Sanofi Aventis; Neuraltus; AstraZeneca; Roche; CytRx; ISIS;
Euroimmune; Allere; Focus; Biokit; BioRad; Diasorin; Chronic Fatigue
Initiative; National Institutes of Health; Neuromuscular Research Fund;
Insmed; Knopp; Genzyme; GSK; Ultragenyx Sanofi; National Institute of
Neurological Disorders and Stroke; Department of Defense; P2ALS; Robert
Packard Center for ALS Research at Johns Hopkins
FX Support for this research was provided by a grant from the National
Institute of Neurological Disorders and Stroke (NINDS), National
Institutes of Health (U01 NS049640-05) and from the Institute of
Clinical and Translational Sciences (UL1 TR000448). The funders (NINDS)
were involved in data and safety monitoring throughout the trial and
approved safety analysis plans. They did not have a role in the decision
to publish. RC is an employee of NINDS and was involved in the
preparation of the manuscript.; JDB has served as a consultant to Biogen
Idec and as a paid speaker for Oakstone Publishing. He receives research
report from the Muscular Dystrophy Association and ALS Therapy Alliance.
JMS has served as a consultant to Biogen Idec, Cytokinetics, Trophos,
ISIS, Glaxo Smith Kline, and receives research support from the Muscular
Dystrophy Association, ALS Association, ALS Therapy Alliance,
Cytokinetics, Biogen Idec, Sanofi Aventis, Neuraltus. RC is employed at
the National Institute of Neurological Disorders and Stroke. DS, over
the last 24 months, has served as a biostatistical consultant to
Averion, Inc, Gerson Lehrman Group, Guidepoint Global, Neuronova,
Cytokinetics, Glaxo Smith Kline, Merck, Aggennix, Pfizer, Biogen Idec,
and Elan. He has received research support from AstraZeneca, Roche,
CytRx, and ISIS. MK has no relevant disclosures to report. DF has
received research funds from Euroimmune, Allere, Focus, Biokit, BioRad
and Diasorin, Chronic Fatigue Initiative. LK has no relevant disclosures
to report. WSD has no relevant disclosures to report. FV has no relevant
disclosures to report. AP receives revenue related to antibody patent
licenses from Athena; owns stock in Johnson & Johnson; directs the
Washington University Neuromuscular Clinical Laboratory which performs
antibody testing; and receives research support from the National
Institutes of Health, Muscular Dystrophy Association, Neuromuscular
Research Fund, Insmed, Knopp, Cytokinetics, Biogen Idec, ISIS, Genzyme,
GSK, Ultragenyx & Sanofi. JBC has no relevant disclosures to report. JK
has no relevant disclosures to report. ES has no relevant disclosures to
report. JR has served on scientific advisory boards and/or as a
consultant for Hill-ROM Inc, Cytokinetics and Avanir Pharmaceuticals. RP
has no relevant disclosures to report. JG receives research support from
the Muscular Dystrophy Association and from the National Institute of
Neurological Disorders and Stroke. KR has no relevant disclosures to
report. JR has research funding from National Institutes of Health,
Department of Defense, P2ALS, Muscular Dystrophy Association, Robert
Packard Center for ALS Research at Johns Hopkins. He has acted as a
consultant to Biogen Idec, Cytokinetics and Psyadon Pharmaceuticals,
Inc. DJG has no relevant disclosures to report. MEC served on DSMB for
Synapse and Trophos and was a consultant for TEVA, Millenium,
GlaxoSmithKline and Biogen. This does not alter the authors' adherence
to all the PLOS ONE policies on sharing data and materials.
NR 30
TC 39
Z9 39
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 17
PY 2013
VL 8
IS 4
AR e61177
DI 10.1371/journal.pone.0061177
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130IK
UT WOS:000317907200036
PM 23613806
ER
PT J
AU Lane, RF
Steele, JW
Cai, DM
Ehrlich, ME
Attie, AD
Gandy, S
AF Lane, Rachel F.
Steele, John W.
Cai, Dongming
Ehrlich, Michelle E.
Attie, Alan D.
Gandy, Sam
TI Protein Sorting Motifs in the Cytoplasmic Tail of SorCS1 Control
Generation of Alzheimer's Amyloid-beta Peptide
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID PRECURSOR PROTEIN; RETROMER COMPLEX; DOWN-SYNDROME; DISEASE; VARIANTS;
SORL1; TRAFFICKING; ASSOCIATION; RECEPTOR; NEURODEGENERATION
AB Endosomal sorting of the Alzheimer amyloid precursor protein (APP) plays a key role in the biogenesis of the amyloid-beta (A beta) peptide. Genetic lesions underlying Alzheimer's disease (AD) can act by interfering with this physiological process. Specifically, proteins involved in trafficking between endosomal compartments and the trans-Golgi network (TGN) [including the retromer complex (Vps35, Vps26) and its putative receptors (sortilin, SorL1, SorCS1)] have been implicated in the molecular pathology of late-onset AD. Previously, we demonstrated a role for SorCS1 in APP metabolism and A beta production and, while we implicated a role for the retromer in this regulation, the underlying mechanism remained poorly understood. Here, we provide evidence for a motif within the SorCS1c cytoplasmic tail that, when manipulated, results in perturbed sorting of APP and/or its fragments to endosomal compartments, decreased retrograde TGN trafficking, and increased A beta production in H4 neuroglioma cells. These perturbations apparently do not involve turnover of the cell surface APP pool, but rather they involve intracellular APP and/or its fragments, downstream of APP endocytosis.
C1 [Lane, Rachel F.; Steele, John W.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Neurol & Psychiat, New York, NY 10029 USA.
[Lane, Rachel F.; Steele, John W.; Gandy, Sam] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA.
[Lane, Rachel F.] Alzheimers Drug Discovery Fdn, New York, NY 10019 USA.
[Steele, John W.] Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA.
[Ehrlich, Michelle E.] Mt Sinai Sch Med, Dept Pediat & Neurol, New York, NY 10029 USA.
[Attie, Alan D.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.
[Cai, Dongming; Gandy, Sam] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
RP Lane, RF (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol & Psychiat, 1 Gustave L Levy Pl, New York, NY 10029 USA.
EM rlane@alzdiscovery.org; Samuel.gandy@mssm.edu
FU National Institutes of Health (NIH) [NS075685]; Cure Alzheimer's Fund;
U.S. Department of Veterans Affairs; National Institute of Diabetes and
Digestive and Kidney Diseases [DK58037, DK66369]; American Diabetes
Association Research Award; National Institute of General Medical
Sciences [T32GM062754]; NIH-National Cancer Institute [5R24
CA095823-04]; National Science Foundation [DBI-9724504]; NIH Shared
Instrumentation Grant [1 S10 RR0 9145-01]
FX This research was supported by National Institutes of Health (NIH) Grant
NS075685 (to S. G.), the Cure Alzheimer's Fund (to S. G.), the U.S.
Department of Veterans Affairs (to S. G.), National Institute of
Diabetes and Digestive and Kidney Diseases Grants DK58037 and DK66369
(to A. D. A.), and an American Diabetes Association Research Award (to
M. E. E). J.W.S. was a trainee in the Integrated Pharmacological
Sciences Training Program supported by Grant T32GM062754 from the
National Institute of General Medical Sciences to Terry Krulwich (Icahn
School of Medicine at Mount Sinai). Confocal laser scanning microscopy
was performed at the Icahn School of Medicine at Mount Sinai Microscopy
Shared Resource Facility, supported with funding from NIH-National
Cancer Institute Shared Resources Grant 5R24 CA095823-04, National
Science Foundation Major Research Instrumentation Grant DBI-9724504, and
NIH Shared Instrumentation Grant 1 S10 RR0 9145-01. We thank Rudolph E.
Tanzi for cDNA constructs.
NR 35
TC 15
Z9 15
U1 0
U2 11
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD APR 17
PY 2013
VL 33
IS 16
BP 7099
EP 7107
DI 10.1523/JNEUROSCI.5270-12.2013
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 127TZ
UT WOS:000317723000040
PM 23595767
ER
PT J
AU Hassol, A
Biddinger, P
Zane, R
AF Hassol, Andrea
Biddinger, Paul
Zane, Richard
TI Hospital Evacuation Decisions in Emergency Situations
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Hassol, Andrea] ABT Associates Inc, Cambridge, MA 02138 USA.
[Biddinger, Paul] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Zane, Richard] Univ Colorado, Sch Med, Dept Emergency Med, Denver, CO USA.
RP Hassol, A (reprint author), ABT Associates Inc, Cambridge, MA 02138 USA.
EM an-drea_hassol@abtassoc.com
RI bebarta, vikhyat/K-3476-2015
NR 3
TC 2
Z9 2
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 17
PY 2013
VL 309
IS 15
BP 1585
EP 1586
DI 10.1001/jama.2013.2470
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 126FY
UT WOS:000317599500015
PM 23592100
ER
PT J
AU Eappen, S
Lane, BH
Rosenberg, B
Lipsitz, SA
Sadoff, D
Matheson, D
Berry, WR
Lester, M
Gawande, AA
AF Eappen, Sunil
Lane, Bennett H.
Rosenberg, Barry
Lipsitz, Stuart A.
Sadoff, David
Matheson, Dave
Berry, William R.
Lester, Mark
Gawande, Atul A.
TI Relationship Between Occurrence of Surgical Complications and Hospital
Finances
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID QUALITY IMPROVEMENT PROGRAM; LENGTH-OF-STAY; POSTOPERATIVE
COMPLICATIONS; SAFETY CHECKLIST; ADVERSE EVENTS; RISK-FACTORS; SURGERY;
COSTS; PERFORMANCE; MORTALITY
AB Importance The effect of surgical complications on hospital finances is unclear.
Objective To determine the relationship between major surgical complications and per-encounter hospital costs and revenues by payer type.
Design, Setting, and Participants Retrospective analysis of administrative data for all inpatient surgical discharges during 2010 from a nonprofit 12-hospital system in the southern United States. Discharges were categorized by principal procedure and occurrence of 1 or more postsurgical complications, using International Classification of Diseases, Ninth Revision, diagnosis and procedure codes. Nine common surgical procedures and 10 major complications across 4 payer types were analyzed. Hospital costs and revenue at discharge were obtained from hospital accounting systems and classified by payer type.
Main Outcomes and Measures Hospital costs, revenues, and contribution margin (defined as revenue minus variable expenses) were compared for patients with and without surgical complications according to payer type.
Results Of 34 256 surgical discharges, 1820 patients (5.3%; 95% CI, 4.4%-6.4%) experienced 1 or more postsurgical complications. Compared with absence of complications, complications were associated with a $39 017 (95% CI, $20 069-$50 394; P<.001) higher contribution margin per patient with private insurance ($55 953 vs $16 936) and a $1749 (95% CI, $976-$3287; P<.001) higher contribution margin per patient with Medicare ($3629 vs $1880). For this hospital system in which private insurers covered 40% of patients (13 544), Medicare covered 45% (15 406), Medicaid covered 4% (1336), and self-payment covered 6% (2202), occurrence of complications was associated with an $8084 (95% CI, $4903-$9740; P<.001) higher contribution margin per patient ($15 726 vs $7642) and with a $7435 lower per-patient total margin (95% CI, $5103-$10 507; P<.001) ($1013 vs -$6422).
Conclusions and Relevance In this hospital system, the occurrence of postsurgical complications was associated with a higher per-encounter hospital contribution margin for patients covered by Medicare and private insurance but a lower one for patients covered by Medicaid and who self-paid. Depending on payer mix, many hospitals have the potential for adverse near-term financial consequences for decreasing postsurgical complications. JAMA. 2013;309(15):1599-1606 www.jama.com
C1 [Eappen, Sunil] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02115 USA.
[Lane, Bennett H.; Rosenberg, Barry; Sadoff, David; Matheson, Dave] Boston Consulting Grp Inc, Boston, MA USA.
[Lipsitz, Stuart A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Surg & Publ Hlth, Boston, MA 02115 USA.
[Berry, William R.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Lester, Mark] Texas Hlth Resources, Arlington, TX USA.
[Gawande, Atul A.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Gawande, Atul A.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Gawande, AA (reprint author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave,Kresge Bldg,Room 400, Boston, MA 02115 USA.
EM agawande@hsph.harvard.edu
OI Gawande, Atul/0000-0002-1824-9176
FU Boston Consulting Group; Texas Health Resources
FX This research was supported by funding from the Boston Consulting Group
and Texas Health Resources.
NR 48
TC 67
Z9 69
U1 0
U2 17
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 17
PY 2013
VL 309
IS 15
BP 1599
EP 1606
DI 10.1001/jama.2013.2773
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 126FY
UT WOS:000317599500023
PM 23592104
ER
PT J
AU Weiner, SJ
Schwartz, A
Sharma, G
Binns-Calvey, A
Ashley, N
Kelly, B
Dayal, A
Patel, S
Weaver, FM
Harris, I
AF Weiner, Saul J.
Schwartz, Alan
Sharma, Gunjan
Binns-Calvey, Amy
Ashley, Naomi
Kelly, Brendan
Dayal, Amit
Patel, Sonal
Weaver, Frances M.
Harris, Ilene
TI Patient-Centered Decision Making and Health Care Outcomes An
Observational Study
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID INTERACTION ANALYSIS SYSTEM; CONTEXTUAL ERRORS; COMMUNICATION
AB Background: Patient-centered decision making (PCDM) is the process of identifying clinically relevant, patient-specific circumstances and behaviors to formulate a contextually appropriate care plan.
Objective: To ascertain whether encounters in which PCDM occurs are followed by improved health care outcomes compared with encounters where there is inattention to patient context.
Design: Patients surreptitiously audio-recorded encounters with their physicians. Medical records of these encounters were then screened for "contextual red flags," such as deteriorating self-management of a chronic condition, that could reflect such underlying contextual factors as competing responsibilities or loss of social support. When a contextual factor was identified, either as a result of physician questioning or because a patient volunteered information, physicians were scored on the basis of whether they adapted the care plan to it.
Setting: Internal medicine clinics at 2 Veterans Affairs facilities.
Participants: 774 patients audio-recorded encounters with 139 resident physicians.
Measurements: Individualized outcome measures were based on the contextual red flag, such as improved blood pressure control in a patient presenting with hypertension and loss of medication coverage. Outcome coders were blinded to physician performance.
Results: Among 548 contextual red flags, 208 contextual factors were confirmed, either when physicians probed or patients volunteered information. Physician attention to contextual factors (both probing for them and addressing them in care plans) varied according to the presenting contextual red flags. Outcome data were available for 157 contextual factors, of which PCDM was found to address 96. Of these, health care outcomes improved in 68 (71%), compared with 28 (46%) of the 61 that were not addressed by PCDM (P = 0.002).
Limitation: The extent to which the findings can be generalized to other clinical settings is unknown.
Conclusion: Attention to patient needs and circumstances when planning care is associated with improved health care outcomes.
C1 Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA.
[Weiner, Saul J.] Univ Illinois, Chicago, IL 60607 USA.
US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
Durham Vet Affairs Med Ctr, Durham, NC USA.
RP Weiner, SJ (reprint author), Univ Illinois, 2730 UH MC 103,601 South Morgan, Chicago, IL 60607 USA.
EM sweiner@uic.edu
OI Schwartz, Alan/0000-0003-3809-6637
FU U.S. Department of Veterans Affairs, Health Services Research &
Development Service
FX U.S. Department of Veterans Affairs, Health Services Research &
Development Service.
NR 15
TC 42
Z9 43
U1 2
U2 22
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 16
PY 2013
VL 158
IS 8
BP 573
EP +
DI 10.7326/0003-4819-158-8-201304160-00001
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 132IW
UT WOS:000318062100013
PM 23588745
ER
PT J
AU Martinez, ME
Ahnen, D
Greenberg, ER
AF Martinez, Maria Elena
Ahnen, Dennis
Greenberg, E. Robert
TI One-Year Risk for Advanced Colorectal Neoplasia RESPONSE
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Martinez, Maria Elena] Moores Canc Ctr, La Jolla, CA USA.
[Martinez, Maria Elena] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.
[Ahnen, Dennis] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Ahnen, Dennis] Univ Colorado, Sch Med, Denver, CO USA.
[Greenberg, E. Robert] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
RP Martinez, ME (reprint author), Moores Canc Ctr, La Jolla, CA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 16
PY 2013
VL 158
IS 8
BP 639
EP 639
DI 10.7326/0003-4819-158-8-201304160-00019
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 132IW
UT WOS:000318062100028
PM 23588762
ER
PT J
AU Zhu, J
Ofek, G
Yang, YP
Zhang, BS
Louder, MK
Lu, G
McKee, K
Pancera, M
Skinner, J
Zhang, ZH
Parks, R
Eudailey, J
Lloyd, KE
Blinn, J
Alam, SM
Haynes, BF
Simek, M
Burton, DR
Koff, WC
Mullikin, JC
Mascola, JR
Shapiro, L
Kwong, PD
AF Zhu, Jiang
Ofek, Gilad
Yang, Yongping
Zhang, Baoshan
Louder, Mark K.
Lu, Gabriel
McKee, Krisha
Pancera, Marie
Skinner, Jeff
Zhang, Zhenhai
Parks, Robert
Eudailey, Joshua
Lloyd, Krissey E.
Blinn, Julie
Alam, S. Munir
Haynes, Barton F.
Simek, Melissa
Burton, Dennis R.
Koff, Wayne C.
Mullikin, James C.
Mascola, John R.
Shapiro, Lawrence
Kwong, Peter D.
CA NISC Comparative Sequencing Progra
TI Mining the antibodyome for HIV-1-neutralizing antibodies with
next-generation sequencing and phylogenetic pairing of heavy/light
chains
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE antibody-affinity maturation; antibodyomics; B-cell ontogeny; DNA
sequencing; immunological tolerance
ID NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODIES; HIV-1; BROAD;
IDENTIFICATION; TECHNOLOGIES; INDIVIDUALS; CARDIOLIPIN; REPERTOIRE;
SELECTION
AB Next-generation sequencing of antibody transcripts from HIV-1-infected individuals with broadly neutralizing antibodies could provide an efficient means for identifying somatic variants and characterizing their lineages. Here, we used 454 pyrosequencing and identity/divergence grid sampling to analyze heavy- and light-chain sequences from donor N152, the source of the broadly neutralizing antibody 10E8. We identified variants with up to 28% difference in amino acid sequence. Heavy- and light-chain phylogenetic trees of identified 10E8 variants displayed similar architectures, and 10E8 variants reconstituted from matched and unmatched phylogenetic branches displayed significantly lower autoreactivity when matched. To test the generality of phylogenetic pairing, we analyzed donor International AIDS Vaccine Initiative 84, the source of antibodies PGT141-145. Heavy- and light-chain phylogenetic trees of PGT141-145 somatic variants also displayed remarkably similar architectures; in this case, branch pairings could be anchored by known PGT141-145 antibodies. Altogether, our findings suggest that phylogenetic matching of heavy and light chains can provide a means to approximate natural pairings.
C1 [Zhu, Jiang; Ofek, Gilad; Yang, Yongping; Zhang, Baoshan; Louder, Mark K.; Lu, Gabriel; McKee, Krisha; Pancera, Marie; Mascola, John R.; Shapiro, Lawrence; Kwong, Peter D.] NHGRI, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
[Skinner, Jeff] NHGRI, Bioinformat & Computat Biosci Branch, Off Cyber Infrastruct & Computat Biol, NIH, Bethesda, MD 20892 USA.
[Mullikin, James C.; NISC Comparative Sequencing Progra] NHGRI, NIH, Intramural Sequencing Ctr, Bethesda, MD 20892 USA.
[Zhang, Zhenhai; Shapiro, Lawrence] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA.
[Parks, Robert; Eudailey, Joshua; Lloyd, Krissey E.; Blinn, Julie; Alam, S. Munir; Haynes, Barton F.] Duke Univ, Med Ctr, Duke Human Vaccine Inst, Durham, NC USA.
[Simek, Melissa; Koff, Wayne C.] IAVI, New York, NY 10004 USA.
[Zhu, Jiang; Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
[Zhu, Jiang; Burton, Dennis R.] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA.
[Burton, Dennis R.] Massachusetts Gen Hosp, MIT, Ragon Inst, Cambridge, MA 02139 USA.
[Burton, Dennis R.] Harvard, Cambridge, MA 02139 USA.
RP Shapiro, L (reprint author), NHGRI, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
EM lss8@columbia.edu; pdkwong@nih.gov
OI Skinner, Jeff/0000-0001-5697-0442
FU Vaccine Research Center, National Institute of Allergy and Infectious
Diseases; National Human Genome Research Institute, National Institutes
of Health; International AIDS Vaccine Initiative; Center for HIV/AIDS
Vaccine Immunology-Immunogen Design, Division of AIDS, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health [UM1 AI100645]
FX We thank H. Coleman, M. Park, B. Schmidt, and A. Young for 454
pyrosequencing at the National Institutes of Health Intramural
Sequencing Center (NISC); J. Huang, L. Laub, and M. Connors for donor
N152 materials and sequence of 10E8; J. Stuckey for assistance with
figures; and Rahul Kohli and members of the Structural Biology Section
and Structural Bioinformatics Core, Vaccine Research Center, for
discussions or comments on the manuscript. Support for this work was
provided by the Intramural Research Program of the Vaccine Research
Center, National Institute of Allergy and Infectious Diseases; the
National Human Genome Research Institute, National Institutes of Health;
the International AIDS Vaccine Initiative; and Center for HIV/AIDS
Vaccine Immunology-Immunogen Design Grant UM1 AI100645 (to B.F.H.) from
the Division of AIDS, National Institute of Allergy and Infectious
Diseases, National Institutes of Health.
NR 29
TC 58
Z9 58
U1 1
U2 31
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 16
PY 2013
VL 110
IS 16
BP 6470
EP 6475
DI 10.1073/pnas.1219320110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 132BA
UT WOS:000318041500054
PM 23536288
ER
PT J
AU Xu, J
Bauer, DE
Kerenyi, MA
Vo, TD
Hou, S
Hsu, YJ
Yao, HL
Trowbridge, JJ
Mandel, G
Orkin, SH
AF Xu, Jian
Bauer, Daniel E.
Kerenyi, Marc A.
Vo, Thuy D.
Hou, Serena
Hsu, Yu-Jung
Yao, Huilan
Trowbridge, Jennifer J.
Mandel, Gail
Orkin, Stuart H.
TI Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE gene regulation; globin switching; hematopoiesis
ID SICKLE-CELL-DISEASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; DEMETHYLASE
1; GAMMA-GLOBIN; MICE; DIFFERENTIATION; ELEMENT; TARGET; STEM
AB Reactivation of fetal hemoglobin (HbF) in adults ameliorates the severity of the common beta-globin disorders. The transcription factor BCL11A is a critical modulator of hemoglobin switching and HbF silencing, yet the molecular mechanism through which BCL11A coordinates the developmental switch is incompletely understood. Particularly, the identities of BCL11A cooperating protein complexes and their roles in HbF expression and erythroid development remain largely unknown. Here we determine the interacting partner proteins of BCL11A in erythroid cells by a proteomic screen. BCL11A is found within multiprotein complexes consisting of erythroid transcription factors, transcriptional corepressors, and chromatin-modifying enzymes. We show that the lysine-specific demethylase 1 and repressor element-1 silencing transcription factor corepressor 1 (LSD1/CoREST) histone demethylase complex interacts with BCL11A and is required for full developmental silencing of mouse embryonic beta-like globin genes and human gamma-globin genes in adult erythroid cells in vivo. In addition, LSD1 is essential for normal erythroid development. Furthermore, the DNA methyltransferase 1 (DNMT1) is identified as a BCL11A-associated protein in the proteomic screen. DNMT1 is required to maintain HbF silencing in primary human adult erythroid cells. DNMT1 haploinsufficiency combined with BCL11A deficiency further enhances gamma-globin expression in adult animals. Our findings provide important insights into the mechanistic roles of BCL11A in HbF silencing and clues for therapeutic targeting of BCL11A in beta-hemoglobinopathies.
C1 [Xu, Jian; Bauer, Daniel E.; Kerenyi, Marc A.; Vo, Thuy D.; Hou, Serena; Hsu, Yu-Jung; Trowbridge, Jennifer J.; Orkin, Stuart H.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Xu, Jian; Bauer, Daniel E.; Kerenyi, Marc A.; Vo, Thuy D.; Hou, Serena; Hsu, Yu-Jung; Trowbridge, Jennifer J.; Orkin, Stuart H.] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Dana Farber Canc Inst,Dept Pediat Oncol, Boston, MA 02115 USA.
[Yao, Huilan; Mandel, Gail] Oregon Hlth & Sci Univ, Howard Hughes Med Inst, Vollum Inst, Portland, OR 97239 USA.
[Orkin, Stuart H.] Howard Hughes Med Inst, Boston, MA 02115 USA.
RP Orkin, SH (reprint author), Harvard Univ, Sch Med, Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
EM stuart_orkin@dfci.harvard.edu
FU National Institutes of Health; National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK); NIDDK [K01DK093543]
FX We thank K. Peterson for providing beta-YAC mice. We thank D.R. Higgs,
D.A. Williams, L.I. Zon, A.B. Cantor, V.G. Sankaran, H. Huang, and A.
Woo for helpful advice and discussions. This work was supported by
funding from the National Institutes of Health (to S.H.O. and G.M.),
including a Center of Excellence in Molecular Hematology Award from the
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
(to S.H.O.). S.H.O. and G.M. are Investigators of the Howard Hughes
Medical Institute (HHMI). J.X. is an HHMI-Helen Hay Whitney Foundation
fellow and is supported by NIDDK Career Development Award K01DK093543.
NR 29
TC 51
Z9 51
U1 2
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 16
PY 2013
VL 110
IS 16
BP 6518
EP 6523
DI 10.1073/pnas.1303976110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 132BA
UT WOS:000318041500062
PM 23576758
ER
PT J
AU Zhang, GD
Panigrahy, D
Mahakian, LM
Yang, J
Liu, JY
Lee, KSS
Wettersten, HI
Ulu, A
Hu, XW
Tam, S
Hwang, SH
Ingham, ES
Kieran, MW
Weiss, RH
Ferrara, KW
Hammock, BD
AF Zhang, Guodong
Panigrahy, Dipak
Mahakian, Lisa M.
Yang, Jun
Liu, Jun-Yan
Lee, Kin Sing Stephen
Wettersten, Hiromi I.
Ulu, Arzu
Hu, Xiaowen
Tam, Sarah
Hwang, Sung Hee
Ingham, Elizabeth S.
Kieran, Mark W.
Weiss, Robert H.
Ferrara, Katherine W.
Hammock, Bruce D.
TI Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis,
tumor growth, and metastasis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID POLYUNSATURATED FATTY-ACIDS; BREAST-CANCER; MACULAR DEGENERATION;
IN-VIVO; FISH CONSUMPTION; CYTOCHROME-P450; CARCINOMA; HYDROLASE; VEGF;
RISK
AB Epidemiological and preclinical evidence supports that omega-3 dietary fatty acids (fish oil) reduce the risks of macular degeneration and cancers, but the mechanisms by which these omega-3 lipids inhibit angiogenesis and tumorigenesis are poorly understood. Here we show that epoxydocosapentaenoic acids (EDPs), which are lipid mediators produced by cytochrome P450 epoxygenases from omega-3 fatty acid docosahexaenoic acid, inhibit VEGF- and fibroblast growth factor 2-induced angiogenesis in vivo, and suppress endothelial cell migration and protease production in vitro via a VEGF receptor 2-dependent mechanism. When EDPs (0.05 mg.kg(-1).d(-1)) are coadministered with a low-dose soluble epoxide hydrolase inhibitor, EDPs are stabilized in circulation, causing similar to 70% inhibition of primary tumor growth and metastasis. Contrary to the effects of EDPs, the corresponding metabolites derived from omega-6 arachidonic acid, epoxyeicosatrienoic acids, increase angiogenesis and tumor progression. These results designate epoxyeicosatrienoic acids and EDPs as unique endogenous mediators of an angiogenic switch to regulate tumorigenesis and implicate a unique mechanistic linkage between omega-3 and omega-6 fatty acids and cancers.
C1 [Zhang, Guodong; Yang, Jun; Liu, Jun-Yan; Lee, Kin Sing Stephen; Ulu, Arzu; Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA.
[Zhang, Guodong; Yang, Jun; Liu, Jun-Yan; Lee, Kin Sing Stephen; Ulu, Arzu; Hwang, Sung Hee; Weiss, Robert H.; Hammock, Bruce D.] Univ Calif Davis, Ctr Comprehens Canc, Davis, CA 95616 USA.
[Panigrahy, Dipak; Kieran, Mark W.] Harvard Univ, Sch Med, Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA.
[Panigrahy, Dipak] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA.
[Mahakian, Lisa M.; Hu, Xiaowen; Tam, Sarah; Ingham, Elizabeth S.; Ferrara, Katherine W.] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.
[Wettersten, Hiromi I.; Weiss, Robert H.] Univ Calif Davis, Dept Internal Med, Div Nephrol, Davis, CA 95616 USA.
[Kieran, Mark W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Pediat Oncol, Boston, MA 02115 USA.
[Weiss, Robert H.] US Dept Vet Affairs, Med Ctr, Sacramento, CA 95655 USA.
RP Hammock, BD (reprint author), Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA.
EM bdhammock@ucdavis.edu
RI Hu, Xiaowen/I-5997-2013; Liu, Jun-Yan/D-8890-2014; Yang,
Jun/B-2262-2010; Lee, Kin Sing Stephen/I-9476-2012;
OI Hu, Xiaowen/0000-0002-4295-0747; Yang, Jun/0000-0002-4630-3838; Lee, Kin
Sing Stephen/0000-0003-4541-3063; Kieran, Mark/0000-0003-2184-7692;
Zhang, Guodong/0000-0001-7780-5470; Ferrara,
Katherine/0000-0002-4976-9107
FU National Institute on Environmental Health Sciences [P42 ES04699, R01
CA134659, R01 CA103828]; University of California Davis; Stop and Shop
Pediatric Brain Tumor Fund; C.J. Buckley Pediatric Brain Tumor Fund;
Medical Service of the US Department of Veterans' Affairs; [R01
ES02710]; [R01 CA148633]; [R01 CA135401]; [R01 DK082690]
FX We thank R. Isseroff and H. Yang for microscopy, Y. Wang for ELISA, B.
Inceoglu and K. Nithipatikom for discussions, and A. Kheirolomoom and J.
Yang for technical assistance. We acknowledge support from R01 ES02710
and National Institute on Environmental Health Sciences Superfund P42
ES04699 (to B.D.H.); R01 CA134659, R01 CA103828, and Research
Investments in the Sciences and Engineering (RISE) Program of University
of California Davis (K.W.F.); R01 CA148633 (to D.P.); Stop and Shop
Pediatric Brain Tumor Fund and the C.J. Buckley Pediatric Brain Tumor
Fund (M.W.K.); and R01 CA135401, R01 DK082690, and the Medical Service
of the US Department of Veterans' Affairs (R.H.W.). B.D.H. is a George
and Judy Marcus Senior Fellow of the American Asthma Society.
NR 51
TC 87
Z9 89
U1 2
U2 53
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 16
PY 2013
VL 110
IS 16
BP 6530
EP 6535
DI 10.1073/pnas.1304321110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 132BA
UT WOS:000318041500064
PM 23553837
ER
PT J
AU Rardin, MJ
Newman, JC
Held, JM
Cusack, MP
Sorensen, DJ
Li, BA
Schilling, B
Mooney, SD
Kahn, CR
Verdin, E
Gibson, BW
AF Rardin, Matthew J.
Newman, John C.
Held, Jason M.
Cusack, Michael P.
Sorensen, Dylan J.
Li, Biao
Schilling, Birgit
Mooney, Sean D.
Kahn, C. Ronald
Verdin, Eric
Gibson, Bradford W.
TI Label-free quantitative proteomics of the lysine acetylome in
mitochondria identifies substrates of SIRT3 in metabolic pathways
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID ALPHA-KETOGLUTARATE-DEHYDROGENASE; FATTY-ACID OXIDATION; CALORIE
RESTRICTION; PROTEIN ACETYLATION; STRESS; DEACETYLATION;
NEURODEGENERATION; QUANTIFICATION; OPPOSES; CYCLE
AB Large-scale proteomic approaches have identified numerous mitochondrial acetylated proteins; however in most cases, their regulation by acetyltransferases and deacetylases remains unclear. Sirtuin 3 (SIRT3) is an NAD(+)-dependent mitochondrial protein deacetylase that has been shown to regulate a limited number of enzymes in key metabolic pathways. Here, we use a rigorous label-free quantitative MS approach (called MS1 Filtering) to analyze changes in lysine acetylation from mouse liver mitochondria in the absence of SIRT3. Among 483 proteins, a total of 2,187 unique sites of lysine acetylation were identified after affinity enrichment. MS1 Filtering revealed that lysine acetylation of 283 sites in 136 proteins was significantly increased in the absence of SIRT3 (at least twofold). A subset of these sites was independently validated using selected reaction monitoring MS. These data show that SIRT3 regulates acetylation on multiple proteins, often at multiple sites, across several metabolic pathways including fatty acid oxidation, ketogenesis, amino acid catabolism, and the urea and tricarboxylic acid cycles, as well as mitochondrial regulatory proteins. The widespread modification of key metabolic pathways greatly expands the number of known substrates and sites that are targeted by SIRT3 and establishes SIRT3 as a global regulator of mitochondrial protein acetylation with the capability of coordinating cellular responses to nutrient status and energy homeostasis.
C1 [Rardin, Matthew J.; Held, Jason M.; Cusack, Michael P.; Sorensen, Dylan J.; Li, Biao; Schilling, Birgit; Mooney, Sean D.; Gibson, Bradford W.] Buck Inst Res Aging, Novato, CA 94945 USA.
[Newman, John C.; Verdin, Eric] Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA.
[Newman, John C.; Verdin, Eric] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA.
[Kahn, C. Ronald] Harvard Univ, Sch Med, Joslin Diabet Ctr, Dept Med, Boston, MA 02215 USA.
RP Kahn, CR (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Dept Med, Boston, MA 02215 USA.
EM c.ronald.kahn@joslin.harvard.edu; bgibson@buckinstitute.org
RI Newman, John/L-8112-2013;
OI Verdin, Eric/0000-0003-3703-3183; Held, Jason/0000-0001-8024-2736
FU National Institutes of Health [T32AG000266, PL1 AG032118, R24 DK085610];
Shared Instrumentation Grant [S10 RR024615]
FX This work was supported by National Institutes of Health Grants
T32AG000266 (to M.J.R.), PL1 AG032118 (to B. W. G.), and R24 DK085610
(to E. V.). This work was also supported in part by the Shared
Instrumentation Grant S10 RR024615 (to B. W. G.) and the generous access
of a TripleTOF 5600 by AB SCIEX at the Buck Institute.
NR 37
TC 130
Z9 422
U1 6
U2 81
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 16
PY 2013
VL 110
IS 16
BP 6601
EP 6606
DI 10.1073/pnas.1302961110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 132BA
UT WOS:000318041500076
PM 23576753
ER
PT J
AU Gaweska, HM
Taylor, AB
Hart, PJ
Fitzpatrick, PF
AF Gaweska, Helena M.
Taylor, Alexander B.
Hart, P. John
Fitzpatrick, Paul F.
TI Structure of the Flavoprotein Tryptophan 2-Monooxygenase, a Key Enzyme
in the Formation of Galls in Plants
SO BIOCHEMISTRY
LA English
DT Article
ID MONOAMINE-OXIDASE-B; MAIZE POLYAMINE OXIDASE; L-PHENYLALANINE OXIDASE;
CONSERVED ACTIVE-SITE; PSEUDOMONAS SP P-501; AMINO-ACID OXIDASE;
CROWN-GALL; CRYSTAL-STRUCTURE; CATALYTIC MECHANISM; INDOLEACETIC-ACID
AB The flavoprotein tryptophan 2-monooxygenase catalyzes the oxidative decarboxylation of tryptophan to yield indole-3-acetamide. This is the initial step in the biosynthesis of the plant growth hormone indole-acetic acid by bacterial pathogens that cause crown gall and related diseases. The structure of the enzyme from Pseudomonas savastanoi has been determined by X-ray diffraction methods to a resolution of 1.95 A. The overall structure of the protein shows that it has the same fold as members of the monoamine oxidase family of flavoproteins, with the greatest similarities to the L-amino acid oxidases. The location of bound indole-3-acetamide in the active site allows identification of residues responsible for substrate binding and specificity. Two residues in the enzyme are conserved in all members of the monoamine oxidase family, Lys365 and Trp466. The K365M mutation decreases the k(cat) and k(cat)/K-Trp values by 60000- and 2 million-fold, respectively. The deuterium kinetic isotope effect increases to 3.2, consistent with carbon-hydrogen bond cleavage becoming rate-limiting in the mutant enzyme. The W466F mutation decreases the k(cat) value <2-fold and the k(cat)/K-Trp, value only 5-fold, while the W466M mutation results in an enzyme lacking Flavin and detectable activity. This is consistent with a role for Trp466 in maintaining the structure of the flavin-binding site in the more conserved FAD domain.
C1 [Gaweska, Helena M.; Taylor, Alexander B.; Hart, P. John; Fitzpatrick, Paul F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, Audie Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
RP Fitzpatrick, PF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
EM fitzpatrick@biochem.uthscsa.edu
FU National Institutes of Health [R01 GM058698, F32 GM097762]; Welch
Foundation [AQ-1399]
FX This work was supported in part by National Institutes of Health Grants
R01 GM058698 to P.F.F. and F32 GM097762 to H.M.G. and by The Welch
Foundation Grant AQ-1399 to P.J.H.
NR 50
TC 6
Z9 7
U1 3
U2 33
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD APR 16
PY 2013
VL 52
IS 15
BP 2620
EP 2626
DI 10.1021/bi4001563
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 128UG
UT WOS:000317794600013
PM 23521653
ER
PT J
AU Dai, N
Wang, WY
Patterson, SE
Bleecker, AB
AF Dai, Ning
Wang, Wuyi
Patterson, Sara E.
Bleecker, Anthony B.
TI The TMK Subfamily of Receptor-Like Kinases in Arabidopsis Display an
Essential Role in Growth and a Reduced Sensitivity to Auxin
SO PLOS ONE
LA English
DT Article
ID ETR1 ETHYLENE RECEPTOR; PROTEIN-KINASE; CELL ELONGATION;
SIGNAL-TRANSDUCTION; GENE ENCODES; SIZE CONTROL; ERECTA GENE; THALIANA;
PLANT; EXPRESSION
AB Mechanisms that govern the size of plant organs are not well understood but believed to involve both sensing and signaling at the cellular level. We have isolated loss-of-function mutations in the four genes comprising the transmembrane kinase TMK subfamily of receptor-like kinases (RLKs) in Arabidopsis. These TMKs have an extracellular leucine-rich-repeat motif, a single transmembrane region, and a cytoplasmic kinase domain. While single mutants do not display discernable phenotypes, unique double and triple mutant combinations result in a severe reduction in organ size and a substantial retardation in growth. The quadruple mutant displays even greater severity of all phenotypes and is infertile. The kinematic studies of root, hypocotyl, and stamen filament growth reveal that the TMKs specifically control cell expansion. In leaves, TMKs control both cell expansion and cell proliferation. In addition, in the tmk double mutants, roots and hypocotyls show reduced sensitivity to applied auxin, lateral root induction and activation of the auxin response reporter DR5: GUS. Thus, taken together with the structural and biochemical evidence, TMKs appear to orchestrate plant growth by regulation of both cell expansion and cell proliferation, and as a component of auxin signaling.
C1 [Dai, Ning; Wang, Wuyi; Bleecker, Anthony B.] Univ Wisconsin, Dept Bot, Madison, WI USA.
[Dai, Ning; Wang, Wuyi; Bleecker, Anthony B.] Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.
[Patterson, Sara E.] Univ Wisconsin, Dept Hort, Madison, WI 53706 USA.
RP Dai, N (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM ning@molbio.mgh.harvard.edu; spatters@wisc.edu
FU Department of Energy [DE-FG02-91ER20029]
FX This project was funded by a Department of Energy grant
(DE-FG02-91ER20029) to ABB and SEP. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 59
TC 16
Z9 23
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 16
PY 2013
VL 8
IS 4
AR e60990
DI 10.1371/journal.pone.0060990
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130DR
UT WOS:000317893400032
PM 23613767
ER
PT J
AU Channick, RN
AF Channick, Richard N.
TI Combination Therapy in Pulmonary Arterial Hypertension
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID CONTINUOUS INTRAVENOUS EPOPROSTENOL; SMOOTH-MUSCLE-CELLS; INHALED
ILOPROST; BOSENTAN THERAPY; ORAL SILDENAFIL; EFFICACY; TREPROSTINIL;
SURVIVAL; TRIAL; PROSTACYCLIN
AB Many potential therapeutic options are now available for patients with pulmonary arterial hypertension. Interest has emerged in using therapies in various combinations. Retrospective experience has suggested that this approach is common and can be efficacious. Data are emerging supporting the benefit of combination therapy; however, limitations and questions remain about this strategy. This report reviewed the rationale for combination therapy and summarized the results from clinical trials. (C) 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111[suppl]:16C-20C)
C1 [Channick, Richard N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Med, Pulm Hypertens & Thromboendarterect Program, Boston, MA USA.
RP Channick, RN (reprint author), Massachusetts Gen Hosp, Pulm Hypertens & Thromboendarterect Program, 55 Fruit St,Cox 2, Boston, MA 02114 USA.
EM RChannick@Partners.org
FU Gilead Sciences, Inc.
FX Publication of this supplement was supported by an educational grant
from Gilead Sciences, Inc.
NR 38
TC 3
Z9 3
U1 0
U2 1
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD APR 16
PY 2013
VL 111
IS 8
SU S
BP 16C
EP 20C
DI 10.1016/j.amjcard.2013.01.320
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 130CP
UT WOS:000317890600004
PM 23558025
ER
PT J
AU Michaelson, MD
Zhu, AX
Ryan, DP
McDermott, DF
Shapiro, GI
Tye, L
Chen, I
Stephenson, P
Patyna, S
Ruiz-Garcia, A
Schwarzberg, AB
AF Michaelson, M. D.
Zhu, A. X.
Ryan, D. P.
McDermott, D. F.
Shapiro, G. I.
Tye, L.
Chen, I.
Stephenson, P.
Patyna, S.
Ruiz-Garcia, A.
Schwarzberg, A. B.
TI Sunitinib in combination with gemcitabine for advanced solid tumours: a
phase I dose-finding study
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE sunitinib; gemcitabine; combination; pharmacokinetics; solid tumours
ID RENAL-CELL CARCINOMA; TYROSINE KINASE INHIBITOR; ENDOTHELIAL
GROWTH-FACTOR; METASTATIC BREAST-CANCER; LUNG-CANCER; INTERFERON-ALPHA;
III TRIAL; SARCOMATOID DIFFERENTIATION; NEUROENDOCRINE TUMORS;
PRECLINICAL MODELS
AB Background: This phase I, dose-finding study determined the maximum tolerated dose (MTD), safety, and pharmacokinetics of sunitinib plus gemcitabine in patients with advanced solid tumours.
Methods: Two schedules with sunitinib (25-50mg per day) and IV gemcitabine (750-1250 mg m(-2)) in escalating doses were studied. First, patients received sunitinib on a 4-weeks-on-2-weeks-off schedule (Schedule 4/2) plus gemcitabine on days 1, 8, 22, and 29. Second, patients received sunitinib on a 2-weeks-on-1-week-off schedule (Schedule 2/1) plus gemcitabine on days 1 and 8. The primary endpoint was determination of MTD and tolerability.
Results: Forty-four patients received the combination (Schedule 4/2, n = 8; Schedule 2/1, n = 36). With no dose-limiting toxicities (DLTs) at maximum dose levels on Schedule 2/1, MTD was not reached. Grade 4 treatment-related AEs and laboratory abnormalities included cerebrovascular accident, hypertension, and pulmonary embolism (n 1 each), and neutropenia (n = 3), thrombocytopenia and increased uric acid (both n 2), and lymphopenia (n = 1). There were no clinically significant drug-drug interactions. Antitumor activity occurred across dose levels and tumour types. In poor-risk and/or high-grade renal cell carcinoma patients (n = 12), 5 had partial responses and 7 stable disease >= 6 weeks.
Conclusion: Sunitinib plus gemcitabine on Schedule 2/1 with growth factor support was well tolerated and safely administered at maximum doses of each drug, without significant drug-drug interactions.
C1 [Michaelson, M. D.; Zhu, A. X.; Ryan, D. P.; Schwarzberg, A. B.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[McDermott, D. F.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Shapiro, G. I.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Tye, L.; Chen, I.; Patyna, S.; Ruiz-Garcia, A.] Pfizer Oncol, La Jolla, CA 92121 USA.
[Stephenson, P.] Rho Inc, Chapel Hill, NC 27517 USA.
RP Michaelson, MD (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Yawkey 7, Boston, MA 02114 USA.
EM dmichaelson1@partners.org
RI Ruiz-Garcia, Ana/O-8252-2014
OI Ruiz-Garcia, Ana/0000-0002-5462-3110
FU Pfizer, Inc.; Pfizer
FX This study was sponsored by Pfizer, Inc. We thank all of the
participating patients and their families, as well as the investigators,
research nurses, study coordinators, and operations staff. Medical
writing support was provided by Andy Gannon and Lisa Cheyne at ACUMED
(Tytherington, UK) and was funded by Pfizer Inc.; AXZ and McD have
reported receiving consultant or advisory fees from Pfizer. LT, SP, and
AR-G are full-time employees of Pfizer and hold Pfizer stock. The
remaining authors declare no conflict of interest.
NR 47
TC 13
Z9 13
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD APR 16
PY 2013
VL 108
IS 7
BP 1393
EP 1401
DI 10.1038/bjc.2013.96
PG 9
WC Oncology
SC Oncology
GA 127WU
UT WOS:000317730400001
PM 23511559
ER
PT J
AU Ahearn, TU
Pettersson, A
Stack, EC
Ma, J
Gerke, T
Meisner, A
Pollak, MN
Finn, S
Stampfer, MJ
Loda, M
Giovannucci, EL
Mucci, LA
AF Ahearn, Thomas U.
Pettersson, Andreas
Stack, Edward C.
Ma, Jing
Gerke, Travis
Meisner, Allison
Pollak, Michael N.
Finn, Stephen
Stampfer, Meir J.
Loda, Massimo
Giovannucci, Edward L.
Mucci, Lorelei A.
TI The IGF/insulin signaling axis TMPRSS2:ERG and prostate cancer survival.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Ahearn, Thomas U.; Pettersson, Andreas; Gerke, Travis; Meisner, Allison; Stampfer, Meir J.; Giovannucci, Edward L.; Mucci, Lorelei A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Stack, Edward C.; Ma, Jing; Finn, Stephen; Loda, Massimo] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Pollak, Michael N.] McGill Univ, Montreal, PQ, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB-28
DI 10.1158/1538-7445.AM2013-LB-28
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601043
ER
PT J
AU Alimzhanov, M
Solban, N
Lee, M
Philbrook, P
Wang, XE
Wei, L
Song, JX
Signoretti, S
Pearsall, RS
Sherman, ML
Kumar, R
Bhatt, RS
AF Alimzhanov, Marat
Solban, Nicolas
Lee, Michael
Philbrook, Phaethon
Wang, Xiaoen
Wei, Lin
Song, Jiaxi
Signoretti, Sabina
Pearsall, R. Scott
Sherman, Matthew L.
Kumar, Ravindra
Bhatt, Rupal S.
TI Inhibiting the ALK1/BMP9 signaling pathway with dalantercept as an
antiangiogenic therapy
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Alimzhanov, Marat; Solban, Nicolas; Lee, Michael; Philbrook, Phaethon; Pearsall, R. Scott; Sherman, Matthew L.; Kumar, Ravindra] Acceleron Pharma, Cambridge, MA USA.
[Wang, Xiaoen; Wei, Lin; Song, Jiaxi; Signoretti, Sabina; Bhatt, Rupal S.] Beth Israel Deaconess Med Ctr, Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 5080
DI 10.1158/1538-7445.AM2013-5080
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220605176
ER
PT J
AU Atreya, CE
Song, EK
Messersmith, W
Purkey, A
Bagby, S
Quackenbush, K
Kelley, RK
Kwak, E
Ryan, D
Venook, A
Arcaroli, JJ
AF Atreya, Chloe E.
Song, Eun-Kee
Messersmith, Wells
Purkey, Alicia
Bagby, Stacey
Quackenbush, Kevin
Kelley, Robin K.
Kwak, Eunice
Ryan, David
Venook, Alan
Arcaroli, John J.
TI Potent antitumor activity of XL184 (cabozantinib), a c-MET and VEGFR2
inhibitor, in colorectal cancer patient-derived tumor explant models.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Atreya, Chloe E.; Kelley, Robin K.; Venook, Alan] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
[Song, Eun-Kee; Messersmith, Wells; Purkey, Alicia; Bagby, Stacey; Quackenbush, Kevin; Arcaroli, John J.] Univ Colorado Denver, Aurora, CO USA.
[Kwak, Eunice; Ryan, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kwak, Eunice; Ryan, David] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB302
DI 10.1158/1538-7445.AM2013-LB-302
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601227
ER
PT J
AU Baca, SC
Prandi, D
Lawrence, MS
Mosquera, JM
Romanei, A
Drier, Y
Park, K
Kitabayashi, N
MacDonald, TY
Van Allen, E
Kryukov, GV
Theurillat, JP
Soong, TD
Nickerson, E
Auclair, D
Tewari, A
Beltran, H
Onofrio, RC
Boysen, G
Guiducci, C
Barbieri, CE
Cibulskis, K
Sivachenko, A
Carter, SL
Voet, D
Saksena, G
Cipicchio, MR
Ardlie, K
Kantoff, PW
Berger, MF
Gabriel, SB
Golub, TR
Meyerson, M
Lander, ES
Elemento, O
Getz, G
Demichelis, F
Rubin, MA
Garraway, LA
AF Baca, Sylvan C.
Prandi, Davide
Lawrence, Michael S.
Mosquera, Juan Miguel
Romanei, Alessandro
Drier, Yotam
Park, Kyung
Kitabayashi, Naoki
MacDonald, Theresa Y.
Van Allen, Eliezer
Kryukov, Gregory V.
Theurillat, Jean-Philippe
Soong, T. David
Nickerson, Elizabeth
Auclair, Daniel
Tewari, Ashutosh
Beltran, Himisha
Onofrio, Robert C.
Boysen, Gunther
Guiducci, Candace
Barbieri, Christopher E.
Cibulskis, Kristian
Sivachenko, Andrey
Carter, Scott L.
Voet, Douglas
Saksena, Gordon
Cipicchio, Michelle R.
Ardlie, Kristin
Kantoff, Philip W.
Berger, Michael F.
Gabriel, Stacey B.
Golub, Todd R.
Meyerson, Matthew
Lander, Eric S.
Elemento, Olivier
Getz, Gad
Demichelis, Francesca
Rubin, Mark A.
Garraway, Levi A.
TI Punctuated evolution of prostate cancer genomes
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Baca, Sylvan C.; Kantoff, Philip W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Prandi, Davide; Romanei, Alessandro; Demichelis, Francesca] Ctr Integrat Biol, Trento, Italy.
[Lawrence, Michael S.; Van Allen, Eliezer; Kryukov, Gregory V.; Theurillat, Jean-Philippe; Nickerson, Elizabeth; Auclair, Daniel; Onofrio, Robert C.; Guiducci, Candace; Cibulskis, Kristian; Sivachenko, Andrey; Carter, Scott L.; Voet, Douglas; Saksena, Gordon; Cipicchio, Michelle R.; Ardlie, Kristin; Gabriel, Stacey B.; Golub, Todd R.; Meyerson, Matthew; Lander, Eric S.; Getz, Gad; Garraway, Levi A.] Broad Inst, Cambridge, MA USA.
[Mosquera, Juan Miguel; Park, Kyung; Kitabayashi, Naoki; MacDonald, Theresa Y.; Soong, T. David; Tewari, Ashutosh; Beltran, Himisha; Boysen, Gunther; Barbieri, Christopher E.; Elemento, Olivier; Rubin, Mark A.] Weill Cornell Med Coll, New York, NY USA.
[Drier, Yotam] Weizmann Inst Sci, IL-76100 Rehovot, Israel.
[Berger, Michael F.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4601
DI 10.1158/1538-7445.AM2013-4601
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604187
ER
PT J
AU Baselga, J
Piccart, M
Rugo, H
Chen, D
Burris, HA
Campone, M
Noguchi, S
Perez, A
Deleu, I
Shtivelband, M
Provencher, L
Derti, A
Huang, A
McDonald, R
Kalfoglou, C
Robinson, D
Taran, T
Sahmoud, T
Lebwohl, D
Hortobagyi, GN
AF Baselga, Jose
Piccart, Martine
Rugo, Hope
Chen, David
Burris, Howard A.
Campone, Mario
Noguchi, Shinzaburo
Perez, Alejandra
Deleu, Inas
Shtivelband, Mikhail
Provencher, Louise
Derti, Adnan
Huang, Alan
McDonald, Rob
Kalfoglou, Creton
Robinson, Douglas
Taran, Tetiana
Sahmoud, Tarek
Lebwohl, David
Hortobagyi, Gabriel N.
TI Assessment of genetic alterations using next-generation sequencing in
postmenopausal women with hormone receptor-positive, HER2-negative
advanced breast cancer: results from the BOLERO-2 phase III trial
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Baselga, Jose] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Baselga, Jose] Harvard Univ, Sch Med, Boston, MA USA.
[Piccart, Martine] Univ Libre Brussels, Inst Jules Bordet, Brussels, Belgium.
[Rugo, Hope] Univ Calif San Francisco, San Francisco Helen Diller Family Comprehens Canc, San Francisco, CA 94143 USA.
[Chen, David; Kalfoglou, Creton; Taran, Tetiana] Novartis Pharmaceut, Florham Pk, NJ USA.
[Burris, Howard A.] Sarah Cannori Res Inst, Nashville, TN USA.
[Campone, Mario] Ctr Rech Cancerol, Inst Cancerol Ouest Rene Gauducheau, Nantes, St Herblain, France.
[Noguchi, Shinzaburo] Osaka Univ, Dept Breast & Endocrine Surg, Osaka, Japan.
[Perez, Alejandra] Mem Canc Inst, Hollywood, FL USA.
[Deleu, Inas] AZ Maria Middelares, Ghent, Belgium.
[Shtivelband, Mikhail] Ironwood Canc & Res Ctr, Chandler, AZ USA.
[Provencher, Louise] CHU Quebec, Hop St Sacrement, Quebec City, PQ, Canada.
[Derti, Adnan; Huang, Alan; McDonald, Rob; Robinson, Douglas] Novartis Inst BioMed Res Inc, Cambridge, MA USA.
[Sahmoud, Tarek; Lebwohl, David] Novartis Pharmaceut, E Hanover, NJ USA.
[Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4564
DI 10.1158/1538-7445.AM2013-4564
PG 2
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604164
ER
PT J
AU Baselga, J
Verma, S
Ro, J
Huober, J
Guardino, E
Fang, L
Olsen, S
Phillips, GL
de Haas, S
Pegram, M
AF Baselga, Jose
Verma, Sunil
Ro, Jungsil
Huober, Jens
Guardino, Ellie
Fang, Liang
Olsen, Steven
Phillips, Gail Lewis
de Haas, Sanne
Pegram, Mark
TI Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a
phase III study of trastuzumab emtansine (T-DM1) in HER2-positive
metastatic breast cancer (MBC).
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Baselga, Jose] Massachusetts Gen Hosp, Canc Ctr Adm, Boston, MA 02114 USA.
[Verma, Sunil] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
[Ro, Jungsil] Natl Canc Ctr, Ctr Breast Canc, Goyang Si, Gyeonggi Do, South Korea.
[Huober, Jens] Univ Dusseldorf, Dusseldorf, Germany.
[Guardino, Ellie; Fang, Liang; Olsen, Steven; Phillips, Gail Lewis] Genentech Inc, San Francisco, CA 94080 USA.
[Guardino, Ellie] Stanford Univ, San Francisco, CA USA.
[de Haas, Sanne] F Hoffmann La Roche, Basel, Switzerland.
[Pegram, Mark] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
NR 0
TC 4
Z9 4
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB63
DI 10.1158/1538-7445.AM2013-LB-63
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601311
ER
PT J
AU Beaver, JA
Valda, P
Jelovac, D
Higgins, MJ
Park, BH
AF Beaver, Julia A.
Valda, Patricia
Jelovac, Danijela
Higgins, Michaela J.
Park, Ben H.
TI Plasma tumor DNA: Changing the paradigm for administering systemic
therapies.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Beaver, Julia A.; Valda, Patricia; Jelovac, Danijela; Park, Ben H.] Johns Hopkins Univ, Baltimore, MD USA.
[Higgins, Michaela J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA SY1101
DI 10.1158/1538-7445.AM2013-SY11-01
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601369
ER
PT J
AU Bhatnagar, N
Luther, W
Sharma, B
Liu, QS
Gray, N
George, RE
AF Bhatnagar, Namrata
Luther, William
Sharma, Bandana
Liu, Qingsong
Gray, Nathanael
George, Rani E.
TI The AXL tyrosine kinase receptor contributes to ALK-inhibitor resistance
in neuroblastoma.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Bhatnagar, Namrata; Luther, William; Sharma, Bandana; Liu, Qingsong; Gray, Nathanael; George, Rani E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4454
DI 10.1158/1538-7445.AM2013-4454
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604059
ER
PT J
AU Birkbak, NJ
Kochupurakkal, B
Izarzugaza, JMG
Li, Y
Liu, J
Szallasi, Z
Matulonis, U
Richardson, AL
Iglehart, JD
Wang, ZGC
AF Birkbak, Nicolai Juul
Kochupurakkal, Bose
Izarzugaza, Jose M. G.
Li, Yang
Liu, Joyce
Szallasi, Zoltan
Matulonis, Ursula
Richardson, Andrea L.
Iglehart, J. Dirk
Wang, Zhigang C.
TI Exome mutation burden predicts clinical outcome in ovarian cancer
carrying mutated BRCA1 and BRCA2 genes
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Birkbak, Nicolai Juul; Izarzugaza, Jose M. G.] Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark.
[Kochupurakkal, Bose; Li, Yang; Liu, Joyce; Matulonis, Ursula; Iglehart, J. Dirk; Wang, Zhigang C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Szallasi, Zoltan] Harvard Univ, Sch Med, Childrens Hosp Informat Program Harvard MIT Div H, Boston, MA USA.
[Richardson, Andrea L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RI Izarzugaza, Jose /N-4503-2014
OI Izarzugaza, Jose /0000-0003-1754-5122
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB255
DI 10.1158/1538-7445.AM2013-LB-255
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601184
ER
PT J
AU Blackburn, JS
Liu, S
Dobrinski, K
Ranalli, J
Martinez, S
Lee, C
Langenau, D
AF Blackburn, Jessica S.
Liu, Sali
Dobrinski, Kimberly
Ranalli, Jayme
Martinez, Sarah
Lee, Charles
Langenau, David
TI Single cell evolution of AKT pathway activation drives T-cell acute
lymphoblastic leukemia relapse
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Blackburn, Jessica S.; Liu, Sali; Ranalli, Jayme; Martinez, Sarah; Langenau, David] Massachusetts Gen Hosp, Charlestown, MA USA.
[Dobrinski, Kimberly; Lee, Charles] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3805
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220603039
ER
PT J
AU Boeke, CE
Eliassen, AH
Chen, WY
Cho, E
Holmes, MD
Rosner, B
Willett, WC
Tamimi, RM
AF Boeke, Caroline E.
Eliassen, A. Heather
Chen, Wendy Y.
Cho, Eunyoung
Holmes, Michelle D.
Rosner, Bernard
Willett, Walter C.
Tamimi, Rulla M.
TI Dietary fat and cholesterol intake in relation to fatal breast cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Boeke, Caroline E.; Eliassen, A. Heather; Holmes, Michelle D.; Rosner, Bernard; Willett, Walter C.; Tamimi, Rulla M.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Boeke, Caroline E.; Eliassen, A. Heather; Chen, Wendy Y.; Cho, Eunyoung; Holmes, Michelle D.; Rosner, Bernard; Willett, Walter C.; Tamimi, Rulla M.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Eliassen, A. Heather; Holmes, Michelle D.; Rosner, Bernard; Willett, Walter C.; Tamimi, Rulla M.] Harvard Univ, Sch Med, Boston, MA USA.
[Chen, Wendy Y.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 144
DI 10.1158/1538-7445.AM2013-144
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220600060
ER
PT J
AU Boucher, Y
Martin, JD
Tolaney, SM
Seano, G
Goel, S
Ancukiewicz, M
Isakoff, SJ
Winer, EP
Krop, IE
Jain, RK
AF Boucher, Yves
Martin, John D.
Tolaney, Sara M.
Seano, Giogio
Goel, Shom
Ancukiewicz, Marek
Isakoff, Steven J.
Winer, Eric P.
Krop, Ian E.
Jain, Rakesh K.
TI Tissue biomarkers and interstitial fluid pressure in a phase II study of
preoperative (preop) bevacizumab (bev) followed by dose-dense
doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with
bey in HER2-negative operable breast cancer (BC)
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Boucher, Yves; Isakoff, Steven J.; Jain, Rakesh K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Martin, John D.] Massachusetts Gen Hosp, MIT, Boston, MA 02114 USA.
[Tolaney, Sara M.; Winer, Eric P.; Krop, Ian E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Seano, Giogio] Harvard Univ, Sch Med, Boston, MA USA.
[Goel, Shom] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ancukiewicz, Marek] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB76
DI 10.1158/1538-7445.AM2013-LB-76
PG 2
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601323
ER
PT J
AU Carter, SL
Landau, DA
Stojanov, P
McKenna, A
Cibulskis, K
Lawrence, MS
Lohr, J
Stevenson, K
Neuberg, D
Meyerson, M
Wu, CJ
Getz, G
AF Carter, Scott L.
Landau, Dan-Avi
Stojanov, Petar
McKenna, Aaron
Cibulskis, Kristian
Lawrence, Michael S.
Lohr, Jens
Stevenson, Kristen
Neuberg, Donna
Meyerson, Matthew
Wu, Catherine J.
Getz, Gad
TI Analysis of clonal evolution in cancer using whole exome sequence data
reveals that subclonal driver mutations predict poor prognosis in
chronic lymphocytic leukemia
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Carter, Scott L.; Stojanov, Petar; McKenna, Aaron; Cibulskis, Kristian; Lawrence, Michael S.; Getz, Gad] Broad Inst, Cambridge, MA USA.
[Landau, Dan-Avi; Lohr, Jens; Stevenson, Kristen; Neuberg, Donna; Meyerson, Matthew; Wu, Catherine J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4600
DI 10.1158/1538-7445.AM2013-4600
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604186
ER
PT J
AU Casper, JA
Bielenberg, DR
Cheng, J
Schmidt, B
Hammock, BD
Zeldin, DC
Kieran, MW
Panigrahy, D
AF Casper, Jessica A.
Bielenberg, Diane R.
Cheng, Jennifer
Schmidt, Birgitta
Hammock, Bruce D.
Zeldin, Darryl C.
Kieran, Mark W.
Panigrahy, Dipak
TI Cytochrome P450-derived eicosanoids regulate pancreatic cancer and
metastasis.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Casper, Jessica A.; Bielenberg, Diane R.; Schmidt, Birgitta; Panigrahy, Dipak] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA USA.
[Cheng, Jennifer; Zeldin, Darryl C.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA.
[Hammock, Bruce D.] Univ Calif Davis, Davis, CA 95616 USA.
[Kieran, Mark W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3952
DI 10.1158/1538-7445.AM2013-3952
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220603186
ER
PT J
AU Chang, DK
Han, T
Clark, RA
Zhu, Q
Kupper, TS
Marasco, WA
AF Chang, DeKuan
Han, Thomas
Clark, Rachael A.
Zhu, Quan
Kupper, Thomas S.
Marasco, Wayne A.
TI A humanized, high affinity anti-CCR4 antibody for immunotherapy of
cutaneous T cell lymphoma and characterization on T cell function
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Chang, DeKuan; Han, Thomas; Zhu, Quan; Marasco, Wayne A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Clark, Rachael A.; Kupper, Thomas S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4754
DI 10.1158/1538-7445.AM2013-4754
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604335
ER
PT J
AU Chen, YA
Chen, ZH
Permuth-Wev, J
Tsai, YY
Lin, HY
Qu, XT
Lawrenson, K
Fenstermacher, D
Phelan, CM
Monteiro, A
Gayther, SA
Narod, SA
Sutphen, R
Birrer, MJ
Wentzensen, N
Schildkraut, JM
Goode, EL
Pharoah, P
Sellers, T
AF Chen, Yian Ann
Chen, Zhihua
Permuth-Wev, Jennifer
Tsai, Ya-Yu
Lin, Hui-Yi
Qu, Xiaotao
Lawrenson, Kate
Fenstermacher, David
Phelan, Catherine M.
Monteiro, Alvaro
Gayther, Simon A.
Narod, Steven A.
Sutphen, Rebecca
Birrer, Michael J.
Wentzensen, Nicolas
Schildkraut, Joellen M.
Goode, Ellen L.
Pharoah, Paul
Sellers, Thomas
TI Variants in long non-coding RNAs are associated with epithelial ovarian
cancer risk in a pooled analysis of three genome-wide association
studies.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Chen, Yian Ann; Chen, Zhihua; Permuth-Wev, Jennifer; Tsai, Ya-Yu; Lin, Hui-Yi; Qu, Xiaotao; Fenstermacher, David; Phelan, Catherine M.; Monteiro, Alvaro; Sellers, Thomas] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Lawrenson, Kate; Gayther, Simon A.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
[Narod, Steven A.] Univ Toronto, Toronto, ON, Canada.
[Sutphen, Rebecca] Univ S Florida, Tampa, FL USA.
[Birrer, Michael J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Wentzensen, Nicolas] NCI, Bethesda, MD 20892 USA.
[Schildkraut, Joellen M.] Duke Univ, Med Ctr, Durham, NC USA.
[Goode, Ellen L.] Mayo Clin, Coll Med, Rochester, MN USA.
[Pharoah, Paul] Univ Cambridge, Cambridge, England.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4579
DI 10.1158/1538-7445.AM2013-4579
PG 2
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220600314
ER
PT J
AU Chin, YMR
Balk, S
Toker, A
AF Chin, Yuet Ming Rebecca
Balk, Steve
Toker, Alex
TI Akt2-specific signaling in prostate cancer maintenance
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Chin, Yuet Ming Rebecca; Balk, Steve; Toker, Alex] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4090
DI 10.1158/1538-7445.AM2013-4090
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220603320
ER
PT J
AU Choi, SH
Lee, HJ
Jin, YB
Lee, M
Kim, J
Yoon, SS
Lee, YS
Lee, YJ
AF Choi, Seo-Hyun
Lee, Hae-June
Jin, Yeung Bae
Lee, Minyoung
Kim, Joon
Yoon, Sam S.
Lee, Yun-Sil
Lee, Yoon-Jin
TI MMP9 processing of HSBP1 regulates tumor metastases
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Choi, Seo-Hyun] Korea Univ, Korea Inst Radiol & Med Sci, Seoul, South Korea.
[Lee, Hae-June; Lee, Minyoung; Lee, Yoon-Jin] Korea Inst Radiol & Med Sci, Seoul, South Korea.
[Jin, Yeung Bae] Korea Atom Energy Res Inst, Adv Radiat Technol Inst, Jeongeup, South Korea.
[Kim, Joon] Korea Univ, Seoul, South Korea.
[Yoon, Sam S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Yoon, Sam S.] Harvard Univ, Sch Med, Boston, MA USA.
[Lee, Yun-Sil] Ewha Womans Univ, Seoul, South Korea.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3873
DI 10.1158/1538-7445.AM2013-3873
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220603107
ER
PT J
AU Choy, E
Butrynski, J
Harmon, D
Morgan, J
George, S
Wagner, A
D'Adamo, D
Cote, G
Rubinstein, Y
Benes, C
Haber, D
Baselga, J
Demetri, G
AF Choy, Edwin
Butrynski, James
Harmon, David
Morgan, Jeffrey
George, Suzanne
Wagner, Andrew
D'Adamo, David
Cote, Greg
Rubinstein, Yael
Benes, Cyril
Haber, Daniel
Baselga, Jose
Demetri, George
TI Translation of preclinical predictive sensitivity of Ewing sarcoma to
PARP inhibition: Phase II study of olaparib in adult patients with
recurrent/metastatic Ewing sarcoma following failure of prior
chemotherapy.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Choy, Edwin; Harmon, David; Cote, Greg; Benes, Cyril; Haber, Daniel] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Butrynski, James; Morgan, Jeffrey; George, Suzanne; Wagner, Andrew; D'Adamo, David; Rubinstein, Yael; Demetri, George] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Baselga, Jose] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB174
DI 10.1158/1538-7445.AM2013-LB-174
PG 2
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601109
ER
PT J
AU Choy, E
Balasubramanian, S
Butrynski, J
Morgan, J
Sirisawad, M
Mani, C
George, S
Wagner, A
Harmon, D
Rubinstein, Y
Duan, ZF
Hornicek, F
Demetri, G
AF Choy, Edwin
Balasubramanian, Sriram
Butrynski, James
Morgan, Jeffrey
Sirisawad, Mint
Mani, Chitra
George, Suzanne
Wagner, Andrew
Harmon, David
Rubinstein, Yael
Duan, Zhenfeng
Hornicek, Francis
Demetri, George
TI Phase I dose escalation study of abexinostat and doxorubicin in patients
with metastatic sarcomas.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Choy, Edwin; Harmon, David; Duan, Zhenfeng; Hornicek, Francis] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Balasubramanian, Sriram; Sirisawad, Mint; Mani, Chitra] Pharmacyclics, Sunnyvale, CA USA.
[Butrynski, James; Morgan, Jeffrey; George, Suzanne; Wagner, Andrew; Rubinstein, Yael; Demetri, George] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB167
DI 10.1158/1538-7445.AM2013-LB-167
PG 2
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601103
ER
PT J
AU Corcoran, RB
Rothenberg, SM
Hata, AN
Faber, AC
Winokur, D
Piris, A
Nazarian, RM
Brown, RD
Godfrey, JT
Mino-Kenudson, M
Settleman, J
Wargo, JA
Flaherty, KT
Haber, DA
Engelman, JA
AF Corcoran, Ryan B.
Rothenberg, Stephen M.
Hata, Aaron N.
Faber, Anthony C.
Winokur, Daniel
Piris, Adriano
Nazarian, Rosalynn M.
Brown, Ronald D.
Godfrey, Jason T.
Mino-Kenudson, Mari
Settleman, Jeffrey
Wargo, Jennifer A.
Flaherty, Keith T.
Haber, Daniel A.
Engelman, Jeffrey a
TI Rapid assessment of TORC1 suppression predicts responsiveness to RAF and
MEK inhibition in BRAF mutant melanoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Corcoran, Ryan B.; Rothenberg, Stephen M.; Hata, Aaron N.; Wargo, Jennifer A.; Flaherty, Keith T.; Haber, Daniel A.; Engelman, Jeffrey a] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Faber, Anthony C.; Winokur, Daniel; Brown, Ronald D.; Godfrey, Jason T.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA.
[Piris, Adriano; Nazarian, Rosalynn M.; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Settleman, Jeffrey] Genentech Inc, San Francisco, CA 94080 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4568
DI 10.1158/1538-7445.AM2013-4568
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604168
ER
PT J
AU Damle, RN
Temburni, S
Aggarwal, P
O'Brien, S
Barrientos, J
Brown, JR
Flinn, IW
Barr, P
Burger, J
Friedberg, JW
Rai, KR
Chang, B
James, D
Buggy, J
Chiorazzi, N
AF Damle, Rajendra N.
Temburni, Sonal
Aggarwal, Prachi
O'Brien, Susan
Barrientos, Jacqueline
Brown, Jennifer R.
Flinn, Ian W.
Barr, Paul
Burger, Jan
Friedberg, Jonathan W.
Rai, Kanti R.
Chang, Betty
James, Danelle
Buggy, Joseph
Chiorazzi, Nicholas
TI Changes in immune cell populations in relapsed/refractory CLL patients
treated with a Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib
(PCI-32765), in combination with Bendamustine and Rituximab (BR)
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Damle, Rajendra N.; Temburni, Sonal; Aggarwal, Prachi; Chiorazzi, Nicholas] Feinstein Inst Med Res, Manhasset, NY USA.
[O'Brien, Susan; Burger, Jan] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Barrientos, Jacqueline; Rai, Kanti R.] Long Isl Jewish Med Ctr, New Hyde Pk, NY 11042 USA.
[Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Flinn, Ian W.] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA.
[Barr, Paul; Friedberg, Jonathan W.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA.
[Chang, Betty; James, Danelle; Buggy, Joseph] Pharmacyclics Inc, Sunnyvale, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3531
DI 10.1158/1538-7445.AM2013-3531
PG 2
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220602235
ER
PT J
AU Demetri, GD
Jeffers, M
Reichardt, P
Kang, YK
Blay, JY
Rutkowski, P
Gelderblom, H
Hohenberger, P
Leahy, M
von Mehren, M
Joensuu, H
Badalamenti, G
Blackstein, M
Le Cesne, A
Schoffski, P
Maki, RG
Bauer, S
Nguyen, BB
Xu, JM
Nishida, T
Chung, J
Lathia, CD
Kappeler, C
Kuss, I
Laurent, D
Casali, PG
AF Demetri, George D.
Jeffers, Michael
Reichardt, Peter
Kang, Yoon-Koo
Blay, Jean-Yves
Rutkowski, Piotr
Gelderblom, Hans
Hohenberger, Peter
Leahy, Michael
von Mehren, Margaret
Joensuu, Heikki
Badalamenti, Giuseppe
Blackstein, Martin
Le Cesne, Axel
Schoffski, Patrick
Maki, Robert G.
Bauer, Sebastian
Binh Bui Nguyen
Xu, Jianming
Nishida, Toshirou
Chung, John
Lathia, Chetan D.
Kappeler, Christian
Kuss, Iris
Laurent, Dirk
Casali, Paolo G.
TI Detection of oncogenic kinase mutations in circulating plasma DNA and
correlation with clinical benefit in the phase III GRID study of
regorafenib vs placebo in TKI-refractory metastatic GIST.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Demetri, George D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Jeffers, Michael] Bayer HealthCare, Montville, NJ USA.
[Reichardt, Peter] HELIOS Klin, Dept Hematol Oncol & Palliat Med, Bad Saarow Pieskow, Germany.
[Kang, Yoon-Koo] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
[Blay, Jean-Yves] Ctr Leon Berard, Leon, France.
[Blay, Jean-Yves] Univ Claude Bernard, Leon, France.
[Rutkowski, Piotr] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland.
[Gelderblom, Hans] Leiden Univ, Med Ctr, Dept Clin Oncol, Leiden, Netherlands.
[Hohenberger, Peter] Univ Mannheim, Med Ctr, Div Surg Oncol & Thorac Surg, D-68131 Mannheim, Germany.
[Leahy, Michael] Christie NHS Fdn Trust, Manchester, Lancs, England.
[von Mehren, Margaret] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Joensuu, Heikki] Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki, Finland.
[Badalamenti, Giuseppe] Univ Palermo, Dept Oncol, Palermo, Italy.
[Blackstein, Martin] Mt Sinai Hosp, Med Oncol Unit, Toronto, ON M5G 1X5, Canada.
[Le Cesne, Axel] Inst Gustave Roussy, Dept Med, Paris, France.
[Schoffski, Patrick] Katholieke Univ Leuven Hosp, Dept Gen Med Oncol, Louvain, Belgium.
[Maki, Robert G.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Bauer, Sebastian] Univ Duisburg Essen, West German Canc Ctr, Sarcoma Ctr, Essen, Germany.
[Binh Bui Nguyen] Inst Bergonie, Bordeaux, France.
[Xu, Jianming] Acad Mil Med Sci, Affiliated Hosp Canc Ctr, Beijing, Peoples R China.
[Nishida, Toshirou] Osaka Police Hosp, Dept Surg, Osaka, Japan.
[Chung, John] Bayer Healthcare Pharmaceut, Wayne, NJ USA.
[Lathia, Chetan D.] Alexion Pharmaceut, Cheshire, CT USA.
[Kappeler, Christian; Kuss, Iris; Laurent, Dirk] Bayer Pharma AG, Berlin, Germany.
[Casali, Paolo G.] Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 2
Z9 2
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB295
DI 10.1158/1538-7445.AM2013-LB-295
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601220
ER
PT J
AU Dranoff, G
AF Dranoff, Glenn
TI Engineering improved cancer vaccines.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Dranoff, Glenn] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA SY2704
DI 10.1158/1538-7445.AM2013-SY27-04
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601397
ER
PT J
AU Drew, L
Engelman, J
Katayama, R
McDermott, B
Saeh, J
Scarpitti, M
Shaw, A
Shen, MH
Wang, SP
Smith, G
AF Drew, Lisa
Engelman, Jeffrey
Katayama, Ryohei
McDermott, Brenda
Saeh, Jamal
Scarpitti, Meghan
Shaw, Alice
Shen, Minhui
Wang, Suping
Smith, Graeme
TI Concurrent roles for IGF1R and EGFR in driving acquired resistance to
crizotinib and ability to overcome with a combination of the ALK/IGF1R
inhibitor AZD3463 and Iressa.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Drew, Lisa; McDermott, Brenda; Saeh, Jamal; Scarpitti, Meghan; Shen, Minhui; Wang, Suping] AstraZeneca R&D Boston, Waltham, MA USA.
[Engelman, Jeffrey; Shaw, Alice] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Katayama, Ryohei] Japanese Fdn Canc Res, Tokyo, Japan.
[Smith, Graeme] AstraZeneca R&D Alderley Pk, Macclesfield, Cheshire, England.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4465
DI 10.1158/1538-7445.AM2013-4465
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604070
ER
PT J
AU Duda, DG
Tolaney, SM
Ancukiewicz, M
Winer, EP
Krop, IE
Jain, RK
AF Duda, Dan G.
Tolaney, Sara M.
Ancukiewicz, Marek
Winer, Eric P.
Krop, Ian E.
Jain, Rakesh K.
TI A study of circulating biomarkers of angiogenesis and inflammation in ER
plus breast cancer (BC) versus triple-negative breast cancer (TNBC)
patients enrolled in a phase II study of preoperative treatment with 1
cycle of Bevacizumab followed by standard chemo
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Duda, Dan G.; Ancukiewicz, Marek; Jain, Rakesh K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Tolaney, Sara M.; Winer, Eric P.; Krop, Ian E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB81
DI 10.1158/1538-7445.AM2013-LB-81
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601328
ER
PT J
AU Edwards, AL
Gavathiotis, E
LaBelle, JL
Braun, CR
Opoku-Nsiah, K
Bird, GH
Walensky, LD
AF Edwards, Amanda L.
Gavathiotis, Evripidis
LaBelle, James L.
Braun, Craig R.
Opoku-Nsiah, Kwadwo
Bird, Gregory H.
Walensky, Loren D.
TI Multimodal activation of apoptosis by a hydrocarbon-stapled PUMA BH3
helix
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Edwards, Amanda L.; Opoku-Nsiah, Kwadwo; Bird, Gregory H.; Walensky, Loren D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gavathiotis, Evripidis] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[LaBelle, James L.] Univ Chicago Med, Chicago, IL USA.
[Braun, Craig R.] Harvard Univ, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4611
DI 10.1158/1538-7445.AM2013-4611
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604197
ER
PT J
AU Emblem, KE
Mouridsen, K
Bjornerud, A
Farrar, CT
Jennings, D
Borra, RJH
Wen, PY
Ivy, P
Batchelor, TT
Rosen, BR
Jain, RK
Sorensen, AG
AF Emblem, Kyrre E.
Mouridsen, Kim
Bjornerud, Atle
Farrar, Christian T.
Jennings, Dominique
Borra, Ronald J. H.
Wen, Patrick Y.
Ivy, Percy
Batchelor, Tracy T.
Rosen, Bruce R.
Jain, Rakesh K.
Sorensen, A. Gregory
TI Vessel architectural imaging identifies cancer patient responders to
anti-angiogenic therapy.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Emblem, Kyrre E.; Farrar, Christian T.; Jennings, Dominique; Borra, Ronald J. H.; Rosen, Bruce R.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Emblem, Kyrre E.; Farrar, Christian T.; Jennings, Dominique; Borra, Ronald J. H.; Rosen, Bruce R.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Mouridsen, Kim] Univ Aarhus, Ctr Functionally Integrat Neurosci, Aarhus, Denmark.
[Mouridsen, Kim] Univ Aarhus, MINDLab, Aarhus, Denmark.
[Bjornerud, Atle] Oslo Univ Hosp, Intervent Ctr, Oslo, Norway.
[Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA.
[Ivy, Percy] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA.
[Batchelor, Tracy T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Jain, Rakesh K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, Boston, MA 02114 USA.
[Sorensen, A. Gregory] Siemens Healthcare Hlth Serv, Malvern, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB297
DI 10.1158/1538-7445.AM2013-LB-297
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601222
ER
PT J
AU Emerling, BM
Benes, C
Bell, E
Poulogiannis, G
Courtney, K
Lui, H
Choo-Wing, R
Bellinger, G
Soltoff, S
Cantley, L
AF Emerling, Brooke M.
Benes, Cyril
Bell, Eric
Poulogiannis, George
Courtney, Kevin
Lui, Hui
Choo-Wing, Rayman
Bellinger, Gary
Soltoff, Stephen
Cantley, Lewis
TI Identification of CDCP1 as a HIF-2 alpha target gene involved in the
regulation of cancer cell migration and metastasis
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Emerling, Brooke M.; Poulogiannis, George; Lui, Hui; Choo-Wing, Rayman; Bellinger, Gary; Cantley, Lewis] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
[Benes, Cyril] Harvard Univ, Sch Med, Boston, MA USA.
[Bell, Eric] MIT, Cambridge, MA 02139 USA.
[Courtney, Kevin] UT Southwestern, Dallas, TX USA.
[Soltoff, Stephen] BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4588
DI 10.1158/1538-7445.AM2013-4588
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604174
ER
PT J
AU Fuchs, CS
Tomasek, J
Cho, JY
Filip, D
Passalacqua, R
Goswami, C
Safran, H
Dos Santos, LV
Aprile, G
Ferry, D
Melichar, B
Tehfe, M
Topuzov, E
Tabernero, J
Zalcberg, JR
Chau, I
Koshiji, M
Hsu, YZ
Schwartz, J
Ajani, J
AF Fuchs, Charles S.
Tomasek, Jiri
Cho, Jae Yong
Filip, Dumitru
Passalacqua, Rodolfo
Goswami, Chancal
Safran, Howard
Dos Santos, Lucas Vieira
Aprile, Giuseppe
Ferry, David
Melichar, Bohuslav
Tehfe, Moustapha
Topuzov, Eldar
Tabernero, Josep
Raymond Zalcberg, John
Chau, Ian
Koshiji, Minori
Hsu, Yanzhi
Schwartz, Jonathan
Ajani, Jaffer
TI REGARD: A phase III, randomized, double-blind trial of ramucirumab and
best supportive care (BSC) versus placebo and BSC in the treatment of
metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
following disease progression on first-line p
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Fuchs, Charles S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tomasek, Jiri] Masaryk Mem Canc Inst, Brno, Czech Republic.
[Cho, Jae Yong] Gangnam Severance Hosp, Seoul, South Korea.
[Filip, Dumitru] Spitalul Judetean Urgenta, Baia Mare, Romania.
[Passalacqua, Rodolfo] Ist Ospitalieri, Cremona, Italy.
[Goswami, Chancal] BP Poddar Hosp & Med Res, Bengal, India.
[Safran, Howard] Brown Univ, Sch Med, Providence, RI 02912 USA.
[Dos Santos, Lucas Vieira] Hosp Canc Barretos, Barretos, Brazil.
[Aprile, Giuseppe] Univ & Gen Hosp, Dept Oncol, Udine, Italy.
[Ferry, David] New Cross Hosp, Wolverhampton, W Midlands, England.
[Melichar, Bohuslav] Palacky Univ, Sch Med, CR-77147 Olomouc, Czech Republic.
[Melichar, Bohuslav] Palacky Univ, Teaching Hosp, CR-77147 Olomouc, Czech Republic.
[Tehfe, Moustapha] Hop Notre Dame CHUM, Montreal, PQ, Canada.
[Topuzov, Eldar] GOU VPO St Petersburg SMA, St Petersburg, Russia.
[Tabernero, Josep] Vall dHebron Univ Hosp, Barcelona, Spain.
[Raymond Zalcberg, John] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Raymond Zalcberg, John] Univ Melbourne, Melbourne, Vic, Australia.
[Chau, Ian] Royal Marsden Hosp, Surrey, England.
[Koshiji, Minori; Hsu, Yanzhi; Schwartz, Jonathan] Eli Lilly & Co, Bridgewater, NJ USA.
[Ajani, Jaffer] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB67
DI 10.1158/1538-7445.AM2013-LB-67
PG 2
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601315
ER
PT J
AU Ge, RB
Wang, ZW
Olumi, AF
AF Ge Rongbin
Wang, Zongwei
Olumi, Aria F.
TI Metformin has an anticancer effect by repressing TWIST/N-cadherin
signaling
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Ge Rongbin; Wang, Zongwei; Olumi, Aria F.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4965
DI 10.1158/1538-7445.AM2013-4965
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220605063
ER
PT J
AU Gordon, MS
Hamid, O
Powderly, J
Anderson, M
Fine, G
Mokatrin, A
Kowanetz, M
Maya, L
Irving, BA
Chen, DS
Hodi, FS
AF Gordon, Michael S.
Hamid, Omid
Powderly, John
Anderson, Maria
Fine, Gregg
Mokatrin, Ahmad
Kowanetz, Marcin
Maya, Leabman
Irving, Bryan A.
Chen, Daniel S.
Hodi, F. Stephen
TI A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients
with locally advanced or metastatic tumors.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Gordon, Michael S.] Premiere Oncol Arizona, Scottsdale, AZ USA.
[Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA USA.
[Powderly, John] Carolina BioOncol Inst, Huntersville, NC USA.
[Anderson, Maria; Fine, Gregg; Mokatrin, Ahmad; Kowanetz, Marcin; Maya, Leabman; Irving, Bryan A.; Chen, Daniel S.] Genentech Inc, San Francisco, CA 94080 USA.
[Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB288
DI 10.1158/1538-7445.AM2013-LB-288
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601213
ER
PT J
AU Haber, DA
Yu, M
Ozkumar, E
Ting, D
Miyamoto, D
Lee, R
Shah, A
Bardia, A
Stott, S
Toner, M
Maheswaran, S
AF Haber, Daniel A.
Yu, Min
Ozkumar, Emre
Ting, David
Miyamoto, David
Lee, Richard
Shah, Ajay
Bardia, Aditya
Stott, Shannon
Toner, Mehmet
Maheswaran, Shyamala
TI Molecular characterization of single circulating tumor cells
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Haber, Daniel A.; Yu, Min; Ozkumar, Emre; Ting, David; Miyamoto, David; Lee, Richard; Shah, Ajay; Bardia, Aditya; Stott, Shannon; Toner, Mehmet; Maheswaran, Shyamala] Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA SY3001
DI 10.1158/1538-7445.AM2013-SY30-01
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220602002
ER
PT J
AU Hansen, JE
Chan, G
Liu, YF
Hegan, DC
Dalal, S
Dray, E
Kwon, Y
Xu, YY
Xu, XH
Peterson-Roth, E
Geiger, E
Liu, YL
Gera, J
Sweasy, JB
Sung, P
Rockwell, S
Nishimura, RN
Weisbart, RH
Glazer, PM
AF Hansen, James E.
Chan, Grace
Liu, Yanfeng
Hegan, Denise C.
Dalal, Shibani
Dray, Eloise
Kwon, Youngho
Xu, Yuanyuan
Xu, Xiaohua
Peterson-Roth, Elizabeth
Geiger, Erik
Liu, Yilun
Gera, Joseph
Sweasy, Joann B.
Sung, Patrick
Rockwell, Sara
Nishimura, Robert N.
Weisbart, Richard H.
Glazer, Peter M.
TI Lupus antibody-based cancer therapy.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Hansen, James E.; Liu, Yanfeng; Hegan, Denise C.; Dalal, Shibani; Dray, Eloise; Kwon, Youngho; Xu, Yuanyuan; Peterson-Roth, Elizabeth; Geiger, Erik; Sweasy, Joann B.; Sung, Patrick; Rockwell, Sara; Glazer, Peter M.] Yale Univ, Sch Med, New Haven, CT USA.
[Chan, Grace; Gera, Joseph; Nishimura, Robert N.; Weisbart, Richard H.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda, CA USA.
[Xu, Xiaohua; Liu, Yilun] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA.
RI Dray, Eloise/E-3938-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4319
DI 10.1158/1538-7445.AM2013-4319
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220603326
ER
PT J
AU He, L
Torres-Lockhart, K
Forster, N
Ramakrishnan, S
Greninger, P
Garnett, MJ
McDermott, U
Rothenberg, SM
Benes, C
Ellisen, L
AF He, Lei
Torres-Lockhart, Kristine
Forster, Nicole
Ramakrishnan, Saranya
Greninger, Patricia
Garnett, Mathew J.
McDermott, Ultan
Rothenberg, S. Michael
Benes, Cyril
Ellisen, Leif
TI Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and
BcI-2 inhibitor synergy in squamous cell carcinoma.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [He, Lei; Torres-Lockhart, Kristine; Forster, Nicole; Ramakrishnan, Saranya; Greninger, Patricia; Rothenberg, S. Michael; Benes, Cyril; Ellisen, Leif] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Garnett, Mathew J.; McDermott, Ultan] Wellcome Trust Sanger Inst, Cambridge, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB212
DI 10.1158/1538-7445.AM2013-LB-212
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601142
ER
PT J
AU Hettmer, S
Schinzel, A
Hahn, WC
Wagers, A
AF Hettmer, Simone
Schinzel, Anna
Hahn, William C.
Wagers, Amy
TI Target identification in rhabdomyosarcomas induced in mouse skeletal
muscle
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Hettmer, Simone; Schinzel, Anna; Hahn, William C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wagers, Amy] Joslin Diabet Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3812
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220603045
ER
PT J
AU Hu, H
Wulf, G
Juvekar, A
Dittmer, DP
Fingeroth, J
AF Hu, Hai
Wulf, Gerburg
Juvekar, Ashish
Dittmer, Dirk P.
Fingeroth, Joyce
TI EBV infection of mammary epithelial cells promotes malignant
transformation
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Hu, Hai; Wulf, Gerburg; Juvekar, Ashish] BIDMC, Boston, MA USA.
[Dittmer, Dirk P.] Univ N Carolina, Chapel Hill, NC USA.
[Fingeroth, Joyce] HMS, BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4781
DI 10.1158/1538-7445.AM2013-4781
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604343
ER
PT J
AU Huang, FW
Hodis, E
Xu, MJ
Kryukov, G
Chin, L
Garraway, LA
AF Huang, Franklin W.
Hodis, Eran
Xu, Mary Jue
Kryukov, Gregory
Chin, Lynda
Garraway, Levi A.
TI The identification of recurrent non-coding mutations in melanoma.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Huang, Franklin W.; Hodis, Eran; Xu, Mary Jue; Kryukov, Gregory; Garraway, Levi A.] Dana Farber Canc Inst, Broad Inst, Boston, MA 02115 USA.
[Chin, Lynda] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB228
DI 10.1158/1538-7445.AM2013-LB-228
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601157
ER
PT J
AU Huang, YH
Yuan, JP
Righi, E
Duda, DG
Fukumura, D
Poznanasky, MC
Jain, RK
AF Huang, Yuhui
Yuan, Jianping
Righi, Elda
Duda, Dan G.
Fukumura, Dai
Poznanasky, Mark C.
Jain, Rakesh K.
TI Vascular normalization as an emerging strategy to enhance cancer
immunotherapy
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Huang, Yuhui; Yuan, Jianping; Righi, Elda; Duda, Dan G.; Fukumura, Dai; Poznanasky, Mark C.; Jain, Rakesh K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB344
DI 10.1158/1538-7445.AM2013-LB-344
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601269
ER
PT J
AU Infante, JR
Gandi, L
Shapiro, G
Rizvi, N
Burris, HA
Bendell, JC
Baselga, J
Hsu, K
von Richter, O
Locatelli, G
Asatiani, E
Heist, RS
AF Infante, Jeffrey R.
Gandi, Leena
Shapiro, Geoffrey
Rizvi, Naiyer
Burris, Howard A.
Bendell, Johanna C.
Baselga, Jose
Hsu, Karl
von Richter, Oliver
Locatelli, Giuseppe
Asatiani, Ekaterine
Heist, Rebecca S.
TI Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the
PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors:
Results of a phase Ib dose-escalation trial.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Infante, Jeffrey R.; Burris, Howard A.; Bendell, Johanna C.] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA.
[Gandi, Leena; Shapiro, Geoffrey] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rizvi, Naiyer] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Baselga, Jose; Heist, Rebecca S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hsu, Karl] Sanofi, Cambridge, MA USA.
[von Richter, Oliver] Merck KGaA, Global Exploratory Med, Darmstadt, Germany.
[Locatelli, Giuseppe] Merck KGaA, Global Res & Early Dev, Darmstadt, Germany.
[Asatiani, Ekaterine] Merck Serono SA, Geneva, Switzerland.
RI von Richter, Oliver/O-6412-2016
OI von Richter, Oliver/0000-0002-5262-9922
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB147
DI 10.1158/1538-7445.AM2013-LB-147
PG 2
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601086
ER
PT J
AU Irimia, D
AF Irimia, Daniel
TI Self-guided migration of cancer epithelial cells in confined
environment.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Irimia, Daniel] Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3779
DI 10.1158/1538-7445.AM2013-3779
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220603013
ER
PT J
AU Jamin, Y
Glass, L
Hallsworth, A
George, RE
Koh, DM
Pearson, ADJ
Chesler, L
Robinson, SP
AF Jamin, Yann
Glass, Laura
Hallsworth, Albert
George, Rani E.
Koh, Dow-Mu
Pearson, Andrew D. J.
Chesler, Louis
Robinson, Simon P.
TI Intrinsic susceptibility magnetic resonance imaging identifies tumors
with ALKF1174L mutation in transgenic murine models of high-risk
neuroblastoma.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Jamin, Yann; Glass, Laura; Hallsworth, Albert; Koh, Dow-Mu; Pearson, Andrew D. J.; Chesler, Louis; Robinson, Simon P.] Inst Canc Res, Sutton, Surrey, England.
[George, Rani E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[George, Rani E.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 5037
DI 10.1158/1538-7445.AM2013-5037
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220605133
ER
PT J
AU Jones, DTW
Hutter, B
Jager, N
Korshunov, A
Kool, M
Lambert, SR
Quang, DAK
Fontebasso, AM
Ryzhova, M
Warnatz, HJ
Zichner, T
Korbel, JO
Wolf, S
Yaspo, ML
Ligon, KL
Kieran, MW
Brors, B
Feisberg, J
Reifenberger, G
Collins, VP
Jabado, N
Elis, R
Lichter, P
Pfister, SM
AF Jones, David T. W.
Hutter, Barbara
Jaeger, Natalie
Korshunov, Andrey
Kool, Marcel
Lambert, Sally R.
Dong Anh Khuong Quang
Fontebasso, Adam M.
Ryzhova, Marina
Warnatz, Hans-Joerg
Zichner, Thomas
Korbel, Jan O.
Wolf, Stephan
Yaspo, Marie-Laure
Ligon, Keith L.
Kieran, Mark W.
Brors, Benedikt
Feisberg, Joerg
Reifenberger, Guido
Collins, V. Peter
Jabado, Nada
Elis, Roland
Lichter, Peter
Pfister, Stefan M.
CA ICGC PedBrain Tumor Project
TI Recurrent FGFR1 hotspot mutations represent a novel therapeutic target
in childhood astrocytorna
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Jones, David T. W.; Hutter, Barbara; Jaeger, Natalie; Kool, Marcel; Wolf, Stephan; Brors, Benedikt; Elis, Roland; Lichter, Peter; Pfister, Stefan M.] German Canc Res Ctr, Heidelberg, Germany.
[Korshunov, Andrey] Heidelberg Univ, Heidelberg, Germany.
[Lambert, Sally R.; Collins, V. Peter] Univ Cambridge, Cambridge, England.
[Dong Anh Khuong Quang; Fontebasso, Adam M.; Jabado, Nada] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada.
[Ryzhova, Marina] Burdenko Neurosurg Inst, Moscow, Russia.
[Warnatz, Hans-Joerg; Yaspo, Marie-Laure] Max Planck Inst Mol Genet, D-14195 Berlin, Germany.
[Zichner, Thomas; Korbel, Jan O.] European Mol Biol Lab, D-69012 Heidelberg, Germany.
[Ligon, Keith L.; Kieran, Mark W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Feisberg, Joerg; Reifenberger, Guido] Univ Dusseldorf, Dusseldorf, Germany.
RI Kool, Marcel/H-2541-2013; Pfister, Stefan/F-6860-2013
OI Pfister, Stefan/0000-0002-5447-5322
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4594
DI 10.1158/1538-7445.AM2013-4594
PG 2
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604180
ER
PT J
AU Juric, D
Dienstmann, R
Cervantes, A
Hidalgo, M
Messersmith, W
Blumenschein, G
Baselga, J
Tabernero, J
Roda, D
Calles, A
Jimeno, A
Amler, L
Stern, H
Sanabria, S
Penuel, E
Pirzkall, A
AF Juric, Dejan
Dienstmann, Rodrigo
Cervantes, Andres
Hidalgo, Manuel
Messersmith, Wells
Blumenschein, George
Baselga, Jose
Tabernero, Josep
Roda, Desamparados
Calles, Antonio
Jimeno, Antonio
Amler, Lukas
Stern, Howard
Sanabria, Sandra
Penuel, Elicia
Pirzkall, Andrea
TI Pharmacodynamic (PD) assessment of drug activity in tumor tissue from
patients (pts) enrolled in a Phase I study of MEHD7945A (MEHD), a
first-in-class HER3/EGFR dual action antibody, in pts with locally
advanced or metastatic epithelial tumors.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Juric, Dejan; Baselga, Jose] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Dienstmann, Rodrigo; Tabernero, Josep] Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain.
[Cervantes, Andres; Roda, Desamparados] Univ Valencia, INCLIVA Hlth Res Inst, Valencia, Spain.
[Hidalgo, Manuel; Calles, Antonio] Spanish Natl Canc Res Ctr, Gastrointestinal Canc Clin Res Unit, Madrid, Spain.
[Messersmith, Wells; Jimeno, Antonio] Univ Colorado, Ctr Canc, Div Med Oncol, Denver, CO 80262 USA.
[Blumenschein, George] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Amler, Lukas; Stern, Howard; Sanabria, Sandra; Penuel, Elicia; Pirzkall, Andrea] Genentech Inc, San Francisco, CA 94080 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3363
DI 10.1158/1538-7445.AM2013-3363
PG 2
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220602070
ER
PT J
AU Juric, D
Krop, I
Ramanathan, RK
Xiao, J
Sanabria, S
Wilson, TR
Choi, YJ
Parmar, H
Hsu, J
Baselga, J
Von Hoff, DD
AF Juric, Dejan
Krop, Ian
Ramanathan, Ramesh K.
Xiao, Jim
Sanabria, Sandra
Wilson, Timothy R.
Choi, YounJeong
Parmar, Hema
Hsu, Jerry
Baselga, Jose
Von Hoff, Daniel D.
TI GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a
first-in-human phase la dose escalation study.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Juric, Dejan; Baselga, Jose] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Krop, Ian] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ramanathan, Ramesh K.; Von Hoff, Daniel D.] Virginia G Piper Canc Ctr TGen, Scottsdale, AZ USA.
[Xiao, Jim; Sanabria, Sandra; Wilson, Timothy R.; Choi, YounJeong; Parmar, Hema; Hsu, Jerry] Genentech Inc, San Francisco, CA 94080 USA.
NR 0
TC 3
Z9 3
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB64
DI 10.1158/1538-7445.AM2013-LB-64
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601312
ER
PT J
AU Katayama, R
Aoyama, A
Yamori, T
Qi, J
Ohara, T
Song, YC
Engelman, JA
Fujita, N
AF Katayama, Ryohei
Aoyama, Aki
Yamori, Takao
Qi, Jie
Ohara, Tomoko
Song, Youngchul
Engelman, Jeffrey A.
Fujita, Naoya
TI Antitumor activity of Tivantinib (ARQ 197) is due to inhibition of
tubulin polymerization in addition to c-Met inhibition.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Katayama, Ryohei; Aoyama, Aki; Yamori, Takao; Ohara, Tomoko; Fujita, Naoya] Japanese Fdn Canc Res, Tokyo, Japan.
[Qi, Jie; Song, Youngchul; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4348
DI 10.1158/1538-7445.AM2013-4348
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220603355
ER
PT J
AU Katiyar, SK
Vaid, M
AF Katiyar, Santosh K.
Vaid, Mudit
TI Bioactive phytochemical proanthocyanidins target beta-catenin signaling
in preventing invasive potential of human melanoma cells.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Katiyar, Santosh K.; Vaid, Mudit] Univ Alabama Birmingham, Birmingham, AL USA.
[Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3683
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220602319
ER
PT J
AU Katiyar, SK
Vaid, M
AF Katiyar, Santosh K.
Vaid, Mudit
TI Bioactive phytochemical proanthocyanidins target beta-catenin signaling
in preventing invasive potential of human melanoma cells
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Katiyar, Santosh K.; Vaid, Mudit] Univ Alabama Birmingham, Birmingham, AL USA.
[Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3683
DI 10.1158/1538-7445.AM2013-3683
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220600303
ER
PT J
AU Kleiman, LB
Krebs, A
Kim, S
Hong, TS
Haigis, KM
AF Kleiman, Laura B.
Krebs, Angela
Kim, Stephen
Hong, Theodore S.
Haigis, Kevin M.
TI Identification and characterization of small molecule inhibitors that
radiosensitize K-RAS mutant rectal cancers
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Kleiman, Laura B.; Krebs, Angela; Kim, Stephen; Hong, Theodore S.; Haigis, Kevin M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4440
DI 10.1158/1538-7445.AM2013-4440
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604045
ER
PT J
AU Kohlenberg, JD
Chen, YL
Best, B
Storz, P
Peterson, RT
Silverstein, R
Ren, B
AF Kohlenberg, Jacob D.
Chen, Yiliang
Best, Brad
Storz, Peter
Peterson, Randall T.
Silverstein, Roy
Ren, Bin
TI A novel LPA-PKD1-FoxO1 pathway in endothelial cells provides an
angiogenic switch via down-regulation of CD36 transcription and
induction of arteriogenic responses
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Kohlenberg, Jacob D.] Med Coll Wisconsin, MD Program, Milwaukee, WI 53226 USA.
[Chen, Yiliang; Best, Brad] Blood Ctr Wisconsin, Blood Res Inst, Milwaukee, WI USA.
[Storz, Peter] Mayo Clin, Mayo Clin Comprehens Canc Ctr, Dept Canc Biol, Jacksonville, FL 32224 USA.
[Peterson, Randall T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Charlestown, MA USA.
[Silverstein, Roy] Med Coll Wisconsin, Blood Ctr Wisconsin, Dept Med, Blood Res Inst, Milwaukee, WI 53226 USA.
[Silverstein, Roy; Ren, Bin] Med Coll Wisconsin, Tumor Microenvironm Res Program, Ctr Canc, Milwaukee, WI 53226 USA.
[Ren, Bin] Med Coll Wisconsin, Blood Ctr Wisconsin, Blood Res Inst, Div Hematol & Oncol, Milwaukee, WI 53226 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB338
DI 10.1158/1538-7445.AM2013-LB-338
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601262
ER
PT J
AU Labidi-Galy, I
Clauss, A
Ng, V
Duraisamy, S
Ganesan, S
Drapkin, R
AF Labidi-Galy, Intidhar
Clauss, Adam
Ng, Vivian
Duraisamy, Sekhar
Ganesan, Shridar
Drapkin, Ronny
TI Elafin is a candidate biomarker that underlies the similarities between
basal-like breast cancer and ovarian cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Labidi-Galy, Intidhar; Clauss, Adam; Ng, Vivian; Duraisamy, Sekhar; Drapkin, Ronny] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ganesan, Shridar] Canc Inst New Jersey, New Brunswick, NJ USA.
RI Drapkin, Ronny/E-9944-2016
OI Drapkin, Ronny/0000-0002-6912-6977
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3455
DI 10.1158/1538-7445.AM2013-3455
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220602161
ER
PT J
AU Li, J
Zhu, S
Kozono, D
Futulan, D
Gonda, D
Kushwaha, D
Kahle, K
Elledge, S
Chen, CC
AF Li, Jie
Zhu, Shan
Kozono, David
Futulan, Diahnn
Gonda, David
Kushwaha, Deepa
Kahle, Kristopher
Elledge, Stephen
Chen, Clark C.
TI ShRNA-based cellular proliferation signaling analysis revealed DRD2 as a
novel therapeutic target for glioblastoma.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Li, Jie; Futulan, Diahnn; Gonda, David; Chen, Clark C.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
[Zhu, Shan; Kozono, David; Kushwaha, Deepa] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Genom Instabil & DNA Repair,Dept Radiat Oncol, Boston, MA 02115 USA.
[Kahle, Kristopher; Elledge, Stephen] Harvard Univ, Sch Med, Dept Genet, Div Genom Instabil & DNA Repair, Boston, MA USA.
RI Li, Jie/L-1737-2015
OI Li, Jie/0000-0002-0590-9817
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4366
DI 10.1158/1538-7445.AM2013-4366
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220603373
ER
PT J
AU Li, WQ
Han, JL
Widlund, H
Correll, M
Wang, YY
Quackenbush, J
Mihm, M
Canales, AL
Golub, T
Hoshida, Y
Hunter, D
Murphy, G
Kupper, T
Qureshi, A
AF Li, Wenqing
Han, Jiali
Widlund, Hans
Correll, Mick
Wang, Yaoyu
Quackenbush, John
Mihm, Martin
Canales, Alvaro Laga
Golub, Todd
Hoshida, Yujin
Hunter, David
Murphy, George
Kupper, Thomas
Qureshi, Abrar
TI CXCR4 pathway associated with family history of melanoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Li, Wenqing; Han, Jiali; Widlund, Hans; Canales, Alvaro Laga; Hunter, David; Murphy, George; Kupper, Thomas; Qureshi, Abrar] Harvard Univ, Sch Med, Boston, MA USA.
[Correll, Mick; Wang, Yaoyu; Quackenbush, John] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mihm, Martin] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Golub, Todd; Hoshida, Yujin] Harvard Univ, Sch Med, Broad Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 1347
DI 10.1158/1538-7445.AM2013-1347
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220600131
ER
PT J
AU Lu-Emerson, C
Snuderl, M
Kirkpatrick, ND
Goveia, J
Taylor, J
Davidson, C
Huang, YH
Riedemann, L
Ivy, SP
Duda, GD
Ancukiewicz, M
Plotkin, SR
Chi, A
Gerstner, ER
Eichler, AF
Dietrich, J
Stemmer-Rachamimov, AO
Batchelor, TT
Jain, RK
AF Lu-Emerson, Christine
Snuderl, Matija
Kirkpatrick, Nathaniel D.
Goveia, Jermaine
Taylor, Jennie
Davidson, Christian
Huang, Yuhui
Riedemann, Lars
Ivy, S. Percy
Duda, G. Dan
Ancukiewicz, Marek
Plotkin, Scott R.
Chi, Andrew
Gerstner, Elizabeth R.
Eichler, April F.
Dietrich, Jorg
Stemmer-Rachamimov, Anat O.
Batchelor, Tracy T.
Jain, Rakesh K.
TI Increase in tumor-associated macrophages (TAMs) after antiangiogenic
therapy is associated with poor survival in recurrent glioblastoma (GBM)
patients
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Lu-Emerson, Christine] Maine Med Ctr, Scarborough, ME USA.
[Snuderl, Matija] NYU, Langone Med Ctr, New York, NY USA.
[Kirkpatrick, Nathaniel D.; Goveia, Jermaine; Taylor, Jennie; Davidson, Christian; Huang, Yuhui; Riedemann, Lars; Duda, G. Dan; Ancukiewicz, Marek; Plotkin, Scott R.; Chi, Andrew; Gerstner, Elizabeth R.; Eichler, April F.; Dietrich, Jorg; Stemmer-Rachamimov, Anat O.; Batchelor, Tracy T.; Jain, Rakesh K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ivy, S. Percy] NCI, Bethesda, MD 20892 USA.
RI Riedemann, Lars/J-5725-2014;
OI Riedemann, Lars/0000-0002-9510-1845; Snuderl, Matija/0000-0003-0752-0917
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB339
DI 10.1158/1538-7445.AM2013-LB-339
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601263
ER
PT J
AU Lui, VWY
Van Allen, E
Li, H
Zhang, F
Zeng, Y
Johnson, JT
Garraway, LA
Mills, GB
Grandis, JR
AF Lui, Vivian W. Y.
Van Allen, Eliezer
Li, Hua
Zhang, Fan
Zeng, Yan
Johnson, Jonas T.
Garraway, Levi A.
Mills, Gordon B.
Grandis, Jennifer Rubin
TI Whole exome sequencing links MAPK1 mutation to exquisite sensitivity to
brief erlotinib monotherapy in head and neck cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Lui, Vivian W. Y.; Li, Hua; Zeng, Yan; Johnson, Jonas T.; Grandis, Jennifer Rubin] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Van Allen, Eliezer; Garraway, Levi A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
RI Lui, Vivian/I-5458-2016
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4565
DI 10.1158/1538-7445.AM2013-4565
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604165
ER
PT J
AU Maertens, O
Johnson, B
Hollstein, P
Frederick, D
Cooper, Z
Messiaen, L
Bronson, R
McMahon, M
Granter, S
Flaherty, K
Wargo, J
Marais, R
Cichowski, K
AF Maertens, Ophella
Johnson, Bryan
Hollstein, Pablo
Frederick, Dennie
Cooper, Zachary
Messiaen, Ludwine
Bronson, Roderick
McMahon, Martin
Granter, Scott
Flaherty, Keith
Wargo, Jennier
Marais, Richard
Cichowski, Karen
TI Elucidating distinct roles for NF1 in melanomagenesis.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Maertens, Ophella; Johnson, Bryan; Hollstein, Pablo; Bronson, Roderick; Granter, Scott; Cichowski, Karen] Brigham & Womens Hosp, Boston, MA USA.
[Maertens, Ophella; Johnson, Bryan; Hollstein, Pablo; Bronson, Roderick; Granter, Scott; Cichowski, Karen] Harvard Med Sch, Boston, MA USA.
[Frederick, Dennie; Cooper, Zachary; Flaherty, Keith; Wargo, Jennier] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Messiaen, Ludwine] Univ Alabama Birmingham, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 5201
DI 10.1158/1538-7445.AM2013-5201
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220605295
ER
PT J
AU McEachern, KA
Cao, YC
DuPont, R
Pablo, L
McCoon, P
Cortes, JE
DeAngelo, DJ
Minden, MD
Hewes, B
Brown, JL
Barrett, C
AF McEachern, Kristen A.
Cao, Yichen
DuPont, Rachel
Pablo, Lourdes
McCoon, Patricia
Cortes, Jorge E.
DeAngelo, Daniel J.
Minden, Mark D.
Hewes, Becker
Brown, Jeffrey L.
Barrett, Carl
TI AZD1208 PIM kinase inhibitor - Preliminary evidence of target pathway
inhibition in Phase I clinical trials of AML
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [McEachern, Kristen A.; Cao, Yichen; DuPont, Rachel; Pablo, Lourdes; McCoon, Patricia; Hewes, Becker; Brown, Jeffrey L.; Barrett, Carl] AstraZeneca R&D Boston, Waltham, MA USA.
[Cortes, Jorge E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Minden, Mark D.] Princess Margaret Canc Ctr, Toronto, ON, Canada.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3516
DI 10.1158/1538-7445.AM2013-3516
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220602220
ER
PT J
AU Miao, BC
Zhang, JM
Ji, ZY
Njauw, CN
Taylor, M
Kumar, R
Gray, N
Tsao, HS
AF Miao, Benchun
Zhang, Jianming
Ji, Zhenyu
Njauw, Ching Ni
Taylor, Michael
Kumar, Raj
Gray, Nathanael
Tsao, Hensin
TI Pharmacologic inhibition of EphA2 in NRAS and BRAF mutant melanomas.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Miao, Benchun; Ji, Zhenyu; Njauw, Ching Ni; Taylor, Michael; Kumar, Raj; Tsao, Hensin] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Zhang, Jianming; Gray, Nathanael] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 5605
DI 10.1158/1538-7445.AM2013-5605
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220606083
ER
PT J
AU Mitchell-Ryan, SK
Wang, L
Orr, S
Kugel, S
Cherian, C
Gangjee, A
Matherly, LH
AF Mitchell-Ryan, Shermaine K.
Wang, Lei
Orr, Steven
Kugel, Sita
Cherian, Christina
Gangjee, Aleem
Matherly, Larry H.
TI Novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate
regioisomers target folate receptor alpha positive ovarian cancer cells
via inhibition of de novo purine nucleotide biosynthesis
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Mitchell-Ryan, Shermaine K.; Matherly, Larry H.] Wayne State Univ, Sch Med, Detroit, MI USA.
[Wang, Lei; Gangjee, Aleem] Duquesne Univ, Pittsburgh, PA 15219 USA.
[Orr, Steven; Cherian, Christina] Barbara Ann Karmanos Canc Inst, Detroit, MI USA.
[Kugel, Sita] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 5494
DI 10.1158/1538-7445.AM2013-5494
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220605373
ER
PT J
AU Montero, J
Letai, A
AF Montero, Joan
Letai, Anthony
TI Personalizing cancer therapy using dynamic BH3 profiling
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Montero, Joan; Letai, Anthony] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4569
DI 10.1158/1538-7445.AM2013-4569
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604169
ER
PT J
AU Mudge, DK
Serhan, K
Bielenberg, DR
Hwang, SH
Hammock, BD
Kieran, MW
Panigrahy, D
AF Mudge, Dayna K.
Serhan, Karolina
Bielenberg, Diane R.
Hwang, Sung Hee
Hammock, Bruce D.
Kieran, Mark W.
Panigrahy, Dipak
TI Control of tumor lymphangiogenesis by epoxyeicosanoids
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Mudge, Dayna K.; Serhan, Karolina; Bielenberg, Diane R.; Panigrahy, Dipak] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA USA.
[Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, Davis, CA 95616 USA.
[Kieran, Mark W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Pediat Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4961
DI 10.1158/1538-7445.AM2013-4961
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220605059
ER
PT J
AU Muvaffak, A
Pan, Q
Middleton, R
Morris, E
Fernandez, R
Lim, J
Dolinski, B
Nguyen, TT
Strack, P
Yan, HY
Chung, R
Wu, S
Zriang, WQ
Hulton, C
Hirsch, H
Nagashimo, K
Wang, Y
AF Muvaffak, Asli
Pan, Qi
Middleton, Richard
Morris, Erick
Fernandez, Rafael
Lim, Jonwong
Dolinski, Brian
Nguyen, Thi T.
Strack, Peter
Yan, Haiyan
Chung, Rossana
Wu, Stephen
Zriang, Weiqun
Hulton, Chris
Hirsch, Heather
Nagashimo, Kumiko
Wang, Yan
TI Evaluating TBK1 as a cancer therapeutic target in cancer cell lines with
activated IRF3
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Muvaffak, Asli; Pan, Qi; Middleton, Richard; Yan, Haiyan; Chung, Rossana; Wu, Stephen; Zriang, Weiqun; Hulton, Chris] Dana Farber Canc Inst, Beifer Inst Appl Canc Sci, Boston, MA 02115 USA.
[Morris, Erick; Fernandez, Rafael; Lim, Jonwong; Dolinski, Brian; Nguyen, Thi T.; Strack, Peter; Hirsch, Heather; Nagashimo, Kumiko; Wang, Yan] Merck Res Labs, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4372
DI 10.1156/1538-7445.M2013-4372
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220603379
ER
PT J
AU Namba, T
Tian, F
Chu, KK
Hwang, SY
Lee, SW
AF Namba, Takushi
Tian, Fang
Chu, Kiki
Hwang, So-Young
Lee, Sam W.
TI CDIP-BAP31 complex bridges endoplasmic reticulum and mitochondria during
ER-stress mediated apoptosis
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 Massachusetts Gen Hosp, Charlestown, MA USA.
Harvard Univ, Sch Med, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4605
DI 10.1158/1538-7445.AM2013-4605
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604191
ER
PT J
AU Nimptsch, K
Zhang, XH
Giovannucci, E
Cassidy, A
O'Reilly, EJ
Pischon, T
Rimm, EB
Lin, J
Willett, WC
Fuchs, CS
Wu, K
AF Nimptsch, Katharina
Zhang, Xuehong
Giovannucci, Edward
Cassidy, Aedin
O'Reilly, Ellis J.
Pischon, Tobias
Rimm, Eric B.
Lin, Jennifer
Willett, Walter C.
Fuchs, Charles S.
Wu, Kana
TI Habitual intake of total flavonoids and flavonoid subclasses and risk of
colorectal cancer in men and women
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Nimptsch, Katharina; Pischon, Tobias] Max Delbruck Ctr Mol Med, Berlin, Germany.
[Zhang, Xuehong] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Zhang, Xuehong] Harvard Univ, Sch Med, Boston, MA USA.
[Giovannucci, Edward; O'Reilly, Ellis J.; Rimm, Eric B.; Willett, Walter C.; Wu, Kana] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Cassidy, Aedin] Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England.
[Lin, Jennifer] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA.
[Fuchs, Charles S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4820
DI 10.1158/1538-7445.AM2013-4820
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220600353
ER
PT J
AU Norris, MD
Gamble, LD
Murray, J
Purqato, S
Miiazzo, G
Ashton, LJ
Oberthuer, A
London, WB
Hogarty, MD
Fischer, M
Ziegler, D
Marshall, GM
Perini, G
Haber, M
AF Norris, Murray D.
Gamble, Laura D.
Murray, Jayne
Purqato, Stefania
Miiazzo, Giorgio
Ashton, Lesley J.
Oberthuer, Andrei
London, Wendy B.
Hogarty, Mike D.
Fischer, Mattias
Ziegler, David
Marshall, Glenn M.
Perini, Giovanni
Haber, Michelle
TI MYCN coordinately regulates the entire polyamine gene pathway to drive
polyamine biosynthesis in neuroblastoma, with expression of every
synthetic and catabolic polyamine pathway gene being highly prognostic
of clinical outcome
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Norris, Murray D.; Gamble, Laura D.; Murray, Jayne; Ashton, Lesley J.; Haber, Michelle] Childrens Canc Inst Australia, Sydney, NSW, Australia.
[Purqato, Stefania; Miiazzo, Giorgio] Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy.
[Oberthuer, Andrei; Fischer, Mattias] Univ Cologne, Dept Pediat Oncol & Hematol, Childrens Hosp Cologne, Cologne, Germany.
[London, Wendy B.] Dana Farber Harvard Canc Ctr, Childrens Oncol Grp Stat, Boston, MA USA.
[London, Wendy B.] Dana Farber Harvard Canc Ctr, Ctr Data, Boston, MA USA.
[London, Wendy B.] Childrens Hosp, Boston, MA 02115 USA.
[Hogarty, Mike D.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Ziegler, David; Marshall, Glenn M.] Sydney Childrens Hosp, Sydney, NSW, Australia.
[Ziegler, David; Marshall, Glenn M.] Childrens Canc Inst Australia, Sydney, NSW, Australia.
[Perini, Giovanni] Univ Bologna, Interdept Ctr Ind Res HST ICIR, Bologna, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3808
PG 2
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220603042
ER
PT J
AU Ojesina, AI
Lichtenstein, L
Ambrogio, L
Cibulskis, K
Freeman, S
Pedamallu, CS
Bertelsen, B
Imaz, I
Vazquez, K
Guadarrama, AS
Trevino, V
Romero-Cordoba, S
Duke, F
Kaplan, B
Rodriguez, I
Castilla, ME
Woie, K
Bjorge, L
Wik, E
Halle, MK
Hoivik, E
Krakstad, C
Macias, GG
Rodriguez, MDLG
Vazquez, J
Rodea, C
Cravioto, A
Cortes, ML
Greulich, H
Crum, CP
Akslen, L
Saldana, HB
Melendez-Zajgla, J
Getz, G
Salvesen, HB
Meyerson, ML
AF Ojesina, Akinyemi I.
Lichtenstein, Lee
Ambrogio, Lauren
Cibulskis, Kristian
Freeman, Samuel
Pedamallu, Chandra Sekhar
Bertelsen, Bjorn
Imaz, Ivan
Vazquez, Karla
Salido Guadarrama, Alberto
Trevino, Victor
Romero-Cordoba, Sandra
Duke, Fujiko
Kaplan, Bethany
Rodriguez, Iram
Espinosa Castilla, Magali
Woie, Katherine
Bjorge, Line
Wik, Elisabeth
Halle, Mari K.
Hoivik, Erling
Krakstad, Camilla
Gomez Macias, Gabriela
Garza Rodriguez, Maria de Lourdes
Vazquez, Jorge
Rodea, Carlos
Cravioto, Adrian
Cortes, Maria L.
Greulich, Heidi
Crum, Christopher P.
Akslen, Lars
Barrera Saldana, Hugo
Melendez-Zajgla, Jorge
Getz, Gad
Salvesen, Helga B.
Meyerson, Matthew L.
TI Landscape of human and viral genomic alterations in cervical carcinomas
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Ojesina, Akinyemi I.; Pedamallu, Chandra Sekhar; Meyerson, Matthew L.] Dana Farber Canc Inst, Broad Inst, Cambridge, MA USA.
[Lichtenstein, Lee; Ambrogio, Lauren; Cibulskis, Kristian; Freeman, Samuel; Bertelsen, Bjorn; Cortes, Maria L.; Getz, Gad] Broad Inst, Cambridge, MA USA.
[Bertelsen, Bjorn; Woie, Katherine; Bjorge, Line; Wik, Elisabeth; Halle, Mari K.; Hoivik, Erling; Krakstad, Camilla; Akslen, Lars; Salvesen, Helga B.] Haukeland Hosp, Bergen, Norway.
[Imaz, Ivan; Vazquez, Karla; Salido Guadarrama, Alberto; Romero-Cordoba, Sandra; Espinosa Castilla, Magali; Melendez-Zajgla, Jorge] Inst Nacl Med Genom, Mexico City, DF, Mexico.
[Trevino, Victor] Inst Tecnol & Estudios Super, Monterrey, Mexico.
[Duke, Fujiko; Kaplan, Bethany] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rodriguez, Iram; Barrera Saldana, Hugo] Univ Autonoma Nuevo Leon, Monterrey, Mexico.
[Gomez Macias, Gabriela] Univ Autonoma Nuevo Leon, Mexico City, DF, Mexico.
[Vazquez, Jorge; Rodea, Carlos; Cravioto, Adrian] Ctr Med Nacl SXXI, Mexico City, DF, Mexico.
[Crum, Christopher P.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RI Trevino, Victor/C-9219-2009; Romero-Cordoba, Sandra Lorena/A-2246-2014;
Akslen, Lars /C-1202-2017; Bjorge, Line/C-1307-2017; salvesen,
Helga/C-1187-2017
OI Trevino, Victor/0000-0002-7472-9844; Ojesina,
Akinyemi/0000-0003-0755-3639; Romero-Cordoba, Sandra
Lorena/0000-0002-5591-696X; Akslen, Lars /0000-0003-2710-9543; Bjorge,
Line/0000-0002-0240-2770; salvesen, Helga/0000-0002-4438-8831
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4604
DI 10.1158/1538-7445.AM2013-4604
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604190
ER
PT J
AU Ondracek, RP
Mohler, JL
Pilarz, C
McEvoy, S
Kasza, K
Morrison, C
Marshall, J
AF Ondracek, Rochelle P.
Mohler, James L.
Pilarz, Catherine
McEvoy, Sarah
Kasza, Karin
Morrison, Carl
Marshall, James
TI Comparison of manual and automated scoring of androgen receptor staining
in prostate tissue
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Ondracek, Rochelle P.; Mohler, James L.; McEvoy, Sarah; Kasza, Karin; Morrison, Carl; Marshall, James] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Pilarz, Catherine] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4852
DI 10.1158/1538-7445.AM2013-4852
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220600384
ER
PT J
AU Polyak, K
AF Polyak, Kornelia
TI Regulators of in situ to invasive breast carcinoma progression.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Polyak, Kornelia] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA SY0201
DI 10.1158/1538-7445.AM2013-SY02-01
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601353
ER
PT J
AU Pugh, TJ
Yu, WY
Yang, JD
Ambrogio, L
Carter, SL
Kiezun, A
McKenna, A
Giannikopoulos, P
Getz, G
Messinger, Y
Meyerson, M
Hill, DA
AF Pugh, Trevor J.
Yu, Weiying
Yang, Jiandong
Ambrogio, Lauren
Carter, Scott L.
Kiezun, Adam
McKenna, Aaron
Giannikopoulos, Petros
Getz, Gad
Messinger, Yoav
Meyerson, Matthew
Hill, D. Ashley
TI Progressive biallelic loss of TP53 is associated with progression of
pleuropulmonary blastoma initiated by germline loss and somatic mutation
of DICER1
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Pugh, Trevor J.; Ambrogio, Lauren; Carter, Scott L.; Kiezun, Adam; McKenna, Aaron; Getz, Gad] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Yu, Weiying; Yang, Jiandong; Hill, D. Ashley] Childrens Natl Med Ctr, Ctr Genet Med Res, Washington, DC 20010 USA.
[Yu, Weiying; Yang, Jiandong; Hill, D. Ashley] Childrens Natl Med Ctr, Dept Pathol, Washington, DC 20010 USA.
[Giannikopoulos, Petros] Canc Therapeut Innovat Grp, New York, NY USA.
[Messinger, Yoav] Childrens Hosp, Minneapolis, MN USA.
[Messinger, Yoav] Clin Minnesota, Minneapolis, MN USA.
[Meyerson, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3806
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220603040
ER
PT J
AU Puissant, A
Frumm, SM
Alexe, G
Bassii, CF
Qi, J
Chanthery, YH
Nekritz, EA
Zeid, R
Gustafson, WC
Greninger, P
Garnett, MJ
McDermott, U
Benes, CH
Kung, AL
Weiss, WA
Bradner, JE
Stegmaier, K
AF Puissant, Alexandre
Frumm, Stacey M.
Alexe, Gabriela
Bassii, Christopher F.
Qi, Jun
Chanthery, Yvan H.
Nekritz, Erin A.
Zeid, Rhamy
Gustafson, W. Clay
Greninger, Patricia
Garnett, Matthew J.
McDermott, Ultan
Benes, Cyril H.
Kung, Andrew L.
Weiss, William A.
Bradner, James E.
Stegmaier, Kimberly
TI Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Puissant, Alexandre; Frumm, Stacey M.; Alexe, Gabriela; Bassii, Christopher F.; Qi, Jun; Chanthery, Yvan H.; Nekritz, Erin A.; Zeid, Rhamy; Gustafson, W. Clay; Greninger, Patricia; Garnett, Matthew J.; McDermott, Ultan; Benes, Cyril H.; Kung, Andrew L.; Weiss, William A.; Bradner, James E.; Stegmaier, Kimberly] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4622
DI 10.1158/1538-7445.AM2013-4622
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604208
ER
PT J
AU Raamanathan, A
Lu, Z
Bast, RC
Skates, SJ
AF Raamanathan, Archana
Lu, Zhen
Bast, Robert C.
Skates, Steven J.
TI Intra-person and inter-person biomarker variation for modeling
longitudinal values of ovarian cancer early detection biomarkers.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Raamanathan, Archana; Lu, Zhen; Bast, Robert C.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Skates, Steven J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Skates, Steven J.] Harvard Univ, Sch Med, Boston, MA USA.
RI Bast, Robert/E-6585-2011
OI Bast, Robert/0000-0003-4621-8462
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3473
DI 10.1158/1538-7445.AM2013-3473
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220602178
ER
PT J
AU Roberts, CWM
AF Roberts, Charles W. M.
TI The SWI/SNF chromatin remodeling complex is frequently mutated in
cancer: Mechanisms and potential therapeutic insights.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Roberts, Charles W. M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA SY0701
DI 10.1158/1538-7445.AM2013-SY07-01
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601363
ER
PT J
AU Rodon, J
Juric, D
Gonzalez-Angulo, AM
Bendell, J
Berlin, J
Bootle, D
Gravelin, K
Huang, A
Derti, A
Lehar, J
Wurthner, J
Boehm, M
van Allen, E
Wagle, N
Garraway, LA
Yelensky, R
Stephens, PJ
Miller, VA
Schlegel, R
Quadt, C
Baselga, J
AF Rodon, Jordi
Juric, Dejan
Gonzalez-Angulo, Ana-Maria
Bendell, Johanna
Berlin, Jordan
Bootle, Douglas
Gravelin, Kathlene
Huang, Alan
Derti, Adnan
Lehar, Joseph
Wuerthner, Jens
Boehm, Markus
van Allen, Eliezer
Wagle, Nikhil
Garraway, Levi A.
Yelensky, Roman
Stephens, Philip J.
Miller, Vincent A.
Schlegel, Robert
Quadt, Cornelia
Baselga, Jose
TI Towards defining the genetic framework for clinical response to
treatment with BYL719, a PI3Kalpha-specific inhibitor.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Rodon, Jordi] Vail dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain.
[Juric, Dejan] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Gonzalez-Angulo, Ana-Maria] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Bendell, Johanna] Sarah Cannon Res Inst, Nashville, TN USA.
[Berlin, Jordan] Vanderbilt Canc Ctr, Nashville, TN USA.
[Bootle, Douglas; Wuerthner, Jens; Boehm, Markus; Quadt, Cornelia] Novartis Pharma AG, Oncol Translat Med, Basel, Switzerland.
[Gravelin, Kathlene; Huang, Alan; Derti, Adnan; Lehar, Joseph; Schlegel, Robert] NIBR Inc, Oncol Translat Med, Cambridge, MA USA.
[van Allen, Eliezer; Wagle, Nikhil; Garraway, Levi A.] Broad Inst, Cambridge, MA USA.
[Yelensky, Roman; Stephens, Philip J.; Miller, Vincent A.] Fdn Med Inc, Cambridge, MA USA.
[Baselga, Jose] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 1
Z9 1
U1 2
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB65
DI 10.1158/1538-7445.AM2013-LB-65
PG 2
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601313
ER
PT J
AU Russo, V
Raccosta, L
Fontana, R
Maggioni, D
Lanterna, C
Paniccia, A
Musumeci, A
Doglioni, C
Leiva, A
Villablanca, EJ
Mora, R
Chiricozzi, E
Ciampa, MG
Mauri, L
Prinetti, A
Sonino, S
Trincavelli, ML
Daniele, S
Martini, C
Steffensen, K
Gustafsson, JA
Feo, SG
Bordignon, C
Traversari, C
Sozzani, S
AF Russo, Vincenzo
Raccosta, Laura
Fontana, Raffaella
Maggioni, Daniela
Lanterna, Claudia
Paniccia, Aida
Musumeci, Andrea
Doglioni, Claudio
Leiva, Andrea
Villablanca, Eduardo J.
Mora, Rodrigo
Chiricozzi, Elena
Ciampa, Maria Grazia
Mauri, Laura
Prinetti, Alessandro
Sonino, Sandro
Trincavelli, Maria Letizia
Daniele, Simona
Martini, Claudia
Steffensen, Knut
Gustafsson, Jan-Ake
Feo, Safive Gozalvo
Bordignon, Claudio
Traversari, Catia
Sozzani, Silvano
TI The Oxysterol-CXCR2 axis plays a key role in the recruitment of tumor
promoting neutrophils
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Russo, Vincenzo; Raccosta, Laura; Fontana, Raffaella; Maggioni, Daniela; Lanterna, Claudia; Paniccia, Aida; Musumeci, Andrea; Doglioni, Claudio; Leiva, Andrea] Ist Sci San Raffaele, I-20132 Milan, Italy.
[Villablanca, Eduardo J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Mora, Rodrigo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Chiricozzi, Elena; Ciampa, Maria Grazia; Mauri, Laura; Prinetti, Alessandro; Sonino, Sandro] Univ Milan, Milan, Italy.
[Trincavelli, Maria Letizia; Daniele, Simona; Martini, Claudia] Univ Pisa, Pisa, Italy.
[Steffensen, Knut] Karolinska Inst, Huddinge, Sweden.
[Gustafsson, Jan-Ake] Univ Houston, Huddhoustoninge, TX USA.
[Feo, Safive Gozalvo] Humanitas Clin & Res Ctr, Milan, Italy.
[Bordignon, Claudio; Traversari, Catia] MolMed SpA, Milan, Italy.
[Sozzani, Silvano] Univ Brescia, Brescia, Italy.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB346
DI 10.1158/1538-7445.AM2013-LB-346
PG 2
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601271
ER
PT J
AU Sasaki, MM
Skol, AD
Pugh, TJ
Meyerson, M
Onel, K
AF Sasaki, Mark M.
Skol, Andrew D.
Pugh, Trevor J.
Meyerson, Matthew
Onel, Kenan
TI Whole exome sequencing analysis of familial Medulloblastoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Sasaki, Mark M.; Skol, Andrew D.; Onel, Kenan] Univ Chicago, Chicago, IL 60637 USA.
[Pugh, Trevor J.] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Meyerson, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4018
DI 10.1158/1538-7445.AM2013-4018
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220603250
ER
PT J
AU Scaltriti, M
Tao, J
Juric, D
Auricchio, N
Castel, P
Morse, N
Kim, P
Singh, S
Hazra, S
Hembrough, T
Burrows, J
Baselga, J
AF Scaltriti, Maurizio
Tao, Jessica
Juric, Dejan
Auricchio, Neil
Castel, Pau
Morse, Natasha
Kim, Phillip
Singh, Sharat
Hazra, Saswati
Hembrough, Todd
Burrows, Jon
Baselga, Jose
TI Combined blockade of PI3K/AKT and EGFR/HER3 enhances antitumor activity
in triple negative breast cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Scaltriti, Maurizio; Castel, Pau; Morse, Natasha; Baselga, Jose] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Tao, Jessica; Juric, Dejan; Auricchio, Neil] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Kim, Phillip; Singh, Sharat; Hazra, Saswati] Prometheus Lab Therapeut & Diagnost, San Diego, CA USA.
[Hembrough, Todd; Burrows, Jon] OncoPlexDx, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4471
DI 10.1158/1538-7445.AM2013-4471
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604076
ER
PT J
AU Serra, V
Eichhorn, PJA
Garcia-Garcia, C
Ibrahim, Y
Prudkin, L
Rodriguez, O
Marlow, S
Prat, A
Hahn, WC
Baselga, J
AF Serra, Violeta
Eichhorn, Pieter J. A.
Garcia-Garcia, Celina
Ibrahim, Yasir
Prudkin, Ludmila
Rodriguez, Olga
Marlow, Sara
Prat, Aleix
Hahn, William C.
Baselga, Jose
TI p90RSK mediates resistance to PI3K-pathway inhibitors in breast cancer.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Serra, Violeta; Garcia-Garcia, Celina; Ibrahim, Yasir; Prudkin, Ludmila; Rodriguez, Olga; Prat, Aleix] Vall dHebron Inst Oncol, Barcelona, Spain.
[Eichhorn, Pieter J. A.; Marlow, Sara] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Hahn, William C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hahn, William C.] Harvard Univ, Sch Med, Boston, MA USA.
[Baselga, Jose] MSKCC, New York, NY USA.
RI Prat, Aleix/P-8561-2014
OI Prat, Aleix/0000-0003-2377-540X
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4452
DI 10.1158/1538-7445.AM2013-4452
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604057
ER
PT J
AU Shapiro, GI
Hilton, J
Cleary, JM
Tolaney, SM
Ghandi, L
Kwak, EL
Clark, JW
Wolanski, A
Bell, T
Schulz, J
Frame, S
Saladino, C
Hogben, M
Rodig, SJ
Chiao, JH
Blake, D
AF Shapiro, Geoffrey I.
Hilton, John
Cleary, James M.
Tolaney, Sara M.
Ghandi, Leena
Kwak, Eunice L.
Clark, Jeffrey W.
Wolanski, Andrew
Bell, Tracy
Schulz, John
Frame, Sheelagh
Saladino, Chiara
Hogben, Morag
Rodig, Scott J.
Chiao, Judy H.
Blake, David
TI Responses to sequential sapacitabine and seliciclib in patients with
BRCA-deficient solid tumors.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Shapiro, Geoffrey I.; Hilton, John; Cleary, James M.; Tolaney, Sara M.; Ghandi, Leena; Wolanski, Andrew; Bell, Tracy; Schulz, John] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kwak, Eunice L.; Clark, Jeffrey W.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Frame, Sheelagh; Saladino, Chiara; Hogben, Morag; Chiao, Judy H.; Blake, David] Cyclacel Ltd, Dundee, Scotland.
[Rodig, Scott J.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB202
DI 10.1158/1538-7445.AM2013-LB-202
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601133
ER
PT J
AU Shaw, DL
Lin, CY
Oakley, RP
Semenkovich, NP
Qi, J
Bradner, JE
AF Shaw, Daniel L.
Lin, Charles Y.
Oakley, Richard P.
Semenkovich, Nicholas P.
Qi, Jun
Bradner, James E.
TI Open innovation drug discovery: A study in JQ1.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Shaw, Daniel L.; Lin, Charles Y.; Oakley, Richard P.; Qi, Jun; Bradner, James E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Semenkovich, Nicholas P.] Washington Univ, St Louis, MO USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB-2
DI 10.1158/1538-7445.AM2013-LB-2
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601019
ER
PT J
AU Song, MY
Wu, KN
Ogino, S
Fuchs, CS
Giovannucci, EL
Chan, AT
AF Song, Mingyang
Wu, Kana
Ogino, Shuji
Fuchs, Charles S.
Giovannucci, Edward L.
Chan, Andrew T.
TI A prospective study of plasma inflammatory markers and risk of
colorectal cancer in men
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Song, Mingyang; Wu, Kana; Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Ogino, Shuji; Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Ogino, Shuji; Fuchs, Charles S.; Chan, Andrew T.] Harvard Univ, Sch Med, Boston, MA USA.
[Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 103
DI 10.1158/1538-7445.AM2013-103
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220600074
ER
PT J
AU Stojenov, P
Carter, SL
Rosshandler, II
Sivachenko, A
Guadarrama, AS
Vazquez, K
Cordoba, SR
Cibulskis, K
Sougnez, C
Voet, D
Saksena, G
Lichtenstein, L
Zou, L
Frazer, S
Stewart, C
Beroukhim, R
Meyerson, M
Lawrence, MS
Getz, G
AF Stojenov, Petar
Carter, Scott L.
Rosshandler, Ivan Imaz
Sivachenko, Andrey
Guadarrama, Alberto Salido
Vazquez, Karie
Cordoba, Sandra Romero
Cibulskis, Kristian
Sougnez, Carrie
Voet, Douglas
Saksena, Gordon
Lichtenstein, Lee
Zou, Lihua
Frazer, Scott
Stewart, Chip
Beroukhim, Rameen
Meyerson, Matthew
Lawrence, Michael S.
Getz, Gad
TI Analysis of formalin-fixed paraffin-embedded (FFPE) samples.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Stojenov, Petar; Carter, Scott L.; Sivachenko, Andrey; Cibulskis, Kristian; Sougnez, Carrie; Voet, Douglas; Saksena, Gordon; Lichtenstein, Lee; Zou, Lihua; Frazer, Scott; Stewart, Chip; Lawrence, Michael S.; Getz, Gad] Broad Inst, Cambridge, MA USA.
[Rosshandler, Ivan Imaz; Guadarrama, Alberto Salido; Vazquez, Karie; Cordoba, Sandra Romero] INMEGEN, Mexico City, DF, Mexico.
[Beroukhim, Rameen; Meyerson, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 5135
DI 10.1158/1538-7445.AM2013-5135
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220605231
ER
PT J
AU Stylianopoulos, T
Martin, JD
Jain, S
Snuderl, M
Chauhan, VP
Munn, LL
Boucher, Y
Jain, RK
AF Stylianopoulos, Triantafyllos
Martin, John D.
Jain, Saloni
Snuderl, Matija
Chauhan, Vikash P.
Munn, Lance L.
Boucher, Yves
Jain, Rakesh K.
TI Evolution of physical forces in the tumor microenvironment and
implications for therapeutic resistance
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Stylianopoulos, Triantafyllos] Univ Cyprus, Nicosia, Cyprus.
[Martin, John D.; Jain, Saloni; Snuderl, Matija; Chauhan, Vikash P.; Munn, Lance L.; Boucher, Yves; Jain, Rakesh K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Martin, John D.; Jain, Saloni; Snuderl, Matija; Chauhan, Vikash P.; Munn, Lance L.; Boucher, Yves; Jain, Rakesh K.] Harvard Univ, Sch Med, Boston, MA USA.
RI Munn, Lance/L-3950-2016
OI Munn, Lance/0000-0003-0698-7232
NR 0
TC 0
Z9 0
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB348
DI 10.1158/1538-7445.AM2013-LB-348
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601273
ER
PT J
AU Sweeney, CJ
Zukotynski, K
Wang, XD
Wick, A
Fredericks, A
Lam, B
Kantoff, P
AF Sweeney, Christopher J.
Zukotynski, Katherine
Wang, Xiaodong
Wick, Andrew
Fredericks, Amanda
Lam, Bon
Kantoff, Philip
TI Cabozantinib (cabo) plus abiraterone (abi) combination therapy in
castration resistant prostate cancer (CRPC): preclinical evaluation and
interim results of an investigator-sponsored phase 1 clinical study.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Sweeney, Christopher J.; Zukotynski, Katherine; Wang, Xiaodong; Wick, Andrew; Fredericks, Amanda; Lam, Bon; Kantoff, Philip] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA LB166
DI 10.1158/1538-7445.AM2013-LB-166
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601102
ER
PT J
AU Tanizaki, J
Okamoto, I
Okabe, T
Sakai, K
Tanaka, K
Hayashi, H
Kaneda, H
Takezawa, K
Nishio, K
Nakagawa, K
AF Tanizaki, Junko
Okamoto, Isamu
Okabe, Takafumi
Sakai, Kazuko
Tanaka, Kaoru
Hayashi, Hidetoshi
Kaneda, Hiroyasu
Takezawa, Ken
Nishio, Kazuto
Nakagawa, Kazuhiko
TI Activation of HER Family signaling as a mechanism of acquired resistance
to ALK Inhibitors in EML4-ALK-positive Non-Small Cell Lung Cancer.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Tanizaki, Junko] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Okamoto, Isamu; Okabe, Takafumi; Sakai, Kazuko; Tanaka, Kaoru; Hayashi, Hidetoshi; Kaneda, Hiroyasu; Takezawa, Ken; Nishio, Kazuto; Nakagawa, Kazuhiko] Kinki Univ, Osaka, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4446
DI 10.1158/1538-7445.AM2013-4446
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604051
ER
PT J
AU Tavera, LE
Westerling, T
Brown, M
AF Tavera, Luz E.
Westerling, Thomas
Brown, Myles
TI Genome-wide analysis of the vitamin D receptor (VDR) binding sites
reveals vitamin D role modulating autophagy and metabolism in
luminal-like breast cancer cells
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Tavera, Luz E.; Westerling, Thomas; Brown, Myles] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3562
DI 10.1158/1538-7445.AM2013-3562
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220600214
ER
PT J
AU Tobi, M
Weinstein, D
Vizgoft, E
Pedersen, S
AF Tobi, Martin
Weinstein, Douglas
Vizgoft, Emma
Pedersen, Susanne
TI Anti-adenoma Adnab-9 antibody recognizes a serum GI cancer candidate
biomarker
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Tobi, Martin; Weinstein, Douglas] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Vizgoft, Emma; Pedersen, Susanne] Clin Genom, N Ryde, NSW, Australia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 3499
DI 10.1158/1538-7445.AM2013-3499
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220602203
ER
PT J
AU Van Allen, EM
Wagle, N
Keizun, A
Kryukov, G
McKenna, A
Huang, F
Hiller, E
Rainville, I
Auclair, D
Ambroaio, L
Gray, S
Joffe, S
Getz, G
Garber, J
Garraway, L
AF Van Allen, Eliezer M.
Wagle, Nikhil
Keizun, Adam
Kryukov, Gregory
McKenna, Aaron
Huang, Franklin
Hiller, Elaine
Rainville, Irene
Auclair, Daniel
Ambroaio, Lauren
Gray, Stacy
Joffe, Steven
Getz, Gad
Garber, Judy
Garraway, Levi
TI An integrated germline analysis platform for comprehensive clinical
cancer genomics
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Van Allen, Eliezer M.; Wagle, Nikhil; Huang, Franklin; Hiller, Elaine; Rainville, Irene; Gray, Stacy; Joffe, Steven; Garber, Judy; Garraway, Levi] Dana Farber Canc Inst, Brookline, MA USA.
[Keizun, Adam; Kryukov, Gregory; Auclair, Daniel; Ambroaio, Lauren; Getz, Gad] Broad Inst, Cambridge, MA USA.
[McKenna, Aaron] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 2570
DI 10.1158/1538-7445.AM2013-2570
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220600208
ER
PT J
AU Walensky, LD
AF Walensky, Loren D.
TI Stapled helical peptides to dissect and target oncogenic protein
interactions.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Walensky, Loren D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA SY0603
DI 10.1158/1538-7445.AM2013-SY06-03
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601362
ER
PT J
AU Wang, YY
Sabbatino, F
Ferrone, S
Wang, XH
AF Wang, Yangyang
Sabbatino, Francesco
Ferrone, Soldano
Wang, Xinhui
TI Inhibition of TNBC cell growth by CSPG4-specific mAb 225.28 with a Sonic
Hedgehog pathway inhibitor.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4741
DI 10.1158/1538-7445.AM2013-4741
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220604323
ER
PT J
AU Wong, J
Harris, J
Rodriguez-Galindo, C
Johnson, K
AF Wong, Jeannette
Harris, Jenine
Rodriguez-Galindo, Carlos
Johnson, Kimberly
TI Incidence trends of childhood and adolescent melanoma in the United
States from 1973-2009
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Wong, Jeannette] NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD USA.
[Harris, Jenine] Washington Univ, St Louis, MO USA.
[Rodriguez-Galindo, Carlos] Harvard Univ, Dana Farber Canc Inst, Cambridge, MA 02138 USA.
[Johnson, Kimberly] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 2530
DI 10.1158/1538-7445.AM2013-2530
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220600169
ER
PT J
AU Xicola, RMM
Doyle, B
Rawson, J
Garre, P
Abuli, A
Lee, E
Murugappan, S
Bessa, X
Bujanda, L
Balaguer, F
Castellvi-Bel, S
Clofent, J
Alenda, C
Jover, R
Ruiz-Ponte, C
Singal, S
Andreu, M
Carracedo, A
Castells, A
Ellis, N
Caldes, T
LLor, X
AF Xicola, Rosa M. Munoz
Doyle, Brian
Rawson, Jamie
Garre, Pilar
Abuli, Anna
Lee, Esther
Murugappan, Sathyaraj
Bessa, Xavier
Bujanda, Luis
Balaguer, Francesc
Castellvi-Bel, Sergi
Clofent, Juan
Alenda, Cristina
Jover, Rodrigo
Ruiz-Ponte, Clara
Singal, Sapna
Andreu, Montserrat
Carracedo, Angel
Castells, Antoni
Ellis, Nathan
Caldes, Trinidad
LLor, Xavier
TI Implication of the 3 ' UTR region of TGF beta R1 with MSS HNPCC and
sporadic colorectal cancer.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Xicola, Rosa M. Munoz; Doyle, Brian; Rawson, Jamie; Lee, Esther; Murugappan, Sathyaraj; Ellis, Nathan; LLor, Xavier] UIC, Chicago, IL USA.
[Garre, Pilar] Hosp Clin San Carlos, Madrid, Spain.
[Abuli, Anna; Bessa, Xavier; Andreu, Montserrat] Hosp del Mar, Barcelona, Spain.
[Bujanda, Luis] Hosp Donostia, Donostia San Sebastian, Spain.
[Balaguer, Francesc; Castellvi-Bel, Sergi; Castells, Antoni] Hosp Clin Barcelona, Barcelona, Spain.
[Clofent, Juan] Hosp Sagunto, Valencia, Spain.
[Alenda, Cristina; Jover, Rodrigo] Hosp Gen Univ Alacant, Alicante, Spain.
[Ruiz-Ponte, Clara; Carracedo, Angel] Univ Santiago de Compostela, Santiago De Compostela, Spain.
[Singal, Sapna] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Caldes, Trinidad] Hosp Clin San Carlos, Madrid, Spain.
RI Ruiz-Ponte, Clara/I-3849-2015; BALAGUER, FRANCESC/G-2389-2016
OI Ruiz-Ponte, Clara/0000-0002-2200-0162;
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 1334
DI 10.1158/1538-7445.AM2013-1334
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220600119
ER
PT J
AU Zhang, XH
Wu, K
Cho, E
Ma, J
Chan, AT
Gao, X
Willett, WC
Fuchs, CS
Giovannucci, EL
AF Zhang, Xuehong
Wu, Kana
Cho, Eunyoung
Ma, Jing
Chan, Andrew T.
Gao, Xiang
Willett, Walter C.
Fuchs, Charles S.
Giovannucci, Edward L.
TI Prospective cohort studies of bowel movement frequency and laxative use
and colorectal cancer incidence in US women and men
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Zhang, Xuehong; Cho, Eunyoung; Ma, Jing; Chan, Andrew T.; Gao, Xiang; Willett, Walter C.; Fuchs, Charles S.; Giovannucci, Edward L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Zhang, Xuehong; Cho, Eunyoung; Ma, Jing; Chan, Andrew T.; Gao, Xiang; Willett, Walter C.; Fuchs, Charles S.; Giovannucci, Edward L.] Harvard Univ, Sch Med, Boston, MA USA.
[Wu, Kana; Gao, Xiang; Willett, Walter C.; Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Chan, Andrew T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Fuchs, Charles S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA 4822
DI 10.1158/1538-7445.AM2013-4822
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220600355
ER
PT J
AU Zon, LI
AF Zon, Leonard I.
TI Transcriptional regulation and epigenetics in zebrafish cancer.
SO CANCER RESEARCH
LA English
DT Meeting Abstract
CT 104th Annual Meeting of the American-Association-for-Cancer-Research
(AACR)
CY APR 06-10, 2013
CL Washington, DC
SP Amer Assoc Canc Res
C1 [Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA.
[Zon, Leonard I.] Childrens Hosp, Boston, MA 02115 USA.
[Zon, Leonard I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, HHMI,Harvard Stem Cell Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
SU 1
MA SY1601
DI 10.1158/1538-7445.AM2013-SY16-01
PG 1
WC Oncology
SC Oncology
GA AA6PP
UT WOS:000331220601377
ER
PT J
AU Cabral, FC
Krajewski, KM
Kim, KW
Ramaiya, NH
Jagannathan, JP
AF Cabral, Fernanda C.
Krajewski, Katherine M.
Kim, Kyung Won
Ramaiya, Nikhil H.
Jagannathan, Jyothi P.
TI Peritoneal lymphomatosis: CT and PET/CT findings and how to
differentiate between carcinomatosis and sarcomatosis
SO CANCER IMAGING
LA English
DT Review
DE Peritoneal lymphomatosis; extranodal lymphoma; peritoneal sarcomatosis;
peritoneal carcinomatosis; positron emission tomography
ID IMAGING FINDINGS
AB Peritoneal lymphomatosis is a rare manifestation of lymphoma, seen most frequently with non-Hodgkin lymphoma, and it is important to be familiar with this condition, because early diagnosis directly affects the management of patients. This review illustrates the spectrum of imaging findings in peritoneal lymphomatosis, highlighting the use of positron emission tomography/computed tomography, showing common and uncommon subtypes of lymphoma associated with this entity, and how to differentiate it from peritoneal carcinomatosis and peritoneal sarcomatosis.
C1 [Cabral, Fernanda C.; Krajewski, Katherine M.; Kim, Kyung Won; Ramaiya, Nikhil H.; Jagannathan, Jyothi P.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Imaging,Sch Med, Boston, MA 02115 USA.
RP Cabral, FC (reprint author), Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02115 USA.
EM fcabral@partners.org
NR 11
TC 5
Z9 5
U1 0
U2 1
PU E-MED
PI LONDON
PA PO BOX 29761, LONDON, NW3 7ZS, ENGLAND
SN 1470-7330
J9 CANCER IMAGING
JI Cancer Imaging
PD APR 15
PY 2013
VL 13
IS 2
BP 162
EP 170
DI 10.1102/1470-7330.2013.0018
PG 9
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 173DM
UT WOS:000321058300003
PM 23598428
ER
PT J
AU Boulant, S
Stanifer, M
Kural, C
Cureton, DK
Massol, R
Nibert, ML
Kirchhausen, T
AF Boulant, Steeve
Stanifer, Megan
Kural, Comert
Cureton, David K.
Massol, Ramiro
Nibert, Max L.
Kirchhausen, Tomas
TI Similar uptake but different trafficking and escape routes of reovirus
virions and infectious subvirion particles imaged in polarized
Madin-Darby canine kidney cells
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Article
ID CAPSID PROTEIN MU-1; NONENVELOPED VIRUS; MAMMALIAN REOVIRUS; SIGMA-1
PROTEIN; SIALIC-ACID; CRYOELECTRON MICROSCOPY; MONOCLONAL-ANTIBODIES;
MEMBRANE PENETRATION; ADHESION MOLECULE; TYPE-1 REOVIRUS
AB Polarized epithelial cells that line the digestive, respiratory, and genitourinary tracts form a barrier that many viruses must breach to infect their hosts. Current understanding of cell entry by mammalian reovirus (MRV) virions and infectious subvirion particles (ISVPs), generated from MRV virions by extracellular proteolysis in the digestive tract, are mostly derived from in vitro studies with nonpolarized cells. Recent live-cell imaging advances allow us for the first time to visualize events at the apical surface of polarized cells. In this study, we used spinning-disk confocal fluorescence microscopy with high temporal and spatial resolution to follow the uptake and trafficking dynamics of single MRV virions and ISVPs at the apical surface of live polarized Madin-Darby canine kidney cells. Both types of particles were internalized by clathrin-mediated endocytosis, but virions and ISVPs exhibited strikingly different trafficking after uptake. While virions reached early and late endosomes, ISVPs did not and instead escaped the endocytic pathway from an earlier location. This study highlights the broad advantages of using live-cell imaging combined with single-particle tracking for identifying key steps in cell entry by viruses.
C1 [Boulant, Steeve; Kural, Comert; Cureton, David K.; Kirchhausen, Tomas] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
[Boulant, Steeve; Kural, Comert; Cureton, David K.; Kirchhausen, Tomas] Program Cellular & Mol Med, Boston, MA 02115 USA.
[Massol, Ramiro] Boston Childrens Hosp, Div Gastroenterol & Nutr, Boston, MA 02115 USA.
[Boulant, Steeve; Stanifer, Megan; Cureton, David K.; Nibert, Max L.] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Boston, MA 02115 USA.
RP Boulant, S (reprint author), Heidelberg Univ, Schaller Res Grp, D-69120 Heidelberg, Germany.
EM s.boulant@dkfz-heidelberg.de
FU National Institutes of Health [NIH] [U54-AI057159, R01-GM075252,
R56-AI067445]; New England Regional Center of Excellence in Biodefense
and Emerging Infectious Diseases; Harvard Digestive Disease Consortium
Feasibility Award; GlaxoSmithKline fellowship; C.H.S. Foundation
FX We thank E. Marino (supported by National Institutes of Health [NIH]
grant U54-AI057159, New England Regional Center of Excellence in
Biodefense and Emerging Infectious Diseases) for maintaining the imaging
resource used in this study. This work was additionally supported by NIH
grants R01-GM075252 (T.K.) and R56-AI067445 (M.L.N). S.B. was also
supported by a Harvard Digestive Disease Consortium Feasibility Award, a
GlaxoSmithKline fellowship, and the C.H.S. Foundation.
NR 63
TC 11
Z9 11
U1 0
U2 4
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA
SN 1059-1524
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PD APR 15
PY 2013
VL 24
IS 8
BP 1196
EP 1207
DI 10.1091/mbc.E12-12-0852
PG 12
WC Cell Biology
SC Cell Biology
GA 174BO
UT WOS:000321127900011
PM 23427267
ER
PT J
AU Powis, KM
McElrath, TF
Hughes, MD
Ogwu, A
Souda, S
Datwyler, SA
von Widenfelt, E
Moyo, S
Nadas, M
Makhema, J
Machakaire, E
Lockman, S
Essex, M
Shapiro, RL
AF Powis, Kathleen M.
McElrath, Thomas F.
Hughes, Michael D.
Ogwu, Anthony
Souda, Sajini
Datwyler, Saul A.
von Widenfelt, Erik
Moyo, Sikhulile
Nadas, Marisa
Makhema, Joseph
Machakaire, Esther
Lockman, Shahin
Essex, Max
Shapiro, Roger L.
TI High Viral Load and Elevated Angiogenic Markers Associated With
Increased Risk of Preeclampsia Among Women Initiating Highly Active
Antiretroviral Therapy in Pregnancy in the Mma Bana Study, Botswana
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV-1; viral load; pregnancy; preeclampsia; HAART
ID GROWTH-FACTOR; RECEPTOR; AUTOANTIBODIES; INFANTS; DEATH
AB Background: Risk factors associated with preeclampsia in HIV-infected women remain largely unknown. Systemic angiogenic imbalance contributes to preeclampsia in HIV-uninfected women, but changes in angiogenic markers after highly active antiretroviral therapy (HAART) initiation have not been studied.
Methods: The Mma Bana study randomized 560 HIV-infected, HAART-naive pregnant women with CD4 counts >= 200 cells per cubic millimeter between 26 and 34 weeks gestation to lopinavir/ritonavir/zidovudine/lamivudine or abacavir/zidovudine/lamivudine. Another 170 participants with CD4 counts less than 200 cells per cubic millimeter initiated nevirapine/zidovudine/lamivudine between 18 and 34 weeks gestation. Characteristics of 11 women who developed preeclampsia were compared with the remaining 722 Mma Bana participants who delivered using logistic regression. Plasma samples drawn at HAART initiation and 1 month later from 60 women without preeclampsia and at HAART initiation for all 11 preeclamptic women were assayed for placental growth factor (PlGF) and soluble FMS toll-like tyrosine kinase-1 (sFlt-1).
Results: Pre-HAART viral load greater than 100,000 copies per milliliter was associated with preeclampsia (odds ratio: 5.8, 95% confidence interval: 1.8 to 19.4, P = 0.004). Median pre-HAART PlGF level was lower and sFlt-1 was higher in women who developed preeclampsia vs those who did not (130 vs 992 pg/mL, P = 0.001; 17.5 vs 9.4 pg/mL, P = 0.03, respectively). In multivariate analysis, PlGF and viral load remained significantly associated with preeclampsia. No significant changes in angiogenic factors were noted after 1 month of HAART treatment among non-preeclamptic women.
Conclusions: Pre-HAART viral load greater than 100,000 copies per milliliter and PlGF predicted preeclampsia among women starting HAART in pregnancy. Among non-preeclamptic women, HAART treatment did not significantly alter levels of PlGF or sFlt-1 after 1 month of treatment.
C1 [Powis, Kathleen M.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Powis, Kathleen M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Powis, Kathleen M.; Lockman, Shahin; Essex, Max; Shapiro, Roger L.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Powis, Kathleen M.; Ogwu, Anthony; von Widenfelt, Erik; Moyo, Sikhulile; Makhema, Joseph; Lockman, Shahin; Essex, Max; Shapiro, Roger L.] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana.
[McElrath, Thomas F.] Brigham & Womens Hosp, Div Maternal Fetal Med, Boston, MA 02115 USA.
[Hughes, Michael D.] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
[Souda, Sajini] Univ Botswana, Sch Med, Gaborone, Botswana.
[Datwyler, Saul A.] Abbott Labs, Abbott Pk, IL 60064 USA.
[Nadas, Marisa] Boston Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA.
[Machakaire, Esther] Ctr Dis Control Botswana, Gaborone, Botswana.
[Lockman, Shahin] Brigham & Womens Hosp, Infect Dis Unit, Boston, MA 02115 USA.
[Shapiro, Roger L.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.
RP Powis, KM (reprint author), 100 Cambridge St,15th Floor, Boston, MA 02114 USA.
EM kpowis@partners.org
RI Moyo, Sikhulile/E-1464-2015
OI Moyo, Sikhulile/0000-0003-3821-4592
FU National Institute of Allergy and Infectious Diseases [U01-AI066454];
Brigham; Women's Global Women's Health; Harvard University Center for
AIDS Research grant [P30 AI060354]; National Institute of Child Health
and Human Development grant [1K23HD070774-01A1]; Fogarty AITRP grant
[D43 TW000004]
FX Supported by a grant (U01-AI066454) from the National Institute of
Allergy and Infectious Diseases. Funding support from Brigham and
Women's Global Women's Health Fellowship supported K.M.P.'s salary
during the Mma Bana study and M.N.'s salary during manuscript
preparation. K.M P. received salary support from Harvard University
Center for AIDS Research grant (P30 AI060354) and National Institute of
Child Health and Human Development grant (1K23HD070774-01A1) during the
period of manuscript preparation. The Fogarty AITRP grant (D43 TW000004)
provided funding for A.O. and S.M. Mma Bana study drugs were provided by
Abbott Pharmaceuticals, GlaxoSmithKline, and the government of Botswana.
NR 29
TC 11
Z9 12
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 15
PY 2013
VL 62
IS 5
BP 517
EP 524
DI 10.1097/QAI.0b013e318286d77e
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 146SS
UT WOS:000319111800014
PM 23344545
ER
PT J
AU Plank, RM
Ndubuka, NO
Wirth, KE
Mwambona, JT
Kebaabetswe, P
Bassil, B
Lesetedi, C
Magetse, J
Nkgau, M
Makhema, J
Mmalane, M
Creek, T
Powis, KM
Shapiro, R
Lockman, S
AF Plank, Rebeca M.
Ndubuka, Nnamdi O.
Wirth, Kathleen E.
Mwambona, Janet T.
Kebaabetswe, Poloko
Bassil, Barbara
Lesetedi, Chiapo
Magetse, Jane
Nkgau, Maggie
Makhema, Joseph
Mmalane, Mompati
Creek, Tracy
Powis, Kathleen M.
Shapiro, Roger
Lockman, Shahin
TI A Randomized Trial of Mogen Clamp Versus Plastibell for Neonatal Male
Circumcision in Botswana
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE neonatal circumcision; Mogen clamp; plastibell; male circumcision; HIV
prevention; Botswana
ID INFANT MALE CIRCUMCISION; HIV PREVENTION; COMPLICATIONS; SUCROSE; KENYA;
PAIN; MEN
AB Background: Male circumcision can reduce the risk of heterosexually acquired HIV-1 infection in men. Neonatal male circumcision (NMC) has many potential advantages over circumcision at older ages, but little is known about its feasibility and safety in resource-limited settings.
Methods: We performed a randomized trial in southeastern Botswana of Mogen clamp and Plastibell, 2 commonly used devices for NMC. Follow-up visits occurred at 6 weeks and 4 months postpartum. Adverse events, parental satisfaction, and staff impressions were recorded.
Results: Of 302 male neonates randomized, 300 (99%) underwent circumcision, 153 (51%) with Mogen clamp, and 147 (49%) with Plastibell. There were no major adverse events in the Mogen clamp arm, but there were 2 major adverse events in the Plastibell arm (both were a proximally migrated ring that had to be removed by study staff). Minor adverse events were more common with the Mogen clamp compared with the Plastibell, specifically removal of too little skin and formation of skin bridges or adhesions (12 versus 1 and 11 versus 3, respectively, all P < 0.05). Five (3%) infants in the Mogen clamp arm and none in the Plastibell arm had minor bleeding (P = 0.03). More than 94% of mothers reported being highly or completely satisfied with the procedure.
Conclusions: NMC can be performed in Botswana with a low rate of adverse events and high parental satisfaction. Although the risk of migration and retention of the Plastibell is small, the Mogen clamp may be safer for NMC in regions where immediate emergent medical attention is not available.
C1 [Plank, Rebeca M.; Lockman, Shahin] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Plank, Rebeca M.; Powis, Kathleen M.; Shapiro, Roger; Lockman, Shahin] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Cambridge, MA 02138 USA.
[Plank, Rebeca M.; Ndubuka, Nnamdi O.; Wirth, Kathleen E.; Magetse, Jane; Nkgau, Maggie; Makhema, Joseph; Mmalane, Mompati; Powis, Kathleen M.; Shapiro, Roger; Lockman, Shahin] Botswana Harvard Sch Publ Hlth AIDS Initiat Partn, Gaborone, Botswana.
[Wirth, Kathleen E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA.
[Kebaabetswe, Poloko] Univ Botswana, Sch Med, Gaborone, Botswana.
[Creek, Tracy] Childrens Healthcare Atlanta, Atlanta, GA USA.
[Powis, Kathleen M.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Powis, Kathleen M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Shapiro, Roger] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA USA.
RP Plank, RM (reprint author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St,PBB A-4, Boston, MA 02115 USA.
EM rplank@partners.org
FU NIH from the National Institutes of Allergy and Infectious Diseases
[5K23AI084579]; President's Emergency Plan for AIDS Relief (PEPFAR)
[U2GPS000941-01]; [08-P0157]
FX Supported by NIH 5K23AI084579 from the National Institutes of Allergy
and Infectious Diseases (R.M.P.). The study was supported through the
President's Emergency Plan for AIDS Relief (PEPFAR) grant
U2GPS000941-01, Program No 08-P0157. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of PEPFAR or the National Institutes of Health.
NR 28
TC 19
Z9 21
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 15
PY 2013
VL 62
IS 5
BP E131
EP E137
DI 10.1097/QAI.0b013e318285d449
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 146SS
UT WOS:000319111800002
PM 23314413
ER
PT J
AU Trautner, BW
Bhimani, RD
Amspoker, AB
Hysong, SJ
Garza, A
Kelly, PA
Payne, VL
Naik, AD
AF Trautner, Barbara W.
Bhimani, Rupal D.
Amspoker, Amber B.
Hysong, Sylvia J.
Garza, Armandina
Kelly, P. Adam
Payne, Velma L.
Naik, Aanand D.
TI Development and validation of an algorithm to recalibrate mental models
and reduce diagnostic errors associated with catheter-associated
bacteriuria
SO BMC MEDICAL INFORMATICS AND DECISION MAKING
LA English
DT Article
DE Catheter-associated bacteriuria; Urinary tract infections; Evidence
based guidelines; Diagnostic errors
ID URINARY-TRACT-INFECTION; ASYMPTOMATIC BACTERIURIA; INAPPROPRIATE
TREATMENT; DISEASES-SOCIETY; NURSING-HOMES; GUIDELINES; CARE; ADULTS;
INTERVENTION; RESIDENTS
AB Background: Overtreatment of catheter-associated bacteriuria is a quality and safety problem, despite the availability of evidence-based guidelines. Little is known about how guidelines-based knowledge is integrated into clinicians' mental models for diagnosing catheter-associated urinary tract infection (CA-UTI). The objectives of this research were to better understand clinicians' mental models for CA-UTI, and to develop and validate an algorithm to improve diagnostic accuracy for CA-UTI.
Methods: We conducted two phases of this research project. In phase one, 10 clinicians assessed and diagnosed four patient cases of catheter associated bacteriuria (n= 40 total cases). We assessed the clinical cues used when diagnosing these cases to determine if the mental models were IDSA guideline compliant. In phase two, we developed a diagnostic algorithm derived from the IDSA guidelines. IDSA guideline authors and non-expert clinicians evaluated the algorithm for content and face validity. In order to determine if diagnostic accuracy improved using the algorithm, we had experts and non-experts diagnose 71 cases of bacteriuria.
Results: Only 21 (53%) diagnoses made by clinicians without the algorithm were guidelines-concordant with fair inter-rater reliability between clinicians (Fleiss' kappa = 0.35, 95% Confidence Intervals (CIs) = 0.21 and 0.50). Evidence suggests that clinicians' mental models are inappropriately constructed in that clinicians endorsed guidelines-discordant cues as influential in their decision-making: pyuria, systemic leukocytosis, organism type and number, weakness, and elderly or frail patient. Using the algorithm, inter-rater reliability between the expert and each non-expert was substantial (Cohen's kappa = 0.72, 95% CIs = 0.52 and 0.93 between the expert and non-expert # 1 and 0.80, 95% CIs = 0.61 and 0.99 between the expert and non-expert # 2).
Conclusions: Diagnostic errors occur when clinicians' mental models for catheter-associated bacteriuria include cues that are guidelines-discordant for CA-UTI. The understanding we gained of clinicians' mental models, especially diagnostic errors, and the algorithm developed to address these errors will inform interventions to improve the accuracy and reliability of CA-UTI diagnoses.
C1 [Trautner, Barbara W.; Amspoker, Amber B.; Hysong, Sylvia J.; Garza, Armandina; Payne, Velma L.; Naik, Aanand D.] Michael E DeBakey VA Med Ctr, Houston Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA.
[Trautner, Barbara W.; Bhimani, Rupal D.; Amspoker, Amber B.; Hysong, Sylvia J.; Garza, Armandina; Naik, Aanand D.] Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USA.
[Kelly, P. Adam] Tulane Univ, Sch Med, Dept Internal Med, New Orleans, LA 70112 USA.
[Trautner, Barbara W.] Michael E DeBakey VA Med Ctr 152, Houston, TX 77030 USA.
RP Naik, AD (reprint author), Michael E DeBakey VA Med Ctr, Houston Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA.
EM anaik@bcm.edu
RI Hysong, Sylvia/B-8420-2008
OI Hysong, Sylvia/0000-0002-9063-5207
FU Veterans Administration, Health Services Research and Development
Program [IIR 09-104]; Houston VA HSR& D Center of Excellence
[HFP90-020]; VA Rehabilitation Research and Development career
development award [B4623]
FX This work was supported by a grant from the Veterans Administration,
Health Services Research and Development Program (IIR 09-104, Trautner
PI) and with resources and use of facilities at the Houston VA HSR& D
Center of Excellence (HFP90-020) at the Michael E. DeBakey VA. Dr.
Trautner received support from a VA Rehabilitation Research and
Development career development award (B4623). Dr. Payne receives support
from the Office of Academic Affiliations, post-doctoral fellowship
program in Health Services Research. Dr. Naik received additional
support from a Doris Duke Charitable Foundation Clinical Scientist
Development Award.
NR 28
TC 17
Z9 18
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6947
J9 BMC MED INFORM DECIS
JI BMC Med. Inform. Decis. Mak.
PD APR 15
PY 2013
VL 13
AR 48
DI 10.1186/1472-6947-13-48
PG 9
WC Medical Informatics
SC Medical Informatics
GA 151FR
UT WOS:000319446600001
PM 23587259
ER
PT J
AU Geng, Y
Sicinski, P
AF Geng, Yan
Sicinski, Piotr
TI Differences in regulation and function of E-cyclins in human cancer
cells
SO CELL CYCLE
LA English
DT News Item
DE E-type cyclins; cyclin E1; cyclin E2; cell cycle; genomic instability;
breast cancer
ID INSTABILITY
C1 [Sicinski, Piotr] Dana Farber Canc Inst, Dept Genet, Harvard Med Sch, Dept Canc Biol, Boston, MA 02115 USA.
RP Sicinski, P (reprint author), Dana Farber Canc Inst, Dept Genet, Harvard Med Sch, Dept Canc Biol, Boston, MA 02115 USA.
EM peter_sicinski@dfci.harvard.edu
FU NCI NIH HHS [R01 CA108950]
NR 8
TC 4
Z9 4
U1 0
U2 1
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD APR 15
PY 2013
VL 12
IS 8
BP 1165
EP 1165
DI 10.4161/cc.24487
PG 1
WC Cell Biology
SC Cell Biology
GA 132KX
UT WOS:000318067700008
PM 23549169
ER
PT J
AU Leone, E
Morelli, E
Di Martino, MT
Amodio, N
Foresta, U
Gulla, A
Rossi, M
Neri, A
Giordano, A
Munshi, NC
Anderson, KC
Tagliaferri, P
Tassone, P
AF Leone, Emanuela
Morelli, Eugenio
Di Martino, Maria T.
Amodio, Nicola
Foresta, Umberto
Gulla, Annamaria
Rossi, Marco
Neri, Antonino
Giordano, Antonio
Munshi, Nikhil C.
Anderson, Kenneth C.
Tagliaferri, Pierosandro
Tassone, Pierfrancesco
TI Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell
Growth
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID BONE-MARROW MICROENVIRONMENT; SUPER-ANTAGONIST SANT7;
ANTITUMOR-ACTIVITY; INDUCED APOPTOSIS; GENE-EXPRESSION; CANCER;
MICRORNAS; DEXAMETHASONE; IDENTIFICATION; PATHOGENESIS
AB Purpose: Deregulated expression of miRNAs plays a role in the pathogenesis and progression of multiple myeloma. Among upregulated miRNAs, miR-21 has oncogenic potential and therefore represents an attractive target for the treatment of multiple myeloma.
Experimental Design: Here, we investigated the in vitro and in vivo anti-multiple myeloma activity of miR-21 inhibitors.
Results: Either transient-enforced expression or lentivirus-based constitutive expression of miR-21 inhibitors triggered significant growth inhibition of primary patient multiple myeloma cells or interleukin-6-dependent/independent multiple myeloma cell lines and overcame the protective activity of human bone marrow stromal cells. Conversely, transfection of miR-21 mimics significantly increased proliferation of multiple myeloma cells, showing its tumor-promoting potential in multiple myeloma. Importantly, upregulation of miR-21 canonical validated targets (PTEN, Rho-B, and BTG2), together with functional impairment of both AKT and extracellular signal-regulated kinase signaling, were achieved by transfection of miR-21 inhibitors into multiple myeloma cells. In vivo delivery of miR-21 inhibitors in severe combined immunodeficient mice bearing human multiple myeloma xenografts expressing miR-21 induced significant antitumor activity. Upregulation of PTEN and downregulation of p-AKT were observed in retrieved xenografts following treatment with miR-21 inhibitors.
Conclusion: Our findings show the first evidence that in vivo antagonism of miR-21 exerts anti-multiple myeloma activity, providing the rationale for clinical development of miR-21 inhibitors in this still incurable disease. Clin Cancer Res; 19(8); 2096-106. (C) 2013 AACR.
C1 [Leone, Emanuela; Morelli, Eugenio; Di Martino, Maria T.; Amodio, Nicola; Foresta, Umberto; Gulla, Annamaria; Rossi, Marco; Tagliaferri, Pierosandro; Tassone, Pierfrancesco] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Med Oncol Unit, I-88100 Catanzaro, Italy.
[Leone, Emanuela; Morelli, Eugenio; Di Martino, Maria T.; Amodio, Nicola; Foresta, Umberto; Gulla, Annamaria; Rossi, Marco; Tagliaferri, Pierosandro; Tassone, Pierfrancesco] T Campanella Canc Ctr, Catanzaro, Italy.
[Neri, Antonino] Univ Milan, Dept Med Sci, IRCCS Policlin Fdn, Milan, Italy.
[Giordano, Antonio] Univ Siena, Human Pathol & Oncol Dept, I-53100 Siena, Italy.
[Munshi, Nikhil C.; Anderson, Kenneth C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Munshi, Nikhil C.] Boston Vet Adm Healthcare Syst, Boston, MA USA.
[Giordano, Antonio; Tassone, Pierfrancesco] Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.
RP Tassone, P (reprint author), Magna Graecia Univ Catanzaro, Viale Europa, I-88100 Catanzaro, Italy.
EM tassone@unicz.it
RI Amodio, Nicola/K-7335-2016; Giordano, Antonio/F-1927-2010;
OI Amodio, Nicola/0000-0002-1345-4410; Giordano,
Antonio/0000-0002-5959-016X; neri, antonino/0000-0001-9047-5912; ROSSI,
Marco/0000-0002-7258-475X
FU Italian Association for Cancer Research (AIRC) [9980]
FX This work has been supported by funds of Italian Association for Cancer
Research (AIRC), Principal Inverstigator: P. Tassone "Special Program
Molecular Clinical Oncology-5 per mille" n. 9980, 2010/15. KCA is an
American Cancer Society Clinical Research Professor.
NR 50
TC 55
Z9 58
U1 4
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 15
PY 2013
VL 19
IS 8
BP 2096
EP 2106
DI 10.1158/1078-0432.CCR-12-3325
PG 11
WC Oncology
SC Oncology
GA 126FG
UT WOS:000317597500019
PM 23446999
ER
PT J
AU Vachon, CM
Suman, VJ
Brandt, KR
Kosel, ML
Buzdar, AU
Olson, JE
Wu, FF
Flickinger, LM
Ursin, G
Elliott, CR
Shepherd, L
Weinshilboum, RM
Goss, PE
Ingle, JN
AF Vachon, Celine M.
Suman, Vera J.
Brandt, Kathleen R.
Kosel, Matthew L.
Buzdar, Aman U.
Olson, Janet E.
Wu, Fang-Fang
Flickinger, Lynn M.
Ursin, Giske
Elliott, Catherine R.
Shepherd, Lois
Weinshilboum, Richard M.
Goss, Paul E.
Ingle, James N.
TI Mammographic Breast Density Response to Aromatase Inhibition
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HORMONE REPLACEMENT THERAPY; CARCINOMA IN-SITU; POSTMENOPAUSAL WOMEN;
CANCER RISK; SEX STEROIDS; TAMOXIFEN; LETROZOLE; ANASTROZOLE; ESTROGEN;
REDUCTION
AB Purpose: Mammographic breast density (MBD) is decreased by tamoxifen, but the effect of aromatase inhibitors is less clear.
Experimental Design: We enrolled early-stage postmenopausal patients with breast cancer initiating adjuvant aromatase inhibitor therapy and ascertained mammograms before and at an average 10 months of aromatase inhibitor therapy. We matched cases to healthy postmenopausal women (controls) from a large mammography screening cohort on age, baseline body mass index, baseline MBD, and interval between mammograms. We estimated change in MBD using a computer-assisted thresholding program (Cumulus) and compared differences between cases and matched controls.
Results: In predominantly White women (96%), we found 14% of the 387 eligible cases had a MBD reduction of at least 5% after an average of 10 months of aromatase inhibitor therapy. MBD reductions were associated with higher baseline MBD, aromatase inhibitor use for more than 12 months, and prior postmenopausal hormone use. Comparing each case with her matched control, there was no evidence of an association of change in MBD with aromatase inhibitor therapy [median case-control difference among 369 pairs was -0.1% (10th and 90th percentile: -5.9%, 5.2%) P = 0.51]. Case-control differences were similar by type of aromatase inhibitor (P's 0.41 and 0.56); prior use of postmenopausal hormones (P = 0.85); baseline MBD (P = 0.55); and length of aromatase inhibitor therapy (P = 0.08).
Conclusions: In postmenopausal women treated with aromatase inhibitors, 14% of cases had a MBD reduction of more than 5%, but these decreases did not differ from matched controls. These data suggest that MBD is not a clinically useful biomarker for predicting the value of aromatase inhibitor therapy in White postmenopausal women. Clin Cancer Res; 19(8); 2144-53. (C) 2013 AACR.
C1 [Vachon, Celine M.; Suman, Vera J.; Brandt, Kathleen R.; Kosel, Matthew L.; Olson, Janet E.; Wu, Fang-Fang; Flickinger, Lynn M.; Weinshilboum, Richard M.; Ingle, James N.] Mayo Clin, Coll Med, Rochester, MN 55905 USA.
[Buzdar, Aman U.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Ursin, Giske] Univ Oslo, Oslo, Norway.
[Ursin, Giske] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Elliott, Catherine R.; Shepherd, Lois] Queens Univ, Clin Trials Grp, NCIC, Kingston, ON, Canada.
[Goss, Paul E.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RP Vachon, CM (reprint author), Mayo Clin, Dept Hlth Sci Res, Charlton 6-239,200 1st St SW, Rochester, MN 55905 USA.
EM vachon.celine@mayo.edu
FU NIH, Specialized Program of Research Excellence (SPORE) in Breast Cancer
[P50 CA116201, R01 CA97396, R01 CA140286]; Mayo Pharmacogenomics
Research Network (PGRN) [U01 GM61388]; Avon Foundation, New York
FX This study was supported, in part, by grants from the NIH, Specialized
Program of Research Excellence (SPORE) in Breast Cancer, P50 CA116201,
R01 CA97396, R01 CA140286, and Mayo Pharmacogenomics Research Network
(PGRN), U01 GM61388. P. E. Goss is supported by the Avon Foundation, New
York.
NR 56
TC 11
Z9 11
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 15
PY 2013
VL 19
IS 8
BP 2144
EP 2153
DI 10.1158/1078-0432.CCR-12-2789
PG 10
WC Oncology
SC Oncology
GA 126FG
UT WOS:000317597500023
PM 23468058
ER
PT J
AU Robert, C
Schadendorf, D
Messina, M
Hodi, FS
O'Day, S
AF Robert, Caroline
Schadendorf, Dirk
Messina, Marianne
Hodi, F. Stephen
O'Day, Steven
CA MDX010-20 Investigators
TI Efficacy and Safety of Retreatment with Ipilimumab in Patients with
Pretreated Advanced Melanoma Who Progressed after Initially Achieving
Disease Control
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ANTI-CTLA-4 ANTIBODIES; METASTATIC MELANOMA; ADVERSE EVENTS; PHASE-II;
CANCER; IMMUNOTHERAPY; ANTIGEN-4; THERAPY; MANAGEMENT; BLOCKADE
AB Purpose: Ipilimumab is a fully human monoclonal antibody against cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) that has been shown to improve survival in patients with pretreated, advanced melanoma in a phase III trial. Some patients in this study who initially responded to ipilimumab treatment but later progressed were eligible for retreatment with their original randomized regimen. Here, outcomes for these patients concerning baseline characteristics, best overall response, and disease control rate are assessed and considered with respect to the overall study population.
Experimental Design: In the phase III study, 676 pretreated patients were randomly allocated to treatment with ipilimumab 3 mg/kg plus gp100 vaccine, ipilimumab 3 mg/kg plus placebo, or gp100 vaccine alone. Of these patients, 32 had a partial or complete objective response or stable disease after treatment and met the eligibility criteria for retreatment, although a total of 40 patients were retreated.
Results: Best overall response rates (complete responses plus partial responses) for 31 retreatment-eligible patients in the ipilimumab plus gp100 and ipilimumab plus placebo groups were 3 of 23 (13.0%) and 3 of 8 (37.5%), respectively, and disease control rates were 65.2% and 75.0%. No new types of toxicities occurred during retreatment and most events were mild-to-moderate.
Conclusion: Ipilimumab provided durable objective responses and/or stable disease in qualifying patients who received retreatment upon disease progression with a similar toxicity profile to that seen during their original treatment regimen. Clin Cancer Res; 19(8); 2232-9. (C) 2013 AACR.
C1 [Robert, Caroline] Inst Gustave Roussy, F-94805 Villejuif, France.
[Schadendorf, Dirk] Univ Hosp Essen, Essen, Germany.
[Messina, Marianne] Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
[Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA.
[O'Day, Steven] Beverly Hills Canc Ctr, Beverly Hills, CA USA.
RP Robert, C (reprint author), Inst Gustave Roussy, Dept Med, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.
EM caroline.robert@igr.fr
FU Bristol-Myers Squibb; Bristol-Myers Squibb [NCT00094653]
FX C. Robert is a consultant/advisory board member of Bristol-Myers Squibb,
Roche, GlaxoSmithKline, and Merck. D. Schadendorf has honoraria from
speakers' bureau from Bristol-Myers Squibb and is a consultant/advisory
board member of Bristol-Myers Squibb, Roche, Novartis, GlaxoSmithKline,
and Amgen. F. S. Hodi has commercial research support and is a
consultant/advisory board member of Bristol-Myers Squibb. S. O'Day has a
commercial research grant, honoraria from speakers' bureau, and is a
consultant/advisory board member of Bristol-Myers Squibb. No potential
conflicts of interest were disclosed by the other author.; The MDX010-20
study (trial registration ID: NCT00094653) was funded by Bristol-Myers
Squibb. Editorial and writing assistance was provided by StemScientific,
funded by Bristol-Myers Squibb.
NR 30
TC 58
Z9 58
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 15
PY 2013
VL 19
IS 8
BP 2232
EP 2239
DI 10.1158/1078-0432.CCR-12-3080
PG 8
WC Oncology
SC Oncology
GA 126FG
UT WOS:000317597500032
PM 23444228
ER
PT J
AU Losman, JA
Kaelin, WG
AF Losman, Julie-Aurore
Kaelin, William G., Jr.
TI What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate,
and cancer
SO GENES & DEVELOPMENT
LA English
DT Review
DE 2-oxoglutarate-dependent dioxygenase; cancer metabolism; chondrosarcoma;
glioma; isocitrate dehydrogenase; leukemia
ID ACUTE MYELOID-LEUKEMIA; NADP(+)-DEPENDENT ISOCITRATE DEHYDROGENASE; CELL
SELF-RENEWAL; HEMATOPOIETIC STEM-CELLS; TRICARBOXYLIC-ACID CYCLE; TET2
MUTATIONS; D-2-HYDROXYGLUTARIC ACIDURIA; MYELODYSPLASTIC SYNDROMES; TCA
CYCLE; IN-VIVO
AB Mutations in metabolic enzymes, including isocitrate dehydrogenase 1 (IDH1) and IDH2, in cancer strongly implicate altered metabolism in tumorigenesis. IDH1 and IDH2 catalyze the interconversion of isocitrate and 2-oxoglutarate (2OG). 2OG is a TCA cycle intermediate and an essential cofactor for many enzymes, including JmjC domain-containing histone demethylases, TET 5-methylcytosine hydroxylases, and EglN prolyl-4-hydroxylases. Cancer-associated IDH mutations alter the enzymes such that they reduce 2OG to the structurally similar metabolite (R)-2-hydroxyglutarate [(R)-2HG]. Here we review what is known about the molecular mechanisms of transformation by mutant IDH and discuss their implications for the development of targeted therapies to treat IDH mutant malignancies.
C1 [Losman, Julie-Aurore; Kaelin, William G., Jr.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02215 USA.
[Kaelin, William G., Jr.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
RP Kaelin, WG (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02215 USA.
EM william_kaelin@dfci.harvard.edu
FU NIH; Breast Cancer Research Foundation; HHMI
FX We thank Dr. Matthew Vander Heiden, Dr. Rafael Bejar, and Dr. Samuel
McBrayer for critical reading of the manuscript. We apologize to
colleagues whose work was not cited due to space limitations or
oversight. Please bring errors and egregious omissions to our attention.
W.G.K. consults for, and owns equity in, Fibrogen, which is developing
EglN inhibitors, and Agios, which is targeting cancer metabolism.
Supported by grants from NIH, HHMI, and the Breast Cancer Research
Foundation.
NR 182
TC 133
Z9 135
U1 5
U2 53
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
J9 GENE DEV
JI Genes Dev.
PD APR 15
PY 2013
VL 27
IS 8
BP 836
EP 852
DI 10.1101/gad.217406.113
PG 17
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 134NB
UT WOS:000318215800002
PM 23630074
ER
PT J
AU Hou, JB
Jia, HB
Huang, XT
Yu, H
Ren, XF
Fang, Y
Han, ZG
Yang, S
Meng, LB
Zhang, SS
Yu, B
Jang, IK
AF Hou, Jingbo
Jia, Haibo
Huang, Xingtao
Yu, Huai
Ren, Xuefeng
Fang, Yan
Han, Zhigang
Yang, Shuang
Meng, Lingbo
Zhang, Shaosong
Yu, Bo
Jang, Ik-Kyung
TI Optical Coherence Tomographic Observations of
Polytetrafluoroethylene-Covered Sirolimus-Eluting Coronary Arterial
Stent
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID FOLLOW-UP; IMPLANTATION; ANEURYSM; GRAFTS; ANGINA; TRIAL
AB The aim of this study was to evaluate neointimal coverage obtained using a new method of polytetrafluoroethylene-covered stent (PCS) implantation combined with underlying longer sirolimus-eluting stent (SES) implantation using optical coherence tomography. Nine patients were enrolled in this study, including patients with coronary artery perforations, original coronary aneurysms, and acquired coronary aneurysms after drug-eluting stent implantation. All patients were first treated with long SES implantation and then with focal PCS implantation. Postprocedural and follow-up angiographic and optical coherence tomographic examinations were performed in all patients, and intravascular ultrasound was performed in 5 patients. All patients were asymptomatic during follow-up, without recurrent angina. There was no stent-edge or stent-segment binary restenosis. Values of late loss for proximal SES segments, PCS segments, and distal SES segments were similar (0.09, 0.07, and 0.04 mm, respectively, p = 0.8113). The mean neointimal thickness of PCS was less than that of proximal and distal SES. However, no malapposed cross sections or uncovered cross sections were found in PCS segments compared with SES segments (p = 0.0011). In conclusion, the combination of PCS and underlying longer SES implantation can offer better angiographic follow-up results. High-resolution optical coherence tomography provided convincing proof of full neointimal coverage of PCS. This new method of combined PCS and SES implantation may be a better choice compared with direct PCS implantation in certain clinical settings. (C) 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:1117-1122)
C1 [Hou, Jingbo; Jia, Haibo; Huang, Xingtao; Yu, Huai; Ren, Xuefeng; Fang, Yan; Han, Zhigang; Yang, Shuang; Meng, Lingbo; Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Harbin, Peoples R China.
[Hou, Jingbo; Jia, Haibo; Huang, Xingtao; Yu, Huai; Ren, Xuefeng; Fang, Yan; Han, Zhigang; Yang, Shuang; Meng, Lingbo; Yu, Bo] Chinese Minist Educ, Key Lab Myocardial Ischemia, Harbin, Peoples R China.
[Zhang, Shaosong] LightLab Imaging, Westford, MA USA.
[Zhang, Shaosong] St Jude Med, St Paul, MN USA.
[Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
RP Yu, B (reprint author), Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Harbin, Peoples R China.
EM yubodr@163.com
NR 15
TC 2
Z9 2
U1 0
U2 4
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD APR 15
PY 2013
VL 111
IS 8
BP 1117
EP 1122
DI 10.1016/j.amjcard.2012.12.036
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 130CK
UT WOS:000317890100007
PM 23351458
ER
PT J
AU Lee, JP
Wang, YJ
AF Lee, Jennifer Pai
Wang, Yi-Jiun
TI Testing the predictive ability of the "spinal cord injury equation" in
estimating vancomycin clearance
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; RENAL-DISEASE; SERUM CREATININE; DIET;
PERFORMANCE; THERAPY
AB Purpose. A new method of estimating drug clearance in patients with spinal cord injury (SCI) was tested against other methods through a retrospective analysis of its predictive ability in estimating vancomycin clearance.
Methods. A retrospective chart-based investigation was conducted at a hospital with a large SCI population. Using data collected from electronic patient records, 179 cases were reviewed, and 87 cases met the inclusion criteria: a diagnosis of longstanding SCI, administration of vancomycin via i.v. infusion during the 18-month study period, and at least one documented steady-state vancomycin concentration. Using the "spinal cord injury equation" (i.e., CLSCI equation), pharmacokinetic analysis was performed to determine patient-specific clearance values, which were compared to values resulting from five widely used methods of estimating the glomerular filtration rate in spinal cord-injured patients. The primary outcome measures were bias and precision, as indicated by statistical analyses to determine the mean prediction error (ME) and the square root of the mean squared prediction error (RMSE) of each method.
Results. Compared with the other evaluated methods, the CLSCI equation was found to be less biased and more precise, with the smallest calculated ME and RMSE values (p < 0.05). The five alternative methods significantly overestimated vancomycin clearance, by 45-92% (p < 0.05). The CLSCI method underestimated vancomycin clearance (by 6%) but not to a significant degree (p = 0.06).
Conclusion. The study results suggest that the CLSCI equation for predicting vancomycin clearance was unbiased and may be more precise relative to other frequently used methods in the study population of patients with long-term SCI. Am J Health-Syst Pharm. 2013; 70:669-74
C1 [Lee, Jennifer Pai] Vet Affairs Long Beach Healthcare Syst, Crit Care, Long Beach, CA 90822 USA.
[Wang, Yi-Jiun] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Lee, JP (reprint author), Vet Affairs Long Beach Healthcare Syst, 5901 East 7th St, Long Beach, CA 90822 USA.
EM jennifer.lee4332a@va.gov
NR 23
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD APR 15
PY 2013
VL 70
IS 8
BP 669
EP 674
DI 10.2146/ajhp120329
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 129AU
UT WOS:000317811600009
PM 23552044
ER
PT J
AU Jeong, SM
Xiao, CY
Finley, LWS
Lahusen, T
Souza, AL
Pierce, K
Li, YH
Wang, XX
Laurent, G
German, NJ
Xu, XL
Li, CL
Wang, RH
Lee, J
Csibi, A
Cerione, R
Blenis, J
Clish, CB
Kimmelman, A
Deng, CX
Haigis, MC
AF Jeong, Seung Min
Xiao, Cuiying
Finley, Lydia W. S.
Lahusen, Tyler
Souza, Amanda L.
Pierce, Kerry
Li, Ying-Hua
Wang, Xiaoxu
Laurent, Gaelle
German, Natalie J.
Xu, Xiaoling
Li, Cuiling
Wang, Rui-Hong
Lee, Jaewon
Csibi, Alfredo
Cerione, Richard
Blenis, John
Clish, Clary B.
Kimmelman, Alec
Deng, Chu-Xia
Haigis, Marcia C.
TI SIRT4 Has Tumor-Suppressive Activity and Regulates the Cellular
Metabolic Response to DNA Damage by Inhibiting Mitochondrial Glutamine
Metabolism
SO CANCER CELL
LA English
DT Article
ID FATTY-ACID OXIDATION; GENOMIC INSTABILITY; CALORIE RESTRICTION;
INSULIN-SECRETION; CYCLE CHECKPOINT; UREA CYCLE; CANCER; CELLS;
SIRTUINS; PROMOTES
AB DNA damage elicits a cellular signaling response that initiates cell cycle arrest and DNA repair. Here, we find that DNA damage triggers a critical block in glutamine metabolism, which is required for proper DNA damage responses. This block requires the mitochondrial SIRT4, which is induced by numerous genotoxic agents and represses the metabolism of glutamine into tricarboxylic acid cycle. SIRT4 loss leads to both increased glutamine-dependent proliferation and stress-induced genomic instability, resulting in tumorigenic phenotypes. Moreover, SIRT4 knockout mice spontaneously develop lung tumors. Our data uncover SIRT4 as an important component of the DNA damage response pathway that orchestrates a metabolic block in glutamine metabolism, cell cycle arrest, and tumor suppression.
C1 [Jeong, Seung Min; Finley, Lydia W. S.; Laurent, Gaelle; German, Natalie J.; Lee, Jaewon; Csibi, Alfredo; Blenis, John; Haigis, Marcia C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Cell Biol, Boston, MA 02115 USA.
[Li, Ying-Hua; Wang, Xiaoxu; Kimmelman, Alec] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Div Genom Stabil & DNA Repair, Boston, MA 02115 USA.
[Xiao, Cuiying; Lahusen, Tyler; Xu, Xiaoling; Li, Cuiling; Wang, Rui-Hong; Deng, Chu-Xia] NIDDKD, Mammalian Genet Sect, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA.
[Souza, Amanda L.; Pierce, Kerry; Clish, Clary B.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Cerione, Richard] Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.
RP Deng, CX (reprint author), NIDDKD, Mammalian Genet Sect, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA.
EM chuxiad@bdg10.niddk.nih.gov; marcia_haigis@hms.harvard.edu
RI deng, chuxia/N-6713-2016
FU National Research Foundation of Korea; Korean Government
[NRF-2010-357-C00087]; NIH [AG032375]; Glenn Foundation for Medical
Research; American Cancer Society; National Cancer Institute [R01
CA157490]; Kimmel Scholar Award; AACR-PanCAN Career Development Award;
Intramural Research Program of the National Institute of Diabetes,
Digestive and Kidney Diseases, National Institutes of Health, USA
FX We thank Roderick T. Bronson for analyzing tumors, Moon Hee Yang for
help with allograft assays, Annie Lee for technical assistance, and the
Nikon Imaging Center at Harvard Medical School. We thank Kevin Haigis
for critical reading of the manuscript. S.M.J. was supported in part by
a National Research Foundation of Korea grant funded by the Korean
Government (NRF-2010-357-C00087). M.C.H. is supported in part by NIH
grant AG032375, the Glenn Foundation for Medical Research, and the
American Cancer Society New Scholar Award. A.K. is supported by the
National Cancer Institute grant R01 CA157490, the Kimmel Scholar Award,
and an AACR-PanCAN Career Development Award. This work was also
supported in part by the Intramural Research Program of the National
Institute of Diabetes, Digestive and Kidney Diseases, National
Institutes of Health, USA.
NR 52
TC 114
Z9 122
U1 2
U2 41
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD APR 15
PY 2013
VL 23
IS 4
BP 450
EP 463
DI 10.1016/j.ccr.2013.02.024
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 130TV
UT WOS:000317943900006
PM 23562301
ER
PT J
AU Xiao, ZX
Jiang, Q
Willette-Brown, J
Xi, SC
Zhu, F
Burkett, S
Back, T
Song, NY
Datla, M
Sun, ZH
Goldszmid, R
Lin, FC
Cohoon, T
Pike, K
Wu, XL
Schrump, DS
Wong, KK
Young, HA
Trinchieri, G
Wiltrout, RH
Hu, YL
AF Xiao, Zuoxiang
Jiang, Qun
Willette-Brown, Jami
Xi, Sichuan
Zhu, Feng
Burkett, Sandra
Back, Timothy
Song, Na-Young
Datla, Mahesh
Sun, Zhonghe
Goldszmid, Romina
Lin, Fanching
Cohoon, Travis
Pike, Kristen
Wu, Xiaolin
Schrump, David S.
Wong, Kwok-Kin
Young, Howard A.
Trinchieri, Giorgio
Wiltrout, Robert H.
Hu, Yinling
TI The Pivotal Role of IKK alpha in the Development of Spontaneous Lung
Squamous Cell Carcinomas
SO CANCER CELL
LA English
DT Article
ID KAPPA-B-KINASE; NITRIC-OXIDE SYNTHASE; STEM-CELLS; CANCER; MICE;
TRANSFORMATION; SUPPRESSOR; SKIN; P63; DIFFERENTIATION
AB Here, we report that kinase-dead IKK alpha knockin mice develop spontaneous lung squamous cell carcinomas (SCCs) associated with IKK alpha downregulation and marked pulmonary inflammation. IKK alpha reduction upregulated the expression of p63, Trim29, and keratin 5 (K5), which serve as diagnostic markers for human lung SCCs. IKK alpha(low)K5(+)p63(hi) cell expansion and SCC formation were accompanied by inflammation-associated deregulation of oncogenes, tumor suppressors, and stem cell regulators. Reintroducing transgenic K5.IKK alpha, depleting macrophages, and reconstituting irradiated mutant animals with wild-type bone marrow (BM) prevented SCC development, suggesting that BM-derived IKKa mutant macrophages promote the transition of I IKK alpha(low)K5(+)p63(hi) to tumor cells. This mouse model resembles human lung SCCs, sheds light on the mechanisms underlying lung malignancy development, and identifies targets for therapy of lung SCCs.
C1 [Xiao, Zuoxiang; Jiang, Qun; Willette-Brown, Jami; Zhu, Feng; Back, Timothy; Song, Na-Young; Datla, Mahesh; Goldszmid, Romina; Lin, Fanching; Young, Howard A.; Trinchieri, Giorgio; Wiltrout, Robert H.; Hu, Yinling] NCI, Ctr Canc Res, Canc & Inflammat Program, Frederick, MD 21701 USA.
[Xi, Sichuan; Schrump, David S.] NCI, Ctr Canc Res, Thorac Oncol Sect, Surg Branch, Frederick, MD 21701 USA.
[Burkett, Sandra] NCI, Ctr Canc Res, Mouse Canc Genet Program, Frederick, MD 21701 USA.
[Sun, Zhonghe; Pike, Kristen; Wu, Xiaolin] SAIC Frederick Inc, Frederick Natl Lab Canc Res, Lab Mol Technol, Frederick, MD 21702 USA.
[Cohoon, Travis; Wong, Kwok-Kin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Wiltrout, RH (reprint author), NCI, Ctr Canc Res, Canc & Inflammat Program, Frederick, MD 21701 USA.
EM wiltrour@mail.nih.gov; huy2@mail.nih.gov
RI Jiang, Qun/A-1358-2014;
OI wong, kwok kin/0000-0001-6323-235X
FU National Cancer Institute [ZIA BC 011212, ZIA BC 011391]
FX We thank Teri Plona, Scott Coccodrilli, Arati Raziuddin, Hue Vuong, Vika
Grinberg, and Robin Stewart from Laboratory of Molecular Technology,
SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research
for sequencing DDR2, Sox2, and PIK3CA genes in mouse lung SCCs and Dr.
Hesed Padilla-Nash and Dr. Thomas Ried from National Institutes of
Health for kindly providing a spontaneously transformed lung murine
epithelial cell line M2C. This work was supported by the National Cancer
Institute (ZIA BC 011212 and ZIA BC 011391 to Y.H.).
NR 43
TC 40
Z9 42
U1 0
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD APR 15
PY 2013
VL 23
IS 4
BP 527
EP 540
DI 10.1016/j.ccr.2013.03.009
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 130TV
UT WOS:000317943900012
PM 23597566
ER
PT J
AU Clough-Gorr, KM
Thwin, SS
Bosco, JLF
Silliman, RA
Buist, DSM
Pawloski, PA
Quinn, VP
Prout, MN
AF Clough-Gorr, Kerri M.
Thwin, Soe Soe
Bosco, Jaclyn L. F.
Silliman, Rebecca A.
Buist, Diana S. M.
Pawloski, Pamala A.
Quinn, Virginia P.
Prout, Marianne N.
TI Incident malignancies among older long-term breast cancer survivors and
an age-matched and site-matched nonbreast cancer comparison group over
10 years of follow-up
SO CANCER
LA English
DT Article
DE breast cancer; breast cancer survivors; incident malignancies;
malignancy; multiple primary malignancies; older women; survivors
ID 2ND PRIMARY CANCERS; COLORECTAL-CANCER; CONTRALATERAL BREAST; ADJUVANT
RADIOTHERAPY; INCREASED RISK; WOMEN; PREVALENCE; THERAPY
AB BACKGROUND: Of the approximately 2.4 million American women with a history of breast cancer, 43% are aged 65 years and are at risk for developing subsequent malignancies. METHODS: Women from 6 geographically diverse sites included 5-year breast cancer survivors (N = 1361) who were diagnosed between 1990 and 1994 at age 65 years with stage I or II disease and a comparison group of women without breast cancer (N = 1361). Women in the comparison group were age-matched and site-matched to breast cancer survivors on the date of breast cancer diagnosis. Follow-up began 5 years after the index date (survivor diagnosis date or comparison enrollment date) until death, disenrollment, or through 15 years after the index date. Data were collected from medical records and electronic sources (cancer registry, administrative, clinical, National Death Index). Analyses included descriptive statistics, crude incidence rates, and Cox proportional hazards regression models for estimating the risk of incident malignancy and were adjusted for death as a competing risk. RESULTS: Survivors and women in the comparison group were similar: >82% were white, 55% had a Charlson Comorbidity Index of 0, and 73% had a body mass index 30 kg/m2. Of all 306 women (N = 160 in the survivor group, N = 146 in the comparison group) who developed a first incident malignancy during follow-up, the mean time to malignancy was similar (4.37 +/- 2.81 years vs 4.03 +/- 2.76 years, respectively; P = .28), whereas unadjusted incidence rates were slightly higher in survivors (1882 vs 1620 per 100,000 person years). The adjusted hazard of developing a first incident malignancy was slightly elevated in survivors in relation to women in the comparison group, but it was not statistically significant (hazard ratio, 1.17; 95% confidence interval, 0.94-1.47). CONCLUSIONS: Older women who survived 5 years after an early stage breast cancer diagnosis were not at an elevated risk for developing subsequent incident malignancies up to 15 years after their breast cancer diagnosis. Cancer 2013. (c) 2012 American Cancer Society.
C1 [Clough-Gorr, Kerri M.] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland.
[Clough-Gorr, Kerri M.; Thwin, Soe Soe; Bosco, Jaclyn L. F.; Silliman, Rebecca A.] Boston Univ, Sch Med, Boston Med Ctr, Sect Geriatr, Boston, MA 02118 USA.
[Clough-Gorr, Kerri M.] Natl Inst Canc Epidemiol & Registrat, Zurich, Switzerland.
[Thwin, Soe Soe] Vet Affairs Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA.
[Bosco, Jaclyn L. F.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Silliman, Rebecca A.; Prout, Marianne N.] Boston Univ, Dept Epidemiol, Sch Publ Heath, Boston, MA 02215 USA.
[Buist, Diana S. M.] Grp Hlth Res Inst, Seattle, WA USA.
[Pawloski, Pamala A.] HealthPartners Res Fdn, Bloomington, MN USA.
[Quinn, Virginia P.] Kaiser Permanente Southern Calif, Res & Evaluat, Pasadena, CA USA.
RP Clough-Gorr, KM (reprint author), Boston Med Ctr, 88 East Newton St,Robinson 2, Boston, MA 02118 USA.
EM kmclough@bu.edu
OI Prout, Marianne/0000-0001-8747-6199
FU Public Health Service grant from the National Cancer Institute, National
Institutes of Health, Department of Health and Human Services
[R01CA093772-05A2]
FX This work was supported by Public Health Service grant R01CA093772-05A2
(Rebecca A. Silliman, principal investigator) from the National Cancer
Institute, National Institutes of Health, Department of Health and Human
Services.
NR 28
TC 3
Z9 3
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD APR 15
PY 2013
VL 119
IS 8
BP 1478
EP 1485
DI 10.1002/cncr.27914
PG 8
WC Oncology
SC Oncology
GA 126LT
UT WOS:000317618700006
PM 23280284
ER
PT J
AU Landry, JC
Feng, Y
Cohen, SJ
Staley, CA
Whittington, R
Sigurdson, ER
Nimeiri, H
Verma, U
Prabhu, RS
Benson, A
AF Landry, Jerome C.
Feng, Yang
Cohen, Steven J.
Staley, Charles A., III
Whittington, Richard
Sigurdson, Elin Ruth
Nimeiri, Halla
Verma, Udit
Prabhu, Roshan S.
Benson, Al Bowen
TI Phase 2 study of preoperative radiation with concurrent capecitabine,
oxaliplatin, and bevacizumab followed by surgery and postoperative
5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in
patients with locally advanced rectal cancer: ECOG 3204
SO CANCER
LA English
DT Article
DE rectal cancer; colorectal cancer; radiation therapy; chemoradiation;
neoadjuvant therapy; combined modality therapy
ID METASTATIC COLORECTAL-CANCER; CHEMORADIOTHERAPY; CHEMORADIATION; THERAPY
AB BACKGROUND: Recent studies have demonstrated the feasibility of combining oxaliplatin with 5-fluorouracil (5-FU) or capecitibine and radiation therapy. The addition of bevacizumab to chemotherapy improves overall survival for metastatic disease. We initiated a phase 2 trial to evaluate preoperative capecitabine, oxaliplatin, and bevacizumab with radiation therapy followed by surgery and postoperative 5-FU, leucovorin, oxaliplatin (FOLFOX) and bevacizumab for locally advanced rectal cancer. METHODS: Fifty-seven patients with resectable T3/T4 rectal adenocarcinoma were enrolled. Preoperative treatment was capecitabine (825 mg/m2 twice daily from Monday to Friday), oxaliplatin (50 mg/m2 weekly), bevacizumab (5 mg/kg on days 1, 15, 29), and radiation therapy (50.4 Gy). Surgery was performed by 6 weeks after neoadjuvant therapy. Beginning 8 to 12 weeks after surgery, patients received FOLFOX plus bevacizumab (5 mg/kg) every 2 weeks for 12 cycles. RESULTS: Fifty-four of 57 enrolled patients were eligible. Forty-nine (91%) patients completed preoperative therapy and underwent surgery. Nine patients (17%; 90% confidence interval, 9%-27%) achieved pathologic complete response. Thirty-two patients (59%) experienced pathologic tumor downstaging, and 53% and 15% of patients experienced worst grade 3 and grade 4 acute toxicity, respectively. Forty-seven percent of patients who underwent surgery experienced a surgical complication. CONCLUSIONS: The primary endpoint of a 30% pathologic complete response rate was not reached; however, the majority of patients experienced pathologic downstaging with this regimen. Increased wound-healing delays and complications may have been related to the addition of bevacizumab, oxaliplatin, or both. Continued observation of these patients will establish the long-term morbidity and efficacy of this combined modality approach. Cancer 2013. (c) 2012 American Cancer Society.
C1 [Landry, Jerome C.; Staley, Charles A., III; Prabhu, Roshan S.] Emory Univ, Atlanta, GA 30322 USA.
[Landry, Jerome C.; Staley, Charles A., III; Prabhu, Roshan S.] Winship Canc Inst, Atlanta, GA USA.
[Feng, Yang] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cohen, Steven J.; Sigurdson, Elin Ruth] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Whittington, Richard] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Nimeiri, Halla; Benson, Al Bowen] Northwestern Univ, Chicago, IL 60611 USA.
[Verma, Udit] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
RP Landry, JC (reprint author), Emory Univ, Dept Radiat Oncol, 1365 Clifton Rd NE, Atlanta, GA 30322 USA.
EM jland01@emory.edu
FU Public Health Service grants [CA23318, CA66636, CA21115, CA27525,
CA15488, CA49957, CA17145]; National Cancer Institute, National
Institutes of Health, and the Department of Health and Human Services;
Genentech
FX This study was conducted by the Eastern Cooperative Oncology Group
(Robert L. Comis, MD) and supported in part by Public Health Service
grants CA23318, CA66636, CA21115, CA27525, CA15488, CA49957, and CA17145
and from the National Cancer Institute, National Institutes of Health,
and the Department of Health and Human Services.; All authors have read
and approved the manuscript. To the best of our knowledge, no conflict
of interest, financial or other, exists except: Steven J Cohen has
received honoraria from Genentech; Halla Nimeiri has received honoraria
from Genentech; Al Bowen Benson has been a consultant/advisor for Sanofi
and Genentech, and has received research funding from Genentech.
NR 23
TC 25
Z9 27
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD APR 15
PY 2013
VL 119
IS 8
BP 1521
EP 1527
DI 10.1002/cncr.27890
PG 7
WC Oncology
SC Oncology
GA 126LT
UT WOS:000317618700011
PM 23288663
ER
PT J
AU Hensley, ML
Wathen, JK
Maki, RG
Araujo, DM
Sutton, G
Priebat, DA
George, S
Soslow, RA
Baker, LH
AF Hensley, Martee L.
Wathen, J. Kyle
Maki, Robert G.
Araujo, Dejka M.
Sutton, Gregory
Priebat, Dennis A.
George, Suzanne
Soslow, Robert A.
Baker, Laurence H.
TI Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma Results
of a Phase 2 Trial (SARC 005)
SO CANCER
LA English
DT Article
DE adjuvant; chemotherapy; uterine; leiomyosarcoma; survival
ID GEMCITABINE PLUS DOCETAXEL; UTERINE SARCOMAS; II TRIAL;
PROGNOSTIC-FACTORS; STAGE-I; CHEMOTHERAPY; IFOSFAMIDE; RADIOTHERAPY;
ADRIAMYCIN; CISPLATIN
AB BACKGROUND: Between 30% and 50% of women who have high-grade uterine leiomyosarcoma (uLMS) limited to the uterus at diagnosis remain progression-free at 2 years. Adjuvant pelvic radiation does not improve outcome. The objective of the current study was to determine the 2-year and 3-year progression-free survival (PFS) among a prospective cohort of women who received adjuvant gemcitabine plus docetaxel followed by doxorubicin. METHODS: Women with uterus-limited, high-grade uLMS and adequate organ function were eligible. Within 12 weeks of complete resection and after confirmation that they had no evidence of disease on computed tomography (CT) images, the patients received 4 cycles of fixed-dose-rate gemcitabine plus docetaxel. Those who were confirmed disease-free on CT scans after cycle 4 received 4 cycles of doxorubicin. CT imaging for recurrence was performed every 3 months for 2 years, then every 6 months for 3 years. RESULTS: In total, 47 women were enrolled (46 evaluable) in 3 years. Characteristics included a median age of 53 years; 1988 International Federation of Gynecology and Obstetrics stage I disease in 81% of patients, stage II disease in 15%, and serosa-only stage IIIA disease in 4%; American Joint Committee on Cancer stage II disease in 13% of patients and stage III disease in 87%; a median tumor size of 8 cm (range, 2.5-30 cm); and a median mitotic rate of 18 mitoses per 10 high-power fields (range, 5-83 mitoses per 10 high-power fields). At a median follow-up of 39.8 months, 21 of 46 patients developed recurrent disease (45.7%). The median time to recurrence was 27.4 months (range, 3-40 months). Seventy-eight percent of patients (95% confidence interval, 67%-91%) were progression-free at 2 years, and 57% (95% confidence interval, 44%-74%) were progression-free at 3 years. The median PFS was not reached and exceeded 36 months. CONCLUSIONS: Among women with high-grade, uterus-limited uLMS who received treatment with adjuvant gemcitabine plus docetaxel followed by doxorubicin, 78% remained progression-free at 2 years, and 57% remained progression-free at 3 years. A randomized trial of adjuvant chemotherapy versus observation to determine whether adjuvant chemotherapy can improve survival in women with uterus-limited uLMS is underway. Cancer 2013. (c) 2013 American Cancer Society.
C1 [Hensley, Martee L.] Mem Sloan Kettering Canc Ctr, Dept Med, Gynecol Med Oncol Serv, New York, NY 10065 USA.
[Hensley, Martee L.] Weill Cornell Med Coll, New York, NY USA.
[Wathen, J. Kyle] Janssen Res & Dev LLC, Titusville, NJ USA.
[Maki, Robert G.] Mt Sinai Med Ctr, Pediat Hematol Oncol Div, New York, NY 10029 USA.
[Araujo, Dejka M.] Univ Texas MD Anderson Canc Ctr, Sarcoma Med Oncol Div, Houston, TX 77030 USA.
[Sutton, Gregory] St Vincents Hosp, Dept Surg, Indianapolis, IN USA.
[Priebat, Dennis A.] Washington Canc Inst, Sect Hematol Oncol, Boston, MA USA.
[George, Suzanne] Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Dept Med Oncol, Boston, MA 02115 USA.
[Soslow, Robert A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA.
[Baker, Laurence H.] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA.
RP Hensley, ML (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, Gynecol Med Oncol Serv, 300 East 66th St,Suite 1355, New York, NY 10065 USA.
EM hensleym@mskcc.org
OI Soslow, Robert/0000-0002-7269-5898
FU Sarcoma Alliance for Research through Collaboration (SARC)
FX Funding for this study was provided by the Sarcoma Alliance for Research
through Collaboration (SARC) (clinicaltrials.gov registration
NCT00282087).
NR 18
TC 49
Z9 51
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD APR 15
PY 2013
VL 119
IS 8
BP 1555
EP 1561
DI 10.1002/cncr.27942
PG 7
WC Oncology
SC Oncology
GA 126LT
UT WOS:000317618700015
PM 23335221
ER
PT J
AU Prabhakar, U
Maeda, H
Jain, RK
Sevick-Muraca, EM
Zamboni, W
Farokhzad, OC
Barry, ST
Gabizon, A
Grodzinski, P
Blakey, DC
AF Prabhakar, Uma
Maeda, Hiroshi
Jain, Rakesh K.
Sevick-Muraca, Eva M.
Zamboni, William
Farokhzad, Omid C.
Barry, Simon T.
Gabizon, Alberto
Grodzinski, Piotr
Blakey, David C.
TI Challenges and Key Considerations of the Enhanced Permeability and
Retention Effect for Nanomedicine Drug Delivery in Oncology
SO CANCER RESEARCH
LA English
DT Editorial Material
ID SOLID TUMORS; MACROMOLECULAR THERAPEUTICS; CANCER; TRANSLATION; AGENTS
AB Enhanced permeability of the tumor vasculature allows macromolecules to enter the tumor interstitial space, whereas the suppressed lymphatic filtration allows them to stay there. This phenomenon, enhanced permeability and retention (EPR), has been the basis of nanotechnology platforms to deliver drugs to tumors. However, progress in developing effective drugs using this approach has been hampered by heterogeneity of EPR effect in different tumors and limited experimental data from patients on effectiveness of this mechanism as related to enhanced drug accumulation. This report summarizes the workshop discussions on key issues of the EPR effect and major gaps that need to be addressed to effectively advance nanoparticle-based drug delivery. Cancer Res; 73(8); 2412-7. (C) 2013 AACR.
C1 [Prabhakar, Uma; Grodzinski, Piotr] NCI, Alliance Nanotechnol Canc, Bethesda, MD 20892 USA.
[Maeda, Hiroshi] Sojo Univ, Inst DDS Res, Kumamoto, Japan.
[Jain, Rakesh K.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Jain, Rakesh K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Farokhzad, Omid C.] Harvard Univ, Sch Med, Boston, MA USA.
[Farokhzad, Omid C.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Sevick-Muraca, Eva M.] Univ Texas Hlth Sci Ctr, Brown Fdn Inst Mol Med, Houston, TX USA.
[Zamboni, William] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, UNC Eshelman Sch Pharm, Chapel Hill, NC USA.
[Barry, Simon T.; Blakey, David C.] AstraZeneca, Macclesfield, Cheshire, England.
[Gabizon, Alberto] Shaare Zedek Med Ctr, Jerusalem, Israel.
[Gabizon, Alberto] Hebrew Univ Jerusalem, Sch Med, IL-91010 Jerusalem, Israel.
RP Prabhakar, U (reprint author), NCI, Off Canc Nanotechnol Res, Bldg 31 Room 10A52, Bethesda, MD 20892 USA.
EM uma.prabhakar@nih.gov; grodzinp@mail.nih.gov
RI Maeda, Hiroshi/N-4471-2016; Sevick-Muraca, Eva/A-4152-2017
OI Sevick-Muraca, Eva/0000-0002-8152-4847
FU NCI NIH HHS [P30 CA016086, U54 CA151652]
NR 16
TC 362
Z9 364
U1 27
U2 185
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
BP 2412
EP 2417
DI 10.1158/0008-5472.CAN-12-4561
PG 6
WC Oncology
SC Oncology
GA 126ER
UT WOS:000317595800005
PM 23423979
ER
PT J
AU O'Connor, KW
Dejsuphong, D
Park, E
Nicolae, CM
Kimmelman, AC
D'Andrea, AD
Moldovan, GL
AF O'Connor, Kevin W.
Dejsuphong, Donniphat
Park, Eunmi
Nicolae, Claudia M.
Kimmelman, Alec C.
D'Andrea, Alan D.
Moldovan, George-Lucian
TI PARI Overexpression Promotes Genomic Instability and Pancreatic
Tumorigenesis
SO CANCER RESEARCH
LA English
DT Article
ID HOMOLOGOUS RECOMBINATION; FANCONI-ANEMIA; DNA-DAMAGE; REPLICATION FORK;
GENE-MUTATIONS; CANCER; REPAIR; BRCA2; CELLS; CARCINOGENESIS
AB Treatment options for patients with pancreatic ductal adenocarcinoma (PDAC) remain limited. Therapeutic targets of interest include mutated molecules that predispose to pancreatic cancer such as KRAS and TP53. Here, we show that an element of the homologous recombination pathway of DNA repair, the PARP-binding protein C12orf48/PARI (PARPBP), is overexpressed specifically in pancreatic cancer cells where it is an appealing candidate for targeted therapy. PARI upregulation in pancreatic cancer cells or avian DT40 cells conferred DNA repair deficiency and genomic instability. Significantly, PARI silencing compromised cancer cell proliferation in vitro, leading to cell-cycle alterations associated with S-phase delay, perturbed DNA replication, and activation of the DNA damage response pathway in the absence of DNA damage stimuli. Conversely, PARI overexpression produced tolerance to DNA damage by promoting replication of damaged DNA. In a mouse xenograft model of pancreatic cancer, PARI silencing was sufficient to reduce pancreatic tumor growth in vivo. Taken together, our findings offered a preclinical proof-of-concept for PARI as candidate therapeutic target to treat PDAC. Cancer Res; 73(8); 2529-39. (C) 2013 AACR.
C1 [O'Connor, Kevin W.; Dejsuphong, Donniphat; Park, Eunmi; Kimmelman, Alec C.; D'Andrea, Alan D.; Moldovan, George-Lucian] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Nicolae, Claudia M.; Moldovan, George-Lucian] Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.
RP Moldovan, GL (reprint author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, 500 Univ Dr, Hershey, PA 17033 USA.
EM gmoldovan@hmc.psu.edu
OI George-Lucian, Moldovan/0000-0003-3825-149X
FU NIH [R01DK43889, R37HL52725, P01HL048546, P01CA092584]; Susan G. Komen
Breast Cancer Foundation
FX This work is supported by NIH grants R01DK43889, R37HL52725,
P01HL048546, and P01CA092584 (A.D. D'Andrea) and by Postdoctoral
Fellowships from the Susan G. Komen Breast Cancer Foundation (G.-L.
Moldovan and E. Park).
NR 45
TC 11
Z9 11
U1 2
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
BP 2529
EP 2539
DI 10.1158/0008-5472.CAN-12-3313
PG 11
WC Oncology
SC Oncology
GA 126ER
UT WOS:000317595800016
PM 23436799
ER
PT J
AU Feng, S
Dakhova, O
Creighton, CJ
Ittmann, M
AF Feng, Shu
Dakhova, Olga
Creighton, Chad J.
Ittmann, Michael
TI Endocrine Fibroblast Growth Factor FGF19 Promotes Prostate Cancer
Progression
SO CANCER RESEARCH
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA; SERUM-CALCIUM; TUMOR-GROWTH; EXPRESSION;
FIBROBLAST-GROWTH-FACTOR-19; KLOTHO; METABOLISM; THERAPY; SPECIFICITY;
DETERMINES
AB Prostate cancer is the most common visceral malignancy and the second leading cause of cancer deaths in US men. There is broad evidence that fibroblast growth factor (FGF) receptors are important in prostate cancer initiation and progression, but the contribution of particular FGFs in this disease is not fully understood. The FGF family members FGF19, FGF21, and FGF23 comprise a distinct subfamily that circulate in serum and act in an endocrine manner. These endocrine FGFs require alpha-Klotho (KL) and/or beta-Klotho (KLB), two related single-pass transmembrane proteins restricted in their tissue distribution, to act as coreceptors along with classic FGF receptors (FGFR) to mediate potent biologic activity. Here we show that FGF19 is expressed in primary and metastatic prostate cancer tissues, where it functions as an autocrine growth factor. Exogenous FGF19 promoted the growth, invasion, adhesion, and colony formation of prostate cancer cells at low ligand concentrations. FGF19 silencing in prostate cancer cells expressing autocrine FGF19 decreased invasion and proliferation in vitro and tumor growth in vivo. Consistent with these observations, KL and/or KLB were expressed in prostate cancer cells in vitro and in vivo, raising the possibility that additional endocrine FGFs may also exert biologic effects in prostate cancer. Our findings support the concept that therapies targeting FGFR signaling may have efficacy in prostate cancer and highlight FGF19 as a relevant endocrine FGF in this setting. Cancer Res; 73(8); 2551-62. (C) 2013 AACR.
C1 [Feng, Shu; Dakhova, Olga; Ittmann, Michael] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
[Feng, Shu; Dakhova, Olga; Ittmann, Michael] Baylor Coll Med, Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Creighton, Chad J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Div Biostat, Houston, TX 77030 USA.
RP Ittmann, M (reprint author), Baylor Coll Med, Dept Pathol & Immunol, 1 Baylor Plaza, Houston, TX 77030 USA.
EM mittmann@bcm.tmc.edu
FU Department of Veterans Affairs Merit Review program; National Cancer
Institute [P30 CA125123]
FX This work was supported by grants from the Department of Veterans
Affairs Merit Review program (MI), the National Cancer Institute to the
Dan L. Duncan Cancer (P30 CA125123), and by the use of the facilities of
the Michael E. DeBakey VAMC.
NR 42
TC 32
Z9 33
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
BP 2551
EP 2562
DI 10.1158/0008-5472.CAN-12-4108
PG 12
WC Oncology
SC Oncology
GA 126ER
UT WOS:000317595800018
PM 23440425
ER
PT J
AU Liu, QS
Xu, CX
Kirubakaran, S
Zhang, X
Hur, W
Liu, Y
Kwiatkowski, NP
Wang, JH
Westover, KD
Gao, P
Ercan, D
Niepel, M
Thoreen, CC
Kang, SA
Patricelli, MP
Wang, YC
Tupper, T
Altabef, A
Kawamura, H
Held, KD
Chou, DM
Elledge, SJ
Janne, PA
Wong, KK
Sabatini, DM
Gray, NS
AF Liu, Qingsong
Xu, Chunxiao
Kirubakaran, Sivapriya
Zhang, Xin
Hur, Wooyoung
Liu, Yan
Kwiatkowski, Nicholas P.
Wang, Jinhua
Westover, Kenneth D.
Gao, Peng
Ercan, Dalia
Niepel, Mario
Thoreen, Carson C.
Kang, Seong A.
Patricelli, Matthew P.
Wang, Yuchuan
Tupper, Tanya
Altabef, Abigail
Kawamura, Hidemasa
Held, Kathryn D.
Chou, Danny M.
Elledge, Stephen J.
Janne, Pasi A.
Wong, Kwok-Kin
Sabatini, David M.
Gray, Nathanael S.
TI Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM,
and ATR
SO CANCER RESEARCH
LA English
DT Article
ID MAMMALIAN TARGET; ANTITUMOR-ACTIVITY; RAPAMYCIN MTOR; SIGNALING
PATHWAYS; HIGHLY POTENT; CANCER-CELLS; PI3K; MUTATIONS; DISCOVERY;
THERAPY
AB mTOR is a highly conserved serine/threonine protein kinase that serves as a central regulator of cell growth, survival, and autophagy. Deregulation of the PI3K/Akt/mTOR signaling pathway occurs commonly in cancer and numerous inhibitors targeting the ATP-binding site of these kinases are currently undergoing clinical evaluation. Here, we report the characterization of Torin2, a second-generation ATP-competitive inhibitor that is potent and selective for mTOR with a superior pharmacokinetic profile to previous inhibitors. Torin2 inhibited mTORC1-dependent T389 phosphorylation on S6K (RPS6KB1) with an EC50 of 250 pmol/L with approximately 800-fold selectivity for cellular mTOR versus phosphoinositide 3-kinase (PI3K). Torin2 also exhibited potent biochemical and cellular activity against phosphatidylinositol-3 kinase-like kinase (PIKK) family kinases including ATM(EC50, 28 nmol/L), ATR (EC50, 35 nmol/L), and DNA-PK (EC50, 118 nmol/L; PRKDC), the inhibition of which sensitized cells to Irradiation. Similar to the earlier generation compound Torin1 and in contrast to other reported mTOR inhibitors, Torin2 inhibited mTOR kinase and mTORC1 signaling activities in a sustained manner suggestive of a slow dissociation from the kinase. Cancer cell treatment with Torin2 for 24 hours resulted in a prolonged block in negative feedback and consequent T308 phosphorylation on Akt. These effects were associated with strong growth inhibition in vitro. Single-agent treatment with Torin2 in vivo did not yield significant efficacy against KRAS-driven lung tumors, but the combination of Torin2 with mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor AZD6244 yielded a significant growth inhibition. Taken together, our findings establish Torin2 as a strong candidate for clinical evaluation in a broad number of oncologic settings where mTOR signaling has a pathogenic role. Cancer Res; 73(8); 2574-86. (C) 2013 AACR.
C1 [Liu, Qingsong; Kirubakaran, Sivapriya; Zhang, Xin; Hur, Wooyoung; Kwiatkowski, Nicholas P.; Wang, Jinhua; Thoreen, Carson C.; Gray, Nathanael S.] Dana Farber Harvard Canc Ctr, Dept Canc Biol, Ludwig Ctr, Boston, MA USA.
[Ercan, Dalia; Janne, Pasi A.] Dana Farber Harvard Canc Ctr, Dept Med Oncol, Ludwig Ctr, Boston, MA USA.
[Xu, Chunxiao; Liu, Yan; Gao, Peng; Altabef, Abigail; Wong, Kwok-Kin] Dana Farber Harvard Canc Ctr, Dept Med, Ludwig Ctr, Boston, MA USA.
[Xu, Chunxiao; Liu, Yan; Gao, Peng; Altabef, Abigail; Wong, Kwok-Kin] Dana Farber Harvard Canc Ctr, Dept Med Oncol, Ludwig Ctr, Boston, MA USA.
[Ercan, Dalia; Janne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA.
[Wang, Yuchuan; Tupper, Tanya] Dana Farber Canc Inst, Lurie Family Imaging Ctr, Boston, MA 02115 USA.
[Chou, Danny M.; Elledge, Stephen J.] Howard Hughes Med Inst, Div Genet, Boston, MA 02115 USA.
[Ercan, Dalia; Janne, Pasi A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Kawamura, Hidemasa; Held, Kathryn D.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Liu, Qingsong; Kirubakaran, Sivapriya; Zhang, Xin; Hur, Wooyoung; Kwiatkowski, Nicholas P.; Wang, Jinhua; Thoreen, Carson C.; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Chou, Danny M.; Elledge, Stephen J.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Niepel, Mario] Harvard Univ, Sch Med, Ctr Cell Decis Proc, Dept Syst Biol, Boston, MA 02115 USA.
[Westover, Kenneth D.] Harvard Radiat Oncol Program, Boston, MA USA.
[Kang, Seong A.; Sabatini, David M.] MIT, Whitehead Inst Biomed Res, Cambridge, MA USA.
[Sabatini, David M.] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA USA.
[Kang, Seong A.; Sabatini, David M.] MIT, Koch Ctr Integrat Canc Res, Cambridge, MA 02139 USA.
[Patricelli, Matthew P.] ActivX Biosci Inc, La Jolla, CA USA.
RP Gray, NS (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 250 Longwood Ave, Boston, MA 02115 USA.
EM Nathanael_Gray@dfci.harvard.edu
RI Niepel, Mario/G-5443-2011;
OI Niepel, Mario/0000-0003-1415-6295; Wang, Yuchuan/0000-0001-5111-6562;
liu, qing song/0000-0002-7829-2547; wong, kwok kin/0000-0001-6323-235X
FU NIH [HG006097, RO1 CA122794, CA140594, RO1 AI47389, CA103866, C06
CA059267]; NIH Lung SPORE [P50CA090578]; American Cancer Society
FX This study was supported by NIH grant HG006097 (Q. Liu and M. Niepel);
C. Xu, Y. Liu, P. Gao, T. Tupper, and K.-K. Wong are supported by NIH
RO1 CA122794, CA140594, and NIH Lung SPORE P50CA090578; C.C. Thoreen is
supported by Postdoctoral fellowship from the American Cancer Society
and S.A. Kang are supported by NIH RO1 AI47389 and CA103866; H.
Kawamura, and K.D. Held are supported by NIH C06 CA059267; S.J. Elledge
and D.M. Sabatini are Howard Hughes Medical Institute investigators.
NR 48
TC 49
Z9 50
U1 4
U2 31
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2013
VL 73
IS 8
BP 2574
EP 2586
DI 10.1158/0008-5472.CAN-12-1702
PG 13
WC Oncology
SC Oncology
GA 126ER
UT WOS:000317595800020
PM 23436801
ER
PT J
AU Niemi, SM
AF Niemi, Steven M.
TI Laboratory animals as veterinary patients
SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID HEART-FAILURE; THERAPY; DISEASE
C1 [Niemi, Steven M.] Massachusetts Gen Hosp, Dept Res Management, Boston, MA 02114 USA.
[Niemi, Steven M.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Niemi, SM (reprint author), Massachusetts Gen Hosp, Dept Res Management, Boston, MA 02114 USA.
EM sniemi@partners.org
NR 21
TC 3
Z9 3
U1 0
U2 4
PU AMER VETERINARY MEDICAL ASSOC
PI SCHAUMBURG
PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA
SN 0003-1488
J9 JAVMA-J AM VET MED A
JI JAVMA-J. Am. Vet. Med. Assoc.
PD APR 15
PY 2013
VL 242
IS 8
BP 1063
EP 1065
PG 3
WC Veterinary Sciences
SC Veterinary Sciences
GA 122LJ
UT WOS:000317319300010
PM 23547666
ER
PT J
AU Cerdeira, AS
Rajakumar, A
Royle, CM
Lo, A
Husain, Z
Thadhani, RI
Sukhatme, VP
Karumanchi, SA
Kopcow, HD
AF Cerdeira, Ana Sofia
Rajakumar, Augustine
Royle, Caroline M.
Lo, Agnes
Husain, Zaheed
Thadhani, Ravi I.
Sukhatme, Vikas P.
Karumanchi, S. Ananth
Kopcow, Hernan D.
TI Conversion of Peripheral Blood NK Cells to a Decidual NK-like Phenotype
by a Cocktail of Defined Factors
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID NATURAL-KILLER-CELLS; HYPOXIA-INDUCIBLE FACTOR-1; FETAL-MATERNAL
INTERFACE; RECEPTOR EXPRESSION; GESTATIONAL-AGE; DNA METHYLATION;
GENE-EXPRESSION; EARLY-PREGNANCY; T-CELLS; GROWTH
AB NK cells that populate the decidua are important regulators of normal placentation. In contrast to peripheral blood NK cells, decidual NK (dNK) cells lack cytotoxicity, secrete proangiogenic factors, and regulate trophoblast invasion. In this study we show that exposure to a combination of hypoxia, TGF-beta 1, and a demethylating agent results in NK cells that express killer cell Ig-like receptors, the dNK cell markers CD9 and CD49a, and a dNK pattern of chemokine receptors. These cells secrete vascular endothelial growth factor (a potent proangiogenic molecule), display reduced cytotoxicity, and promote invasion of human trophoblast cell lines. These findings have potential therapeutic applications for placental disorders associated with altered NK cell biology. The Journal of Immunology, 2013, 190: 3939-3948.
C1 [Cerdeira, Ana Sofia; Rajakumar, Augustine; Royle, Caroline M.; Lo, Agnes; Husain, Zaheed; Sukhatme, Vikas P.; Karumanchi, S. Ananth; Kopcow, Hernan D.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Cerdeira, Ana Sofia] Gulbenkian Program Adv Med Educ, P-1067001 Lisbon, Portugal.
[Cerdeira, Ana Sofia] Univ Porto, Dept Obstet & Gynecol, Ctr Hosp Porto, P-4099001 Oporto, Portugal.
[Rajakumar, Augustine; Karumanchi, S. Ananth] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
[Thadhani, Ravi I.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA.
[Kopcow, Hernan D.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
RP Kopcow, HD (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, 330 Brookline Ave,RN359, Boston, MA 02215 USA.
EM sananth@bidmc.harvard.edu; hkopcow@bidmc.harvard.edu
FU Harvard Building Interdisciplinary Research Careers in Women's Health
Program [K12 HD051959]; National Institutes of Health; Office of
Research in Women's Health; Howard Hughes Medical Institute; Burroughs
Welcome Fund; Fundacao Calouste Gulbenkian, Portugal; Fundacao
Champalimaud, Portugal; Ministerio da Saude, Portugal; Fundacao para a
Ciencia e Tecnologia, Portugal
FX This work was supported by the Harvard Building Interdisciplinary
Research Careers in Women's Health Program Project K12 HD051959
supported by the National Institutes of Health, the Office of Research
in Women's Health (to H.D.K.), the Howard Hughes Medical Institute, and
the Burroughs Welcome Fund (to S.A.K.). The Gulbenkian Program for
Advanced Medical Education is sponsored by Fundacao Calouste Gulbenkian,
Fundacao Champalimaud, Ministerio da Saude e Fundacao para a Ciencia e
Tecnologia, Portugal.
NR 55
TC 37
Z9 39
U1 0
U2 12
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD APR 15
PY 2013
VL 190
IS 8
BP 3939
EP 3948
DI 10.4049/jimmunol.1202582
PG 10
WC Immunology
SC Immunology
GA 121WC
UT WOS:000317274500013
PM 23487420
ER
PT J
AU Grimm, MJ
Vethanayagam, RR
Almyroudis, NG
Dennis, CG
Khan, ANH
D'Auria, AC
Singel, KL
Davidson, BA
Knight, PR
Blackwell, TS
Hohl, TM
Mansour, MK
Vyas, JM
Rohm, M
Urban, CF
Kelkka, T
Holmdahl, R
Segal, BH
AF Grimm, Melissa J.
Vethanayagam, R. Robert
Almyroudis, Nikolaos G.
Dennis, Carly G.
Khan, A. Nazmul H.
D'Auria, Anthony C.
Singel, Kelly L.
Davidson, Bruce A.
Knight, Paul R.
Blackwell, Timothy S.
Hohl, Tobias M.
Mansour, Michael K.
Vyas, Jatin M.
Rohm, Marc
Urban, Constantin F.
Kelkka, Tiina
Holmdahl, Rikard
Segal, Brahm H.
TI Monocyte- and Macrophage-Targeted NADPH Oxidase Mediates Antifungal Host
Defense and Regulation of Acute Inflammation in Mice
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CHRONIC GRANULOMATOUS-DISEASE; ASPERGILLUS-FUMIGATUS CONIDIA;
P47(PHOX-/-) MOUSE MODEL; ACUTE LUNG INJURY; ALVEOLAR MACROPHAGES;
FUNGAL-INFECTIONS; NEUTROPHILS; CELLS; ACTIVATION; DECTIN-1
AB Chronic granulomatous disease, an inherited disorder of the NADPH oxidase in which phagocytes are defective in the generation of superoxide anion and downstream reactive oxidant species, is characterized by severe bacterial and fungal infections and excessive inflammation. Although NADPH oxidase isoforms exist in several lineages, reactive oxidant generation is greatest in neutrophils, where NADPH oxidase has been deemed vital for pathogen killing. In contrast, the function and importance of NADPH oxidase in macrophages are less clear. Therefore, we evaluated susceptibility to pulmonary aspergillosis in globally NADPH oxidase-deficient mice versus transgenic mice with monocyte/macrophage-targeted NADPH oxidase activity. We found that the lethal inoculum was >100-fold greater in transgenic versus globally NADPH oxidase-deficient mice. Consistent with these in vivo results, NADPH oxidase in mouse alveolar macrophages limited germination of phagocytosed Aspergillus fumigatus spores. Finally, globally NADPH oxidase-deficient mice developed exuberant neutrophilic lung inflammation and proinflammatory cytokine responses to zymosan, a fungal cell wall-derived product composed principally of particulate beta-glucans, whereas inflammation in transgenic and wild-type mice was mild and transient. Taken together, our studies identify a central role for monocyte/macrophage NADPH oxidase in controlling fungal infection and in limiting acute lung inflammation. The Journal of Immunology, 2013, 190: 4175-4184.
C1 [Grimm, Melissa J.; Vethanayagam, R. Robert; Almyroudis, Nikolaos G.; Dennis, Carly G.; Khan, A. Nazmul H.; D'Auria, Anthony C.; Singel, Kelly L.; Segal, Brahm H.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA.
[Almyroudis, Nikolaos G.; Segal, Brahm H.] SUNY Buffalo, Sch Med & Biomed Sci, Dept Med, Buffalo, NY 12414 USA.
[Davidson, Bruce A.; Knight, Paul R.] SUNY Buffalo, Sch Med & Biomed Sci, Dept Anesthesiol, Buffalo, NY 12414 USA.
[Blackwell, Timothy S.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA.
[Hohl, Tobias M.] Fred Hutchinson Canc Res Ctr, Dept Infect Dis, Seattle, WA 98109 USA.
[Mansour, Michael K.; Vyas, Jatin M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Rohm, Marc; Urban, Constantin F.] Umea Univ, Dept Clin Microbiol, Lab Mol Infect Med Sweden, S-90185 Umea, Sweden.
[Kelkka, Tiina] Turku Univ, Turku Doctoral Program Biomed Sci, MediCity, Turku 20521, Finland.
[Kelkka, Tiina; Holmdahl, Rikard] Turku Univ, MediCity, Turku 20521, Finland.
[Kelkka, Tiina; Holmdahl, Rikard] Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.
[Segal, Brahm H.] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA.
RP Segal, BH (reprint author), Roswell Pk Canc Inst, Dept Med, Elm & Carlton St, Buffalo, NY 14263 USA.
EM brahm.segal@roswellpark.org
RI Vyas, Jatin/Q-1627-2016;
OI Vyas, Jatin/0000-0002-9985-9565; Hohl, Tobias/0000-0002-9097-5412;
Urban, Constantin/0000-0003-1438-1134
FU Chronic Granulomatous Disorder Research Trust; National Institute of
Allergy and Infectious Diseases [R01AI079253]; National Cancer Institute
Cancer Center Support Grant [CA016056]; Academy of Finland; European
Union Grant Masterswitch [HEALTH-F2-2008-223404]
FX This work was supported by the Chronic Granulomatous Disorder Research
Trust (to B. H. S.), National Institute of Allergy and Infectious
Diseases Grant R01AI079253 (to B. H. S.), National Cancer Institute
Cancer Center Support Grant CA016056 to Roswell Park Cancer Institute,
and by the Academy of Finland and the European Union Grant Masterswitch
(HEALTH-F2-2008-223404).
NR 65
TC 28
Z9 29
U1 0
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD APR 15
PY 2013
VL 190
IS 8
BP 4175
EP 4184
DI 10.4049/jimmunol.1202800
PG 10
WC Immunology
SC Immunology
GA 121WC
UT WOS:000317274500035
PM 23509361
ER
PT J
AU de Schepper, EIT
Overdevest, GM
Suri, P
Peul, WC
Oei, EHG
Koes, BW
Bierma-Zeinstra, SMA
Luijsterburg, PAJ
AF de Schepper, Evelien I. T.
Overdevest, Gijsbert M.
Suri, Pradeep
Peul, Wilco C.
Oei, Edwin H. G.
Koes, Bart W.
Bierma-Zeinstra, Sita M. A.
Luijsterburg, Pim A. J.
TI Diagnosis of Lumbar Spinal Stenosis An Updated Systematic Review of the
Accuracy of Diagnostic Tests
SO SPINE
LA English
DT Review
DE lumbar spinal stenosis; diagnostic accuracy; systematic review
ID LOW-BACK-PAIN; COMPUTER-ASSISTED TOMOGRAPHY; CANAL STENOSIS; SUPPORT
TOOL; METRIZAMIDE MYELOGRAPHY; FORAMINAL STENOSIS; CLINICAL SCIENCES;
DISK HERNIATION; 1984 VOLVO; ULTRASOUND
AB Study Design. Systematic review of diagnostic studies.
Objective. To update our previous systematic review on the diagnostic accuracy of tests used to diagnose lumbar spinal stenosis.
Summary of Background Data. A wide range of clinical, radiological, and electrodiagnostic tests are used to diagnose lumbar spinal stenosis. An accurate diagnosis is vital, because lumbar spinal stenosis may require specific medical advice and treatment. Therefore, it is important to know the accuracy of these diagnostic tests currently available.
Methods. A comprehensive literature search was conducted for original diagnostic studies on lumbar spinal stenosis, in which one or more diagnostic tests were evaluated with a reference standard, and diagnostic accuracy was reported or could be calculated. Our previous systematic review included studies up to March 2004; this review is current up to March 2011. Included studies were assessed for their methodological quality using the QUADAS tool. Study characteristics and reported diagnostic accuracy were extracted.
Results. Twenty-two additional articles in addition to the 24 included in the previous review met the inclusion criteria. Combined, this resulted in 20 articles concerning imaging tests, 11 articles evaluating electrodiagnostic tests, and 15 articles evaluating clinical tests. Estimates of the diagnostic accuracy of the tests differed considerably.
Conclusion. There is a need for a consensus on criteria to define and classify lumbar spinal stenosis. At present, the most promising imaging test for lumbar spinal stenosis is magnetic resonance imaging, avoiding myelography because of its invasiveness and lack of superior accuracy. Electrodiagnostic studies showed no superior accuracy for conventional electrodiagnostic testing compared with magnetic resonance imaging. These tests should be considered in the context of those presenting symptoms with the highest diagnostic value, including radiating leg pain that is exacerbated while standing up, the absence of pain when seated, the improvement of symptoms when bending forward, and a wide-based gait.
C1 [de Schepper, Evelien I. T.; Koes, Bart W.; Bierma-Zeinstra, Sita M. A.; Luijsterburg, Pim A. J.] Univ Med Ctr, Erasmus MC, Dept Gen Practice, NL-3000 CA Rotterdam, Netherlands.
[Overdevest, Gijsbert M.; Peul, Wilco C.] Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Netherlands.
[Suri, Pradeep] VA Boston Healthcare Syst, Dept Div Phys Med & Rehabil, Boston, MA USA.
[Suri, Pradeep] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
[Suri, Pradeep] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA.
[Oei, Edwin H. G.] Univ Med Ctr, Erasmus MC, Dept Radiol, NL-3000 CA Rotterdam, Netherlands.
RP de Schepper, EIT (reprint author), Univ Med Ctr, Erasmus MC, Dept Gen Practice, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM e.deschepper@erasmusmc.nl
RI Koes, Bart/K-4614-2016
OI Koes, Bart/0000-0002-0450-9969
NR 61
TC 17
Z9 17
U1 2
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0362-2436
J9 SPINE
JI SPINE
PD APR 15
PY 2013
VL 38
IS 8
BP E469
EP E481
DI 10.1097/BRS.0b013e31828935ac
PG 13
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 125TY
UT WOS:000317565400005
PM 23385136
ER
PT J
AU Vaid, M
Prasad, R
Singh, T
Elmets, CA
Xu, H
Katiyar, SK
AF Vaid, Mudit
Prasad, Ram
Singh, Tripti
Elmets, Craig A.
Xu, Hui
Katiyar, Santosh K.
TI Silymarin inhibits ultraviolet radiation-induced immune suppression
through DNA repair-dependent activation of dendritic cells and
stimulation of effector T cells
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE DNA repair; Contact hypersensitivity; Cyclobutane pyrimidine dimer;
Nucleotide excision repair; Silymarin; Ultraviolet radiation
ID UV-INDUCED IMMUNOSUPPRESSION; ANTIGEN-PRESENTING ACTIVITY; CONTACT
HYPERSENSITIVITY; SKIN-CANCER; TRANSPLANT RECIPIENTS; PYRIMIDINE DIMERS;
IRRADIATED MICE; RISK-FACTOR; IN-VITRO; INDUCTION
AB Silymarin inhibits UVB-induced immunosuppression in mouse skin. To identify the molecular mechanisms underlying this effect, we used an adoptive transfer approach in which dendritic cells (DCs) from the draining lymph nodes of donor mice that had been UVB-exposed and sensitized to 2,4,-dinitrofluorobenzene (DNFB) were transferred into naive recipient mice. The contact hypersensitivity (CHS) response of the recipient mice to DNFB was then measured. When DCs were obtained from UVB-exposed donor mice that were not treated with silymarin, the CHS response was suppressed confirming-the role of DCs in the UVB-induced immunosuppression. Silymarin treatment of UVB-exposed donor mice relieved this suppression of the CHS response in the recipients. Silymarin treatment was associated with rapid repair of UVB-induced cyclobutane pyrimidine dimers (CPDs) in DCs and silymarin treatment did not prevent UV-induced immunosuppression in XPA-deficient mice which are unable to repair UV-induced DNA damage. The CHS response in mice receiving DCs from silymarin-treated UV-exposed donor mice also was associated with enhanced secretion of Th1-type cytokines and stimulation of T cells. Adoptive transfer of T cells revealed that transfer of either CD8(+) or CD4(+) cells from silymarin-treated, UVB-exposed donors resulted in enhancement of the CHS response. Cell culture study showed enhanced secretion of IL-2 and IFN gamma by CD8(+) T cells, and reduced secretion of Th2 cytokines by CD4(+) T cells, obtained from silymarin-treated UVB-exposed mice. These data suggest that DNA repair-dependent functional activation of DCs, a reduction in CD4(+) regulatory T-cell activity, and stimulation of CD8(+) effector T cells contribute to silymarin-mediated inhibition of UVB-induced immunosuppression. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Vaid, Mudit; Prasad, Ram; Singh, Tripti; Elmets, Craig A.; Xu, Hui; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
[Elmets, Craig A.; Xu, Hui; Katiyar, Santosh K.] Univ Alabama Birmingham, Skin Dis Res Ctr, Birmingham, AL 35294 USA.
[Elmets, Craig A.; Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU National Institutes of Health [CA140197]; DAB Skin Diseases Research
Center [AR050948]; Veterans Administration Merit Review Award
[5I01BX001059, 1I01BX001410]
FX This work was supported by the funds from National Institutes of Health
(Grant # CA140197) to S.K.K. and H.X., the DAB Skin Diseases Research
Center (AR050948), and the Veterans Administration Merit Review Award
(5I01BX001059 and 1I01BX001410) to C.A.E. and S.K.K. We thank Dr. Fiona
Hunter for her assistance in editing the manuscript.
NR 39
TC 5
Z9 6
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD APR 15
PY 2013
VL 85
IS 8
BP 1066
EP 1076
DI 10.1016/j.bcp.2013.01.026
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 115XS
UT WOS:000316845800005
PM 23395695
ER
PT J
AU Li, XB
Hartwell, KJ
Owens, M
LeMatty, T
Borckardt, JJ
Hanlon, CA
Brady, KT
George, MS
AF Li, Xingbao
Hartwell, Karren J.
Owens, Max
LeMatty, Todd
Borckardt, Jeffrey J.
Hanlon, Colleen A.
Brady, Kathleen T.
George, Mark S.
TI Repetitive Transcranial Magnetic Stimulation of the Dorsolateral
Prefrontal Cortex Reduces Nicotine Cue Craving
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Craving; dorsolateral prefrontal cortex; nicotine; smoking; tobacco;
transcranial magnetic stimulation
ID PREDICTING SMOKING-CESSATION; FAGERSTROM TEST; STRIATAL DOPAMINE;
RANDOMIZED-TRIAL; TOBACCO SMOKING; MOTOR CORTEX; DEPRESSION; DEPENDENCE;
ADDICTION; BRAIN
AB Background: Repetitive transcranial magnetic stimulation (rTMS) can noninvasively stimulate the brain and transiently amplify or block behaviors mediated through a region. We hypothesized that a single high-frequency rTMS session over the left dorsolateral prefrontal cortex (DLPFC) would reduce cue craving for cigarettes compared with a sham TMS session.
Methods: Sixteen non-treatment-seeking, nicotine-dependent participants were randomized to receive either real high-frequency rTMS (10 Hz, 100% resting motor threshold, 5-sec on, 10-sec off for 15 min; 3000 pulses) or active sham (eSham) TMS over the DLPFC in two visits with 1 week between visits. The participants received cue exposure before and after rTMS and rated their craving after each block of cue presentation.
Results: Stimulation of the left DLFPC with real, but not sham, rTMS reduced craving significantly from baseline (64.1 +/- .5.9 vs. 45.7 +/- 6.4, t = 2.69, p = .018). When compared with neutral cue craving, the effect of real TMS on cue craving was significantly greater than the effect of sham TMS (12.5 +/- 10.4 vs. 9.1 +/- 10.4; t = 2.07, p = .049). More decreases in subjective craving induced by TMS correlated positively with higher Fagerstrom Test for Nicotine Dependence score (r = .58, p =.031) and more cigarettes smoked per day (r = .57, p = .035).
Conclusions: One session of high-frequency rTMS (10 Hz) of the left DLPFC significantly reduced subjective craving induced by smoking cues in nicotine-dependent participants. Additional studies are needed to explore rTMS as an aid to smoking cessation.
C1 [Li, Xingbao; Hartwell, Karren J.; Owens, Max; LeMatty, Todd; Borckardt, Jeffrey J.; Hanlon, Colleen A.; Brady, Kathleen T.; George, Mark S.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Hartwell, Karren J.; Brady, Kathleen T.; George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Li, XB (reprint author), Med Univ South Carolina IOP, Dept Psychiat, Brain Stimulat Lab, 502 N,67 President St, Charleston, SC 29425 USA.
EM lixi@musc.edu
FU Brain Stimulation Laboratory at the Medical University of South
Carolina; National Institute of Health [5R21DA026085]; Cyberonics; Force
Protection; GlaxoSmithKline; Jazz Pharmaceuticals; MECTA; Neurospace;
Pure Tech Ventures
FX The study was funded by a Grant-in-Kind from the Brain Stimulation
Laboratory at the Medical University of South Carolina and a grant from
National Institute of Health (Grant No. 5R21DA026085 to KTB, MSG); Mark
George has served as a paid consultant to or received research support
from Cyberonics, Force Protection, GlaxoSmithKline, Jazz
Pharmaceuticals, MECTA, Neurospace, and Pure Tech Ventures and as an
unpaid consultant to Brainsonix, Brainsway, Cephos, MECTA, NeoSync, and
Neuronetics. All other authors report no biomedical financial interests
or potential conflicts of interest.
NR 68
TC 35
Z9 36
U1 6
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD APR 15
PY 2013
VL 73
IS 8
BP 714
EP 720
DI 10.1016/j.biopsych.2013.01.003
PG 7
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 120GT
UT WOS:000317159500005
PM 23485014
ER
PT J
AU Mayer, KH
Zanoni, BC
AF Mayer, Kenneth H.
Zanoni, Brian C.
TI HIV Chemoprophylaxis for Adolescents: Educable Moment, Not Magic Bullet
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
DE HIV; prevention; adolescents; preexposure prophylaxis
ID UNITED-STATES; PREEXPOSURE PROPHYLAXIS; AFRICAN-AMERICAN;
SEXUAL-BEHAVIOR; RISK REDUCTION; PREVENTION; TRIAL; INTERVENTIONS;
SURVEILLANCE; TRANSMISSION
C1 [Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA 02215 USA.
[Mayer, Kenneth H.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.
[Mayer, Kenneth H.; Zanoni, Brian C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Zanoni, Brian C.] Massachusetts Gen Hosp, MIT, Ragon Inst, Charlestown, MA USA.
[Zanoni, Brian C.] Harvard, Charlestown, MA USA.
RP Mayer, KH (reprint author), Fenway Hlth, 1340 Boylston St, Boston, MA 02215 USA.
EM kmayer@fenwayhealth.org
FU NIAID NIH HHS [T32 AI052074]
NR 25
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD APR 15
PY 2013
VL 56
IS 8
BP 1156
EP 1158
DI 10.1093/cid/cis1026
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 113WM
UT WOS:000316700100020
PM 23223593
ER
PT J
AU Chi, W
Wu, E
Morgan, BA
AF Chi, Woo
Wu, Eleanor
Morgan, Bruce A.
TI Dermal papilla cell number specifies hair size, shape and cycling and
its reduction causes follicular decline
SO DEVELOPMENT
LA English
DT Article
DE Hair; Dermal papilla; Stem cell niche
ID BETA-CATENIN ACTIVITY; STEM-CELLS; REGENERATION; ACTIVATION; EXPRESSION;
FOLLICLES; MATRIX; GROWTH; BEHAVIORS; VOLUME
AB Although the hair shaft is derived from the progeny of keratinocyte stem cells in the follicular epithelium, the growth and differentiation of follicular keratinocytes is guided by a specialized mesenchymal population, the dermal papilla (DP), that is embedded in the hair bulb. Here we show that the number of DP cells in the follicle correlates with the size and shape of the hair produced in the mouse pelage. The same stem cell pool gives rise to hairs of different sizes or types in successive hair cycles, and this shift is accompanied by a corresponding change in DP cell number. Using a mouse model that allows selective ablation of DP cells in vivo, we show that DP cell number dictates the size and shape of the hair. Furthermore, we confirm the hypothesis that the DP plays a crucial role in activating stem cells to initiate the formation of a new hair shaft. When DP cell number falls below a critical threshold, hair follicles with a normal keratinocyte compartment fail to generate new hairs. However, neighbouring follicles with a few more DP cells can re-enter the growth phase, and those that do exploit an intrinsic mechanism to restore both DP cell number and normal hair growth. These results demonstrate that the mesenchymal niche directs stem and progenitor cell behaviour to initiate regeneration and specify hair morphology. Degeneration of the DP population in mice leads to the types of hair thinning and loss observed during human aging, and the results reported here suggest novel approaches to reversing hair loss.
C1 [Morgan, Bruce A.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Boston, MA 02114 USA.
RP Morgan, BA (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02114 USA.
EM bruce.morgan@cbrc2.mgh.harvard.edu
FU National Institutes of Health, National Institute of Arthritis,
Musculoskeletal and Skin Diseases [R01AR055256]
FX This work was supported by a grant from the National Institutes of
Health, National Institute of Arthritis, Musculoskeletal and Skin
Diseases [R01AR055256 to B.A.M.]. Deposited in PMC for release after 12
months.
NR 25
TC 53
Z9 55
U1 0
U2 11
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 0950-1991
J9 DEVELOPMENT
JI Development
PD APR 15
PY 2013
VL 140
IS 8
BP 1676
EP 1683
DI 10.1242/dev.090662
PG 8
WC Developmental Biology
SC Developmental Biology
GA 114HH
UT WOS:000316731200007
PM 23487317
ER
PT J
AU Twigg, SRF
Babbs, C
van den Elzen, MEP
Goriely, A
Taylor, S
McGowan, SJ
Giannoulatou, E
Lonie, L
Ragoussis, J
Akha, ES
Knight, SJL
Zechi-Ceide, RM
Hoogeboom, JAM
Pober, BR
Toriello, HV
Wall, SA
Passos-Bueno, MR
Brunner, HG
Mathijssen, IMJ
Wilkie, AOM
AF Twigg, Stephen R. F.
Babbs, Christian
van den Elzen, Marijke E. P.
Goriely, Anne
Taylor, Stephen
McGowan, Simon J.
Giannoulatou, Eleni
Lonie, Lorne
Ragoussis, Jiannis
Akha, Elham Sadighi
Knight, Samantha J. L.
Zechi-Ceide, Roseli M.
Hoogeboom, Jeannette A. M.
Pober, Barbara R.
Toriello, Helga V.
Wall, Steven A.
Rita Passos-Bueno, M.
Brunner, Han G.
Mathijssen, Irene M. J.
Wilkie, Andrew O. M.
TI Cellular interference in craniofrontonasal syndrome: males mosaic for
mutations in the X-linked EFNB1 gene are more severely affected than
true hemizygotes
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID VARIABLE EXPRESSION; EPHRIN-B1; DYSPLASIA; INHERITANCE; PHENOTYPE;
HUMANS; FAMILY
AB Craniofrontonasal syndrome (CFNS), an X-linked disorder caused by loss-of-function mutations of EFNB1, exhibits a paradoxical sex reversal in phenotypic severity: females characteristically have frontonasal dysplasia, craniosynostosis and additional minor malformations, but males are usually more mildly affected with hypertelorism as the only feature. X-inactivation is proposed to explain the more severe outcome in heterozygous females, as this leads to functional mosaicism for cells with differing expression of EPHRIN-B1, generating abnormal tissue boundariesua process that cannot occur in hemizygous males. Apparently challenging this model, males occasionally present with a more severe female-like CFNS phenotype. We hypothesized that such individuals might be mosaic for EFNB1 mutations and investigated this possibility in multiple tissue samples from six sporadically presenting males. Using denaturing high performance liquid chromatography, massively parallel sequencing and multiplex-ligation-dependent probe amplification (MLPA) to increase sensitivity above standard dideoxy sequencing, we identified mosaic mutations of EFNB1 in all cases, comprising three missense changes, two gene deletions and a novel point mutation within the 5 untranslated region (UTR). Quantification by Pyrosequencing and MLPA demonstrated levels of mutant cells between 15 and 69. The 5 UTR variant mutates the stop codon of a small upstream open reading frame that, using a dual-luciferase reporter construct, was demonstrated to exacerbate interference with translation of the wild-type protein. These results demonstrate a more severe outcome in mosaic than in constitutionally deficient males in an X-linked dominant disorder and provide further support for the cellular interference mechanism, normally related to X-inactivation in females.
C1 [Twigg, Stephen R. F.; Babbs, Christian; Goriely, Anne; Giannoulatou, Eleni; Wilkie, Andrew O. M.] Univ Oxford, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
[Taylor, Stephen; McGowan, Simon J.; Giannoulatou, Eleni] Univ Oxford, Weatherall Inst Mol Med, Computat Biol Res Grp, Oxford OX3 9DS, England.
[van den Elzen, Marijke E. P.; Mathijssen, Irene M. J.] Univ Med Ctr, Erasmus MC, Dept Plast & Reconstruct Surg, Rotterdam, Netherlands.
[Hoogeboom, Jeannette A. M.] Univ Med Ctr, Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands.
[Lonie, Lorne; Ragoussis, Jiannis] Univ Oxford, Wellcome Trust Ctr Human Genet, Genom Grp, Oxford OX3 9DS, England.
[Akha, Elham Sadighi; Knight, Samantha J. L.] Univ Oxford, Wellcome Trust Ctr Human Genet, NIHR Biomed Res Ctr Oxford, Oxford OX3 9DS, England.
[Zechi-Ceide, Roseli M.] Univ Sao Paulo, Dept Clin Genet, Hosp Rehabil & Craniofacial Anomalies, Sao Paulo, Brazil.
[Pober, Barbara R.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Pober, Barbara R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Toriello, Helga V.] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA.
[Wall, Steven A.; Wilkie, Andrew O. M.] Oxford Univ Hosp NHS Trust, Craniofacial Unit, Oxford, England.
[Rita Passos-Bueno, M.] Univ Sao Paulo, Inst Biociencias, Ctr Estudos Genoma Humano, Sao Paulo, Brazil.
[Brunner, Han G.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
RP Wilkie, AOM (reprint author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
EM andrew.wilkie@imm.ox.ac.uk
RI Brunner, Han/C-9928-2013; Zechi-Ceide, Roseli /I-8178-2013;
Passos-Bueno, Maria Rita/I-6796-2016;
OI Zechi-Ceide, Roseli /0000-0002-4526-3336; Passos-Bueno, Maria
Rita/0000-0002-9248-3008; Twigg, Stephen/0000-0001-5024-049X;
Giannoulatou, Eleni/0000-0002-7084-6736; McGowan,
Simon/0000-0001-9720-1914; Goriely, Anne/0000-0001-9229-7216; Wilkie,
Andrew/0000-0002-2972-5481
FU Wellcome Trust [090532/Z/09/Z, 075491/Z/04, 078666, 093329]; NIHR
Biomedical Research Centre, Oxford; Department of Health's NIHR
Biomedical Research Centres funding scheme
FX This work was supported by the Wellcome Trust (Award Grant Number
090532/Z/09/Z to S.J.L.K.; 075491/Z/04 to L. L. and J.R.; 078666 to
A.O.M.W.; 093329 to S. R. F. T. and A.O.M.W.). S.J.L.K. was supported by
the NIHR Biomedical Research Centre, Oxford, with funding from the
Department of Health's NIHR Biomedical Research Centres funding scheme.
The views expressed in this publication are those of the authors and not
necessarily those of the Department of Health. Funding to pay the Open
Access publication charges for this article was provided by the Wellcome
Trust.
NR 33
TC 17
Z9 17
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD APR 15
PY 2013
VL 22
IS 8
BP 1654
EP 1662
DI 10.1093/hmg/ddt015
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 117PK
UT WOS:000316965400015
PM 23335590
ER
PT J
AU Ganesh, SK
Tragante, V
Guo, W
Guo, YR
Lanktree, MB
Smith, EN
Johnson, T
Castillo, BA
Barnard, J
Baumert, J
Chang, YPC
Elbers, CC
Farrall, M
Fischer, ME
Franceschini, N
Gaunt, TR
Gho, JMIH
Gieger, C
Gong, Y
Isaacs, A
Kleber, ME
Leach, IM
McDonough, CW
Meijs, MFL
Mellander, O
Molony, CM
Nolte, IM
Padmanabhan, S
Price, TS
Rajagopalan, R
Shaffer, J
Shah, S
Shen, HQ
Soranzo, N
van der Most, PJ
Van Iperen, EPA
Van Setten, JA
Vonk, JM
Zhang, L
Beitelshees, AL
Berenson, GS
Bhatt, DL
Boer, JMA
Boerwinkle, E
Burkley, B
Burt, A
Chakravarti, A
Chen, W
Cooper-DeHoff, RM
Curtis, SP
Dreisbach, A
Duggan, D
Ehret, GB
Fabsitz, RR
Fornage, M
Fox, E
Furlong, CE
Gansevoort, RT
Hofker, MH
Hovingh, GK
Kirkland, SA
Kottke-Marchant, K
Kutlar, A
LaCroix, AZ
Langaee, TY
Li, YR
Lin, HH
Liu, K
Maiwald, S
Malik, R
Murugesan, G
Newton-Cheh, C
OConnell, JR
Onland-Moret, NC
Ouwehand, WH
Palmas, W
Penninx, BW
Pepine, CJ
Pettinger, M
Polak, JF
Ramachandran, VS
Ranchalis, J
Redline, S
Ridker, PM
Rose, LM
Scharnag, H
Schork, NJ
Shimbo, D
Shuldiner, AR
Srinivasan, SR
Stolk, RP
Taylor, HA
Thorand, B
Trip, MD
van Duijn, CM
Verschuren, WM
Wijmenga, C
Winkelmann, BR
Wyatt, S
Young, JH
Boehm, BO
Caulfield, MJ
Chasman, DI
Davidson, KW
Doevendans, PA
FitzGerald, GA
Gums, JG
Hakonarson, H
Hillege, HL
Illig, T
Jarvik, GP
Johnson, JA
Kastelein, JJP
Koenig, W
Marz, W
Mitchell, BD
Murray, SS
Oldehinkel, AJ
Rader, DJ
Reilly, MP
Reiner, AP
Schadt, EE
Silverstein, RL
Snieder, H
Stanton, AV
Uitterlinden, AG
van der Harst, P
van der Schouw, YT
Samani, NJ
Johnson, AD
Munroe, PB
de Bakker, PIW
Zhu, XF
Levy, D
Keating, BJ
Asselbergs, FW
AF Ganesh, Santhi K.
Tragante, Vinicius
Guo, Wei
Guo, Yiran
Lanktree, Matthew B.
Smith, Erin N.
Johnson, Toby
Castillo, Berta Almoguera
Barnard, John
Baumert, Jens
Chang, Yen-Pei Christy
Elbers, Clara C.
Farrall, Martin
Fischer, Mary E.
Franceschini, Nora
Gaunt, Tom R.
Gho, Johannes M. I. H.
Gieger, Christian
Gong, Yan
Isaacs, Aaron
Kleber, Marcus E.
Leach, Irene Mateo
McDonough, Caitrin W.
Meijs, Matthijs F. L.
Mellander, Olle
Molony, Cliona M.
Nolte, Ilja M.
Padmanabhan, Sandosh
Price, Tom S.
Rajagopalan, Ramakrishnan
Shaffer, Jonathan
Shah, Sonia
Shen, Haiqing
Soranzo, Nicole
van der Most, Peter J.
Van Iperen, Erik P. A.
Van Setten, Jessic A.
Vonk, Judith M.
Zhang, Li
Beitelshees, Amber L.
Berenson, Gerald S.
Bhatt, Deepak L.
Boer, Jolanda M. A.
Boerwinkle, Eric
Burkley, Ben
Burt, Amber
Chakravarti, Aravinda
Chen, Wei
Cooper-DeHoff, Rhonda M.
Curtis, Sean P.
Dreisbach, Albert
Duggan, David
Ehret, Georg B.
Fabsitz, Richard R.
Fornage, Myriam
Fox, Ervin
Furlong, Clement E.
Gansevoort, Ron T.
Hofker, Marten H.
Hovingh, G. Kees
Kirkland, Susan A.
Kottke-Marchant, Kandice
Kutlar, Abdullah
LaCroix, Andrea Z.
Langaee, Taimour Y.
Li, Yun R.
Lin, Honghuang
Liu, Kiang
Maiwald, Steffi
Malik, Rainer
Murugesan, Gurunathan
Newton-Cheh, Christopher
OConnell, Jeffery R.
Onland-Moret, N. Charlotte
Ouwehand, Willem H.
Palmas, Walter
Penninx, Brenda W.
Pepine, Carl J.
Pettinger, Mary
Polak, Joseph F.
Ramachandran, Vasan S.
Ranchalis, Jane
Redline, Susan
Ridker, Paul M.
Rose, Lynda M.
Scharnag, Hubert
Schork, Nicholas J.
Shimbo, Daichi
Shuldiner, Alan R.
Srinivasan, Sathanur R.
Stolk, Ronald P.
Taylor, Herman A.
Thorand, Barbara
Trip, Mieke D.
van Duijn, Cornelia M.
Verschuren, W. Monique
Wijmenga, Cisca
Winkelmann, Bernhard R.
Wyatt, Sharon
Young, J. Hunter
Boehm, Bernhard O.
Caulfield, Mark J.
Chasman, Daniel I.
Davidson, Karina W.
Doevendans, Pieter A.
FitzGerald, Garret A.
Gums, John G.
Hakonarson, Hakon
Hillege, Hans L.
Illig, Thomas
Jarvik, Gail P.
Johnson, Julie A.
Kastelein, John J. P.
Koenig, Wolfgang
Maerz, Winfried
Mitchell, Braxton D.
Murray, Sarah S.
Oldehinkel, Albertine J.
Rader, Daniel J.
Reilly, Muredach P.
Reiner, Alex P.
Schadt, Eric E.
Silverstein, Roy L.
Snieder, Harold
Stanton, Alice V.
Uitterlinden, Andre G.
van der Harst, Pim
van der Schouw, Yvonne T.
Samani, Nilesh J.
Johnson, Andrew D.
Munroe, Patricia B.
de Bakker, Paul I. W.
Zhu, Xiaofeng
Levy, Daniel
Keating, Brendan J.
Asselbergs, Folkert W.
CA CARDIOGRAM
METASTROKE
LifeLines Cohort Study
TI Loci influencing blood pressure identified using a cardiovascular
gene-centric array
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; HISTAMINE-RECEPTOR H-1; CORONARY-HEART-DISEASE;
PULSE PRESSURE; EXPRESSION; P53; HYPERTENSION; MDM2; MICE; METAANALYSIS
AB Blood pressure (BP) is a heritable determinant of risk for cardiovascular disease (CVD). To investigate genetic associations with systolic BP (SBP), diastolic BP (DBP), mean arterial pressure (MAP) and pulse pressure (PP), we genotyped 50 000 single-nucleotide polymorphisms (SNPs) that capture variation in 2100 candidate genes for cardiovascular phenotypes in 61 619 individuals of European ancestry from cohort studies in the USA and Europe. We identified novel associations between rs347591 and SBP (chromosome 3p25.3, in an intron of HRH1) and between rs2169137 and DBP (chromosome1q32.1 in an intron of MDM4) and between rs2014408 and SBP (chromosome 11p15 in an intron of SOX6), previously reported to be associated with MAP. We also confirmed 10 previously known loci associated with SBP, DBP, MAP or PP (ADRB1, ATP2B1, SH2B3/ATXN2, CSK, CYP17A1, FURIN, HFE, LSP1, MTHFR, SOX6) at array-wide significance (P 2.4 10(6)). We then replicated these associations in an independent set of 65 886 individuals of European ancestry. The findings from expression QTL (eQTL) analysis showed associations of SNPs in the MDM4 region with MDM4 expression. We did not find any evidence of association of the two novel SNPs in MDM4 and HRH1 with sequelae of high BP including coronary artery disease (CAD), left ventricular hypertrophy (LVH) or stroke. In summary, we identified two novel loci associated with BP and confirmed multiple previously reported associations. Our findings extend our understanding of genes involved in BP regulation, some of which may eventually provide new targets for therapeutic intervention.
C1 [Ganesh, Santhi K.; Scharnag, Hubert] Univ Michigan Hlth Syst, Div Cardiovasc Med, Ann Arbor, MI USA.
[Tragante, Vinicius; Gho, Johannes M. I. H.; Meijs, Matthijs F. L.; Doevendans, Pieter A.; Asselbergs, Folkert W.] Univ Med Ctr Utrecht, Dept Cardiol, Div Heart & Lungs, NL-3508 GA Utrecht, Netherlands.
[Tragante, Vinicius; Elbers, Clara C.; Van Setten, Jessic A.; Onland-Moret, N. Charlotte; de Bakker, Paul I. W.; Asselbergs, Folkert W.] Univ Med Ctr Utrecht, Dept Med Genet, NL-3508 GA Utrecht, Netherlands.
[Elbers, Clara C.; Onland-Moret, N. Charlotte; van der Schouw, Yvonne T.; de Bakker, Paul I. W.; Asselbergs, Folkert W.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands.
[Guo, Wei; Zhu, Xiaofeng] Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
[Silverstein, Roy L.] Case Western Reserve Univ, Cleveland Clin Lerner Coll Med, Dept Mol Med, Cleveland, OH 44106 USA.
[Guo, Yiran; Castillo, Berta Almoguera; Li, Yun R.; Hakonarson, Hakon; Keating, Brendan J.] Childrens Hosp Philadelphia, Ctr Appl Genom, Abramson Res Ctr, Philadelphia, PA 19104 USA.
[Lanktree, Matthew B.] Univ Western Ontario, Dept Med, Schulich Sch Med & Dent, London, ON, Canada.
[Lanktree, Matthew B.] Univ Western Ontario, Dept Biochem, Schulich Sch Med & Dent, London, ON, Canada.
[Smith, Erin N.] Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA.
[Smith, Erin N.] Univ Calif San Diego, Sch Med, Radys Childrens Hosp, La Jolla, CA 92093 USA.
[Johnson, Toby; Caulfield, Mark J.; Munroe, Patricia B.] Queen Mary Univ London, London EC1M 6BQ, England.
[Johnson, Toby; Caulfield, Mark J.; Munroe, Patricia B.] Queen Mary Univ London, Barts & London Genome Ctr, William Harvey Res Inst, London EC1M 6BQ, England.
[Johnson, Toby; Munroe, Patricia B.] Queen Mary Univ London, Barts & London Sch Med & Dent, London EC1M 6BQ, England.
[Barnard, John; Zhang, Li; Beitelshees, Amber L.] Cleveland Clin, Lerner Res Inst, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA.
[Silverstein, Roy L.] Cleveland Clin, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44106 USA.
[Baumert, Jens; Thorand, Barbara] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 2, Neuherberg, Germany.
[Gieger, Christian] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Genet Epidemiol, Neuherberg, Germany.
[Illig, Thomas] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, Neuherberg, Germany.
[Chang, Yen-Pei Christy; Shen, Haiqing] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.
[Chang, Yen-Pei Christy; OConnell, Jeffery R.; Shuldiner, Alan R.; Mitchell, Braxton D.] Univ Maryland, Sch Med, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA.
[Farrall, Martin] Univ Oxford, Wellcome Trust Ctr Human Genet, Dept Cardiovasc Med, Oxford OX3 7BN, England.
[Fischer, Mary E.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
[Franceschini, Nora] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[Gaunt, Tom R.] Univ Bristol, Sch Social & Community Med, MRC Ctr Causal Anal Translat Epidemiol, Bristol BS8 2BN, Avon, England.
[Gong, Yan; McDonough, Caitrin W.; Burkley, Ben; Cooper-DeHoff, Rhonda M.; Langaee, Taimour Y.; Gums, John G.; Johnson, Julie A.] Univ Florida, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA.
[Gong, Yan; McDonough, Caitrin W.; Burkley, Ben; Cooper-DeHoff, Rhonda M.; Langaee, Taimour Y.; Johnson, Julie A.] Univ Florida, Ctr Pharmacogen, Gainesville, FL USA.
[Gums, John G.] Univ Florida, Dept Community Hlth & Family Med, Gainesville, FL USA.
[Isaacs, Aaron; van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, Genet Epidemiol Unit, Rotterdam, Netherlands.
[Uitterlinden, Andre G.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
[Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
[Kleber, Marcus E.] LURIC Study Nonprofit LLC, Freiburg, Germany.
[Kleber, Marcus E.; Maerz, Winfried] Heidelberg Univ, Mannheim Med Fac, Mannheim Inst Publ Hlth Social & Prevent Med, Mannheim, Germany.
[Leach, Irene Mateo; Hillege, Hans L.; van der Harst, Pim] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.
[Nolte, Ilja M.; van der Most, Peter J.; Vonk, Judith M.; Stolk, Ronald P.; Snieder, Harold] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands.
[Gansevoort, Ron T.] Univ Groningen, Univ Med Ctr Groningen, Dept Med, Div Nephrol, Groningen, Netherlands.
[Hofker, Marten H.] Univ Groningen, Univ Med Ctr Groningen, Med Biol Sect, Dept Pathol & Med Biol, Groningen, Netherlands.
[Wijmenga, Cisca] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands.
[LifeLines Cohort Study] Univ Groningen, Univ Med Ctr Groningen, LifeLines Cohort Study, Groningen, Netherlands.
[Oldehinkel, Albertine J.] Univ Groningen, Univ Med Ctr Groningen, Interdisciplinary Ctr Psychopathol & Emot Regulat, Groningen, Netherlands.
[Mellander, Olle] Lund Univ, Dept Clin Sci, Malmo, Sweden.
[Mellander, Olle] Skane Univ Hosp, Ctr Emergency Med, Malmo, Sweden.
[Molony, Cliona M.] Rosetta Inpharmat, Dept Genet, Seattle, WA USA.
[Padmanabhan, Sandosh] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland.
[Price, Tom S.] Inst Psychiat, MRC SGDP Ctr, London, England.
[Rajagopalan, Ramakrishnan; Burt, Amber; Furlong, Clement E.; Ranchalis, Jane; Jarvik, Gail P.] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA.
[Shaffer, Jonathan; Palmas, Walter; Shimbo, Daichi; Davidson, Karina W.] Columbia Univ, Dept Med, New York, NY USA.
[Shah, Sonia] UCL, UCL Genet Inst, Dept Genet Evolut & Environm, London WC1E 6BT, England.
[Soranzo, Nicole] Univ Cambridge, Cambridge, England.
[Ouwehand, Willem H.] Univ Cambridge, Dept Haematol, Cambridge, England.
[Ouwehand, Willem H.] NHS Blood & Transplant, Cambridge, England.
[Ouwehand, Willem H.] Wellcome Trust Sanger Inst, Hinxton, England.
[Van Iperen, Erik P. A.; Asselbergs, Folkert W.] AMC, Durrer Ctr Cardiogenet Res, Amsterdam, Netherlands.
[Van Iperen, Erik P. A.] AMC, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam, Netherlands.
[Hovingh, G. Kees; Kastelein, John J. P.] AMC, Dept Vasc Med, Amsterdam, Netherlands.
[Trip, Mieke D.] AMC, Dept Cardiol, Amsterdam, Netherlands.
[Berenson, Gerald S.; Chen, Wei; Srinivasan, Sathanur R.] Tulane Univ, Dept Epidemiol, New Orleans, LA 70118 USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
[Boer, Jolanda M. A.; Verschuren, W. Monique] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands.
[Boerwinkle, Eric; Fornage, Myriam] Univ Texas Hlth Sci Ctr, Ctr Human Genet, Houston, TX USA.
[Boerwinkle, Eric; Fornage, Myriam] Univ Texas Hlth Sci Ctr, Inst Mol Med, Houston, TX USA.
[Boerwinkle, Eric; Fornage, Myriam] Univ Texas Hlth Sci Ctr, Div Epidemiol, Houston, TX USA.
Univ Texas Hlth Sci Ctr Houston, Houston, TX USA.
[Chakravarti, Aravinda; Ehret, Georg B.] Johns Hopkins Univ, Sch Med, Ctr Complex Dis Genom, McKusick Nathans Inst Genet Med, Baltimore, MD USA.
[Young, J. Hunter] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Curtis, Sean P.] Merck Res Labs, Rahway, NJ 07065 USA.
[Dreisbach, Albert; Fox, Ervin; Taylor, Herman A.] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA.
[Wyatt, Sharon] Univ Mississippi, Med Ctr, Sch Nursing, Jackson, MS 39216 USA.
[Duggan, David] Translat Genom Res Inst, Phoenix, AZ USA.
[Fabsitz, Richard R.; Pettinger, Mary] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA.
[Levy, Daniel] NHLBI, Ctr Populat Studies, Framingham, MA USA.
[Kirkland, Susan A.] Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS B3H 3J5, Canada.
[Kottke-Marchant, Kandice; Murugesan, Gurunathan] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA.
[Kutlar, Abdullah] Med Coll Georgia, Augusta, GA 30912 USA.
[LaCroix, Andrea Z.; Reiner, Alex P.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
[Lin, Honghuang; Ramachandran, Vasan S.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Ramachandran, Vasan S.; Johnson, Andrew D.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Liu, Kiang] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.
[Maiwald, Steffi] Univ Amsterdam, Dept Vasc Med, Amsterdam, Netherlands.
[Malik, Rainer] Univ Munich, Klinikum Grosshadern, Inst Stroke & Dementia Res, D-80539 Munich, Germany.
[Malik, Rainer] Univ Munich, Klinikum Grosshadern, Neurol Klin, D-80539 Munich, Germany.
[Newton-Cheh, Christopher; de Bakker, Paul I. W.] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Newton-Cheh, Christopher] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Penninx, Brenda W.] Vrije Univ Amsterdam Med Ctr, EMGO Inst, Dept Psychiat, Amsterdam, Netherlands.
[Pepine, Carl J.] Univ Florida, Coll Med, Div Cardiovasc Med, Gainesville, FL USA.
[Polak, Joseph F.] Tufts Med Ctr, Dept Radiol, Boston, MA USA.
[Redline, Susan; Ridker, Paul M.; Rose, Lynda M.; Chasman, Daniel I.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[de Bakker, Paul I. W.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Genet, Boston, MA 02115 USA.
[Scharnag, Hubert] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, Austria.
[Schork, Nicholas J.; Murray, Sarah S.] Scripps Translat Sci Inst, La Jolla, CA USA.
[Schork, Nicholas J.] Scripps Res Inst, La Jolla, CA 92037 USA.
[Shuldiner, Alan R.] Vet Adm Med Ctr, Geriatr Res & Educ Clin Ctr, Baltimore, MD 21218 USA.
[Winkelmann, Bernhard R.] Cardiol Grp, Frankfurt, Germany.
[Boehm, Bernhard O.] Univ Ulm, Med Ctr, Div Endocrinol, D-89069 Ulm, Germany.
[Koenig, Wolfgang] Univ Ulm, Med Ctr, Dept Internal Med Cardiol 1, D-89069 Ulm, Germany.
[Davidson, Karina W.] Columbia Univ, Dept Psychiat, New York, NY USA.
[FitzGerald, Garret A.] Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA.
[Illig, Thomas] Hannover Med Sch, Hannover Unified Biobank, Hannover, Germany.
[Maerz, Winfried] Synlab Acad, Mannheim, Germany.
[Murray, Sarah S.] Scripps Hlth, La Jolla, CA USA.
[Rader, Daniel J.; Reilly, Muredach P.] Univ Penn, Perelman Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA.
[Schadt, Eric E.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA.
[Stanton, Alice V.] Royal Coll Surgeons Ireland, Dublin 2, Ireland.
[Samani, Nilesh J.] Univ Leicester, Dept Cardiovasc Sci, Leicester LE3 9QP, Leics, England.
[Samani, Nilesh J.] Glenfield Gen Hosp, Leicester NIHR Biomed Res Unit Cardiovasc Dis, Leicester LE3 9QP, Leics, England.
RP Keating, BJ (reprint author), Univ Penn, Dept Pediat, Off 1016 Abramson Bldg,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM bkeating@mail.med.upenn.edu; f.w.asselbergs@umcutrecht.nl
RI Jarvik, Gail/N-6476-2014; Gaunt, Tom/O-3918-2014; Johnson,
Andrew/G-6520-2013; sebastianovitsch, stepan/G-8507-2013; Stanton,
Alice/F-4697-2012; de Bakker, Paul/B-8730-2009; Shah, Sonia/N-7547-2013;
Wijmenga, Cisca/D-2173-2009; van der Schouw, Yvonne/F-8327-2014;
Thorand, Barbara/B-5349-2014; Guo, Yiran/H-4120-2011; Price,
Thomas/B-7372-2008; EHRET, Georg/A-9532-2009; Boehm,
Bernhard/F-8750-2015; Onland-Moret, N. Charlotte/G-9185-2011;
Padmanabhan, Sandosh/S-3963-2016;
OI Jarvik, Gail/0000-0002-6710-8708; Gaunt, Tom/0000-0003-0924-3247; de
Bakker, Paul/0000-0001-7735-7858; Shah, Sonia/0000-0001-5860-4526; van
der Schouw, Yvonne/0000-0002-4605-435X; Thorand,
Barbara/0000-0002-8416-6440; Guo, Yiran/0000-0002-6549-8589; Price,
Thomas/0000-0001-7356-2109; Gieger, Christian/0000-0001-6986-9554;
Wijmenga, Cisca/0000-0002-5635-1614; van Iperen,
Erik/0000-0001-7107-3168; Mitchell, Braxton/0000-0003-4920-4744;
Ouwehand, Willem/0000-0002-7744-1790; Kleber,
Marcus/0000-0003-0663-7275; EHRET, Georg/0000-0002-5730-0675; Lanktree,
Matthew/0000-0002-5750-6286; Lin, Honghuang/0000-0003-3043-3942;
Stanton, Alice/0000-0002-4961-165X; Johnson, Toby/0000-0002-5998-3270;
Padmanabhan, Sandosh/0000-0003-3869-5808; Ramachandran,
Vasan/0000-0001-7357-5970; Soranzo, Nicole/0000-0003-1095-3852
FU National Heart, Lung and Blood Institute; Broad Institute [N01-HC-65226]
FX We thank the National Heart, Lung and Blood Institute and the research
institutions, study investigators and field staff for their support in
creating the CARe program for biomedical research. We also thank the
study participants, without whom this endeavor would not have been
possible. DNA samples were genotyped in part through the Broad Institute
(N01-HC-65226).
NR 63
TC 61
Z9 61
U1 1
U2 49
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD APR 15
PY 2013
VL 22
IS 8
BP 1663
EP 1678
DI 10.1093/hmg/dds555
PG 16
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 117PK
UT WOS:000316965400016
PM 23303523
ER
PT J
AU Johnson, NP
Chavez, JF
Mosley, WJ
Flaherty, JD
Fox, JM
AF Johnson, Nils P.
Chavez, Jose F.
Mosley, William J., II
Flaherty, James D.
Fox, Justin M.
TI Performance of electrocardiographic criteria to differentiate Takotsubo
cardiomyopathy from acute anterior ST elevation myocardial infarction
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Electrocardiogram; Takotsubo cardiomyopathy; ST-segment elevation
myocardial infarction; Diagnostic criteria; Diagnostic accuracy
ID SEGMENT ELEVATION; TAKO-TSUBO; DIAGNOSIS; ECG
AB Background: The initial electrocardiogram (ECG) in Takotsubo cardiomyopathy (TC) can mimic an acute, anterior ST-segment elevation myocardial infarction (STEMI). Given the profound and immediate treatment differences between TC and STEMI, it would be clinically valuable to distinguish them using ECG criteria.
Methods: Presenting ECGs for proven cases of TC and acute, anterior STEMI were retrospectively collected. QRS onset and J-point were manually identified using custom software to compute median ST deviation for each lead. Six published ECG criteria were examined for diagnostic accuracy using the clinical diagnosis as the gold standard.
Results: 33 TC and 263 acute, anterior STEMI cases were identified. ST-segment deviation differed significantly between groups for all leads except aVR, I, V5, and V6. All six published ECG criteria showed a marked reduction in diagnostic accuracy in our validation cohort, except for a combination of ST-elevation in leads V2<1.75 mm and V3<2.5 mm (sensitivity 79%, specificity 73% for TC).
Conclusion: Our study demonstrates the limited diagnostic accuracy of published ECG rules to distinguish TC from acute, anterior STEMI. Given the rarity of TC and the clinical consequences of a "false positive" TC diagnosis based on ECG criteria alone, such rules should not be used in practice. TC remains a diagnosis of exclusion after emergent angiography in patients with an acute coronary syndrome and significant ST-segment elevation. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Johnson, Nils P.; Chavez, Jose F.; Mosley, William J., II; Flaherty, James D.; Fox, Justin M.] Northwestern Univ, Dept Med, Div Cardiol, Feinberg Sch Med, Chicago, IL 60611 USA.
[Johnson, Nils P.] Univ Texas Houston, Weatherhead PET Ctr Preventing & Reversing Athero, Div Cardiol, Dept Med,Med Sch, Houston, TX 77030 USA.
[Johnson, Nils P.] Mem Hermann Hosp, Houston, TX USA.
[Fox, Justin M.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
RP Johnson, NP (reprint author), Univ Texas Houston, Weatherhead PET Ctr Preventing & Reversing Athero, Med Sch Houston, 6431 Fannin St,Room 4-256 MSB, Houston, TX 77030 USA.
EM Nils.Johnson@uth.tmc.edu
NR 16
TC 12
Z9 12
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD APR 15
PY 2013
VL 164
IS 3
BP 345
EP 348
DI 10.1016/j.ijcard.2011.07.029
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 112NT
UT WOS:000316599700023
PM 21802749
ER
PT J
AU Gramfort, A
Strohmeier, D
Haueisen, J
Hamalainen, MS
Kowalski, M
AF Gramfort, A.
Strohmeier, D.
Haueisen, J.
Haemaelaeinen, M. S.
Kowalski, M.
TI Time-frequency mixed-norm estimates: Sparse M/EEG imaging with
non-stationary source activations
SO NEUROIMAGE
LA English
DT Article
DE Inverse problem; Magnetoencephalography (MEG); Electroencephalography
(EEG); Sparse structured priors; Convex optimization; Time-frequency;
Algorithms
ID INVERSE PROBLEM; SOURCE RECONSTRUCTION; CORTICAL ACTIVITY; EEG; MEG;
LOCALIZATION; PERFORMANCE; SHRINKAGE; ALGORITHM; PURSUIT
AB Magnetoencephalography (MEG) and electroencephalography (EEG) allow functional brain imaging with high temporal resolution. While solving the inverse problem independently at every time point can give an image of the active brain at every millisecond, such a procedure does not capitalize on the temporal dynamics of the signal. Linear inverse methods (minimum-norm, dSPM, sLORETA, beamformers) typically assume that the signal is stationary: regularization parameter and data covariance are independent of time and the time varying signal-to-noise ratio (SNR). Other recently proposed non-linear inverse solvers promoting focal activations estimate the sources in both space and time while also assuming stationary sources during a time interval. However such a hypothesis holds only for short time intervals. To overcome this limitation, we propose time-frequency mixed-norm estimates (TF-MxNE), which use time-frequency analysis to regularize the ill-posed inverse problem. This method makes use of structured sparse priors defined in the time-frequency domain, offering more accurate estimates by capturing the non-stationary and transient nature of brain signals. State-of-the-art convex optimization procedures based on proximal operators are employed, allowing the derivation of a fast estimation algorithm. The accuracy of the TF-MxNE is compared with recently proposed inverse solvers with help of simulations and by analyzing publicly available MEG datasets. (c) 2013 Elsevier Inc. All rights reserved.
C1 [Gramfort, A.] Telecom ParisTech, Inst Mines Telecom, CNRS LTCI, F-75014 Paris, France.
[Gramfort, A.] INRIA, Parietal Team, Saclay, France.
[Gramfort, A.] CEA Saclay, F-91191 Gif Sur Yvette, France.
[Gramfort, A.; Haemaelaeinen, M. S.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Gramfort, A.; Haemaelaeinen, M. S.] Harvard Univ, Sch Med, Charlestown, MA USA.
[Strohmeier, D.; Haueisen, J.] Ilmenau Univ Technol, Inst Biomed Engn & Informat, Ilmenau, Germany.
[Haueisen, J.] Univ Hosp Jena, Dept Neurol, Biomagnet Ctr, Jena, Germany.
[Kowalski, M.] Supelec CNRS Univ Paris Sud, Lab Signaux & Syst L2S, F-91192 Gif Sur Yvette, France.
RP Gramfort, A (reprint author), Telecom ParisTech, Inst Mines Telecom, CNRS LTCI, 37-39 Rue Dareau, F-75014 Paris, France.
EM alexandre.gramfort@telecom-pariste.fr
RI Hamalainen, Matti/C-8507-2013; Haueisen, Jens/B-7183-2011
OI Haueisen, Jens/0000-0003-3871-2890
FU National Center for Research Resources [41 RR014075-11]; National
Institute of Biomedical Imaging and Bioengineering [5R01EB009048, R01
EB006385]; German Research Foundation [Ha 2899/8-2]; French Agence
Nationale de la Recherche (ANR) [ViMAGINEANR-08-BLAN-0250-02]
FX This work was supported by the National Center for Research Resources
P41 RR014075-11, the National Institute of Biomedical Imaging and
Bioengineering grants 5R01EB009048 and R01 EB006385, the German Research
Foundation (Ha 2899/8-2), and the French Agence Nationale de la
Recherche (ANR) grant ViMAGINEANR-08-BLAN-0250-02.
NR 46
TC 49
Z9 50
U1 0
U2 35
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD APR 15
PY 2013
VL 70
BP 410
EP 422
DI 10.1016/j.neuroimage.2012.12.051
PG 13
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 100LX
UT WOS:000315703800040
PM 23291276
ER
PT J
AU McKenna, JT
Yang, C
Franciosi, S
Winston, S
Abarr, KK
Rigby, MS
Yanagawa, Y
McCarley, RW
Brown, RE
AF McKenna, James T.
Yang, Chun
Franciosi, Serena
Winston, Stuart
Abarr, Kathleen K.
Rigby, Matthew S.
Yanagawa, Yuchio
McCarley, Robert W.
Brown, Ritchie E.
TI Distribution and intrinsic membrane properties of basal forebrain
GABAergic and parvalbumin neurons in the mouse
SO JOURNAL OF COMPARATIVE NEUROLOGY
LA English
DT Article
DE green fluorescent protein; glutamic acid decarboxylase; electrical
coupling; H-current; parvalbumin
ID RETICULAR THALAMIC NUCLEUS; GREEN FLUORESCENT PROTEIN; SLEEP-WAKE STATE;
CEREBRAL-CORTEX; VISUAL-CORTEX; CHOLINE-ACETYLTRANSFERASE; PROJECTION
NEURONS; DIAGONAL BAND; IN-VITRO; IMMUNOHISTOCHEMICAL LOCALIZATION
AB The basal forebrain (BF) strongly regulates cortical activation, sleep homeostasis, and attention. Many BF neurons involved in these processes are GABAergic, including a subpopulation of projection neurons containing the calcium-binding protein, parvalbumin (PV). However, technical difficulties in identification have prevented a precise mapping of the distribution of GABAergic and GABA/PV+ neurons in the mouse or a determination of their intrinsic membrane properties. Here we used mice expressing fluorescent proteins in GABAergic (GAD67-GFP knock-in mice) or PV+ neurons (PV-Tomato mice) to study these neurons. Immunohistochemical staining for GABA in GAD67-GFP mice confirmed that GFP selectively labeled BF GABAergic neurons. GFP+ neurons and fibers were distributed throughout the BF, with the highest density in the magnocellular preoptic area (MCPO). Immunohistochemistry for PV indicated that the majority of PV+ neurons in the BF were large (>20 m) or medium-sized (1520 m) GFP+ neurons. Most medium and large-sized BF GFP+ neurons, including those retrogradely labeled from the neocortex, were fast-firing and spontaneously active in vitro. They exhibited prominent hyperpolarization-activated inward currents and subthreshold spikelets, suggestive of electrical coupling. PV+ neurons recorded in PV-Tomato mice had similar properties but had significantly narrower action potentials and a higher maximal firing frequency. Another population of smaller GFP+ neurons had properties similar to striatal projection neurons. The fast firing and electrical coupling of BF GABA/PV+ neurons, together with their projections to cortical interneurons and the thalamic reticular nucleus, suggest a strong and synchronous control of the neocortical fast rhythms typical of wakefulness and REM sleep. J. Comp. Neurol., 521:12251250, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [McKenna, James T.; Yang, Chun; Franciosi, Serena; Winston, Stuart; McCarley, Robert W.; Brown, Ritchie E.] VA Boston Healthcare Syst, Neurosci Lab, Brockton, MA 02301 USA.
[McKenna, James T.; Yang, Chun; Franciosi, Serena; Winston, Stuart; McCarley, Robert W.; Brown, Ritchie E.] Harvard Univ, Sch Med, Dept Psychiat, Brockton, MA 02301 USA.
[Franciosi, Serena] Univ Milan, Sch Med, Inst Human Physiol 2, Milan, Italy.
[Abarr, Kathleen K.; Rigby, Matthew S.] Stonehill Coll, Easton, MA 02357 USA.
[Yanagawa, Yuchio] Gunma Univ, Grad Sch Med, Dept Genet & Behav Neurosci, Maebashi, Gumma 3718511, Japan.
[Yanagawa, Yuchio] JST, CREST, Maebashi, Gumma 3718511, Japan.
RP Brown, RE (reprint author), VA Boston Healthcare Syst, Dept Psychiat, In Vitro Neurophysiol Lab, 940 Belmont St, Brockton, MA 02301 USA.
EM Ritchie_Brown@hms.harvard.edu
RI McCarley, Robert/N-5562-2014;
OI McCarley, Robert/0000-0001-5705-7495; Brown, Ritchie/0000-0002-7164-4132
FU Department of Veterans Affairs Medical Research Service Award; NIMH [R01
MH039683, R21 MH094803]; NHLBI [HL095491]; MEXT, Japan; Takeda Science
Foundation
FX Grant sponsor: Department of Veterans Affairs Medical Research Service
Award (to R.W. McCarley); NIMH; Grant number: R01 MH039683; Grant
sponsor: NHLBI; Grant number: HL095491 (to R.W. McCarley); Grant
sponsor: NIMH; Grant number: R21 MH094803 (to R.E. Brown); Grant
sponsor: Grants-in-Aids for Scientific Research from MEXT, Japan and
Takeda Science Foundation (to Y. Yanagawa).
NR 87
TC 21
Z9 22
U1 2
U2 32
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9967
J9 J COMP NEUROL
JI J. Comp. Neurol.
PD APR 15
PY 2013
VL 521
IS 6
BP 1225
EP 1250
DI 10.1002/cne.23290
PG 26
WC Neurosciences; Zoology
SC Neurosciences & Neurology; Zoology
GA 095IT
UT WOS:000315328600003
PM 23254904
ER
PT J
AU Kopeikina, KJ
Polydoro, M
Tai, HC
Yaeger, E
Carlson, GA
Pitstick, R
Hyman, BT
Spires-Jones, TL
AF Kopeikina, Katherine J.
Polydoro, Manuela
Tai, Hwan-Ching
Yaeger, Erich
Carlson, George A.
Pitstick, Rose
Hyman, Bradley T.
Spires-Jones, Tara L.
TI Synaptic alterations in the rTg4510 mouse model of tauopathy
SO JOURNAL OF COMPARATIVE NEUROLOGY
LA English
DT Article
DE Alzheimer's disease; tauopathy; hyperphosphorylated tau; array
tomography
ID PAIRED HELICAL FILAMENTS; OLIGOMERIC AMYLOID-BETA; WILD-TYPE TAU;
ALZHEIMERS-DISEASE; AXONAL-TRANSPORT; TRANSGENIC MICE; NEURONAL LOSS;
DENDRITIC SPINES; IN-VIVO; MITOCHONDRIAL DYSFUNCTION
AB Synapse loss, rather than the hallmark amyloid- (A) plaques or tau-filled neurofibrillary tangles (NFT), is considered the most predictive pathological feature associated with cognitive status in the Alzheimer's disease (AD) brain. The role of A in synapse loss is well established, but despite data linking tau to synaptic function, the role of tau in synapse loss remains largely undetermined. Here we test the hypothesis that human mutant P301L tau overexpression in a mouse model (rTg4510) will lead to age-dependent synaptic loss and dysfunction. Using array tomography and two methods of quantification (automated, threshold-based counting and a manual stereology-based technique) we demonstrate that overall synapse density is maintained in the neuropil, implicating synapse loss commensurate with the cortical atrophy known to occur in this model. Multiphoton in vivo imaging reveals close to 30% loss of apical dendritic spines of individual pyramidal neurons, suggesting these cells may be particularly vulnerable to tau-induced degeneration. Postmortem, we confirm the presence of tau in dendritic spines of rTg4510-YFP mouse brain by array tomography. These data implicate tau-induced loss of a subset of synapses that may be accompanied by compensatory increases in other synaptic subtypes, thereby preserving overall synapse density. Biochemical fractionation of synaptosomes from rTg4510 brain demonstrates a significant decrease in expression of several synaptic proteins, suggesting a functional deficit of remaining synapses in the rTg4510 brain. Together, these data show morphological and biochemical synaptic consequences in response to tau overexpression in the rTg4510 mouse model. J. Comp. Neurol., 521:13341353, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Kopeikina, Katherine J.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA.
[Kopeikina, Katherine J.; Polydoro, Manuela; Tai, Hwan-Ching; Yaeger, Erich; Hyman, Bradley T.; Spires-Jones, Tara L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA.
[Carlson, George A.; Pitstick, Rose] McLaughlin Res Inst, Great Falls, MT 59405 USA.
RP Spires-Jones, TL (reprint author), MGH Neurol, 114 16th St, Charlestown, MA 02129 USA.
EM tspires@partners.org
OI TAI, HWAN-CHING/0000-0003-0668-9163
FU National Institutes of Health [AG08487, T32AG000277, AG026249,
R00AG33670]; Alzheimer's Association
FX Grant sponsor: National Institutes of Health; Grant numbers: AG08487,
T32AG000277, AG026249, R00AG33670; Grant sponsor: Alzheimer's
Association Zenith Award.
NR 88
TC 26
Z9 26
U1 1
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9967
EI 1096-9861
J9 J COMP NEUROL
JI J. Comp. Neurol.
PD APR 15
PY 2013
VL 521
IS 6
BP 1334
EP 1353
DI 10.1002/cne.23234
PG 20
WC Neurosciences; Zoology
SC Neurosciences & Neurology; Zoology
GA 095IT
UT WOS:000315328600008
PM 23047530
ER
PT J
AU Ueno, K
Hirata, H
Hinoda, Y
Dahiya, R
AF Ueno, Koji
Hirata, Hiroshi
Hinoda, Yuji
Dahiya, Rajvir
TI Frizzled homolog proteins, microRNAs and Wnt signaling in cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Review
DE FZD; cancer; microRNA; Wnt signaling
ID RENAL-CELL CARCINOMA; HUMAN HEPATOCELLULAR-CARCINOMA; WNT/BETA-CATENIN
PATHWAY; EPITHELIAL-MESENCHYMAL TRANSITION; POTENTIAL THERAPEUTIC
TARGET; HUMAN SYNOVIAL SARCOMA; HUMAN BLADDER-CANCER; BETA-CATENIN;
MOLECULAR-CLONING; OVARIAN-CANCER
AB Wnt signaling pathways play important roles in tumorigenesis and are initiated by binding of Wnt to various receptors including frizzleds (FZDs). FZDs are one of several families of receptors comprised of FZD/LRP/ROR2/RYK in the Wnt signaling pathway. Expression of some FZD receptors are up regulated, thereby activating the Wnt signaling pathway and is correlated with cancer malignancy and patient outcomes (recurrence and survival) in many cancers. The FZD family contains ten genes in humans and their function has not been completely examined including the regulatory mechanisms of FZD genes in cancer. Knockdown of FZDs may suppress the Wnt signaling pathway resulting in decreased cell growth, invasion, motility and metastasis of cancer cells. Recently a number of microRNAs (miRNAs) have been identified and reported to be important in several cancers. MiRNAs regulate target gene expression at both the transcription and translation levels. The study of miRNA is a newly emerging field and promises to be helpful in understanding the pathogenesis of FZDs in cancer. In addition, miRNAs may be useful in regulating FZDs in cancer cells. Therefore, the aim of this review is to discuss current knowledge of the functional mechanisms of FZDs in cancer, including regulation by miRNAs and the potential for possible use of miRNAs and FZDs in future clinical applications.
C1 [Ueno, Koji; Hirata, Hiroshi; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA.
[Ueno, Koji; Hirata, Hiroshi; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94121 USA.
[Hinoda, Yuji] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Yamaguchi, Japan.
RP Dahiya, R (reprint author), Vet Affairs Med Ctr, Urol Res Ctr 112F, 4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU National Center for Research Resources of the National Institutes of
Health [R01CA138642, R01CA130860, R01CA160079]; VA Merit Review; VA
Program Project
FX Grant sponsors: National Center for Research Resources of the National
Institutes of Health; Grant numbers: R01CA138642, R01CA130860,
R01CA160079; Grant sponsors: VA Merit Review, VA Program Project
NR 158
TC 24
Z9 26
U1 2
U2 93
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD APR 15
PY 2013
VL 132
IS 8
BP 1731
EP 1740
DI 10.1002/ijc.27746
PG 10
WC Oncology
SC Oncology
GA 090OE
UT WOS:000314987800002
PM 22833265
ER
PT J
AU Ghosh, SK
Uchida, M
Yoo, B
Ross, AW
Gendler, SJ
Gong, JL
Moore, A
Medarova, Z
AF Ghosh, Subrata K.
Uchida, Masashi
Yoo, Byunghee
Ross, Alana W.
Gendler, Sandra J.
Gong, Jianlin
Moore, Anna
Medarova, Zdravka
TI Targeted imaging of breast tumor progression and therapeutic response in
a human uMUC-1 expressing transgenic mouse model
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE breast cancer; underglycosylated MUC-1 antigen; molecular imaging;
target-specific contrast agent; antigen downregulation
ID CARCINOMA IN-SITU; CA 15-3; SIRNA DELIVERY; CANCER; MUC1; CELLS;
ANTIGEN; IMMUNOTHERAPY; METASTASES; DIAGNOSIS
AB The ability to monitor breast cancer initiation and progression on the molecular level would provide an effective tool for early diagnosis and therapy. In the present study, we focused on the underglycosylated MUC-1 tumor antigen (uMUC-1), which is directly linked to tumor progression from pre-malignancy to advanced malignancy in breast cancer and has been identified as the independent predictor of local recurrence and tumor response to chemotherapy. We investigated whether changes in uMUC-1 expression during tumor development and therapeutic intervention could be monitored non-invasively using molecular imaging approach with the uMUC-1-specific contrast agent (MN-EPPT) detectable by magnetic resonance and fluorescence optical imaging. This was done in mice that express human uMUC-1 tumor antigen (MMT mice) and develop spontaneous mammary carcinoma in a stage-wise fashion. After the injection of MN-EPPT there was a significant reduction in average T2 relaxation times of the mammary fat pad between pre-malignancy and cancer. In addition, T2 relaxation times were already altered at pre-malignant state in these mice compared to non-tumor bearing mice. This indicated that targeting uMUC-1 could be useful for detecting pre-malignant transformation in the mammary fat pad. We also probed changes in uMUC-1 expression with MN-EPPT during therapy with doxorubicin (Dox). We observed that tumor delta-T2s were significantly reduced by treatment with Dox indicating lower accumulation of MN-EPPT. This correlated with a lower level of MUC-1 expression in the Dox-treated tumors, as confirmed by immunoblotting. Our study could provide a very sensitive molecular imaging approach for monitoring tumor progression and therapeutic response.
C1 [Ghosh, Subrata K.; Uchida, Masashi; Yoo, Byunghee; Ross, Alana W.; Moore, Anna; Medarova, Zdravka] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Radiol,Mol Imaging Lab, HST Athinoula A Martinos Ctr Biomed Imaging,MGH, Boston, MA USA.
[Gendler, Sandra J.] Mayo Clin, Dept Biochem & Mol Biol, Scottsdale, AZ USA.
[Gong, Jianlin] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
RP Moore, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,MGH,Mol Imaging Lab, HMS Athinoula A Martinos Ctr Biomed Imaging,MIT, Bldg 75,13th St, Charlestown, MA 02129 USA.
EM amoore@helix.mgh.harvard.edu; zmedarova@partners.org
FU NIH [1RO1CA135650]
FX This study was supported in part by the NIH grant award 1RO1CA135650 to
A. M. and Z.M.
NR 38
TC 9
Z9 10
U1 0
U2 35
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD APR 15
PY 2013
VL 132
IS 8
BP 1860
EP 1867
DI 10.1002/ijc.27872
PG 8
WC Oncology
SC Oncology
GA 090OE
UT WOS:000314987800015
PM 23015160
ER
PT J
AU Singh, H
Ash, JS
Sittig, DF
AF Singh, Hardeep
Ash, Joan S.
Sittig, Dean F.
TI Safety Assurance Factors for Electronic Health Record Resilience
(SAFER): study protocol
SO BMC MEDICAL INFORMATICS AND DECISION MAKING
LA English
DT Article
DE Electronic health records; Health information technology; Patient
safety; Risk assessment; Resilience
ID PHYSICIAN ORDER ENTRY; INFORMATION-TECHNOLOGY; PATIENT-SAFETY;
MEDICATION ERRORS; CLASSIFICATION; SYSTEMS; CARE; MANAGEMENT
AB Background: Implementation and use of electronic health records (EHRs) could lead to potential improvements in quality of care. However, the use of EHRs also introduces unique and often unexpected patient safety risks. Proactive assessment of risks and vulnerabilities can help address potential EHR-related safety hazards before harm occurs; however, current risk assessment methods are underdeveloped. The overall objective of this project is to develop and validate proactive assessment tools to ensure that EHR-enabled clinical work systems are safe and effective.
Methods/Design: This work is conceptually grounded in an 8-dimension model of safe and effective health information technology use. Our first aim is to develop self-assessment guides that can be used by health care institutions to evaluate certain high-risk components of their EHR-enabled clinical work systems. We will solicit input from subject matter experts and relevant stakeholders to develop guides focused on 9 specific risk areas and will subsequently pilot test the guides with individuals representative of likely users. The second aim will be to examine the utility of the self-assessment guides by beta testing the guides at selected facilities and conducting on-site evaluations. Our multidisciplinary team will use a variety of methods to assess the content validity and perceived usefulness of the guides, including interviews, naturalistic observations, and document analysis. The anticipated output of this work will be a series of self-administered EHR safety assessment guides with clear, actionable, checklist-type items.
Discussion: Proactive assessment of patient safety risks increases the resiliency of health care organizations to unanticipated hazards of EHR use. The resulting products and lessons learned from the development of the assessment guides are expected to be helpful to organizations that are beginning the EHR selection and implementation process as well as those that have already implemented EHRs. Findings from our project, currently underway, will inform future efforts to validate and implement tools that can be used by health care organizations to improve the safety of EHR-enabled clinical work systems.
C1 [Singh, Hardeep] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Singh, Hardeep] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA.
[Ash, Joan S.] Oregon Hlth & Sci Univ, Sch Med, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
[Sittig, Dean F.] Univ Texas Houston, Sch Biomed Informat, Houston, TX USA.
[Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA.
RP Singh, H (reprint author), Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM hardeeps@bcm.edu
FU Westat [HHSP-23320095655WC0095655]; Office of the National Coordinator
for Health Information Technology (ONC) [HHSP23337003T]; Houston VA
Health Services Research and Development Center of Excellence
[HFP90-020]
FX The SAFER project is supported through a subcontract from Westat
(HHSP-23320095655WC0095655; Anticipating the Unintended Consequences of
Health IT) funded by the Office of the National Coordinator for Health
Information Technology (ONC) (HHSP23337003T; to Drs. Singh, Ash, and
Sittig); and the Houston VA Health Services Research and Development
Center of Excellence (HFP90-020) (Dr. Singh). Neither ONC nor its funds
were involved in the manuscript writing process.
NR 33
TC 9
Z9 9
U1 3
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6947
J9 BMC MED INFORM DECIS
JI BMC Med. Inform. Decis. Mak.
PD APR 12
PY 2013
VL 13
AR 46
DI 10.1186/1472-6947-13-46
PG 8
WC Medical Informatics
SC Medical Informatics
GA 139FH
UT WOS:000318566700001
PM 23587208
ER
PT J
AU Dolga, AM
Netter, MF
Perocchi, F
Doti, N
Meissner, L
Tobaben, S
Grohm, J
Zischka, H
Plesnila, N
Decher, N
Culmsee, C
AF Dolga, Amalia M.
Netter, Michael F.
Perocchi, Fabiana
Doti, Nunzianna
Meissner, Lilja
Tobaben, Svenja
Grohm, Julia
Zischka, Hans
Plesnila, Nikolaus
Decher, Niels
Culmsee, Carsten
TI Mitochondrial Small Conductance SK2 Channels Prevent Glutamate-induced
Oxytosis and Mitochondrial Dysfunction
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID CA2+-ACTIVATED K+ CHANNELS; NEURONAL CELL-DEATH; POTASSIUM CHANNELS; ATP
CHANNEL; PROVIDES NEUROPROTECTION; INTEGRATIVE GENOMICS; THERAPEUTIC
TARGETS; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; CALCIUM UNIPORTER
AB Small conductance calcium-activated potassium (SK2/K(Ca)2.2) channels are known to be located in the neuronal plasma membrane where they provide feedback control of NMDA receptor activity. Here, we provide evidence that SK2 channels are also located in the inner mitochondrial membrane of neuronal mitochondria. Patch clamp recordings in isolated mitoplasts suggest insertion into the inner mitochondrial membrane with the C and N termini facing the intermembrane space. Activation of SK channels increased mitochondrial K+ currents, whereas channel inhibition attenuated these currents. In a model of glutamate toxicity, activation of SK2 channels attenuated the loss of the mitochondrial transmembrane potential, blocked mitochondrial fission, prevented the release of proapoptotic mitochondrial proteins, and reduced cell death. Neuroprotection was blocked by specific SK2 inhibitory peptides and siRNA targeting SK2 channels. Activation of mitochondrial SK2 channels may therefore represent promising targets for neuroprotective strategies in conditions of mitochondrial dysfunction.
C1 [Dolga, Amalia M.; Doti, Nunzianna; Tobaben, Svenja; Grohm, Julia; Culmsee, Carsten] Univ Marburg, Inst Pharmakol & Klin Pharm, Fachbereich Pharm, D-35032 Marburg, Germany.
[Netter, Michael F.; Decher, Niels] Univ Marburg, Inst Physiol & Pathophysiol, Fachbereich Med, D-35037 Marburg, Germany.
[Perocchi, Fabiana] Harvard Univ, Sch Med, Dept Syst Biol & Med, Boston, MA 02114 USA.
[Perocchi, Fabiana] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Perocchi, Fabiana] Univ Munich, Gene Ctr, D-81377 Munich, Germany.
[Doti, Nunzianna; Plesnila, Nikolaus] Royal Coll Surgeons Ireland, Dept Neurodegenerat, Dublin 2, Ireland.
[Doti, Nunzianna] CNR, Inst Biostruct & Bioimaging, I-1680131 Naples, Italy.
[Meissner, Lilja; Plesnila, Nikolaus] Univ Munich, Sch Med, Inst Stroke & Dementia Res, D-81377 Munich, Germany.
[Zischka, Hans] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Inst Toxicol, D-85764 Neuherberg, Germany.
RP Dolga, AM (reprint author), Univ Marburg, Inst Pharmakol & Klin Pharm, Fachbereich Pharm, Karl von Frisch Str 1, D-35032 Marburg, Germany.
EM dolga@staff.uni-marburg.de; culmsee@staff.uni-marburg.de
FU Alzheimer Forschung Initiative e.V
FX This work was supported in part by a grant from Alzheimer Forschung
Initiative e.V.
NR 51
TC 12
Z9 13
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 12
PY 2013
VL 288
IS 15
BP 10792
EP 10804
DI 10.1074/jbc.M113.453522
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 125TU
UT WOS:000317565000057
PM 23430260
ER
PT J
AU Dell'Italia, LJ
Ferrario, CM
AF Dell'Italia, Louis J.
Ferrario, Carlos M.
TI The Never-ending Story of Angiotensin Peptides Beyond Angiotensin I and
II
SO CIRCULATION RESEARCH
LA English
DT Editorial Material
DE Editorial; alamandine; angiotensin-converting enzyme; renin-angiotensin
system
ID SYSTEM; RENIN; RECEPTORS; ENZYMES; FAMILY; HEART; MAS
C1 [Dell'Italia, Louis J.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Dell'Italia, Louis J.] UAB Comprehens Cardiovasc Ctr, Birmingham, AL USA.
[Ferrario, Carlos M.] Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Div Surg Sci, Winston Salem, NC 27103 USA.
RP Dell'Italia, LJ (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiol, 434 BMRII,901 19th St S, Birmingham, AL 35294 USA.
EM loudell@uab.edu
FU NHLBI NIH HHS [P01 HL051952]
NR 18
TC 3
Z9 3
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7330
J9 CIRC RES
JI Circ.Res.
PD APR 12
PY 2013
VL 112
IS 8
BP 1086
EP 1087
DI 10.1161/CIRCRESAHA.113.301246
PG 2
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Hematology
GA 124QW
UT WOS:000317481700002
PM 23580768
ER
PT J
AU Gorgun, GT
Whitehill, G
Anderson, JL
Hideshima, T
Maguire, C
Laubach, J
Raje, N
Munshi, NC
Richardson, PG
Anderson, KC
AF Goerguen, Guellue Topal
Whitehill, Gregory
Anderson, Jennifer L.
Hideshima, Teru
Maguire, Craig
Laubach, Jacob
Raje, Noopur
Munshi, Nikhil C.
Richardson, Paul G.
Anderson, Kenneth C.
TI Tumor-promoting immune-suppressive myeloid-derived suppressor cells in
the multiple myeloma microenvironment in humans
SO BLOOD
LA English
DT Article
ID T-REGULATORY CELLS; CANCER-PATIENTS; DENDRITIC CELLS; BONE-MARROW;
PERIPHERAL-BLOOD; IDENTIFICATION; PROGRESSION; GROWTH;
IMMUNOSUPPRESSION; DIFFERENTIATION
AB Myeloid-derived suppressor cells (MDSCs) are a heterogeneous, immature myeloid cell population with the ability to suppress immune responses. MDSCs have been characterized in infections, inflammatory diseases, and solid tumors; however, their presence and role in the tumor-promoting, immune-suppressive microenvironment in hematologic malignancies remains unclear. We assessed the presence, frequency, and functional characteristics of MDSCs in patients with newly diagnosed, relapsed, and relapsed/refractory multiple myeloma (MM) compared with healthy donors. Additionally, we evaluated the immunomodulatory effects of lenalidomide and bortezomib on MDSCs in MM. CD11b(+)CD14-HLA-DR(-/low)CD33(+)CD15(+) MDSCs were significantly increased in both the peripheral blood and the bone marrow of patients with active MM compared with healthy donors. Furthermore, MDSCs induced MM growth while suppressing T-cell-mediated immune responses. Conversely, MM cells induced the development of MDSCs from healthy donor peripheral blood mononuclear cells, confirming a bidirectional interaction between MDSCs and MM cells and immune effector cells. Our results further suggest that MDSCs may be associated with the activity of disease in MM. Importantly, our studies suggest that inhibition of the tumor-promoting and immune-suppressive functions of MDSCs in MM may represent a promising novel immune-based therapeutic strategy.
C1 [Goerguen, Guellue Topal; Whitehill, Gregory; Anderson, Jennifer L.; Hideshima, Teru; Maguire, Craig; Laubach, Jacob; Munshi, Nikhil C.; Richardson, Paul G.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Whitehill, Gregory] Haverford Coll, Haverford, PA 19041 USA.
[Anderson, Jennifer L.] Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA.
[Raje, Noopur] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Munshi, Nikhil C.] VA Boston Healthcare Syst, Boston, MA USA.
RP Gorgun, GT (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM gullu_gorgun@dfci.harvard.edu
FU National Institutes of Health National Cancer Institute Specialized
Program of Research Excellence in Myeloma [P50 CA100707]; National
Institutes of Health National Cancer Institute Host-Tumor Cell
Interactions in Myeloma: Therapeutic Applications [P01 CA78378];
National Institutes of Health National Cancer Institute Molecular
Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
[R01 CA50947]; Amgen; Celgene; Novartis; AstraZeneca
FX This work was supported by the National Institutes of Health National
Cancer Institute Specialized Program of Research Excellence in Myeloma
(grant P50 CA100707) (K. C. A.); the National Institutes of Health
National Cancer Institute Host-Tumor Cell Interactions in Myeloma:
Therapeutic Applications (grant P01 CA78378) (K. C. A.); and the
National Institutes of Health National Cancer Institute Molecular
Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
(grant R01 CA50947) (K.C.A.).; K.C.A. is an honoraria of Celgene,
Millennium, Onyx; P. G. R. is an honoraria of Celgene, Millennium,
Johnson & Johnson; N.C.M. is an honoraria of Celgene, Millennium,
Novartis; and N.R. received research funding from, and is an honoraria
of Amgen, Celgene, Novartis, AstraZeneca. The remaining authors declare
no competing financial interests.
NR 49
TC 93
Z9 97
U1 1
U2 17
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 11
PY 2013
VL 121
IS 15
BP 2975
EP 2987
DI 10.1182/blood-2012-08-448548
PG 13
WC Hematology
SC Hematology
GA 183OH
UT WOS:000321825700022
PM 23321256
ER
PT J
AU Chen, CM
Shanmugasundaram, K
Rigby, AC
Kung, AL
AF Chen, Changmin
Shanmugasundaram, Kumaran
Rigby, Alan C.
Kung, Andrew L.
TI Shikonin, a natural product from the root of Lithospermum erythrorhizon,
is a cytotoxic DNA-binding agent
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Shikonin; Ewing sarcoma; Cytotoxic chemotherapy; Natural product;
Transcription; High throughput screen
ID EWINGS-SARCOMA; ALPHASCREEN(TM) TECHNOLOGY; CARCINOMA-CELLS;
GROOVE-BINDERS; BREAST-CANCER; INHIBITION; ASSAY; INDUCTION; EXPRESSION;
APOPTOSIS
AB To search for compounds that disrupt binding of the EWS-FLII fusion protein to its cognate targets, we developed a homogeneous high-throughput proximity assay and screened 5200 small molecule compounds. Many well-known DNA-binding chemotherapeutic agents, such as actinomycin D, cisplatin, doxorubicin, daunorubicin, and epirubicin scored in the assay and not surprising also disrupted the binding of other transcription factors. Unexpectedly, we found that Shikonin, a natural product from the root of Lithospermum erythrorhizon, similarly disrupted protein-DNA interactions. Mechanistic studies demonstrated that Shikonin displaces SYBR green from binding to the minor groove of DNA and is able to inhibit topoisomerase mediated DNA relaxation. In cells, Shikonin blocked the binding of EWS-FLI1 to the NR0B1 promoter, and attenuated gene expression. Shikonin rapidly induced G2/M arrest and apoptosis in Ewing sarcoma cells. These results demonstrate that contrary to other purported mechanisms of action, Shikonin is a DNA-binding cytotoxic agent. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Chen, Changmin] Harvard Univ, Sch Med, Dept Pediat Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA.
[Chen, Changmin] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA 02215 USA.
[Shanmugasundaram, Kumaran; Rigby, Alan C.] Harvard Univ, Sch Med, Div Mol & Vasc Med, Ctr Vasc Biol Res,Dept Med,Beth Israel Deaconess, Boston, MA 02215 USA.
[Kung, Andrew L.] Columbia Univ, Med Ctr, Div Pediat Hematol Oncol Stem Cell Transplant, New York, NY 10032 USA.
RP Kung, AL (reprint author), Columbia Univ, Med Ctr, 3959 Broadway, New York, NY 10032 USA.
EM akung@columbia.edu
OI Kung, Andrew/0000-0002-9091-488X
NR 47
TC 9
Z9 11
U1 1
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-0987
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD APR 11
PY 2013
VL 49
IS 1
BP 18
EP 26
DI 10.1016/j.ejps.2013.02.003
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 126SA
UT WOS:000317640300003
PM 23422689
ER
PT J
AU Asch, DA
Muller, RW
Volpp, KG
AF Asch, David A.
Muller, Ralph W.
Volpp, Kevin G.
TI Conflicts and Compromises in Not Hiring Smokers
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Asch, David A.; Volpp, Kevin G.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
[Asch, David A.; Muller, Ralph W.; Volpp, Kevin G.] Univ Penn, Ctr Hlth Incent & Behav Econ, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Muller, Ralph W.] Univ Penn, Univ Penn Hlth Syst, Philadelphia, PA 19104 USA.
RP Asch, DA (reprint author), Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
OI Asch, David/0000-0002-7970-286X
NR 5
TC 11
Z9 11
U1 0
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 11
PY 2013
VL 368
IS 15
BP 1371
EP 1373
DI 10.1056/NEJMp1303632
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 122QT
UT WOS:000317333600002
PM 23534547
ER
PT J
AU Ryan, DP
Friedmann, AM
Schmitz, MD
Ryan, RJH
AF Ryan, Daniel P.
Friedmann, Alison M.
Schmitz, Matthew D.
Ryan, Russell J. H.
TI Case 11-2013: A 4-Year-Old Boy with Fever and Abdominal Pain
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ACUTE APPENDICITIS; BURKITTS-LYMPHOMA; CHILDREN; APPENDECTOMY;
METAANALYSIS; PHLEGMON; ABSCESS; CELLS; RISK
C1 [Ryan, Daniel P.] Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA.
[Friedmann, Alison M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Schmitz, Matthew D.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Ryan, Russell J. H.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Ryan, Daniel P.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Friedmann, Alison M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Schmitz, Matthew D.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Ryan, Russell J. H.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Ryan, DP (reprint author), Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA.
NR 16
TC 2
Z9 2
U1 0
U2 4
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 11
PY 2013
VL 368
IS 15
BP 1435
EP 1444
DI 10.1056/NEJMcpc1209304
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 122QT
UT WOS:000317333600013
PM 23574123
ER
PT J
AU Bhatt, DL
AF Bhatt, Deepak L.
TI Timely PCI for STEMI - Still the Treatment of Choice
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED-TRIALS; ANGIOPLASTY; THERAPY
C1 [Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Bhatt, DL (reprint author), Brigham & Womens Hosp, VA Boston Healthcare Syst, 75 Francis St, Boston, MA 02115 USA.
NR 10
TC 14
Z9 15
U1 0
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 11
PY 2013
VL 368
IS 15
BP 1446
EP 1447
DI 10.1056/NEJMe1302670
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 122QT
UT WOS:000317333600014
PM 23473397
ER
PT J
AU Wu, H
AF Wu, Hao
TI Higher-Order Assemblies in a New Paradigm of Signal Transduction
SO CELL
LA English
DT Article
ID CRYSTAL-STRUCTURE; RECEPTOR; COMPLEX; ACTIVATION; APOPTOSIS; MECHANISM;
REVEALS; KINASE; TRAF6; FORMS
AB Recent studies have revealed that multiple intracellular signaling proteins may assemble into structured, yet sometimes infinite, higher-order signaling machines for transmission of receptor activation information to cellular responses. These studies advance our understanding of cell signaling and implicate new molecular mechanisms in proximity-driven enzyme activation, threshold behavior, signal amplification, reduction of biological noise, and temporal and spatial control of signal transduction.
C1 [Wu, Hao] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Wu, Hao] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
RP Wu, H (reprint author), Childrens Hosp, Program Cellular & Mol Med, 300 Longwood Ave, Boston, MA 02115 USA.
EM hao.wu@childrens.harvard.edu
FU National Institutes of Health
FX I apologize for incomplete citations due to space limitation and thank
my colleagues and lab members for many insightful discussions, in
particular Kai Wucherpfennig, Hong Qian, Qi Qiao, Qian Yin, and Neer
Asherie. This work is supported by the National Institutes of Health.
NR 24
TC 95
Z9 95
U1 5
U2 47
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD APR 11
PY 2013
VL 153
IS 2
BP 287
EP 292
DI 10.1016/j.cell.2013.03.013
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 122WR
UT WOS:000317349700009
PM 23582320
ER
PT J
AU Whyte, WA
Orlando, DA
Hnisz, D
Abraham, BJ
Lin, CY
Kagey, MH
Rahl, PB
Lee, TI
Young, RA
AF Whyte, Warren A.
Orlando, David A.
Hnisz, Denes
Abraham, Brian J.
Lin, Charles Y.
Kagey, Michael H.
Rahl, Peter B.
Lee, Tong Ihn
Young, Richard A.
TI Master Transcription Factors and Mediator Establish Super-Enhancers at
Key Cell Identity Genes
SO CELL
LA English
DT Article
ID EMBRYONIC STEM-CELLS; WNT SIGNALING PATHWAY; HUMAN GENOME; SELF-RENEWAL;
RNAI SCREEN; COACTIVATOR COMPLEX; EXPRESSION; PLURIPOTENCY;
DIFFERENTIATION; CIRCUITRY
AB Master transcription factors Oct4, Sox2, and Nanog bind enhancer elements and recruit Mediator to activate much of the gene expression program of pluripotent embryonic stem cells (ESCs). We report here that the ESC master transcription factors form unusual enhancer domains at most genes that control the pluripotent state. These domains, which we call super-enhancers, consist of clusters of enhancers that are densely occupied by the master regulators and Mediator. Super-enhancers differ from typical enhancers in size, transcription factor density and content, ability to activate transcription, and sensitivity to perturbation. Reduced levels of Oct4 or Mediator cause preferential loss of expression of super-enhancer-associated genes relative to other genes, suggesting how changes in gene expression programs might be accomplished during development. In other more differentiated cells, super-enhancers containing cell-type-specific master transcription factors are also found at genes that define cell identity. Super-enhancers thus play key roles in the control of mammalian cell identity.
C1 [Whyte, Warren A.; Orlando, David A.; Hnisz, Denes; Abraham, Brian J.; Lin, Charles Y.; Kagey, Michael H.; Rahl, Peter B.; Lee, Tong Ihn; Young, Richard A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Lin, Charles Y.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Young, Richard A.] MIT, Dept Biol, Cambridge, MA 02139 USA.
RP Young, RA (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
EM young@wi.mit.edu
RI Young, Richard/F-6495-2012
OI Young, Richard/0000-0001-8855-8647
FU National Institutes of Health [HG002668, CA146445]
FX We thank Tom Volkert, Jennifer Love, Sumeet Gupta, and Jeong-Ah Kwon at
the Whitehead Genome Technologies Core for Solexa sequencing; Lee M.
Lawton, Jessica Reddy, Ana D'Alessio, and Jasmine M. De Cock for
experimental assistance; and Alla A. Sigova, Alan C. Mullen, Roshan M.
Kumar, and members of the Young lab for helpful discussion. This work
was supported by the National Institutes of Health grants HG002668
(R.A.Y.) and CA146445 (R.A.Y. and T.I.L.). R.A.Y. is a founder and
D.A.O. and P.B.R. have become employees of Syros Pharmaceuticals.
NR 75
TC 614
Z9 620
U1 14
U2 161
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD APR 11
PY 2013
VL 153
IS 2
BP 307
EP 319
DI 10.1016/j.cell.2013.03.035
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 122WR
UT WOS:000317349700011
PM 23582322
ER
PT J
AU Loven, J
Hoke, HA
Lin, CY
Lau, A
Orlando, DA
Vakoc, CR
Bradner, JE
Lee, TI
Young, RA
AF Loven, Jakob
Hoke, Heather A.
Lin, Charles Y.
Lau, Ashley
Orlando, David A.
Vakoc, Christopher R.
Bradner, James E.
Lee, Tong Ihn
Young, Richard A.
TI Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
SO CELL
LA English
DT Article
ID RNA-POLYMERASE-II; BROMODOMAIN PROTEIN BRD4; MULTIPLE-MYELOMA;
GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; C-MYC; THERAPEUTIC TARGET;
CANCER EPIGENETICS; BET BROMODOMAINS; MEDIATOR COMPLEX
AB Chromatin regulators have become attractive targets for cancer therapy, but it is unclear why inhibition of these ubiquitous regulators should have gene-specific effects in tumor cells. Here, we investigate how inhibition of the widely expressed transcriptional coactivator BRD4 leads to selective inhibition of the MYC oncogene in multiple myeloma (MM). BRD4 and Mediator were found to co-occupy thousands of enhancers associated with active genes. They also co-occupied a small set of exceptionally large super-enhancers associated with genes that feature prominently in MM biology, including the MYC oncogene. Treatment of MM tumor cells with the BET-bromodomain inhibitor JQ1 led to preferential loss of BRD4 at super-enhancers and consequent transcription elongation defects that preferentially impacted genes with super-enhancers, including MYC. Super-enhancers were found at key oncogenic drivers in many other tumor cells. These observations have implications for the discovery of cancer therapeutics directed at components of super-enhancers in diverse tumor types.
C1 [Loven, Jakob; Hoke, Heather A.; Lin, Charles Y.; Lau, Ashley; Orlando, David A.; Lee, Tong Ihn; Young, Richard A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Hoke, Heather A.; Lau, Ashley; Young, Richard A.] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Lin, Charles Y.] MIT, Computat & Syst Biol Program, Cambridge, MA 02139 USA.
[Vakoc, Christopher R.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
[Lin, Charles Y.; Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Bradner, James E.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Young, RA (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
EM young@wi.mit.edu
RI Young, Richard/F-6495-2012;
OI Young, Richard/0000-0001-8855-8647; Vakoc,
Christopher/0000-0002-1158-7180
FU Swedish Research Council [VR-B0086301]; Damon-Runyon Cancer Research
Foundation; Burroughs-Welcome CAMS award; NCI Cancer Center Support
Grant Development Fund [CA45508]; National Institutes of Health
[HG002668, CA146445]
FX We thank Zi Peng Fan for bioinformatics support; Michael R. McKeown for
help with cell viability assays; Jun Qi for providing JQ1; Tom Volkert,
Jennifer Love, Sumeet Gupta, and Jeong-Ah Kwon at the Whitehead Genome
Technologies Core for Solexa sequencing; and members of the Young,
Bradner, and Vakoc labs for helpful discussion. This work was supported
by a Swedish Research Council Postdoctoral Fellowship VR-B0086301
(J.L.), the Damon-Runyon Cancer Research Foundation (J.E.B.), a
Burroughs-Welcome CAMS award and NCI Cancer Center Support Grant
Development Fund CA45508 (C.R.V.), and National Institutes of Health
grants HG002668 (R.A.Y.) and CA146445 (R.A.Y., T. I. L.). R.A.Y. and
J.E.B. are founders, J.L. and D.A.O. have become employees, and C.R.V.
is a scientific advisor of Syros Pharmaceuticals.
NR 74
TC 471
Z9 476
U1 19
U2 169
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD APR 11
PY 2013
VL 153
IS 2
BP 320
EP 334
DI 10.1016/j.cell.2013.03.036
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 122WR
UT WOS:000317349700012
PM 23582323
ER
PT J
AU Xiong, Y
McCormack, M
Li, L
Hall, Q
Xiang, CB
Sheen, J
AF Xiong, Yan
McCormack, Matthew
Li, Lei
Hall, Qi
Xiang, Chengbin
Sheen, Jen
TI Glucose-TOR signalling reprograms the transcriptome and activates
meristems
SO NATURE
LA English
DT Article
ID E2F TARGET GENES; ARABIDOPSIS; ROOT; GROWTH; RAPAMYCIN; PROLIFERATION;
EXPRESSION; NUTRIENT; ENERGY; DIFFERENTIATION
AB Meristems encompass stem/progenitor cells that sustain postembryonic growth of all plant organs. How meristems are activated and sustained by nutrient signalling remains enigmatic in photosynthetic plants. Combining chemical manipulations and chemical genetics at the photoautotrophic transition checkpoint, we reveal that shoot photosynthesis-derived glucose drives target-of-rapamycin (TOR) signalling relays through glycolysis and mitochondrial bioenergetics to control root meristem activation, which is decoupled from direct glucose sensing, growth-hormone signalling and stem-cell maintenance. Surprisingly, glucose-TOR signalling dictates transcriptional reprogramming of remarkable gene sets involved in central and secondary metabolism, cell cycle, transcription, signalling, transport and protein folding. Systems, cellular and genetic analyses uncover TOR phosphorylation of E2Fa transcription factor for an unconventional activation of S-phase genes, and glucose-signalling defects in e2fa root meristems. Our findings establish pivotal roles of glucose-TOR signalling in unprecedented transcriptional networks wiring central metabolism and biosynthesis for energy and biomass production, and integrating localized stem/progenitor-cell proliferation through inter-organ nutrient coordination to control developmental transition and growth.
C1 [Xiong, Yan; McCormack, Matthew; Li, Lei; Hall, Qi; Sheen, Jen] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Xiong, Yan; McCormack, Matthew; Li, Lei; Hall, Qi; Sheen, Jen] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Xiong, Yan; McCormack, Matthew; Li, Lei; Hall, Qi; Sheen, Jen] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.
[Xiang, Chengbin] Univ Sci & Technol China, Sch Life Sci, Hefei 230023, Peoples R China.
RP Xiong, Y (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM xiong@molbio.mgh.harvard.edu; sheen@molbio.mgh.harvard.edu
RI Li, Lei/F-9826-2015
FU MGH Tosteson Postdoctoral Fellowship; Chinese Academy of Sciences
[KSCX3-YW-N-007]; NSF; NIH; WJC Special Project RDA-Korea [PJ009106]
FX We thank N. Dai and J. Avruch for S6K antibodies and advice, J. L.
Celenza for stimulating discussion, M. D. Curtis and Y. J. Niu for the
oestradiol-inducible binary vector, L. Li and J. Bush for seeds and
plants, B. Muller for TCS::GFP, J. Friml for DR5::GFP, N. S. Gray and D.
M. Sabatini for torin1, and J. F. Li, H. Lee and M. Ramon for critical
reading of the manuscript. Y. X. is supported by the MGH Tosteson
Postdoctoral Fellowship. C. X. is supported by Chinese Academy of
Sciences (KSCX3-YW-N-007). The Research is supported by the NSF, NIH and
WJC Special Project (PJ009106) RDA-Korea to J.S.
NR 42
TC 122
Z9 127
U1 12
U2 174
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD APR 11
PY 2013
VL 496
IS 7444
BP 181
EP +
DI 10.1038/nature12030
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 122VM
UT WOS:000317346300033
PM 23542588
ER
PT J
AU Tannahill, GM
Curtis, AM
Adamik, J
Palsson-McDermott, EM
McGettrick, AF
Goel, G
Frezza, C
Bernard, NJ
Kelly, B
Foley, NH
Zheng, L
Gardet, A
Tong, Z
Jany, SS
Corr, SC
Haneklaus, M
Caffrey, BE
Pierce, K
Walmsley, S
Beasley, FC
Cummins, E
Nizet, V
Whyte, M
Taylor, CT
Lin, H
Masters, SL
Gottlieb, E
Kelly, VP
Clish, C
Auron, PE
Xavier, RJ
O'Neill, LAJ
AF Tannahill, G. M.
Curtis, A. M.
Adamik, J.
Palsson-McDermott, E. M.
McGettrick, A. F.
Goel, G.
Frezza, C.
Bernard, N. J.
Kelly, B.
Foley, N. H.
Zheng, L.
Gardet, A.
Tong, Z.
Jany, S. S.
Corr, S. C.
Haneklaus, M.
Caffrey, B. E.
Pierce, K.
Walmsley, S.
Beasley, F. C.
Cummins, E.
Nizet, V.
Whyte, M.
Taylor, C. T.
Lin, H.
Masters, S. L.
Gottlieb, E.
Kelly, V. P.
Clish, C.
Auron, P. E.
Xavier, R. J.
O'Neill, L. A. J.
TI Succinate is an inflammatory signal that induces IL-1 beta through HIF-1
alpha
SO NATURE
LA English
DT Article
ID RECEPTOR GPR91; HYPOXIA; ACTIVATION; PROTEIN; CELLS; GAMMA; LINKS;
METABOLISM; INHIBITION; MECHANISM
AB Macrophages activated by the Gram-negative bacterial product lipopolysaccharide switch their core metabolism from oxidative phosphorylation to glycolysis(1). Here we show that inhibition of glycolysis with 2-deoxyglucose suppresses lipopolysaccharide-induced interleukin-1 beta but not tumour-necrosis factor-a in mouse macrophages. A comprehensive metabolic map of lipopolysaccharide-activated macrophages shows upregulation of glycolytic and down-regulation of mitochondrial genes, which correlates directly with the expression profiles of altered metabolites. Lipopolysaccharide strongly increases the levels of the tricarboxylic-acid cycle intermediate succinate. Glutamine-dependent anerplerosis is the principal source of succinate, although the 'GABA (gamma-aminobutyric acid) shunt' pathway also has a role. Lipopolysaccharide-induced succinate stabilizes hypoxia-inducible factor-1 alpha, an effect that is inhibited by 2-deoxyglucose, with interleukin-1 beta as an important target. Lipopolysaccharide also increases succinylation of several proteins. We therefore identify succinate as a metabolite in innate immune signalling, which enhances interleukin-1 beta production during inflammation.
C1 [Tannahill, G. M.; Curtis, A. M.; Palsson-McDermott, E. M.; McGettrick, A. F.; Bernard, N. J.; Kelly, B.; Foley, N. H.; Jany, S. S.; Corr, S. C.; Haneklaus, M.; Kelly, V. P.; O'Neill, L. A. J.] Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Dublin 2, Ireland.
[Adamik, J.; Auron, P. E.] Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA.
[Goel, G.; Xavier, R. J.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Richard B Simches Res Ctr, Boston, MA 02114 USA.
[Frezza, C.; Zheng, L.; Gottlieb, E.] Beatson Inst Canc Res, Apoptosis & Tumour Physiol Lab, Glasgow G61 1BD, Lanark, Scotland.
[Frezza, C.; Xavier, R. J.] Hutchison MRC Res Ctr, Med Res Council Canc Cell Unit, Cambridge CB2 0X2, England.
[Gardet, A.; Pierce, K.; Clish, C.] Broad Inst MIT & Harvard, Cambridge Ctr 7, Cambridge, MA 02142 USA.
[Tong, Z.; Lin, H.] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA.
[Caffrey, B. E.] Trinity Coll Dublin, Smurfit Inst Genet, Dublin 2, Ireland.
[Walmsley, S.; Whyte, M.] Univ Sheffield, Dept Infect & Immun, Acad Unit Resp Med, Sheffield S10 2RX, S Yorkshire, England.
[Beasley, F. C.; Nizet, V.] Univ Calif San Diego, Ctr Neural Circuits & Behav, Div Pediat, V Nizet Lab, La Jolla, CA 92093 USA.
[Cummins, E.; Taylor, C. T.] Univ Coll Dublin, Conway Inst, Dublin 4, Ireland.
[Masters, S. L.] Walter & Eliza Hall Inst Med Res, Inflammat Div, Parkville, Vic 3052, Australia.
RP O'Neill, LAJ (reprint author), Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Dublin 2, Ireland.
EM laoneill@tcd.ie
RI Gottlieb, Eyal/G-6450-2010; Masters, Seth/N-2886-2013;
OI Gottlieb, Eyal/0000-0002-9770-0956; Masters, Seth/0000-0003-4763-576X;
Corr, Sinead/0000-0001-9930-5039; Adamik, Juraj/0000-0002-3604-158X;
Bernard, Nicholas/0000-0002-9483-7922
FU European Research Council; Science Foundation Ireland; Health Research
Board; European Union FP7 programme 'TIMER'; Wellcome Trust; National
Institutes of Health; Helmsley Trust; Nestle Research Centre; VESKI;
Duquesne University Hunkele Dreaded Disease Award; Interleukin
Foundation; National Health and Medical Research Council
FX We thank the European Research Council, Science Foundation Ireland, the
Health Research Board, European Union FP7 programme 'TIMER', Wellcome
Trust, National Institutes of Health, Helmsley Trust, Nestle Research
Centre, VESKI, The Duquesne University Hunkele Dreaded Disease Award,
The Interleukin Foundation and the National Health and Medical Research
Council for funding. We also thank R. Thompson for assistance with
Hif1a-/- mice and M. Murphy for discussions.
NR 30
TC 391
Z9 395
U1 14
U2 123
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD APR 11
PY 2013
VL 496
IS 7444
BP 238
EP +
DI 10.1038/nature11986
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 122VM
UT WOS:000317346300045
PM 23535595
ER
PT J
AU Goss, PE
Ingle, JN
Pritchard, KI
Ellis, MJ
Sledge, GW
Budd, GT
Rabaglio, M
Ansari, RH
Johnson, DB
Tozer, R
D'Souza, DP
Chalchal, H
Spadafora, S
Stearns, V
Perez, EA
Liedke, PER
Lang, I
Elliott, C
Gelmon, KA
Chapman, JAW
Shepherd, LE
AF Goss, Paul E.
Ingle, James N.
Pritchard, Kathleen I.
Ellis, Matthew J.
Sledge, George W.
Budd, G. Thomas
Rabaglio, Manuela
Ansari, Rafat H.
Johnson, David B.
Tozer, Richard
D'Souza, David P.
Chalchal, Haji
Spadafora, Silvana
Stearns, Vered
Perez, Edith A.
Liedke, Pedro E. R.
Lang, Istvan
Elliott, Catherine
Gelmon, Karen A.
Chapman, Judy-Anne W.
Shepherd, Lois E.
TI Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast
Cancer: NCIC CTG MA.27-A Randomized Controlled Phase III Trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID NONSTEROIDAL AROMATASE INHIBITORS; ADJUVANT ENDOCRINE THERAPY;
TAMOXIFEN; ADHERENCE
AB Purpose
In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole. The steroidal inhibitor exemestane is partially non-cross-resistant with nonsteroidal aromatase inhibitors and is a mild androgen and could prove superior to anastrozole regarding efficacy and toxicity, specifically with less bone loss.
Patients and Methods
We designed an open-label, randomized, phase III trial of 5 years of exemestane versus anastrozole with a two-sided test of superiority to detect a 2.4% improvement with exemestane in 5-year event-free survival (EFS). Secondary objectives included assessment of overall survival, distant disease-free survival, incidence of contralateral new primary breast cancer, and safety.
Results
In the study, 7,576 women (median age, 64.1 years) were enrolled. At median follow-up of 4.1 years, 4-year EFS was 91% for exemestane and 91.2% for anastrozole (stratified hazard ratio, 1.02; 95% CI, 0.87 to 1.18; P = .85). Overall, distant disease-free survival and disease-specific survival were also similar. In all, 31.6% of patients discontinued treatment as a result of adverse effects, concomitant disease, or study refusal. Osteoporosis/osteopenia, hypertriglyceridemia, vaginal bleeding, and hypercholesterolemia were less frequent on exemestane, whereas mild liver function abnormalities and rare episodes of atrial fibrillation were less frequent on anastrozole. Vasomotor and musculoskeletal symptoms were similar between arms.
Conclusion
This first comparison of steroidal and nonsteroidal classes of aromatase inhibitors showed neither to be superior in terms of breast cancer outcomes as 5-year initial adjuvant therapy for postmenopausal breast cancer by two-way test. Less toxicity on bone is compatible with one hypothesis behind MA. 27 but requires confirmation. Exemestane should be considered another option as up-front adjuvant therapy for postmenopausal hormone receptor-positive breast cancer. J Clin Oncol 31:1398-1404. (C) 2013 by American Society of Clinical Oncology
C1 [Goss, Paul E.; Liedke, Pedro E. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ingle, James N.] Mayo Clin, Rochester, MN USA.
[Ellis, Matthew J.] Washington Univ, Siteman Canc Ctr, St Louis, MO USA.
[Sledge, George W.] Indiana Univ Hlth, Indianapolis, IN USA.
[Ansari, Rafat H.] Northern Indiana Canc Res Consortium, South Bend, IN USA.
[Budd, G. Thomas] Cleveland Clin, Cleveland, OH 44106 USA.
[Johnson, David B.] Canc Ctr Kansas, Wichita, KS USA.
[Stearns, Vered] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Perez, Edith A.] Mayo Clin, Jacksonville, FL 32224 USA.
[Pritchard, Kathleen I.] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
[Pritchard, Kathleen I.] Univ Toronto, Toronto, ON, Canada.
[Tozer, Richard] Juravinski Canc Ctr, Hamilton, ON, Canada.
[D'Souza, David P.] London Reg Canc Program, London, England.
[Spadafora, Silvana] Algoma Reg Canc Ctr, Sault Ste Marie, ON, Canada.
[Elliott, Catherine; Chapman, Judy-Anne W.; Shepherd, Lois E.] NCIC Clin Trials Grp, Kingston, ON, Canada.
[Chalchal, Haji] Regina Gen Hosp, Regina, SK, Canada.
[Gelmon, Karen A.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
[Rabaglio, Manuela] Int Breast Canc Study Grp Coordinating Ctr, Bern, Switzerland.
[Rabaglio, Manuela] Univ Bern, Inselspital, CH-3010 Bern, Switzerland.
[Lang, Istvan] Natl Inst Oncol, Budapest, Hungary.
RP Goss, PE (reprint author), Massachusetts Gen Hosp, Ctr Canc, Lawrence House,55 Fruit St,LRH 302, Boston, MA 02114 USA.
EM pgoss@partners.org
FU Canadian Cancer Society Research Institute [015469]; National Institutes
of Health [2U10CA077202, CA32102]; Pfizer; Avon Foundation, New York,
NY; AstraZeneca; Novartis
FX Supported by Canadian Cancer Society Research Institute Grant No.
015469, National Institutes of Health Grants No. 2U10CA077202 and
CA32102, and Pfizer. P. E. G. and P. E. R. L. are supported by the Avon
Foundation, New York, NY.; Research Funding: Matthew J. Ellis,
AstraZeneca; Vered Stearns, Novartis, Pfizer
NR 29
TC 72
Z9 75
U1 1
U2 12
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR 10
PY 2013
VL 31
IS 11
BP 1398
EP 1404
DI 10.1200/JCO.2012.44.7805
PG 7
WC Oncology
SC Oncology
GA 120MM
UT WOS:000317174400012
PM 23358971
ER
PT J
AU Argiris, A
Ghebremichael, M
Gilbert, J
Lee, JW
Sachidanandam, K
Kolesar, JM
Burtness, B
Forastiere, AA
AF Argiris, Athanassios
Ghebremichael, Musie
Gilbert, Jill
Lee, Ju-Whei
Sachidanandam, Kamakshi
Kolesar, Jill M.
Burtness, Barbara
Forastiere, Arlene A.
TI Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or
Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An
Eastern Cooperative Oncology Group Trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; LUNG-CANCER; SOMATIC
MUTATIONS; TYROSINE KINASE; CLINICAL-TRIALS; PLUS CETUXIMAB;
COLON-CANCER; OLDER-ADULTS; ERLOTINIB
AB Purpose
We hypothesized that the addition of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic efficacy in squamous cell carcinoma of the head and neck (SCCHN).
Patients and Methods
Patients with recurrent or metastatic SCCHN with Eastern Cooperative Oncology Group (ECOG) performance status of 2, or patients with ECOG performance status of 0 to 2 but were previously treated with chemotherapy, were randomly assigned to receive weekly docetaxel plus either placebo (arm A) or gefitinib 250 mg/d, orally (arm B) until disease progression. At the time of progression, patients in the placebo arm could receive single-agent gefitinib. EGFR, c-MET, and KRAS mutations and polymorphisms in drug metabolizing enzymes and transporters were evaluated by pyrosequencing.
Results
Two hundred seventy patients were enrolled before the study was closed early at interim analysis (arm A, n = 136; arm B, n = 134). Median overall survival was 6.0 months in arm A versus 7.3 months in arm B (hazard ratio, 0.93; 95% CI, 0.72 to 1.21; P = .60). An unplanned subset analysis showed that gefitinib improved survival in patients younger than 65 years (median 7.6 v 5.2 months; P = .04). Also, there was a trend for improved survival in patients with c-MET wild-type (5.7 v 3.6 months; P = .09) regardless of treatment. Grade 3/4 toxicities were comparable between the two arms except that grade 3/4 diarrhea was more common with docetaxel/gefitinib. Of 18 eligible patients who received gefitinib after disease progression in arm A, one patient had a partial response.
Conclusion
The addition of gefitinib to docetaxel was well tolerated but did not improve outcomes in poor prognosis but otherwise unselected patients with SCCHN. J Clin Oncol 31:1405-1414. (C) 2013 by American Society of Clinical Oncology
C1 [Argiris, Athanassios] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Lee, Ju-Whei] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gilbert, Jill] Vanderbilt Univ, Nashville, TN USA.
[Sachidanandam, Kamakshi; Kolesar, Jill M.] Univ Wisconsin, Madison, WI USA.
[Burtness, Barbara] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Forastiere, Arlene A.] Johns Hopkins Univ, Baltimore, MD USA.
RP Argiris, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Div Hematol Oncol, 7979 Wurzbach Rd,MC8232,Zeller Bldg,4th Floor,Roo, San Antonio, TX 78229 USA.
EM Argiris@uthscsa.edu
FU Public Health Service from the National Cancer Institute, National
Institutes of Health, US Department of Health and Human Services
[CA23318, CA66636, CA21115, CA39229, CA16116]; AstraZeneca; Genentech;
sanofi-aventis
FX Supported in part by Public Health Service Grants No. CA23318, CA66636,
CA21115, CA39229, and CA16116 from the National Cancer Institute,
National Institutes of Health, US Department of Health and Human
Services.; Athanassios Argiris, AstraZeneca; Jill M. Kolesar,
AstraZeneca; Barbara Burtness, Genentech, sanofi-aventis
NR 49
TC 60
Z9 60
U1 0
U2 7
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR 10
PY 2013
VL 31
IS 11
BP 1405
EP 1414
DI 10.1200/JCO.2012.45.4272
PG 10
WC Oncology
SC Oncology
GA 120MM
UT WOS:000317174400013
PM 23460714
ER
PT J
AU Neuss, MN
Malin, JL
Chan, S
Kadlubek, PJ
Adams, JL
Jacobson, JO
Blayney, DW
Simone, JV
AF Neuss, Michael N.
Malin, Jennifer L.
Chan, Stephanie
Kadlubek, Pamela J.
Adams, John L.
Jacobson, Joseph O.
Blayney, Douglas W.
Simone, Joseph V.
TI Measuring the Improving Quality of Outpatient Care in Medical Oncology
Practices in the United States
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID CANCER CARE; AMERICAN-SOCIETY; PRACTICE GUIDELINES; OF-CARE;
CHEMOTHERAPY
AB Purpose
The American Society of Clinical Oncology Quality Oncology Practice Initiative (QOPI) has provided a method for measuring process-based practice quality since 2006. We sought to determine whether QOPI scores showed improvement in measured quality over time and, if change was demonstrated, which factors in either the measures or participants were associated with improvement.
Methods
The analysis included 156 practice groups from a larger group of 308 that submitted data from 2006 to 2010. One hundred fifty-two otherwise eligible practices were excluded, most commonly for insufficient data submission. A linear regression model that controlled for varied initial performance was used to estimate the effect of participation over time and evaluate participant and measure characteristics of improvement.
Results
Participants completed a mean of 5.06 (standard deviation, 1.94) rounds of data collection. Adjusted mean quality scores improved from 0.71 (95% CI, 0.42 to 0.91) to 0.85 (95% CI, 0.60 to 0.95). Overall odds ratio of improvement over time was 1.09 (P < .001). The greatest improvement was seen in measures that assessed newly introduced clinical information, in which the mean scores improved from 0.05 (95% CI, 0.01 to 0.17) to 0.69 (95% CI, 0.33 to 0.91; P < .001). Many measures showed no change over time.
Conclusion
Many US oncologists have participated in QOPI over the past 6 years. Participation over time was highly correlated with improvement in measured performance. Greater and faster improvement was seen in measures concerning newly introduced clinical information. Some measures showed no change despite opportunity for improvement. J Clin Oncol 31:1471-1477. (C) 2013 by American Society of Clinical Oncology
C1 [Neuss, Michael N.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.
[Malin, Jennifer L.] WellPoint, Indianapolis, IN USA.
[Chan, Stephanie; Adams, John L.] RAND Corp, Santa Monica, CA USA.
[Blayney, Douglas W.] Stanford Med Ctr, Stanford Canc Ctr, Palo Alto, CA USA.
[Kadlubek, Pamela J.] Amer Soc Clin Oncol, Alexandria, VA USA.
[Jacobson, Joseph O.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Simone, Joseph V.] Simone Consulting, Dunwoody, GA USA.
RP Neuss, MN (reprint author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, 2220 Pierce Ave,694 Preston Res Bldg, Nashville, TN 37232 USA.
EM michael.n.neuss@vanderbilt.edu
FU Blue Cross Blue Shield of Michigan
FX Douglas W. Blayney, Blue Cross Blue Shield of Michigan
NR 27
TC 20
Z9 20
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR 10
PY 2013
VL 31
IS 11
BP 1471
EP 1477
DI 10.1200/JCO.2012.43.3300
PG 7
WC Oncology
SC Oncology
GA 120MM
UT WOS:000317174400022
PM 23478057
ER
PT J
AU Giedt, RJ
Koch, PD
Weissleder, R
AF Giedt, Randy J.
Koch, Peter D.
Weissleder, Ralph
TI Single Cell Analysis of Drug Distribution by Intravital Imaging
SO PLOS ONE
LA English
DT Article
ID IN-VIVO; SELECTION METHOD; OPEN-LABEL; SEGMENTATION; INHIBITION;
MULTICENTER; OLAPARIB; KINASE; CANCER; TUMORS
AB Recent advances in the field of intravital imaging have for the first time allowed us to conduct pharmacokinetic and pharmacodynamic studies at the single cell level in live animal models. Due to these advances, there is now a critical need for automated analysis of pharmacokinetic data. To address this, we began by surveying common thresholding methods to determine which would be most appropriate for identifying fluorescently labeled drugs in intravital imaging. We then developed a segmentation algorithm that allows semi-automated analysis of pharmacokinetic data at the single cell level. Ultimately, we were able to show that drug concentrations can indeed be extracted from serial intravital imaging in an automated fashion. We believe that the application of this algorithm will be of value to the analysis of intravital microscopy imaging particularly when imaging drug action at the single cell level.
C1 [Giedt, Randy J.; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Koch, Peter D.; Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA.
RP Weissleder, R (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
EM rweissleder@mgh.harvard.edu
FU National Institutes of Health [R01 CA164448, P01 CA139980, T32 CA079443]
FX This work was supported by grants R01 CA164448, P01 CA139980 and T32
CA079443 from the National Institutes of Health. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 42
TC 6
Z9 6
U1 1
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 10
PY 2013
VL 8
IS 4
AR e60988
DI 10.1371/journal.pone.0060988
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 123IQ
UT WOS:000317382000035
PM 23593370
ER
PT J
AU Shanechi, MM
Williams, ZM
Wornell, GW
Hu, RC
Powers, M
Brown, EN
AF Shanechi, Maryam M.
Williams, Ziv M.
Wornell, Gregory W.
Hu, Rollin C.
Powers, Marissa
Brown, Emery N.
TI A Real-Time Brain-Machine Interface Combining Motor Target and
Trajectory Intent Using an Optimal Feedback Control Design
SO PLOS ONE
LA English
DT Article
ID POSTERIOR PARIETAL CORTEX; GOAL-DIRECTED MOVEMENTS; PREMOTOR CORTEX;
CORTICAL-NEURONS; NEURAL PROSTHETICS; COMPUTER INTERFACE; SPIKING
ACTIVITY; REACHING TASK; ARM MOVEMENTS; STATE
AB Real-time brain-machine interfaces (BMI) have focused on either estimating the continuous movement trajectory or target intent. However, natural movement often incorporates both. Additionally, BMIs can be modeled as a feedback control system in which the subject modulates the neural activity to move the prosthetic device towards a desired target while receiving real-time sensory feedback of the state of the movement. We develop a novel real-time BMI using an optimal feedback control design that jointly estimates the movement target and trajectory of monkeys in two stages. First, the target is decoded from neural spiking activity before movement initiation. Second, the trajectory is decoded by combining the decoded target with the peri-movement spiking activity using an optimal feedback control design. This design exploits a recursive Bayesian decoder that uses an optimal feedback control model of the sensorimotor system to take into account the intended target location and the sensory feedback in its trajectory estimation from spiking activity. The real-time BMI processes the spiking activity directly using point process modeling. We implement the BMI in experiments consisting of an instructed-delay center-out task in which monkeys are presented with a target location on the screen during a delay period and then have to move a cursor to it without touching the incorrect targets. We show that the two-stage BMI performs more accurately than either stage alone. Correct target prediction can compensate for inaccurate trajectory estimation and vice versa. The optimal feedback control design also results in trajectories that are smoother and have lower estimation error. The two-stage decoder also performs better than linear regression approaches in offline cross-validation analyses. Our results demonstrate the advantage of a BMI design that jointly estimates the target and trajectory of movement and more closely mimics the sensorimotor control system.
C1 [Shanechi, Maryam M.] Cornell Univ, Sch Elect & Comp Engn, Ithaca, NY 14853 USA.
[Shanechi, Maryam M.] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA.
[Shanechi, Maryam M.; Wornell, Gregory W.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
[Shanechi, Maryam M.; Williams, Ziv M.; Hu, Rollin C.; Powers, Marissa] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Shanechi, Maryam M.; Williams, Ziv M.; Hu, Rollin C.; Brown, Emery N.] Harvard Univ, Sch Med, Boston, MA USA.
[Brown, Emery N.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Brown, Emery N.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Brown, Emery N.] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA.
RP Shanechi, MM (reprint author), Cornell Univ, Sch Elect & Comp Engn, Ithaca, NY 14853 USA.
EM shanechi@cornell.edu
FU National Institutes of Health (NIH) [DP1-0D003646-01, R01-EB006385]
FX This work was supported by National Institutes of Health (NIH) Grant
Nos. DP1-0D003646-01 and R01-EB006385. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 73
TC 22
Z9 22
U1 1
U2 34
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 10
PY 2013
VL 8
IS 4
AR e59049
DI 10.1371/journal.pone.0059049
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 123IQ
UT WOS:000317382000003
PM 23593130
ER
PT J
AU Clark, KB
Hassert, DL
AF Clark, Kevin B.
Hassert, Derrick L.
TI Undecidability and opacity of metacognition in animals and humans
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Editorial Material
ID SELF-AWARENESS; MINDS; CONFIDENCE; CHILDREN
C1 [Clark, Kevin B.] Vet Affairs Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA 90073 USA.
[Hassert, Derrick L.] Trinity Christian Coll, Dept Psychol, Palos Hts, IL USA.
RP Clark, KB (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA 90073 USA.
EM kbclarkphd@yahoo.com
NR 42
TC 2
Z9 2
U1 2
U2 11
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD APR 9
PY 2013
VL 4
AR 171
DI 10.3389/fpsyg.2013.00171
PG 3
WC Psychology, Multidisciplinary
SC Psychology
GA AA2PU
UT WOS:000330937300001
PM 23576999
ER
PT J
AU Maeda, A
Okazaki, M
Baron, DM
Dean, T
Khatri, A
Mahon, M
Segawa, H
Abou-Samra, AB
Juppner, H
Bloch, KD
Potts, JT
Gardella, TJ
AF Maeda, Akira
Okazaki, Makoto
Baron, David M.
Dean, Thomas
Khatri, Ashok
Mahon, Mathew
Segawa, Hiroko
Abou-Samra, Abdul B.
Jueppner, Harald
Bloch, Kenneth D.
Potts, John T., Jr.
Gardella, Thomas J.
TI Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in
regulating acute responses to PTH
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE calcium homeostasis; family B GPCR; phosphate homeostasis; receptor
phosphorylation
ID (PTH)/PTH-RELATED PROTEIN-RECEPTOR; PLASMA CALCIUM; BETA-ARRESTIN;
INTERNALIZATION; HYPERPARATHYROIDISM; CONFORMATIONS; HOMEOSTASIS;
SELECTIVITY; INJECTION; BINDING
AB Agonist-induced phosphorylation of the parathyroid hormone (PTH) receptor 1 (PTHR1) regulates receptor signaling in vitro, but the role of this phosphorylation in vivo is uncertain. We investigated this role by injecting "knock-in" mice expressing a phosphorylation-deficient (PD) PTHR1 with PTH ligands and assessing acute biologic responses. Following injection with PTH (1-34), or with a unique, long-acting PTH analog, PD mice, compared with WT mice, exhibited enhanced increases in CAMP levels in the blood, as well as enhanced cAMP production and gene expression responses in bone and kidney tissue. Surprisingly, however, the hallmark hypercalcemic and hypophosphatemic responses were markedly absent in the PD mice, such that paradoxical hypocalcemic and hyperphosphatemic responses were observed, quite strikingly with the long-acting PTH analog. Spot urine analyses revealed a marked defect in the capacity of the PD mice to excrete phosphate, as well as CAMP, into the urine in response to PTH injection. This defect in renal excretion was associated with a severe, PTH-induced impairment in glomerular filtration, as assessed by the rate of FITC-inulin clearance from the blood, which, in turn, was explainable by an overly exuberant systemic hypotensive response. The overall findings demonstrate the importance in vivo of PTH-induced phosphorylation of the PTHR1,in regulating acute ligand responses, and they serve to focus attention on mechanisms that underlie the acute calcemic response to PTH and factors, such as blood phosphate levels, that influence it.
C1 [Maeda, Akira; Okazaki, Makoto; Dean, Thomas; Khatri, Ashok; Mahon, Mathew; Segawa, Hiroko; Jueppner, Harald; Potts, John T., Jr.; Gardella, Thomas J.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Maeda, Akira; Okazaki, Makoto; Baron, David M.; Dean, Thomas; Khatri, Ashok; Mahon, Mathew; Segawa, Hiroko; Jueppner, Harald; Bloch, Kenneth D.; Potts, John T., Jr.; Gardella, Thomas J.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Baron, David M.; Bloch, Kenneth D.] Massachusetts Gen Hosp, Anesthesia Ctr Crit Care Res, Boston, MA 02114 USA.
[Abou-Samra, Abdul B.] Hamad Med Corp, Doha, Qatar.
RP Potts, JT (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
EM potts.john@mgh.harvard.edu; gardella@helix.mgh.harvard.edu
FU National Institutes of Health [DK-11794]
FX Monica Reyes assisted with animal breeding. This work was supported by
National Institutes of Health Grant DK-11794.
NR 33
TC 17
Z9 17
U1 2
U2 38
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 9
PY 2013
VL 110
IS 15
BP 5864
EP 5869
DI 10.1073/pnas.1301674110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 125KE
UT WOS:000317537900031
PM 23533279
ER
PT J
AU Wu, CL
Schroeder, BE
Ma, XJ
Cutie, CJ
Wu, SL
Salunga, R
Zhang, Y
Kattan, MW
Schnabel, CA
Erlander, MG
McDougal, WS
AF Wu, Chin-Lee
Schroeder, Brock E.
Ma, Xiao-Jun
Cutie, Christopher J.
Wu, Shulin
Salunga, Ranelle
Zhang, Yi
Kattan, Michael W.
Schnabel, Catherine A.
Erlander, Mark G.
McDougal, W. Scott
TI Development and validation of a 32-gene prognostic index for prostate
cancer progression
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; RADICAL PROSTATECTOMY; ADJUVANT RADIOTHERAPY;
BIOCHEMICAL FAILURE; POSTOPERATIVE NOMOGRAM; PREOPERATIVE NOMOGRAM;
DISEASE RECURRENCE; BREAST-CANCER; RISK; CARCINOMA
AB The accurate determination of the risk of cancer recurrence is an important unmet need in the management of prostate cancer. Patients and physicians must weigh the benefits of currently avail: able therapies against the potential morbidity of these treatments. Herein we describe the development of a gene expression-based continuous risk index and a validation of this test in an independent, blinded cohort of post-radical prostatectomy (RP) patients. A gene expression signature, prognostic for prostate-specific antigen (PSA) recurrence, was identified through a bioinformatic analysis of the expression of 1,536 genes in malignant prostate tissue from a training cohort of consecutive patients treated with RP. The assay was transferred to a real-time RT-PCR platform, and a continuous risk index model was constructed based on the expression of 32 genes. This 32-gene risk index model was validated in an independent, blinded cohort of 270 RP patients. In multivariate analyses, the risk index was prognostic for risk of PSA recurrence and had added value over standard prognostic markers such as Gleason score, pathologic tumor stage, surgical margin status, and presurgery PSA (hazard ratio, 4.05; 95% confidence interval, 1.50-10.94; P = 0.0057). Furthermore, RP patients could be stratified based on the risk of PSA recurrence and the development of metastatic disease. The 32-gene signature identified here is a robust prognostic marker for disease recurrence. This assay may aid in postoperative treatment selection and has the potential to impact decision making at the biopsy stage.
C1 [Wu, Chin-Lee; Wu, Shulin] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Wu, Chin-Lee; Cutie, Christopher J.; McDougal, W. Scott] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
[Wu, Chin-Lee; Cutie, Christopher J.; McDougal, W. Scott] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Schroeder, Brock E.; Ma, Xiao-Jun; Salunga, Ranelle; Zhang, Yi; Schnabel, Catherine A.; Erlander, Mark G.] bioTheranostics Inc, San Diego, CA 92121 USA.
[Kattan, Michael W.] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA.
RP McDougal, WS (reprint author), Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
EM WMCDOUGAL@PARTNERS.ORG
FU bioTheranostics, Inc.; John and Claire Bertucci Prostate Cancer
Foundation
FX The authors thank Hongying Yi, PhD, for statistical support; Jingmei Su,
Yen Tran, and J. Todd Tuggle for study assistance; Sandra Kirley, BA,
for collection of data and preparation of tissue samples; and Dennis
Sgroi, MD, and Donald S. Kaufman, MD, for advice. C.-L.W. received
research funding from bioTheranostics, Inc. John and Claire Bertucci
Prostate Cancer Foundation provided funding support.
NR 34
TC 18
Z9 20
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 9
PY 2013
VL 110
IS 15
BP 6121
EP 6126
DI 10.1073/pnas.1215870110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 125KE
UT WOS:000317537900075
PM 23533275
ER
PT J
AU Mandawat, A
Curtis, JP
Mandawat, A
Njike, VY
Lampert, R
AF Mandawat, Anant
Curtis, Jeptha P.
Mandawat, Aditya
Njike, Valentine Y.
Lampert, Rachel
TI Safety of Pacemaker Implantation in Nonagenarians An Analysis of the
Healthcare Cost and Utilization Project-Nationwide Inpatient Sample
SO CIRCULATION
LA English
DT Article
DE biological pacemakers; complications; epidemiology; geriatrics;
population
ID ELDERLY-PATIENTS; UNITED-STATES; PERMANENT PACEMAKER; COMPLICATIONS;
OUTCOMES; SURVIVAL; RISK; AGE; DEFIBRILLATORS; COMORBIDITY
AB Background-Data are scarce on outcomes of pacemaker implantation in nonagenarians (age >= 90 years).
Methods and Results-We identified patients >70 years of age (n=115 683) who underwent initial pacemaker implantation in the 2004 to 2008 Healthcare Cost and Utilization Project-Nationwide Inpatient Sample. Outcomes included in-hospital mortality, complications, length of stay, and charges. Unadjusted outcomes were compared using chi(2) and Mantel-Haenszel tests. Multivariate hierarchical logistic models and stepwise linear regression models adjusted for case-mix variation and clustering. Eleven percent (12 917) were >90 years of age. Relative to patients aged 70 to 79 years, patients >90 years of age were more likely to have moderate/severe comorbidity (Charlson score >1; 43.2% versus 40.1%) and less likely to be admitted electively (17.5% versus 29.9%), all P<0.001. The unadjusted mortality and complication rates in patients aged 70 to 79 years were 0.60% (confidence interval [CI], 0.53-0.67%) and 5.61% (CI, 5.40-5.82%), respectively, and in patients aged >90 years were 1.87% (CI, 1.63-2.11%) and 6.31% (CI, 5.89-6.72%). Length of stay and charges in patients aged 70 to 79 years were 3.22 days (CI, 3.20-3.24 days) and $38 871 (CI, $38 700-$39 043), and in patients aged >90 years, 4.27 days (CI, 4.25-4.30 days) and $41 373 (CI, $41 190-$41 556). Multivariable analysis revealed severe comorbidity (odds ratio, 5.00; 95% CI, 4.05-6.17) was a greater predictor of mortality than increasing age (odds ratio, 2.81 per decade; CI, 2.35-3.35), all P<0.001. Similarly, severe comorbidity (Charlson score >5) was more strongly associated with complications, length of stay, and charges than age.
Conclusions-Although increasing age predicts worsening outcomes in the elderly, the absolute rates are modest, even in nonagenarians, and comorbidity is a stronger predictor. (Circulation. 2013;127:1453-1465.)
C1 [Mandawat, Anant; Curtis, Jeptha P.; Lampert, Rachel] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06520 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
[Curtis, Jeptha P.] Yale Univ, Sch Med, Ctr Outcomes Res & Evaluat, New Haven, CT 06520 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
[Njike, Valentine Y.] Yale Univ, Yale Griffin Prevent Res Ctr, Sch Publ Hlth, Derby, CT USA.
RP Lampert, R (reprint author), Yale Univ, Sch Med, Sect Cardiovasc Med, 789 Howard Ave,Dana 319, New Haven, CT 06520 USA.
EM rachel.lampert@yale.edu
FU Harvard Catalyst/The Harvard Clinical and Translational Science Center
(National Center for Research Resources) [8UL1TR000170-05]; Harvard
Catalyst/The Harvard Clinical and Translational Science Center (National
Center for Advancing Translational Sciences, National Institutes of
Health) [8UL1TR000170-05]; Harvard University; Medtronic; St. Jude
Medical; Boston Scientific
FX This work was conducted with support from Harvard Catalyst/The Harvard
Clinical and Translational Science Center (National Center for Research
Resources and the National Center for Advancing Translational Sciences,
National Institutes of Health award 8UL1TR000170-05 and financial
contributions from Harvard University and its affiliated academic health
care centers). The content is solely the responsibility of the authors
and does not necessarily represent the official views of Harvard
Catalyst, Harvard University and its affiliated academic health care
centers, or the National Institutes of Health.; Dr Curtis reports
significant ownership interest in Medtronic. Dr Lampert reports
significant research grants from Medtronic, St. Jude Medical, and Boston
Scientific and modest honoraria from Medtronic. The other authors report
no conflicts.
NR 38
TC 11
Z9 11
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD APR 9
PY 2013
VL 127
IS 14
BP 1453
EP +
DI 10.1161/CIRCULATIONAHA.113.001434
PG 15
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 122VS
UT WOS:000317346900012
PM 23513066
ER
PT J
AU Bonaca, MP
Scirica, BM
Creager, MA
Olin, J
Bounameaux, H
Dellborg, M
Lamp, JM
Murphy, SA
Braunwald, E
Morrow, DA
AF Bonaca, Marc P.
Scirica, Benjamin M.
Creager, Mark A.
Olin, Jeffrey
Bounameaux, Henri
Dellborg, Mikael
Lamp, Jessica M.
Murphy, Sabina A.
Braunwald, Eugene
Morrow, David A.
TI Vorapaxar in Patients With Peripheral Artery Disease Results From TRA2
degrees P-TIMI 50
SO CIRCULATION
LA English
DT Article
DE ischemia; outcome assessment; peripheral arterial disease; platelet
aggregation inhibitors; vorapaxar
ID SECONDARY PREVENTION; ATHEROTHROMBOTIC EVENTS; CARDIOVASCULAR EVENTS;
MYOCARDIAL-INFARCTION; RANDOMIZED-TRIALS; CHARISMA TRIAL; ASPIRIN; RISK;
METAANALYSIS; CLOPIDOGREL
AB Background-Vorapaxar is a novel antagonist of protease-activated receptor-1, the primary receptor for thrombin on human platelets that is also present on vascular endothelium and smooth muscle. Patients with peripheral artery disease are at risk of systemic atherothrombotic events, as well as acute and chronic limb ischemia and the need for peripheral revascularization.
Methods and Results-The Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA2 degrees P-TIMI 50) was a randomized, double-blind, placebo-controlled trial of vorapaxar in 26 449 patients with stable atherosclerotic vascular disease (myocardial infarction, stroke, or peripheral artery disease). Patients with qualifying peripheral artery disease (n=3787) had a history of claudication and an ankle-brachial index of <0.85 or prior revascularization for limb ischemia. The primary efficacy end point was cardiovascular death, myocardial infarction, or stroke, and the principal safety end point was Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) bleeding. In the peripheral artery disease cohort, the primary end point did not differ significantly with vorapaxar (11.3% versus 11.9%; hazard ratio, 0.94; 95% confidence interval, 0.78-1.14; P=0.53). However, rates of hospitalization for acute limb ischemia (2.3% versus 3.9%; hazard ratio, 0.58; 95% confidence interval, 0.39-0.86; P=0.006) and peripheral artery revascularization (18.4% versus 22.2%; hazard ratio, 0.84; 95% confidence interval, 0.73-0.97; P=0.017) were significantly lower in patients randomized to vorapaxar. Bleeding occurred more frequently with vorapaxar compared with placebo (7.4% versus 4.5%; hazard ratio, 1.62; 95% confidence interval, 1.21-2.18; P=0.001).
Conclusions-Vorapaxar did not reduce the risk of cardiovascular death, myocardial infarction, or stroke in patients with peripheral artery disease; however, vorapaxar significantly reduced acute limb ischemia and peripheral revascularization. The beneficial effects of protease-activated receptor-1 antagonism on limb vascular events were accompanied by an increased risk of bleeding.
C1 [Bonaca, Marc P.; Scirica, Benjamin M.; Creager, Mark A.; Lamp, Jessica M.; Murphy, Sabina A.; Braunwald, Eugene; Morrow, David A.] Brigham & Womens Hosp, TIMI Study Grp, Cardiovasc Div, Boston, MA 02115 USA.
[Bonaca, Marc P.; Scirica, Benjamin M.; Creager, Mark A.; Lamp, Jessica M.; Murphy, Sabina A.; Braunwald, Eugene; Morrow, David A.] Harvard Univ, Sch Med, Boston, MA USA.
[Olin, Jeffrey] Mt Sinai Sch Med, Wiener Cardiovasc Inst, New York, NY USA.
[Olin, Jeffrey] Mt Sinai Sch Med, Henry R Kravis Ctr Cardiovasc Hlth, New York, NY USA.
[Bounameaux, Henri] Univ Hosp Geneva, Fac Med Geneva, Div Angiol & Hemostasis, Dept Med Specialties, Geneva, Switzerland.
[Dellborg, Mikael] Univ Gothenburg, Inst Med, Sahlgrenska Acad, Gothenburg, Sweden.
[Dellborg, Mikael] Sahlgrens Univ Hosp, Gothenburg, Sweden.
RP Bonaca, MP (reprint author), Brigham & Womens Hosp, TIMI Study Grp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA.
EM mbonaca@partners.org
FU Merck and Co.; Accumetrics; Amgen; AstraZeneca; Beckman Coulter;
Bristol-Myers Squibb; CV Therapeutics; Daiichi Sankyo Co Ltd; Eli Lilly
and Co; GlaxoSmithKline; Integrated Therapeutics; Nanosphere; Novartis
Pharmaceuticals; Nuvelo; OrthoClinical Diagnostics; Pfizer; Roche
Diagnostics; Sanofi-Aventis; Sanofi-Synthelabo; Siemens Medical
Solutions; Singulex; National Heart, Lung, and Blood Institute [K12
HL083786]; Lexicon; Arena; Gilead; Eisai; Aastrom Biosciences; Baxter
Healthcare; Genzyme; Merck; Plurestem; Swiss National Foundation;
Bayer-Schering Pharma; Schering-Plow; Daiichi-Sankyo;
Boehringer-Ingelheim; Actelion; Eli Lilly; Amarin Pharmaceuticals;
Beckman-Coulter; Critical Diagnostics; Genentech; Instrumentation
Laboratory; Novartis; Servier
FX The TRA2 degrees P-TIMI 50 Trial was sponsored by Merck and Co.; The
TIMI Study Group has received significant research grant support from
Accumetrics, Amgen, AstraZeneca, Beckman Coulter, Bristol-Myers Squibb,
CV Therapeutics, Daiichi Sankyo Co Ltd, Eli Lilly and Co,
GlaxoSmithKline, Integrated Therapeutics, Merck and Co, Nanosphere,
Novartis Pharmaceuticals, Nuvelo, OrthoClinical Diagnostics, Pfizer,
Roche Diagnostics, Sanofi-Aventis, Sanofi-Synthelabo, Siemens Medical
Solutions, and Singulex. Dr Bonaca was supported by a Research Career
Development Award (K12 HL083786) from the National Heart, Lung, and
Blood Institute. Dr Scirica has received consulting fees from Lexicon,
Arena, Gilead, and Eisai. Dr Creager has received consulting fees from
Aastrom Biosciences, AstraZeneca, Baxter Healthcare, and Genzyme. Dr
Olin has received consulting fees from Merck and Plurestem. Dr
Bounameaux has received research support, consulting fees, and/or
honoraria for lectures from the Swiss National Foundation,
Bayer-Schering Pharma, Schering-Plow, Daiichi-Sankyo,
Bristol-Myers-Squibb, GlaxoSmithKline, Pfizer, Boehringer-Ingelheim, and
sanofi-aventis. Dr Dellborg has received consulting fees and/or
honoraria for lectures from Schering-Plow, Pfizer, Merck,
Boehringer-Ingelheim, and Actelion. S.A. Murphy has received consulting
fees from Eli Lilly and Amarin Pharmaceuticals. Dr Braunwald has served
as a consultant for Merck (no compensation), Amorcyte, Daiichi Sankyo,
Medicines Co, Ikaria, CardioRentis, Sanofi-Aventis, and CVRx (no
compensation). Dr Morrow has received consulting fees from
Beckman-Coulter, Boehringer-Ingelheim, Critical Diagnostics, Genentech,
Gilead, Instrumentation Laboratory, Merck, Novartis, Roche Diagnostics,
and Servier. J.M. Lamp reports no conflicts.
NR 22
TC 70
Z9 72
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD APR 9
PY 2013
VL 127
IS 14
BP 1522
EP +
DI 10.1161/CIRCULATIONAHA.112.000679
PG 14
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 122VS
UT WOS:000317346900019
PM 23501976
ER
PT J
AU Mauer, AC
Baron, SJ
Yeh, RW
Scott, NS
AF Mauer, Andreas C.
Baron, Suzanne J.
Yeh, Robert W.
Scott, Nandita S.
TI Caesarian Dissection A Case of Chest Pain and Dyspnea During Delivery
SO CIRCULATION
LA English
DT Article
DE acute coronary syndrome; coronary artery dissection, spontaneous; heart
failure; pregnancy; tomography, optical coherence
ID CORONARY-ARTERY DISSECTION; OPTICAL COHERENCE TOMOGRAPHY; ACUTE
MYOCARDIAL-INFARCTION; BRAIN NATRIURETIC PEPTIDE; INTRAVASCULAR
ULTRASOUND; HEART-DISEASE; PREGNANCY; MANAGEMENT; INTERVENTION;
DIAGNOSIS
C1 [Mauer, Andreas C.; Baron, Suzanne J.; Yeh, Robert W.; Scott, Nandita S.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Mauer, AC (reprint author), Massachusetts Gen Hosp, 55 Fruit St,GRB8-813, Boston, MA 02114 USA.
EM amauer@partners.org
NR 25
TC 0
Z9 0
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD APR 9
PY 2013
VL 127
IS 14
BP 1530
EP 1535
DI 10.1161/CIRCULATIONAHA.112.000858
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 122VS
UT WOS:000317346900020
PM 23569120
ER
PT J
AU Januzzi, JL
AF Januzzi, James L., Jr.
TI Natriuretic Peptides, Ejection Fraction, and Prognosis
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Editorial Material
DE heart failure; natriuretic peptides; preserved ejection fraction;
prognosis
ID EMERGENCY-DEPARTMENT PRIDE; HEART-FAILURE; DYSPNEA; PREDICTION;
MORTALITY; PROBNP; TRIAL; CHF
C1 [Januzzi, James L., Jr.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Januzzi, JL (reprint author), Massachusetts Gen Hosp, Yawkey 5984,32 Fruit St, Boston, MA 02114 USA.
EM jjanuzzi@partners.org
NR 9
TC 7
Z9 7
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 9
PY 2013
VL 61
IS 14
BP 1507
EP 1509
DI 10.1016/j.jacc.2013.01.039
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 120SL
UT WOS:000317192300007
PM 23500284
ER
PT J
AU Schonberg, MA
Walter, LC
AF Schonberg, Mara A.
Walter, Louise C.
TI Talking About Stopping Cancer Screening-Not So Easy
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID OLDER; WOMEN; CARE
C1 [Schonberg, Mara A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gen Med & Primary Care,Dept Med, Boston, MA 02215 USA.
[Walter, Louise C.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Schonberg, MA (reprint author), Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, 1309 Beacon,Off 219, Brookline, MA 02446 USA.
EM mschonbe@bidmc.harvard.edu
FU NCI NIH HHS [R01 CA134425]; NIA NIH HHS [K23AG028584, K24AG041180]
NR 10
TC 4
Z9 4
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR 8
PY 2013
VL 173
IS 7
BP 532
EP 533
DI 10.1001/jamainternmed.2013.3233
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 154NR
UT WOS:000319683400011
PM 23479053
ER
PT J
AU Gross, AL
Jones, RN
Inouye, SK
AF Gross, Alden L.
Jones, Richard N.
Inouye, Sharon K.
TI The Meaning of Delirium reply
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
ID DEMENTIA
C1 [Gross, Alden L.; Jones, Richard N.; Inouye, Sharon K.] Harvard Univ, Sch Med, Inst Aging Res, Hebrew SeniorLife,Aging Brain Ctr, Boston, MA 02131 USA.
[Gross, Alden L.; Jones, Richard N.; Inouye, Sharon K.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02131 USA.
[Inouye, Sharon K.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02131 USA.
[Inouye, Sharon K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02131 USA.
RP Gross, AL (reprint author), Harvard Univ, Sch Med, Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA.
EM aldengross@hsl.harvard.edu
NR 5
TC 0
Z9 0
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD APR 8
PY 2013
VL 173
IS 7
BP 598
EP 599
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 154NR
UT WOS:000319683400039
ER
PT J
AU Singh, T
Katiyar, SK
AF Singh, Tripti
Katiyar, Santosh K.
TI Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting
PGE(2)-Mediated Activation of beta-Catenin Signaling
SO PLOS ONE
LA English
DT Article
ID NATURAL-PRODUCT; NITRIC-OXIDE; GUANYLATE-CYCLASE; COX-2 EXPRESSION;
COLON-CANCER; IN-VIVO; CYCLOOXYGENASE-2; APOPTOSIS; CARCINOMA; GROWTH
AB Lung cancer remains a leading cause of death due to its metastasis to distant organs. We have examined the effect of honokiol, a bioactive constituent from the Magnolia plant, on human non-small cell lung cancer (NSCLC) cell migration and the molecular mechanisms underlying this effect. Using an in vitro cell migration assay, we found that treatment of A549, H1299, H460 and H226 NSCLC cells with honokiol resulted in inhibition of migration of these cells in a dose-dependent manner, which was associated with a reduction in the levels of cyclooxygenase-2 (COX-2) and prostaglandin E-2 (PGE(2)). Celecoxib, a COX-2 inhibitor, also inhibited cell migration. Honokiol inhibited PGE(2)-enhanced migration of NSCLC cells, inhibited the activation of NF-kappa B/p65, an upstream regulator of COX-2, in A549 and H1299 cells, and treatment of cells with caffeic acid phenethyl ester, an inhibitor of NF-kappa B, also inhibited migration of NSCLC cells. PGE(2) has been shown to activate beta-catenin signaling, which contributes to cancer cell migration. Therefore, we checked the effect of honokiol on beta-catenin signaling. It was observed that treatment of NSCLC cells with honokiol degraded cytosolic beta-catenin, reduced nuclear accumulation of beta-catenin and down-regulated matrix metalloproteinase (MMP)-2 and MMP-9, which are the down-stream targets of beta-catenin and play a crucial role in cancer cell metastasis. Honokiol enhanced: (i) the levels of casein kinase-1 alpha, glycogen synthase kinase-3 beta, and (ii) phosphorylation of beta-catenin on critical residues Ser(45), Ser(33/37) and Thr(41). These events play important roles in degradation or inactivation of beta-catenin. Treatment of celecoxib also reduced nuclear accumulation of beta-catenin in NSCLC cells. FH535, an inhibitor of Wnt/beta-catenin pathway, inhibited PGE(2)-enhanced cell migration of A549 and H1299 cells. These results indicate that honokiol inhibits non-small cell lung cancer cells migration by targeting PGE(2)-mediated activation of delta-catenin signaling.
C1 [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Singh, Tripti; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
RP Katiyar, SK (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
EM skatiyar@uab.edu
FU Veterans Administration [1I01BX001410-01]
FX This research was financially supported by the Veterans Administration
Merit Review Award (1I01BX001410-01, S.K.K.). The funding agencies had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 40
TC 25
Z9 29
U1 3
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 8
PY 2013
VL 8
IS 4
AR e60749
DI 10.1371/journal.pone.0060749
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130FG
UT WOS:000317898000059
PM 23580348
ER
PT J
AU Dearling, JLJ
Looby, R
Caravan, PD
Packard, AB
AF Dearling, Jason L. J.
Looby, Richard
Caravan, Peter D.
Packard, Alan B.
TI Simple approach to high sensitivity trace metal analysis
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 245th National Spring Meeting of the American-Chemical-Society (ACS)
CY APR 07-11, 2013
CL New Orleans, LA
SP Amer Chem Soc
C1 [Dearling, Jason L. J.; Packard, Alan B.] Boston Childrens Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02115 USA.
[Looby, Richard; Caravan, Peter D.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Dearling, Jason L. J.; Caravan, Peter D.; Packard, Alan B.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
EM alan.packard@childrens.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD APR 7
PY 2013
VL 245
MA 68-NUCL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 216SF
UT WOS:000324303602666
ER
PT J
AU Greer, A
Kimani, S
Ghosh, G
Ghogare, A
Rudshteyn, B
Bartusik, D
Hasan, T
AF Greer, Alexander
Kimani, Stanley
Ghosh, Goutam
Ghogare, Ashwini
Rudshteyn, Benjamin
Bartusik, Dorota
Hasan, Tayyaba
TI Synthesis and characterization of PEGylated chlorin sensitizers for the
photodynamic killing of human ovarian cancer cells
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 245th National Spring Meeting of the American-Chemical-Society (ACS)
CY APR 07-11, 2013
CL New Orleans, LA
SP Amer Chem Soc
C1 [Greer, Alexander; Kimani, Stanley; Ghosh, Goutam; Ghogare, Ashwini; Rudshteyn, Benjamin; Bartusik, Dorota] CUNY Brooklyn Coll, Dept Chem, Brooklyn, NY 11210 USA.
[Hasan, Tayyaba] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Hasan, Tayyaba] Harvard Univ, Sch Med, Boston, MA 02114 USA.
EM agreer@brooklyn.cuny.edu
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD APR 7
PY 2013
VL 245
MA 760-ORGN
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 216SF
UT WOS:000324303603418
ER
PT J
AU Rai, PR
AF Rai, Prakash R.
TI Triple combination nanochemoprevention of breast cancer
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 245th National Meeting of the American-Chemical-Society (ACS)
CY APR 07-11, 2013
CL New Orleans, LA
SP Amer Chem Soc
C1 [Rai, Prakash R.] Univ Massachusetts, Dept Chem Engn, Lowell, MA 01854 USA.
[Rai, Prakash R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg,Ctr Engn Med, Boston, MA 02114 USA.
EM Prakash_Rai@uml.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD APR 7
PY 2013
VL 245
MA 58-COLL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 210RD
UT WOS:000323851303714
ER
PT J
AU Verdine, GL
AF Verdine, Gregory L.
TI Next-generation therapeutics
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
CT 245th National Meeting of the American-Chemical-Society (ACS)
CY APR 07-11, 2013
CL New Orleans, LA
SP Amer Chem Soc
C1 [Verdine, Gregory L.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Verdine, Gregory L.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
[Verdine, Gregory L.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
[Verdine, Gregory L.] Dana Farber Canc Inst, Chem Biol Initiat, Boston, MA 02214 USA.
[Verdine, Gregory L.] Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02214 USA.
EM gregory_verdine@harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD APR 7
PY 2013
VL 245
MA 118-BIOL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA 210RD
UT WOS:000323851300720
ER
PT J
AU Petibon, Y
Ouyang, J
Zhu, X
Huang, C
Reese, TG
Chun, SY
Li, Q
El Fakhri, G
AF Petibon, Y.
Ouyang, J.
Zhu, X.
Huang, C.
Reese, T. G.
Chun, S. Y.
Li, Q.
El Fakhri, G.
TI Cardiac motion compensation and resolution modeling in simultaneous
PET-MR: a cardiac lesion detection study
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID POSITRON-EMISSION-TOMOGRAPHY; RESPIRATORY MOTION; IMAGE-RECONSTRUCTION;
HUMAN-OBSERVER; GATED PET; 3D PET; REGISTRATION; DISPLACEMENT; FRACTION;
PET/MRI
AB Cardiac motion and partial volume effects (PVE) are two of the main causes of image degradation in cardiac PET. Motion generates artifacts and blurring while PVE lead to erroneous myocardial activity measurements. Newly available simultaneous PET-MR scanners offer new possibilities in cardiac imaging as MRI can assess wall contractility while collecting PET perfusion data. In this perspective, we develop a list-mode iterative reconstruction framework incorporating both tagged-MR derived non-rigid myocardial wall motion and position dependent detector point spread function (PSF) directly into the PET system matrix. In this manner, our algorithm performs both motion 'deblurring' and PSF deconvolution while reconstructing images with all available PET counts. The proposed methods are evaluated in a beating non-rigid cardiac phantom whose hot myocardial compartment contains small transmural and non-transmural cold defects. In order to accelerate imaging time, we investigate collecting full and half k-space tagged MR data to obtain tagged volumes that are registered using non-rigid B-spline registration to yield wall motion information. Our experimental results show that tagged-MR based motion correction yielded an improvement in defect/myocardium contrast recovery of 34-206% as compared to motion uncorrected studies. Likewise, lesion detectability improved by respectively 115-136% and 62-235% with MR-based motion compensation as compared to gating and no motion correction and made it possible to distinguish non-transmural from transmural defects, which has clinical significance given the inherent limitations of current single modality imaging in identifying the amount of residual ischemia. The incorporation of PSF modeling within the framework of MR-based motion compensation significantly improved defect/myocardium contrast recovery (5.1-8.5%, p < 0.01) and defect detectability (39-56%, p < 0.01). No statistical difference was found in PET contrast and lesion detectability based on motion fields obtained with half and full k-space tagged data.
C1 [Petibon, Y.; Ouyang, J.; Zhu, X.; Huang, C.; Reese, T. G.; Chun, S. Y.; Li, Q.; El Fakhri, G.] Massachusetts Gen Hosp, Dept Radiol, Ctr Adv Med Imaging Sci Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Reese, T. G.] Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
RP El Fakhri, G (reprint author), Massachusetts Gen Hosp, Dept Radiol, Ctr Adv Med Imaging Sci Nucl Med & Mol Imaging, Boston, MA 02114 USA.
EM elfakhri@pet.mgh.harvard.edu
RI Chun, Se Young/B-6653-2013;
OI Huang, Chuan/0000-0001-6052-0663; Chun, Se Young/0000-0001-8739-8960
FU [NIH-R21-EB012326]; [R01-CA165221]
FX This work was supported by NIH-R21-EB012326 and R01-CA165221. The
authors would like to thank Grae Arabasz for his help during the point
sources and phantom acquisitions.
NR 44
TC 25
Z9 25
U1 1
U2 23
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD APR 7
PY 2013
VL 58
IS 7
BP 2085
EP 2102
DI 10.1088/0031-9155/58/7/2085
PG 18
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 106YJ
UT WOS:000316181300008
PM 23470288
ER
PT J
AU Carabe, A
Espana, S
Grassberger, C
Paganetti, H
AF Carabe, Alejandro
Espana, Samuel
Grassberger, Clemens
Paganetti, Harald
TI Clinical consequences of relative biological effectiveness variations in
proton radiotherapy of the prostate, brain and liver
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID LOW-ENERGY PROTONS; LINEAR-QUADRATIC MODEL; HAMSTER V79 CELLS; BEAM
THERAPY; RBE; CANCER; HYPOFRACTIONATION; MICRODOSIMETRY; FRACTIONATION;
INACTIVATION
AB Proton relative biological effectiveness (RBE) is known to depend on the (alpha/beta)(x) of irradiated tissues, with evidence of similar to 60% variation over (alpha/beta)(x) values from 1-10 Gy. The range of (alpha/beta)(x) values reported for prostate tumors (1.2-5.0 Gy), brain tumors (10-15 Gy) and liver tumors (13-17 Gy) imply that the proton RBE for these tissues could vary significantly compared to the commonly used generic value of 1.1. Our aim is to evaluate the impact of this uncertainty on the proton dose in Gy(RBE) absorbed in normal and tumor tissues. This evaluation was performed for standard and hypofractionated regimens. RBE-weighted total dose (RWTD) distributions for 15 patients (five prostate tumors, five brain tumors and five liver tumors) were calculated using an in-house developed RBE model as a function of dose, dose-averaged linear energy transfer (LETd) and (alpha/beta)(x). Variations of the dose-volume histograms (DVHs) for the gross tumor volume (GTV) and the organs at risk due to changes of (alpha/beta)(x) and fractionation regimen were calculated and the RWTD received by 10% and 90% of the organ volume reported. The goodness of the plan, bearing the uncertainties, was then evaluated compared to the delivered plan, which considers a constant RBE of 1.1. For standard fractionated regimens, the prostate tumors, liver tumors and all critical structures in the brain showed typically larger RBE values than 1.1. However, in hypofractionated regimens lower values of RBE than 1.1 were observed in most cases. Based on DVH analysis we found that the RBE variations were clinically significant in particular for the prostate GTV and the critical structures in the brain. Despite the uncertainties in the biological input parameters when estimating RBE values, the results show that the use of a variable RBE with dose, LETd and (alpha/beta)(x) could help to further optimize the target dose in proton treatment planning. Most importantly, this study shows that the consideration of RBE variations could influence the comparison of proton and photon treatments in clinical trials, in particular in the case of the prostate.
C1 [Carabe, Alejandro] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
[Espana, Samuel] Univ Ghent, Dept Med Imaging & Signal Proc MEDISIP, B-9000 Ghent, Belgium.
[Grassberger, Clemens; Paganetti, Harald] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Grassberger, Clemens; Paganetti, Harald] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Carabe, A (reprint author), Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
EM a.carabe@uphs.upenn.edu
RI Espana, Samuel/E-9240-2010
OI Espana, Samuel/0000-0001-9092-4597
FU Federal Share of program [C06 CA059267]
FX The project was supported by the Federal Share of program income earned
by Massachusetts General Hospital on C06 CA059267, Proton Therapy
Research and Treatment Center. Thanks are extended to Professor Roger G
Dale for his useful comments on the BED calculations.
NR 37
TC 16
Z9 16
U1 2
U2 12
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD APR 7
PY 2013
VL 58
IS 7
BP 2103
EP 2117
DI 10.1088/0031-9155/58/7/2103
PG 15
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 106YJ
UT WOS:000316181300009
PM 23470339
ER
PT J
AU Jacobson, CA
Freedman, AS
AF Jacobson, Caron A.
Freedman, Arnold S.
TI First-line treatment of indolent lymphoma: axing CHOP?
SO LANCET
LA English
DT Editorial Material
ID NON-HODGKINS-LYMPHOMA; LARGE-CELL LYMPHOMA; FOLLICULAR LYMPHOMA; PLUS
RITUXIMAB; LOW-GRADE; CHEMOTHERAPY; CYCLOPHOSPHAMIDE; MAINTENANCE;
VINCRISTINE; SURVIVAL
C1 [Jacobson, Caron A.; Freedman, Arnold S.] Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Freedman, AS (reprint author), Dana Farber Canc Inst, Boston, MA 02215 USA.
EM arnold_freedman@dfci.harvard.edu
NR 12
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 6
PY 2013
VL 381
IS 9873
BP 1163
EP 1165
DI 10.1016/S0140-6736(12)61965-5
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 122WU
UT WOS:000317350100006
PM 23433738
ER
PT J
AU Huo, YL
Choy, JS
Wischgoll, T
Luo, T
Teague, SD
Bhatt, DL
Kassab, GS
AF Huo, Yunlong
Choy, Jenny Susana
Wischgoll, Thomas
Luo, Tong
Teague, Shawn D.
Bhatt, Deepak L.
Kassab, Ghassan S.
TI Computed tomography-based diagnosis of diffuse compensatory enlargement
of coronary arteries using scaling power laws
SO JOURNAL OF THE ROYAL SOCIETY INTERFACE
LA English
DT Article
DE coronary compensatory enlargement; scaling power law; computed
tomography
ID BLOOD-FLOW; TREE; MORPHOMETRY; DISEASE; ATHEROSCLEROSIS; EXTRACTION
AB Glagov's positive remodelling in the early stages of coronary atherosclerosis often results in plaque rupture and acute events. Because positive remodelling is generally diffused along the epicardial coronary arterial tree, it is difficult to diagnose non-invasively. Hence, the objective of the study is to assess the use of scaling power law for the diagnosis of positive remodelling of coronary arteries based on computed tomography (CT) images. Epicardial coronary arterial trees were reconstructed from CT scans of six Ossabaw pigs fed on a high-fat, high-cholesterol, atherogenic diet for eight months as well as the same number of body-weight-matched farm pigs fed on a lean chow (101.9 +/- 16.1 versus 91.5 +/- 13.1 kg). The high-fat diet Ossabaw pig model showed diffuse positive remodelling of epicardial coronary arteries. Good fit of measured coronary data to the length-volume scaling power law (L-c = KLVVc7/9, where L-c and V-c are crown length and volume) were found for both the high-fat and control groups (R-2 = 0.95 +/- 0.04 and 0.99 +/- 0.01, respectively). The coefficient, K-LV, decreased significantly in the high-fat diet group when compared with the control (14.6 +/- 2.6 versus 40.9 +/- 5.6). The flow-length scaling power law, however, was nearly unaffected by the positive remodelling. The length-volume and flow-length scaling power laws were preserved in epicardial coronary arterial trees after positive remodelling. K-LV < 18 in the length-volume scaling relation is a good index of positive remodelling of coronary arteries. These findings provide a clinical rationale for simple, accurate and non-invasive diagnosis of positive remodelling of coronary arteries, using conventional CT scans.
C1 [Huo, Yunlong; Choy, Jenny Susana; Luo, Tong; Teague, Shawn D.; Kassab, Ghassan S.] Indiana Univ Purdue Univ, Indianapolis, IN 46202 USA.
[Wischgoll, Thomas] Wright State Univ, Dayton, OH 45435 USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Huo, Yunlong] Peking Univ, Beijing 100871, Peoples R China.
RP Kassab, GS (reprint author), Indiana Univ Purdue Univ, Indianapolis, IN 46202 USA.
EM gkassab@iupui.edu
RI Huo, Yunlong/N-8155-2013;
OI Huo, Yunlong/0000-0003-4121-3224
FU National Institute of Health-National Heart, Lung and Blood Institute
[HL-092048]; American Heart Association Scientist Development [0830181N]
FX This study is supported in part by the National Institute of
Health-National Heart, Lung and Blood Institute grant no. HL-092048
(G.S.K.) and the American Heart Association Scientist Development grant
no. 0830181N (Y.H.).
NR 24
TC 5
Z9 5
U1 1
U2 8
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1742-5689
J9 J R SOC INTERFACE
JI J. R. Soc. Interface
PD APR 6
PY 2013
VL 10
IS 81
AR 20121015
DI 10.1098/rsif.2012.1015
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093NY
UT WOS:000315199800020
PM 23365197
ER
PT J
AU Browne, RW
Kantarci, A
LaMonte, MJ
Andrews, CA
Hovey, KM
Falkner, KL
Cekici, A
Stephens, D
Genco, RJ
Scannapieco, FA
Van Dyke, TE
Wactawski-Wende, J
AF Browne, Richard W.
Kantarci, Alpdogan
LaMonte, Michael J.
Andrews, Christopher A.
Hovey, Kathleen M.
Falkner, Karen L.
Cekici, Ali
Stephens, Danielle
Genco, Robert J.
Scannapieco, Frank A.
Van Dyke, Thomas E.
Wactawski-Wende, Jean
TI Performance of Multiplex Cytokine Assays in Serum and Saliva among
Community-Dwelling Postmenopausal Women
SO PLOS ONE
LA English
DT Article
ID INTERNAL QUALITY-CONTROL; BIOLOGICAL VARIATION; ELISA; VALIDATION;
RULES; IDENTIFICATION; QUANTITATION; INFLAMMATION; IMMUNOASSAYS;
TECHNOLOGY
AB Multiplexing arrays increase the throughput and decrease sample requirements for studies employing multiple biomarkers. The goal of this project was to examine the performance of Multiplex arrays for measuring multiple protein biomarkers in saliva and serum. Specimens from the OsteoPerio ancillary study of the Women's Health Initiative Observational Study were used. Participants required the presence of at least 6 teeth and were excluded based on active cancer and certain bone issues but were not selected on any specific condition. Quality control (QC) samples were created from pooled serum and saliva. Twenty protein markers were measured on five multiplexing array panels. Sample pretreatment conditions were optimized for each panel. Recovery, lower limit of quantification (LLOQ) and imprecision were determined for each analyte. Statistical adjustment at the plate level was used to reduce imprecision estimates and increase the number of usable observations. Sample pre-treatment improved recovery estimates for many analytes. The LLOQ for each analyte agreed with manufacturer specifications except for MMP-1 and MMP-2 which were significantly higher than reported. Following batch adjustment, 17 of 20 biomarkers in serum and 9 of 20 biomarkers in saliva demonstrated acceptable precision, defined as <20% coefficient of variation (<25% at LLOQ). The percentage of cohort samples having levels within the reportable range for each analyte varied from 10% to 100%. The ratio of levels in saliva to serum varied from 1:100 to 28:1. Correlations between saliva and serum were of moderate positive magnitude and significant for CRP, MMP-2, insulin, adiponectin, GM-CSF and IL-5. Multiplex arrays exhibit high levels of analytical imprecision, particularly at the batch level. Careful sample pre-treatment can enhance recovery and reduce imprecision. Following statistical adjustments to reduce batch effects, we identified biomarkers that are of acceptable quality in serum and to a lesser degree in saliva using Multiplex arrays.
C1 [Browne, Richard W.] SUNY Buffalo, Dept Biotech & Clin Lab Sci, Buffalo, NY 14260 USA.
[Kantarci, Alpdogan; Cekici, Ali; Stephens, Danielle; Van Dyke, Thomas E.] Forsyth Inst, Dept Periodontol, Boston, MA USA.
[LaMonte, Michael J.; Hovey, Kathleen M.; Falkner, Karen L.; Wactawski-Wende, Jean] SUNY Buffalo, Dept Social & Prevent Med, New York, NY USA.
[Andrews, Christopher A.] SUNY Buffalo, Dept Biostat, Buffalo, NY 14260 USA.
[Genco, Robert J.; Scannapieco, Frank A.] SUNY Buffalo, Dept Oral Biol, New York, NY USA.
RP Browne, RW (reprint author), SUNY Buffalo, Dept Biotech & Clin Lab Sci, Buffalo, NY 14260 USA.
EM rwbrowne@buffalo.edu
OI Scannapieco, Frank/0000-0002-8804-6593
FU NHLBI
FX The funder NHLBI had a role in the study design but not in the data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 39
TC 10
Z9 10
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 5
PY 2013
VL 8
IS 4
AR e59498
DI 10.1371/journal.pone.0059498
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RZ
UT WOS:000319109800011
PM 23577067
ER
PT J
AU Jiang, HB
Chen, W
Zhu, GC
Zhang, LJ
Tucker, BR
Hao, L
Feng, SM
Ci, HL
Ma, JQ
Wang, L
Stashenko, P
Li, YP
AF Jiang, Hongbing
Chen, Wei
Zhu, Guochun
Zhang, Lijie
Tucker, Byron
Hao, Liang
Feng, Shengmei
Ci, Hongliang
Ma, Junqing
Wang, Lin
Stashenko, Philip
Li, Yi-Ping
TI RNAi-Mediated Silencing of Atp6i and Atp6i Haploinsufficiency Prevents
Both Bone Loss and Inflammation in a Mouse Model of Periodontal Disease
SO PLOS ONE
LA English
DT Article
ID ADENOASSOCIATED VIRUS VECTORS; IN-VITRO; T-CELL; OSTEOCLAST
DIFFERENTIATION; ALLOGRAFT-REJECTION; PARKINSONS-DISEASE;
MEMBRANE-PROTEIN; IMMUNE-RESPONSE; B-LYMPHOCYTE; GENE-THERAPY
AB Periodontal disease affects about 80% of adults in America, and is characterized by oral bacterial infection-induced gingival inflammation, oral bone resorption, and tooth loss. Periodontitis is also associated with other diseases such as rheumatoid arthritis, diabetes, and heart disease. Although many efforts have been made to develop effective therapies for this disease, none have been very effective and there is still an urgent need for better treatments and preventative strategies. Herein we explored for the first time the possibility that adeno-associated virus (AAV)-mediated RNAi knockdown could be used to treat periodontal disease with improved efficacy. For this purpose, we used AAV-mediated RNAi knockdown of Atp6i/TIRC7 gene expression to target bone resorption and gingival inflammation simultaneously. Mice were infected with the oral pathogen Porphyromonas gingivalis W50 (P. gingivalis) in the maxillary periodontium to induce periodontitis. We found that Atp6i depletion impaired extracellular acidification and osteoclast-mediated bone resorption. Furthermore, local injection of AAV-shRNA-Atp6i/TIRC7 into the periodontal tissues in vivo protected mice from P. gingivalis infection-stimulated bone resorption by >85% and decreased the T-cell number in periodontal tissues. Notably, AAV-mediated Atp6i/TIRC7 knockdown also reduced the expression of osteoclast marker genes and inflammation-induced cytokine genes. Atp6i(+/-) mice with haploinsufficiency were similarly protected from P. gingivalis infection-stimulated bone loss and gingival inflammation. This suggests that AAV-shRNA-Atp6i/TIRC7 therapeutic treatment may significantly improve the health of millions who suffer from P. gingivalis-mediated periodontal disease.
C1 [Jiang, Hongbing; Chen, Wei; Zhu, Guochun; Tucker, Byron; Hao, Liang; Feng, Shengmei; Ci, Hongliang; Ma, Junqing; Li, Yi-Ping] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Jiang, Hongbing; Ma, Junqing; Wang, Lin] Nanjing Med Univ, Coll Stomatol, Nanjing, Jiangsu, Peoples R China.
[Tucker, Byron] Harvard Univ, Sch Dent Med, Dept Restorat Dent & Endodont, Boston, MA 02115 USA.
[Zhang, Lijie; Stashenko, Philip] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA USA.
[Zhang, Lijie] Hebei Med Univ, Hosp 3, Dept Clin Lab, Shijiazhuang, Hebei Province, Peoples R China.
RP Chen, W (reprint author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
EM wechen@uab.edu; ypli@uab.edu
FU National Institutes of Health [DE-020533-01, R01-AR-055307]
FX This work was supported by National Institutes of Health grants
DE-020533-01 (Y.P.L.) and R01-AR-055307 (Y.P.L.). The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 54
TC 14
Z9 14
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 5
PY 2013
VL 8
IS 4
AR e58599
DI 10.1371/journal.pone.0058599
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RZ
UT WOS:000319109800004
PM 23577057
ER
PT J
AU Sung, RJ
Zhang, M
Qi, Y
Verdine, GL
AF Sung, Rou-Jia
Zhang, Michael
Qi, Yan
Verdine, Gregory L.
TI Structural and Biochemical Analysis of DNA Helix Invasion by the
Bacterial 8-Oxoguanine DNA Glycosylase MutM
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ESCHERICHIA-COLI; PROTEIN-STRUCTURE; REPAIR ENZYME; FPG PROTEIN; LESION;
7,8-DIHYDRO-8-OXOGUANINE; SYSTEM; RECOGNITION; VALIDATION; COMPLEXES
AB MutM is a bacterial DNA glycosylase that serves as the first line of defense against the highly mutagenic 8-oxoguanine (oxoG) lesion, catalyzing glycosidic bond cleavage of oxoG to initiate base excision DNA repair. Previous work has shown that MutM actively interrogates DNA for the presence of an intrahelical oxoG lesion. This interrogation process involves significant buckling and bending of the DNA to promote extrusion of oxoG from the duplex. Structural snapshots have revealed several different highly conserved residues that are prominently inserted into the duplex in the vicinity of the target oxoG before and after base extrusion has occurred. However, the roles of these helix-invading residues during the lesion recognition and base extrusion process remain unclear. In this study, we set out to probe the function of residues Phe(114) and Met(77) in oxoG recognition and repair. Here we report a detailed biochemical and structural characterization of MutM variants containing either a F114A or M77A mutation, both of which showed significant decreases in the efficiency of oxoG repair. These data reveal that Met77 plays an important role in stabilizing the lesion-extruded conformation of the DNA. Phe(114), on the other hand, appears to destabilize the intrahelical state of the oxoG lesion, primarily by buckling the target base pair. We report the observation of a completely unexpected interaction state, in which the target base pair is ruptured but remains fully intrahelical; this structure vividly illustrates the disruptive influence of MutM on the target base pair.
C1 [Sung, Rou-Jia; Verdine, Gregory L.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
[Zhang, Michael; Verdine, Gregory L.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
[Sung, Rou-Jia; Verdine, Gregory L.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Verdine, Gregory L.] Dana Farber Canc Inst, Chem Biol Initiat, Boston, MA 02115 USA.
[Verdine, Gregory L.] Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02115 USA.
[Qi, Yan] Harvard Univ, Sch Med, Grad Program Biophys, Boston, MA 02115 USA.
RP Verdine, GL (reprint author), 12 Oxford St, Cambridge, MA 02138 USA.
EM gregory_verdine@harvard.edu
FU National Institutes of Health [GM044853, CA100742]; Harvard College
Research Program; National Science Foundation
FX This work was supported, in whole or in part, by National Institutes of
Health Grants GM044853 and CA100742.; Supported by a grant by the
Harvard College Research Program.; Supported by a predoctoral fellowship
from the National Science Foundation.
NR 33
TC 13
Z9 13
U1 0
U2 17
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 5
PY 2013
VL 288
IS 14
BP 10012
EP 10023
DI 10.1074/jbc.M112.415612
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 119RB
UT WOS:000317114000040
PM 23404556
ER
PT J
AU Apps, R
Qi, Y
Carlson, JM
Chen, HY
Gao, XJ
Thomas, R
Yuki, Y
Del Prete, GQ
Goulder, P
Brumme, ZL
Brumme, CJ
John, M
Mallal, S
Nelson, G
Bosch, R
Heckerman, D
Stein, JL
Soderberg, KA
Moody, MA
Denny, TN
Zeng, X
Fang, JY
Moffett, A
Lifson, JD
Goedert, JJ
Buchbinder, S
Kirk, GD
Fellay, J
McLaren, P
Deeks, SG
Pereyra, F
Walker, B
Michael, NL
Weintrob, A
Wolinsky, S
Liao, W
Carrington, M
AF Apps, Richard
Qi, Ying
Carlson, Jonathan M.
Chen, Haoyan
Gao, Xiaojiang
Thomas, Rasmi
Yuki, Yuko
Del Prete, Greg Q.
Goulder, Philip
Brumme, Zabrina L.
Brumme, Chanson J.
John, Mina
Mallal, Simon
Nelson, George
Bosch, Ronald
Heckerman, David
Stein, Judy L.
Soderberg, Kelly A.
Moody, M. Anthony
Denny, Thomas N.
Zeng, Xue
Fang, Jingyuan
Moffett, Ashley
Lifson, Jeffrey D.
Goedert, James J.
Buchbinder, Susan
Kirk, Gregory D.
Fellay, Jacques
McLaren, Paul
Deeks, Steven G.
Pereyra, Florencia
Walker, Bruce
Michael, Nelson L.
Weintrob, Amy
Wolinsky, Steven
Liao, Wilson
Carrington, Mary
TI Influence of HLA-C Expression Level on HIV Control
SO SCIENCE
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; T-CELL RESPONSES; DETERMINANTS;
ASSOCIATIONS; METAANALYSIS; ALLELES; SYNAPSE; ESCAPE; NUMBER
AB A variant upstream of human leukocyte antigen C (HLA-C) shows the most significant genome-wide effect on HIV control in European Americans and is also associated with the level of HLA-C expression. We characterized the differential cell surface expression levels of all common HLA-C allotypes and tested directly for effects of HLA-C expression on outcomes of HIV infection in 5243 individuals. Increasing HLA-C expression was associated with protection against multiple outcomes independently of individual HLA allelic effects in both African and European Americans, regardless of their distinct HLA-C frequencies and linkage relationships with HLA-B and HLA-A. Higher HLA-C expression was correlated with increased likelihood of cytotoxic T lymphocyte responses and frequency of viral escape mutation. In contrast, high HLA-C expression had a deleterious effect in Crohn's disease, suggesting a broader influence of HLA expression levels in human disease.
C1 [Apps, Richard; Qi, Ying; Gao, Xiaojiang; Thomas, Rasmi; Yuki, Yuko; Carrington, Mary] SAIC Frederick Inc, Frederick Natl Lab Canc Res, Expt Immunol Lab, Canc & Inflammat Program, Frederick, MD 21702 USA.
[Apps, Richard; Qi, Ying; Gao, Xiaojiang; Yuki, Yuko; Goulder, Philip; Pereyra, Florencia; Walker, Bruce; Carrington, Mary] Massachusetts Gen Hosp, MIT, Ragon Inst, Boston, MA 02114 USA.
[Apps, Richard; Qi, Ying; Gao, Xiaojiang; Yuki, Yuko; Goulder, Philip; Pereyra, Florencia; Walker, Bruce; Carrington, Mary] Harvard Univ, Boston, MA 02114 USA.
[Carlson, Jonathan M.; Heckerman, David; Zeng, Xue] Microsoft Res, ESci Grp, Los Angeles, CA 90024 USA.
[Chen, Haoyan; Fang, Jingyuan; Liao, Wilson] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94115 USA.
[Chen, Haoyan; Lifson, Jeffrey D.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Digest Dis, Dept Gastroenterol,Ren Ji Hosp, Shanghai 200001, Peoples R China.
[Del Prete, Greg Q.] SAIC Frederick Inc, Frederick Natl Lab Canc Res, AIDS & Canc Virus Program, Frederick, MD 21702 USA.
[Goulder, Philip] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Doris Duke Med Res Inst, HIV Pathogenesis Programme, Durban, South Africa.
[Goulder, Philip] Univ Oxford, Dept Paediat, Oxford OX1 3SY, England.
[Brumme, Zabrina L.; Brumme, Chanson J.] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada.
[Brumme, Zabrina L.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada.
[John, Mina; Mallal, Simon] Murdoch Univ, Inst Immunol & Infect Dis, Murdoch, WA 6150, Australia.
[Nelson, George] SAIC Frederick Inc, Frederick Natl Lab Canc Res, Ctr Canc Res Genet Core, Basic Res Program, Frederick, MD 21702 USA.
[Bosch, Ronald] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
[Stein, Judy L.; Soderberg, Kelly A.; Moody, M. Anthony; Denny, Thomas N.] Duke Univ, Duke Human Vaccine Inst, Durham, NC 27710 USA.
[Zeng, Xue] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Dermatol, Beijing 100053, Peoples R China.
[Moffett, Ashley] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England.
[Goedert, James J.] NCI, Div Canc Epidemiol & Genet, Infect & Immunoepidemiol Branch, Bethesda, MD 20892 USA.
[Buchbinder, Susan] San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA.
[Kirk, Gregory D.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.
[Fellay, Jacques; McLaren, Paul] Univ Lausanne Hosp, Inst Microbiol, CH-1015 Lausanne, Switzerland.
[Fellay, Jacques; McLaren, Paul] Ecole Polytech Fed Lausanne, Sch Life Sci, CH-1015 Lausanne, Switzerland.
[Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94105 USA.
[Michael, Nelson L.] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD 20910 USA.
[Weintrob, Amy] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20817 USA.
[Wolinsky, Steven] Northwestern Univ, Feinberg Sch Med, Div Infect Dis, Chicago, IL 60611 USA.
RP Carrington, M (reprint author), SAIC Frederick Inc, Frederick Natl Lab Canc Res, Expt Immunol Lab, Canc & Inflammat Program, Frederick, MD 21702 USA.
EM carringm@mail.nih.gov
RI Del Prete, Gregory/C-2030-2012; Moffett, Ashley/J-9754-2013; SHCS, int.
coll. A/G-4083-2011; Fellay, Jacques/A-6681-2009; SHCS, all/G-4072-2011;
OI Fellay, Jacques/0000-0002-8240-939X; Denny, Thomas/0000-0002-7364-8276;
Wolinsky, Steven/0000-0002-9625-6697; Moody, Tony/0000-0002-3890-5855;
Brumme, Chanson/0000-0003-2722-5288
FU National Institutes of Health (NIH) [HHSN261200800001E, N02-CP-55504,
RO1-AI046995, R01-DA04334, R01-DA12568, R01-AI060460]; Bill & Melinda
Gates Foundation [38599]; Mark and Lisa Schwartz Foundation; Wellcome
Trust; NIH National Institute of Allergy and Infectious Diseases (NIAID)
Center for HIV/AIDS Vaccine Immunology [U01-AI-067854]; Australian
National Health and Medical Research Council [384702]; National
Institutes of Health [K08AR057763, R01-DA-04334, R01-DA-12568]; Creative
and Novel Ideas in HIV Research Program [P30 AI027767-24]; Swiss
National Science Foundation [33CSC0-108787]; NIAID; National Cancer
Institute; National Heart, Lung, and Blood Institute [UO1-AI-35042,
5-MO1-RR-00722 (GCRC), UO1-AI-35043, UO1-AI-37984, UO1-AI-35039,
UO1-AI-35040, UO1-AI-37613, UO1-AI-35041]; [RO1 AI087145];
[K24AI069994]; [P30 AI027763]; [UL1 RR024131]; [P30 MH62246]; [R24
AI067039]
FX This study makes use of data generated by the Wellcome Trust Case
Control Consortium (WTCCC); a full list of investigators who contributed
to the generation of this data is available at www.wtccc.org.uk. The
data reported in this paper are tabulated in the main paper and
supplementary materials. Data and materials will be shared subject to
institutional review board (IRB) provisions regarding patient privacy.
Please contact the corresponding author. Those interested in obtaining
Center for HIV/AIDS Vaccine Immunology (CHAVI) samples used in this
study should contact M. C. and M. A. M. A Simple Letter Agreement for
the Transfer of Materials will be executed between the institutions
involved, and an IRB approval/exemption should be obtained by the
recipient institution when appropriate. Clinical specimens from the
Multicenter AIDS Cohort Study (MACS) are subject to the terms and
conditions of the MACS Master Material Transfer Agreement for Non-Profit
Institutions. The project has been funded in part with federal funds
from the National Institutes of Health (NIH) under contracts
HHSN261200800001E, N02-CP-55504, RO1-AI046995, R01-DA04334, R01-DA12568,
and R01-AI060460. The content of this publication does not necessarily
reflect the views or policies of the Department of Health and Human
Services or the Department of Defense, nor does mention of trade names,
commercial products, or organizations imply endorsement by the U. S.
Government. This research was supported in part by grants from the Bill
& Melinda Gates Foundation as part of the Collaboration for AIDS Vaccine
Discovery and grant ID38599, the Mark and Lisa Schwartz Foundation, the
Wellcome Trust, the NIH National Institute of Allergy and Infectious
Diseases (NIAID) Center for HIV/AIDS Vaccine Immunology (U01-AI-067854),
and the Australian National Health and Medical Research Council (Program
Grant 384702). Further funding was from the National Institutes of
Health grant K08AR057763 and the Creative and Novel Ideas in HIV
Research Program through a supplement to the University of Alabama at
the Birmingham Center For AIDS Research funding (P30 AI027767-24), made
possible by collaborative efforts of the Office of AIDS Research, NIAID,
and the International AIDS Society. We thank M. Trubey and A. Lara for
cytometry assistance and all the patients and investigators contributing
to samples studied in the WTCCC, CHAVI, Multicenter Hemophilia Cohort
Study, San Francisco City Clinic Cohort, Massachusetts General Hospital
Controller Cohort, United States Military HIV Natural History Study, DC
Gay Cohort Study, British Columbia HOMER cohort, Western Australian HIV
Cohort Study, US AIDS Clinical Trials Group, Durban, AIDS Linked to
Intravenous Experience (supported by National Institutes of Health
grants R01-DA-04334 and R01-DA-12568), Swiss HIV Cohort Study (supported
by the Swiss National Science Foundation grant number 33CSC0-108787),
Study on the Consequences of Protease Inhibitor Era (supported by grants
RO1 AI087145, K24AI069994, P30 AI027763, UL1 RR024131, P30 MH62246, and
R24 AI067039), and MACS cohorts (funded by NIAID, with supplemental
funding from the National Cancer Institute and the National Heart, Lung,
and Blood Institute [grants UO1-AI-35042, 5-MO1-RR-00722 (GCRC),
UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613,
and UO1-AI-35041].
NR 25
TC 117
Z9 118
U1 2
U2 51
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD APR 5
PY 2013
VL 340
IS 6128
BP 87
EP 91
DI 10.1126/science.1232685
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 118XS
UT WOS:000317061100052
PM 23559252
ER
PT J
AU Ding, QR
Regan, SN
Xia, YL
Oostrom, LA
Cowan, CA
Musunuru, K
AF Ding, Qiurong
Regan, Stephanie N.
Xia, Yulei
Oostrom, Leonie A.
Cowan, Chad A.
Musunuru, Kiran
TI Enhanced Efficiency of Human Pluripotent Stem Cell Genome Editing
through Replacing TALENs with CRISPRs
SO CELL STEM CELL
LA English
DT Letter
C1 [Ding, Qiurong; Regan, Stephanie N.; Xia, Yulei; Oostrom, Leonie A.; Cowan, Chad A.; Musunuru, Kiran] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Ding, Qiurong; Regan, Stephanie N.; Xia, Yulei; Oostrom, Leonie A.; Cowan, Chad A.; Musunuru, Kiran] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Cowan, Chad A.; Musunuru, Kiran] Broad Inst, Cambridge, MA 02142 USA.
[Cowan, Chad A.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Musunuru, Kiran] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA.
RP Musunuru, K (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
EM kiranmusunuru@gmail.com
FU NHLBI NIH HHS [R00-HL098364, R00 HL098364, R01 HL118744, R01-HL118744,
U01 HL107440]; NIDDK NIH HHS [R01 DK095384, R01 DK097768, R01-DK097768]
NR 7
TC 168
Z9 200
U1 3
U2 55
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD APR 4
PY 2013
VL 12
IS 4
BP 393
EP 394
DI 10.1016/j.stem.2013.03.006
PG 2
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VD
UT WOS:000329569500006
PM 23561441
ER
PT J
AU Beerman, I
Bock, C
Garrison, BS
Smith, ZD
Gu, HC
Meissner, A
Rossi, DJ
AF Beerman, Isabel
Bock, Christoph
Garrison, Brian S.
Smith, Zachary D.
Gu, Hongcang
Meissner, Alexander
Rossi, Derrick J.
TI Proliferation-Dependent Alterations of the DNA Methylation Landscape
Underlie Hematopoietic Stem Cell Aging
SO CELL STEM CELL
LA English
DT Article
ID SELF-RENEWAL CAPACITY; IN-VIVO; AGE; DIFFERENTIATION; TRANSPLANTATION;
DAMAGE; TRANSCRIPTION; COMMITMENT; FREQUENCY; EXPANSION
AB The functional potential of hematopoietic stem cells (HSCs) declines during aging, and in doing so, significantly contributes to hematopoietic pathophysiology in the elderly. To explore the relationship between age-associated HSC decline and the epigenome, we examined global DNA methylation of HSCs during ontogeny in combination with functional analysis. Although the DNA methylome is generally stable during aging, site-specific alterations of DNA methylation occur at genomic regions associated with hematopoietic lineage potential and selectively target genes expressed in downstream progenitor and effector cells. We found that age-associated HSC decline, replicative limits, and DNA methylation are largely dependent on the proliferative history of HSCs, yet appear to be telomere-length independent. Physiological aging and experimentally enforced proliferation of HSCs both led to DNA hypermethylation of genes regulated by Polycomb Repressive Complex 2. Our results provide evidence that epigenomic alterations of the DNA methylation landscape contribute to the functional decline of HSCs during aging.
C1 [Beerman, Isabel; Garrison, Brian S.; Rossi, Derrick J.] Boston Childrens Hosp, Div Hematol Oncol, Program Cellular & Mol Med, Boston, MA 02116 USA.
[Beerman, Isabel; Garrison, Brian S.; Rossi, Derrick J.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Beerman, Isabel; Bock, Christoph; Garrison, Brian S.; Smith, Zachary D.; Meissner, Alexander; Rossi, Derrick J.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Bock, Christoph; Smith, Zachary D.; Gu, Hongcang; Meissner, Alexander] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Meissner, Alexander; Rossi, Derrick J.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
RP Meissner, A (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
EM alexander_meissner@harvard.edu; derrick.rossi@childrens.harvard.edu
RI Bock, Christoph/B-6723-2008
OI Bock, Christoph/0000-0001-6091-3088
FU Harvard Stem Cell Institute; Pew Charitable Trusts
FX We would like to thank A. Zguro, R. Gazit, L. Fang, and M. Ziller for
technical assistance; P. Mandal for helpful discussions; and E. Beerman
for editorial help. This work was supported by a grant from the Harvard
Stem Cell Institute. A. M. is supported by the Pew Charitable Trusts.
D.J.R. and A. M. are New York Stem Cell Foundation, Robertson
Investigators.
NR 60
TC 126
Z9 130
U1 4
U2 23
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD APR 4
PY 2013
VL 12
IS 4
BP 413
EP 425
DI 10.1016/j.stem.2013.01.017
PG 13
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VD
UT WOS:000329569500009
PM 23415915
ER
PT J
AU Huertas-Vazquez, A
Nelson, CP
Guo, XQ
Reinier, K
Uy-Evanado, A
Teodorescu, C
Ayala, J
Jerger, K
Chugh, H
Braund, PS
Deloukas, P
Hall, AS
Balmforth, AJ
Jones, M
Taylor, KD
Pulit, SL
Newton-Cheh, C
Gunson, K
Jui, J
Rotter, JI
Albert, CM
Samani, NJ
Chugh, SS
AF Huertas-Vazquez, Adriana
Nelson, Christopher P.
Guo, Xiuqing
Reinier, Kyndaron
Uy-Evanado, Audrey
Teodorescu, Carmen
Ayala, Jo
Jerger, Katherine
Chugh, Harpriya
Braund, Peter S.
Deloukas, Panos
Hall, Alistair S.
Balmforth, Anthony J.
Jones, Michelle
Taylor, Kent D.
Pulit, Sara L.
Newton-Cheh, Christopher
Gunson, Karen
Jui, Jonathan
Rotter, Jerome I.
Albert, Christine M.
Samani, Nilesh J.
Chugh, Sumeet S.
CA WTCCC
TI Novel Loci Associated with Increased Risk of Sudden Cardiac Death in the
Context of Coronary Artery Disease
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; ACUTE MYOCARDIAL-INFARCTION; COMMON VARIANTS;
UNEXPECTED DEATH; SUSCEPTIBILITY LOCI; BINDING PROTEIN; HEART-DISEASE;
QRS DURATION; PR INTERVAL; POPULATION
AB Background: Recent genome-wide association studies (GWAS) have identified novel loci associated with sudden cardiac death (SCD). Despite this progress, identified DNA variants account for a relatively small portion of overall SCD risk, suggesting that additional loci contributing to SCD susceptibility await discovery. The objective of this study was to identify novel DNA variation associated with SCD in the context of coronary artery disease (CAD).
Methods and Findings: Using the MetaboChip custom array we conducted a case-control association analysis of 119,117 SNPs in 948 SCD cases (with underlying CAD) from the Oregon Sudden Unexpected Death Study (Oregon-SUDS) and 3,050 controls with CAD from the Wellcome Trust Case-Control Consortium (WTCCC). Two newly identified loci were significantly associated with increased risk of SCD after correction for multiple comparisons at: rs6730157 in the RAB3GAP1 gene on chromosome 2 (P = 4.93 x 10(-12), OR = 1.60) and rs2077316 in the ZNF365 gene on chromosome 10 (P = 3.64 x 10(-8), OR = 2.41).
Conclusions: Our findings suggest that RAB3GAP1 and ZNF365 are relevant candidate genes for SCD and will contribute to the mechanistic understanding of SCD susceptibility.
C1 [Huertas-Vazquez, Adriana; Reinier, Kyndaron; Uy-Evanado, Audrey; Teodorescu, Carmen; Ayala, Jo; Jerger, Katherine; Chugh, Harpriya; Chugh, Sumeet S.] Cedars Sinai Med Ctr, Inst Heart, Los Angeles, CA 90048 USA.
[Nelson, Christopher P.; Braund, Peter S.; Samani, Nilesh J.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England.
[Nelson, Christopher P.; Samani, Nilesh J.] Glenfield Hosp, NIHR Leicester Cardiovasc Biomed Res Unit Cardiov, Leicester, Leics, England.
[Guo, Xiuqing; Taylor, Kent D.; Rotter, Jerome I.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
[Deloukas, Panos] Wellcome Trust Sanger Inst, Hinxton, England.
[Hall, Alistair S.; Balmforth, Anthony J.] Univ Leeds, Dept Clin Cardiol, Leeds, W Yorkshire, England.
[Jones, Michelle] Cedars Sinai Med Ctr, Dept Med, Div Endocrinol & Metab, Los Angeles, CA 90048 USA.
[Pulit, Sara L.; Newton-Cheh, Christopher] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Gunson, Karen] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Jui, Jonathan] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Albert, Christine M.] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp,Div Prevent Med,Ctr Arrhyth, Boston, MA USA.
RP Samani, NJ (reprint author), Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England.
EM njs@le.ac.uk; sumeet.chugh@cshs.org
RI Deloukas, Panos/B-2922-2013; Breen, Gerome/A-5540-2010;
OI Hattersley, Andrew/0000-0001-5620-473X; Newman,
William/0000-0002-6382-4678; Deloukas, Panos/0000-0001-9251-070X; Breen,
Gerome/0000-0003-2053-1792; Maller, Julian/0000-0002-1565-9559; Hocking,
Lynne J/0000-0002-2414-2826; Wain, Louise/0000-0003-4951-1867; Burren,
Oliver/0000-0002-3388-5760; Lango Allen, Hana/0000-0002-7803-8688;
Zeggini, Eleftheria/0000-0003-4238-659X; Eyre,
Stephen/0000-0002-1251-6974; Ouwehand, Willem/0000-0002-7744-1790
FU British Heart Foundation (BHF); British Cardiovascular Society
FX The Oregon Sudden Unexpected Death Study acknowledges the significant
contribution of American Medical Response and the Portland/Gresham fire
departments. SSC holds the Pauline and Harold Price Chair in Cardiac
Electrophysiology at the Cedars-Sinai Heart Institute. Recruitment of
the British Heart Foundation Heart Family Heart Study was funded by the
British Heart Foundation (BHF) and the PRAMIS Study by the British
Cardiovascular Society. NJS holds a Chair funded by the BHF and is a UK
National Institute for Health Research (NIHR) Senior Investigator. This
work falls under the portfolio of research conducted within the NIHR
Leicester Cardiovascular Biomedical Research Unit. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 39
TC 14
Z9 14
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2013
VL 8
IS 4
AR e59905
DI 10.1371/journal.pone.0059905
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RK
UT WOS:000319108100011
PM 23593153
ER
PT J
AU Chekaluk, Y
Wu, CL
Rosenberg, J
Riester, M
Dai, QS
Lin, S
Guo, YA
McDougal, WS
Kwiatkowski, DJ
AF Chekaluk, Yvonne
Wu, Chin-Lee
Rosenberg, Jonathan
Riester, Markus
Dai, Qishan
Lin, Sharron
Guo, Yanan
McDougal, W. Scott
Kwiatkowski, David J.
TI Identification of Nine Genomic Regions of Amplification in Urothelial
Carcinoma, Correlation with Stage, and Potential Prognostic and
Therapeutic Value
SO PLOS ONE
LA English
DT Article
ID COPY NUMBER ALTERATIONS; TRANSITIONAL-CELL CARCINOMA; PAPILLARY
BLADDER-CANCER; CHROMOSOMAL-ABERRATIONS; GENETIC ALTERATIONS;
HYBRIDIZATION; MUTATIONS; FREQUENT; TUMORS; TARGET
AB We performed a genome wide analysis of 164 urothelial carcinoma samples and 27 bladder cancer cell lines to identify copy number changes associated with disease characteristics, and examined the association of amplification events with stage and grade of disease. Multiplex inversion probe (MIP) analysis, a recently developed genomic technique, was used to study 80 urothelial carcinomas to identify mutations and copy number changes. Selected amplification events were then analyzed in a validation cohort of 84 bladder cancers by multiplex ligation-dependent probe assay (MLPA). In the MIP analysis, 44 regions of significant copy number change were identified using GISTIC. Nine gene-containing regions of amplification were selected for validation in the second cohort by MLPA. Amplification events at these 9 genomic regions were found to correlate strongly with stage, being seen in only 2 of 23 (9%) Ta grade 1 or 1-2 cancers, in contrast to 31 of 61 (51%) Ta grade 3 and T2 grade 2 cancers, p<0.001. These observations suggest that analysis of genomic amplification of these 9 regions might help distinguish non-invasive from invasive urothelial carcinoma, although further study is required. Both MIP and MLPA methods perform well on formalin-fixed paraffin-embedded DNA, enhancing their potential clinical use. Furthermore several of the amplified genes identified here (ERBB2, MDM2, CCND1) are potential therapeutic targets.
C1 [Chekaluk, Yvonne; Guo, Yanan; Kwiatkowski, David J.] Brigham & Womens Hosp, Div Translat Med, Boston, MA 02115 USA.
[Wu, Chin-Lee; Lin, Sharron; Guo, Yanan] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Rosenberg, Jonathan] Mem Sloan Kettering Canc Ctr, Div Genitourinary Oncol, York, NY USA.
[Riester, Markus] Harvard Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA USA.
[Riester, Markus] Harvard Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[McDougal, W. Scott] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
RP McDougal, WS (reprint author), Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
EM WMCDOUGAL@PARTNERS.ORG; dk@rics.bwh.harvard.edu
OI Rosenberg, Jonathan/0000-0003-2637-4249; Riester,
Markus/0000-0002-4759-8332
FU National Institutes of Health (NIH), National Cancer Institute (NCI)
[1P01CA120964]
FX This work was supported by National Institutes of Health (NIH), National
Cancer Institute (NCI) 1P01CA120964. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 48
TC 14
Z9 14
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2013
VL 8
IS 4
AR e60927
DI 10.1371/journal.pone.0060927
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RK
UT WOS:000319108100069
PM 23593348
ER
PT J
AU D'Addio, F
Ueno, T
Clarkson, M
Zhu, BG
Vergani, A
Freeman, GJ
Sayegh, MH
Ansari, MJI
Fiorina, P
Habicht, A
AF D'Addio, Francesca
Ueno, Takuya
Clarkson, Michael
Zhu, Baogong
Vergani, Andrea
Freeman, Gordon J.
Sayegh, Mohamed H.
Ansari, Mohammed Javeed I.
Fiorina, Paolo
Habicht, Antje
TI CD160Ig Fusion Protein Targets a Novel Costimulatory Pathway and
Prolongs Allograft Survival
SO PLOS ONE
LA English
DT Article
ID CD8(+) T-CELLS; MHC CLASS-I; HERPESVIRUS ENTRY MEDIATOR; CHRONIC
VIRAL-INFECTION; CARDIAC ALLOGRAFTS; CUTTING EDGE; NK CELLS;
TRANSPLANTATION TOLERANCE; CD28-DEFICIENT MICE; SUPPRESSOR-CELLS
AB CD160 is a cell surface molecule expressed by most NK cells and approximately 50% of CD8(+) cytotoxic T lymphocytes. Engagement of CD160 by MHC class-I directly triggers a costimulatory signal to TCR-induced proliferation, cytokine production and cytotoxic effector functions. The role of CD160 in alloimmunity is unknown. Using a newly generated CD160 fusion protein (CD160Ig) we examined the role of the novel costimulatory molecule CD160 in mediating CD4(+) or CD8(+) T cell driven allograft rejection. CD160Ig inhibits alloreactive CD8(+) T cell proliferation and IFN-gamma production in vitro, in particular in the absence of CD28 costimulation. Consequently CD160Ig prolongs fully mismatched cardiac allograft survival in CD4(-/-), C28(-/-) knockout and CTLA4Ig treated WT recipients, but not in WT or CD8(-/-) knockout recipients. The prolonged cardiac allograft survival is associated with reduced alloreactive CD8(+) T cell proliferation, effector/memory responses and alloreactive IFN-gamma production. Thus, CD160 signaling is particularly important in CD28-independent effector/memory CD8(+) alloreactive T cell activation in vivo and therefore may serve as a novel target for prevention of allograft rejection.
C1 [D'Addio, Francesca; Ueno, Takuya; Clarkson, Michael; Vergani, Andrea; Sayegh, Mohamed H.; Ansari, Mohammed Javeed I.; Fiorina, Paolo; Habicht, Antje] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal,Transplantat Res Ctr, Boston, MA 02115 USA.
[D'Addio, Francesca; Ueno, Takuya; Clarkson, Michael; Vergani, Andrea; Sayegh, Mohamed H.; Ansari, Mohammed Javeed I.; Fiorina, Paolo; Habicht, Antje] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA.
[D'Addio, Francesca; Fiorina, Paolo] Ist Sci San Raffaele, Transplantat & Internal Med Div, I-20132 Milan, Italy.
[Clarkson, Michael] Cork Univ Hosp, Dept Renal Med, Cork, Ireland.
[Zhu, Baogong; Freeman, Gordon J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Habicht, Antje] Univ Hosp, Transplant Ctr Munich LMU, Munich, Germany.
RP Habicht, A (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Renal,Transplantat Res Ctr, Boston, MA 02115 USA.
EM antje.habicht@med.uni-muenchen.de
RI D'Addio, Francesca/F-3417-2017
OI D'Addio, Francesca/0000-0002-0345-0694
FU National Kidney Foundation; AST-Wyeth Basic Science Faculty; National
Institutes of Health [K08 AI080836-01]; ERA-EDTA; SISQT-Biotest
Fellowship; ISSNAF-Fondazione Marche fellowship grant; [AI56299];
[AI1051559]
FX AH was supported by a National Kidney Foundation fellowship grant, MJA
was supported by an AST-Wyeth Basic Science Faculty development grant
and a National Institutes of Health grant K08 AI080836-01. MHS and GJF
were supported by AI56299 and AI1051559. FD was supported by the
ERA-EDTA and the SISQT-Biotest Fellowship, and she is the recipient of
ISSNAF-Fondazione Marche fellowship grant. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 51
TC 9
Z9 9
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2013
VL 8
IS 4
AR e60391
DI 10.1371/journal.pone.0060391
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RK
UT WOS:000319108100037
PM 23593209
ER
PT J
AU Elman, I
Gurvits, TV
Tschibelu, E
Spring, JD
Lasko, NB
Pitman, RK
AF Elman, Igor
Gurvits, Tamara V.
Tschibelu, Evelyne
Spring, Justin D.
Lasko, Natasha B.
Pitman, Roger K.
TI Neurological Soft Signs in Individuals with Pathological Gambling
SO PLOS ONE
LA English
DT Article
ID OBSESSIVE-COMPULSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; IMPULSE
CONTROL DISORDERS; AUTONOMIC AROUSAL; COCAINE USE; CARDIOVASCULAR
COMPLICATIONS; SCHIZOPHRENIC-PATIENTS; PROBLEM GAMBLERS; DRUG-ABUSE;
HEART-RATE
AB Increased neurological soft signs (NSSs) have been found in a number of neuropsychiatric syndromes, including chemical addiction. The present study examined NSSs related to perceptual-motor and visuospatial processing in a behavioral addiction viz., pathological gambling (PG). As compared to mentally healthy individuals, pathological gamblers displayed significantly poorer ability to copy two- and three-dimensional figures, to recognize objects against a background noise, and to orient in space on a road-map test. Results indicated that PG is associated with subtle cerebral cortical abnormalities. Further prospective clinical research is needed to address the NSSs' origin and chronology (e. g., predate or follow the development of PG) as well as their response to therapeutic interventions and/or their ability to predict such a response.
C1 [Elman, Igor] Harvard Univ, Sch Med, Providence VA Med Ctr, Cambridge, MA 02138 USA.
[Elman, Igor; Tschibelu, Evelyne] Harvard Univ, Sch Med, Cambridge Hlth Alliance, Cambridge, MA 02138 USA.
[Gurvits, Tamara V.; Spring, Justin D.; Lasko, Natasha B.; Pitman, Roger K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA.
RP Elman, I (reprint author), Harvard Univ, Sch Med, Providence VA Med Ctr, Cambridge, MA 02138 USA.
EM ielman@cha.harvard.edu
FU National Institute on Drug Abuse [017959]
FX This work was supported by grant DA #017959 (to IE) from the National
Institute on Drug Abuse. This study was also supported with resources
and the use of facilities at the Providence VA Medical Center. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 110
TC 3
Z9 3
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2013
VL 8
IS 4
AR UNSP e60885
DI 10.1371/journal.pone.0060885
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RK
UT WOS:000319108100067
PM 23593341
ER
PT J
AU LeBlanc, MA
Fairn, GD
Russo, SB
Czyz, O
Zaremberg, V
Cowart, LA
McMaster, CR
AF LeBlanc, Marissa A.
Fairn, Gregory D.
Russo, Sarah B.
Czyz, Ola
Zaremberg, Vanina
Cowart, L. Ashley
McMaster, Christopher R.
TI The Yeast Oxysterol Binding Protein Kes1 Maintains Sphingolipid Levels
SO PLOS ONE
LA English
DT Article
ID PLASMA-MEMBRANE ATPASE; SACCHAROMYCES-CEREVISIAE; STEROL MOVEMENT;
TRAFFICKING; PATHWAYS; CELL; ER; PHOSPHATIDYLINOSITOL; HOMEOSTASIS;
METABOLISM
AB The oxysterol binding protein family are amphitropic proteins that bind oxysterols, sterols, and possibly phosphoinositides, in a conserved binding pocket. The Saccharomyces cerevisiae oxysterol binding protein family member Kes1 (also known as Osh4) also binds phosphoinositides on a distinct surface of the protein from the conserved binding pocket. In this study, we determine that the oxysterol binding protein family member Kes1 is required to maintain the ratio of complex sphingolipids and levels of ceramide, sphingosine-phosphate and sphingosine. This inability to maintain normal sphingolipid homeostasis resulted in misdistribution of Pma1, a protein that requires normal sphingolipid synthesis to occur to partition into membrane rafts at the Golgi for its trafficking to the plasma membrane.
C1 [LeBlanc, Marissa A.] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada.
[Fairn, Gregory D.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada.
[Russo, Sarah B.; Cowart, L. Ashley] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Czyz, Ola; Zaremberg, Vanina] Univ Calgary, Dept Biol, Calgary, AB T2N 1N4, Canada.
[Cowart, L. Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[McMaster, Christopher R.] Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 4H7, Canada.
RP McMaster, CR (reprint author), Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 4H7, Canada.
EM christopher.mcmaster@dal.ca
FU CIHR; NIH; VA; NSERC
FX This work was supported by CIHR (http://www.cihr-irsc.gc.ca/e/193.html),
NIH (http://www.nih.gov/), VA (http://www.research.va.gov/funding/), and
NSERC (http://www.nserc-crsng.gc.ca/). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 24
TC 4
Z9 5
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2013
VL 8
IS 4
AR e60485
DI 10.1371/journal.pone.0060485
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RK
UT WOS:000319108100047
PM 23593226
ER
PT J
AU Moy, ML
Teylan, M
Weston, NA
Gagnon, DR
Garshick, E
AF Moy, Marilyn L.
Teylan, Merilee
Weston, Nicole A.
Gagnon, David R.
Garshick, Eric
TI Daily Step Count Predicts Acute Exacerbations in a US Cohort with COPD
SO PLOS ONE
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; 6-MINUTE WALK DISTANCE; MINIMAL IMPORTANT
DIFFERENCE; PHYSICAL-ACTIVITY; FUNCTIONAL STATUS; HEALTH-STATUS;
LUNG-DISEASE; RISK-FACTORS; HOSPITALIZATION; POPULATION
AB Background: COPD is characterized by variability in exercise capacity and physical activity (PA), and acute exacerbations (AEs). Little is known about the relationship between daily step count, a direct measure of PA, and the risk of AEs, including hospitalizations.
Methods: In an observational cohort study of 169 persons with COPD, we directly assessed PA with the StepWatch Activity Monitor, an ankle-worn accelerometer that measures daily step count. We also assessed exercise capacity with the 6-minute walk test (6MWT) and patient-reported PA with the St. George's Respiratory Questionnaire Activity Score (SGRQ-AS). AEs and COPD-related hospitalizations were assessed and validated prospectively over a median of 16 months.
Results: Mean daily step count was 5804 +/- 3141 steps. Over 209 person-years of observation, there were 263 AEs (incidence rate 1.3 +/- 1.6 per person-year) and 116 COPD-related hospitalizations (incidence rate 0.56 +/- 1.09 per person-year). Adjusting for FEV1 % predicted and prednisone use for AE in previous year, for each 1000 fewer steps per day walked at baseline, there was an increased rate of AEs (rate ratio 1.07; 95%CI = 1.003-1.15) and COPD-related hospitalizations (rate ratio 1.24; 95%CI = 1.08-1.42). There was a significant linear trend of decreasing daily step count by quartiles and increasing rate ratios for AEs (P = 0.008) and COPD-related hospitalizations (P = 0.003). Each 30-meter decrease in 6MWT distance was associated with an increased rate ratio of 1.07 (95%CI = 1.01-1.14) for AEs and 1.18 (95%CI = 1.07-1.30) for COPD-related hospitalizations. Worsening of SGRQ-AS by 4 points was associated with an increased rate ratio of 1.05 (95%CI = 1.01-1.09) for AEs and 1.10 (95%CI = 1.02-1.17) for COPD-related hospitalizations.
Conclusions: Lower daily step count, lower 6MWT distance, and worse SGRQ-AS predict future AEs and COPD-related hospitalizations, independent of pulmonary function and previous AE history. These results support the importance of assessing PA in patients with COPD, and provide the rationale to promote PA as part of exacerbation-prevention strategies.
C1 [Moy, Marilyn L.; Garshick, Eric] Vet Hlth Adm, Rehabil Res & Dev Serv, Dept Veteran Affairs, Washington, DC USA.
[Moy, Marilyn L.; Teylan, Merilee; Weston, Nicole A.; Garshick, Eric] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Boston, MA USA.
[Moy, Marilyn L.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
[Garshick, Eric] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Moy, Marilyn L.; Garshick, Eric] Harvard Univ, Sch Med, Boston, MA USA.
[Gagnon, David R.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Gagnon, David R.] VA Cooperat Studies, Boston, MA USA.
RP Moy, ML (reprint author), Vet Hlth Adm, Rehabil Res & Dev Serv, Dept Veteran Affairs, Washington, DC USA.
EM marilyn.moy@va.gov
OI Gagnon, David/0000-0002-6367-3179
FU Department of Veteran Affairs, Veterans Health Administration,
Rehabilitation Research; Development Service through a VA Career
Development Award; CIMIT: Center for Integration of Medicine and
Innovative Technology; VA Rehabilitation Research and Development Merit
Review [B6618R]
FX The research reported here was supported by the Department of Veteran
Affairs, Veterans Health Administration, Rehabilitation Research and
Development Service through a VA Career Development Award to Dr. Moy.
Supported in part by CIMIT: Center for Integration of Medicine and
Innovative Technology (Dr. Moy). Supported in part by VA Rehabilitation
Research and Development Merit Review Grant B6618R (Dr. Garshick). This
study was initiated by the investigators. The results of the present
study do not constitute endorsement of the StepWatch Activity Monitor by
the authors. Orthocare Innovations had no involvement in the study
design, the collection, analysis, and interpretation of data, in the
writing of the manuscript, or in the decision to submit the paper for
publication. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 51
TC 24
Z9 24
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2013
VL 8
IS 4
AR e60400
DI 10.1371/journal.pone.0060400
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RK
UT WOS:000319108100038
PM 23593211
ER
PT J
AU Yeh, WL
Shioda, K
Coser, KR
Rivizzigno, D
McSweeney, KR
Shioda, T
AF Yeh, Wei-Lan
Shioda, Keiko
Coser, Kathryn R.
Rivizzigno, Danielle
McSweeney, Kristen R.
Shioda, Toshi
TI Fulvestrant-Induced Cell Death and Proteasomal Degradation of Estrogen
Receptor alpha Protein in MCF-7 Cells Require the CSK c-Src Tyrosine
Kinase
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER CELLS; E-SCREEN ASSAY; ER-ALPHA; ENDOCRINE THERAPY; DYNEIN
LIGHT-CHAIN-1; MEDIATED DEGRADATION; POSTMENOPAUSAL WOMEN;
STEROID-RECEPTORS; PROSTATE-CANCER; GENE-EXPRESSION
AB Fulvestrant is a representative pure antiestrogen and a Selective Estrogen Receptor Down-regulator (SERD). In contrast to the Selective Estrogen Receptor Modulators (SERMs) such as 4-hydroxytamoxifen that bind to estrogen receptor alpha (ER alpha) as antagonists or partial agonists, fulvestrant causes proteasomal degradation of ERa protein, shutting down the estrogen signaling to induce proliferation arrest and apoptosis of estrogen-dependent breast cancer cells. We performed genome-wide RNAi knockdown screenings for protein kinases required for fulvestrant-induced apoptosis of the MCF-7 estrogendependent human breast caner cells and identified the c-Src tyrosine kinase (CSK), a negative regulator of the oncoprotein c-Src and related protein tyrosine kinases, as one of the necessary molecules. Whereas RNAi knockdown of CSK in MCF-7 cells by shRNA-expressing lentiviruses strongly suppressed fulvestrant-induced cell death, CSK knockdown did not affect cytocidal actions of 4-hydroxytamoxifen or paclitaxel, a chemotherapeutic agent. In the absence of CSK, fulvestrant-induced proteasomal degradation of ER alpha protein was suppressed in both MCF-7 and T47D estrogen-dependent breast cancer cells whereas the TP53-mutated T47D cells were resistant to the cytocidal action of fulvestrant in the presence or absence of CSK. MCF-7 cell sensitivities to fulvestrant-induced cell death or ERa protein degradation was not affected by small-molecular-weight inhibitors of the tyrosine kinase activity of c-Src, suggesting possible involvement of other signaling molecules in CSK-dependent MCF-7 cell death induced by fulvestrant. Our observations suggest the importance of CSK in the determination of cellular sensitivity to the cytocidal action of fulvestrant.
C1 [Shioda, Toshi] Massachusetts Gen Hosp, Ctr Canc, Ctr Canc Res, Charlestown, MA USA.
Harvard Univ, Sch Med, Charlestown, MA USA.
RP Shioda, T (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Canc Res, Charlestown, MA USA.
EM tshioda@partners.org
FU Susan G. Komen for Cure grant [FAS0703860, KG090515]; AstraZeneca
[IRUSFULV0066]
FX This research was supported by Susan G. Komen for Cure grants FAS0703860
and KG090515, and AstraZeneca Preclinical Study Support IRUSFULV0066,
awarded to T. Shioda. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 98
TC 20
Z9 21
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2013
VL 8
IS 4
AR UNSP e60889
DI 10.1371/journal.pone.0060889
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146RK
UT WOS:000319108100068
PM 23593342
ER
PT J
AU Marneros, AG
Beck, AE
Turner, EH
McMillin, MJ
Edwards, MJ
Field, M
Sobreira, NLD
Perez, ABA
Fortes, JAR
Lampe, AK
Uzielli, MLG
Gordon, CT
Plessis, G
Le Merrer, M
Amiel, J
Reichenberger, E
Shively, KM
Cerrato, F
Labow, BI
Tabor, HK
Smith, JD
Shendure, J
Nickerson, DA
Bamshad, MJ
AF Marneros, Alexander G.
Beck, Anita E.
Turner, Emily H.
McMillin, Margaret J.
Edwards, Matthew J.
Field, Michael
Sobreira, Nara Lygia de Macena
Perez, Ana Beatriz A.
Fortes, Jose A. R.
Lampe, Anne K.
Uzielli, Maria Luisa Giovannucci
Gordon, Christopher T.
Plessis, Ghislaine
Le Merrer, Martine
Amiel, Jeanne
Reichenberger, Ernst
Shively, Kathryn M.
Cerrato, Felecia
Labow, Brian I.
Tabor, Holly K.
Smith, Joshua D.
Shendure, Jay
Nickerson, Deborah A.
Bamshad, Michael J.
CA Univ Washington
TI Mutations in KCTD1 Cause Scalp-Ear-Nipple Syndrome
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID FINLAY-MARKS-SYNDROME; BTB DOMAIN; ADDITIONAL MANIFESTATIONS; FAMILY
AB Scalp-ear-nipple (SEN) syndrome is a rare, autosomal-dominant disorder characterized by cutis aplasia of the scalp; minor anomalies of the external ears, digits, and nails; and malformations of the breast. We used linkage analysis and exome sequencing of a multiplex family affected by SEN syndrome to identify potassium-channel tetramerization-domain-containing 1 (KCTD1) mutations that cause SEN syndrome. Evaluation of a total of ten families affected by SEN syndrome revealed KCTD1 missense mutations in each family tested. All of the mutations occurred in a KCTD1 region encoding a highly conserved bric-a-brac, tram track, and broad complex (BTB) domain that is required for transcriptional repressor activity. KCTD1 inhibits the transactivation of the transcription factor AP-2 alpha (TFAP2A) via its BTB domain, and mutations in TFAP2A cause cutis aplasia in individuals with branchiooculofacial syndrome (BOFS), suggesting a potential overlap in the pathogenesis of SEN syndrome and BOFS. The identification of KCTD1 mutations in SEN syndrome reveals a role for this BTB-domain-containing transcriptional repressor during ectodermal development.
C1 [Marneros, Alexander G.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
[Beck, Anita E.; McMillin, Margaret J.; Shively, Kathryn M.; Bamshad, Michael J.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
[Turner, Emily H.; Smith, Joshua D.; Shendure, Jay; Nickerson, Deborah A.; Bamshad, Michael J.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
[Edwards, Matthew J.] Univ Western Sydney Macarthur, Sch Med, Campbelltown, NSW 2560, Australia.
[Field, Michael] Genet Learning Disabil Serv, Newcastle, NSW 2298, Australia.
[Sobreira, Nara Lygia de Macena] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA.
[Perez, Ana Beatriz A.] Univ Fed Sao Paulo, Dept Morphol & Genet, Clin Genet Ctr, BR-04021001 Sao Paulo, Brazil.
[Fortes, Jose A. R.] Pontificia Univ Catolica Parana, Dept Internal Med, BR-1155 Curitiba, Parana, Brazil.
[Lampe, Anne K.] Western Gen Hosp, South East Scotland Clin Genet Serv, Edinburgh EH4 2XU, Midlothian, Scotland.
[Uzielli, Maria Luisa Giovannucci] Univ Florence, Dept Genet & Mol Med, I-50132 Florence, Italy.
[Gordon, Christopher T.] Hop Necker Enfants Malad, Dept Genet, INSERM, U781, F-75015 Paris, France.
[Gordon, Christopher T.] Univ Paris Descartes Sorbonne Paris Cite, Inst Imagine, F-75015 Paris, France.
[Plessis, Ghislaine; Le Merrer, Martine; Amiel, Jeanne] Hop Cote Nacre, CHU Caen, Serv Genet, F-14033 Caen 9, France.
[Reichenberger, Ernst] Univ Connecticut, Ctr Hlth, Dept Reconstruct Sci, Farmington, CT 06030 USA.
[Cerrato, Felecia; Labow, Brian I.] Boston Childrens Hosp, Dept Plast & Oral Surg, Boston, MA 02115 USA.
[Tabor, Holly K.] Treuman Katz Ctr Pediat Bioeth, Seattle Childrens Res Inst, Seattle, WA 98101 USA.
RP Bamshad, MJ (reprint author), Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
EM mbamshad@uw.edu
RI sebastianovitsch, stepan/G-8507-2013; Gordon, Christopher/F-1267-2017;
OI Gordon, Christopher/0000-0002-9300-8399; Turner,
Emily/0000-0001-9040-9229; Shendure, Jay/0000-0002-1516-1865
FU National Institutes of Health National Human Genome Research Institute
[1U54HG006493, 1RC2HG005608, 5RO1HG004316]; Life Sciences Discovery Fund
[2065508, 0905001]; Washington Research Foundation
FX We thank the families for their participation and support; Tracy
Dudding-Byth for clinical assistance; Kati Buckingham and Christa Poel
for technical assistance; and Jennifer E. Below for discussion. Our work
was supported in part by grants from the National Institutes of Health
National Human Genome Research Institute (1U54HG006493 to M.B., D.N.,
and J.S.; 1RC2HG005608 to M.B., D.N., and J.S.; and 5RO1HG004316 to
H.T.), the Life Sciences Discovery Fund (2065508 and 0905001), and the
Washington Research Foundation.
NR 19
TC 14
Z9 15
U1 1
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD APR 4
PY 2013
VL 92
IS 4
BP 621
EP 626
DI 10.1016/j.ajhg.2013.03.002
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 124FR
UT WOS:000317449700015
PM 23541344
ER
PT J
AU Bhatt, DL
Stone, GW
Mahaffey, KW
Gibson, CM
Steg, PG
Hamm, CW
Price, MJ
Leonardi, S
Gallup, D
Bramucci, E
Radke, PW
Widimsky, P
Tousek, F
Tauth, J
Spriggs, D
McLaurin, BT
Angiolillo, DJ
Genereux, P
Liu, TP
Prats, J
Todd, M
Skerjanec, S
White, HD
Harrington, RA
AF Bhatt, Deepak L.
Stone, Gregg W.
Mahaffey, Kenneth W.
Gibson, C. Michael
Steg, P. Gabriel
Hamm, Christian W.
Price, Matthew J.
Leonardi, Sergio
Gallup, Dianne
Bramucci, Ezio
Radke, Peter W.
Widimsky, Petr
Tousek, Frantisek
Tauth, Jeffrey
Spriggs, Douglas
McLaurin, Brent T.
Angiolillo, Dominick J.
Genereux, Philippe
Liu, Tiepu
Prats, Jayne
Todd, Meredith
Skerjanec, Simona
White, Harvey D.
Harrington, Robert A.
CA CHAMPION PHOENIX Investigators
TI Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic
Events
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ACUTE CORONARY SYNDROMES; ELEVATION MYOCARDIAL-INFARCTION; ACHIEVE
OPTIMAL MANAGEMENT; ANTIPLATELET THERAPY; CLOPIDOGREL PRETREATMENT;
CARDIOVASCULAR EVENTS; STANDARD THERAPY; CHAMPION TRIALS; INTERVENTION;
METAANALYSIS
AB BACKGROUND
The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI) is an important determinant of PCI-related ischemic complications. Cangrelor is a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts rapidly and has quickly reversible effects.
METHODS
In a double-blind, placebo-controlled trial, we randomly assigned 11,145 patients who were undergoing either urgent or elective PCI and were receiving guideline-recommended therapy to receive a bolus and infusion of cangrelor or to receive a loading dose of 600 mg or 300 mg of clopidogrel. The primary efficacy end point was a composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours after randomization; the key secondary end point was stent thrombosis at 48 hours. The primary safety end point was severe bleeding at 48 hours.
RESULTS
The rate of the primary efficacy end point was 4.7% in the cangrelor group and 5.9% in the clopidogrel group (adjusted odds ratio with cangrelor, 0.78; 95% confidence interval [CI], 0.66 to 0.93; P = 0.005). The rate of the primary safety end point was 0.16% in the cangrelor group and 0.11% in the clopidogrel group (odds ratio, 1.50; 95% CI, 0.53 to 4.22; P = 0.44). Stent thrombosis developed in 0.8% of the patients in the cangrelor group and in 1.4% in the clopidogrel group (odds ratio, 0.62; 95% CI, 0.43 to 0.90; P = 0.01). The rates of adverse events related to the study treatment were low in both groups, though transient dyspnea occurred significantly more frequently with cangrelor than with clopidogrel (1.2% vs. 0.3%). The benefit from cangrelor with respect to the primary end point was consistent across multiple prespecified subgroups.
CONCLUSIONS
Cangrelor significantly reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding. (Funded by the Medicines Company; CHAMPION PHOENIX ClinicalTrials.gov number, NCT01156571.)
C1 [Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
[Stone, Gregg W.] Columbia Univ, Med Ctr, New York, NY USA.
[Stone, Gregg W.] Cardiovasc Res Fdn, New York, NY USA.
[Mahaffey, Kenneth W.; Gallup, Dianne] Duke Clin Res Inst, Durham, NC USA.
[Gibson, C. Michael] Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA.
[Steg, P. Gabriel] Univ Paris Diderot, INSERM, U698, Paris, France.
[Steg, P. Gabriel] Hop Bichat Claude Bernard, AP HP, F-75877 Paris, France.
[Hamm, Christian W.] Kerckhoff Heart & Thorax Ctr, Bad Nauheim, Germany.
[Price, Matthew J.] Scripps Clin, La Jolla, CA 92037 USA.
[Price, Matthew J.] Scripps Translat Sci Inst, La Jolla, CA USA.
[Leonardi, Sergio; Bramucci, Ezio] Fdn IRCCS Policlin S Matteo, Pavia, Italy.
[Radke, Peter W.] Univ Klinikum Schleswig Holstein, D-23538 Lubeck, Germany.
[Widimsky, Petr] Fak Nemocnice Kralovske Vinohrady, Prague, Czech Republic.
[Tousek, Frantisek] Nemocnice Ceske Budejovice, Ceske Budejovice, Czech Republic.
[Tauth, Jeffrey] Natl Pk Med Ctr, Hot Springs, AR USA.
[Spriggs, Douglas] Clearwater Cardiovasc & Intervent Consultants, Clearwater, FL USA.
[McLaurin, Brent T.] AnMed Hlth, Anderson, SC USA.
[Angiolillo, Dominick J.] Univ Florida, Coll Med, Jacksonville, FL USA.
[Liu, Tiepu; Prats, Jayne; Todd, Meredith; Skerjanec, Simona] Med Co, Parsippany, NJ USA.
[White, Harvey D.] Green Lane Cardiovasc Serv, Auckland, New Zealand.
[Harrington, Robert A.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
RP Bhatt, DL (reprint author), VA Boston Healthcare Syst, 1400 VFW Pkwy, Boston, MA 02132 USA.
EM dlbhattmd@post.harvard.edu
RI Verheugt, F.W.A./H-8105-2014; Vasilieva, Elena/B-2137-2016; Poerner,
Tudor/L-1755-2016; Widimsky, Petr/P-8088-2016;
OI Poerner, Tudor/0000-0001-9303-6165; Widimsky, Petr/0000-0001-5686-7752;
Leonardi, Sergio/0000-0002-4800-6132; Van de Werf,
Frans/0000-0001-9479-7767; Brilakis, Emmanouil/0000-0001-9416-9701
FU Medicines Company; CHAMPION PHOENIX
FX Funded by the Medicines Company; CHAMPION PHOENIX
ClinicalTrials.govnumber, NCT01156571.)
NR 33
TC 249
Z9 261
U1 7
U2 39
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 4
PY 2013
VL 368
IS 14
BP 1303
EP 1313
DI 10.1056/NEJMoa1300815
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 117YT
UT WOS:000316989900007
PM 23473369
ER
PT J
AU Hussain, M
Tangen, CM
Berry, DL
Higano, CS
Crawford, ED
Liu, G
Wilding, G
Prescott, S
Sundaram, SK
Small, EJ
Dawson, NA
Donnelly, BJ
Venner, PM
Vaishampayan, UN
Schellhammer, PF
Quinn, DI
Raghavan, D
Ely, B
Moinpour, CM
Vogelzang, NJ
Thompson, IM
AF Hussain, Maha
Tangen, Catherine M.
Berry, Donna L.
Higano, Celestia S.
Crawford, E. David
Liu, Glenn
Wilding, George
Prescott, Stephen
Sundaram, Subramanian Kanaga
Small, Eric Jay
Dawson, Nancy Ann
Donnelly, Bryan J.
Venner, Peter M.
Vaishampayan, Ulka N.
Schellhammer, Paul F.
Quinn, David I.
Raghavan, Derek
Ely, Benjamin
Moinpour, Carol M.
Vogelzang, Nicholas J.
Thompson, Ian M., Jr.
TI Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID QUALITY-OF-LIFE; CLINICAL-TRIAL; SUPPRESSION; FLUTAMIDE; LEUPROLIDE;
CARCINOMA; THERAPY
AB Background
Castration resistance occurs in most patients with metastatic hormone-sensitive prostate cancer who are receiving androgen-deprivation therapy. Replacing androgens before progression of the disease is hypothesized to prolong androgen dependence.
Methods
Men with newly diagnosed, metastatic, hormone-sensitive prostate cancer, a performance status of 0 to 2, and a prostate-specific antigen (PSA) level of 5 ng per milliliter or higher received a luteinizing hormone-releasing hormone analogue and an antiandrogen agent for 7 months. We then randomly assigned patients in whom the PSA level fell to 4 ng per milliliter or lower to continuous or intermittent androgen deprivation, with patients stratified according to prior or no prior hormonal therapy, performance status, and extent of disease (minimal or extensive). The coprimary objectives were to assess whether intermittent therapy was noninferior to continuous therapy with respect to survival, with a one-sided test with an upper boundary of the hazard ratio of 1.20, and whether quality of life differed between the groups 3 months after randomization.
Results
A total of 3040 patients were enrolled, of whom 1535 were included in the analysis: 765 randomly assigned to continuous androgen deprivation and 770 assigned to intermittent androgen deprivation. The median follow-up period was 9.8 years. Median survival was 5.8 years in the continuous-therapy group and 5.1 years in the intermittent-therapy group (hazard ratio for death with intermittent therapy, 1.10; 90% confidence interval, 0.99 to 1.23). Intermittent therapy was associated with better erectile function and mental health (P<0.001 and P = 0.003, respectively) at month 3 but not thereafter. There were no significant differences between the groups in the number of treatment-related high-grade adverse events.
Conclusions
Our findings were statistically inconclusive. In patients with metastatic hormone-sensitive prostate cancer, the confidence interval for survival exceeded the upper boundary for noninferiority, suggesting that we cannot rule out a 20% greater risk of death with intermittent therapy than with continuous therapy, but too few events occurred to rule out significant inferiority of intermittent therapy. Intermittent therapy resulted in small improvements in quality of life. (Funded by the National Cancer Institute and others; ClinicalTrials.govnumber, NCT00002651.)
C1 [Hussain, Maha] Univ Michigan, Ann Arbor, MI 48109 USA.
[Tangen, Catherine M.; Ely, Benjamin] SW Oncol Grp, Ctr Stat, Seattle, WA USA.
[Higano, Celestia S.] Univ Washington, Seattle, WA 98195 USA.
[Berry, Donna L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Crawford, E. David] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA.
[Liu, Glenn; Wilding, George] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA.
[Prescott, Stephen] St James Univ Hosp, Leeds, W Yorkshire, England.
[Sundaram, Subramanian Kanaga] Pinderfields Gen Hosp, Mid Yorkshire Hosp, Wakefield, W Yorkshire, England.
[Small, Eric Jay] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Dawson, Nancy Ann] Georgetown Univ, Hosp Lombardi, Ctr Comprehens Canc, Washington, DC USA.
[Donnelly, Bryan J.] Prostate Canc Ctr, Calgary, AB, Canada.
[Venner, Peter M.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
[Vaishampayan, Ulka N.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
[Schellhammer, Paul F.] Urol Virginia, Norfolk, VA USA.
[Quinn, David I.] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
[Raghavan, Derek] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA.
[Moinpour, Carol M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Vogelzang, Nicholas J.] US Oncol Res, McKesson Specialty Hlth, The Woodlands, TX USA.
[Thompson, Ian M., Jr.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
[Vogelzang, Nicholas J.] Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
RP Hussain, M (reprint author), Univ Michigan, Div Hematol Oncol, 1500 E Med Ctr Dr,7314 CC, Ann Arbor, MI 48109 USA.
EM mahahuss@umich.edu
RI Quinn, David/F-4343-2015
OI Quinn, David/0000-0002-1411-0417
FU National Cancer Institute; National Cancer Institute [CA32102, CA38926,
CA14028, CA55582, CA42777, CA35192, CA46441, CA46282, CA27057, CA128567,
CA45807, CA20319, CA58416]; AstraZeneca; Fonds Cancer (FOCA) from
Belgium; National Cancer Institute. [CA46113, CA04919, CA76132, CA58861,
CA58686, CA68183, CA12644, CA35261, CA35431, CA46368, CA22433, CA63848,
CA67575, CA76447, CA67663, CA46136, CA86780, CA35281, CA63844, CA45560,
CA37981, CA11083, CA35178, CA95860, CA35176, CA21115, CA31949, CA77202,
CCSRI 015469]
FX Funded by the National Cancer Institute and others;
ClinicalTrials.govnumber, NCT00002651.; Supported in part by PHS
Cooperative Agreements awarded by the National Cancer Institute
(CA32102, CA38926, CA14028, CA55582, CA42777, CA35192, CA46441, CA46282,
CA27057, CA128567, CA45807, CA20319, CA58416, CA46113, CA04919, CA76132,
CA58861, CA58686, CA68183, CA12644, CA35261, CA35431, CA46368, CA22433,
CA63848, CA67575, CA76447, CA67663, CA46136, CA86780, CA35281, CA63844,
CA45560, CA37981, CA11083, CA35178, CA95860, CA35176, CA21115, CA31949,
CA77202, and CCSRI 015469) and in part by AstraZeneca. The contribution
of EORTC to this study was supported by Fonds Cancer (FOCA) from
Belgium.
NR 26
TC 167
Z9 176
U1 0
U2 19
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 4
PY 2013
VL 368
IS 14
BP 1314
EP 1325
DI 10.1056/NEJMoa1212299
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 117YT
UT WOS:000316989900008
PM 23550669
ER
PT J
AU Houchens, N
Dhaliwal, G
Askari, F
Kim, B
Saint, S
AF Houchens, Nathan
Dhaliwal, Gurpreet
Askari, Frederick
Kim, Benjamin
Saint, Sanjay
TI The Essential Element
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ALKALINE-PHOSPHATASE ACTIVITY; FULMINANT HEPATIC-FAILURE; ACUTE
LIVER-FAILURE; WILSONS-DISEASE; HEMOLYTIC-ANEMIA; DIAGNOSIS; UPDATE
C1 [Houchens, Nathan; Askari, Frederick; Saint, Sanjay] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
[Saint, Sanjay] Hlth Serv Res & Dev Ctr Excellence, Dept Vet Affairs VA, Ann Arbor, MI USA.
[Dhaliwal, Gurpreet; Kim, Benjamin] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Houchens, N (reprint author), Univ Michigan Hlth Syst, 3119 Taubman Ctr,1500 E Med Ctr Dr,SPC 5376, Ann Arbor, MI 48109 USA.
EM nathanho@umich.edu
FU Doximity
FX Dr. Saint reports receiving payment for board membership from and
holding stock in Doximity. No other potential conflict of interest
relevant to this article was reported.
NR 15
TC 0
Z9 0
U1 0
U2 6
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 4
PY 2013
VL 368
IS 14
BP 1345
EP 1351
DI 10.1056/NEJMcps1203173
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 117YT
UT WOS:000316989900013
PM 23550673
ER
PT J
AU Ribas, A
Hodi, FS
Callahan, M
Konto, C
Wolchok, J
AF Ribas, Antoni
Hodi, F. Stephen
Callahan, Margaret
Konto, Cyril
Wolchok, Jedd
TI Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID ANTITUMOR-ACTIVITY; IMMUNOTHERAPY; MELANOMA
C1 [Ribas, Antoni] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
[Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Callahan, Margaret; Wolchok, Jedd] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Konto, Cyril] Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
RP Ribas, A (reprint author), Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
EM wolchokj@mskcc.org
FU NCI NIH HHS [P30 CA008748]
NR 5
TC 299
Z9 304
U1 3
U2 21
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 4
PY 2013
VL 368
IS 14
BP 1365
EP 1366
DI 10.1056/NEJMc1302338
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 117YT
UT WOS:000316989900026
PM 23550685
ER
PT J
AU Son, J
Lyssiotis, CA
Ying, H
Wang, X
Hua, S
Ligorio, M
Perera, RM
Ferrone, CR
Mullarky, E
Ng, SC
Kang, Y
Fleming, JB
Bardeesy, N
Asara, JM
Haigis, MC
DePinho, RA
Cantley, LC
Kimmelman, AC
AF Son, Jaekyoung
Lyssiotis, Costas A.
Ying, Haoqiang
Wang, Xiaoxu
Hua, Sujun
Ligorio, Matteo
Perera, Rushika M.
Ferrone, Cristina R.
Mullarky, Edouard
Ng Shyh-Chang
Kang, Ya'an
Fleming, Jason B.
Bardeesy, Nabeel
Asara, John M.
Haigis, Marcia C.
DePinho, Ronald A.
Cantley, Lewis C.
Kimmelman, Alec C.
TI Glutamine supports pancreatic cancer growth through a KRAS-regulated
metabolic pathway
SO NATURE
LA English
DT Article
ID MASS-SPECTROMETRY; TRANSFORMED-CELLS; ADDICTION; GLUCOSE
AB Cancer cells have metabolic dependencies that distinguish them from their normal counterparts(1). Among these dependencies is an increased use of the amino acid glutamine to fuel anabolic processes(2). Indeed, the spectrum of glutamine-dependent tumours and the mechanisms whereby glutamine supports cancer metabolism remain areas of active investigation. Here we report the identification of a non-canonical pathway of glutamine use in human pancreatic ductal adenocarcinoma (PDAC) cells that is required for tumour growth. Whereas most cells use glutamate dehydrogenase (GLUD1) to convert glutamine-derived glutamate into alpha-ketoglutarate in the mitochondria to fuel the tricarboxylic acid cycle, PDAC relies on a distinct pathway in which glutamine-derived aspartate is transported into the cytoplasm where it can be converted into oxaloacetate by aspartate transaminase (GOT1). Subsequently, this oxaloacetate is converted into malate and then pyruvate, ostensibly increasing the NADPH/NADP(+) ratio which can potentially maintain the cellular redox state. Importantly, PDAC cells are strongly dependent on this series of reactions, as glutamine deprivation or genetic inhibition of any enzyme in this pathway leads to an increase in reactive oxygen species and a reduction in reduced glutathione. Moreover, knockdown of any component enzyme in this series of reactions also results in a pronounced suppression of PDAC growth in vitro and in vivo. Furthermore, we establish that the reprogramming of glutamine metabolism is mediated by oncogenic KRAS, the signature genetic alteration in PDAC, through the transcriptional upregulation and repression of key metabolic enzymes in this pathway. The essentiality of this pathway in PDAC and the fact that it is dispensable in normal cells may provide novel therapeutic approaches to treat these refractory tumours.
C1 [Son, Jaekyoung; Wang, Xiaoxu; Kimmelman, Alec C.] Dana Farber Canc Inst, Dept Radiat Oncol, Div Genom Stabil & DNA Repair, Boston, MA 02215 USA.
[Lyssiotis, Costas A.; Mullarky, Edouard; Ng Shyh-Chang; Cantley, Lewis C.] Harvard Univ, Dept Syst Biol, Sch Med, Boston, MA 02215 USA.
[Lyssiotis, Costas A.; Mullarky, Edouard; Cantley, Lewis C.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA.
[Ying, Haoqiang; Hua, Sujun; DePinho, Ronald A.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.
[Ligorio, Matteo; Ferrone, Cristina R.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Perera, Rushika M.; Bardeesy, Nabeel] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Ng Shyh-Chang] Childrens Hosp, Div Pediat Hematol Oncol, Stem Cell Transplantat Program, Stem Cell Program, Boston, MA 02130 USA.
[Ng Shyh-Chang] Dana Farber Canc Inst, Boston, MA 02130 USA.
[Kang, Ya'an; Fleming, Jason B.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
[Asara, John M.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Haigis, Marcia C.] Harvard Univ, Dept Cell Biol, Sch Med, Boston, MA 02215 USA.
RP Cantley, LC (reprint author), Harvard Univ, Dept Syst Biol, Sch Med, Boston, MA 02215 USA.
EM lec2014@med.cornell.edu; Alec_Kimmelman@DFCI.harvard.edu
RI Cantley, Lewis/D-1800-2014;
OI Cantley, Lewis/0000-0002-1298-7653; Shyh-Chang, Ng/0000-0003-3138-9525
FU Dana Farber Cancer Institute; National Cancer Institute [R01 CA157490];
Kimmel Scholar Award; AACR-PanCAN Career Development Award; NIH [T32
CA009382-26, P01 CA117969, 5P01CA120964-05]; Dana-Farber/Harvard Cancer
Center Support Grant [5P30CA006516-46]
FX We would like to thank D. Anastasiou for advice and helpful comments on
the manuscript; M. Yuan and S. Breitkopf for technical help with mass
spectrometry experiments; J. Erickson, R. Cerione and J. Escobedo for
the GLS inhibitors. Grant support derives from the Dana Farber Cancer
Institute (A. C. K.), National Cancer Institute Grant R01 CA157490 (A.
C. K.), Kimmel Scholar Award (A. C. K.), AACR-PanCAN Career Development
Award (A. C. K.), NIH grants T32 CA009382-26 (H.Y.) and P01 CA117969 (L.
C. C. and R. A. D.). C. A. L. is the Amgen Fellow of the Damon Runyon
Cancer Research Foundation (DRG-2056-10). NIH grants 5P01CA120964-05 and
Dana-Farber/Harvard Cancer Center Support Grant 5P30CA006516-46
(J.M.A.).
NR 25
TC 332
Z9 345
U1 24
U2 187
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD APR 4
PY 2013
VL 496
IS 7443
BP 101
EP +
DI 10.1038/nature12040
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 117ZZ
UT WOS:000316993400033
PM 23535601
ER
PT J
AU Jiang, H
Khan, S
Wang, Y
Charron, G
He, B
Sebastian, C
Du, JT
Kim, R
Ge, E
Mostoslavsky, R
Hang, HC
Hao, Q
Lin, HN
AF Jiang, Hong
Khan, Saba
Wang, Yi
Charron, Guillaume
He, Bin
Sebastian, Carlos
Du, Jintang
Kim, Ray
Ge, Eva
Mostoslavsky, Raul
Hang, Howard C.
Hao, Quan
Lin, Hening
TI SIRT6 regulates TNF-alpha secretion through hydrolysis of long-chain
fatty acyl lysine
SO NATURE
LA English
DT Article
ID HISTONE DEACETYLASE; MAMMALIAN-CELLS; PROTEIN; PRECURSOR; ACYLATION;
SIRTUINS; INSIGHTS; NAD(+); MICE
AB The Sir2 family of enzymes or sirtuins are known as nicotinamide adenine dinucleotide (NAD)-dependent deacetylases(1) and have been implicated in the regulation of transcription, genome stability, metabolism and lifespan(2,3). However, four of the seven mammalian sirtuins have very weak deacetylase activity in vitro. Here we show that human SIRT6 efficiently removes long-chain fatty acyl groups, such as myristoyl, from lysine residues. The crystal structure of SIRT6 reveals a large hydrophobic pocket that can accommodate long-chain fatty acyl groups. We demonstrate further that SIRT6 promotes the secretion of tumour necrosis factor-alpha (TNF-alpha) by removing the fatty acyl modification on K19 and K20 of TNF-alpha. Protein lysine fatty acylation has been known to occur in mammalian cells, but the function and regulatory mechanisms of this modification were unknown. Our data indicate that protein lysine fatty acylation is a novel mechanism that regulates protein secretion. The discovery of SIRT6 as an enzyme that controls protein lysine fatty acylation provides new opportunities to investigate the physiological function of a protein post-translational modification that has been little studied until now.
C1 [Jiang, Hong; Khan, Saba; He, Bin; Du, Jintang; Kim, Ray; Ge, Eva; Lin, Hening] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA.
[Wang, Yi; Hao, Quan] Univ Hong Kong, Dept Physiol, Hong Kong, Hong Kong, Peoples R China.
[Charron, Guillaume; Hang, Howard C.] Rockefeller Univ, Lab Chem Biol & Microbial Pathogenesis, New York, NY 10065 USA.
[Sebastian, Carlos; Mostoslavsky, Raul] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RP Lin, HN (reprint author), Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA.
EM qhao@hku.hk; hl379@cornell.edu
RI Hao, Quan/C-4304-2009
FU NIH [R01GM086703, R01GM093072, R01GM087544]; [GRF766510]
FX This work was supported in part by NIH R01GM086703 (H. L.), R01GM093072
(R. M.), Hong Kong GRF766510 (Q. H.) and NIH R01GM087544 (H. C. H.). We
thank C. Zhang for help with the cloning of SIRT6 WT and H133Y to
generate lentiviral particles and the staff at the Shanghai Synchrotron
Radiation Facility for assistance during the data collection.
NR 29
TC 189
Z9 198
U1 4
U2 77
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD APR 4
PY 2013
VL 496
IS 7443
BP 110
EP +
DI 10.1038/nature12038
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 117ZZ
UT WOS:000316993400035
PM 23552949
ER
PT J
AU Targum, SD
Nakagawa, A
Sato, Y
AF Targum, Steven D.
Nakagawa, Atsuo
Sato, Yuji
TI A cross-cultural comparison study of depression assessments conducted in
Japan
SO ANNALS OF GENERAL PSYCHIATRY
LA English
DT Article
DE Cross-cultural comparison; Depression ratings; Asian culture; MADRS
ID MONTGOMERY-ASBERG DEPRESSION
AB Background: The advent of global clinical trials has necessitated the use of English-based rating instruments in diverse cultures where English is clearly not the primary language. The cross-cultural applicability of rating instruments developed in one language with only one cultural group is an important issue in both research and clinical settings where these instruments might be used. We examined the cross-cultural applicability of the Montgomery-Asberg Depression Rating Scale (MADRS) in Japan.
Methods: As part of a rater-training program for a clinical trial in Japan, we assessed inter-rater agreement using two videotaped MADRS interviews administered in Japanese and produced with English subtitles. We looked for possible interpretational variance that might have been generated by cultural differences between Japanese raters in Japan and English-speaking raters in the USA scoring the same interviews.
Results: The US and Japanese raters demonstrated high inter-rater agreement and no significant scoring difference on the total MADRS score. The subtitles in English did not adversely affect the overall scoring. We separately analyzed the 10 individual items from each of the two MADRS interviews used for rater training. Of the 20 items, 18 were concordant between the US and Japanese raters. In one interview, the US raters scored lassitude significantly higher (p = 0.013) and the inability to feel significantly lower (p = 0.037) than the Japanese raters, reflecting a possible interpretational difference on these items.
Conclusion: Although developed in Europe, these findings support the general applicability of the MADRS to assess the severity of depressive symptoms in Japan. We did note significant scoring differences on 2 of the 20 individual items, suggesting a possible cultural difference. It is possible that more interviews might have revealed more interpretational differences. These findings highlight the need for cultural familiarity when assessing psychiatric patients.
C1 [Targum, Steven D.] Clintara LLC, Boston, MA 02116 USA.
[Targum, Steven D.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nakagawa, Atsuo] Keio Univ, Sch Med, Translat Med Ctr, Natl Ctr Neurol & Psychiat, Tokyo 1608582, Japan.
[Nakagawa, Atsuo] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo 1608582, Japan.
[Sato, Yuji] Keio Univ, Sch Med, Ctr Clin Res, Tokyo 1608582, Japan.
RP Targum, SD (reprint author), Clintara LLC, 505 Tremont St,907, Boston, MA 02116 USA.
EM sdtargum@yahoo.com
FU Clintara LLC.
FX The authors thank Tina Oakes (Eli Lilly and Company) and Maurizio Fava
(Massachusetts General Hospital). In addition, the staff from Keio
University (Tokyo, Japan), Clintara LLC and CTNI-Massachusetts General
Hospital who participated in the coordination of this program are also
acknowledged. Financial support for this study came from a research
grant from Clintara LLC.
NR 17
TC 1
Z9 1
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1744-859X
J9 ANN GEN PSYCHIATR
JI Ann. Gen. Psychiatr.
PD APR 3
PY 2013
VL 12
AR 9
DI 10.1186/1744-859X-12-9
PG 6
WC Psychiatry
SC Psychiatry
GA 188HD
UT WOS:000322182500001
PM 23551964
ER
PT J
AU Jiang, XJ
Castelao, JE
Vandenberg, D
Carracedo, A
Redondo, CM
Conti, DV
Cotore, JPP
Potter, JD
Newcomb, PA
Passarelli, MN
Jenkins, MA
Hopper, JL
Gallinger, S
Le Marchand, L
Martinez, ME
Ahnen, DJ
Baron, JA
Lindor, NM
Haile, RW
Gago-Dominguez, M
AF Jiang, Xuejuan
Esteban Castelao, J.
Vandenberg, David
Carracedo, Angel
Redondo, Carmen M.
Conti, David V.
Paredes Cotore, Jesus P.
Potter, John D.
Newcomb, Polly A.
Passarelli, Michael N.
Jenkins, Mark A.
Hopper, John L.
Gallinger, Steven
Le Marchand, Loic
Martinez, Maria E.
Ahnen, Dennis J.
Baron, John A.
Lindor, Noralane M.
Haile, Robert W.
Gago-Dominguez, Manuela
TI Genetic Variations in SMAD7 Are Associated with Colorectal Cancer Risk
in the Colon Cancer Family Registry
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; GROWTH-FACTOR-BETA; TGF-BETA; CANDIDATE GENES;
SUSCEPTIBILITY; EXPRESSION; VARIANTS; CELLS; 18Q21; EPIDEMIOLOGY
AB Background: Recent genome-wide studies identified a risk locus for colorectal cancer at 18q21, which maps to the SMAD7 gene. Our objective was to confirm the association between SMAD7 SNPs and colorectal cancer risk in the multi-center Colon Cancer Family Registry.
Materials and Methods: 23 tagging SNPs in the SMAD7 gene were genotyped among 1,592 population-based and 253 clinic-based families. The SNP-colorectal cancer associations were assessed in multivariable conditional logistic regression.
Results: Among the population-based families, both SNPs rs12953717 (odds ratio, 1.29; 95% confidence interval, 1.12-1.49), and rs11874392 (odds ratio, 0.80; 95% confidence interval, 0.70-0.92) were associated with risk of colorectal cancer. These associations were similar among the population-and the clinic-based families, though they were significant only among the former. Marginally significant differences in the SNP-colorectal cancer associations were observed by use of nonsteroidal anti-inflammatory drugs, cigarette smoking, body mass index, and history of polyps.
Conclusions: SMAD7 SNPs were associated with colorectal cancer risk in the Colon Cancer Family Registry. There was evidence suggesting that the association between rs12953717 and colorectal cancer risk may be modified by factors such as smoking and use of nonsteroidal anti-inflammatory drugs.
C1 [Jiang, Xuejuan; Vandenberg, David; Conti, David V.; Haile, Robert W.] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
[Esteban Castelao, J.; Redondo, Carmen M.] Complejo Hosp Univ Vigo, Oncol & Genet Unit, Serv Galego Saude SERGAS, Vigo, Spain.
[Carracedo, Angel; Gago-Dominguez, Manuela] Complejo Hosp Univ Santiago, Genom Med Grp, Galician Fdn Genom Med, Serv Galego Saude SERGAS,Inst Invest Sanitaria Sa, Santiago De Compostela, Spain.
[Paredes Cotore, Jesus P.] Univ Hosp Santiago de Compostela, Dept Surg, Santiago De Compostela, Spain.
[Potter, John D.; Newcomb, Polly A.; Passarelli, Michael N.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Jenkins, Mark A.; Hopper, John L.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Sch Populat & Global Hlth, Melbourne, Vic 3010, Australia.
[Gallinger, Steven] Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
[Le Marchand, Loic] Univ Hawaii, Canc Res Ctr, Honolulu, HI 96813 USA.
[Martinez, Maria E.] Univ Calif San Diego, San Diego Moores Canc Ctr, San Diego, CA 92103 USA.
[Ahnen, Dennis J.] Denver VA Med Ctr, Denver, CO USA.
[Ahnen, Dennis J.] Univ Colorado, Denver, CO 80202 USA.
[Baron, John A.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA.
[Lindor, Noralane M.] Mayo Clin, Dept Hlth Sci Res, Scottsdale, AZ USA.
RP Gago-Dominguez, M (reprint author), Complejo Hosp Univ Santiago, Genom Med Grp, Galician Fdn Genom Med, Serv Galego Saude SERGAS,Inst Invest Sanitaria Sa, Santiago De Compostela, Spain.
EM manuela.gago.dominguez@sergas.es
RI Gallinger, Steven/E-4575-2013; Jenkins, Mark/P-7803-2015;
OI Jenkins, Mark/0000-0002-8964-6160; Potter, John/0000-0001-5439-1500;
Carracedo, Angel/0000-0003-1085-8986
FU National Cancer Institute, National Institutes of Health
[5R01CA114472-02, RFA CA-95-011]; Australasian Colorectal Cancer Family
Registry [U01 CA097735]; University of Southern California Familial
Colorectal Neoplasia Collaborative Group [U01 CA074799]; Mayo Clinic
Cooperative Family Registry for Colon Cancer Studies [U01 CA074800];
Ontario Registry for Studies of Familial Colorectal Cancer [U01
CA074783]; Seattle Colorectal Cancer Family Registry [U01 CA074794];
University of Hawaii Colorectal Cancer Family Registry [U01 CA074806];
University of California, Irvine Informatics Center [U01 CA078296];
Accion Estrategica de Salud del Instituto de Salud Carlos III [FIS
PI12/02125]; FIS Intrasalud [PS09/02368]; Botin Foundation
FX This work was supported by National Cancer Institute, National
Institutes of Health, grant # 5R01CA114472-02 and RFA # CA-95-011 and
through cooperative agreements with members of the Colon Cancer Family
Registry and P.I.s: the Australasian Colorectal Cancer Family Registry
(U01 CA097735); the University of Southern California Familial
Colorectal Neoplasia Collaborative Group (U01 CA074799); the Mayo Clinic
Cooperative Family Registry for Colon Cancer Studies (U01 CA074800); the
Ontario Registry for Studies of Familial Colorectal Cancer (U01
CA074783); the Seattle Colorectal Cancer Family Registry (U01 CA074794);
the University of Hawaii Colorectal Cancer Family Registry (U01
CA074806); the University of California, Irvine Informatics Center (U01
CA078296); FIS PI12/02125 Accion Estrategica de Salud del Instituto de
Salud Carlos III; FIS Intrasalud (PS09/02368); and the Botin Foundation.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 34
TC 7
Z9 7
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 3
PY 2013
VL 8
IS 4
AR e60464
DI 10.1371/journal.pone.0060464
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 143BA
UT WOS:000318840100075
PM 23560096
ER
PT J
AU Matsuoka, K
Koreth, J
Kim, HT
Bascug, G
McDonough, S
Kawano, Y
Murase, K
Cutler, C
Ho, VT
Alyea, EP
Armand, P
Blazar, BR
Antin, JH
Soiffer, RJ
Ritz, J
AF Matsuoka, Ken-ichi
Koreth, John
Kim, Haesook T.
Bascug, Gregory
McDonough, Sean
Kawano, Yutaka
Murase, Kazuyuki
Cutler, Corey
Ho, Vincent T.
Alyea, Edwin P.
Armand, Philippe
Blazar, Bruce R.
Antin, Joseph H.
Soiffer, Robert J.
Ritz, Jerome
TI Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in
Patients with Chronic Graft-Versus-Host Disease
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID IN-VIVO; PLASMA-LEVELS; CHRONIC GVHD; IL-2; RECEPTOR; TRANSPLANTATION;
EXPANSION; MAINTENANCE; EXPRESSION; MECHANISMS
AB CD4(+)Foxp3(+) regulatory T cells (T-regs) play a central role in the maintenance of immune tolerance after allogeneic hematopoietic stem cell transplantation. We recently reported that daily administration of low-dose interleukin-2 (IL-2) induces selective expansion of functional T-regs and clinical improvement of chronic graft-versus-host disease (GVHD). To define the mechanisms of action of IL-2 therapy, we examined the immunologic effects of this treatment on homeostasis of CD4(+) T cell subsets after transplant. We first demonstrated that chronic GVHD is characterized by constitutive phosphorylation of signal transducer and activator of transcription 5 (Stat5) in conventional CD4(+) T cells (T-cons) associated with elevated amounts of IL-7 and IL-15 and relative functional deficiency of IL-2. IL-2 therapy resulted in the selective increase of Stat5 phosphorylation in T-regs and a decrease of phosphorylated Stat5 in T-cons. Over an 8-week period, IL-2 therapy induced a series of changes in T-reg homeostasis, including increased proliferation, increased thymic export, and enhanced resistance to apoptosis. Low-dose IL-2 had minimal effects on T-cons. These findings define the mechanisms whereby low-dose IL-2 therapy restores the homeostasis of CD4(+) T cell subsets and promotes the reestablishment of immune tolerance.
C1 [Matsuoka, Ken-ichi; Koreth, John; Bascug, Gregory; McDonough, Sean; Kawano, Yutaka; Murase, Kazuyuki; Cutler, Corey; Ho, Vincent T.; Alyea, Edwin P.; Armand, Philippe; Antin, Joseph H.; Soiffer, Robert J.; Ritz, Jerome] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02215 USA.
[Matsuoka, Ken-ichi; Koreth, John; Kawano, Yutaka; Murase, Kazuyuki; Cutler, Corey; Ho, Vincent T.; Alyea, Edwin P.; Armand, Philippe; Antin, Joseph H.; Soiffer, Robert J.; Ritz, Jerome] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Kim, Haesook T.; Ritz, Jerome] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02215 USA.
[Kim, Haesook T.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Blazar, Bruce R.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.
[Blazar, Bruce R.] Univ Minnesota, Dept Pediat, Div Blood & Marrow Transplantat, Minneapolis, MN 55455 USA.
[Ritz, Jerome] Harvard Stem Cell Inst, Boston, MA 02138 USA.
RP Ritz, J (reprint author), Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02215 USA.
EM Jerome_Ritz@dfci.harvard.edu
FU NIH [AI29530, CA142106]; Jock and Bunny Adams Research and Education
Endowment; Ted and Eileen Pasquarello Research Fund; Dana-Farber Dunkin'
Donuts Rising Star award; American Society of Blood and Marrow
Transplantation/Pharmion New Investigator award
FX Funding: This work was supported by NIH grants AI29530 and CA142106, the
Jock and Bunny Adams Research and Education Endowment, and the Ted and
Eileen Pasquarello Research Fund. J.K. is supported in part by a
Dana-Farber Dunkin' Donuts Rising Star award and an American Society of
Blood and Marrow Transplantation/Pharmion New Investigator award.
NR 47
TC 93
Z9 97
U1 0
U2 8
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD APR 3
PY 2013
VL 5
IS 179
AR 179ra43
DI 10.1126/scitranslmed.3005265
PG 11
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 118PF
UT WOS:000317037000006
PM 23552371
ER
PT J
AU Ozkumur, E
Shah, AM
Ciciliano, JC
Emmink, BL
Miyamoto, DT
Brachtel, E
Yu, M
Chen, PI
Morgan, B
Trautwein, J
Kimura, A
Sengupta, S
Stott, SL
Karabacak, NM
Barber, TA
Walsh, JR
Smith, K
Spuhler, PS
Sullivan, JP
Lee, RJ
Ting, DT
Luo, X
Shaw, AT
Bardia, A
Sequist, LV
Louis, DN
Maheswaran, S
Kapur, R
Haber, DA
Toner, M
AF Ozkumur, Emre
Shah, Ajay M.
Ciciliano, Jordan C.
Emmink, Benjamin L.
Miyamoto, David T.
Brachtel, Elena
Yu, Min
Chen, Pin-i
Morgan, Bailey
Trautwein, Julie
Kimura, Anya
Sengupta, Sudarshana
Stott, Shannon L.
Karabacak, Nezihi Murat
Barber, Thomas A.
Walsh, John R.
Smith, Kyle
Spuhler, Philipp S.
Sullivan, James P.
Lee, Richard J.
Ting, David T.
Luo, Xi
Shaw, Alice T.
Bardia, Aditya
Sequist, Lecia V.
Louis, David N.
Maheswaran, Shyamala
Kapur, Ravi
Haber, Daniel A.
Toner, Mehmet
TI Inertial Focusing for Tumor Antigen-Dependent and -Independent Sorting
of Rare Circulating Tumor Cells
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID CANCER-PATIENTS; PERIPHERAL-BLOOD; SEPARATION; ENRICHMENT; ANTIBODIES;
DEPLETION; FLOW
AB Circulating tumor cells (CTCs) are shed into the bloodstream from primary and metastatic tumor deposits. Their isolation and analysis hold great promise for the early detection of invasive cancer and the management of advanced disease, but technological hurdles have limited their broad clinical utility. We describe an inertial focusing-enhanced microfluidic CTC capture platform, termed "CTC-iChip," that is capable of sorting rare CTCs from whole blood at 10(7) cells/s. Most importantly, the iChip is capable of isolating CTCs using strategies that are either dependent or independent of tumor membrane epitopes, and thus applicable to virtually all cancers. We specifically demonstrate the use of the iChip in an expanded set of both epithelial and nonepithelial cancers including lung, prostate, pancreas, breast, and melanoma. The sorting of CTCs as unfixed cells in solution allows for the application of high-quality clinically standardized morphological and immunohistochemical analyses, as well as RNA-based single-cell molecular characterization. The combination of an unbiased, broadly applicable, high-throughput, and automatable rare cell sorting technology with generally accepted molecular assays and cytology standards will enable the integration of CTC-based diagnostics into the clinical management of cancer.
C1 [Ozkumur, Emre; Shah, Ajay M.; Emmink, Benjamin L.; Chen, Pin-i; Morgan, Bailey; Stott, Shannon L.; Karabacak, Nezihi Murat; Barber, Thomas A.; Walsh, John R.; Smith, Kyle; Spuhler, Philipp S.; Kapur, Ravi; Toner, Mehmet] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA.
[Ciciliano, Jordan C.; Miyamoto, David T.; Yu, Min; Trautwein, Julie; Kimura, Anya; Sengupta, Sudarshana; Stott, Shannon L.; Sullivan, James P.; Lee, Richard J.; Ting, David T.; Luo, Xi; Shaw, Alice T.; Bardia, Aditya; Sequist, Lecia V.; Maheswaran, Shyamala; Haber, Daniel A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02114 USA.
[Miyamoto, David T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA.
[Brachtel, Elena; Louis, David N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA.
[Yu, Min; Luo, Xi; Haber, Daniel A.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
[Sullivan, James P.; Lee, Richard J.; Ting, David T.; Shaw, Alice T.; Bardia, Aditya; Sequist, Lecia V.; Haber, Daniel A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA.
[Maheswaran, Shyamala; Toner, Mehmet] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA.
RP Toner, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA.
EM mtoner@hms.harvard.edu
RI sebastianovitsch, stepan/G-8507-2013; Karabacak, N Murat/D-7227-2013;
OI Karabacak, N Murat/0000-0003-2761-5593; Ting, David/0000-0002-3261-2322
FU NIH P41 Biotechnology Resource Center; NIH National Institute of
Biomedical Imaging and Bioengineering; Stand Up to Cancer; Howard Hughes
Medical Institute; Prostate Cancer Foundation; Charles Evans Foundation;
Department of Defense Prostate Cancer Research Program; Mazzone-DF/HCC
(Dana-Farber/Harvard Cancer Center); Conquer Cancer Foundation; Johnson
Johnson
FX Funding: This work was partially supported by NIH P41 Biotechnology
Resource Center (M. T.), NIH National Institute of Biomedical Imaging
and Bioengineering (M. T. and D. A. H.), Stand Up to Cancer (D. A. H.,
M. T., and S. M.), Howard Hughes Medical Institute (D. A. H.), Prostate
Cancer Foundation and Charles Evans Foundation (D. A. H. and M. T.),
Department of Defense Prostate Cancer Research Program (D. T. M. and
R.J.L.), Mazzone-DF/HCC (Dana-Farber/Harvard Cancer Center) (D. T. M.),
Conquer Cancer Foundation (R.J.L.), Prostate Cancer Foundation (R.J.L.),
and Johnson & Johnson (M.T. and S.M.).
NR 30
TC 152
Z9 161
U1 24
U2 227
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD APR 3
PY 2013
VL 5
IS 179
AR 179ra47
DI 10.1126/scitranslmed.3005616
PG 11
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 118PF
UT WOS:000317037000008
PM 23552373
ER
PT J
AU O'Hare, AM
AF O'Hare, Ann M.
TI Measures to Define Chronic Kidney Disease
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID MORTALITY RISK; AGE
C1 VA Puget Sound Healthcare Syst, Hosp & Specialty Med Serv, Seattle, WA USA.
RP O'Hare, AM (reprint author), VA Puget Sound Healthcare Syst, Hosp & Specialty Med Serv, Seattle, WA USA.
EM ann.o'hare@va.gov
NR 5
TC 4
Z9 4
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 3
PY 2013
VL 309
IS 13
BP 1343
EP 1343
DI 10.1001/jama.2013.1328
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 117EC
UT WOS:000316934500010
PM 23549569
ER
PT J
AU Joynt, KE
Orav, EJ
Jha, AK
AF Joynt, Karen E.
Orav, E. John
Jha, Ashish K.
TI Mortality Rates for Medicare Beneficiaries Admitted to Critical Access
and Non-Critical Access Hospitals, 2002-2010
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID QUALITY-OF-CARE; RURAL HOSPITALS; MYOCARDIAL-INFARCTION; 30-DAY
MORTALITY; PATIENT OUTCOMES; PERFORMANCE; IMPROVEMENT; COSTS
AB Importance Critical access hospitals (CAHs) provide inpatient care to Americans living in rural communities. These hospitals are at high risk of falling behind with respect to quality improvement, owing to their limited resources and vulnerable patient populations. How they have fared on patient outcomes during the past decade is unknown.
Objective To evaluate trends in mortality for patients receiving care at CAHs and compare these trends with those for patients receiving care at non-CAHs.
Design, Setting, and Patients Retrospective observational study using data from Medicare fee-for-service patients admitted to US acute care hospitals with acute myocardial infarction (1 902 586 admissions), congestive heart failure (4 488 269 admissions), and pneumonia (3 891 074 admissions) between 2002 and 2010.
Main Outcome Measures Trends in risk-adjusted 30-day mortality rates for CAHs and other acute care US hospitals.
Results Accounting for differences in patient, hospital, and community characteristics, CAHs had mortality rates comparable with those of non-CAHs in 2002 (composite mortality across all 3 conditions, 12.8% vs 13.0%; difference, -0.3% [95% CI, -0.7% to 0.2%]; P=.25). Between 2002 and 2010, mortality rates increased 0.1% per year in CAHs but decreased 0.2% per year in non-CAHs, for an annual difference in change of 0.3% (95% CI, 0.2% to 0.3%; P<.001). Thus, by 2010, CAHs had higher mortality rates compared with non-CAHs (13.3% vs 11.4%; difference, 1.8% [95% CI, 1.4% to 2.2%]; P<.001). The patterns were similar when each individual condition was examined separately. Comparing CAHs with other small, rural hospitals, similar patterns were found.
Conclusions and Relevance Among Medicare beneficiaries with acute myocardial infarction, congestive heart failure, or pneumonia, 30-day mortality rates for those admitted to CAHs, compared with those admitted to other acute care hospitals, increased from 2002 to 2010. New efforts may be needed to help CAHs improve. JAMA. 2013;309(13):1379-1387 www.jama.com
C1 [Joynt, Karen E.; Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Orav, E. John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Joynt, Karen E.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA.
[Orav, E. John; Jha, Ashish K.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA.
[Joynt, Karen E.; Jha, Ashish K.] VA Boston Healthcare Syst, Boston, MA USA.
RP Joynt, KE (reprint author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.
EM kjoynt@partners.org
FU National Heart, Lung, and Blood Institute, National Institutes of Health
[1K23HL109177-01]
FX Dr Joynt was supported by grant 1K23HL109177-01 from the National Heart,
Lung, and Blood Institute, National Institutes of Health.
NR 29
TC 23
Z9 23
U1 0
U2 15
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 3
PY 2013
VL 309
IS 13
BP 1379
EP 1387
DI 10.1001/jama.2013.2366
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 117EC
UT WOS:000316934500027
PM 23549583
ER
PT J
AU Rozental, TD
Deschamps, LN
Taylor, A
Earp, B
Zurakowski, D
Day, CS
Bouxsein, ML
AF Rozental, Tamara D.
Deschamps, Laura N.
Taylor, Alexander
Earp, Brandon
Zurakowski, David
Day, Charles S.
Bouxsein, Mary L.
TI Premenopausal Women with a Distal Radial Fracture Have Deteriorated
Trabecular Bone Density and Morphology Compared with Controls without a
Fracture
SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
LA English
DT Article
ID IN-VIVO ASSESSMENT; HR-PQCT IMAGES; OSTEOPOROTIC FRACTURES;
POSTMENOPAUSAL WOMEN; MINERAL DENSITY; FOREARM FRACTURES; SKELETAL
SITES; HIP FRACTURE; FRAGILITY FRACTURES; BODY-COMPOSITION
AB Background: Measurement of bone mineral density by dual x-ray absorptiometry combined with clinical risk factors is currently the gold standard in diagnosing osteoporosis. Advanced imaging has shown that older patients with fragility fractures have poor bone microarchitecture, often independent of low bone mineral density. We hypothesized that premenopausal women with a fracture of the distal end of the radius have similar bone mineral density but altered bone microarchitecture compared with control subjects without a fracture.
Methods: Forty premenopausal women with a recent distal radial fracture were prospectively recruited and matched with eighty control subjects without a fracture. Primary outcome variables included trabecular and cortical microarchitecture at the distal end of the radius and tibia by high-resolution peripheral quantitative computed tomography. Bone mineral density at the wrist, hip, and lumbar spine was also measured by dual x-ray absorptiometry.
Results: The fracture and control groups did not differ with regard to age, race, or body mass index. Bone mineral density was similar at the femoral neck, lumbar spine, and distal one-third of the radius, but tended to be lower in the fracture group at the hip and ultradistal part of the radius (p = 0.06). Trabecular microarchitecture was deteriorated in the fracture group compared with the control group at both the distal end of the radius and distal end of the tibia. At the distal end of the radius, the fracture group had lower total density and lower trabecular density, number, and thickness compared with the control group (-6% to 14%; p < 0.05 for all). At the distal end of the tibia, total density, trabecular density, trabecular thickness, and cortical thickness were lower in the fracture group than in the control group (-7% to 14%; p < 0.01). Conditional logistic regression showed that trabecular density, thickness, separation, and distribution of trabecular separation remained significantly associated with fracture after adjustment for age and ultradistal radial bone mineral density (adjusted odds ratios [OR]: 2.01 to 2.98; p < 0.05). At the tibia, total density, trabecular density, thickness, cortical area, and cortical thickness remained significantly associated with fracture after adjustment for age and femoral neck bone mineral density (adjusted OR:1.62 to 2.40; p < 0.05).
Conclusions: Despite similar bone mineral density values by dual x-ray absorptiometry, premenopausal women with a distal radial fracture have significantly poorer bone microarchitecture at the distal end of the radius and tibia compared with control subjects without a fracture. Early identification of women with poor bone health offers opportunities for interventions aimed at preventing further deterioration and reducing fracture risk.
C1 Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Orthopaed Surg, Boston, MA 02215 USA.
Brigham & Womens Hosp, Dept Orthopaed Surg, Boston, MA 02215 USA.
Massachusetts Gen Hosp, Div Endocrine, Dept Med, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Dept Anesthesiol, Boston Childrens Hosp, Boston, MA USA.
RP Rozental, TD (reprint author), Beth Israel Deaconess Med Ctr, Dept Orthopaed Surg, 330 Brookline Ave,Stoneman 10, Boston, MA 02215 USA.
NR 64
TC 21
Z9 23
U1 1
U2 4
PU JOURNAL BONE JOINT SURGERY INC
PI NEEDHAM
PA 20 PICKERING ST, NEEDHAM, MA 02192 USA
SN 0021-9355
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg.-Am. Vol.
PD APR 3
PY 2013
VL 95A
IS 7
BP 633
EP 642
DI 10.2106/JBJS.L.00588
PG 10
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA AF8MZ
UT WOS:000334971600009
PM 23553299
ER
PT J
AU Pace-Schott, EF
AF Pace-Schott, Edward F.
TI Dreaming as a story-telling instinct
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Editorial Material
ID EYE-MOVEMENT SLEEP; BRAINS DEFAULT NETWORK; HYPOTHALAMIC FUNCTIONAL
CONNECTIVITY; SLOW-WAVE SLEEP; REM-SLEEP; COGNITIVE NEUROSCIENCE; MODE
NETWORK; STORY COMPREHENSION; WAKING; ACTIVATION
C1 [Pace-Schott, Edward F.] Harvard Univ, Sch Med, Dept Psychiat, Charlestown, MA USA.
[Pace-Schott, Edward F.] Massachusetts Gen Hosp, Charlestown, MA USA.
RP Pace-Schott, EF (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Charlestown, MA USA.
EM epace-schott@partners.org
FU NIMH NIH HHS [R21 MH090357]
NR 75
TC 9
Z9 9
U1 3
U2 9
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD APR 2
PY 2013
VL 4
AR 159
DI 10.3389/fpsyg.2013.00159
PG 4
WC Psychology, Multidisciplinary
SC Psychology
GA AA1FQ
UT WOS:000330842300001
PM 23565105
ER
PT J
AU Rajakumari, S
Wu, J
Ishibashi, J
Lim, HW
Giang, AH
Won, KJ
Reed, RR
Seale, P
AF Rajakumari, Sona
Wu, Jun
Ishibashi, Jeff
Lim, Hee-Woong
Giang, An-Hoa
Won, Kyoung-Jae
Reed, Randall R.
Seale, Patrick
TI EBF2 Determines and Maintains Brown Adipocyte Identity
SO CELL METABOLISM
LA English
DT Article
ID DIET-INDUCED THERMOGENESIS; ACTIVATED RECEPTOR-GAMMA; ADIPOSE-TISSUE;
PPAR-GAMMA; WHITE FAT; GENE-EXPRESSION; ADULT HUMANS; TRANSCRIPTIONAL
COMPLEX; INSULIN-RESISTANCE; TRANSGENIC MICE
AB The master transcription factor Ppar gamma regulates the general differentiation program of both brown and white adipocytes. However, it has been unclear whether Ppar gamma also controls fat lineage-specific characteristics. Here, we show that early B cell factor-2 (Ebf2) regulates Ppar gamma binding activity to determine brown versus white adipocyte identity. The Ebf DNA-binding motif was highly enriched within brown adipose-specific Ppar gamma binding sites that we identified by genome-wide ChIP-Seq. Of the Ebf isoforms, Ebf2 was selectively expressed in brown relative to white adipocytes and was bound at brown adipose-specific Ppar gamma target genes. When expressed in myoblasts or white preadipose cells, Ebf2 recruited Ppar gamma to its brown-selective binding sites and reprogrammed cells to a brown fat fate. Brown adipose cells and tissue from Ebf2-deficient mice displayed a loss of brown-specific characteristics and thermogenic capacity. Together, these results identify Ebf2 as a key transcriptional regulator of brown fat cell fate and function.
C1 [Rajakumari, Sona; Ishibashi, Jeff; Lim, Hee-Woong; Won, Kyoung-Jae; Seale, Patrick] Univ Penn, Perelman Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA.
[Rajakumari, Sona; Ishibashi, Jeff; Seale, Patrick] Univ Penn, Perelman Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.
[Lim, Hee-Woong; Won, Kyoung-Jae] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA.
[Wu, Jun; Giang, An-Hoa] Harvard Univ, Dana Farber Canc Inst, Sch Med, Boston, MA 02215 USA.
[Reed, Randall R.] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Ctr Sensory Biol,Dept Neurosci, Baltimore, MD 21205 USA.
RP Seale, P (reprint author), Univ Penn, Perelman Sch Med, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA.
EM sealep@upenn.edu
OI Lim, Hee-Woong/0000-0001-8599-1808
FU NIH [1K01DK094824]; NIDDK/NIH [R00 DK081605]; NIGMS/NIH [DP2OD007288];
Searle Scholars Award
FX We thank Drs. Mitch Lazar and Dave Steger for expert guidance with ChIP
studies, Dr. Mary Selak for help with oxygen consumption assays, Li
Huang for expert technical assistance, and members of the Seale lab for
helpful discussions. We are grateful to the Functional Genomics Core of
the Penn Diabetes and Endocrinology Research Center (DK19525) for
high-throughput sequencing and data analyses. J.W. is supported by an
NIH grant (1K01DK094824). This work was supported by NIDDK/NIH award R00
DK081605, NIGMS/NIH award DP2OD007288, and a Searle Scholars Award to
P.S.
NR 45
TC 84
Z9 88
U1 2
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD APR 2
PY 2013
VL 17
IS 4
BP 562
EP 574
DI 10.1016/j.cmet.2013.01.015
PG 13
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 242TR
UT WOS:000326265600011
PM 23499423
ER
PT J
AU Brudner, M
Karpel, M
Lear, C
Chen, L
Yantosca, LM
Scully, C
Sarraju, A
Sokolovska, A
Zariffard, MR
Eisen, DP
Mungall, BA
Kotton, DN
Omari, A
Huang, IC
Farzan, M
Takahashi, K
Stuart, L
Stahl, GL
Ezekowitz, AB
Spear, GT
Olinger, GG
Schmidt, EV
Michelow, IC
AF Brudner, Matthew
Karpel, Marshall
Lear, Calli
Chen, Li
Yantosca, L. Michael
Scully, Corinne
Sarraju, Ashish
Sokolovska, Anna
Zariffard, M. Reza
Eisen, Damon P.
Mungall, Bruce A.
Kotton, Darrell N.
Omari, Amel
Huang, I-Chueh
Farzan, Michael
Takahashi, Kazue
Stuart, Lynda
Stahl, Gregory L.
Ezekowitz, Alan B.
Spear, Gregory T.
Olinger, Gene G.
Schmidt, Emmett V.
Michelow, Ian C.
TI Lectin-Dependent Enhancement of Ebola Virus Infection via Soluble and
Transmembrane C-type Lectin Receptors
SO PLOS ONE
LA English
DT Article
ID MANNOSE-BINDING LECTIN; RP-C4-CYP21-TNX RCCX MODULES;
POLYMERASE-CHAIN-REACTION; COPY-NUMBER VARIATIONS; WEST NILE VIRUS;
ENVELOPE GLYCOPROTEINS; INFLAMMATORY RESPONSE; SURFACE GLYCOPROTEIN;
FALCIPARUM-MALARIA; SERINE PROTEASE-2
AB Mannose-binding lectin (MBL) is a key soluble effector of the innate immune system that recognizes pathogen-specific surface glycans. Surprisingly, low-producing MBL genetic variants that may predispose children and immunocompromised individuals to infectious diseases are more common than would be expected in human populations. Since certain immune defense molecules, such as immunoglobulins, can be exploited by invasive pathogens, we hypothesized that MBL might also enhance infections in some circumstances. Consequently, the low and intermediate MBL levels commonly found in human populations might be the result of balancing selection. Using model infection systems with pseudotyped and authentic glycosylated viruses, we demonstrated that MBL indeed enhances infection of Ebola, Hendra, Nipah and West Nile viruses in low complement conditions. Mechanistic studies with Ebola virus (EBOV) glycoprotein pseudotyped lentiviruses confirmed that MBL binds to N-linked glycan epitopes on viral surfaces in a specific manner via the MBL carbohydrate recognition domain, which is necessary for enhanced infection. MBL mediates lipid-raft-dependent macropinocytosis of EBOV via a pathway that appears to require less actin or early endosomal processing compared with the filovirus canonical endocytic pathway. Using a validated RNA interference screen, we identified C1QBP (gC1qR) as a candidate surface receptor that mediates MBL-dependent enhancement of EBOV infection. We also identified dectin-2 (CLEC6A) as a potentially novel candidate attachment factor for EBOV. Our findings support the concept of an innate immune haplotype that represents critical interactions between MBL and complement component C4 genes and that may modify susceptibility or resistance to certain glycosylated pathogens. Therefore, higher levels of native or exogenous MBL could be deleterious in the setting of relative hypocomplementemia which can occur genetically or because of immunodepletion during active infections. Our findings confirm our hypothesis that the pressure of infectious diseases may have contributed in part to evolutionary selection of MBL mutant haplotypes.
C1 [Brudner, Matthew; Karpel, Marshall; Chen, Li; Yantosca, L. Michael; Sarraju, Ashish; Sokolovska, Anna; Takahashi, Kazue; Stuart, Lynda; Ezekowitz, Alan B.; Schmidt, Emmett V.; Michelow, Ian C.] Massachusetts Gen Hosp, Dept Pediat, Programs Dev Immunol, Boston, MA 02114 USA.
[Lear, Calli; Scully, Corinne; Olinger, Gene G.] USA, Div Virol, Med Res Inst Infect Dis, Frederick, MD USA.
[Zariffard, M. Reza] Rush Univ, Dept Immunol & Microbiol, Med Ctr, Chicago, IL 60612 USA.
[Eisen, Damon P.] Royal Melbourne Hosp, Victorian Infect Dis Serv, Parkville, Vic 3050, Australia.
[Mungall, Bruce A.] Commonwealth Sci & Ind Res Org CSIRO Livestock In, Australian Anim Hlth Lab, Geelong, Vic, Australia.
[Kotton, Darrell N.; Omari, Amel] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Huang, I-Chueh; Farzan, Michael] New England Reg Primate Res Ctr, Southborough, MA 01772 USA.
[Stahl, Gregory L.] Brigham & Womens Hosp, CETRI, Boston, MA 02115 USA.
[Huang, I-Chueh; Farzan, Michael; Takahashi, Kazue; Stuart, Lynda; Stahl, Gregory L.; Schmidt, Emmett V.; Michelow, Ian C.] Harvard Univ, Sch Med, Boston, MA USA.
RP Schmidt, EV (reprint author), Massachusetts Gen Hosp, Dept Pediat, Programs Dev Immunol, Boston, MA 02114 USA.
EM eschmidt@partners.org; ian_michelow@brown.edu
OI Olinger, Gene/0000-0001-7338-0292; Kotton, Darrell/0000-0002-9604-8476
FU National Institutes of Health [U01 AI070330]; United States Department
of Defense, Defense Threat Reduction Agency Biological Therapeutics
Program [4.10006, 4.10007]
FX This work was supported by National Institutes of Health Grant U01
AI070330 (to EVS) and by United States Department of Defense, Defense
Threat Reduction Agency Biological Therapeutics Program Grants 4.10006
and 4.10007 (to GGO). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 102
TC 17
Z9 17
U1 1
U2 22
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2013
VL 8
IS 4
AR e60838
DI 10.1371/journal.pone.0060838
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 127RY
UT WOS:000317717300151
PM 23573288
ER
PT J
AU Raeder, H
Vesterhus, M
El Ouaamari, A
Paulo, JA
McAllister, FE
Liew, CW
Hu, J
Kawamori, D
Molven, A
Gygi, SP
Njolstad, PR
Kahn, CR
Kulkarni, RN
AF Raeder, Helge
Vesterhus, Mette
El Ouaamari, Abdelfattah
Paulo, Joao A.
McAllister, Fiona E.
Liew, Chong Wee
Hu, Jiang
Kawamori, Dan
Molven, Anders
Gygi, Steven P.
Njolstad, Pal R.
Kahn, C. Ronald
Kulkarni, Rohit N.
TI Absence of Diabetes and Pancreatic Exocrine Dysfunction in a Transgenic
Model of Carboxyl-Ester Lipase-MODY (Maturity-Onset Diabetes of the
Young)
SO PLOS ONE
LA English
DT Article
ID CRE RECOMBINASE; REPORTER STRAIN; GENE-EXPRESSION; KNOCKOUT MICE; MOUSE;
MUTATIONS; ABSORPTION; DEFICIENCY; RECEPTOR; CELLS
AB Background: CEL-MODY is a monogenic form of diabetes with exocrine pancreatic insufficiency caused by mutations in CARBOXYL-ESTER LIPASE (CEL). The pathogenic processes underlying CEL-MODY are poorly understood, and the global knockout mouse model of the CEL gene (CELKO) did not recapitulate the disease. We therefore aimed to create and phenotype a mouse model specifically over-expressing mutated CEL in the pancreas.
Methods: We established a monotransgenic floxed (flanking LOX sequences) mouse line carrying the human CEL mutation c.1686delT and crossed it with an elastase-Cre mouse to derive a bitransgenic mouse line with pancreas-specific overexpression of CEL carrying this disease-associated mutation (TgCEL). Following confirmation of murine pancreatic expression of the human transgene by real-time quantitative PCR, we phenotyped the mouse model fed a normal chow and compared it with mice fed a 60% high fat diet (HFD) as well as the effects of short-term and long-term cerulein exposure.
Results: Pancreatic exocrine function was normal in TgCEL mice on normal chow as assessed by serum lipid and lipid-soluble vitamin levels, fecal elastase and fecal fat absorption, and the normoglycemic mice exhibited normal pancreatic morphology. On 60% HFD, the mice gained weight to the same extent as controls, had normal pancreatic exocrine function and comparable glucose tolerance even after resuming normal diet and follow up up to 22 months of age. The cerulein-exposed TgCEL mice gained weight and remained glucose tolerant, and there were no detectable mutation-specific differences in serum amylase, islet hormones or the extent of pancreatic tissue inflammation.
Conclusions: In this murine model of human CEL-MODY diabetes, we did not detect mutation-specific endocrine or exocrine pancreatic phenotypes, in response to altered diets or exposure to cerulein.
C1 [Raeder, Helge; Vesterhus, Mette; El Ouaamari, Abdelfattah; Liew, Chong Wee; Hu, Jiang; Kawamori, Dan; Molven, Anders; Njolstad, Pal R.; Kahn, C. Ronald; Kulkarni, Rohit N.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
[Raeder, Helge; Vesterhus, Mette; Molven, Anders; Njolstad, Pal R.] Univ Bergen, Dept Clin Med, KG Jebsen Ctr Diabet Res, Bergen, Norway.
[Raeder, Helge; Vesterhus, Mette; Njolstad, Pal R.] Haukeland Hosp, Dept Pediat, N-5021 Bergen, Norway.
[Raeder, Helge] Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway.
[Paulo, Joao A.; McAllister, Fiona E.; Gygi, Steven P.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA.
[Molven, Anders] Univ Bergen, Gade Inst, Bergen, Norway.
[Molven, Anders] Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway.
[Njolstad, Pal R.] Broad Inst Harvard & MIT, Cambridge, MA USA.
RP Raeder, H (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
EM helge.rader@uib.no
FU National Institutes of Health (NIH) [RO1 DK67536]; Norwegian Research
Foundation; Haukeland University Hospital; Innovest; University of
Bergen, Norway; ESPE Sabbatical Leave Programme; Fulbright Foundation;
Norwegian Research Council; Western Norway Regional Health Authority
grant; Norwegian Endocrine Society; National Institutes of Health
[DK33201, DK55545]; Joslin Diabetes and Endocrinology Research Center
[DK34834]
FX The funds to develop some reagents in this study were supported by
National Institutes of Health (NIH) Grant RO1 DK67536 (to RNK). This
study was supported in part by funds from the Norwegian Research
Foundation, Haukeland University Hospital, Innovest, and University of
Bergen, Norway, and an ESPE Sabbatical Leave Programme and the Fulbright
Foundation (to PRN), a Leiv Eiriksson Mobility Grant from The Norwegian
Research Council (to MV and HR), a Western Norway Regional Health
Authority grant (to HR), a Norwegian Endocrine Society grant (to HR), a
Fulbright Foundation grant (to HR), and by National Institutes of Health
Grants DK33201 and DK55545 (to CRK), and the Joslin Diabetes and
Endocrinology Research Center Grant DK34834. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 37
TC 2
Z9 2
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2013
VL 8
IS 4
AR e60229
DI 10.1371/journal.pone.0060229
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 127RY
UT WOS:000317717300072
ER
PT J
AU Junco, SE
Wang, RJ
Gaipa, JC
Taylor, AB
Schirf, V
Gearhart, MD
Bardwell, VJ
Demeler, B
Hart, PJ
Kim, CA
AF Junco, Sarah E.
Wang, Renjing
Gaipa, John C.
Taylor, Alexander B.
Schirf, Virgil
Gearhart, Micah D.
Bardwell, Vivian J.
Demeler, Borries
Hart, P. John
Kim, Chongwoo A.
TI Structure of the Polycomb Group Protein PCGF1 in Complex with BCOR
Reveals Basis for Binding Selectivity of PCGF Homologs
SO STRUCTURE
LA English
DT Article
ID SOMATIC MUTATIONS; REPRESSIVE COMPLEX; COREPRESSOR; DOMAIN; PRC1;
IDENTIFICATION; LEUKEMIA; SUBTYPE; SYSTEM; RING1B
AB Polycomb-group RING finger homologs (PCGF1, PCGF2, PCGF3, PCGF4, PCGF5, and PCGF6) are critical components in the assembly of distinct Polycomb repression complex 1 (PRC1)-related complexes. Here, we identify a protein interaction domain in BCL6 corepressor, BCOR, which binds the RING finger- and WD40-associated ubiquitin-like (RAWUL) domain of PCGF1 (NSPC1) and PCGF3 but not of PCGF2 (MEL18) or PCGF4 (BMW. Because of the selective binding, we have named this domain PCGF Ub-like fold discriminator (PUFD). The structure of BCOR PUFD bound to PCGF1 reveals that (1) PUFD binds to the same surfaces as observed for a different Polycomb group RAWUL domain and (2) the ability of PUFD to discriminate among RAWULs stems from the identity of specific residues within these interaction surfaces. These data show the molecular basis for determining the binding preference for a PCGF homolog, which ultimately helps determine the identity of the larger PRC1-like assembly.
C1 [Junco, Sarah E.; Wang, Renjing; Gaipa, John C.; Taylor, Alexander B.; Schirf, Virgil; Demeler, Borries; Hart, P. John; Kim, Chongwoo A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Junco, Sarah E.; Wang, Renjing; Gaipa, John C.; Taylor, Alexander B.; Schirf, Virgil; Demeler, Borries; Hart, P. John; Kim, Chongwoo A.] Univ Texas Hlth Sci Ctr San Antonio, CTRC, San Antonio, TX 78229 USA.
[Gearhart, Micah D.; Bardwell, Vivian J.] Univ Minnesota, Dept Genet Cell Biol & Dev, Mason Canc Ctr, Minneapolis, MN 55455 USA.
[Gearhart, Micah D.; Bardwell, Vivian J.] Univ Minnesota, Ctr Dev Biol, Minneapolis, MN 55455 USA.
[Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
RP Kim, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, MSC 7760,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM chong@biochem.uthscsa.edu
FU American Heart Association [0830111N]; American Cancer Society
[RSG-08-285-01-GMC]; Department of Defense Breast Cancer Research
Program [BC075278]; National Institutes of Health [5R01CA071540];
NIH-NCI [2P30 CA054174-17]; XSEDE [TG-MCB070039]; Welch Foundation
[AQ-1399]; UTHSCSA Executive Research Committee; Cancer Therapy Research
Center; Office of Science, Office of Basic Energy Sciences, of the U.S.
Department of Energy [DE-AC02-05CH11231]; U.S. Department of Energy,
Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357];
Michigan Economic Development Corporation; Michigan Technology
Tr-Corridor [085P1000817]
FX This work was supported by the American Heart Association (0830111N to
OAK.), the American Cancer Society (RSG-08-285-01-GMC to C.A.K.), the
Department of Defense Breast Cancer Research Program (BC075278 to
C.A.K.), the National Institutes of Health (5R01CA071540 to V.J.B.),
NIH-NCI (2P30 CA054174-17 to B.D. and P.J.H.), XSEDE (TG-MCB070039 to
B.D.), and the Welch Foundation (AQ-1399 to P.J.H.). UTHSCSA core
facilities are supported by the UTHSCSA Executive Research Committee and
the Cancer Therapy Research Center. This work is based upon research at
Beamline 4.2.2 of the Molecular Biology Consortium at the Advance Light
Source (ALS). ALS is supported by the Director, Office of Science,
Office of Basic Energy Sciences, of the U.S. Department of Energy under
Contract No. DE-AC02-05CH11231. Advanced Photon Source is supported by
the U.S. Department of Energy, Office of Science, Office of Basic Energy
Sciences, under Contract No. DE-AC02-06CH11357. LS-CAT Sector 21 was
supported by the Michigan Economic Development Corporation and the
Michigan Technology Tr-Corridor (Grant 085P1000817). We also thank Dr.
Jay Nix (ALS) and Dr. Dmitri Ivanov (APS) for assistance with the data
collection.
NR 42
TC 24
Z9 28
U1 1
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0969-2126
J9 STRUCTURE
JI Structure
PD APR 2
PY 2013
VL 21
IS 4
BP 665
EP 671
DI 10.1016/j.str.2013.02.013
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 128WJ
UT WOS:000317800100016
PM 23523425
ER
PT J
AU Lee, JH
Park, S
Hyun, H
Bordo, MW
Oketokoun, R
Nasr, KA
Frangioni, JV
Choi, HS
AF Lee, Jeong Heon
Park, Sunny
Hyun, Hoon
Bordo, Mark W.
Oketokoun, Rafiou
Nasr, Khaled A.
Frangioni, John V.
Choi, Hak Soo
TI High-Throughput Screening of Small Molecule Ligands Targeted to Live
Bacteria Surface
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID DECONVOLUTION MICROSCOPY; IDENTIFICATION; ASSAYS
AB The discovery of small molecule ligands targeted to the surface of live pathogenic bacteria would enable an entirely new class of antibiotics. We report the development and validation of a microarray-based high-throughput screening platform for bacteria that exploits 300 mu m diameter chemical spots in a 1 in. x 3 in. nanolayered glass slide format. Using 24 model compounds and 4 different bacterial strains, we optimized the screening technology, including fluorophore-based optical deconvolution for automated scoring of affinity and cyan-magenta-yellow-key (CMYK) color-coding for scoring of both affinity and specificity. The latter provides a lossless, one-dimensional view of multidimensional data. By linking in silico analysis with cell binding affinity and specificity, we could also begin to identify the physicochemical factors that affect ligand performance. The technology we describe could form the foundation for developing new classes of antibiotics.
C1 [Lee, Jeong Heon; Hyun, Hoon; Bordo, Mark W.; Oketokoun, Rafiou; Frangioni, John V.; Choi, Hak Soo] Beth Israel Deaconess Med Ctr, Robot Chem Grp, Ctr Mol Imaging, Boston, MA 02215 USA.
[Lee, Jeong Heon; Hyun, Hoon; Bordo, Mark W.; Oketokoun, Rafiou; Frangioni, John V.; Choi, Hak Soo] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA.
[Frangioni, John V.] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA.
[Park, Sunny] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA.
[Nasr, Khaled A.] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA.
RP Choi, HS (reprint author), BIDMC, Room SL-436A,330 Brookline Ave, Boston, MA 02215 USA.
EM jfrangio@bidmc.harvard.edu; hchoi@bidmc.harvard.edu
RI Choi, Hak Soo/C-9954-2011
FU Nehemias Gorin Foundation; National Institutes of Health; NCI BRP
[R01-CA-115296]; NIBIB [R01-EB-010022, R01-EB-011523]; Dana Foundation
Program in Brain and Immuno-Imaging
FX We thank Alex Allardyce (ChemAxon, Budapest, Hungary), Marsha Paul
(Caliper LS, Hopkinton, MA), Brian Stall (Bruker Daltonics, Billerica,
MA), Rene Schena (ArrayIt Corp., Sunnyvale, CA), Colin Johnson (LAE
Technologies, Barrie, Canada), and Yangsun Kim (HST, Newark, NJ) for
technical support and many helpful discussions. We thank David
Burrington, Jr. for editing and Eugenia Trabucchi for administrative
assistance. This study was supported by a grant from the Nehemias Gorin
Foundation and the following grants from the National Institutes of
Health, NCI BRP grant #R01-CA-115296 (JVF), NIBIB grant #R01-EB-010022
(J.V.F. and H.S.C.), and NIBIB grant #R01-EB-011523 (H.S.C. and J.V.F.),
and the Dana Foundation Program in Brain and Immuno-Imaging (H.S.C.).
NR 22
TC 8
Z9 8
U1 2
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD APR 2
PY 2013
VL 85
IS 7
BP 3508
EP 3514
DI 10.1021/ac303199x
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 120MA
UT WOS:000317173200010
PM 23461528
ER
PT J
AU Kullgren, JT
Troxel, AB
Loewenstein, G
Asch, DA
Norton, LA
Wesby, L
Tao, YY
Zhu, JS
Volpp, KG
AF Kullgren, Jeffrey T.
Troxel, Andrea B.
Loewenstein, George
Asch, David A.
Norton, Laurie A.
Wesby, Lisa
Tao, Yuanyuan
Zhu, Jingsan
Volpp, Kevin G.
TI Individual- Versus Group-Based Financial Incentives for Weight Loss A
Randomized, Controlled Trial
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID LOSS PROGRAM; EATING QUESTIONNAIRE-R18; MONETARY INCENTIVES; FOOD
PROVISION; OBESITY; HEALTH; PREDICTORS; OVERWEIGHT; ATTRITION; REGRET
AB Background: Data on the effectiveness of employer-sponsored financial incentives for employee weight loss are limited.
Objective: To test the effectiveness of 2 financial incentive designs for promoting weight loss among obese employees.
Design: Randomized, controlled trial. (ClinicalTrials.gov: NCT01208350)
Setting: Children's Hospital of Philadelphia.
Participants: 105 employees with a body mass index between 30 and 40 kg/m(2).
Intervention: 24 weeks of monthly weigh-ins (control group; n = 35); individual incentive, designed as $100 per person per month for meeting or exceeding weight-loss goals (n = 35); and group incentive, designed as $500 per month split among participants within groups of 5 who met or exceeded weight-loss goals (n = 35).
Measurements: Weight loss after 24 weeks (primary outcome) and 36 weeks and changes in behavioral mediators of weight loss (secondary outcomes).
Results: Group-incentive participants lost more weight than control participants (mean between-group difference, 4.4 kg [95% CI, 2.0 to 6.7 kg]; P < 0.001) and individual-incentive participants (mean between-group difference, 3.2 kg [CI, 0.9 to 5.5 kg]; P = 0.008). Twelve weeks after incentives ended and after adjustment for 3-group comparisons, group-incentive participants maintained greater weight loss than control group participants (mean between-group difference, 2.9 kg [CI, 0.5 to 5.3 kg]; P = 0.016) but not greater than individual-incentive participants (mean between-group difference, 2.7 kg [CI, 0.4 to 5.0 kg]; P = 0.024).
Limitation: Single employer and short follow-up.
Conclusion: A group-based financial incentive was more effective than an individual incentive and monthly weigh-ins at promoting weight loss among obese employees at 24 weeks.
C1 Univ Michigan, Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, Sch Med, Ann Arbor, MI 48109 USA.
Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.
Univ Penn, Perelman Sch Med,Ctr Hlth Incent & Behav Econ, Leonard Davis Inst Hlth Econ, Penn CMU Roybal Ctr Behav Econ & Hlth, Philadelphia, PA 19104 USA.
Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
RP Kullgren, JT (reprint author), Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, POB 130170, Ann Arbor, MI 48113 USA.
EM jkullgre@med.umich.edu
OI Asch, David/0000-0002-7970-286X; Troxel, Andrea/0000-0002-1393-3075
FU National Institute on Aging [RC2103282621]; Department of Veterans
Affairs; Robert Wood Johnson Foundation
FX National Institute on Aging.; By grant RC2103282621 (National Institute
on Aging). Support was also provided by the Department of Veterans
Affairs and the Robert Wood Johnson Foundation.
NR 52
TC 57
Z9 57
U1 2
U2 29
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 2
PY 2013
VL 158
IS 7
BP 505
EP +
DI 10.7326/0003-4819-158-7-201304020-00002
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA 123VM
UT WOS:000317419400001
PM 23546562
ER
PT J
AU Caverzagie, KJ
Iobst, WF
Aagaard, EM
Hood, S
Chick, DA
Kane, GC
Brigham, TP
Swing, SR
Meade, LB
Bazari, H
Bush, RW
Kirk, LM
Green, ML
Hinchey, KT
Smith, CD
AF Caverzagie, Kelly J.
Iobst, William F.
Aagaard, Eva M.
Hood, Sarah
Chick, Davoren A.
Kane, Gregory C.
Brigham, Timothy P.
Swing, Susan R.
Meade, Lauren B.
Bazari, Hasan
Bush, Roger W.
Kirk, Lynne M.
Green, Michael L.
Hinchey, Kevin T.
Smith, Cynthia D.
TI The Internal Medicine Reporting Milestones and the Next Accreditation
System
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Editorial Material
C1 Univ Nebraska Med Ctr, Omaha, NE 68198 USA.
Thomas Jefferson Univ, Jefferson Med Coll, Amer Board Internal Med, Philadelphia, PA 19107 USA.
Amer Coll Physicians, Philadelphia, PA USA.
Univ Colorado, Sch Med, Aurora, CO USA.
Univ Michigan, Sch Med, Ann Arbor, MI USA.
Accreditat Council Grad Med Educ, Chicago, IL 60654 USA.
Baystate Med Ctr, Springfield, MA 01199 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Virginia Mason Med Ctr, Seattle, WA 98101 USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Yale Univ, Sch Med, New Haven, CT USA.
RP Caverzagie, KJ (reprint author), Univ Nebraska Med Ctr, Dept Internal Med, 985185 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM kelly.caverzagie@unmc.edu
RI sebastianovitsch, stepan/G-8507-2013
NR 8
TC 35
Z9 35
U1 1
U2 5
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 2
PY 2013
VL 158
IS 7
BP 557
EP +
DI 10.7326/0003-4819-158-7-201304020-00593
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 123VM
UT WOS:000317419400007
PM 23358671
ER
PT J
AU Rose, JJ
Newby, LK
Broderick, S
Chiswell, K
Van de Werf, F
Armstrong, PW
Mahaffey, KW
Harrington, RA
Ohman, EM
Giugliano, RP
Goodman, SG
White, HD
Califf, RM
Granger, CB
Lopes, RD
AF Rose, Jason J.
Newby, L. Kristin
Broderick, Samuel
Chiswell, Karen
Van de Werf, Frans
Armstrong, Paul W.
Mahaffey, Kenneth W.
Harrington, Robert A.
Ohman, E. Magnus
Giugliano, Robert P.
Goodman, Shaun G.
White, Harvey D.
Califf, Robert M.
Granger, Christopher B.
Lopes, Renato D.
TI Left Bundle Branch Block in Non-ST-Segment Elevation Acute Coronary
Syndromes Incidence, Angiographic Characteristics, and Clinical Outcomes
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Letter
ID ACUTE MYOCARDIAL-INFARCTION
C1 [Rose, Jason J.; Newby, L. Kristin; Broderick, Samuel; Chiswell, Karen; Harrington, Robert A.; Ohman, E. Magnus; Giugliano, Robert P.; Califf, Robert M.; Granger, Christopher B.; Lopes, Renato D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA.
[Van de Werf, Frans] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium.
[Van de Werf, Frans] Leuven Coordinating Ctr, Louvain, Belgium.
[Armstrong, Paul W.] Univ Alberta, Div Cardiol, Edmonton, AB, Canada.
[Giugliano, Robert P.] Brigham & Womens Hosp, Div Cardiovasc Med, TIMI Study Grp, Boston, MA 02115 USA.
[Goodman, Shaun G.] Univ Toronto, St Michaels Hosp, Terrence Donnelly Heart Ctr, Div Cardiol, Toronto, ON M5B 1W8, Canada.
[White, Harvey D.] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.
RP Lopes, RD (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, Box 3850 2400 Pratt St Room 0311,Terrace Level, Durham, NC 27705 USA.
EM renato.lopes@duke.edu
RI Granger, Christopher/D-3458-2014;
OI Granger, Christopher/0000-0002-0045-3291; Van de Werf,
Frans/0000-0001-9479-7767
NR 5
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 2
PY 2013
VL 61
IS 13
BP 1461
EP 1463
DI 10.1016/j.jacc.2012.12.032
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 120SB
UT WOS:000317191200017
PM 23500249
ER
PT J
AU Efstathiou, JA
Gray, PJ
Zietman, AL
AF Efstathiou, J. A.
Gray, P. J.
Zietman, A. L.
TI Proton beam therapy and localised prostate cancer: current status and
controversies
SO BRITISH JOURNAL OF CANCER
LA English
DT Review
DE proton beam; radiation; prostate cancer; quality of life; cost; evidence
ID INTENSITY-MODULATED RADIOTHERAPY; CONFORMAL RADIATION-THERAPY;
RANDOMIZED CONTROLLED-TRIAL; DOSE-ESCALATION; PHASE-II; RISK; TOXICITY;
IMRT; ADENOCARCINOMA; REDUCTION
AB Proton therapy is a promising, but costly, treatment for prostate cancer. Theoretical physical advantages exist; yet to date, it has been shown only to be comparably safe and effective when compared with the alternatives and not necessarily superior. If clinically meaningful benefits do exist for patients, more rigorous study will be needed to detect them and society will require this to justify the investment of time and money. New technical advances in proton beam delivery coupled with shortened overall treatment times and declining device costs have the potential to make this a more cost-effective therapy in the years ahead.
C1 [Efstathiou, J. A.; Gray, P. J.; Zietman, A. L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA.
RP Efstathiou, JA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA.
EM jefstathiou@partners.org
NR 49
TC 18
Z9 18
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD APR 2
PY 2013
VL 108
IS 6
BP 1225
EP 1230
DI 10.1038/bjc.2013.100
PG 6
WC Oncology
SC Oncology
GA 118PX
UT WOS:000317038800001
PM 23481182
ER
PT J
AU Lesnock, JL
Darcy, KM
Tian, C
DeLoia, JA
Thrall, MM
Zahn, C
Armstrong, DK
Birrer, MJ
Krivak, TC
AF Lesnock, J. L.
Darcy, K. M.
Tian, C.
DeLoia, J. A.
Thrall, M. M.
Zahn, C.
Armstrong, D. K.
Birrer, M. J.
Krivak, T. C.
TI BRCA1 expression and improved survival in ovarian cancer patients
treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic
Oncology Group Study
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE ovarian cancer; intraperitoneal chemotherapy; BRCA1 immunohistochemistry
ID SPORADIC OVARIAN; DNA-REPAIR; PROTEIN EXPRESSION; MESSENGER-RNA;
CHEMOTHERAPY; MUTATIONS; CARCINOMA; RESISTANCE; BRCANESS; BREAST
AB Background: Breast cancer 1, early onset (BRCA1) is a tumour-suppressor gene associated with familial epithelial ovarian cancer (EOC). Reduced BRCA1 expression is associated with enhanced sensitivity to platinum-based chemotherapy. We sought to examine the prognostic relevance of BRCA1 expression in EOC patients treated with intraperitoneal platinum/taxane.
Methods: The GOG-172 was a phase III, multi-institutional randomised trial of intravenous paclitaxel and cisplatin (IV therapy) vs intravenous paclitaxel, intraperitoneal cisplatin plus paclitaxel (IP therapy) in patients with optimally resected stage III EOC. The BRCA1 expression was assessed with immunohistochemistry (IHC) staining blinded to clinical outcome in archival tumour specimens. Slides with <= 10% staining were defined as aberrant and >10% as normal. Correlations between BRCA1 expression and progression-free survival (PFS) and overall survival (OS) were analysed using Kaplan-Meier method and Cox regression analysis.
Results: Of the 393 patients, 189 tumours had aberrant expression, and 204 had normal BRCA1 expression. There was an interaction between BRCA1 expression and route of administration on OS (P = 0.014) but not PFS (P = 0.054). In tumours with normal BRCA1 expression, the median OS was 58 months for IP group vs 50 months for IV group (P = 0.818). In tumours with aberrant BRCA1 expression, the median OS was 84 vs 47 months in the IP vs IV group, respectively (P = 0.0002). Aberrant BRCA1 expression was an independent prognostic factor for better survival in women randomised to IP therapy (hazard ratio (HR) = 0.67, 95% confidence interval (CI) = 0.47-0.97, P = 0.032). Similar survival was observed in the IV and IP patients with normal BRCA1 expression. Multivariate but not univariate modelling demonstrated that IV patients with aberrant vs normal BRCA1 expression had worse survival.
Conclusion: Decreased BRCA1 expression is associated with a 36-month survival improvement in patients with EOC treated with IP chemotherapy. Although these results merit validation in future studies, the results suggest that decreased BRCA1 expression predicts for improved response to cisplatin-based IP chemotherapy with cisplatin and paclitaxel.
C1 [Lesnock, J. L.; Krivak, T. C.] UPMC, Magee Womens Hosp, Div Gynecol Oncol, Pittsburgh, PA 15213 USA.
[Darcy, K. M.; Tian, C.] Roswell Pk Canc Inst, Gynecol Oncol Grp, Stat & Data Ctr, Buffalo, NY 14263 USA.
[DeLoia, J. A.] Georgetown Univ, Med Ctr, Washington, DC 20057 USA.
[Thrall, M. M.] Univ Washington, Seattle, WA 98195 USA.
[Zahn, C.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.
[Armstrong, D. K.] Johns Hopkins Sch Med, Kimmel Canc Ctr, Baltimore, MD 21231 USA.
[Birrer, M. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Krivak, TC (reprint author), UPMC, Magee Womens Hosp, Div Gynecol Oncol, Pittsburgh, PA 15213 USA.
EM Tkrivak@mail.magee.edu
FU National Cancer Institute [CA 27469, CA 37517]; Gynecologic Oncology
Group/Ovarian Cancer Research Fund New Investigator Award
FX This study was supported by National Cancer Institute grants to the
Gynecologic Oncology Group (GOG) Administrative Office and the GOG
Tissue Bank (CA 27469), the GOG Statistical and Data Center (CA 37517)
as well as a grant from the Gynecologic Oncology Group/Ovarian Cancer
Research Fund New Investigator Award (to TCK).
NR 37
TC 32
Z9 35
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD APR 2
PY 2013
VL 108
IS 6
BP 1231
EP 1237
DI 10.1038/bjc.2013.70
PG 7
WC Oncology
SC Oncology
GA 118PX
UT WOS:000317038800002
PM 23462720
ER
PT J
AU Kumar, RS
Douglas, PS
Peterson, ED
Anstrom, KJ
Dai, D
Brennan, JM
Hui, PYM
Booth, ME
Messenger, JC
Shaw, RE
AF Kumar, Robert S.
Douglas, Pamela S.
Peterson, Eric D.
Anstrom, Kevin J.
Dai, David
Brennan, J. Matthew
Hui, Peter Y. M.
Booth, Michael E.
Messenger, John C.
Shaw, Richard E.
TI Effect of Race and Ethnicity on Outcomes With Drug-Eluting and Bare
Metal Stents Results in 423 965 Patients in the Linked National
Cardiovascular Data Registry and Centers for Medicare & Medicaid
Services Payer Databases
SO CIRCULATION
LA English
DT Article
DE continental population groups; coronary artery disease; drug-eluting
stents; ethnic groups; outcome assessment; percutaneous coronary
intervention
ID PERCUTANEOUS CORONARY INTERVENTION; RACIAL-DIFFERENCES; DYNAMIC
REGISTRY; ARTERY-DISEASE; HEART-DISEASE; REVASCULARIZATION; VETERANS;
SURVIVAL; RISK
AB Background-Black, Hispanic, and Asian patients have been underrepresented in percutaneous coronary intervention clinical trials; therefore, there are limited data available on outcomes for these race/ethnicity groups.
Methods and Results-We examined outcomes in 423 965 patients in the National Cardiovascular Data Registry CathPCI Registry database linked to Medicare claims for follow-up. Within each race/ethnicity group, we examined trends in drug-eluting stent (DES) use, 30-month outcomes, and relative outcomes of DES versus bare metal stents. Overall, 390 351 white, 20 191 black, 9342 Hispanic, and 4171 Asian patients >65 years of age underwent stent implantation from 2004 through 2008 at 940 National Cardiovascular Data Registry participating sites. Trends in adoption of DES were similar across all groups. Relative to whites, black and Hispanic patients undergoing percutaneous coronary intervention had higher long-term risks of death and myocardial infarction (blacks: hazard ratio, 1.28; 95% confidence interval, 1.24-1.32; Hispanics: hazard ratio, 1.15; 95% confidence interval, 1.10-1.21). Long-term outcomes were similar in Asians and whites (hazard ratio, 0.99; 95% confidence interval, 0.92-1.08). Use of DES was associated with better 30-month survival and lower myocardial infarction rates compared with the use of bare metal stents among all race/ethnicity groups except Hispanics, who had similar outcomes with DES or bare metal stents.
Conclusions-Black and Hispanic patients undergoing percutaneous coronary intervention had worse long-term outcomes relative to white and Asian patients. Compared with bare metal stent use, DES use was generally associated with superior long-term outcomes in all racial and ethnic groups, although these differences were not statistically significant in Hispanic patients. (Circulation. 2013;127:1395-1403.)
C1 [Kumar, Robert S.] Lenox Hill Hosp, New York, NY 10021 USA.
[Douglas, Pamela S.; Peterson, Eric D.; Anstrom, Kevin J.; Dai, David; Brennan, J. Matthew; Booth, Michael E.] Duke Clin Res Inst, Durham, NC USA.
[Hui, Peter Y. M.; Shaw, Richard E.] Calif Pacific Med Ctr, San Francisco, CA USA.
[Messenger, John C.] Denver VA Med Ctr, Denver, CO USA.
RP Kumar, RS (reprint author), Virginia Hart, Lenox Hill Intervent Cardiac & Vasc Serv, 130 E 77th St,9th Floor Black Hall, New York, NY 10075 USA.
EM robertskumar@gmail.com
FU Agency for Healthcare Research and Quality, US Department of Health and
Human Services, Rockville, MD, as part of the Cardiovascular Consortium;
Developing Evidence to Inform Decisions About Effectiveness (DEcIDE)
program [24-EHC-1, HHSAA290-2005-0032-TO4-WA2]; Eli Lilly; Johnson
Johnson; AstraZeneca; Eli Lilly Co; Medtronic; Proctor and Gamble
FX This project was sponsored by the Agency for Healthcare Research and
Quality, US Department of Health and Human Services, Rockville, MD, as
part of the Cardiovascular Consortium and funded under project
identification 24-EHC-1 and work assignment number
HHSAA290-2005-0032-TO4-WA2 as part of the Developing Evidence to Inform
Decisions About Effectiveness (DEcIDE) program. The authors of this
report are responsible for its content. Statements in the report should
not be construed as endorsement by the Agency for Healthcare Research
and Quality or the US Department of Health and Human Service.; Dr
Peterson reports research support from Eli Lilly and Johnson & Johnson.
Dr. Anstrom has received research support from AstraZeneca, Eli Lilly &
Co, Medtronic, and Proctor and Gamble; has served as a consultant for
Abbott Vascular, AstraZeneca, Bristol Meyer Squibb, and Ikaria; and has
served on Data Monitoring committees for Pfizer and Vertex. The other
authors report no conflicts.
NR 27
TC 15
Z9 16
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD APR 2
PY 2013
VL 127
IS 13
BP 1395
EP +
DI 10.1161/CIRCULATIONAHA.113.001437
PG 12
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 117JG
UT WOS:000316948900015
PM 23547179
ER
PT J
AU Ganzfried, BF
Riester, M
Haibe-Kains, B
Risch, T
Tyekucheva, S
Jazic, I
Wang, XV
Ahmadifar, M
Birrer, MJ
Parmigiani, G
Huttenhower, C
Waldron, L
AF Ganzfried, Benjamin Frederick
Riester, Markus
Haibe-Kains, Benjamin
Risch, Thomas
Tyekucheva, Svitlana
Jazic, Ina
Wang, Xin Victoria
Ahmadifar, Mahnaz
Birrer, Michael J.
Parmigiani, Giovanni
Huttenhower, Curtis
Waldron, Levi
TI curatedOvarianData: clinically annotated data for the ovarian cancer
transcriptome
SO DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION
LA English
DT Article
ID GENE-EXPRESSION PROFILE; SURVIVAL; CARCINOMA; BIOCONDUCTOR; SIGNATURE;
R/BIOCONDUCTOR; BIOINFORMATICS; PROGNOSIS; NETWORK; PACKAGE
AB This article introduces a manually curated data collection for gene expression meta-analysis of patients with ovarian cancer and software for reproducible preparation of similar databases. This resource provides uniformly prepared microarray data for 2970 patients from 23 studies with curated and documented clinical metadata. It allows users to efficiently identify studies and patient subgroups of interest for analysis and to perform meta-analysis immediately without the challenges posed by harmonizing heterogeneous microarray technologies, study designs, expression data processing methods and clinical data formats. We confirm that the recently proposed biomarker CXCL12 is associated with patient survival, independently of stage and optimal surgical debulking, which was possible only through meta-analysis owing to insufficient sample sizes of the individual studies. The database is implemented as the curatedOvarianData Bioconductor package for the R statistical computing language, providing a comprehensive and flexible resource for clinically oriented investigation of the ovarian cancer transcriptome. The package and pipeline for producing it are available from http://bcb.dfci.harvard.edu/ovariancancer.
C1 [Ganzfried, Benjamin Frederick; Riester, Markus; Risch, Thomas; Tyekucheva, Svitlana; Jazic, Ina; Wang, Xin Victoria; Ahmadifar, Mahnaz; Parmigiani, Giovanni; Waldron, Levi] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Ganzfried, Benjamin Frederick; Riester, Markus; Tyekucheva, Svitlana; Wang, Xin Victoria; Parmigiani, Giovanni; Huttenhower, Curtis; Waldron, Levi] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Haibe-Kains, Benjamin] Inst Rech Clin Montreal, Bioinformat & Computat Genom Lab, Montreal, PQ H2W 1R7, Canada.
[Birrer, Michael J.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA.
RP Waldron, L (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
EM levi@jimmy.harvard.edu
RI Haibe-Kains, Benjamin/D-3702-2011;
OI Haibe-Kains, Benjamin/0000-0002-7684-0079; Riester,
Markus/0000-0002-4759-8332; Waldron, Levi/0000-0003-2725-0694;
Huttenhower, Curtis/0000-0002-1110-0096
FU National Cancer Institute at the National Institutes of Health
[1RC4CA156551-01]; National Science Foundation [CAREER DBI-1053486];
National Cancer Institute [U54CA143798]
FX National Cancer Institute at the National Institutes of Health
[1RC4CA156551-01 to G. P. and M. B.]; the National Science Foundation
[CAREER DBI-1053486 to C. H.]. M. R. acknowledges support from the
National Cancer Institute initiative to found Physical Science Oncology
Centers [U54CA143798]. Funding for open access charge: National Science
Foundation [CAREER DBI-1053486 to C. H.].
NR 46
TC 33
Z9 33
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1758-0463
J9 DATABASE-OXFORD
JI Database
PD APR 2
PY 2013
AR bat013
DI 10.1093/database/bat013
PG 10
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA 117DH
UT WOS:000316931800001
ER
PT J
AU Stone, JH
AF Stone, John H.
TI Aortitis, retroperitoneal fibrosis, and IgG4-related disease
SO PRESSE MEDICALE
LA English
DT Article; Proceedings Paper
CT 16th International Vasculitis and ANCA Workshop
CY APR 14-17, 2013
CL Inst Cordeliers, Paris, FRANCE
HO Inst Cordeliers
ID LYMPHOPLASMACYTIC AORTITIS; SYSTEMIC-DISEASE; ANEURYSM; PANCREATITIS;
PATHOLOGY
C1 [Stone, John H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol,Rheumatol Unit, Boston, MA USA.
RP Stone, JH (reprint author), Massachusetts Gen Hosp, Rheumatol Unit, Yawkey 2,55,Fruit St, Boston, MA 02114 USA.
EM jhstone@partners.org
NR 26
TC 1
Z9 3
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0755-4982
EI 2213-0276
J9 PRESSE MED
JI Presse Med.
PD APR
PY 2013
VL 42
IS 4
BP 622
EP 625
DI 10.1016/j.lpm.2013.01.042
PN 2
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA AA3FO
UT WOS:000330978500048
PM 23465296
ER
PT J
AU Pendergraft, W
Mcgrath, M
Murphy, A
Murphy, P
Laliberte, K
Niles, J
AF Pendergraft, W.
Mcgrath, M.
Murphy, A.
Murphy, P.
Laliberte, K.
Niles, J.
TI Characterization of drug-induced ANCA vasculitis at Massachusetts's
general hospital (MGH): 1989-2012
SO PRESSE MEDICALE
LA English
DT Meeting Abstract
C1 [Pendergraft, W.; Murphy, A.; Murphy, P.; Laliberte, K.; Niles, J.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
[Mcgrath, M.] Brigham & Womens Hosp, Dept Med, Div Nephrol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0755-4982
EI 2213-0276
J9 PRESSE MED
JI Presse Med.
PD APR
PY 2013
VL 42
IS 4
BP 654
EP 655
DI 10.1016/j.lpm.2013.02.011
PN 2
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AA3FO
UT WOS:000330978500065
ER
PT J
AU Roth, A
Ooi, J
Hess, J
Van Timmeren, M
Berg, E
Poulton, C
Mcgregor, J
Burkart, M
Hogan, S
Hu, Y
Winnik, W
Nachman, P
Stegeman, C
Niles, J
Heeringa, P
Free, M
Kitching, R
Holdsworth, S
Jennette, C
Preston, G
Falk, R
AF Roth, A.
Ooi, J.
Hess, J.
Van Timmeren, M.
Berg, E.
Poulton, C.
Mcgregor, J.
Burkart, M.
Hogan, S.
Hu, Y.
Winnik, W.
Nachman, P.
Stegeman, C.
Niles, J.
Heeringa, P.
Free, M.
Kitching, R.
Holdsworth, S.
Jennette, C.
Preston, G.
Falk, R.
TI ANCA epitope specificity determines pathogenicity, detectability and
clinical predictive value
SO PRESSE MEDICALE
LA English
DT Meeting Abstract
C1 [Roth, A.; Hess, J.; Berg, E.; Poulton, C.; Mcgregor, J.; Burkart, M.; Hogan, S.; Hu, Y.; Nachman, P.; Free, M.; Jennette, C.; Preston, G.; Falk, R.] Univ N Carolina, Chapel Hill, NC USA.
[Ooi, J.; Kitching, R.; Holdsworth, S.] Monash Univ, Clayton, Vic, Australia.
[Van Timmeren, M.; Stegeman, C.; Heeringa, P.] Univ Groningen, Groningen, Netherlands.
[Winnik, W.] US EPA, Res Triangle Pk, NC 27711 USA.
[Niles, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0755-4982
EI 2213-0276
J9 PRESSE MED
JI Presse Med.
PD APR
PY 2013
VL 42
IS 4
BP 664
EP 664
DI 10.1016/j.lpm.2013.02.033
PN 2
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA AA3FO
UT WOS:000330978500087
ER
PT J
AU Xie, G
Roschandel, D
Sherva, R
Monach, P
Lu, Y
Kung, T
Carrington, K
Carette, S
Dellaripa, P
Edberg, J
Hoffman, G
Khalidi, N
Langford, C
Mahr, A
St Clair, EW
Seo, P
Specks, U
Spiera, R
Stone, J
Ytterberg, S
Raychaudhuri, S
De Bakker, P
Farrer, L
Amos, C
Merkel, P
Siminovitch, K
AF Xie, G.
Roschandel, D.
Sherva, R.
Monach, P.
Lu, Y.
Kung, T.
Carrington, K.
Carette, S.
Dellaripa, P.
Edberg, J.
Hoffman, G.
Khalidi, N.
Langford, C.
Mahr, A.
St Clair, E. W.
Seo, P.
Specks, U.
Spiera, R.
Stone, J.
Ytterberg, S.
Raychaudhuri, S.
De Bakker, P.
Farrer, L.
Amos, C.
Merkel, P.
Siminovitch, K.
TI Granulomatosis with polyangiitis (Wegener's) is associated with
HLA-DPB1*04 and EMA6A gene variants. Evidence from a genome-wide
analysis
SO PRESSE MEDICALE
LA English
DT Meeting Abstract
C1 [Xie, G.; Roschandel, D.; Kung, T.; Carrington, K.; Carette, S.; Siminovitch, K.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
[Sherva, R.; Monach, P.; Farrer, L.] Boston Univ, Boston, MA 02215 USA.
[Lu, Y.; Dellaripa, P.; Raychaudhuri, S.; De Bakker, P.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Edberg, J.] Univ Alabama Birmingham, Birmingham, AL USA.
[Hoffman, G.; Langford, C.] Cleveland Clin, Cleveland, OH 44106 USA.
[Khalidi, N.] McMaster Univ, Toronto, ON, Canada.
[Mahr, A.; St Clair, E. W.] Univ Paris, F-75252 Paris, France.
[Seo, P.] Johns Hopkins Univ, Baltimore, MD USA.
[Specks, U.; Ytterberg, S.] Mayo Clin, Rochester, MN USA.
[Spiera, R.] Hosp Special Surg, New York, NY 10021 USA.
[Stone, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Amos, C.] Dartmouth Coll, Hanover, NH USA.
[Merkel, P.] Univ Penn, Philadelphia, PA 19104 USA.
RI de Bakker, Paul/B-8730-2009
OI de Bakker, Paul/0000-0001-7735-7858
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0755-4982
EI 2213-0276
J9 PRESSE MED
JI Presse Med.
PD APR
PY 2013
VL 42
IS 4
BP 668
EP 668
DI 10.1016/j.lpm.2013.02.042
PN 2
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA AA3FO
UT WOS:000330978500096
ER
PT J
AU Clain, J
Specks, U
Stone, J
AF Clain, J.
Specks, U.
Stone, J.
TI The association of IgM ANCA with alveolar hemorrhage revisited
SO PRESSE MEDICALE
LA English
DT Meeting Abstract
C1 [Clain, J.; Specks, U.] Mayo Clin, Rochester, MN USA.
[Stone, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 1
TC 1
Z9 1
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0755-4982
EI 2213-0276
J9 PRESSE MED
JI Presse Med.
PD APR
PY 2013
VL 42
IS 4
BP 685
EP 685
DI 10.1016/j.lpm.2013.02.080
PN 2
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA AA3FO
UT WOS:000330978500133
ER
PT J
AU Unizony, S
Keroack, B
Stone, JH
AF Unizony, S.
Keroack, B.
Stone, J. H.
TI Tocilizumab for the treatment of giant cell arteritis: Extended
follow-up
SO PRESSE MEDICALE
LA English
DT Meeting Abstract
C1 [Unizony, S.; Stone, J. H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Keroack, B.] Tufts Univ, Sch Med, Maine Med Ctr, Portland, ME USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0755-4982
EI 2213-0276
J9 PRESSE MED
JI Presse Med.
PD APR
PY 2013
VL 42
IS 4
BP 727
EP 727
DI 10.1016/j.lpm.2013.02.178
PN 2
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA AA3FO
UT WOS:000330978500231
ER
PT J
AU Tomasson, G
Davis, JC
Hoffman, GS
Mccune, WJ
Specks, U
Spiera, R
St Clair, EW
Stone, JH
Merkel, PA
AF Tomasson, G.
Davis, J. C.
Hoffman, G. S.
Mccune, W. J.
Specks, U.
Spiera, R.
St Clair, E. W.
Stone, J. H.
Merkel, P. A.
TI The value of a patient global assessment for disease activity in
granulomatosis with polyangiitis
SO PRESSE MEDICALE
LA English
DT Meeting Abstract
C1 [Tomasson, G.] Univ Iceland, Reykjavik, Iceland.
[Davis, J. C.] Genentech Inc, San Francisco, CA 94080 USA.
[Hoffman, G. S.] Cleveland Clin, Cleveland, OH 44106 USA.
[Mccune, W. J.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Specks, U.] Mayo Clin, Rochester, MN USA.
[Spiera, R.] Hosp Special Surg, New York, NY 10021 USA.
[St Clair, E. W.] Duke Univ, Durham, NC 27706 USA.
[Stone, J. H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Merkel, P. A.] Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0755-4982
EI 2213-0276
J9 PRESSE MED
JI Presse Med.
PD APR
PY 2013
VL 42
IS 4
BP 749
EP 749
DI 10.1016/j.lpm.2013.02.229
PN 2
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA AA3FO
UT WOS:000330978500282
ER
PT J
AU Pendergraft, W
Cortazar, F
Wenger, J
Murphy, A
Laliberte, K
Niles, J
AF Pendergraft, W.
Cortazar, F.
Wenger, J.
Murphy, A.
Laliberte, K.
Niles, J.
TI Maintenance therapy using rituximab-induced continuous B cell depletion
for ANCA vasculitis
SO PRESSE MEDICALE
LA English
DT Meeting Abstract
C1 [Pendergraft, W.; Cortazar, F.; Wenger, J.; Murphy, A.; Laliberte, K.; Niles, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0755-4982
EI 2213-0276
J9 PRESSE MED
JI Presse Med.
PD APR
PY 2013
VL 42
IS 4
BP 774
EP 775
DI 10.1016/j.lpm.2013.02.292
PN 2
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AA3FO
UT WOS:000330978500344
ER
PT J
AU Pendergraft, W
Mcgrath, M
Murphy, A
Murphy, P
Laliberte, K
Niles, J
AF Pendergraft, W.
Mcgrath, M.
Murphy, A.
Murphy, P.
Laliberte, K.
Niles, J.
TI Gestational rituximab exposure in women with vasculitis
SO PRESSE MEDICALE
LA English
DT Meeting Abstract
C1 [Pendergraft, W.; Murphy, A.; Murphy, P.; Laliberte, K.; Niles, J.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
[Mcgrath, M.] Brigham & Womens Hosp, Dept Med, Div Nephrol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0755-4982
EI 2213-0276
J9 PRESSE MED
JI Presse Med.
PD APR
PY 2013
VL 42
IS 4
BP 776
EP 777
DI 10.1016/j.lpm.2013.02.296
PN 2
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AA3FO
UT WOS:000330978500348
ER
PT J
AU Miloslavsky, E
Specks, U
Merkel, P
Seo, P
Spiera, R
Langford, C
Hoffman, G
Kallenberg, C
St Clair, W
Tchao, N
Ding, L
Ikle, D
Jepson, B
Brunetta, P
Stone, J
AF Miloslavsky, E.
Specks, U.
Merkel, P.
Seo, P.
Spiera, R.
Langford, C.
Hoffman, G.
Kallenberg, C.
St Clair, W.
Tchao, N.
Ding, L.
Ikle, D.
Jepson, B.
Brunetta, P.
Stone, J.
TI Retreatment with Rituximab in the RAVE Trial
SO PRESSE MEDICALE
LA English
DT Meeting Abstract
ID MAINTENANCE
C1 [Miloslavsky, E.; Stone, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Specks, U.] Mayo Clin, Rochester, MN USA.
[Merkel, P.] Univ Penn, Philadelphia, PA 19104 USA.
[Seo, P.] Johns Hopkins Univ, Baltimore, MD USA.
[Spiera, R.] Hosp Special Surg, New York, NY 10021 USA.
[Langford, C.; Hoffman, G.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Kallenberg, C.] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
[St Clair, W.] Duke Univ, Durham, NC 27706 USA.
[Tchao, N.] Immune Tolerance Network, Bethesda, MD USA.
[Ding, L.] NIAID, Bethesda, MD 20892 USA.
[Ikle, D.; Jepson, B.] Rho, Chapel Hill, NC USA.
[Brunetta, P.] Genentech Inc, San Francisco, CA 94080 USA.
NR 3
TC 2
Z9 2
U1 0
U2 0
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0755-4982
EI 2213-0276
J9 PRESSE MED
JI Presse Med.
PD APR
PY 2013
VL 42
IS 4
BP 778
EP 778
DI 10.1016/j.lpm.2013.02.300
PN 2
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA AA3FO
UT WOS:000330978500352
ER
PT J
AU Miloslavsky, E
Specks, U
Merkel, P
Seo, P
Spiera, R
Langford, C
Hoffman, G
Kallenberg, C
St Clair, W
Tchao, N
Ding, L
Ikle, D
Jepson, B
Brunetta, P
Stone, J
AF Miloslavsky, E.
Specks, U.
Merkel, P.
Seo, P.
Spiera, R.
Langford, C.
Hoffman, G.
Kallenberg, C.
St Clair, W.
Tchao, N.
Ding, L.
Ikle, D.
Jepson, B.
Brunetta, P.
Stone, J.
TI Safety of remission induction with rituximab versus cyclophosphamide in
patients 65 and older with severe ANCA-associated vasculitis
SO PRESSE MEDICALE
LA English
DT Meeting Abstract
ID POLYARTERITIS-NODOSA
C1 [Miloslavsky, E.; Stone, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Specks, U.] Mayo Clin, Rochester, MN USA.
[Merkel, P.] Univ Penn, Philadelphia, PA 19104 USA.
[Seo, P.] Johns Hopkins Univ, Baltimore, MD USA.
[Spiera, R.] Hosp Special Surg, New York, NY 10021 USA.
[Langford, C.; Hoffman, G.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Kallenberg, C.] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
[St Clair, W.] Duke Univ, Durham, NC 27706 USA.
[Tchao, N.] Immune Tolerance Network, Bethesda, MD USA.
[Ding, L.] NIAID, Bethesda, MD 20892 USA.
[Ikle, D.; Jepson, B.] Rho, Chapel Hill, NC USA.
[Brunetta, P.] Genentech Inc, San Francisco, CA 94080 USA.
NR 3
TC 1
Z9 1
U1 1
U2 4
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0755-4982
EI 2213-0276
J9 PRESSE MED
JI Presse Med.
PD APR
PY 2013
VL 42
IS 4
BP 779
EP 780
DI 10.1016/j.lpm.2013.02.302
PN 2
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AA3FO
UT WOS:000330978500354
ER
PT J
AU Ibrahim, SA
Franklin, PD
AF Ibrahim, Said A.
Franklin, Patricia D.
TI Race and Elective Joint Replacement: Where a Disparity Meets Patient
Preference
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Editorial Material
C1 [Ibrahim, Said A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Ibrahim, Said A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Franklin, Patricia D.] Univ Massachusetts, Med Ctr, Dept Orthoped & Phys Rehabil, Worcester, MA USA.
RP Ibrahim, SA (reprint author), Philadelphia VA Med Ctr ANNEX, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM said.ibrahim2@va.gov
OI Franklin, Patricia D/0000-0002-4441-0533
FU AHRQ HHS [P50 HS018910-01, P50 HS018910]; NIAMS NIH HHS [K24 AR055259,
1K24AR055259-01]
NR 6
TC 6
Z9 6
U1 0
U2 0
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD APR
PY 2013
VL 103
IS 4
BP 583
EP 584
DI 10.2105/AJPH.2012.301077
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA0DU
UT WOS:000330766100019
PM 23409914
ER
PT J
AU Edmondson, D
Gamboa, C
Cohen, A
Anderson, AH
Kutner, N
Kronish, I
Mills, MA
Muntner, P
AF Edmondson, Donald
Gamboa, Christopher
Cohen, Andrew
Anderson, Amanda H.
Kutner, Nancy
Kronish, Ian
Mills, Mary A.
Muntner, Paul
TI Association of Posttraumatic Stress Disorder and Depression With
All-Cause and Cardiovascular Disease Mortality and Hospitalization Among
Hurricane Katrina Survivors With End-Stage Renal Disease
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID ACUTE CORONARY SYNDROME; ACUTE MYOCARDIAL-INFARCTION; NATIONAL
COMORBIDITY SURVEY; ADVERSE CARDIAC EVENTS; HEMODIALYSIS-PATIENTS;
HEART-DISEASE; MAJOR DEPRESSION; MENTAL-ILLNESS; SYMPTOMS; PTSD
AB Objectives. We determined the association of psychiatric symptoms in the year after Hurricane Katrina with subsequent hospitalization and mortality in end-stage renal disease (ESRD) patients.
Methods. A prospective cohort of ESRD patients (n = 391) treated at 9 hemodialysis centers in the New Orleans, Louisiana, area in the weeks before Hurricane Katrina were assessed for posttraumatic stress disorder (PTSD) and depression symptoms via telephone interview 9 to 15 months later. Two combined outcomes through August 2009 (maximum 3.5-year follow-up) were analyzed: (1) all-cause and (2) cardiovascular-related hospitalization and mortality.
Results. Twenty-four percent of participants screened positive for PTSD and 46% for depression; 158 participants died (79 cardiovascular deaths), and 280 participants were hospitalized (167 for cardiovascular-related causes). Positive depression screening was associated with 33% higher risk of all-cause (hazard ratio [HR] = 1.33; 95% confidence interval [CI] = 1.06, 1.66) and cardiovascular-related hospitalization and mortality (HR = 1.33; 95% CI = 1.01, 1.76). PTSD was not significantly associated with either outcome.
Conclusions. Depression in the year after Hurricane Katrina was associated with increased risk of hospitalization and mortality in ESRD patients, underscoring the long-term consequences of natural disasters for vulnerable populations.
C1 [Edmondson, Donald; Kronish, Ian] Columbia Univ, Med Ctr, Ctr Behav Cardiovasc Hlth, New York, NY USA.
[Gamboa, Christopher; Muntner, Paul] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Cohen, Andrew] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
[Anderson, Amanda H.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Kutner, Nancy] Emory Univ, US Renal Data Syst, Atlanta, GA 30322 USA.
[Mills, Mary A.] Boston VA Healthcare Syst, Boston, MA USA.
RP Muntner, P (reprint author), Univ Alabama Birmingham, Dept Epidemiol, 1665 Univ Blvd,Suite 230J, Birmingham, AL 35294 USA.
EM pmuntner@uab.edu
RI Edmondson, Donald/G-7486-2016;
OI Kronish, Ian/0000-0003-0945-2380
FU Columbia University's Clinical and Translational Science Awards from the
National Center for Advancing Translational Science-National Center for
Research Resources/National Institutes of Health [UL1 RR024156];
National Institutes of Health [KM1 CA-156709, HL-088117, K01 DK092353,
N01-DK-1-2471, HHSN267200715004C,, N01-DK-7-5004]
FX This study was supported in part by Columbia University's Clinical and
Translational Science Awards from the National Center for Advancing
Translational Science-National Center for Research Resources/National
Institutes of Health (grant UL1 RR024156). D. Edmondson is supported by
the National Institutes of Health (grants KM1 CA-156709 and HL-088117).
A. H. Anderson is supported by the National Institutes of Health (grant
K01 DK092353). This study was supported by a subcontract to Tulane
University from the National Institutes of Health (contract
N01-DK-1-2471) and by the National Institutes of Health (contract
HHSN267200715004C, ADB No. N01-DK-7-5004).
NR 47
TC 3
Z9 3
U1 5
U2 8
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD APR
PY 2013
VL 103
IS 4
BP E130
EP E137
DI 10.2105/AJPH.2012.301146
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA0DU
UT WOS:000330766100017
PM 23409901
ER
PT J
AU Wakeman, SE
AF Wakeman, Sarah E.
TI LANGUAGE AND ADDICTION: CHOOSING WORDS WISELY
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Letter
ID CARE
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Wakeman, SE (reprint author), Massachusetts Gen Hosp, 55 Fruit St,GRB 740, Boston, MA 02114 USA.
EM swakeman@partners.org
NR 8
TC 4
Z9 4
U1 0
U2 4
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD APR
PY 2013
VL 103
IS 4
BP E1
EP E2
DI 10.2105/AJPH.2012.301191
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA0DU
UT WOS:000330766100001
PM 23409913
ER
PT J
AU Gupta, S
Vemulakonda, GA
Suhler, EB
Yeh, S
Albini, TA
Mandelcorn, E
Flaxel, CJ
AF Gupta, Seema
Vemulakonda, G. A.
Suhler, Eric B.
Yeh, Steven
Albini, Thomas A.
Mandelcorn, Efrem
Flaxel, Christina J.
TI Cytomegalovirus retinitis in the absence of AIDS
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID IMMUNOCOMPETENT PATIENT; TRIAMCINOLONE; INFECTION; ADULT
AB Objective: The purpose of this study was to evaluate systemic and ophthalmic features associated with Cytomegalovirus (CMV) retinitis in immunocompetent patients.
Design: Retrospective chart review.
Participants: Nine patients with CMV retinitis who were clinically immunocompetent at the time of diagnosis.
Methods: Retrospective chart review of patients evaluated at the Casey Eye Institute, University of Washington, Bascom Palmer Eye Institute and University of Toronto. IRB approval was obtained. Retrospective chart review of patients evaluated at the Casey Eye Institute, University of Washington, Bascom Palmer Eye Institute and University of Toronto. IRB approval was obtained.
Results: Seven of the nine patients in our series were 60 years of age or above. Three patients had intravitreal steroid and VEGF inhibitor injections in the preceding year in the affected eye. Five of the nine patients were initially misdiagnosed to have acute retinal necrosis (ARN) for which they were on Valacyclovir for a variable period of time. Seven patients had anterior chamber and eight had vitreous inflammation. Six of the nine patients exhibited vascular attenuation or obliteration. All patients showed improvement in retinitis within weeks following therapy with intravitreal foscarnet and/or ganciclovir and systemic valganciclovir.
C1 [Gupta, Seema; Suhler, Eric B.; Flaxel, Christina J.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
[Vemulakonda, G. A.] Univ Washington, Seattle, WA 98195 USA.
[Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA.
[Yeh, Steven] Emory Eye Ctr, Decatur, GA USA.
[Albini, Thomas A.] Bascom Palmer Eye Inst, Miami, FL USA.
[Mandelcorn, Efrem] Univ Toronto, Toronto, ON, Canada.
RP Flaxel, CJ (reprint author), OHSU, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM flaxelc@ohsu.edu
OI Albini, Thomas/0000-0003-2199-9047
NR 10
TC 8
Z9 8
U1 0
U2 1
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD APR
PY 2013
VL 48
IS 2
BP 126
EP 129
DI 10.1016/j.jcjo.2012.12.002
PG 4
WC Ophthalmology
SC Ophthalmology
GA AA5NX
UT WOS:000331147800026
PM 23561607
ER
PT J
AU Leng, J
Ho, HP
Yu, XG
Chang, E
Lichterfeld, M
AF Leng, Jin
Ho, Hsin-Pin
Yu, Xu G.
Chang, Emmanuel
Lichterfeld, Mathias
TI Cell-intrinsic mechanisms of HIV-1 immune defense in elite controllers
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Meeting Abstract
CT 14th Annual International Meeting of the Institute-of-Human-Virology
CY OCT 14-17, 2012
CL Univ Maryland Sch Med, Baltimore, MD
SP Inst Human Virol
HO Univ Maryland Sch Med
C1 [Leng, Jin; Ho, Hsin-Pin; Yu, Xu G.; Chang, Emmanuel; Lichterfeld, Mathias] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR
PY 2013
VL 62
SU 1
BP 43
EP 43
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 300IQ
UT WOS:000330458000026
ER
PT J
AU Reinherz, EL
AF Reinherz, Ellis L.
TI The cardinal rule of antibody- and CTL-eliciting vaccine design:
specificity in a biological context
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Meeting Abstract
CT 14th Annual International Meeting of the Institute-of-Human-Virology
CY OCT 14-17, 2012
CL Univ Maryland Sch Med, Baltimore, MD
SP Inst Human Virol
HO Univ Maryland Sch Med
C1 [Reinherz, Ellis L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR
PY 2013
VL 62
SU 1
BP 46
EP 46
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 300IQ
UT WOS:000330458000033
ER
PT J
AU Moye, J
Sabatino, CP
Brendel, RW
AF Moye, Jennifer
Sabatino, Charles P.
Brendel, Rebecca Weintraub
TI Evaluation of the Capacity to Appoint a Healthcare Proxy
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Advance directives; capacity; competency; healthcare power of attorney;
healthcare proxy; informed consent
ID DECISION-MAKING CAPACITY; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT;
PATIENTS COMPETENCE; ADVANCE DIRECTIVES; BIPOLAR DISORDER;
INFORMED-CONSENT; OLDER-ADULTS; DEMENTIA; PARTICIPATION
AB The appointment of a healthcare proxy is the most common way through which patients appoint a surrogate decision maker in anticipation of a future time in which they may lack the ability to make medical decisions themselves. In some situations, when a patient has not previously appointed a surrogate decision maker through an advance directive, the healthcare team may ask whether the patient, although lacking the capacity to make a healthcare decision, might still have the capacity to appoint a healthcare proxy. In this article the authors summarize the existing, albeit limited, legal and empirical basis for this capacity and propose a model for assessing capacity to appoint a healthcare proxy that incorporates clinical factors in the context of the risks and benefits specific to surrogate appointment under the law. In particular, it is important to weigh patients' understanding and choice within the context of the risks and benefits of the medical and interpersonal factors. Questions to guide capacity assessment are provided for clinical use and refinement through future research.
C1 [Moye, Jennifer] VA Boston Healthcare Syst, Brockton Div, Brockton, MA 02301 USA.
[Moye, Jennifer; Brendel, Rebecca Weintraub] Harvard Univ, Sch Med, Boston, MA USA.
[Sabatino, Charles P.] Amer Bar Assoc, Chicago, IL 60611 USA.
[Brendel, Rebecca Weintraub] Massachusetts Gen Hosp, Ctr Law Brain & Behav, Boston, MA 02114 USA.
RP Moye, J (reprint author), VA Boston Healthcare Syst, Brockton Div, 940 Belmont St, Brockton, MA 02301 USA.
EM Jennifer.moye@va.gov
RI Moye, Jennifer/F-2240-2017
OI Moye, Jennifer/0000-0002-3434-347X
FU Intramural VA [VA999999]; NIMH NIH HHS [R29 MH057104]
NR 40
TC 6
Z9 6
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD APR
PY 2013
VL 21
IS 4
BP 326
EP 336
DI 10.1016/j.jagp.2012.09.001
PG 11
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 298WS
UT WOS:000330355800003
PM 23498379
ER
PT J
AU Wayangankar, SA
Abu-Fadel, MS
Aronow, HD
Kennedy, KF
Gupta, R
Yeh, RW
Gray, WA
Rosenfield, K
Hennebry, TA
AF Wayangankar, Siddharth A.
Abu-Fadel, Mazen S.
Aronow, Herbert D.
Kennedy, Kevin F.
Gupta, Raghav
Yeh, Robert W.
Gray, William A.
Rosenfield, Kenneth
Hennebry, Thomas A.
TI Hemorrhagic and Ischemic Outcomes After Bivalirudin Versus
Unfractionated Heparin During Carotid Artery Stenting A Propensity Score
Analysis From the NCDR
SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE bivalirudin; bleeding; carotid artery stenting; heparin
ID PERCUTANEOUS CORONARY INTERVENTION; ELEVATION MYOCARDIAL-INFARCTION;
ACADEMIC RESEARCH CONSORTIUM; ENDARTERECTOMY; REGISTRY; NEUROPROTECTION;
ANTICOAGULANT; ASSOCIATION; AGE
AB Background-The direct thrombin inhibitor, bivalirudin, is associated with similar efficacy and superior safety in patients undergoing percutaneous coronary intervention. However, the role of direct thrombin inhibitors in carotid artery stenting is not well defined. The objective of this study was to compare the safety and effectiveness of bivalirudin and unfractionated heparin (UFH) for carotid artery stenting. We hypothesized that bivalirudin would be associated with less in-hospital postprocedure bleeding than UFH but similar rates of in-hospital and 30-day ischemic outcomes.
Methods and Results-We compared the incidence of in-hospital hemorrhagic and in-hospital/30-day ischemic outcomes among patients in the CARE Registry who underwent carotid artery stenting between May 2005 and March 2012 using bivalirudin or UFH. Propensity score matching was used to obtain a balanced cohort of 3555 patients in each treatment group. Patients treated with bivalirudin had a significantly lower incidence of bleeding or hematoma requiring red blood cell transfusions (0.9% versus 1.5%; odds ratio, 0.57 [0.36-0.89]; P=0.01) when compared with UFH-treated patients. The incidence of in-hospital and 30-day ischemic outcomes, including death, myocardial infarction, stroke, transient ischemic attack, and the composite outcome, death/myocardial infarction/stroke, did not differ significantly between groups.
Conclusions-Bivalirudin was associated with lower rates of hemorrhagic outcomes compared with UFH during the index hospitalization for carotid artery stenting. In-hospital and 30-day ischemic events were similar between the 2 groups. Randomized comparisons of these agents are needed to confirm these findings.
C1 [Wayangankar, Siddharth A.; Abu-Fadel, Mazen S.; Gupta, Raghav] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Aronow, Herbert D.] Michigan Heart & Vasc Inst, Ann Arbor, MI USA.
[Kennedy, Kevin F.] St Lukes Hosp, Mid Amer Heart & Vasc Inst, Kansas City, MO USA.
[Gray, William A.] Columbia Univ, Med Ctr, New York, NY USA.
[Yeh, Robert W.; Rosenfield, Kenneth] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hennebry, Thomas A.] Oklahoma Heart Hosp, Oklahoma City, OK USA.
RP Wayangankar, SA (reprint author), OUHSC, Dept Med, Cardiovasc Dis Sect, 920 Stanton L Young Blvd,POB 26901,WP3010, Oklahoma City, OK 73104 USA.
EM siddharth-wayangankar@ouhsc.edu
FU National Cardiovascular Data Registry of the American College of
Cardiology Foundation
FX This research was supported by the National Cardiovascular Data Registry
of the American College of Cardiology Foundation. The views expressed in
this article represent those of the author(s) and do not necessarily
represent the official views of the National Cardiovascular Data
Registry or its associated professional societies identified at
www.ncdr.com.
NR 22
TC 10
Z9 10
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7640
EI 1941-7632
J9 CIRC-CARDIOVASC INTE
JI Circ.-Cardiovasc. Interv.
PD APR
PY 2013
VL 6
IS 2
BP 131
EP 138
DI 10.1161/CIRCINTERVENTIONS.112.974857
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 298YT
UT WOS:000330361600011
PM 23532554
ER
PT J
AU Myat, A
Redwood, SR
Qureshi, AC
Thackray, S
Cleland, JGF
Bhatt, DL
Williams, B
Gersh, BJ
AF Myat, Aung
Redwood, Simon R.
Qureshi, Ayesha C.
Thackray, Simon
Cleland, John G. F.
Bhatt, Deepak L.
Williams, Bryan
Gersh, Bernard J.
TI Renal Sympathetic Denervation Therapy for Resistant Hypertension A
Contemporary Synopsis and Future Implications
SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS
LA English
DT Review
DE apparent resistant hypertension; radiofrequency ablation; renal
denervation; sympathetic nervous system; true resistant hypertension
ID LEFT-VENTRICULAR HYPERTROPHY; RANDOMIZED CONTROLLED-TRIAL; SYMPLICITY
HTN-2 TRIAL; HIGH-BLOOD-PRESSURE; HIGH-RISK; ARTERIAL-HYPERTENSION;
ATRIAL-FIBRILLATION; NERVOUS-SYSTEM; UNITED-STATES; SLEEP-APNEA
C1 [Myat, Aung; Redwood, Simon R.] Kings Coll London, BHF Ctr Res Excellence, London WC2R 2LS, England.
[Qureshi, Ayesha C.] Univ London, London, England.
[Thackray, Simon; Cleland, John G. F.] Univ Hull, Kingston Upon Hull, Yorks, England.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
[Williams, Bryan] UCL, London, England.
[Williams, Bryan] NIHR UCL Hosp Biomed Res Ctr, London, England.
[Gersh, Bernard J.] Mayo Clin, Coll Med, Rochester, MN 55905 USA.
RP Gersh, BJ (reprint author), Mayo Clin, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA.
EM Gersh.Bernard@mayo.edu
OI Cleland, John/0000-0002-1471-7016
FU British Heart Foundation [FS/11/70/28917]; Department of Health
NR 96
TC 14
Z9 18
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-7640
EI 1941-7632
J9 CIRC-CARDIOVASC INTE
JI Circ.-Cardiovasc. Interv.
PD APR
PY 2013
VL 6
IS 2
BP 184
EP 197
DI 10.1161/CIRCINTERVENTIONS.112.000037
PG 14
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 298YT
UT WOS:000330361600018
PM 23591420
ER
PT J
AU Greeson, J
Douglas, H
Hoge, EA
Chesney, MA
AF Greeson, Jeffrey
Douglas, Haley
Hoge, Elizabeth A.
Chesney, Margaret A.
TI THE IMPACT OF MINDFULNESS-BASED INTERVENTIONS ON MECHANISMS OF STRESS
REACTIVITY & RECOVERY
SO PSYCHOSOMATIC MEDICINE
LA English
DT Meeting Abstract
CT 71st Annual Scientific Meeting of the American-Psychosomatic-Society
CY MAR 13-16, 2013
CL Miami, FL
SP Amer Psychosomat Soc
C1 [Greeson, Jeffrey] Duke Univ, Med Ctr, Durham, NC USA.
[Douglas, Haley] Univ Washington, Seattle, WA 98195 USA.
[Hoge, Elizabeth A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Chesney, Margaret A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RI Greeson, Jeffrey/A-9272-2009
OI Greeson, Jeffrey/0000-0003-4871-1197
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD APR
PY 2013
VL 75
IS 3
BP A2
EP A2
PG 1
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 300MG
UT WOS:000330467400002
ER
PT J
AU Hoge, EA
Metcalf, CA
Morris, LK
Simon, NM
AF Hoge, Elizabeth A.
Metcalf, Christina A.
Morris, Laura K.
Simon, Naomi M.
TI MINDFULNESS MEDITATION FOR GENERALIZED ANXIETY DISORDER: EFFECTS ON
RESILIENCE, ANXIETY, AND HYPOTHALAMIC PITUITARY ADRENAL (HPA) AXIS
SO PSYCHOSOMATIC MEDICINE
LA English
DT Meeting Abstract
CT 71st Annual Scientific Meeting of the American-Psychosomatic-Society
CY MAR 13-16, 2013
CL Miami, FL
SP Amer Psychosomat Soc
C1 [Hoge, Elizabeth A.; Metcalf, Christina A.; Morris, Laura K.; Simon, Naomi M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 2
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD APR
PY 2013
VL 75
IS 3
BP A2
EP A2
PG 1
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 300MG
UT WOS:000330467400004
ER
PT J
AU Huffman, JC
Celano, CM
Suarez, L
Mastromauro, CA
Januzzi, JL
AF Huffman, Jeff C.
Celano, Christopher M.
Suarez, Laura
Mastromauro, Carol A.
Januzzi, James L.
TI FEASIBILITY AND UTILITY OF SCREENING FOR DEPRESSION AND ANXIETY
DISORDERS IN PATIENTS WITH CARDIOVASCULAR DISEASE
SO PSYCHOSOMATIC MEDICINE
LA English
DT Meeting Abstract
CT 71st Annual Scientific Meeting of the American-Psychosomatic-Society
CY MAR 13-16, 2013
CL Miami, FL
SP Amer Psychosomat Soc
C1 [Huffman, Jeff C.; Celano, Christopher M.; Januzzi, James L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Suarez, Laura; Mastromauro, Carol A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD APR
PY 2013
VL 75
IS 3
BP A146
EP A146
PG 1
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 300MG
UT WOS:000330467400464
ER
PT J
AU Russell, DC
Smith, TL
Krahn, DD
Graskamp, P
Singh, D
Kolden, GG
Sigmund, H
Zhang, ZJ
AF Russell, Douglas C.
Smith, Tracey L.
Krahn, Dean D.
Graskamp, Peter
Singh, Dalip
Kolden, Gregory G.
Sigmund, Heidi
Zhang, Zhengjun
TI HEMODYNAMIC EFFECTS OF COGNITIVE BEHAVORAL STRESS MANAGEMENT IN
RECIPIENTS OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS: A RANDOMIZED
CLINICAL TRIAL
SO PSYCHOSOMATIC MEDICINE
LA English
DT Meeting Abstract
CT 71st Annual Scientific Meeting of the American-Psychosomatic-Society
CY MAR 13-16, 2013
CL Miami, FL
SP Amer Psychosomat Soc
C1 [Russell, Douglas C.; Smith, Tracey L.; Krahn, Dean D.; Sigmund, Heidi] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Graskamp, Peter; Singh, Dalip] Med Coll Wisconsin, Zablocki Vet Adm Med Ctr, Milwaukee, WI 53226 USA.
[Kolden, Gregory G.; Zhang, Zhengjun] Univ Wisconsin, Madison, WI USA.
RI Smith, Tracey/J-2030-2014
OI Smith, Tracey/0000-0001-5338-9142
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD APR
PY 2013
VL 75
IS 3
BP A50
EP A51
PG 2
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA 300MG
UT WOS:000330467400163
ER
PT J
AU Carroll, L
AF Carroll, L.
TI The effect of intensive care unit work environment on nurse perceptions
of family presence during resuscitation and invasive procedures
SO EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING
LA English
DT Meeting Abstract
C1 [Carroll, L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 2
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1474-5151
EI 1873-1953
J9 EUR J CARDIOVASC NUR
JI Eur. J. Cardiovasc. Nurs.
PD APR
PY 2013
VL 12
SU 1
MA P210
BP S80
EP S80
PG 1
WC Cardiac & Cardiovascular Systems; Nursing
SC Cardiovascular System & Cardiology; Nursing
GA 276FW
UT WOS:000328735000156
ER
PT J
AU Potter, MP
Buxton, D
Bostic, JQ
AF Potter, Mona Patel
Buxton, David
Bostic, Jeff Q.
TI Coping Strategies for Child Bully-Victims
SO PEDIATRIC ANNALS
LA English
DT Article
ID SCHOOL-STUDENTS; PARENTAL MALTREATMENT; MIDDLE SCHOOL; VICTIMIZATION;
ASSOCIATIONS; RISK; INTERVENTION; ADOLESCENCE; EXPERIENCES; DEPRESSION
C1 [Potter, Mona Patel; Bostic, Jeff Q.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA.
[Buxton, David] Massachusetts Gen Hosp, McLean Hosp, Boston, MA 02114 USA.
[Bostic, Jeff Q.] Massachusetts Gen Hosp, Dept Psychiat, Sch Psychiat, Boston, MA 02114 USA.
RP Bostic, JQ (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 55 Fruit St, Boston, MA 02114 USA.
EM jbostic@partners.org
NR 31
TC 0
Z9 0
U1 1
U2 10
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0090-4481
EI 1938-2359
J9 PEDIATR ANN
JI Pediatr. Annu.
PD APR
PY 2013
VL 42
IS 4
BP 57
EP 61
DI 10.3928/00904481-20130326-08
PG 5
WC Pediatrics
SC Pediatrics
GA 273RB
UT WOS:000328552900001
ER
PT J
AU Buxton, D
Clancy, S
O'Malley, P
AF Buxton, David
Clancy, Sandra
O'Malley, Patricia
TI Working with Families Perceived as Difficult
SO PEDIATRIC ANNALS
LA English
DT Article
ID CARE; CHILDREN
C1 [Buxton, David] Massachusetts Gen Hosp, McLean Hosp, Boston, MA 02114 USA.
[Clancy, Sandra; O'Malley, Patricia] Massachusetts Gen Hosp, Pediat Palliat Care Serv, Boston, MA 02114 USA.
[Clancy, Sandra] Massachusetts Gen Hosp Children, Family Advisory Council, Boston, MA USA.
[O'Malley, Patricia] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Buxton, D (reprint author), 151 Tremont St,Apt 18U, Boston, MA 02111 USA.
EM dbuxton80@yahoo.com
NR 6
TC 1
Z9 1
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0090-4481
EI 1938-2359
J9 PEDIATR ANN
JI Pediatr. Annu.
PD APR
PY 2013
VL 42
IS 4
BP 167
EP 171
DI 10.3928/00904481-20130326-13
PG 5
WC Pediatrics
SC Pediatrics
GA 273RB
UT WOS:000328552900018
PM 23556530
ER
PT J
AU Nguyen, T
Edmonds, S
Solimeo, S
Wolinsky, F
Roblin, D
Saag, K
Cram, P
AF Thuy Nguyen
Edmonds, Stephanie
Solimeo, Samantha
Wolinsky, Fredric
Roblin, Douglas
Saag, Kenneth
Cram, Peter
TI SEX AND RACIAL DIFFERENCES OF OSTEO POROSIS KNOWLEDGE AMONG PATIENTS
PRESENTING FOR DXA
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Meeting Abstract
CT Interdisciplinary Symposium on Osteoporosis - Patient-Centered Care -
Developing Successful Bone Health Teams
CY APR 18-21, 2013
CL Chicago, IL
SP Natl Osteoporosis Fdn
C1 [Thuy Nguyen; Edmonds, Stephanie; Wolinsky, Fredric; Cram, Peter] Univ Iowa, Iowa City, IA USA.
[Solimeo, Samantha] US Dept Vet Affairs, Iowa City, IA USA.
[Roblin, Douglas] Kaiser Permanente, Atlanta, GA USA.
[Saag, Kenneth] Univ Alabama Birmingham, Birmingham, AL USA.
RI Cram, Peter/K-4472-2014
OI Cram, Peter/0000-0002-1910-346X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
EI 1433-2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD APR
PY 2013
VL 24
SU 2
MA P25
BP S436
EP S437
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 270WN
UT WOS:000328350000025
ER
PT J
AU Cucciare, MA
Simpson, T
Hoggatt, KJ
Gifford, E
Timko, C
AF Cucciare, Michael A.
Simpson, Tracy
Hoggatt, Katherine J.
Gifford, Elizabeth
Timko, Christine
TI SUBSTANCE USE AMONG WOMEN VETERANS: EPIDEMIOLOGY TO EVIDENCE-BASED
TREATMENT
SO JOURNAL OF ADDICTIVE DISEASES
LA English
DT Article
DE Substance misuse; women Veterans; alcohol; drugs; screening;
evidence-based treatment
ID BRIEF ALCOHOL INTERVENTION; BEHAVIORAL-COUNSELING INTERVENTIONS;
RANDOMIZED CONTROLLED-TRIAL; DRUG-DEPENDENT WOMEN; AFFAIRS HEALTH-CARE;
USE DISORDERS; FEMALE VETERANS; GENDER-DIFFERENCES; PREGNANT-WOMEN;
CLINICAL-TRIAL
AB An increasing percentage of women are U.S. Military Veterans. We review the substance misuse rates and comorbidities and the risk factors for and consequences of substance use among women Veterans. Women Veterans may have higher rates of substance misuse and comorbid psychiatric and medical disorders than male Veterans and women who are not Veterans. Studies support the AUDIT-C as a scaled marker of alcohol-related risk among female Veterans, but validated drug screening instruments are needed. We discuss evidence-based approaches in terms of treating women Veterans' substance misuse in primary and specialty care settings, along with knowledge gaps and potential research priorities to improve care in this special population.
C1 [Cucciare, Michael A.; Gifford, Elizabeth; Timko, Christine] Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA.
[Simpson, Tracy] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA.
[Simpson, Tracy] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Hoggatt, Katherine J.] Vet Affairs Greater Los Angeles Hlth Care Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA USA.
[Gifford, Elizabeth] Vet Affairs Palo Alto Hlth Care Syst, Program Evaluat Resource Ctr, Menlo Pk, CA 94025 USA.
[Timko, Christine] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA.
RP Cucciare, MA (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, 795 Willow Rd 152, Menlo Pk, CA 94025 USA.
EM michael.cucciare@va.gov
NR 98
TC 14
Z9 14
U1 4
U2 12
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1055-0887
EI 1545-0848
J9 J ADDICT DIS
JI J. Addict. Dis.
PD APR 1
PY 2013
VL 32
IS 2
BP 119
EP 139
DI 10.1080/10550887.2013.795465
PG 21
WC Substance Abuse
SC Substance Abuse
GA 262SD
UT WOS:000327757000001
PM 23815420
ER
PT J
AU Kalapatapu, RK
Lewis, DF
Vinogradov, S
Batki, SL
Winhusen, T
AF Kalapatapu, Raj K.
Lewis, Daniel F.
Vinogradov, Sophia
Batki, Steven L.
Winhusen, Theresa
TI RELATIONSHIP OF AGE TO IMPULSIVITY AND DECISION MAKING: A BASELINE
SECONDARY ANALYSIS OF A BEHAVIORAL TREATMENT STUDY IN STIMULANT USE
DISORDERS
SO JOURNAL OF ADDICTIVE DISEASES
LA English
DT Article
DE Cocaine; methamphetamine; aging; addiction; neurocognitive
ID RANDOMIZED CONTROLLED-TRIAL; SUBSTANCE USE DISORDERS; COCAINE-DEPENDENT
INDIVIDUALS; IOWA GAMBLING TASK; BORDERLINE PERSONALITY-DISORDER;
DRUG-ABUSE; OLDER-ADULTS; COGNITIVE REHABILITATION; METHAMPHETAMINE USE;
EXECUTIVE FUNCTIONS
AB Because stimulant use disorders remain prevalent across the lifespan, cognition is an important area of clinical care and research focus among aging adults with stimulant use disorders. This secondary analysis of a National Institute on Drug Abuse Clinical Trials Network study suggests that decision making, verbal learning/memory, executive function, and set shifting are important cognitive domains to screen clinically and treat in aging adults with stimulant use disorders. Some suggestions are made on how clinical treatment providers can practically use these results. An important direction for future research is the development of cognitively remediating treatments for impaired cognitive domains in aging adults with stimulant use disorders.
C1 [Kalapatapu, Raj K.; Vinogradov, Sophia; Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Kalapatapu, Raj K.; Vinogradov, Sophia; Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Lewis, Daniel F.; Winhusen, Theresa] Univ Cincinnati, Coll Med, Cincinnati Addict Res Ctr, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA.
RP Kalapatapu, RK (reprint author), San Francisco VA Med Ctr, Bldg 8 Mental Hlth,Room 4C,4150 Clement St, San Francisco, CA 94121 USA.
EM kalapatapu.raj.k@gmail.com
OI Winhusen, Theresa/0000-0002-3364-0739
FU NIDA NIH HHS [T32 DA007294, U10DA013732, K23 DA034883, K23DA 034883, U10
DA013732]
NR 94
TC 2
Z9 2
U1 1
U2 10
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1055-0887
EI 1545-0848
J9 J ADDICT DIS
JI J. Addict. Dis.
PD APR 1
PY 2013
VL 32
IS 2
BP 206
EP 216
DI 10.1080/10550887.2013.795471
PG 11
WC Substance Abuse
SC Substance Abuse
GA 262SD
UT WOS:000327757000007
PM 23815427
ER
PT J
AU Berman, NC
Calkins, AW
Abramowitz, JS
AF Berman, Noah C.
Calkins, Amanda W.
Abramowitz, Jonathan S.
TI Longer-term effects of inducing harm related intrusions: Implications
for research on obsessional phenomena
SO JOURNAL OF OBSESSIVE-COMPULSIVE AND RELATED DISORDERS
LA English
DT Article
DE Thought Action Fusion; In Vivo; OCD; Experimental Paradigm
ID THOUGHT-ACTION FUSION; COMPULSIVE DISORDER; COGNITIVE THEORY;
NEUTRALIZATION; QUESTIONNAIRE; VALIDATION; INVENTORY; BELIEFS
AB Although numerous researchers use in vivo thought induction paradigms to study obsessional phenomena, institutional review boards (IRBs) frequently raise questions about the potential harm that these studies might cause non-treatment seeking participants and clinical psychologists have argued that these paradigms might violate the APA ethics code. Thus, the current study examined longer-term psychological effects of inducing harm-related intrusive thoughts in non-treatment seeking undergraduates. Participants were asked to think about a close relative or friend getting into a car collision and then rated their level of distress and thought action fusion-like (TAF) beliefs. One week later, participants completed an online survey that assessed their current level of distress, TAF beliefs, and their interpretation of intrusions. We found significant decreases in vivo ratings of: anxiety, likelihood TAF, moral TAF, and the urge to neutralize the effects of thinking the thought. Additionally, participants considered their intrusive thoughts to be less significant and dangerous after a week's time. Our data suggest that thought induction paradigms are not associated with longer-term psychological risk and provide a safe and non-intrusive way of studying OCD phenomena in a laboratory setting. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Berman, Noah C.; Abramowitz, Jonathan S.] Univ N Carolina, Chapel Hill, NC 27599 USA.
[Calkins, Amanda W.] Boston Univ, Ctr Anxiety Related Disorders, Boston, MA 02215 USA.
RP Berman, NC (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St,ACC 815, Boston, MA 02114 USA.
EM berman.noah@gmail.com
OI Baker, Amanda/0000-0002-0103-5411
NR 25
TC 0
Z9 0
U1 2
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2211-3649
J9 J OBSESS-COMPULS REL
JI J. Obsessive-Compuls. Relat. Disord.
PD APR
PY 2013
VL 2
IS 2
BP 109
EP 113
DI 10.1016/j.jocrd.2013.01.006
PG 5
WC Psychiatry
SC Psychiatry
GA 257VB
UT WOS:000327414800006
ER
PT J
AU Goetter, EM
Herbert, JD
Forman, EM
Yuen, EK
Gershkovich, M
Glassman, LH
Rabin, SJ
Goldstein, SP
AF Goetter, Elizabeth M.
Herbert, James D.
Forman, Evan M.
Yuen, Erica K.
Gershkovich, Marina
Glassman, Lisa H.
Rabin, Stephanie J.
Goldstein, Stephanie P.
TI Delivering exposure and ritual prevention for obsessive-compulsive
disorder via videoconference: Clinical considerations and
recommendations
SO JOURNAL OF OBSESSIVE-COMPULSIVE AND RELATED DISORDERS
LA English
DT Article
DE Obsessive-compulsive disorder; Exposure and ritual prevention;
Telehealth; Videoconference-mediated exposure therapy
ID COGNITIVE-BEHAVIORAL THERAPY; QUALITY-OF-LIFE;
POSTTRAUMATIC-STRESS-DISORDER; WORKING ALLIANCE INVENTORY; BECK
DEPRESSION INVENTORY; RESPONSE PREVENTION; CONTROLLED-TRIAL;
COMORBIDITY; PSYCHOTHERAPY; VALIDATION
AB Exposure and ritual prevention (ERP) has been shown to be effective for treating obsessive-compulsive disorder (OCD), but many people with OCD are not able to access this specialized, evidence-based mental health treatment. Internet-mediated technologies, e.g., videoconferencing, represent a way to increase the availability of evidence-based treatments such as ERP, but given that OCD is a complex disorder requiring a nuanced treatment approach, clinicians attempting to implement ERP remotely should appreciate not only the advantages but also the challenges associated with treating OCD from a distance. Using a case example, we describe this treatment method and discuss relevant clinical considerations. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Goetter, Elizabeth M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Goetter, Elizabeth M.; Herbert, James D.; Forman, Evan M.; Gershkovich, Marina; Glassman, Lisa H.; Rabin, Stephanie J.; Goldstein, Stephanie P.] Drexel Univ, Philadelphia, PA 19104 USA.
[Yuen, Erica K.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Yuen, Erica K.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29401 USA.
[Rabin, Stephanie J.] Minneapolis VA Hlth Care Syst, Minneapolis, MN 55417 USA.
RP Goetter, EM (reprint author), Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Disorders, 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA.
EM egoetter@partners.org
RI Forman, Evan/I-1042-2012;
OI Rabin, Stephanie/0000-0002-8282-0867
NR 70
TC 6
Z9 6
U1 4
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2211-3649
J9 J OBSESS-COMPULS REL
JI J. Obsessive-Compuls. Relat. Disord.
PD APR
PY 2013
VL 2
IS 2
BP 137
EP U108
DI 10.1016/j.jocrd.2013.01.003
PG 9
WC Psychiatry
SC Psychiatry
GA 257VB
UT WOS:000327414800010
ER
PT J
AU Rasmussen, JL
Brown, TA
Steketee, GS
Barlow, DH
AF Rasmussen, Jessica L.
Brown, Timothy A.
Steketee, Gail S.
Barlow, David H.
TI Impulsivity in hoarding
SO JOURNAL OF OBSESSIVE-COMPULSIVE AND RELATED DISORDERS
LA English
DT Article
DE Hoarding; Acquisition; Impulsivity
ID OBSESSIVE-COMPULSIVE DISORDER; COGNITIVE-BEHAVIORAL THERAPY; RISK-TASK
BART; DECISION-MAKING; COMMUNITY SAMPLE; SYMPTOM; MODEL; AGE;
INHIBITION; COMORBIDITY
AB Acquisition in hoarding appears to have impulsive features likely to be evident in behavioral impulsivity and response inhibition. This study used a multi-dimensional model of impulsivity to examine this construct in participants with hoarding (n=32) and anxiety disorders (n=32) who received a diagnostic assessment and completed self-report forms and neuropsychological tasks measuring impulsivity. A diagnosis of hoarding predicted higher levels of self-reported urgency, as well as greater difficulties with response inhibition and lowered adaptive and maladaptive risk taking, independent of social phobia, generalized anxiety disorder and major depressive disorder. However, when age was controlled, hoarding ceased to predict these outcomes independent of other psychiatric diagnoses. Although specific symptoms of hoarding appeared significantly related to some aspects of impulsivity, analyses indicated that age accounted for these findings. In the present study, as in other studies, hoarding participants averaged approximately 25 years older than those with anxiety disorders, rendering examination of response inhibition and risk taking in hoarding versus anxiety disorders more difficult. Further research on other aspects of impulsivity (e.g., reward delay, planning/foresight) in hoarding and other psychiatric conditions with age matched comparison samples can advance understanding of these disorders and potentially lead to innovative treatments. Published by Elsevier Inc.
C1 [Rasmussen, Jessica L.; Brown, Timothy A.; Barlow, David H.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
[Steketee, Gail S.] Boston Univ, Sch Social Work, Boston, MA 02215 USA.
RP Rasmussen, JL (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 185 Cambridge St,2nd Floor, Boston, MA 02215 USA.
EM jrasmuss@bu.edu
FU university dissertation award
FX Funding for this study was provided by a university dissertation award.
The grantees of the award had no role in the study design, collection,
analysis or interpretation of data, writing the manuscript or the
decision to submit the manuscript for publication.
NR 50
TC 6
Z9 6
U1 6
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2211-3649
J9 J OBSESS-COMPULS REL
JI J. Obsessive-Compuls. Relat. Disord.
PD APR
PY 2013
VL 2
IS 2
BP 183
EP 191
DI 10.1016/j.jocrd.2013.02.004
PG 9
WC Psychiatry
SC Psychiatry
GA 257VB
UT WOS:000327414800016
ER
PT J
AU Sampaio, AS
Hounie, AG
Petribu, K
Cappi, C
Morais, IA
Quarantini, LC
Filho, HPV
do Rosario, MD
Stewart, SE
Fargeness, J
Matthews, C
Arnold, P
Richter, M
Kennedy, J
Hanna, GL
Pauls, DL
Miguel, EC
AF Sampaio, A. S.
Hounie, A. G.
Petribu, K.
Cappi, C.
Morais, I. A.
Quarantini, L. C.
Filho, H. P. V.
da Conceicao do Rosario, M.
Stewart, S. E.
Fargeness, J.
Matthews, C.
Arnold, P.
Richter, M.
Kennedy, J.
Hanna, G. L.
Pauls, D. L.
Miguel Filho, E. C.
TI Association between MAO-A and Obsessive-Compulsive Disorder related
phenotypes
SO JOURNAL OF OBSESSIVE-COMPULSIVE AND RELATED DISORDERS
LA English
DT Meeting Abstract
DE Obsessive-Compulsive Disorder; Catechol-O-Methyltransferase; Monoamine
Oxidase; Genetic Association Study
C1 [Sampaio, A. S.; Hounie, A. G.; Cappi, C.; Morais, I. A.; Filho, H. P. V.; Miguel Filho, E. C.] Univ Sao Paulo, Fac Med, Dept & Inst Psychiat, Sao Paulo, Brazil.
[Sampaio, A. S.; Quarantini, L. C.] Univ Fed Bahia, UFBA Fed Univ Bahia, Fac Med, Salvador, BA, Brazil.
[Petribu, K.] Univ Pernambuco, UPE, Fac Ciencias Med, Recife, PE, Brazil.
[da Conceicao do Rosario, M.] Univ Fed Sao Paulo, UNIFESP, Sao Paulo, Brazil.
[Stewart, S. E.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Stewart, S. E.; Fargeness, J.; Pauls, D. L.] Massachusetts Gen Hosp, PNGU, Boston, MA 02114 USA.
[Matthews, C.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Arnold, P.; Richter, M.; Kennedy, J.] Univ Toronto, Toronto, ON, Canada.
[Hanna, G. L.] Univ Michigan, Ann Arbor, MI 48109 USA.
RI Stewart, Evelyn/K-6961-2014;
OI Stewart, S. Evelyn/0000-0002-0994-6383
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2211-3649
J9 J OBSESS-COMPULS REL
JI J. Obsessive-Compuls. Relat. Disord.
PD APR
PY 2013
VL 2
IS 2
BP 228
EP 228
PG 1
WC Psychiatry
SC Psychiatry
GA 257VB
UT WOS:000327414800038
ER
PT J
AU Zivin, K
AF Zivin, Kara
TI How Are Prescribing Decisions Made?
SO PSYCHIATRIC SERVICES
LA English
DT Editorial Material
C1 [Zivin, Kara] US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI USA.
[Zivin, Kara] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA.
RP Zivin, K (reprint author), US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD APR
PY 2013
VL 64
IS 4
BP 295
EP 295
PG 1
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255VL
UT WOS:000327268100007
PM 23543162
ER
PT J
AU Rosen, MI
Afshartous, DR
Nwosu, S
Scott, MC
Jackson, JC
Marx, BP
Murdoch, M
Sinnott, PL
Speroff, T
AF Rosen, Marc I.
Afshartous, David R.
Nwosu, Samuel
Scott, Melanie C.
Jackson, James C.
Marx, Brian P.
Murdoch, Maureen
Sinnott, Patricia L.
Speroff, Theodore
TI Racial Differences in Veterans' Satisfaction With Examination of
Disability From Posttraumatic Stress Disorder
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID PATIENT SATISFACTION; ATTITUDES; CARE; CLINICIAN; DISPARITIES; BENEFITS;
SCALE
AB Objective: The examination that determines if a veteran has service-connected posttraumatic stress disorder (PTSD) affects veterans' lives for years. This study examined factors potentially associated with veterans' perception of their examination's quality. Methods: Veterans (N=384) being evaluated for an initial PTSD service-connection claim were randomly assigned to receive either a semistructured interview or the examiner's usual interview. Immediately after the interview, veterans completed confidential ratings of the examinations' quality and of their examiners' interpersonal qualities and competence. Extensive data characterizing the veterans, the 33 participating examiners, and the examinations themselves were collected. Results: Forty-seven percent of Caucasian veterans and 34% of African-American veterans rated their examination quality as excellent. African Americans were less likely than Caucasians to assign a higher quality rating (odds ratio=.61, 95% confidence interval=.38-.99, p=.047). Compared with Caucasians, African Americans rated their examiners as having significantly worse interpersonal qualities but not lower competence. Ratings were not significantly related to the veterans' age, gender, marital status, eventual diagnosis of PTSD, Global Assessment of Functioning score, the examiner's perception of the prevalence of malingering, or the presence of a third party during the examination. Conclusions: Ratings of disability examinations were generally high, although ratings were less favorable among African-American veterans than among Caucasian veterans.
C1 [Rosen, Marc I.] Vet Affairs VA Connecticut Healthcare Syst, Dept Psychiat, West Haven, CT 06516 USA.
[Scott, Melanie C.] Vet Affairs VA Connecticut Healthcare Syst, Dept Psychol, West Haven, CT 06516 USA.
[Rosen, Marc I.; Scott, Melanie C.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Afshartous, David R.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA.
[Nwosu, Samuel; Jackson, James C.; Speroff, Theodore] VA Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA.
[Nwosu, Samuel; Jackson, James C.; Speroff, Theodore] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
[Speroff, Theodore] VA Boston Healthcare Syst, Dept Biostat, Boston, MA USA.
[Jackson, James C.] VA Boston Healthcare Syst, Dept Medicine, Boston, MA USA.
[Marx, Brian P.] VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Boston, MA USA.
Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Murdoch, Maureen] Univ Minnesota, Sch Med, Gen Internal Med Sect, Ctr Chron Dis Outcomes Res,Minneapolis VA Hlth Ca, Minneapolis, MN 55455 USA.
[Murdoch, Maureen] Univ Minnesota, Sch Med, Dept Internal Med, Minneapolis, MN 55455 USA.
[Sinnott, Patricia L.] VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Palo Alto, CA USA.
[Sinnott, Patricia L.] Stanford Univ, Ctr Hlth Policy, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA.
RP Rosen, MI (reprint author), Vet Affairs VA Connecticut Healthcare Syst, Dept Psychiat, 116A, West Haven, CT 06516 USA.
EM marc.rosen@yale.edu
FU Veterans Affairs (VA) Health Services Research and Development Quality
Enhancement Research Initiative Program [SDR 06-331]; Veterans
Integrated Service Network 1 Mental Illness Research, Education and
Clinical Center; Raytheon BBN Technologies; Charles River Analytics
FX This project was supported by the Veterans Affairs (VA) Health Services
Research and Development Quality Enhancement Research Initiative Program
(SDR 06-331) and by the Veterans Integrated Service Network 1 Mental
Illness Research, Education and Clinical Center. The authors thank the
E3-PTSD collaborative investigators for their work in this study,
including Heather Davis-Underwood, Elliot Fielstein, Elise Ratchford,
Katherine Strickland, Dorothy Scanlan, Karin E. Thompson, Sheila
Corrigan, Janet C'deBaca, Mitzi Dearborn, Michelle Sharp, Christina M.
Klauber, Elizabeth Jones, Erin Olgren, Eli Reich, Rachel Coleman,
Yordanka Koleva, and Lisa Fenton; the Veterans Benefits Administration
Systematic Technical Accuracy Review program; and the VA medical centers
that participated in this project.; Dr. Marx receives support from
Raytheon BBN Technologies and Charles River Analytics. The other authors
report no competing interests.
NR 32
TC 1
Z9 1
U1 1
U2 2
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD APR
PY 2013
VL 64
IS 4
BP 354
EP 359
DI 10.1176/appi.ps.201100526
PG 6
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255VL
UT WOS:000327268100017
PM 23318842
ER
PT J
AU Marx, BP
Pollack, S
AF Marx, Brian P.
Pollack, Stacey
TI A False Dilemma and an Unfair Characterization of Veterans
SO PSYCHIATRIC SERVICES
LA English
DT Letter
ID POSTTRAUMATIC-STRESS-DISORDER; THERAPY
C1 [Marx, Brian P.] VA Boston Healthcare Syst, VA Natl Ctr Posttraumat Stress Disorder, Boston, MA USA.
[Marx, Brian P.] Boston Univ, Sch Med, Boston, MA 02215 USA.
[Pollack, Stacey] US Dept Vet Affairs, Washington, DC USA.
RP Marx, BP (reprint author), VA Boston Healthcare Syst, VA Natl Ctr Posttraumat Stress Disorder, Boston, MA USA.
NR 6
TC 1
Z9 1
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD APR
PY 2013
VL 64
IS 4
BP 392
EP 392
PG 1
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255VL
UT WOS:000327268100026
PM 23543170
ER
PT J
AU Yang, S
AF Yang, Suzanne
TI The Routledge Handbook of Deviant Behavior
SO PSYCHIATRIC SERVICES
LA English
DT Book Review
C1 [Yang, Suzanne] Vet Affairs Pittsburgh Healthcare Syst, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Yang, S (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA.
NR 1
TC 0
Z9 0
U1 0
U2 1
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD APR
PY 2013
VL 64
IS 4
BP E4
EP E4
PG 1
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 255VL
UT WOS:000327268100004
ER
PT J
AU Alonso, A
Krijthe, BP
Aspelund, T
Stepas, KA
Pencina, MJ
Moser, CB
Sinner, MF
Sotoodehnia, N
Fontes, JD
Janssens, ACJW
Kronmal, RA
Magnani, JW
Witteman, JC
Chamberlain, AM
Lubitz, SA
Schnabel, RB
Agarwal, SK
McManus, DD
Ellinor, PT
Larson, MG
Burke, GL
Launer, LJ
Hofman, A
Levy, D
Gottdiener, JS
Kaab, S
Couper, D
Harris, TB
Soliman, EZ
Stricker, BHC
Gudnason, V
Heckbert, SR
Benjamin, EJ
AF Alonso, Alvaro
Krijthe, Bouwe P.
Aspelund, Thor
Stepas, Katherine A.
Pencina, Michael J.
Moser, Carlee B.
Sinner, Moritz F.
Sotoodehnia, Nona
Fontes, Joao D.
Janssens, A. Cecile J. W.
Kronmal, Richard A.
Magnani, Jared W.
Witteman, Jacqueline C.
Chamberlain, Alanna M.
Lubitz, Steven A.
Schnabel, Renate B.
Agarwal, Sunil K.
McManus, David D.
Ellinor, Patrick T.
Larson, Martin G.
Burke, Gregory L.
Launer, Lenore J.
Hofman, Albert
Levy, Daniel
Gottdiener, John S.
Kaeaeb, Stefan
Couper, David
Harris, Tamara B.
Soliman, Elsayed Z.
Stricker, Bruno H. C.
Gudnason, Vilmundur
Heckbert, Susan R.
Benjamin, Emelia J.
TI Simple Risk Model Predicts Incidence of Atrial Fibrillation in a
Racially and Geographically Diverse Population: the CHARGE-AF Consortium
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE atrial fibrillation; epidemiology; risk factors
ID ATHEROSCLEROSIS RISK; AFRICAN-AMERICANS; SURVIVAL ANALYSIS;
HEART-FAILURE; COMMUNITIES; FLUTTER; DESIGN; STROKE; PREVALENCE; WHITES
AB Background-Tools for the prediction of atrial fibrillation (AF) may identify high-risk individuals more likely to benefit from preventive interventions and serve as a benchmark to test novel putative risk factors.
Methods and Results-Individual-level data from 3 large cohorts in the United States (Atherosclerosis Risk in Communities [ARIC] study, the Cardiovascular Health Study [CHS], and the Framingham Heart Study [FHS]), including 18 556 men and women aged 46 to 94 years (19% African Americans, 81% whites) were pooled to derive predictive models for AF using clinical variables. Validation of the derived models was performed in 7672 participants from the Age, Gene and Environment-Reykjavik study (AGES) and the Rotterdam Study (RS). The analysis included 1186 incident AF cases in the derivation cohorts and 585 in the validation cohorts. A simple 5-year predictive model including the variables age, race, height, weight, systolic and diastolic blood pressure, current smoking, use of antihypertensive medication, diabetes, and history of myocardial infarction and heart failure had good discrimination (C-statistic, 0.765; 95% CI, 0.748 to 0.781). Addition of variables from the electrocardiogram did not improve the overall model discrimination (C-statistic, 0.767; 95% CI, 0.750 to 0.783; categorical net reclassification improvement, -0.0032; 95% CI, -0.0178 to 0.0113). In the validation cohorts, discrimination was acceptable (AGES C-statistic, 0.664; 95% CI, 0.632 to 0.697 and RS C-statistic, 0.705; 95% CI, 0.664 to 0.747) and calibration was adequate.
Conclusion-A risk model including variables readily available in primary care settings adequately predicted AF in diverse populations from the United States and Europe.
C1 [Alonso, Alvaro] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA.
[Krijthe, Bouwe P.; Janssens, A. Cecile J. W.; Witteman, Jacqueline C.; Hofman, Albert; Stricker, Bruno H. C.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
[Stricker, Bruno H. C.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
[Stricker, Bruno H. C.] Erasmus MC, Dept Med Informat, Rotterdam, Netherlands.
[Aspelund, Thor; Gudnason, Vilmundur] Iceland Heart Assoc, Res Inst, Kopavogur, Iceland.
[Aspelund, Thor; Gudnason, Vilmundur] Univ Iceland, Reykjavik, Iceland.
[Stepas, Katherine A.; Pencina, Michael J.; Moser, Carlee B.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Lubitz, Steven A.; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
[Sotoodehnia, Nona] Univ Washington, Dept Med, Div Cardiol, Seattle, WA USA.
[Sotoodehnia, Nona] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Kronmal, Richard A.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Sinner, Moritz F.; Fontes, Joao D.; Magnani, Jared W.; McManus, David D.; Larson, Martin G.; Levy, Daniel; Benjamin, Emelia J.] NHLBI, Framingham, MA USA.
[Sinner, Moritz F.; Fontes, Joao D.; Magnani, Jared W.; McManus, David D.; Larson, Martin G.; Levy, Daniel; Benjamin, Emelia J.] Boston Univ, Framingham Heart Study, Framingham, MA USA.
[Magnani, Jared W.; Benjamin, Emelia J.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Chamberlain, Alanna M.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
[Sinner, Moritz F.; Lubitz, Steven A.; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA.
[Schnabel, Renate B.] Univ Heart Ctr Hamburg Eppendorf, Dept Gen & Intervent Cardiol, Eppendorf, Germany.
[Agarwal, Sunil K.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA.
[Couper, David] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC USA.
[Burke, Gregory L.] Wake Forest Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA.
[Launer, Lenore J.; Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, NIH, Bethesda, MD 20892 USA.
[Levy, Daniel] NHLBI, Ctr Populat Studies, Bethesda, MD 20892 USA.
[Gottdiener, John S.] Univ Maryland, Med Ctr, Div Cardiol, Baltimore, MD 21201 USA.
[Sinner, Moritz F.; Kaeaeb, Stefan] Univ Munich, Univ Hosp Munich, Dept Med 1, Munich, Germany.
[Soliman, Elsayed Z.] Wake Forest Univ, Sch Med, Dept Epidemiol & Prevent, Epidemiol Cardiol Res Ctr EPICARE, Winston Salem, NC 27109 USA.
[Stricker, Bruno H. C.] Inspectorate Hlth Care, The Hague, Netherlands.
[Kaeaeb, Stefan] Munich Heart Alliance, Munich, Germany.
[McManus, David D.] Univ Massachusetts, Dept Med, Worcester, MA 01605 USA.
[McManus, David D.] Univ Massachusetts, Dept Quantitat Hlth Sci, Worcester, MA 01605 USA.
[McManus, David D.] Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA.
RP Alonso, A (reprint author), Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, 1300 S 2nd St,Suite 300, Minneapolis, MN 55454 USA.
EM alonso@umn.edu; emelia@bu.edu
RI Schnabel, Renate/F-6527-2014; Aspelund, Thor/C-5983-2008; Gudnason,
Vilmundur/K-6885-2015; Alonso, Alvaro/A-4917-2010;
OI Aspelund, Thor/0000-0002-7998-5433; Gudnason,
Vilmundur/0000-0001-5696-0084; Alonso, Alvaro/0000-0002-2225-8323;
Larson, Martin/0000-0002-9631-1254; Janssens, A
Cecile/0000-0002-6153-4976; Benjamin, Emelia/0000-0003-4076-2336
FU NIH [N01-AG-12100]; NIA Intramural Research Program, Hjartavernd (the
Icelandic Heart Association); Althingi (the Icelandic Parliament);
National Heart, Lung, and Blood Institute [HHSN268201100005C,
HHSN268201100006C, HHSN268201100007C, HHSN268201100008C,
HHSN268201100009C, HHSN268201100010C, HHSN268201100011C,
HHSN268201100012C]; NHLBI [RC1HL099452, RC1HL101056, N01-HC-85239,
N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222,
N01-HC-75150, N01-HC-45133, HL080295, R01HL088456]; American Heart
Association [09SDG2280087, 09FTF2190028]; NIA [AG-023629, AG-15928,
AG-20098, AG-027058]; German Heart Foundation; Erasmus Medical Center;
Erasmus University, Rotterdam, Netherlands Organization for the Health
Research and Development (ZonMw); Research Institute for Diseases in the
Elderly (RIDE); Ministry of Education, Culture and Science; Ministry for
Health, Welfare and Sports; European Commission (DG XII); Municipality
of Rotterdam
FX AGES: The Age, Gene/Environment Susceptibility Reykjavik Study has been
funded by NIH contract N01-AG-12100, the NIA Intramural Research
Program, Hjartavernd (the Icelandic Heart Association), and the Althingi
(the Icelandic Parliament). ARIC: The Atherosclerosis Risk in
Communities Study is carried out as a collaborative study supported by
National Heart, Lung, and Blood Institute contracts (HHSN268201100005C,
HHSN268201100006C, HHSN268201100007C, HHSN268201100008C,
HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and
HHSN268201100012C). This work was additionally funded by grants
RC1HL099452 and RC1HL101056 from NHLBI and 09SDG2280087 from the
American Heart Association. CHS: The Cardiovascular Health Study was
supported by NHLBI contracts N01-HC-85239, N01-HC-85079 through
N01-HC-85086; N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150,
N01-HC-45133 and NHLBI grants HL080295 and R01HL088456, with additional
contribution from NINDS. Additional support was provided through
AG-023629, AG-15928, AG-20098, and AG-027058 from the NIA. See also
http://www.chs-nhlbi.org/pi.htm. FHS: 6R01-NS 17950, N01-HC 25195,
1R01HL092577 (to Drs. Ellinor and Benjamin), 1RC1HL101056 (to Drs.
Alonso and Benjamin), 1R01HL102214 (to Drs. Heckbert and Benjamin),
1R01AG028321 (to Dr. Benjamin), American Heart Association award
09FTF2190028 (to Dr. Magnani) and 1R21HL106092 (to Dr. Magnani). Dr.
Sinner was supported by the German Heart Foundation. RS: The Rotterdam
Study is funded by Erasmus Medical Center and Erasmus University,
Rotterdam, Netherlands Organization for the Health Research and
Development (ZonMw), the Research Institute for Diseases in the Elderly
(RIDE), the Ministry of Education, Culture and Science, the Ministry for
Health, Welfare and Sports, the European Commission (DG XII), and the
Municipality of Rotterdam.
NR 40
TC 115
Z9 116
U1 2
U2 22
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD APR
PY 2013
VL 2
IS 2
AR UNSP e000102
DI 10.1161/JAHA.112.000102
PG 20
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 243ST
UT WOS:000326338400002
PM 23537808
ER
PT J
AU Schwamm, LH
AF Schwamm, Lee H.
TI When in Rome, Do Like the Romans: Certifying Stroke Centers With the Rod
of Aesculapius or the Medical Caduceus of Hermes?
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Editorial Material
ID BRAIN ATTACK COALITION; ACUTE ISCHEMIC-STROKE; RECOMMENDATIONS;
ESTABLISHMENT; ASSOCIATION; STATEMENT
C1 [Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Schwamm, LH (reprint author), Massachusetts Gen Hosp, C Miller Fisher Endowed Chair, Dept Neurol ACC 720, MGH,55 Fruit St, Boston, MA 02114 USA.
EM lschwamm@partners.org
OI Schwamm, Lee/0000-0003-0592-9145
NR 21
TC 2
Z9 2
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD APR
PY 2013
VL 2
IS 2
AR UNSP e000120
DI 10.1161/JAHA.113.000120
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 243ST
UT WOS:000326338400001
PM 23557752
ER
PT J
AU Carl, JR
Soskin, DP
Kerns, C
Barlow, DH
AF Carl, Jenna R.
Soskin, David P.
Kerns, Caroline
Barlow, David H.
TI Positive emotion regulation in emotional disorders: A theoretical review
SO CLINICAL PSYCHOLOGY REVIEW
LA English
DT Review
DE Emotion regulation; Positive emotion; Anxiety; Depression; Bipolar
ID MAJOR DEPRESSIVE DISORDER; GENERALIZED ANXIETY DISORDER; LOVING-KINDNESS
MEDITATION; DSM-IV ANXIETY; AFFECTIVE STARTLE MODULATION; APPROACH
SYSTEM BAS; BIPOLAR DISORDER; ATTENTIONAL BIAS; BEHAVIORAL ACTIVATION;
NEGATIVE AFFECT
AB Conceptualizations of emotion regulation have led to the identification of cognitive and behavioral regulatory abnormalities that contribute to the development and maintenance of emotional disorders. However, existing research on emotion regulation in anxiety and mood disorders has primarily focused on the regulation of negative emotions rather than positive emotions. Recent findings indicate that disturbances in positive emotion regulation occur across emotional disorders, and may be a generative target for treatment research. The aims of this paper are to: 1. Present a transdiagnostic model of positive emotion disturbances in emotional disorders; 2. Review evidence for disturbances in positive emotion regulation in emotional disorders across categories of emotion regulation; and 3. Propose treatment strategies that may address these disturbances. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Carl, Jenna R.; Kerns, Caroline; Barlow, David H.] Boston Univ, Ctr Anxiety & Related Disorders, Dept Psychol, Boston, MA 02215 USA.
[Soskin, David P.] Harvard Univ, Sch Med, Ctr Treatment Resistant Depress, Depress Clin & Res Program,Massachusetts Gen Hosp, Boston, MA USA.
RP Carl, JR (reprint author), Boston Univ, Ctr Anxiety & Related Disorders, 648 Beacon St,6th Floor, Boston, MA 02215 USA.
EM jcarl@bu.edu
NR 189
TC 43
Z9 48
U1 17
U2 95
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0272-7358
EI 1873-7811
J9 CLIN PSYCHOL REV
JI Clin. Psychol. Rev.
PD APR
PY 2013
VL 33
IS 3
BP 343
EP 360
DI 10.1016/j.cpr.2013.01.003
PG 18
WC Psychology, Clinical
SC Psychology
GA 229DI
UT WOS:000325241600002
PM 23399829
ER
PT J
AU Tofthagen, C
Visovsky, CM
Hopgood, R
AF Tofthagen, Cindy
Visovsky, Constance M.
Hopgood, Rachelle
TI Chemotherapy-Induced Peripheral Neuropathy: An Algorithm to Guide
Nursing Management
SO CLINICAL JOURNAL OF ONCOLOGY NURSING
LA English
DT Article
ID PHARMACOLOGICAL MANAGEMENT; PAIN; RECOMMENDATIONS; STRENGTH; CANCER; GO
AB Oncology nurses play a critical role in the assessment and management of chemotherapy-induced peripheral neuropathy (CIPN). Baseline and ongoing evaluation of physical function is a critical but often overlooked aspect of assessment of CIPN. The diversity of symptoms and the complexity associated with neuromuscular assessment lead to challenges in evaluation and management of CIPN. To meet this challenge, the authors devised a feasible algorithm to guide oncology nurses in the assessment and management of CIPN using techniques that can easily be implemented in a variety of clinical settings. Managing pain, maintaining safety, and maximizing physical function are the primary goals for nursing management of CIPN.
C1 [Tofthagen, Cindy; Visovsky, Constance M.; Hopgood, Rachelle] Univ S Florida, Coll Nursing, Tampa, FL 33620 USA.
[Tofthagen, Cindy] Dana Farber Canc Inst, Phyllis F Cantor Ctr Res Nursing & Patient Care S, Boston, MA USA.
[Tofthagen, Cindy] Univ Massachusetts Boston, Boston, MA USA.
RP Tofthagen, C (reprint author), Univ S Florida, Coll Nursing, Tampa, FL 33620 USA.
EM ctofthag@health.usf.edu
FU NCI NIH HHS [U54 CA156732, U54 CA156734]
NR 36
TC 6
Z9 7
U1 2
U2 9
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 1092-1095
J9 CLIN J ONCOL NURS
JI Clin. J. Oncol. Nurs.
PD APR
PY 2013
VL 17
IS 2
BP 138
EP 144
DI 10.1188/13.CJON.138-144
PG 7
WC Oncology; Nursing
SC Oncology; Nursing
GA 220EC
UT WOS:000324563800008
PM 23538249
ER
PT J
AU Spiegel, BMR
AF Spiegel, Brennan M. R.
TI Patient-Reported Outcomes in Gastroenterology: Clinical and Research
Applications
SO JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY
LA English
DT Review
DE Gastroenterology; Patient-reported outcomes; Quality of life
ID QUALITY-OF-LIFE; GASTROESOPHAGEAL-REFLUX DISEASE;
IRRITABLE-BOWEL-SYNDROME; TREATMENT SATISFACTION QUESTIONNAIRE; UPPER
GASTROINTESTINAL DISORDERS; LAPAROSCOPIC NISSEN FUNDOPLICATION; FECAL
INCONTINENCE QUESTIONNAIRE; RANDOMIZED CONTROLLED-TRIAL;
INFORMATION-SYSTEM PROMIS; NEPEAN DYSPEPSIA INDEX
AB Patient-generated reports, also known as Patient-Reported Outcomes (PROs), capture the patients' illness experience in a structured format and may help bridge the gap between patients and providers. PROs measure any aspect of patient-reported health (e. g., physical, emotional or social symptoms) and can help to direct care and improve clinical outcomes. When clinicians systematically collect patient-reported data in the right place at the right time, PRO measurement can effectively aid in detection and management of conditions, improve satisfaction with care and enhance the patient-provider relationship. This review article summarizes the latest approaches to PRO measuring for clinical trials and clinical practice, with a focus on use of PROs in gastroenterology.
C1 [Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA.
[Spiegel, Brennan M. R.] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA.
RP Spiegel, BMR (reprint author), 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA.
EM bspiegel@mednet.ucla.edu
NR 139
TC 9
Z9 9
U1 2
U2 6
PU KOREAN SOC NEUROGASTERONTEROL & MOTILITY
PI GANGNAM-GU
PA RM 305, LOTTE GOLD ROSE VILL II, 31 SEOLLEUNG-RO 86-GIL, GANGNAM-GU,
SEOUL 135-839, SOUTH KOREA
SN 2093-0879
J9 J NEUROGASTROENTEROL
JI J. Neurogastroenterol. Motil.
PD APR
PY 2013
VL 19
IS 2
BP 137
EP 148
DI 10.5056/jnm.2013.19.2.137
PG 12
WC Gastroenterology & Hepatology; Clinical Neurology
SC Gastroenterology & Hepatology; Neurosciences & Neurology
GA 225ZV
UT WOS:000325004700004
PM 23667745
ER
PT J
AU Lin, PC
Giannopoulou, EG
Park, K
Mosquera, JM
Sboner, A
Tewari, AK
Garraway, LA
Beltran, H
Rubin, MA
Elemento, O
AF Lin, Pei-Chun
Giannopoulou, Eugenia G.
Park, Kyung
Mosquera, Juan Miguel
Sboner, Andrea
Tewari, Ashutosh K.
Garraway, Levi A.
Beltran, Himisha
Rubin, Mark A.
Elemento, Olivier
TI Epigenomic Alterations in Localized and Advanced Prostate Cancer
SO NEOPLASIA
LA English
DT Article
ID CANDIDATE TUMOR-SUPPRESSOR; DNA METHYLATION; DOWN-REGULATION;
MASS-SPECTROMETRY; GENOME; GENE; HYPERMETHYLATION; CELLS;
IDENTIFICATION; PROTEINS
AB Although prostate cancer (PCa) is the second leading cause of cancer death among men worldwide, not all men diagnosed with PCa will die from the disease. A critical challenge, therefore, is to distinguish indolent PCa from more advanced forms to guide appropriate treatment decisions. We used Enhanced Reduced Representation Bisulfite Sequencing, a genome-wide high-coverage single-base resolution DNA methylation method to profile seven localized PCa samples, seven matched benign prostate tissues, and six aggressive castration-resistant prostate cancer (CRPC) samples. We integrated these data with RNA-seq and whole-genome DNA-seq data to comprehensively characterize the PCa methylome, detect changes associated with disease progression, and identify novel candidate prognostic biomarkers. Our analyses revealed the correlation of cytosine guanine dinucleotide island (CGI)-specific hypermethylation with disease severity and association of certain breakpoints (deletion, tandem duplications, and interchromosomal translocations) with DNA methylation. Furthermore, integrative analysis of methylation and single-nucleotide polymorphisms (SNPs) uncovered widespread allele-specific methylation (ASM) for the first time in PCa. We found that most DNA methylation changes occurred in the context of ASM, suggesting that variations in tumor epigenetic landscape of individuals are partly mediated by genetic differences, which may affect PCa disease progression. We further selected a panel of 13 CGIs demonstrating increased DNA methylation with disease progression and validated this panel in an independent cohort of 20 benign prostate tissues, 16 PCa, and 8 aggressive CRPCs. These results warrant clinical evaluation in larger cohorts to help distinguish indolent PCa from advanced disease.
C1 [Lin, Pei-Chun; Park, Kyung; Mosquera, Juan Miguel; Sboner, Andrea; Rubin, Mark A.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA.
[Lin, Pei-Chun; Rubin, Mark A.] Weill Cornell Med Coll, Grad Sch Med Sci, Grad Program Biochem & Struct Biol Cell & Dev Bio, New York, NY 10065 USA.
[Giannopoulou, Eugenia G.; Elemento, Olivier] Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY 10065 USA.
[Giannopoulou, Eugenia G.; Sboner, Andrea; Elemento, Olivier] Weill Cornell Med Coll, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsau, New York, NY 10065 USA.
[Tewari, Ashutosh K.] Weill Cornell Med Coll, Dept Urol, New York, NY 10065 USA.
[Tewari, Ashutosh K.] Weill Cornell Med Coll, LeFrak Ctr Robot Surg, New York, NY 10065 USA.
[Garraway, Levi A.] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Garraway, Levi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Beltran, Himisha] Weill Cornell Med Coll, Dept Med, Div Hematol Oncol, New York, NY 10065 USA.
RP Elemento, O (reprint author), Weill Cornell Med Coll, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsau, Dept Physiol & Biophys, 1305 York Ave, New York, NY 10065 USA.
EM rubinma@med.cornell.edu; ole2001@med.cornell.edu
RI Sboner, Andrea/C-6487-2008;
OI Sboner, Andrea/0000-0001-6915-3070; Rubin, Mark/0000-0002-8321-9950
FU Early Detection Research Network [U01 CA 11275-07]; Prostate Cancer
Foundation Young Investigator Award; National Science Foundation CAREER
grant
FX This study was funded by the Early Detection Research Network grant U01
CA 11275-07 (M.A.R.), the Prostate Cancer Foundation Young Investigator
Award (H.B.), and the National Science Foundation CAREER grant (O.E.).
NR 48
TC 25
Z9 26
U1 2
U2 6
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648
USA
SN 1522-8002
J9 NEOPLASIA
JI Neoplasia
PD APR
PY 2013
VL 15
IS 4
BP 373
EP +
DI 10.1593/neo.122146
PG 15
WC Oncology
SC Oncology
GA 219DO
UT WOS:000324486000003
PM 23555183
ER
PT J
AU Salazar, G
Yeddula, K
Wicky, S
Oklu, R
Ganguli, S
Waltman, AC
Walker, TG
Kalva, SP
AF Salazar, Gloria
Yeddula, Kalpana
Wicky, Stephan
Oklu, Ramhi
Ganguli, Suvranu
Waltman, Arthur C.
Walker, Thomas G.
Kalva, Sanjeeva P.
TI Image-guided placement of port catheters: Is there an increased risk of
infection if the port is immediately accessed and used?
SO JOURNAL OF VASCULAR ACCESS
LA English
DT Article
DE Catheter-related infection; Central venous catheterization;
Chemotherapy; Interventional radiology; Ports; Vascular access
ID CENTRAL VENOUS ACCESS
AB Purpose: To compare complication rates in patients who have port-a-catheters inserted and left accessed for immediate use and those who have ports inserted but not accessed.
Methods: In this retrospective, IRB-approved study, medical records of patients who received a port catheter between 9/2009 and 2/2010 were reviewed. The data collected included patient demographics, diagnosis, procedure and complications. The patients were categorized into two groups: accessed (patients in whom the port was accessed with a Huber needle for immediate intravenous use and the patient left the procedure area with needle indwelling) and control (patients in whom the ports were not accessed). Complications were classified according to Society of Interventional Radiology guidelines. Results are given as mean +/- SD. Statistical analysis was performed with student t test and statistical significance was considered at P<.05.
Results: A total of 467 ports were placed in 465 patients (Men: 206); 10.7% in the accessed group (n=50, age: 60 +/- 13.9) and 89.3% in the control group (n=417, age: 59 +/- 13.5). There were no statistically significant differences in patient demographics between the groups. The overall complication rate was 0.6% (n=3). Two complications (hematoma causing skin necrosis and thrombosis of the port) occurred in the control group and one (infection) in the accessed group. Infection rates after procedures were 2% (1/50) in the accessed group and 0% (0/417) in the control group. There was no statistically significant difference in overall complication (P=.1) and infection (P=.1) rates among the groups.
Conclusions: Leaving the port accessed immediately after placement does not increase the risk of infection or other complications.
C1 [Salazar, Gloria; Yeddula, Kalpana; Wicky, Stephan; Oklu, Ramhi; Ganguli, Suvranu; Waltman, Arthur C.; Walker, Thomas G.; Kalva, Sanjeeva P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Salazar, G (reprint author), Massachusetts Gen Hosp, 55 Fruit St GRB 293, Boston, MA 02114 USA.
EM gmsalazar@partners.org
NR 10
TC 0
Z9 0
U1 0
U2 2
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1129-7298
J9 J VASC ACCESS
JI J. Vasc. Access
PD APR-JUN
PY 2013
VL 14
IS 2
BP 170
EP 174
DI 10.5301/jva.5000110
PG 5
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 210UQ
UT WOS:000323860600013
PM 23080333
ER
PT J
AU Walter, J
Tirosh, I
Frugoni, F
Lee, YN
Lo, M
Notarangelo, LD
Dunham, J
Pillai, S
Luning-Prak, N
AF Walter, Jolan
Tirosh, Irit
Frugoni, Francesco
Lee, Yu Nee
Lo, Mindy
Notarangelo, Luigi D.
Dunham, Jonathan
Pillai, Shiv
Luning-Prak, Nina
TI LUPUS PATIENT WITH IMPAIRED RECEPTOR EDITING HAS HETEROZYGOUS RAG2
MUTATION
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Walter, Jolan] MassGen Hosp Children, Dept Pediat, Div Allergy Immunol, Boston, MA USA.
[Walter, Jolan; Tirosh, Irit; Frugoni, Francesco; Lee, Yu Nee; Lo, Mindy] Boston Childrens Hosp, Boston, MA USA.
[Notarangelo, Luigi D.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA USA.
[Dunham, Jonathan; Luning-Prak, Nina] Univ Penn, Philadelphia, PA 19104 USA.
[Pillai, Shiv] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RI Notarangelo, Luigi/F-9718-2016
OI Notarangelo, Luigi/0000-0002-8335-0262
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD APR
PY 2013
VL 33
IS 3
BP 682
EP 682
PG 1
WC Immunology
SC Immunology
GA 201EO
UT WOS:000323123700047
ER
PT J
AU Walker, MA
Slate, N
Lax, T
Alejos, A
Volpi, S
Sweetser, DA
Sims, KB
Walter, J
AF Walker, Melissa A.
Slate, Nancy
Lax, Timothy
Alejos, Alexandra
Volpi, Stefano
Sweetser, David A.
Sims, Katherine B.
Walter, Jolan
TI PREDISPOSITION TO INFECTION AND SIRS IN OXIDATIVE PHOSPHORYLATION
DISORDERS: 8 YEARS' EXPERIENCE IN A NEW ENGLAND COHORT FOLLOWED AT
MASSACHUSETTS GENERAL HOSPITAL AND PARTNERS AFFLIATES
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Walker, Melissa A.; Slate, Nancy; Sweetser, David A.] MassGen Hosp Children, Boston, MA USA.
[Lax, Timothy] Masschusetts Gen Hosp, Boston, MA USA.
[Alejos, Alexandra] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Volpi, Stefano] Childrens Hosp, Boston, MA 02115 USA.
[Sims, Katherine B.] MassGen Hosp Children, Div Neurol, Dept Pediat, Boston, MA USA.
[Walter, Jolan] MassGen Hosp Children, Div Allergy Immunol, Dept Pediat, Boston, MA USA.
RI Volpi, Stefano/O-3717-2014
OI Volpi, Stefano/0000-0002-7129-868X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD APR
PY 2013
VL 33
IS 3
BP 683
EP 683
PG 1
WC Immunology
SC Immunology
GA 201EO
UT WOS:000323123700049
ER
PT J
AU Farough, S
Walker, MA
Canapari, CA
Van Cleave, J
Slate, N
Verbsky, JW
Sweetser, DA
Sims, KB
Walter, J
AF Farough, Samira
Walker, Melissa A.
Canapari, Craig A.
Van Cleave, Jeanne
Slate, Nancy
Verbsky, James W.
Sweetser, David A.
Sims, Katherine B.
Walter, Jolan
TI IMMUNE DYSFUNCTION WITH COENZYME Q10 DEFICIENCY IMPROVES AFTER COENZYME
Q10 REPLACEMENT IN A FOUR YEAR-OLD CHILD WITH RECURRENT INFECTIONS
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Farough, Samira; Canapari, Craig A.; Walter, Jolan] MassGen Hosp Children, Dept Pediat, Div Pulm Allergy Immunol, Boston, MA USA.
[Walker, Melissa A.; Van Cleave, Jeanne; Slate, Nancy; Sweetser, David A.] MassGen Hosp Children, Boston, MA USA.
[Verbsky, James W.] Med Coll Wisconsin, Dept Pediat, Div Rheumatol, Milwaukee, WI 53226 USA.
[Sims, Katherine B.] MassGen Hosp Children, Div Neurol, Dept Pediat, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD APR
PY 2013
VL 33
IS 3
BP 684
EP 685
PG 2
WC Immunology
SC Immunology
GA 201EO
UT WOS:000323123700053
ER
PT J
AU Lax, T
Torgerson, TR
Schneider, L
Sims, KB
Shah, U
Friedmann, A
Walter, J
AF Lax, Timothy
Torgerson, Troy R.
Schneider, Lynda
Sims, Katherine B.
Shah, Uzma
Friedmann, Alison
Walter, Jolan
TI IMMUNE DYSREGULATION, TELOMERE SHORTENING, AND LIVER DISEASE IN A
PEDIATRIC PATIENT: A THERAPEUTIC DILEMMA
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
C1 [Lax, Timothy] Masschusetts Gen Hosp, Boston, MA USA.
[Torgerson, Troy R.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA.
[Schneider, Lynda] Boston Childrens Hosp, Dept Pediat, Div Allergy Immunol, Boston, MA USA.
[Sims, Katherine B.] MassGen Hosp Children, Dept Pediat, Div Neurol, Boston, MA USA.
[Shah, Uzma] MassGen Hosp Children, PediatricDept Pediat, Div Gastroenterol & Nutr, Boston, MA USA.
[Friedmann, Alison] MassGen Hosp Children, Dept Pediat, Boston, MA USA.
[Walter, Jolan] MassGen Hosp Children, Dept Pediat, Div Pulm Allergy Immunol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD APR
PY 2013
VL 33
IS 3
BP 685
EP 685
PG 1
WC Immunology
SC Immunology
GA 201EO
UT WOS:000323123700055
ER
PT J
AU Basu, P
Siriki, R
Shah, NJ
Farhat, S
Mittimani, K
Atluri, S
Rahaman, M
Brown, RS
AF Basu, P.
Siriki, R.
Shah, N. J.
Farhat, S.
Mittimani, K.
Atluri, S.
Rahaman, M.
Brown, R. S., Jr.
TI EFFECT OF N ACETYLCYSTEINE (NAC) IN HYPOXIA INDUCED LIVER INJURY (HILI)
- A RANDOMIZED PLACEBO CONTROL CLINICAL TRIAL
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Basu, P.; Farhat, S.; Brown, R. S., Jr.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
[Basu, P.; Siriki, R.; Mittimani, K.; Atluri, S.; Rahaman, M.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, N. J.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA.
EM ravisiriki@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 358
BP S148
EP S148
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983000359
ER
PT J
AU Basu, PP
Siriki, R
Shah, NJ
Farhat, S
Mittimani, K
Atluri, S
Rahaman, M
Brown, RS
AF Basu, P. P.
Siriki, R.
Shah, N. J.
Farhat, S.
Mittimani, K.
Atluri, S.
Rahaman, M.
Brown, R. S., Jr.
TI ROMIPLOSTIM'S EFFECT TO OPTIMIZE SVR WITH TELAPRAVIR, RIBAVIRIN, AND PEG
INTERFERON-alfa 2a IN THROMBOCYTOPENIC CIRRHOTICS WITH CHRONIC HEPATITIS
C. RESTRAINT C- PLACEBO RCT
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Basu, P. P.; Farhat, S.; Brown, R. S., Jr.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
[Basu, P. P.; Siriki, R.; Mittimani, K.; Atluri, S.; Rahaman, M.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, N. J.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA.
EM ravisiriki@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 906
BP S373
EP S374
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983001168
ER
PT J
AU Basu, PP
Siriki, R
Shah, NJ
Farhat, S
Mittimani, K
Atluri, S
Rahaman, M
Brown, RS
AF Basu, P. P.
Siriki, R.
Shah, N. J.
Farhat, S.
Mittimani, K.
Atluri, S.
Rahaman, M.
Brown, R. S., Jr.
TI TELAPREVIR WITH ADJUSTED DOSE OF RIBAVIRIN IN NAIVE CHC-G1: EFFICACY AND
TREATMENT IN CHC IN HEMODIALYSIS POPULATION. TARGET C (RCT)
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Basu, P. P.; Farhat, S.; Brown, R. S., Jr.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
[Basu, P. P.; Siriki, R.; Mittimani, K.; Atluri, S.; Rahaman, M.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, N. J.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA.
EM basu.patrick@gmail.com
NR 0
TC 7
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 67
BP S30
EP S31
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983000068
ER
PT J
AU Jon, AF
Khan, AN
Cheema, AR
Karellas, A
Malik, Z
Khosa, F
Welty, FK
Clouse, ME
AF Jon, A. F.
Khan, A. N.
Cheema, A. R.
Karellas, A.
Malik, Z.
Khosa, F.
Welty, F. K.
Clouse, M. E.
TI QUANTIFICATION OF LIVER FAT USING NON-CONTRAST CT: COMPARISON OF
LIVER/SPLEEN RATIO (CTL/S), LIVER-SPLEEN DIFFERENCE (CTL-T) WITH LIVER
FAT PERCENTAGE (CTLFP)
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Jon, A. F.] Harvard Univ, Beth Israel Deaconness Med Ctr, Boston, MA 02115 USA.
[Khan, A. N.] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA.
[Cheema, A. R.; Malik, Z.; Welty, F. K.; Clouse, M. E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Karellas, A.] Univ Massacheusetts, Med Ctr, Worcester, MA USA.
[Khosa, F.] Emory Univ, Med Ctr, Atlanta, GA 30322 USA.
EM mclouse@bidmc.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 1324
BP S534
EP S534
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983001583
ER
PT J
AU Mohanty, A
Erqou, S
Butt, AA
AF Mohanty, A.
Erqou, S.
Butt, A. A.
TI ERYTHROPOIETIN USE FOR THERAPY ASSOCIATED ANEMIA IN HEPATITIS C VIRUS
INFECTION AND RISK OF MORTALITY
SO JOURNAL OF HEPATOLOGY
LA English
DT Meeting Abstract
CT International Liver Congress / 48th Annual Meeting of the
European-Association-for-the-Study-of-the-Liver (EASL)
CY APR 24-28, 2013
CL Amsterdam, NETHERLANDS
SP European Assoc Study Liver (EASL)
C1 [Mohanty, A.; Erqou, S.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Butt, A. A.] Univ Pittsburgh, Sch Med, Div Infect Dis, Pittsburgh, PA USA.
[Butt, A. A.] VA Pittsburgh Healthcare Syst, Div Infect Dis, Internal Med, Pittsburgh, PA USA.
[Butt, A. A.] Sheikh Khalifa Med City, Internal Med, Abu Dhabi, U Arab Emirates.
EM mohantya@upmc.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
J9 J HEPATOL
JI J. Hepatol.
PD APR
PY 2013
VL 58
SU 1
MA 478
BP S196
EP S196
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 199GQ
UT WOS:000322983000479
ER
PT J
AU Alvarez-Breckenridge, CA
Yu, JH
Caligiuri, MA
Chiocca, EA
AF Alvarez-Breckenridge, Christopher A.
Yu, Jianhua
Caligiuri, Michael A.
Chiocca, E. Antonio
TI Uncovering a novel mechanism whereby NK cells interfere with
glioblastoma virotherapy
SO ONCOIMMUNOLOGY
LA English
DT Article
DE brain tumor; cancer; glioblastoma; innate immunity; oncolytic virus
ID VESICULAR STOMATITIS-VIRUS; GLIOMA VIROTHERAPY; SUPPRESSION; RESPONSES;
INNATE; POTENCY
AB Despite initial promising results, the success of clinical trials testing oncolytic viruses in glioblastoma patients has been limited. Innate immunity appears to be one among several barriers against successful viral oncolysis. Recent findings suggest a mechanism by which natural killer cells limit the efficacy of oncolytic viruses via natural cytotoxicity receptors.
C1 [Alvarez-Breckenridge, Christopher A.] Ohio State Univ, Med Ctr, Med Scientist Training Program, Columbus, OH 43210 USA.
[Alvarez-Breckenridge, Christopher A.; Chiocca, E. Antonio] Ohio State Univ, Med Ctr, Dept Neurol Surg, Dardinger Lab Neurooncol & Neurosci, Columbus, OH 43210 USA.
[Yu, Jianhua; Caligiuri, Michael A.; Chiocca, E. Antonio] Ohio State Univ, Med Ctr, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Chiocca, E. Antonio] Harvard Univ, Brigham & Womens Hosp, Dept Neurosurg, Dana Farber Canc Inst,Med Sch, Boston, MA 02115 USA.
RP Chiocca, EA (reprint author), Ohio State Univ, Med Ctr, Dept Neurol Surg, Dardinger Lab Neurooncol & Neurosci, Columbus, OH 43210 USA.
EM eachiocca@partners.org
FU NCI NIH HHS [R01 CA155521]
NR 10
TC 6
Z9 6
U1 0
U2 1
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2162-4011
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD APR 1
PY 2013
VL 2
IS 4
AR e23658
DI 10.4161/onci.23658
PG 3
WC Oncology; Immunology
SC Oncology; Immunology
GA 193NJ
UT WOS:000322566200016
PM 23734319
ER
PT J
AU Waldron, TJ
Quatromoni, JG
Karakasheva, TA
Singhal, S
Rustgi, AK
AF Waldron, Todd J.
Quatromoni, Jon G.
Karakasheva, Tatiana A.
Singhal, Sunil
Rustgi, Anil K.
TI Myeloid derived suppressor cells: Targets for therapy
SO ONCOIMMUNOLOGY
LA English
DT Article
DE Myeloid derived suppressor cells; docetaxol; RNA aptamer; CpG
oligodeoxynucleotides (ODN); cyclophosphamide; gemcitabine; curcumin
ID TUMOR-BEARING HOST; NITRIC-OXIDE SYNTHASE; CD8(+) T-CELLS;
CANCER-PATIENTS; IMMUNOSUPPRESSIVE ACTIVITY; ESTABLISHED TUMORS;
ANTITUMOR IMMUNITY; EQUILIBRIUM STATE; POOR SURVIVAL; OCCULT CANCER
AB The goal of achieving measurable response with cancer immunotherapy requires counteracting the immunosuppressive characteristics of tumors. One of the mechanisms that tumors utilize to escape immunosurveillance is the activation of myeloid derived suppressor cells (MDSCs). Upon activation by tumor-derived signals, MDSCs inhibit the ability of the host to mount an anti-tumor immune response via their capacity to suppress both the innate and adaptive immune systems. Despite their relatively recent discovery and characterization, anti-MDSC agents have been identified, which may improve immunotherapy efficacy.
C1 [Waldron, Todd J.; Karakasheva, Tatiana A.; Rustgi, Anil K.] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
[Waldron, Todd J.; Karakasheva, Tatiana A.; Rustgi, Anil K.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Quatromoni, Jon G.; Singhal, Sunil] Hosp Univ Penn, Dept Surg, Div Thorac Surg, Sch Med, Philadelphia, PA 19104 USA.
[Singhal, Sunil] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA.
[Rustgi, Anil K.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA.
RP Rustgi, AK (reprint author), Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
EM anil2@mail.med.upenn.edu
FU National Institutes of Health/NCI [P01-CA098101, U01-CA14305603];
National Institutes of Health/NIDDK [T32-DK007066]; National Institutes
of Health [F32-CA162719]; National Institutes of Health/NIDDK Center for
Molecular Studies in Digestive and Liver Diseases [P30-DK050306];
American Cancer Society [RP-10-033-01-CCE]
FX This work was supported by the National Institutes of Health/NCI grant
P01-CA098101 (AKR, TW), National Institutes of Health/NCI grant
U01-CA14305603 (AKR), National Institutes of Health/NIDDK (T32-DK007066)
(TW), National Institutes of Health (F32-CA162719) (TW), National
Institutes of Health/NIDDK Center for Molecular Studies in Digestive and
Liver Diseases (P30-DK050306), and American Cancer Society
(RP-10-033-01-CCE). We are grateful for members of the Rustgi and
Singhal labs for discussions.
NR 89
TC 24
Z9 24
U1 0
U2 5
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2162-4011
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD APR 1
PY 2013
VL 2
IS 4
AR e24117
DI 10.4161/onci.24117
PG 7
WC Oncology; Immunology
SC Oncology; Immunology
GA 193NJ
UT WOS:000322566200024
PM 23734336
ER
PT J
AU McKee, AC
AF McKee, Ann C.
TI Interneuronal spreading of tau pathology in chronic traumatic
encephalopathy
SO PRION
LA English
DT Meeting Abstract
DE chronic traumatic encephalopathy; tau protein; traumatic brain injury
ID PROPAGATION; DISEASE
C1 [McKee, Ann C.] Boston Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02118 USA.
NR 8
TC 0
Z9 0
U1 1
U2 6
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1933-6896
J9 PRION
JI Prion
PD APR-MAY
PY 2013
VL 7
SU S
BP 9
EP 9
PG 1
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 202LL
UT WOS:000323217500022
ER
PT J
AU Silva, TB
Mauad, EC
Carvalho, AL
Jacobs, LA
Shulman, LN
AF Silva, T. B.
Mauad, E. C.
Carvalho, A. L.
Jacobs, L. A.
Shulman, L. N.
TI Difficulties in implementing an organized screening program for breast
cancer in Brazil with emphasis on diagnostic methods
SO RURAL AND REMOTE HEALTH
LA English
DT Article
DE Brazil; breast cancer; community health systems; diagnosis; screening;
symptoms
ID SERVICES TASK-FORCE; RANDOMIZED-TRIAL; UNITED-STATES; HEALTH-CARE;
MAMMOGRAPHY; WOMEN; KNOWLEDGE; COUNTRIES; PERFORMANCE; PREDICTORS
AB Introduction: Breast cancer is the most common type of cancer among women, and the leading cause of cancer deaths worldwide. Among early detection methods, screening by mammography has been used in most developed countries as gold standard. The goal of this study was to evaluate the difficulties and opportunities in implementing breast cancer screening in Brazil, with an emphasis on the diagnostic methods used according to stage distribution.
Methods: Between 2007 and 2009, 248 women were diagnosed with breast cancer in the Barretos region. Most of these were interviewed in their homes using a questionnaire with sociodemographic and preventive breast cancer screening questions. All other data were obtained from Barretos Cancer Hospital (BCH) medical records.
Results: The screening program conducted by BCH was responsible for 46.1% of diagnosed cases, with 30.1% of these referred from the private system and 23.8% from the public system. Among asymptomatic women screened by the BCH Screening Program 70.8% had clinical stage 0-I disease, compared with 58.1% in the private and 50% in the public systems. Monthly breast self-examination was reported by 48.5% of the women. Clinical breast examinations were regularly performed by 88.9% of gynecologists in the private and 40.7% in the public health systems. Only 5.6% of the women reported difficulty in accessing mammography and this was most frequently due to fear of the disease or lack of knowledge about mammography in asymptomatic women.
Conclusion: This breast cancer screening program resulted in a substantial number of patients presenting with clinical stage (CS) 0-I disease. The success of this program was due to intensive community interventions, free mammography, and the availability of health care and mammography close to patients' homes.
C1 [Silva, T. B.; Mauad, E. C.; Carvalho, A. L.] Barretos Canc Hosp, Dept Prevencao, Sao Paulo, Brazil.
[Jacobs, L. A.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Shulman, L. N.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Shulman, L. N.] Harvard Univ, Sch Med, Boston, MA USA.
RP Silva, TB (reprint author), Barretos Canc Hosp, Dept Prevencao, Sao Paulo, Brazil.
RI Carvalho, Andre/C-1185-2011; Carvalho, Andre/S-7053-2016
OI Carvalho, Andre/0000-0001-7214-6402; Carvalho, Andre/0000-0001-7214-6402
NR 45
TC 5
Z9 5
U1 1
U2 9
PU AUSTRALIAN RURAL HEALTH EDUC NETWORK
PI DEAKIN WEST
PA PO BOX 242, DEAKIN WEST, ACT 2600, AUSTRALIA
SN 1445-6354
J9 RURAL REMOTE HEALTH
JI Rural Remote Health
PD APR-JUN
PY 2013
VL 13
IS 2
AR 2321
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 190UF
UT WOS:000322365600017
PM 23597169
ER
PT J
AU Shimizu, M
Zaninotto, G
Nagata, K
Graham, DY
Lauwers, GY
AF Shimizu, Michio
Zaninotto, Giovanni
Nagata, Koji
Graham, David Y.
Lauwers, Gregory Y.
TI Esophageal squamous cell carcinoma with special reference to its early
stage
SO BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE Early esophageal squamous cell carcinoma; Squamous intraepithelial
neoplasia; Endoscopic mucosal resection (EMR); Endoscopic submucosal
dissection (ESD); Chromoendoscopy; Narrow band imaging (NBI);
Esophagectomy
ID ENDOSCOPIC SUBMUCOSAL DISSECTION; LYMPH-NODE DISSECTION;
BARRETTS-ESOPHAGUS; INTRAEPITHELIAL NEOPLASIA; MUCOSAL RESECTION;
CLINICAL-OUTCOMES; CANCER; RISK; ADENOCARCINOMA; DYSPLASIA
AB The term 'early squamous cell carcinoma of the oesophagus', which was previously restricted to superficial carcinoma with no lymph node metastasis, now encompasses intramucosal carcinoma regardless of the nodal status. Such lesions are rare in Western countries, where the experience is limited. In recent years, the development and greater use of chromoendoscopy and narrow band imaging (NBI), both of which facilitate the evaluation of mucosal morphology, have played an important role in the detection of early esophageal squamous cell carcinoma. In addition, the techniques and indications of endoscopic resection (mucosal resection [EMR] and mucosal dissection [ESD]) are still being refined. In the present article, we will discuss the clinical and pathologic features of esophageal early squamous cell carcinoma, as well as the epidemiology and aetiology of esophageal cancer in general. In addition, we will provide a therapeutic decision tree taking into account endoscopic and surgical modalities as they apply to early esophageal squamous cell carcinoma. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Shimizu, Michio; Nagata, Koji] Saitama Med Univ, Saitama Int Med Ctr, Dept Pathol, Hidaka City, Saitama 3501298, Japan.
[Zaninotto, Giovanni] Univ Padua, Sch Med, Dept Surg Gastroenterol & Oncol, Padua, Italy.
[Graham, David Y.] Michael E DeBakey VA Med Ctr, Dept Med, Houston, TX USA.
[Graham, David Y.] Baylor Coll Med, Houston, TX 77030 USA.
[Lauwers, Gregory Y.] Massachusetts Gen Hosp, Div Surg Pathol, Boston, MA 02114 USA.
[Lauwers, Gregory Y.] Massachusetts Gen Hosp, Gastrointestinal Pathol Serv, Boston, MA 02114 USA.
RP Shimizu, M (reprint author), Saitama Med Univ, Saitama Int Med Ctr, Dept Pathol, 1397-1 Yamane, Hidaka City, Saitama 3501298, Japan.
EM shimizu@saitama-med.ac.jp
NR 77
TC 13
Z9 19
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521-6918
J9 BEST PRACT RES CL GA
JI Best Pract. Res. Clin. Gastroenterol.
PD APR
PY 2013
VL 27
IS 2
BP 171
EP 186
DI 10.1016/j.bpg.2013.03.010
PG 16
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 187DC
UT WOS:000322096100003
PM 23809239
ER
PT J
AU Jokhi, V
Ashley, J
Nunnari, J
Noma, A
Ito, N
Wakabayashi-Ito, N
Moore, MJ
Budnik, V
AF Jokhi, Vahbiz
Ashley, James
Nunnari, John
Noma, Akiko
Ito, Naoto
Wakabayashi-Ito, Noriko
Moore, Melissa J.
Budnik, Vivian
TI Torsin Mediates Primary Envelopment of Large Ribonucleoprotein Granules
at the Nuclear Envelope
SO CELL REPORTS
LA English
DT Article
ID PROTEIN COMPLEXES; SYNAPSE FORMATION; WNT; PLASTICITY; MECHANISM;
WINGLESS; ATPASES; COMMON; EXPORT; APKC
AB A previously unrecognized mechanism through which large ribonucleoprotein (megaRNP) granules exit the nucleus is by budding through the nuclear envelope (NE). This mechanism is akin to the nuclear egress of herpes-type viruses and is essential for proper synapse development. However, the molecular machinery required to remodel the NE during this process is unknown. Here, we identify Torsin, an AAA-ATPase that in humans is linked to dystonia, as a major mediator of primary megaRNP envelopment during NE budding. In torsin mutants, megaRNPs accumulate within the perinuclear space, and the messenger RNAs contained within fail to reach synaptic sites, preventing normal synaptic protein synthesis and thus proper synaptic bouton development. These studies begin to establish the cellular machinery underlying the exit of megaRNPs via budding, offer an explanation for the "nuclear blebbing" phenotype found in dystonia models, and provide an important link between Torsin and the synaptic phenotypes observed in dystonia.
C1 [Jokhi, Vahbiz; Ashley, James; Nunnari, John; Budnik, Vivian] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Worcester, MA 01605 USA.
[Noma, Akiko; Moore, Melissa J.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Dept Biochem & Mol Pharmacol,RNA Inst, Worcester, MA 01605 USA.
[Noma, Akiko; Moore, Melissa J.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Dept Biochem & Mol Pharmacol,Neuro Therapeut Inst, Worcester, MA 01605 USA.
[Ito, Naoto; Wakabayashi-Ito, Noriko] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol & Radiol, Sch Med, Boston, MA 02114 USA.
[Ito, Naoto; Wakabayashi-Ito, Noriko] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02114 USA.
RP Budnik, V (reprint author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Worcester, MA 01605 USA.
EM vivian.budnik@umassmed.edu
FU University of Massachusetts Medical School Electron Microscopy Facility;
National Institutes of Health [R01 NS063228]
FX We thank Drs. Xandra Breakefield, Mary Munson, Reid Gilmore, Emiliano
Ricci, and members of the Budnik lab for helpful comments on the
manuscript and discussions. We would like to thank the University of
Massachusetts Medical School Electron Microscopy Facility for support in
our ultrastructural studies and the Vienna Drosophila RNAi facility for
providing the Torsin-RNAi line. We also thank Drs. Pamela Gayer, Yosef
Gruenbaum, Georg Krohne, and Gertrud Schupbach for the generous gift of
antibodies. This work was supported by National Institutes of Health
grant R01 NS063228 (to V.B.). M.J.M. is a Howard Hughes Medical
Institute investigator. V.J. carried out most of the experiments and
contributed intellectually to the project. J.A. carried out some of the
ultrastructural studies and contributed intellectually to the project
and manuscript writing. J.N. carried out most the ultrastructural
experiments. A.N. performed supporting FISH in wild-type and mutant
larvae. N.I. and N.W.-I. provided the unpublished TorsinDelta
E fly strain and contributed to discussions. M.J.M. provided
critical intellectual input and helped write the manuscript. V.B.
directed the project and wrote the manuscript.
NR 29
TC 51
Z9 51
U1 0
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD APR
PY 2013
VL 3
IS 4
BP 988
EP 995
DI 10.1016/j.celrep.2013.03.015
PG 8
WC Cell Biology
SC Cell Biology
GA 184NH
UT WOS:000321897100003
PM 23583177
ER
PT J
AU Barker, CF
Markmann, JF
AF Barker, Clyde F.
Markmann, James F.
TI Historical Overview of Transplantation
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID DONOR BONE-MARROW; SKIN HOMOGRAFTS; HUMAN-KIDNEY; RENAL
HOMOTRANSPLANTATION; IMMUNOLOGICAL-TOLERANCE; CYCLOSPORIN-A; CLINICAL
TRANSPLANTATION; ANTILYMPHOCYTIC-SERUM; IDENTICAL-TWINS; THORACIC-DUCT
AB Except for legends and claims of miracles, most histories of transplantation cover only the last 60 years because there were no earlier successes. However, the story of even this era has been documented in such rich detail that a full account would fill several volumes. Thus, this brief summary must be limited to highly selected "landmarks." Some landmarks had an immediate impact, but the importance of others went unrecognized for decades. Some findings that deserved landmark status were overlooked or forgotten, whereas others of no biological significance had major impact. Placing these events in perspective is challenging. Several of transplantation's pioneers are still alive, and most of the others are within living memory. Virtually all of them have produced their own accounts. For the most part, they agree on what the "landmarks" are, but their differences in emphasis and perspective make an interesting story.
C1 [Barker, Clyde F.] Hosp Univ Penn, Dept Surg, Philadelphia, PA 19104 USA.
[Barker, Clyde F.; Markmann, James F.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02114 USA.
[Barker, Clyde F.; Markmann, James F.] Massachusetts Gen Hosp, Div Transplantat, Boston, MA 02114 USA.
RP Barker, CF (reprint author), Hosp Univ Penn, Dept Surg, 3400 Spruce St, Philadelphia, PA 19104 USA.
EM clyde.barker@uphs.upenn.edu
FU NIAID NIH HHS [R01 AI057851]
NR 119
TC 2
Z9 2
U1 1
U2 3
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD APR
PY 2013
VL 3
IS 4
AR a014977
DI 10.1101/cshperspect.a014977
PG 18
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 187ZK
UT WOS:000322160300001
PM 23545575
ER
PT J
AU Bauman, J
Langer, C
Quon, H
Algazy, K
Lin, A
Desai, A
Mutale, F
Weiss, J
AF Bauman, Jessica
Langer, Corey
Quon, Harry
Algazy, Kenneth
Lin, Alexander
Desai, Arati
Mutale, Faith
Weiss, Jared
TI Induction chemotherapy with cetuximab, carboplatin and paclitaxel for
the treatment of locally advanced squamous cell carcinoma of the head
and neck
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE locally advanced squamous cell carcinoma of the head and neck; head and
neck cancer; induction chemotherapy; chemoradiotherapy
ID HUMAN-PAPILLOMAVIRUS; PLUS CETUXIMAB; CANCER; SURVIVAL; FLUOROURACIL;
RADIOTHERAPY; CISPLATIN; DOCETAXEL; CHEMORADIOTHERAPY; RADIATION
AB Although controversy exists in the management of locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN), clinicians often use induction chemotherapy for treatment of the most advanced cases. One promising regimen combines weekly cetuximab (400 mg/m(2) loading dose followed by 250 mg/m(2)) with carboplatin (AUC of 2) and paclitaxel (90 mg/m(2)). We retrospectively evaluated patients treated with this regimen prior to definitive chemoradiation or surgery between May 2008 and December 2011. The primary endpoint used for this retrospective analysis was feasibility. Thirty consecutive, unselected patients were included. Median follow-up was 13.7 months (range, 5.0-38.7 months). All but one patient had stage IV SCCHN. Dose intensity was high for carboplatin (92%), paclitaxel (93%) and cetuximab (85%). Grade 3-4 toxicities occurred in <7% of the study population and were limited to rash, neutropenia and infusion reactions. Response rate (RR) to induction chemotherapy was 97% (30% complete response, 67% partial response). All patients completed subsequent chemoradiotherapy or surgery. Nineteen patients (63%) demonstrated a complete response and 11 patients (37%) demonstrated a partial response. Median overall survival and progression-free survival data are not yet mature. The RR to therapy in our off-protocol experience is at least comparable to that observed in the two phase II studies of this regimen and appears superior to that observed with docetaxel, cisplatin and fluorouracil (TPF).
C1 [Bauman, Jessica] Dana Farber Canc Inst, Div Hematol & Oncol, Boston, MA 02115 USA.
[Langer, Corey; Algazy, Kenneth; Desai, Arati; Mutale, Faith] Univ Penn, Div Hematol & Oncol, Philadelphia, PA 19104 USA.
[Quon, Harry] Johns Hopkins Univ, Dept Radiat Oncol, Baltimore, MD 21205 USA.
[Lin, Alexander] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
[Weiss, Jared] Univ N Carolina, Div Hematol & Oncol, Chapel Hill, NC 27599 USA.
RP Weiss, J (reprint author), Univ N Carolina, 170 Manning Dr,Campus Box 7305, Chapel Hill, NC 27599 USA.
EM jared_weiss@med.unc.edu
FU Celgene; GSK; Astellas
FX Dr Corey Langer is currently a member of the Advisory Boards of BMS,
Imclone and Lilly, and a former member of their Speaker's Bureaus. Dr
Jared Weiss has received research funding from Celgene, GSK and
Astellas.
NR 24
TC 5
Z9 6
U1 1
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
J9 EXP THER MED
JI Exp. Ther. Med.
PD APR
PY 2013
VL 5
IS 4
BP 1247
EP 1253
DI 10.3892/etm.2013.948
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 185AK
UT WOS:000321937400053
PM 23599744
ER
PT J
AU Sykes, SM
Scadden, DT
AF Sykes, Stephen M.
Scadden, David T.
TI Modeling Human Hematopoietic Stem Cell Biology in the Mouse
SO SEMINARS IN HEMATOLOGY
LA English
DT Article
ID BONE-MARROW MICROENVIRONMENT; PROGENITOR CELLS; ENDOTHELIAL-CELLS;
DEFINITIVE HEMATOPOIESIS; MYELODYSPLASTIC SYNDROME;
DYSKERATOSIS-CONGENITA; COMMON PRECURSOR; DEFICIENT MICE; YOLK-SAC;
IN-VIVO
AB Hematopoietic stem cells (HSCs) have the immense task of supplying an organism with enough blood to sustain a lifespan. Much of what is known about how this scant population of cells can meet the varying demand of producing more than 10(11) cells per day comes from studies conducted in an animal that is a fraction of our size and lives roughly 1/30th of our lifespan. The differences in longevity can be expected to impose different demands on a cell essential for existence. It is therefore unsurprising that while the mouse has proven invaluable in defining the organizing principals of how hematopoiesis is governed, mediators of cell localization as well as a range of experimental methods, the differences in cell cycling, DNA repair and specific molecular features of HSCs in humans are evident and important. Here, the utility and drawbacks of the mouse as an experimental model for human HSC biology are discussed. Semin Hematol 50:92-100. (C) 2013 Published by Elsevier Inc.
C1 [Sykes, Stephen M.] Fox Chase Canc Ctr, Res Inst, Philadelphia, PA 19111 USA.
[Scadden, David T.] Harvard Univ, Ctr Regenerat Med, Dept Stem Cell & Regenerat Biol, Harvard Stem Cell Inst,Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
RP Sykes, SM (reprint author), Fox Chase Canc Ctr, Res Inst, Immune Cell Dev & Host Def, 333 Cottman Ave, Philadelphia, PA 19111 USA.
EM Stephen_Sykes@fccc.edu; David_Scadden@harvard.edu
FU NCI NIH HHS [R00 CA158461]; NHLBI NIH HHS [R01 HL044851, U01 HL100402];
NIBIB NIH HHS [R01 EB014703]; NIDDK NIH HHS [R01 DK050234]
NR 80
TC 4
Z9 4
U1 1
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0037-1963
J9 SEMIN HEMATOL
JI Semin. Hematol.
PD APR
PY 2013
VL 50
IS 2
BP 92
EP 100
DI 10.1053/j.seminhematol.2013.03.029
PG 9
WC Hematology
SC Hematology
GA 174NZ
UT WOS:000321164000003
PM 24216169
ER
PT J
AU Arnstein, P
Herr, K
AF Arnstein, Paul
Herr, Keela
TI Risk Evaluation and Mitigation Strategies for Older Adults with
Persistent Pain
SO JOURNAL OF GERONTOLOGICAL NURSING
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NONMALIGNANT PAIN; AMERICAN
SOCIETY; OPIOID THERAPY; MEDICATION USE; POPULATION; MANAGEMENT;
STATEMENT; OVERDOSE; BRAIN
AB The U.S. Food and Drug Administration issued Risk Evaluation and Mitigation Strategies for certain analgesic agents, but all medicines for older adults warrant risk-reduction considerations. Although not all older adults have pain, a higher prevalence of persistent pain exists in this population. Nursing actions are needed to minimize the negative impact persistent pain, analgesic agents, or both have on physical, mental, and social functioning. Practices vary considerably, ranging from failing to use analgesic agents for older adults with considerable pain to exposing them to potentially life-threatening toxicities, overdoses, or drug interactions. Older adults tend to be more vulnerable to side effects and drug interactions due to differences in drug distribution, metabolism, and elimination; thus, vigilant assessment and monitoring is needed to mitigate risks whenever analgesic agents are used. This review delineates these vulnerabilities while informing clinicians of the strategies needed to promote safe, effective use of medications when treating pain in older adults.
C1 [Arnstein, Paul] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Herr, Keela] Univ Iowa, Coll Nursing, Iowa City, IA 52242 USA.
RP Arnstein, P (reprint author), Massachusetts Gen Hosp GRB 1034, 55 Fruit St, Boston, MA 02114 USA.
EM pmarnstein@partners.org
FU Connell Nursing Research Scholars Program at Massachusetts General
Hospital
FX The authors have disclosed no conflicts of interest, financial or
otherwise. Dr. Arnstein acknowledges that this project was sponsored in
part with support from the Connell Nursing Research Scholars Program at
Massachusetts General Hospital.
NR 44
TC 1
Z9 1
U1 1
U2 6
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0098-9134
J9 J GERONTOL NURS
JI J. Gerontol. Nurs.
PD APR
PY 2013
VL 39
IS 4
BP 56
EP +
DI 10.3928/00989134-20130221-01
PG 11
WC Geriatrics & Gerontology; Gerontology; Nursing
SC Geriatrics & Gerontology; Nursing
GA 164XG
UT WOS:000320444800008
PM 23445186
ER
PT J
AU Ofman, P
Khawaja, O
Rahilly-Tierney, CR
Peralta, A
Hoffmeister, P
Reynolds, MR
Gaziano, JM
Djousse, L
AF Ofman, Peter
Khawaja, Owais
Rahilly-Tierney, Catherine R.
Peralta, Adelqui
Hoffmeister, Peter
Reynolds, Mathew R.
Gaziano, J. Michael
Djousse, Luc
TI Regular Physical Activity and Risk of Atrial Fibrillation A Systematic
Review and Meta-analysis
SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
LA English
DT Article
DE atrial fibrillation; epidemiology; physical exercise; risk factors
ID ENDURANCE SPORT PRACTICE; CARDIOVASCULAR-DISEASE; TASK-FORCE; FOLLOW-UP;
FLUTTER; MEN; PREVENTION; MANAGEMENT; EXERCISE; ADULTS
AB Background-Although previous studies have suggested that competitive athletes have a higher risk of atrial fibrillation than the general population, limited and inconsistent data are available on the association between regular physical activity and the risk of atrial fibrillation.
Methods and Results-A systematic, comprehensive literature search was performed using MEDLINE, EMBASE, and COCHRANE until 2011. Extracted data from the eligible studies were meta-analyzed using fixed effects model. Four studies, which included 95 526 subjects, were eligible for meta-analysis. For all of the studies included, the extreme groups (ie, maximum versus minimal amount of physical activity) were used for the current analyses. The total number of participants belonging to the extreme groups was 43 672. The pooled odds ratio (95% confidence interval) for atrial fibrillation among regular exercisers was 1.08 (0.97-1.21).
Conclusions-Our data do not support a statistically significant association between regular physical activity and increased incidence of atrial fibrillation.
C1 [Ofman, Peter; Peralta, Adelqui; Hoffmeister, Peter; Reynolds, Mathew R.; Gaziano, J. Michael] Harvard Univ, Sch Med, Div Cardiol, VA Boston Healthcare Syst, Boston, MA USA.
[Ofman, Peter; Rahilly-Tierney, Catherine R.; Gaziano, J. Michael; Djousse, Luc] Harvard Univ, Sch Med, Div Aging, Dept Med, Boston, MA 02115 USA.
[Rahilly-Tierney, Catherine R.; Gaziano, J. Michael] Harvard Univ, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
[Ofman, Peter; Rahilly-Tierney, Catherine R.; Gaziano, J. Michael; Djousse, Luc] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol & Res Informat Ctr MA, Boston, MA USA.
[Gaziano, J. Michael; Djousse, Luc] VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr GRECC, Boston, MA USA.
[Khawaja, Owais] Dartmouth Hitchcock Med Ctr, Sect Crit Care, Lebanon, NH 03766 USA.
RP Ofman, P (reprint author), VA Boston Healthcare Syst, Dept Cardiol, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.
EM Peter.Ofman@VA.gov
RI Djousse, Luc/F-5033-2017
OI Djousse, Luc/0000-0002-9902-3047
NR 21
TC 40
Z9 40
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-3149
J9 CIRC-ARRHYTHMIA ELEC
JI Circ.-Arrhythmia Electrophysiol.
PD APR
PY 2013
VL 6
IS 2
BP 252
EP 256
DI 10.1161/CIRCEP.113.000147
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 167XB
UT WOS:000320667700011
PM 23515264
ER
PT J
AU Stengel, A
Rivier, J
Tache, Y
AF Stengel, Andreas
Rivier, Jean
Tache, Yvette
TI Modulation of the adaptive response to stress by brain activation of
selective somatostatin receptor subtypes
SO PEPTIDES
LA English
DT Review
DE ACTH; Anxiety; Autonomic nervous system; Catecholamines; CRF; Food
intake; Gastrointestinal motility; Octreotide; ODT8-SST; Stress
ID CORTICOTROPIN-RELEASING-FACTOR; CENTRAL-NERVOUS-SYSTEM; COLONIC MOTOR
FUNCTION; GROWTH-HORMONE SECRETION; FOOD-INTAKE; INDUCED INHIBITION;
MESSENGER-RNA; NEUROPEPTIDE-Y; CENTRAL CRF; C-FOS
AB Somatostatin-14 was discovered in 1973 in the hypothalamus as a peptide inhibiting growth hormone release. Somatostatin interacts with five receptor subtypes (sst(1-5)) which are widely distributed in the brain with a distinct, but overlapping, expression pattern. During the last few years, the development of highly selective peptide agonists and antagonists provided new insight to characterize the role of somatostatin receptor subtypes in the pleiotropic actions of somatostatin. Recent evidence in rodents indicates that the activation of selective somatostatin receptor subtypes in the brain blunts stress-corticotropin-releasing factor (CRF) related ACTH release (sst(2/5)), sympathetic-adrenal activaton (sst(5)), stimulation of colonic motility (sst(1)), delayed gastric emptying (sst(5)), suppression of food intake (sst(2)) and the anxiogenic-like (sst(2)) response. These findings suggest that brain somatostatin signaling pathways may play an important role in dampening CRF-mediated endocrine, sympathetic, behavioral and visceral responses to stress. Published by Elsevier Inc.
C1 [Stengel, Andreas; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA.
[Stengel, Andreas; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Los Angeles, CA 90095 USA.
[Stengel, Andreas; Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Stengel, Andreas] Charite Med Ctr, Dept Med, Div Psychosomat Med, Berlin, Germany.
[Stengel, Andreas] Charite Med Ctr, Dept Med, Obes Ctr Berlin, Berlin, Germany.
[Stengel, Andreas] Univ Berlin, Berlin, Germany.
[Rivier, Jean] Salk Inst Biol Studies, Peptide Biol Labs, La Jolla, CA USA.
RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM ytache@mednet.ucla.edu
FU German Research Foundation [STE 1765/3-1]; Charite university [89441
176]; Sonnenfeld foundation; VA Research Career Scientist Award; VA
Merit Award; NIH R01 [DK 33061, DK57238]
FX A.S. received funding from the German Research Foundation (STE 1765/3-1)
Charite university funding (89441 176) and an equipment grant of the
Sonnenfeld foundation. Y.T. is in receipt of the VA Research Career
Scientist Award, VA Merit Award and NIH R01grants DK 33061 and DK57238.
J.R. is the Dr. Frederik Paulsen Chair in Neurosciences Professor.
NR 109
TC 9
Z9 9
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-9781
J9 PEPTIDES
JI Peptides
PD APR
PY 2013
VL 42
BP 70
EP 77
DI 10.1016/j.peptides.2012.12.022
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
Pharmacology & Pharmacy
GA 165OI
UT WOS:000320492800010
PM 23287111
ER
PT J
AU Bacallado, S
Favaro, S
Trippa, L
AF Bacallado, Sergio
Favaro, Stefano
Trippa, Lorenzo
TI BAYESIAN NONPARAMETRIC ANALYSIS OF REVERSIBLE MARKOV CHAINS
SO ANNALS OF STATISTICS
LA English
DT Article
DE Reversibility; mixtures of Markov chains; reinforced random walks;
Bayesian nonparametrics; species sampling; two-parameter Hoppe urn;
molecular dynamics
ID REINFORCED RANDOM-WALK
AB We introduce a three-parameter random walk with reinforcement, called the (theta, alpha, beta) scheme, which generalizes the linearly edge reinforced random walk to uncountable spaces. The parameter beta smoothly tunes the (theta, alpha, beta) scheme between this edge reinforced random walk and the classical exchangeable two-parameter Hoppe urn scheme, while the parameters a and theta modulate how many states are typically visited. Resorting to de Finetti's theorem for Markov chains, we use the (theta, alpha, beta) scheme to define a nonparametric prior for Bayesian analysis of reversible Markov chains. The prior is applied in Bayesian nonparametric inference for species sampling problems with data generated from a reversible Markov chain with an unknown transition kernel. As a real example, we analyze data from molecular dynamics simulations of protein folding.
C1 [Bacallado, Sergio] Stanford Univ, Dept Stat, Clark Ctr, Stanford, CA 94305 USA.
[Favaro, Stefano] Univ Turin, Dept Econ & Stat, I-10134 Turin, Italy.
Coll Carlo Alberto, Moncalieri, Italy.
Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA.
[Trippa, Lorenzo] Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Bacallado, S (reprint author), Stanford Univ, Dept Stat, Clark Ctr, S296, Stanford, CA 94305 USA.
EM sergiob@stanford.edu; stefano.favaro@unito.it; ltrippa@jimmy.harvard.edu
FU NSF [DMS-09-00700]; European Research Council (ERC) through StG "N-BNP"
[306406]; [NIH-R01-GM062868]
FX Supported by Grant NIH-R01-GM062868 and NSF Grant DMS-09-00700.;
Supported by the European Research Council (ERC) through StG "N-BNP"
306406.
NR 28
TC 2
Z9 2
U1 0
U2 4
PU INST MATHEMATICAL STATISTICS
PI CLEVELAND
PA 3163 SOMERSET DR, CLEVELAND, OH 44122 USA
SN 0090-5364
J9 ANN STAT
JI Ann. Stat.
PD APR
PY 2013
VL 41
IS 2
BP 870
EP 896
DI 10.1214/13-AOS1102
PG 27
WC Statistics & Probability
SC Mathematics
GA 165MO
UT WOS:000320488200017
ER
PT J
AU Downes, J
Dewhirst, FE
Tanner, ACR
Wade, WG
AF Downes, Julia
Dewhirst, Floyd E.
Tanner, Anne C. R.
Wade, William G.
TI Description of Alloprevotella rava gen. nov., sp nov., isolated from the
human oral cavity, and reclassification of Prevotella tannerae Moore et
al. 1994 as Alloprevotella tannerae gen. nov., comb. nov.
SO INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY
LA English
DT Article
ID ACIDS
AB Five strains of anaerobic, Gram-negative bacilli isolated from the human oral cavity were subjected to a comprehensive range of phenotypic and genotypic tests and were found to comprise a homogeneous group. Phylogenetic analysis of full-length 16S rRNA gene sequences showed that these strains represented a novel group within the family Prevotellaceae, and the most closely related species was Prevotella tannerae. P. tannerae and the novel taxon are deeply branched from the genus Prevotella, with sequence identities to the type strain of the type species of Prevotella, Prevotella melaninogenica, of 82.2 and 85.6%, respectively. The novel genus Alloprevotella gen. nov. is proposed to accommodate the novel species Alloprevotella rava gen. nov., sp. nov. and the previously named Prevotella tannerae Moore et al. 1994 as Alloprevotella tannerae gen. nov., comb. nov. The type species is Alloprevotella tannerae. The type strain of Alloprevotella rava is 81/4-12(T) (=DSM 22548(T) =CCUG 58091(T)) and the type strain of Alloprevotella tannerae is ATCC 51259(T) =CCUG 34292(T) =CIP 104476(T) =NCTC 13073(T). Alloprevotella rava is weakly to moderately saccharolytic and produces moderate amounts of acetic acid and major amounts of succinic acid as end products of fermentation. Strains are sensitive to 20% bile and hydrolyse gelatin. The principal cellular long-chain fatty acids are anteiso-C-15:0, iso-C-15:0, C-16:0, iso-C-17:0 and iso-C-17:0 3-OH. The G+C content of the DNA of the type strain is 47 mol%.
C1 [Downes, Julia; Wade, William G.] Kings Coll London, Inst Dent, London SE1 9RT, England.
[Dewhirst, Floyd E.; Tanner, Anne C. R.] Forsyth Inst, Dept Mol Genet, Cambridge, MA 02142 USA.
[Dewhirst, Floyd E.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
RP Wade, WG (reprint author), Kings Coll London, Inst Dent, Guys Campus, London SE1 9RT, England.
EM william.wade@kcl.ac.uk
OI Wade, William/0000-0003-2685-826X
FU Guy's and St Thomas' Charity [R050724]; UK Department of Health via the
National Institute for Health Research (NIHR) comprehensive Biomedical
Research Centre; King's College London; National Institute for Dental
Research [DE016937]
FX This research was supported by a grant from the Guy's and St Thomas'
Charity (ref. R050724). The authors acknowledge financial support from
the UK Department of Health via the National Institute for Health
Research (NIHR) comprehensive Biomedical Research Centre award to Guy's
& St Thomas' NHS Foundation Trust in partnership with King's College
London. Investigators F. E. D., A. C. R. T. and W. G. W. were supported
in part by National Institute for Dental Research grant DE016937.
NR 15
TC 17
Z9 17
U1 0
U2 6
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
BERKS, ENGLAND
SN 1466-5026
J9 INT J SYST EVOL MICR
JI Int. J. Syst. Evol. Microbiol.
PD APR
PY 2013
VL 63
BP 1214
EP 1218
DI 10.1099/ijs.0.041376-0
PN 4
PG 5
WC Microbiology
SC Microbiology
GA 155YF
UT WOS:000319785700001
PM 22753527
ER
PT J
AU Wolfgang, WJ
Passaretti, TV
Jose, R
Cole, J
Coorevits, A
Carpenter, AN
Jose, S
Van Landschoot, A
Izard, J
Kohlerschmidt, DJ
Vandamme, P
Dewhirst, FE
Fisher, MA
Musser, KA
AF Wolfgang, William J.
Passaretti, Teresa V.
Jose, Reashma
Cole, Jocelyn
Coorevits, An
Carpenter, Andrea N.
Jose, Sherly
Van Landschoot, Anita
Izard, Jacques
Kohlerschmidt, Donna J.
Vandamme, Peter
Dewhirst, Floyd E.
Fisher, Mark A.
Musser, Kimberlee A.
TI Neisseria oralis sp nov., isolated from healthy gingival plaque and
clinical samples
SO INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY
LA English
DT Article
ID MICROBIOME; STRAINS; HYBRIDIZATION; LIKELIHOOD; DIVERSITY; ALGORITHM;
SPECIMENS; SEQUENCES; ACCURATE; SKIN
AB A polyphasic analysis was undertaken of seven independent isolates of Gram-negative cocci collected from pathological clinical samples from New York, Louisiana, Florida and Illinois and healthy subgingival plaque from a patient in Virginia, USA. The 16S rRNA gene sequence similarity among these isolates was 99.7-100%, and the closest species with a validly published name was Neisseria lactamica (96.9% similarity to the type strain). DNA-DNA hybridization confirmed that these isolates are of the same species and are distinct from their nearest phylogenetic neighbour, N. lactamica. Phylogenetic analysis of 16S and 23S rRNA gene sequences indicated that the novel species belongs in the genus Neisseria. The predominant cellular fatty acids were C-16:0, summed feature 3 (C-16:1 omega 7c and/or iso-C-15:0 2-OH) and C-18:1 omega 7c. The cellular fatty acid profile, together with other phenotypic characters, further supports the inclusion of the novel species in the genus Neisseria. The name Neisseria oralis sp. nov. (type strain 6332(T) =DSM 25276(T) =LMG 26725(T)) is proposed.
C1 [Wolfgang, William J.; Passaretti, Teresa V.; Jose, Reashma; Cole, Jocelyn; Carpenter, Andrea N.; Jose, Sherly; Kohlerschmidt, Donna J.; Musser, Kimberlee A.] New York State Dept Hlth, Wadsworth Ctr, Bacteriol Lab, Albany, NY 12201 USA.
[Wolfgang, William J.; Musser, Kimberlee A.] SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA.
[Coorevits, An; Van Landschoot, Anita] Univ Coll Ghent, Dept Appl Engn Sci, Lab Biochem & Brewing, B-9000 Ghent, Belgium.
[Coorevits, An; Van Landschoot, Anita; Vandamme, Peter] Univ Ghent, Dept Biochem & Microbiol, Lab Microbiol LM UGent, B-9000 Ghent, Belgium.
[Izard, Jacques; Dewhirst, Floyd E.] Forsyth Inst, Dept Mol Genet, Cambridge, MA 02142 USA.
[Izard, Jacques; Dewhirst, Floyd E.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Fisher, Mark A.] Inst Clin & Expt Pathol, Salt Lake City, UT USA.
[Fisher, Mark A.] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA.
RP Wolfgang, WJ (reprint author), New York State Dept Hlth, Wadsworth Ctr, Bacteriol Lab, POB 22002, Albany, NY 12201 USA.
EM wwolfgan@wadsworth.org
RI Vandamme, Peter/B-7967-2009;
OI Izard, Jacques/0000-0002-5904-5436; Wolfgang,
William/0000-0003-1769-0215; Vandamme, Peter/0000-0002-5581-7937
FU University College Ghent; NIDCR [DE016937]
FX The authors wish to thank the Wadsworth Center Applied Genomic
Technologies Core and the Broad Institute of MIT and Harvard for
sequencing, the Wadsworth Center Orphan Bacterium Collection for
curation of the novel strains described in this study, Margo Cnockaert
for assistance with the DNA hybridization studies and Dr Andrea Habura
for helpful discussions relating to the phylogenetic analysis of the
novel species. A. C. received a grant from the research fund of
University College Ghent. F. E. D. and J. I. were supported by NIDCR
grant DE016937.
NR 26
TC 9
Z9 9
U1 0
U2 12
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
BERKS, ENGLAND
SN 1466-5026
J9 INT J SYST EVOL MICR
JI Int. J. Syst. Evol. Microbiol.
PD APR
PY 2013
VL 63
BP 1323
EP 1328
DI 10.1099/ijs.0.041731-0
PN 4
PG 6
WC Microbiology
SC Microbiology
GA 155YF
UT WOS:000319785700018
PM 22798652
ER
PT J
AU Lu, L
Hannoush, RN
Goess, BC
Varadarajan, S
Shair, MD
Kirchhausen, T
AF Lu, Lei
Hannoush, Rami N.
Goess, Brian C.
Varadarajan, Shankar
Shair, Matthew D.
Kirchhausen, Tom
TI The small molecule dispergo tubulates the endoplasmic reticulum and
inhibits export
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Article
ID TRANS-GOLGI NETWORK; MEMBRANE-PROTEIN; ER CISTERNAE; TUBULES; CELLS;
APPARATUS; LOCALIZATION; MICROTUBULES; ORGANIZATION; MECHANISMS
AB The mammalian endoplasmic reticulum (ER) is an organelle that maintains a complex, compartmentalized organization of interconnected cisternae and tubules while supporting a continuous flow of newly synthesized proteins and lipids to the Golgi apparatus. Using a phenotypic screen, we identify a small molecule, dispergo, that induces reversible loss of the ER cisternae and extensive ER tubulation, including formation of ER patches comprising densely packed tubules. Dispergo also prevents export from the ER to the Golgi apparatus, and this traffic block results in breakdown of the Golgi apparatus, primarily due to maintenance of the constitutive retrograde transport of its components to the ER. The effects of dispergo are reversible, since its removal allows recovery of the ER cisternae at the expense of the densely packed tubular ER patches. This recovery occurs together with reactivation of ER-to-Golgi traffic and regeneration of a functional Golgi with correct morphology. Because dispergo is the first small molecule that reversibly tubulates the ER and inhibits its export function, it will be useful in studying these complex processes.
C1 [Lu, Lei; Hannoush, Rami N.; Kirchhausen, Tom] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
[Lu, Lei; Hannoush, Rami N.; Kirchhausen, Tom] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Lu, Lei] Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore.
[Hannoush, Rami N.; Goess, Brian C.; Shair, Matthew D.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
[Hannoush, Rami N.] Genentech Inc, Dept Early Discovery Biochem, San Francisco, CA 94080 USA.
[Goess, Brian C.] Furman Univ, Dept Chem, Greenville, SC 29613 USA.
[Varadarajan, Shankar] Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England.
RP Kirchhausen, T (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
EM Kirchhausen@crystal.harvard.edu
RI Lu, Lei/A-2225-2011
OI Lu, Lei/0000-0002-8192-1471
FU Canadian Institutes of Health Research; National Sciences and
Engineering Research Council of Canada; U.S. Department of Defense
(National Defense Science and Engineering Graduate Fellowship); National
Institutes of Health [GM-075252]; New England Regional Center of
Excellence in Biodefense and Emerging Infectious Disease, Core Imaging
Facility, Boston, MA [U54 AI057159]; SBS SUG [P01 GM62556, M58080013]
FX We thank M. Ericsson for help with electron microscopy and E. Marino for
maintaining the imaging resources in the Kirchhausen laboratory, and
Yoshiki Tanaka for assistance with the nuclear magnetic resonance,
infrared, and high-resolution mass spectrometry characterization of
dispergo. R.H. was a recipient of postdoctoral fellowships from the
Canadian Institutes of Health Research and National Sciences and
Engineering Research Council of Canada. B.G. was a recipient of a
doctoral fellowship from the U.S. Department of Defense (National
Defense Science and Engineering Graduate Fellowship). This work was
supported in part by National Institutes of Health Grant GM-075252 (to
T.K.) and U54 AI057159 (New England Regional Center of Excellence in
Biodefense and Emerging Infectious Disease, Core Imaging Facility,
Boston, MA), as well as P01 GM62556 (to T.K. and M.S.) and SBS SUG
M58080013 (to L.L.).
NR 36
TC 5
Z9 5
U1 1
U2 23
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA
SN 1059-1524
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PD APR 1
PY 2013
VL 24
IS 7
BP 1020
EP 1029
DI 10.1091/mbc.E12-08-0575
PG 10
WC Cell Biology
SC Cell Biology
GA 173YY
UT WOS:000321120900013
PM 23389632
ER
PT J
AU Katz, NP
Birnbaum, H
Brennan, MJ
Freedman, JD
Gilmore, GP
Jay, D
Kenna, GA
Madras, BK
McElhaney, L
Weiss, RD
White, AG
AF Katz, Nathaniel P.
Birnbaum, Howard
Brennan, Michael J.
Freedman, John D.
Gilmore, Gary P.
Jay, Dennis
Kenna, George A.
Madras, Bertha K.
McElhaney, Lisa
Weiss, Roger D.
White, Alan G.
TI Prescription Opioid Abuse: Challenges and Opportunities for Payers
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID CHRONIC PAIN PATIENTS; SUBSTANCE USE DISORDERS; CHRONIC NONCANCER PAIN;
NEW-YORK-STATE; UNITED-STATES; PRIMARY-CARE; UNIVERSAL PRECAUTIONS;
BENZODIAZEPINE USE; MEDICAID-PATIENTS; ILLICIT DRUG
AB Objectives: Prescription opioid abuse and addiction are serious problems with growing societal and medical costs, resulting in billions of dollars of excess costs to private and governmental health insurers annually. Although difficult to accurately assess, prescription opioid abuse also leads to increased insurance costs in the form of property and liability claims, and costs to state and local governments for judicial, emergency, and social services. This manuscript's objective is to provide payers with strategies to control these costs, while supporting safe use of prescription opioid medications for patients with chronic pain.
Method: A Tufts Health Care Institute Program on Opioid Risk Management meeting was convened in June 2010 with private and public payer representatives, public health and law enforcement officials, pain specialists, and other stakeholders to present research and develop recommendations on solutions that payers might implement to combat this problem.
Results: While protecting access to prescription opioids for patients with pain, private and public payers can implement strategies to mitigate financial risks associated with opioid abuse, using internal strategies such as formulary controls, claims data surveillance, and claims matching; and external policies and procedures that support and educate physicians on reducing opioid risks among patients with chronic pain.
Conclusions: Reimbursement policies, incentives, and health technology systems that encourage physicians to use universal precautions, to consult prescription monitoring program (PMP) data, and to implement Screening, Brief Intervention, and Referral to Treatment protocols have a high potential to reduce insurer risks while addressing a serious public health problem.
C1 [Katz, Nathaniel P.] Tufts Univ, Sch Med, Tufts Hlth Care Inst, Program Opioid Risk Management, Boston, MA 02111 USA.
[Birnbaum, Howard; White, Alan G.] Anal Grp Inc, Boston, MA USA.
[Brennan, Michael J.] Bridgeport Hosp, Bridgeport, CT USA.
[Freedman, John D.] Freedman Healthcare LLC, Newton, MA USA.
[Gilmore, Gary P.] MassHlth, Boston, MA USA.
[Gilmore, Gary P.] Univ Massachusetts, Sch Med, Boston, MA 02125 USA.
[Jay, Dennis] Coalit Insurance Fraud, Washington, DC USA.
[Kenna, George A.] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA.
[Madras, Bertha K.] Harvard Univ, Sch Med, NEPRC, Southborough, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
[McElhaney, Lisa] Natl Assoc Drug Divers Investigators, Lutherville Timonium, MD USA.
[Weiss, Roger D.] Harvard Univ, Sch Med, Boston, MA USA.
[Weiss, Roger D.] McLean Hosp, Belmont, MA 02178 USA.
RP Katz, NP (reprint author), Analges Solut, 232 Pond St, Natick, MA 01760 USA.
EM nkatz@analgesicsolutions.com
FU Tufts Health Care Institute Program on Opioid Risk Management; National
Institutes of Health [RR00168, OD0111303]; National Institute on Drug
Abuse [U10 DA 15831, K24 DA022288]
FX Funding for this manuscript is provided by the Tufts Health Care
Institute Program on Opioid Risk Management. Dr Madras is supported by
the National Institutes of Health (RR00168, OD0111303). Dr Weiss reports
that his work is supported by grants U10 DA 15831 and K24 DA022288 from
the National Institute on Drug Abuse.
NR 79
TC 23
Z9 23
U1 6
U2 20
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD APR
PY 2013
VL 19
IS 4
BP 295
EP 302
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 155WX
UT WOS:000319782200004
PM 23725361
ER
PT J
AU Mroz, P
Parwani, AV
Kulesza, P
AF Mroz, Pawel
Parwani, Anil V.
Kulesza, Piotr
TI Central Pathology Review for Phase III Clinical Trials
SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
LA English
DT Review
ID COOPERATIVE ONCOLOGY GROUP; ANATOMIC PATHOLOGY; SURGICAL PATHOLOGY;
QUALITY ASSURANCE; DIAGNOSIS; EXPERIENCE; FUTURE; GLIOMA
AB Context.-Central pathology review (CPR) was initially designed as a quality control measure. The potential of CPR in clinical trials was recognized as early as in the 1960s and quickly became embedded as an integral part of many clinical trials since.
Objective.-To review the current experience with CPR in clinical trials, to summarize current developments in virtual microscopy, and to discuss the potential advantages and disadvantages of this technology in the context of CPR.
Data Sources.-A PubMed (US National Library of Medicine) search for published studies was conducted, and the relevant articles were reviewed, accompanied by the authors' experience at their practicing institution.
Conclusions.-The review of the available literature strongly suggests the growing importance of CPR both in the clinical trial setting as well as in second opinion cases. However, the currently applied approach significantly impedes efficient transfer of slides and patient data. Recent advances in imaging, digital microscopy, and Internet technologies suggest that the CPR process may be dramatically streamlined in the foreseeable future to allow for better diagnosis and quality assurance than ever before. In particular, whole slide imaging may play an important role in this process and result in a substantial reduction of the overall turnaround time required for slide review at the central location. Above all, this new approach may benefit the large clinical trials organized by oncology cooperative groups, since most of those trials involve complicated logistics owing to enrollment of large number of patients at several remotely located participating institutions.
C1 [Mroz, Pawel; Kulesza, Piotr] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA.
[Mroz, Pawel] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
[Parwani, Anil V.] Univ Pittsburgh, Sch Med, Dept Pathol, Shadyside Hosp, Pittsburgh, PA USA.
RP Kulesza, P (reprint author), Northwestern Univ, ECOG ACRIN PCO RL, Pathol Core Facil, 251 E Huron St,Galter Pavil 7-132E, Chicago, IL 60611 USA.
EM p-kulesza@northwestern.edu
NR 29
TC 4
Z9 5
U1 0
U2 3
PU COLL AMER PATHOLOGISTS
PI NORTHFIELD
PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA
SN 0003-9985
J9 ARCH PATHOL LAB MED
JI Arch. Pathol. Lab. Med.
PD APR
PY 2013
VL 137
IS 4
BP 492
EP 495
DI 10.5858/arpa.2012-0093-RA
PG 4
WC Medical Laboratory Technology; Medicine, Research & Experimental;
Pathology
SC Medical Laboratory Technology; Research & Experimental Medicine;
Pathology
GA 155VT
UT WOS:000319777200007
PM 23544938
ER
PT J
AU Ahmad, R
Alam, M
Rajabi, H
Kufe, DW
AF Ahmad, Rehan
Alam, Maroof
Rajabi, Hasan
Kufe, Donald W.
TI MUC1-C ACTIVATES C/EBP beta-MEDIATED INDUCTION OF ALDEHYDE DEHYDROGENASE
EXPRESSION IN BREAST CANCER CELLS
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Ahmad, Rehan] King Saud Univ, Coll Med, Riyadh 11461, Saudi Arabia.
[Alam, Maroof; Rajabi, Hasan; Kufe, Donald W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA lb99
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883503333
ER
PT J
AU Amendt, BA
Zhang, ZC
Gutierrez, D
Li, X
Bidlack, F
Cao, HJ
Wang, JB
Margolis, HC
AF Amendt, Brad A.
Zhang, Zichao
Gutierrez, Diana
Li, Xiao
Bidlack, Felicitas
Cao, Huojun
Wang, Jianbo
Margolis, Henry C.
TI The LIM Homeodomain Transcription Factor Lhx6: A Transcriptional
Repressor that Interacts with Pituitary Homeobox 2 (PITX2) to Regulate
Odontogenesis
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Amendt, Brad A.; Zhang, Zichao; Gutierrez, Diana; Li, Xiao; Cao, Huojun; Wang, Jianbo] Univ Iowa, Iowa City, IA USA.
[Bidlack, Felicitas; Margolis, Henry C.] Forsyth Inst, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 522.1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883500157
ER
PT J
AU Bar-Peled, L
Chantranupong, L
Cherniack, A
Chen, W
Ottina, K
Grabiner, B
Spear, E
Carter, S
Meyerson, M
Sabatini, DM
AF Bar-Peled, Liron
Chantranupong, Lynne
Cherniack, Andrew
Chen, Walter
Ottina, Kathleen
Grabiner, Brian
Spear, Eric
Carter, Scott
Meyerson, Matthew
Sabatini, David M.
TI A tumor suppressor complex with GAP activity for the Rag GTPases that
signal amino acid sufficiency to mTORC1
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Bar-Peled, Liron; Chantranupong, Lynne; Chen, Walter; Ottina, Kathleen; Grabiner, Brian; Sabatini, David M.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Cherniack, Andrew; Carter, Scott] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Spear, Eric] Johns Hopkins Sch Med, Baltimore, MD USA.
[Meyerson, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sabatini, David M.] Howard Hughes Med Inst, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 832.1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883500335
ER
PT J
AU Bautista, PA
Yagi, Y
AF Bautista, Pinky Abarca
Yagi, Yukako
TI Improved color visualization of histological structures through
multispectral image fusion
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Bautista, Pinky Abarca] Massachusetts Gen, Pathol, Boston, MA USA.
[Yagi, Yukako] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 52.6
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883502179
ER
PT J
AU Bechard, LJ
Feldman, HA
Gura, K
Venick, R
Guinan, EC
Gordon, C
Duggan, C
AF Bechard, Lori J.
Feldman, Henry A.
Gura, Kathleen
Venick, Robert
Guinan, Eva C.
Gordon, Catherine
Duggan, Christopher
TI Bone loss during hematopoietic cell transplantation (HCT) in children
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Bechard, Lori J.; Duggan, Christopher] Childrens Hosp, Ctr Nutr, Boston, MA 02115 USA.
[Feldman, Henry A.] Childrens Hosp, Clin Res Program, Boston, MA 02115 USA.
[Gura, Kathleen] Childrens Hosp, Dept Pharm, Boston, MA 02115 USA.
[Venick, Robert] Univ Calif Los Angeles, Mattel Childrens Hosp, Los Angeles, CA USA.
[Guinan, Eva C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gordon, Catherine] Hasbro Childrens Hosp, Providence, RI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 372.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883502167
ER
PT J
AU Beloiartsev, A
Ventocilla, C
Winkler, JD
Bloch, KD
Zapol, WM
AF Beloiartsev, Arkadi
Ventocilla, Christian
Winkler, Jeffrey D.
Bloch, Kenneth D.
Zapol, Warren M.
TI Inhibition of Soluble Epoxide Hydrolase Augments Hypoxic Pulmonary
Vasoconstriction and Improves Gas Exchange in Mice
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Beloiartsev, Arkadi; Bloch, Kenneth D.; Zapol, Warren M.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Ventocilla, Christian; Winkler, Jeffrey D.] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1140.1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860505386
ER
PT J
AU Bird, SS
Gregory, KE
Gross, VS
Marur, VR
Lazarev, AV
Walker, WA
Kristal, BS
AF Bird, Susan S.
Gregory, Katherine E.
Gross, Vera S.
Marur, Vasant R.
Lazarev, Alexander V.
Walker, W. Allen
Kristal, Bruce S.
TI Fecal Lipidomics Analysis using Liquid Chromatography- Mass Spectrometry
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Bird, Susan S.; Marur, Vasant R.; Kristal, Bruce S.] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
[Gregory, Katherine E.] Brigham & Womens Hosp, Dept Nursing, Boston, MA 02115 USA.
[Gross, Vera S.; Lazarev, Alexander V.] Pressure BioSci Inc, South Easton, MA USA.
[Walker, W. Allen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 3
U2 8
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 815.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883501019
ER
PT J
AU Camarata, T
Vasilyev, A
Arnaout, A
AF Camarata, Troy
Vasilyev, Aleksandr
Arnaout, Amin
TI Role of Sca-1 after ischemia/reperfusion injury in adult mouse kidney
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Camarata, Troy; Vasilyev, Aleksandr; Arnaout, Amin] Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 750.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883501330
ER
PT J
AU Cho, EY
Nan, HM
Giovannucci, EL
Wu, KN
Selhub, J
Paul, L
Rosner, B
Fuchs, C
AF Cho, Eunyoung
Nan, Hongmei
Giovannucci, Edward L.
Wu, Kana
Selhub, Jacob
Paul, Ligi
Rosner, Bernard
Fuchs, Charles
TI Pre-diagnostic Leukocyte Genomic DNA Methylation and the Risk of
Colorectal Cancer in Women
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Cho, Eunyoung; Nan, Hongmei; Giovannucci, Edward L.; Rosner, Bernard] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Cho, Eunyoung; Nan, Hongmei; Giovannucci, Edward L.; Rosner, Bernard] Harvard Univ, Sch Med, Boston, MA USA.
[Wu, Kana] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Selhub, Jacob; Paul, Ligi] Tufts Univ, Boston, MA 02111 USA.
[Fuchs, Charles] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 120.5
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883503369
ER
PT J
AU Christensen, HL
Damkier, HH
Brown, D
Praetorius, J
AF Christensen, Henriette Lajgaard
Damkier, Helle Hasager
Brown, Dennis
Praetorius, Jeppe
TI The choroid plexus regulation of cerebrospinal fluid pH
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Christensen, Henriette Lajgaard; Damkier, Helle Hasager; Praetorius, Jeppe] Aarhus Univ, Dept Biomed, Aarhus C, Denmark.
[Brown, Dennis] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Membrane Biol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 730.11
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860501277
ER
PT J
AU Coon, S
Schwartz, J
Singh, S
AF Coon, Steven
Schwartz, John
Singh, Satish
TI GIP Regulates Pept1 via Akt and EPAC Signaling Pathways in Intestinal
Epithelial Cells
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Coon, Steven; Schwartz, John; Singh, Satish] Boston Univ, Dept Med, Boston, MA 02215 USA.
[Coon, Steven] Boston Univ Clin Transit Sci Inst, Boston, MA USA.
[Singh, Satish] VA Boston Healthcare Syst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1162.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860501458
ER
PT J
AU Cowart, LA
AF Cowart, L. Ashley
TI Dietary Fat Composition Modifies Cell Sphingolipid Biosynthesis to
Mediate the consequences of obesity.
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Cowart, L. Ashley] Med Univ S Carolina, Charleston, SC 29425 USA.
[Cowart, L. Ashley] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 453.2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883500557
ER
PT J
AU Crivello, N
Spires-Jones, T
Shukitt-Hale, B
Carey, A
Roe, A
Smith, D
Blusztajn, JK
Hyman, B
Rosenberg, I
AF Crivello, Natalia
Spires-Jones, Tara
Shukitt-Hale, Barbara
Carey, Amanda
Roe, Annie
Smith, Donald
Blusztajn, Jan Krzysztof
Hyman, Bradley
Rosenberg, Irwin
TI Folate deficiency accelerates Alzheimer's disease related pathology in
APP/PS1 mice
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Crivello, Natalia; Shukitt-Hale, Barbara; Carey, Amanda; Roe, Annie; Rosenberg, Irwin] Tufts Univ, Aging & Neurosci Lab, JM USDA HNRCA, Boston, MA 02111 USA.
[Smith, Donald] Tufts Univ, JM USDA HNRCA, Comparat Biol Unit, Boston, MA 02111 USA.
[Spires-Jones, Tara; Hyman, Bradley] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA USA.
[Blusztajn, Jan Krzysztof] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1077.8
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883503354
ER
PT J
AU Desai, R
Savechenkov, P
Ge, R
Bruzik, K
Raines, D
Miller, K
AF Desai, Rooma
Savechenkov, Pavel
Ge, Rile
Bruzik, Karol
Raines, Douglas
Miller, Keith
TI R- and S-mTFD-MPPB, an Anesthetic and a Convulsant, Have Opposing Effect
on gamma-Aminobutyric acid (GABA) type A Receptors
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Desai, Rooma; Ge, Rile; Raines, Douglas; Miller, Keith] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Savechenkov, Pavel; Bruzik, Karol] Univ Illinois, Chicago, IL USA.
NR 0
TC 1
Z9 1
U1 0
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA lb556
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860500355
ER
PT J
AU Donnelly, BF
Needham, PG
Snyder, AC
Roy, A
Khadem, S
Brodsky, JL
Subramanya, AR
AF Donnelly, Bridget F.
Needham, Patrick G.
Snyder, Avin C.
Roy, Ankita
Khadem, Shaheen
Brodsky, Jeffrey L.
Subramanya, Arohan R.
TI Cytoplasmic Hsp70 and Hsp90 regulate functionally distinct ER quality
control checkpoints during thiazide-sensitive NaCl cotransporter
biogenesis
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Donnelly, Bridget F.; Snyder, Avin C.; Roy, Ankita; Khadem, Shaheen; Subramanya, Arohan R.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA.
[Needham, Patrick G.; Brodsky, Jeffrey L.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.
[Khadem, Shaheen; Subramanya, Arohan R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1210.1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860505287
ER
PT J
AU Doslikova, B
Garfield, A
Shaw, J
Evans, M
Burdakov, D
Billups, B
Heisler, L
AF Doslikova, Barbora
Garfield, Alastair
Shaw, Jill
Evans, Mark
Burdakov, Denis
Billups, Brian
Heisler, Lora
TI 5-HT2C Receptor agonist anorectic efficacy potentiated by 5-HT1B
Receptor agonist co-application; an effect mediated via augmented
pro-opiomelanocortin neuron activation
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Doslikova, Barbora; Shaw, Jill; Billups, Brian; Heisler, Lora] Univ Cambridge, Cambridge, England.
[Evans, Mark] Univ Cambridge, IMS, Cambridge, England.
[Garfield, Alastair] BIDMC, Boston, MA USA.
[Burdakov, Denis] MRC NIMR, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA lb521
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860504450
ER
PT J
AU Eguchi, T
Calderwood, S
AF Eguchi, Takanori
Calderwood, Stuart
TI Cooperative role of MMP-3 and HP1 in heat shock protein transcription
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Eguchi, Takanori; Calderwood, Stuart] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 977.1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883500373
ER
PT J
AU Fasler-Kan, E
Barteneva, N
Meyer, P
AF Fasler-Kan, Elizaveta
Barteneva, Natasha
Meyer, Peter
TI Exploring phospho-signaling pathways in patients with agerelated macular
degeneration (AMD), human pigment epithelial cell line ARPE-19 and
porcine ocular tissue
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Fasler-Kan, Elizaveta] Inst Chem & Bioanalyt, Muttenz, Switzerland.
[Barteneva, Natasha] Immune Dis Inst, Flow Cytometry Core, Boston, MA USA.
[Meyer, Peter] Univ Basel, Ophtalmol Dept, Basel, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 645.11
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860504379
ER
PT J
AU Gao, AQ
Kantarci, A
Gao, HW
Van Dyke, T
AF Gao, Anqi
Kantarci, Alpdogan
Gao, Hongwei
Van Dyke, Thomas
TI Novel role of Suppressor of Cytokine Signaling 3 in regulating
LPS-induced Matrix Metalloproteinase 13 gene expression in osteoblasts
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Gao, Anqi; Kantarci, Alpdogan; Van Dyke, Thomas] Forsyth Inst, Cambridge, MA USA.
[Gao, Hongwei] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 132.9
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860501189
ER
PT J
AU Gosselin, K
Bechard, LJ
Feldman, HA
Kellogg, M
Gura, K
Sonis, A
Venick, R
Gordon, CM
Guinan, EC
Duggan, C
AF Gosselin, Kerri
Bechard, Lori J.
Feldman, Henry A.
Kellogg, Mark
Gura, Kathleen
Sonis, Andrew
Venick, Robert
Gordon, Catherine M.
Guinan, Eva C.
Duggan, Christopher
TI Changes in serum citrulline during hematopoietic cell transplantation
(HCT) in children
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Gosselin, Kerri; Bechard, Lori J.; Feldman, Henry A.; Kellogg, Mark; Gura, Kathleen; Sonis, Andrew; Duggan, Christopher] Boston Childrens Hosp, Boston, MA USA.
[Venick, Robert] UCLA Mattel Childrens Hosp, Los Angeles, CA USA.
[Gordon, Catherine M.] Brown Univ, Providence, RI 02912 USA.
[Guinan, Eva C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 846.8
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860501298
ER
PT J
AU Grigoryeva, L
Hill, E
Da Silva, N
AF Grigoryeva, Lubov
Hill, Eric
Da Silva, Nicolas
TI Postnatal development of mononuclear phagocytes in the mouse epididymis
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 734.4
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860503355
ER
PT J
AU Gruionu, G
Bazou, D
Song, J
AF Gruionu, Gabriel
Bazou, Despina
Song, Johnatan
TI Untangling Tumor Vasculature
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 Massachusetss Gen Hosp, Charlestown, MA USA.
Massachusetss Gen Hosp, Edwin I Steele Lab Tumor Biol, Charlestown, MA USA.
Harvard Univ, Sch Med, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 685.13
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860505300
ER
PT J
AU Gruionu, G
Gruionu, L
Munn, LL
AF Gruionu, Gabriel
Gruionu, Lucian
Munn, Lance L.
TI Flow-Induced Structural Adaptation of Tumor Vasculature by Selective
Micro-Laser Ablation
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Gruionu, Gabriel; Munn, Lance L.] Massachusetss Gen Hosp, Charlestown, MA USA.
[Gruionu, Gabriel; Munn, Lance L.] Harvard Univ, Sch Med, Charlestown, MA USA.
[Gruionu, Gabriel; Gruionu, Lucian] Univ Med & Pharm Craiova, Res Ctr Gastroenterol & Hepatol, Craiova, Romania.
[Gruionu, Lucian] Univ Craiova, Craiova, Romania.
RI Gruionu, Lucian/F-6121-2011; Munn, Lance/L-3950-2016
OI Gruionu, Lucian/0000-0002-4526-0864; Munn, Lance/0000-0003-0698-7232
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 898.16
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860504431
ER
PT J
AU Hashimoto, N
Tanaka, T
Snuderl, M
Yagi, Y
AF Hashimoto, Noriaki
Tanaka, Toru
Snuderl, Matija
Yagi, Yukako
TI Development of a viewing system for a whole tissue from multiple tissue
blocks
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Hashimoto, Noriaki; Tanaka, Toru; Snuderl, Matija; Yagi, Yukako] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hashimoto, Noriaki; Snuderl, Matija; Yagi, Yukako] Harvard Univ, Sch Med, Boston, MA USA.
[Tanaka, Toru] Chiba Univ, Chiba, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 52.4
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883501566
ER
PT J
AU Herter-Sprie, GS
Wong, KK
AF Herter-Sprie, Grit Sophie
Wong, Kwok-Kin
TI Mouse models of cancer - how to optimize their predictive value in
cancer drug development
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Herter-Sprie, Grit Sophie; Wong, Kwok-Kin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Herter-Sprie, Grit Sophie; Wong, Kwok-Kin] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1088.17
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883504409
ER
PT J
AU Hotta, R
Carreon-Rodriguez, A
Belkind-Gerson, J
Goldstein, AM
AF Hotta, Ryo
Carreon-Rodriguez, Alfonso
Belkind-Gerson, Jaime
Goldstein, Allan M.
TI Isolation and Characterization of Enteric Nervous System Stem Cells
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Hotta, Ryo; Carreon-Rodriguez, Alfonso; Belkind-Gerson, Jaime; Goldstein, Allan M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Carreon-Rodriguez, Alfonso] Inst Nacl Salud Publ, Ctr Invest Salud Poblac, Cuernavaca, Morelos, Mexico.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 752.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883501643
ER
PT J
AU Hruby, A
O'Donnell, CJ
Jacques, PF
Meigs, JB
Wood, RJ
McKeown, NM
AF Hruby, Adela
O'Donnell, Christopher J.
Jacques, Paul F.
Meigs, James B.
Wood, Richard J.
McKeown, Nicola M.
TI Associations of magnesium intake with coronary artery calcification in
the Framingham Heart Study
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Hruby, Adela; Jacques, Paul F.; McKeown, Nicola M.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
[O'Donnell, Christopher J.] Massachusetts Gen Hosp, Dept Med, Div Cardiovasc, Boston, MA 02114 USA.
[O'Donnell, Christopher J.; Meigs, James B.] Harvard Univ, Sch Med, Boston, MA USA.
[Meigs, James B.] Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA.
[O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Wood, Richard J.] Univ Massachusetts, Dept Nutr, Amherst, MA 01003 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 622.6
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883502472
ER
PT J
AU Hung, DT
AF Hung, Deborah T.
TI Small molecules, toxins and cell death pathways
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Hung, Deborah T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Broad Inst, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 213.2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883501188
ER
PT J
AU Iacovelli, J
Arany, Z
Saint-Geniez, M
AF Iacovelli, Jared
Arany, Zoltan
Saint-Geniez, Magali
TI PGC-1 isoforms modulate the antioxidant response of photoreceptors to
photo-oxidative stress
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Iacovelli, Jared; Saint-Geniez, Magali] Mass Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA USA.
[Iacovelli, Jared; Arany, Zoltan; Saint-Geniez, Magali] Harvard Univ, Sch Med, Boston, MA USA.
[Arany, Zoltan] Beth Israel Deaconess Med Ctr, Cadiovasc Inst, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1086.10
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860504579
ER
PT J
AU Ingram, KH
Thalacker-Mercer, A
Garvey, WT
AF Ingram, Katherine Heimburger
Thalacker-Mercer, Anna
Garvey, W. Timothy
TI Individual amino acids and insulin sensitivity: relationships determined
by race and gender
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Ingram, Katherine Heimburger] Kennesaw State Univ, Kennesaw, GA USA.
[Thalacker-Mercer, Anna] Cornell Univ, Ithaca, NY USA.
[Garvey, W. Timothy] Univ Alabama Birmingham, Birmingham, AL USA.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 631.4
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883504260
ER
PT J
AU Irie, T
Sips, P
Tokuda, K
Ichinose, F
AF Irie, Tomoya
Sips, Patrick
Tokuda, Kentaro
Ichinose, Fumito
TI Protein S-nitrosylation regulates Ca2+handling and myofilament
Ca2+sensitivity in beta-adrenergic signaling
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Irie, Tomoya; Sips, Patrick; Tokuda, Kentaro; Ichinose, Fumito] Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 921.5
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860502032
ER
PT J
AU Jacques, PF
Cassidy, A
Rogers, G
Meigs, JB
Dwyer, JT
AF Jacques, Paul F.
Cassidy, Aedin
Rogers, Gail
Meigs, James B.
Dwyer, Johanna T.
TI Intakes of Dietary Flavonoid Sub-classes and Incidence of Type 2
Diabetes
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Jacques, Paul F.; Rogers, Gail; Dwyer, Johanna T.] Tufts Univ, USDA, Human Nutr Res Ctr, Boston, MA 02111 USA.
[Cassidy, Aedin] Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England.
[Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Dwyer, Johanna T.] Tufts Med Ctr, Frances Stern Nutr Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 106.2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883505460
ER
PT J
AU Jung, S
Je, Y
Giovannucci, E
Willet, WC
Rosner, B
Ogino, S
Cho, E
AF Jung, Seungyoun
Je, Youjin
Giovannucci, Edward
Willet, Walter C.
Rosner, Bernard
Ogino, Shuji
Cho, Eunyoung
TI Development of dietary methyl score using plasma homocysteine level in
the large two US cohort study
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Jung, Seungyoun; Giovannucci, Edward; Willet, Walter C.; Rosner, Bernard; Cho, Eunyoung] Channing Div Network Med, Dept Med, Boston, MA USA.
[Je, Youjin] Kyung Hee Univ, Seoul, South Korea.
[Giovannucci, Edward; Willet, Walter C.; Rosner, Bernard; Ogino, Shuji] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Ogino, Shuji] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 622.10
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883506048
ER
PT J
AU Karastergiou, K
Bredella, MA
Smith, SR
Miller, KK
Fried, SK
AF Karastergiou, Kalypso
Bredella, Miriam A.
Smith, Steven R.
Miller, Karen K.
Fried, Susan K.
TI Growth Hormone Receptor In Human Subcutaneous Adipose Tissue: Gluteal
Versus Abdominal Depots
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Karastergiou, Kalypso; Fried, Susan K.] Boston Univ, Boston, MA 02215 USA.
[Bredella, Miriam A.; Miller, Karen K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Smith, Steven R.] Florida Hosp, Sanford Burnham Inst, Orlando, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 630.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883505349
ER
PT J
AU Kashambwa, R
Chiuve, S
Meyerhardt, J
Sato, K
Hu, F
Fung, T
AF Kashambwa, Rutendo
Chiuve, Stephanie
Meyerhardt, Jeffrey
Sato, Kaori
Hu, Frank
Fung, Teresa
TI Post diagnosis diet quality and colorectal cancer survival
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Kashambwa, Rutendo; Chiuve, Stephanie; Hu, Frank; Fung, Teresa] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Meyerhardt, Jeffrey; Sato, Kaori] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Fung, Teresa] Simmons Coll, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 372.7
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883504501
ER
PT J
AU Kellogg, DL
Zhao, J
Wu, YB
Roman, L
Johnson, JM
AF Kellogg, Dean Lundt
Zhao, Joan
Wu, Yubo
Roman, Linda
Johnson, John Marshall
TI Evidence that chronic inhibition of the mammalian Target of Rapamycin
(mTOR) reduces skin blood flow in humans
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Kellogg, Dean Lundt] South Texas Vet Hlth Care Syst, Geriatr Educ & Clin Ctr, San Antonio, TX USA.
[Kellogg, Dean Lundt; Zhao, Joan; Wu, Yubo; Roman, Linda; Johnson, John Marshall] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA lb668
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860506258
ER
PT J
AU Kim, B
Da Silva, N
Roy, J
Shum, W
Breton, S
AF Kim, Bongki
Da Silva, Nicolas
Roy, Jeremy
Shum, Winnie
Breton, Sylvie
TI Luminal testicular factors are essential for the luminalreaching
property of basal cells in the mouse epididymis
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Kim, Bongki; Da Silva, Nicolas; Roy, Jeremy; Shum, Winnie; Breton, Sylvie] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Membrane Biol,Ctr Syst Biol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 734.11
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860503126
ER
PT J
AU Kingston, RE
Armache, KJ
Simon, MD
West, J
Grau, D
Garlick, J
Davis, C
AF Kingston, Robert E.
Armache, Karim-Jean
Simon, Matthew D.
West, Jason
Grau, Daniel
Garlick, Joseph
Davis, Chris
TI Epigenetic mechanism: silent nucleosomal structures and non-coding RNAs.
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Kingston, Robert E.; Armache, Karim-Jean; Simon, Matthew D.; West, Jason; Grau, Daniel; Garlick, Joseph; Davis, Chris] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kingston, Robert E.; Armache, Karim-Jean; Simon, Matthew D.; West, Jason; Grau, Daniel; Garlick, Joseph] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Davis, Chris] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 456.2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883500146
ER
PT J
AU Koh, HJ
Toyoda, T
Jung, MM
Lee, MY
Hirshman, MF
Goodyear, LJ
AF Koh, Ho-Jin
Toyoda, Taro
Jung, Michelle M.
Lee, Min-Young
Hirshman, Michael F.
Goodyear, Laurie J.
TI The Role of Skeletal Muscle Tribbles 3 (TRB3) on Endoplasmic Reticulum
(ER) stress- and high fat diet-induced insulin resistance
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Koh, Ho-Jin; Toyoda, Taro; Jung, Michelle M.; Lee, Min-Young; Hirshman, Michael F.; Goodyear, Laurie J.] Joslin Diabet Ctr Inc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1154.5
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860504485
ER
PT J
AU Kunert, C
Padera, TP
Munn, LL
AF Kunert, Christian
Padera, Timothy P.
Munn, Lance L.
TI Dynamics of Nitric Oxide Activity are Sufficient and Optimal to Drive
Lymphatic Pumping
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Kunert, Christian; Padera, Timothy P.; Munn, Lance L.] Harvard Univ, Sch Med, Mass Gen Hosp, Boston, MA USA.
RI Munn, Lance/L-3950-2016
OI Munn, Lance/0000-0003-0698-7232
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 681.1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860504390
ER
PT J
AU Leone, VA
Huang, E
Wang, YW
Devkota, S
Zale, E
Dalal, S
Chang, EB
AF Leone, Vanessa A.
Huang, Edmond
Wang, Yunwei
Devkota, Suzanne
Zale, Elizabeth
Dalal, Sushila
Chang, Eugene B.
TI Antibiotic-Induced Gut Microbiota Alters Period-2 Circadian Gene
Expression in Liver
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Leone, Vanessa A.; Huang, Edmond; Wang, Yunwei; Zale, Elizabeth; Dalal, Sushila; Chang, Eugene B.] Univ Chicago, Chicago, IL 60637 USA.
[Devkota, Suzanne] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1205.2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883501509
ER
PT J
AU Lezcano, C
Kleffel, S
Laga, AC
Zhan, Q
DoRosario, A
Frank, MH
Wang, LD
Murphy, GF
Schatton, T
AF Lezcano, Cecilia
Kleffel, Sonja
Laga, Alvaro C.
Zhan, Qian
DoRosario, Andrew
Frank, Markus H.
Wang, Linda
Murphy, George F.
Schatton, Tobias
TI Expression of MDR-transporter, ABCB5, in Merkel cell carcinoma
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Lezcano, Cecilia; Kleffel, Sonja; Laga, Alvaro C.; Zhan, Qian; Frank, Markus H.; Murphy, George F.; Schatton, Tobias] Brigham & Womens Hosp, Boston, MA 02115 USA.
[DoRosario, Andrew] Dana Farber Canc Inst, Ctr Cutaneous Oncol, Boston, MA 02115 USA.
[Frank, Markus H.; Schatton, Tobias] Childrens Hosp, Transplantat Res Ctr, Boston, MA 02115 USA.
[Wang, Linda] St Johns Mercy Med Ctr, Inst Canc Care, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1087.8
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860501406
ER
PT J
AU Li, Y
Friedman, AA
Yu, ZS
Tamez, H
Wenger, J
Thadhani, R
Watkins, BA
AF Li, Yong
Friedman, Allon A.
Yu, Zhangsheng
Tamez, Hector
Wenger, Julia
Thadhani, Ravi
Watkins, Bruce A.
TI Phospholipid PUFA: a better indicator for assessing health risks
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Li, Yong; Watkins, Bruce A.] Univ Connecticut, Diet & Hlth Initiat, Storrs, CT USA.
[Friedman, Allon A.; Yu, Zhangsheng] Indiana Univ Sch Med, Indianapolis, IN USA.
[Tamez, Hector; Wenger, Julia; Thadhani, Ravi] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1072.16
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883504571
ER
PT J
AU Ma, JT
Sloan, M
Fox, CS
Hoffmann, U
Jacques, PF
McKeown, NM
AF Ma, Jiantao
Sloan, Matthew
Fox, Caroline S.
Hoffmann, Udo
Jacques, Paul F.
McKeown, Nicola M.
TI Sugar-sweetened beverage consumption is associated with relative
distribution of abdominal adipose tissue in the Framingham Heart Study
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Ma, Jiantao] Tufts Univ, Jean Mayer USDA HNRCA, Boston, MA 02111 USA.
[Sloan, Matthew] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Fox, Caroline S.] NHLBI, Framingham, MA USA.
[Fox, Caroline S.] Harvard Univ, Sch Med, Boston, MA USA.
[Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Jacques, Paul F.; McKeown, Nicola M.] Tutfs Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 126.1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860500120
ER
PT J
AU Marshansky, V
Hosokawa, H
Zhuang, ZJ
Randazzo, PA
Gruber, G
Ausiello, DA
AF Marshansky, Vladimir
Hosokawa, Hiroyuki
Zhuang, Zhenjie
Randazzo, Paul A.
Grueber, Gerhard
Ausiello, Dennis A.
TI Novel role of cytohesin-2 in regulation of macropinocytosis pathway and
cell proliferation
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Marshansky, Vladimir; Hosokawa, Hiroyuki; Zhuang, Zhenjie; Ausiello, Dennis A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Membrane Biol,Ctr Syst Biol, Boston, MA USA.
[Randazzo, Paul A.] NCI, Lab Cel Mol Biol, Ctr Canc Res, Bethesda, MD 20892 USA.
[Grueber, Gerhard] Nanyang Technol Univ, Sch Biol Sci, Div Struct Biol Biochem, Singapore, Singapore.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 591.8
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883500220
ER
PT J
AU Meng, SS
Zhang, XH
Giovannucci, EL
Ma, J
Fuchs, C
Cho, EY
AF Meng, Shasha
Zhang, Xuehong
Giovannucci, Edward L.
Ma, Jing
Fuchs, Charles
Cho, Eunyoung
TI No association between garlic intake and risk of colorectal cancer
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Meng, Shasha; Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Zhang, Xuehong; Giovannucci, Edward L.; Ma, Jing; Cho, Eunyoung] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Zhang, Xuehong; Giovannucci, Edward L.; Ma, Jing; Cho, Eunyoung] Harvard Univ, Sch Med, Boston, MA USA.
[Fuchs, Charles] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 847.20
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883505447
ER
PT J
AU Meyerson, M
AF Meyerson, Matthew
TI Somatic genome alterations in triple-negative breast cancer
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Meyerson, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 328.2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860500500
ER
PT J
AU Mougios, V
Huh, JY
Panagiotou, G
Kabasakalis, A
Mantzoros, C
AF Mougios, Vasileios
Huh, Joo Young
Panagiotou, Grigorios
Kabasakalis, Athanasios
Mantzoros, Christos
TI Responses of circulating irisin to different exercises in humans
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Mougios, Vasileios; Kabasakalis, Athanasios] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece.
[Huh, Joo Young; Panagiotou, Grigorios; Mantzoros, Christos] Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA.
[Huh, Joo Young; Panagiotou, Grigorios; Mantzoros, Christos] Harvard Univ, Sch Med, Endocrinol Sect, Boston VA Healthcare Syst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 712.17
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860502499
ER
PT J
AU Mudge, D
Bielenberg, DR
Serhan, K
Hwang, SH
Hammock, BD
Kieran, MW
Panigrahy, D
AF Mudge, Dayna
Bielenberg, Diane R.
Serhan, Karolina
Hwang, Sung Hee
Hammock, Bruce D.
Kieran, Mark W.
Panigrahy, Dipak
TI Epoxyeicosanoid regulation of tumor lymphangiogenesis
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Mudge, Dayna; Bielenberg, Diane R.; Serhan, Karolina; Kieran, Mark W.; Panigrahy, Dipak] Boston Childrens Hosp, Vasc Biol Program, Boston, MA USA.
[Mudge, Dayna; Serhan, Karolina; Kieran, Mark W.; Panigrahy, Dipak] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Pediat Oncol, Boston, MA 02115 USA.
[Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA.
[Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, Canc Res Ctr, Davis, CA 95616 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA lb457
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883502570
ER
PT J
AU Murshid, A
Chou, SD
Eguchi, T
Calderwood, S
AF Murshid, Ayesha
Chou, Shiuh Dih
Eguchi, Takanori
Calderwood, Stuart
TI Role of HSF1 and FoxO3 in proteotoxic stress induced Macroautophagy
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Murshid, Ayesha; Chou, Shiuh Dih; Eguchi, Takanori; Calderwood, Stuart] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 994.1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860502055
ER
PT J
AU Nagy, N
Akbareian, S
Steiger, C
Molnar, D
Barad, C
Goldstein, AM
AF Nagy, Nandor
Akbareian, Sophie
Steiger, Casey
Molnar, David
Barad, Csilla
Goldstein, Allan M.
TI Expression and function of tenascin-C during colorectal enteric nervous
system development
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Nagy, Nandor; Molnar, David; Barad, Csilla] Semmelweis Univ, Fac Med, Dept Human Morphol & Dev Biol, H-1085 Budapest, Hungary.
[Nagy, Nandor; Akbareian, Sophie; Steiger, Casey; Goldstein, Allan M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Surg, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 965.4
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883501059
ER
PT J
AU Nanthakumar, NN
Meng, D
Newburg, DS
AF Nanthakumar, Nanda N.
Meng, Di
Newburg, David S.
TI Microbiota and glucocorticoids regulate postnatal developmental of
intestinal Fut2 gene expression
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Nanthakumar, Nanda N.; Newburg, David S.] Boston Coll, Chestnut Hill, MA 02167 USA.
[Meng, Di] Harvard Univ, Sch Med, Charlestown, MA USA.
[Meng, Di] Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 951.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860502053
ER
PT J
AU Nichols, JM
Maiellaro, I
Abi-Jaoude, J
Curci, S
Hofer, AM
AF Nichols, Jonathan Michael
Maiellaro, Isabella
Abi-Jaoude, Joanne
Curci, Silvana
Hofer, Aldebaran M.
TI Involvement of Store-operated cAMP signaling in the regulation of
colonic secretory function
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Nichols, Jonathan Michael; Maiellaro, Isabella; Abi-Jaoude, Joanne; Curci, Silvana; Hofer, Aldebaran M.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, West Roxbury, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1163.2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860500073
ER
PT J
AU Noel, S
Manjourides, J
Scott, TM
Spiro, A
Tucker, KL
AF Noel, Sabrina
Manjourides, Justin
Scott, Tammy M.
Spiro, Avron, III
Tucker, Katherine L.
TI Coffee intake and cognitive functioning in men
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Noel, Sabrina; Manjourides, Justin; Tucker, Katherine L.] Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USA.
[Scott, Tammy M.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
[Spiro, Avron, III] VA Boston Healthcare Syst, Boston, MA USA.
[Spiro, Avron, III] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Spiro, Avron, III] Boston Univ, Sch Med, Boston, MA 02118 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 840.15
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860505551
ER
PT J
AU Nunes, P
Ernandez, T
Roth, I
Qiao, XM
Feraille, E
Brown, D
Hasler, U
AF Nunes, Paula
Ernandez, Thomas
Roth, Isabelle
Qiao, Xiaomu
Feraille, Eric
Brown, Dennis
Hasler, Udo
TI Autophagy is induced by hypertonic stress and is associated with
microtubule-dependent pericentrosomsal clustering of autolysosomes
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Nunes, Paula; Ernandez, Thomas; Roth, Isabelle; Qiao, Xiaomu; Feraille, Eric; Hasler, Udo] Univ Geneva, Dept Cellular Physiol & Metab, Geneva, Switzerland.
[Nunes, Paula; Brown, Dennis; Hasler, Udo] Massachusetts Gen Hosp, Program Membrane Biol, Boston, MA 02114 USA.
[Nunes, Paula; Brown, Dennis; Hasler, Udo] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 728.2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860501576
ER
PT J
AU Park, CY
Burger, S
Frykenberg, M
Tambe, D
Zhou, EH
Krishnan, R
Marinkovic, A
Tschumperlin, D
Butler, J
Lavoie, T
Dowell, M
Chen, BH
Gardel, M
Green, G
Solway, J
Fredberg, J
AF Park, Chan Young
Burger, Stephanie
Frykenberg, Matthew
Tambe, Dhananjay
Zhou, Enhua
Krishnan, Ramaswamy
Marinkovic, Aleksander
Tschumperlin, Daniel
Butler, James
Lavoie, Tera
Dowell, Maria
Chen, Bohao
Gardel, Margaret
Green, Geoffrey
Solway, Julian
Fredberg, Jeffrey
TI HIGH-THROUGHPUT SCREENING BY TRACTION MICROSCOPY
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Park, Chan Young; Tambe, Dhananjay; Zhou, Enhua; Marinkovic, Aleksander; Tschumperlin, Daniel; Butler, James; Fredberg, Jeffrey] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Burger, Stephanie; Frykenberg, Matthew] Northeastern Univ, Boston, MA 02115 USA.
[Krishnan, Ramaswamy] BIDMC, Boston, MA USA.
[Lavoie, Tera; Dowell, Maria; Chen, Bohao; Gardel, Margaret; Green, Geoffrey; Solway, Julian] Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 894.7
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860502287
ER
PT J
AU Park, E
D'Andrea, AD
AF Park, Eunmi
D'Andrea, Alan D.
TI The Fanconi Anemia Pathway Induces Senescence and Suppresses
Tumorigenesis in Vivo
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Park, Eunmi; D'Andrea, Alan D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA lb400
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860505498
ER
PT J
AU Patel, SR
Sheth, S
Mian, M
Bourne, S
Flaherty, A
Eskandar, E
AF Patel, Shaun R.
Sheth, Sameer
Mian, Matt
Bourne, Sarah
Flaherty, Alice
Eskandar, Emad
TI Correlation and Causation: Systems Level Understanding of
Decision-Making Signals at the Single-Neuronal Level in the Human Brain
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Patel, Shaun R.; Sheth, Sameer; Mian, Matt; Bourne, Sarah; Flaherty, Alice; Eskandar, Emad] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1124.1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883503177
ER
PT J
AU Paunescu, TG
Huynh, C
Lechner, L
Goetze, B
Stern, L
Breton, S
Brown, D
AF Paunescu, Teodor G.
Huynh, Chuong
Lechner, Lorenz
Goetze, Bernhard
Stern, Lewis
Breton, Sylvie
Brown, Dennis
TI Helium ion microscopy of the rodent kidney and male reproductive tract
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Paunescu, Teodor G.; Breton, Sylvie; Brown, Dennis] Massachusetts Gen Hosp, Program Membrane Biol, Ctr Syst Biol, Boston, MA 02114 USA.
[Paunescu, Teodor G.; Breton, Sylvie; Brown, Dennis] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA.
[Paunescu, Teodor G.; Breton, Sylvie; Brown, Dennis] Harvard Univ, Sch Med, Boston, MA USA.
[Huynh, Chuong; Lechner, Lorenz; Goetze, Bernhard; Stern, Lewis] Carl Zeiss Microscopy LLC, Peabody, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 683.1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860503093
ER
PT J
AU Pazos, MA
Hurley, BP
AF Pazos, Michael A.
Hurley, Bryan P.
TI Hepoxilin A(3) is a key driver of neutrophil migration in a model of
acute P. aeruginosa infection
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Pazos, Michael A.; Hurley, Bryan P.] Massachusetts Gen Hosp, Mucosal Immunol Lab, Charlestown, MA USA.
[Pazos, Michael A.; Hurley, Bryan P.] Harvard Univ, Sch Med, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1215.4
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860501496
ER
PT J
AU Picard, N
Hennings, JC
Huebner, A
Stauber, T
Maier, H
Brown, D
Jentsch, T
Vargas-Poussou, R
Eladari, D
Huebner, C
AF Picard, Nicolas
Hennings, Jean-Christopher
Huebner, Antje
Stauber, Tobias
Maier, Hannes
Brown, Dennis
Jentsch, Thomas
Vargas-Poussou, Rosa
Eladari, Dominique
Huebner, Christian
TI Vacuolar proton pump a4 subunit is critical for inner ear development
and renal function
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Picard, Nicolas; Eladari, Dominique] INSERM, Paris, France.
[Hennings, Jean-Christopher; Huebner, Antje; Huebner, Christian] Inst Human Genet & Anthropol, Jena, Germany.
[Stauber, Tobias; Jentsch, Thomas] Max Delbruck Ctr Mol Med, Berlin, Germany.
[Maier, Hannes] Hannover Med Sch, D-30623 Hannover, Germany.
[Brown, Dennis] Massachusetts Gen Hosp, Program Membrane Biol, Boston, MA 02114 USA.
[Brown, Dennis] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA.
[Vargas-Poussou, Rosa] Hop Georges Pompidou, Paris, France.
RI Stauber, Tobias/E-4005-2010; Hannes, Maier/A-9457-2012; Picard,
Nicolas/B-6677-2012
OI Stauber, Tobias/0000-0003-0727-6109; Hannes, Maier/0000-0001-8457-5327;
Picard, Nicolas/0000-0002-1695-3389
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1115.24
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860501428
ER
PT J
AU Priolo, C
Pyne, S
McDunn, J
Rose, J
Ravasz, E
Zadra, G
Photopoulos, C
Scaglia, N
DeMarzo, A
Loda, M
AF Priolo, Carmen
Pyne, Saumyadipta
McDunn, Jonathan
Rose, Joshua
Ravasz, Erzsebet
Zadra, Giorgia
Photopoulos, Cornelia
Scaglia, Natalia
DeMarzo, Angelo
Loda, Massimo
TI The Metabolic Fingerprints of Prostate Cancer
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Priolo, Carmen; Pyne, Saumyadipta; Rose, Joshua; Zadra, Giorgia; Photopoulos, Cornelia; Scaglia, Natalia; Loda, Massimo] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[McDunn, Jonathan] Metabolon Inc, Durham, NC USA.
[Ravasz, Erzsebet] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[DeMarzo, Angelo] Johns Hopkins Univ, Baltimore, MD USA.
[Loda, Massimo] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 471.9
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883503389
ER
PT J
AU Reddy, AT
Lakshmi, SP
Dornadula, S
Pinni, S
Rampa, DR
Reddy, RC
AF Reddy, Aravind T.
Lakshmi, Sowmya P.
Dornadula, Sireesh
Pinni, Sudheer
Rampa, Dileep R.
Reddy, Raju C.
TI Suppressing Allergic Airway Disease with Nitrated Fatty Acids
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1216.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860500483
ER
PT J
AU Ross, JS
Hu, W
Rosen, B
Snider, AJ
Obeid, LM
Cowart, LA
AF Ross, Jessica Shavonne
Hu, Wei
Rosen, Bess
Snider, Ashley J.
Obeid, Lina M.
Cowart, L. Ashley
TI Sphingosine Kinase 1 is regulated by PPAR alpha in response to free
fatty acids and mediates skeletal muscle IL-6 production and signaling
in diet-induced obesity
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Ross, Jessica Shavonne; Hu, Wei; Snider, Ashley J.; Cowart, L. Ashley] Med Univ S Carolina, Charleston, SC 29425 USA.
[Ross, Jessica Shavonne] Med Univ S Carolina, Mol & Cellular Biol & Pathobiol Program, Charleston, SC 29425 USA.
[Rosen, Bess] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Snider, Ashley J.; Cowart, L. Ashley] Ralph H Johnson VA Ctr, Charleston, SC USA.
[Obeid, Lina M.] SUNY Stony Brook, Stony Brook, NY 11794 USA.
[Obeid, Lina M.] Northport VA Ctr, Northport, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 813.18
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883505050
ER
PT J
AU Roy, J
Ruan, YC
Hill, E
Visconti, P
Krapf, D
Vinegoni, C
Breton, S
AF Roy, Jeremy
Ruan, Ye Chun
Hill, Eric
Visconti, Pablo
Krapf, Dario
Vinegoni, Claudio
Breton, Sylvie
TI Regulation of basal cell plasticity by epidermal growth factor (EGF) and
c-Src in vivo in the mouse epididymis
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Roy, Jeremy; Ruan, Ye Chun; Hill, Eric; Breton, Sylvie] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Membrane Biol,Ctr Syst Biol, Boston, MA USA.
[Vinegoni, Claudio] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA USA.
[Visconti, Pablo; Krapf, Dario] Univ Massachusetts, Amherst, MA 01003 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 734.12
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860502252
ER
PT J
AU Russo, SB
Tidhar, R
Futerman, A
Cowart, LA
AF Russo, Sarah Brice
Tidhar, Rotem
Futerman, Anthony
Cowart, L. Ashley
TI Myristate-derived d16:o-sphingolipids constitute an abundant cardiac
sphingolipid pool with distinct synthetic routes and functional
properties
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Russo, Sarah Brice; Cowart, L. Ashley] Med Univ S Carolina, Charleston, SC 29425 USA.
[Tidhar, Rotem; Futerman, Anthony] Weizmann Inst Sci, IL-76100 Rehovot, Israel.
[Cowart, L. Ashley] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 813.15
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883504450
ER
PT J
AU Shirozu, K
Tokuda, K
Marutani, E
Lefer, D
Wang, R
Ichinose, F
AF Shirozu, Kazuhiro
Tokuda, Kentaro
Marutani, Eizo
Lefer, David
Wang, Rui
Ichinose, Fumito
TI Cystathione-gamma-lyase deficiency protects mice from
galactosamine/LPS-induced acute liver failure
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Shirozu, Kazuhiro; Tokuda, Kentaro; Marutani, Eizo; Ichinose, Fumito] Massachusetts Gen Hosp, Charlestown, MA USA.
[Shirozu, Kazuhiro; Tokuda, Kentaro; Marutani, Eizo; Ichinose, Fumito] Harvard Univ, Sch Med, Charlestown, MA USA.
[Lefer, David] Emory Univ, Sch Med, Atlanta, GA USA.
[Wang, Rui] Lakehead Univ, Thunder Bay, ON P7B 5E1, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1161.7
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860502139
ER
PT J
AU Sholl, LM
Garcia, E
Jia, YH
MacConaill, L
Lindeman, N
AF Sholl, Lynette Marie
Garcia, Elizabeth
Jia, Yonghui
MacConaill, Laura
Lindeman, Neal
TI High throughput mutation profiling of lung adenocarcinoma
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Sholl, Lynette Marie; Lindeman, Neal] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Garcia, Elizabeth; Jia, Yonghui; MacConaill, Laura] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 58.4
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883500209
ER
PT J
AU Sips, PY
Zou, L
Irie, T
Nguyen, R
Chao, W
Kaneki, M
Ichinose, F
AF Sips, Patrick Yves
Zou, Lin
Irie, Tomoya
Rebecca Nguyen
Chao, Wei
Kaneki, Masao
Ichinose, Fumito
TI Septic cardiomyopathy is improved by enhancing cardiomyocyte
denitrosylation capacity
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Sips, Patrick Yves; Zou, Lin; Irie, Tomoya; Rebecca Nguyen; Chao, Wei; Kaneki, Masao; Ichinose, Fumito] Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 921.8
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860503395
ER
PT J
AU Song, JW
Bazou, D
Munn, LL
AF Song, Jonathan W.
Bazou, Despina
Munn, Lance L.
TI Flow-mediated Vessel Guidance
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 Massachusetts Gen Hosp, Charlestown, MA USA.
Harvard Univ, Sch Med, Charlestown, MA USA.
RI Munn, Lance/L-3950-2016
OI Munn, Lance/0000-0003-0698-7232
NR 0
TC 0
Z9 0
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 688.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860501248
ER
PT J
AU Thalacker-Mercer, A
Ingram, KH
Garvey, WT
AF Thalacker-Mercer, Anna
Ingram, Katherine Heimburger
Garvey, W. Timothy
TI Fat utilization impacts the negative relationship between insulin
sensitivity and Leucine
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Thalacker-Mercer, Anna] Cornell Univ, Ithaca, NY USA.
[Ingram, Katherine Heimburger] Kennesaw State Univ, Kennesaw, GA USA.
[Garvey, W. Timothy] Univ Alabama Birmingham, Birmingham, AL USA.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 226.2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883504131
ER
PT J
AU Unger, ER
Panicker, G
Wong, J
Wallstrom, G
Haddad, R
D'Souza, G
Posner, M
Anderson, KS
AF Unger, Elizabeth R.
Panicker, Gitika
Wong, Jessica
Wallstrom, Garrick
Haddad, Robert
D'Souza, Gypsyamber
Posner, Marshall
Anderson, Karen S.
TI Differential antibody responses to HPV16 in cervical and oropharyngeal
cancer
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Unger, Elizabeth R.; Panicker, Gitika] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Wong, Jessica; Haddad, Robert] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wallstrom, Garrick; Anderson, Karen S.] Arizona State Univ, Tempe, AZ USA.
[D'Souza, Gypsyamber] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA.
[Posner, Marshall] Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1087.10
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860504008
ER
PT J
AU Wakiyama, A
Black, KM
Pacak, CA
Ericsson, M
Barnett, RJ
Drumm, C
Seth, P
Bloch, DB
Levitsky, S
Cowan, DB
McCully, JD
AF Wakiyama, Akihiro
Black, Kendra M.
Pacak, Christina A.
Ericsson, Maria
Barnett, Reanne J.
Drumm, Ciara
Seth, Pankaj
Bloch, Donald B.
Levitsky, Sidney
Cowan, Douglas B.
McCully, James D.
TI Transplantation of Autologously-Derived Mitochondria Protects the Heart
from Ischemia-Reperfusion Injury
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Wakiyama, Akihiro; Black, Kendra M.; Barnett, Reanne J.; Drumm, Ciara; Levitsky, Sidney; McCully, James D.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Seth, Pankaj] Beth Israel Deaconess Med Ctr, Div Interdisciplinary Med & Biotechnol, Boston, MA 02215 USA.
[Pacak, Christina A.; Cowan, Douglas B.] Bosto Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA USA.
[Ericsson, Maria; Seth, Pankaj; Bloch, Donald B.; Levitsky, Sidney; Cowan, Douglas B.; McCully, James D.] Harvard Univ, Sch Med, Boston, MA USA.
[Bloch, Donald B.] Massachusetts Gen Hosp, Rheumatol Allergy & Immunol 5Div, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 1209.7
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860502171
ER
PT J
AU Wang, JM
Iacovelli, J
Spencer, C
Saint-Geniez, M
AF Wang, Jinmei
Iacovelli, Jared
Spencer, Carrie
Saint-Geniez, Magali
TI New insights on sodium iodate-induced retinal degeneration
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Wang, Jinmei; Iacovelli, Jared; Spencer, Carrie; Saint-Geniez, Magali] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 873.15
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883505060
ER
PT J
AU White, J
Ruas, J
Rao, R
Kleiner, S
Wu, J
Spiegelman, B
AF White, James
Ruas, Jorge
Rao, Rajesh
Kleiner, Sandra
Wu, Jun
Spiegelman, Bruce
TI A novel PGC-1a isoform induced by resistance training regulates skeletal
muscle hypertrophy
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [White, James; Ruas, Jorge; Rao, Rajesh; Kleiner, Sandra; Wu, Jun; Spiegelman, Bruce] Harvard Univ, Sch Med, DFCI, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 5
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 940.18
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860504158
ER
PT J
AU Wilkinson, CW
Colasurdo, EA
Pagulayan, KF
Shofer, JB
Peskind, ER
AF Wilkinson, Charles W.
Colasurdo, Elizabeth A.
Pagulayan, Kathleen F.
Shofer, Jane B.
Peskind, Elaine R.
TI Prevalence of chronic hypopituitarism after blast concussion
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Wilkinson, Charles W.; Colasurdo, Elizabeth A.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
[Pagulayan, Kathleen F.; Peskind, Elaine R.] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr, VA Northwest Network Mental Illness Res, Seattle, WA USA.
[Wilkinson, Charles W.; Pagulayan, Kathleen F.; Shofer, Jane B.; Peskind, Elaine R.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 935.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860500321
ER
PT J
AU Yagi, Y
Bautista, PA
Klepeis, V
Mino-Kenudson, M
AF Yagi, Yukako
Bautista, Pinky Abarca
Klepeis, Veronica
Mino-Kenudson, Mari
TI 3D-based approach for efficient analysis of immunostained histology
images in evaluating downstream pathway activation in malignant tumors
with molecular targets
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Yagi, Yukako; Bautista, Pinky Abarca; Klepeis, Veronica; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 52.5
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883503215
ER
PT J
AU Yang, JL
Zahr, A
Alcaide, P
Jones, A
Gregory-Ksander, M
Luscinskas, FW
Ksander, B
Argueso, P
D'Amore, PA
AF Yang, Jinling
Zahr, Alisar
Alcaide, Pilar
Jones, Alexander
Gregory-Ksander, Meredith
Luscinskas, Francis W.
Ksander, Bruce
Argueso, Pablo
D'Amore, Patricia A.
TI A role for endomucin-1 in maintaining a non-inflammatory endothelial
surface and in the regulation of leukocyte-endothelial cell interactions
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Yang, Jinling; Zahr, Alisar; Jones, Alexander; Gregory-Ksander, Meredith; Ksander, Bruce; Argueso, Pablo; D'Amore, Patricia A.] Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA 02114 USA.
[Yang, Jinling; Zahr, Alisar; Gregory-Ksander, Meredith; Ksander, Bruce; Argueso, Pablo; D'Amore, Patricia A.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Alcaide, Pilar] Tufts Med Ctr, Mol Cardiol Res Inst, Boston, MA USA.
[Luscinskas, Francis W.] Harvard Univ, Brigham & Womens Hosp, Div Vasc Res, Sch Med, Boston, MA 02115 USA.
[Luscinskas, Francis W.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 57.4
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860504241
ER
PT J
AU Yu, BL
Lei, C
Shahid, M
Beloiartsev, A
Bloch, KD
Zapol, WM
AF Yu, Binglan
Lei, Chong
Shahid, Mohd
Beloiartsev, Arkadi
Bloch, Kenneth D.
Zapol, Warren M.
TI Inhaled nitric oxide attenuates the adverse effects of transfusing
stored red blood cells in mice with endothelial dysfunction after
hemorrhagic shock
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Yu, Binglan; Lei, Chong; Shahid, Mohd; Beloiartsev, Arkadi; Bloch, Kenneth D.; Zapol, Warren M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 920.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 156YK
UT WOS:000319860503394
ER
PT J
AU Zamarioli, A
Morse, L
Battaglino, R
Maranho, D
Volpon, JB
Paula, FA
Shimano, AC
AF Zamarioli, Ariane
Morse, Leslie
Battaglino, Ricardo
Maranho, Daniel
Volpon, Jose B.
Paula, Francisco A.
Shimano, Antonio C.
TI Morphological, mechanical and biochemical changes in long bones
following spinal cord injury
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Joint Annual Meeting of the ASPET/BPS at Experimental Biology (EB)
CY APR 20-24, 2013
CL Boston, MA
SP ASPET, British Pharmacol Soc (BPS)
C1 [Zamarioli, Ariane; Maranho, Daniel; Volpon, Jose B.; Paula, Francisco A.; Shimano, Antonio C.] Univ Sao Paulo, BR-14049 Ribeirao Preto, Brazil.
[Morse, Leslie] Spaulding Rehabil, Boston, MA USA.
[Battaglino, Ricardo] Forsyth Inst, Cambridge, MA USA.
RI Zamarioli, Ariane/K-7001-2012; Volpon, Jose /D-3041-2012; Maranho,
Daniel Augusto/C-1337-2013; Shimano, Antonio/E-1455-2014
OI Zamarioli, Ariane/0000-0002-7939-0528; Volpon, Jose
/0000-0002-2120-0138; Maranho, Daniel Augusto/0000-0002-3893-0292;
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
MA 521.3
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 157GG
UT WOS:000319883501236
ER
EF